cell_id,assay_tissue,assay_organism,curated_by,src_id,tid,assay_type,relationship_type,assay_test_type,variant_id,tissue_id,confidence_score,chembl_id,assay_category,assay_tax_id,assay_id,src_assay_id,description,assay_subcellular_fraction,doc_id,assay_strain,assay_cell_type,bao_format
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615117,,,1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,11087,,,BAO_0000019
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615118,,,2,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,684,,,BAO_0000219
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615119,,,3,,,,15453,,,BAO_0000019
,,Bos taurus,Autocuration,1,104729,B,H,,,,4,CHEMBL615120,,9913.0,4,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,17841,,,BAO_0000249
163.0,,Homo sapiens,Intermediate,1,80001,F,N,,,,1,CHEMBL615121,,9606.0,5,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,17430,,143B,BAO_0000219
163.0,,Homo sapiens,Intermediate,1,80001,F,N,,,,1,CHEMBL615122,,9606.0,6,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,17430,,143B,BAO_0000219
163.0,,Mus musculus,Intermediate,1,80001,F,N,,,,1,CHEMBL615123,,10090.0,7,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,13799,,143B,BAO_0000219
163.0,,Homo sapiens,Expert,1,80001,F,N,,,,1,CHEMBL615124,,9606.0,8,,In vitro cell cytotoxicity was determined against 143B cell line,,17774,,143B,BAO_0000219
163.0,,Homo sapiens,Intermediate,1,80001,F,N,,,,1,CHEMBL615125,,9606.0,9,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,3801,,143B,BAO_0000219
163.0,,Homo sapiens,Intermediate,1,80001,F,N,,,,1,CHEMBL615126,,9606.0,10,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,17430,,143B,BAO_0000219
163.0,,Homo sapiens,Intermediate,1,80001,F,N,,,,1,CHEMBL615127,,9606.0,11,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,17430,,143B,BAO_0000219
163.0,,Homo sapiens,Expert,1,80001,F,N,,,,1,CHEMBL615128,,9606.0,12,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,17774,,143B,BAO_0000219
,,Staphylococcus aureus,Intermediate,1,50185,F,N,,,,1,CHEMBL857900,,1280.0,13,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,,BAO_0000218
,,Staphylococcus aureus,Intermediate,1,50185,F,N,,,,1,CHEMBL615129,,1280.0,14,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,,BAO_0000218
,,Staphylococcus aureus,Intermediate,1,50185,F,N,,,,1,CHEMBL615130,,1280.0,15,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,,BAO_0000218
,,Staphylococcus aureus,Intermediate,1,50185,F,N,,,,1,CHEMBL615131,,1280.0,16,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,11324,,,BAO_0000218
,,Rattus norvegicus,Expert,1,100122,A,D,,,,9,CHEMBL884521,,10116.0,17,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,11347,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615132,,,18,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,16474,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615133,,,19,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,10091,,,BAO_0000019
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615134,,,20,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,16474,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615135,,,21,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,16474,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615136,,,22,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,16474,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615137,,,23,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,16474,,,BAO_0000357
,,,Autocuration,1,12054,B,H,,,,8,CHEMBL615138,,,24,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,16474,,,BAO_0000357
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL836324,,,25,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,14352,,,BAO_0000219
,,Oryctolagus cuniculus,Autocuration,1,12054,B,H,,,,8,CHEMBL615139,,9986.0,26,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,5646,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,12054,B,H,,,,8,CHEMBL615140,,9986.0,27,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,5646,,,BAO_0000357
,,,Autocuration,1,12426,B,H,,,,8,CHEMBL615141,,,28,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,10997,,,BAO_0000219
,,soya bean,Autocuration,1,12054,B,H,,,,8,CHEMBL615142,,3847.0,29,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,6309,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL615143,,3847.0,30,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,167,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL615144,,3847.0,31,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,167,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL872867,,3847.0,32,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,11087,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL615145,,3847.0,33,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,11087,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL615146,,3847.0,34,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,13622,,,BAO_0000357
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL615147,,3847.0,35,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,13622,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,22226,A,U,,,,0,CHEMBL615148,,10116.0,36,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,11347,,,BAO_0000019
,,Escherichia coli,Autocuration,1,22226,B,U,,,,0,CHEMBL615149,,562.0,37,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,5926,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615150,,,38,,Dissociation constant with dimeric 16S rRNA RNA construct B,,4567,,,BAO_0000019
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615151,,,39,,Dissociation constant towards 16S rRNA construct A,,3782,,,BAO_0000225
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615152,,,40,,Dissociation constant towards 16S rRNA construct B,,3782,,,BAO_0000225
,,Escherichia coli,Expert,1,100263,B,M,,,,3,CHEMBL615153,,562.0,41,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,4466,,,BAO_0000225
,,Escherichia coli,Expert,1,100263,B,M,,,,3,CHEMBL615154,,562.0,42,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,6592,,,BAO_0000225
,,,Autocuration,1,13053,B,H,,,,8,CHEMBL615155,,,43,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,,BAO_0000019
,,,Autocuration,1,13053,B,H,,,,8,CHEMBL615156,,,44,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,,BAO_0000019
,,Homo sapiens,Autocuration,1,20001,B,H,,,,8,CHEMBL615157,,9606.0,45,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,13163,,,BAO_0000019
,,Homo sapiens,Autocuration,1,20001,B,H,,,,8,CHEMBL615158,,9606.0,46,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,13163,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12971,B,D,,,,9,CHEMBL615159,,10116.0,47,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10691,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12971,B,D,,,,9,CHEMBL615172,,10116.0,48,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,10691,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12971,B,D,,,,9,CHEMBL615173,,10116.0,49,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10691,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12971,B,D,,,,9,CHEMBL615174,,10116.0,50,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,10691,,,BAO_0000019
,,,Autocuration,1,13053,B,H,,,,8,CHEMBL884518,,,51,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,898,,,BAO_0000019
,,,Autocuration,1,11512,B,H,,,,8,CHEMBL615175,,,52,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,912,,,BAO_0000357
,,,Autocuration,1,11512,B,H,,,,8,CHEMBL615176,,,53,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,912,,,BAO_0000357
,,,Autocuration,1,11512,B,H,,,,8,CHEMBL615177,,,54,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,912,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,104740,B,D,,,,5,CHEMBL615178,,10116.0,55,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Membranes,15103,,,BAO_0000249
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615179,,9606.0,56,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,5116,,1A9,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104835,F,D,,,,7,CHEMBL615180,,10116.0,57,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,14578,,Oocytes,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104821,F,D,,,,7,CHEMBL615181,,10116.0,58,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,14578,,Oocytes,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104848,F,D,,,,7,CHEMBL615182,,10116.0,59,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,14578,,Oocytes,BAO_0000219
506.0,,Homo sapiens,Expert,1,80002,F,N,,,,1,CHEMBL615183,,9606.0,60,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,4787,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615184,,9606.0,61,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,4787,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615185,,9606.0,62,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,3547,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615186,,9606.0,63,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,3547,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615187,,9606.0,64,,Effective dose of compound against replication of 1A9 cell line was evaluated,,6726,,1A9,BAO_0000219
506.0,,Homo sapiens,Expert,1,80002,F,N,,,,1,CHEMBL885343,,9606.0,65,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,3455,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615188,,9606.0,66,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,5726,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615189,,9606.0,67,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,5726,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615190,,9606.0,68,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,5726,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615191,,9606.0,69,,Inhibitory activity against Taxol resistant 1A9 cell lines,,3395,,1A9,BAO_0000219
506.0,,Homo sapiens,Expert,1,80002,F,N,,,,1,CHEMBL615192,,9606.0,70,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,3415,,1A9,BAO_0000219
506.0,,Homo sapiens,Expert,1,80002,F,N,,,,1,CHEMBL827083,,9606.0,71,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,3415,,1A9,BAO_0000219
506.0,,Homo sapiens,Expert,1,80002,F,N,,,,1,CHEMBL615193,,9606.0,72,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,17099,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615194,,9606.0,73,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,17099,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615195,,9606.0,74,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,17099,,1A9,BAO_0000219
506.0,,Homo sapiens,Intermediate,1,80002,F,N,,,,1,CHEMBL615196,,9606.0,75,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,17099,,1A9,BAO_0000219
503.0,,Homo sapiens,Intermediate,1,81072,F,N,,,,1,CHEMBL615197,,9606.0,76,,Inhibitory concentration against Jurkat cells,,17721,,Jurkat,BAO_0000219
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL615198,,,77,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,1229,,,BAO_0000019
,,Rattus norvegicus,Expert,1,100121,A,D,,,,9,CHEMBL615199,,10116.0,78,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,11347,,,BAO_0000357
,,,Expert,1,11231,B,H,,,,8,CHEMBL615200,,,79,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,17117,,,BAO_0000357
,,,Expert,1,11231,B,H,,,,8,CHEMBL615201,,,80,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,17117,,,BAO_0000357
,,,Expert,1,11231,B,H,,,,8,CHEMBL615202,,,81,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,17117,,,BAO_0000357
,,Candida albicans,Autocuration,1,11231,B,H,,,,8,CHEMBL615203,,5476.0,82,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Microsomes,11375,,,BAO_0000251
,,Candida albicans,Autocuration,1,11231,B,H,,,,8,CHEMBL615204,,5476.0,83,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Microsomes,11375,,,BAO_0000251
,,Saccharomyces cerevisiae,Autocuration,1,11231,B,H,,,,8,CHEMBL615205,,4932.0,84,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Microsomes,11375,,,BAO_0000251
,,Saccharomyces cerevisiae,Autocuration,1,11231,B,H,,,,8,CHEMBL615206,,4932.0,85,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Microsomes,11375,,,BAO_0000251
,Liver,Sus scrofa,Autocuration,1,12083,B,H,,,2107.0,8,CHEMBL615207,,9823.0,86,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Microsomes,11375,,,BAO_0000251
,,Rattus norvegicus,Autocuration,1,11231,B,H,,,,8,CHEMBL827084,,10116.0,87,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,791,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,11231,B,H,,,,8,CHEMBL615208,,10116.0,88,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,791,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,11231,B,H,,,,8,CHEMBL615209,,10116.0,89,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,791,,,BAO_0000019
,Liver,Rattus norvegicus,Autocuration,1,12083,B,D,,,2107.0,9,CHEMBL615210,,10116.0,90,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Microsomes,11375,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12083,B,D,,,2107.0,9,CHEMBL615211,,10116.0,91,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,11375,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12083,B,D,,,2107.0,9,CHEMBL615212,,10116.0,92,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,153,,,BAO_0000251
,,,Expert,1,11377,B,H,,,,8,CHEMBL615213,,,93,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,8269,,,BAO_0000357
,,,Expert,1,11377,B,H,,,,8,CHEMBL615273,,,94,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,8269,,,BAO_0000357
726.0,,Homo sapiens,Expert,1,81020,F,N,,,,1,CHEMBL615274,,9606.0,95,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,17653,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615275,,9606.0,96,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,14277,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615276,,9606.0,97,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,1717,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615277,,9606.0,98,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,14091,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615326,,9606.0,99,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,14091,,HepG2,BAO_0000219
,,Hepatitis B virus,Expert,1,50606,F,N,,,,1,CHEMBL883130,,10407.0,100,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,17653,,,BAO_0000218
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL884519,,9606.0,101,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,13105,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615327,,9606.0,102,,Concentration required to inhibit 50% of 2.2.15 cell line,,1717,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,A,N,,,,1,CHEMBL615328,,9606.0,103,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,13105,,HepG2,BAO_0000219
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615329,,9606.0,104,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,13600,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615330,,9606.0,105,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,13467,,2.2.15,BAO_0000218
,,Hepatitis B virus,Expert,1,50606,F,N,,,,1,CHEMBL615331,,10407.0,106,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,17477,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615332,,9606.0,107,,In vitro anti-HBV activity in 2.2.15 cells,,1593,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615333,,9606.0,108,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,1593,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615334,,9606.0,109,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,15089,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615335,,9606.0,110,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,15089,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615336,,9606.0,111,,Cytotoxicity in 2.2.15 cells,,1593,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615337,,9606.0,112,,Cytotoxicity in 2.2.15 cells; Not determined,,1593,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615338,,9606.0,113,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,13600,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615339,,9606.0,114,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,13467,,2.2.15,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,F,N,,,,1,CHEMBL615340,,9606.0,115,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,13467,,2.2.15,BAO_0000218
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615341,,9606.0,116,,Antiviral activity against HBV was determined in 2.215 cell line,,14764,,HepG2,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615342,,9606.0,117,,Inhibition of 20-HETE synthesis in human renal microsomes,Microsomes,6531,,,BAO_0000251
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615343,,,118,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,17322,,,BAO_0000019
388.0,,Homo sapiens,Intermediate,1,80612,F,N,,,,1,CHEMBL615344,,9606.0,119,,Inhibitory concentration against 2008 (ovarian) cells,,17072,,2008,BAO_0000219
388.0,,Homo sapiens,Intermediate,1,80612,F,N,,,,1,CHEMBL615345,,9606.0,120,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,16936,,2008,BAO_0000219
388.0,,Homo sapiens,Intermediate,1,80612,F,N,,,,1,CHEMBL615346,,9606.0,121,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,16936,,2008,BAO_0000219
388.0,,Homo sapiens,Intermediate,1,80612,F,N,,,,1,CHEMBL615347,,9606.0,122,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,17146,,2008,BAO_0000219
388.0,,Homo sapiens,Intermediate,1,80612,F,N,,,,1,CHEMBL615348,,9606.0,123,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,17146,,2008,BAO_0000219
561.0,,Homo sapiens,Intermediate,1,80613,F,N,,,,1,CHEMBL827085,,9606.0,124,,In vitro inhibition of 2008/R ovarian cancer cell line,,10797,,2008/R,BAO_0000219
561.0,,Homo sapiens,Intermediate,1,80613,F,N,,,,1,CHEMBL615349,,9606.0,125,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,10797,,2008/R,BAO_0000219
389.0,,Homo sapiens,Intermediate,1,80614,F,N,,,,1,CHEMBL615350,,9606.0,126,,In vitro inhibition of 2008/S ovarian cancer cell line,,10797,,2008/S,BAO_0000219
389.0,,Homo sapiens,Intermediate,1,80614,F,N,,,,1,CHEMBL615351,,9606.0,127,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,10797,,2008/S,BAO_0000219
,,Homo sapiens,Expert,1,100256,B,S,,,,2,CHEMBL615352,,9606.0,128,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,4823,,,BAO_0000220
,,Homo sapiens,Intermediate,1,100256,B,S,,,,2,CHEMBL615353,,9606.0,129,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,12912,,,BAO_0000220
,,,Expert,1,100256,B,S,,,,2,CHEMBL615354,,,130,,Inhibition of chymotrypsin-like activity of 20S proteasome,,2957,,,BAO_0000220
,,,Expert,1,100256,B,S,,,,2,CHEMBL615355,,,131,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,2957,,,BAO_0000220
,,,Intermediate,1,100256,B,S,,,,2,CHEMBL615356,,,132,,Inhibitory activity against 20S proteosome,,3260,,,BAO_0000220
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615357,,9606.0,133,,Compound was tested for inhibitory activity against tryptase,,3451,,,BAO_0000019
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL615358,,9606.0,134,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,13885,,HepG2,BAO_0000219
726.0,,Homo sapiens,Intermediate,1,81020,F,N,,,,1,CHEMBL827086,,9606.0,135,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,13885,,HepG2,BAO_0000219
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615359,,,136,,Compound was tested for the inhibition of Alpha-glucosidase,,3676,,,BAO_0000019
,,,Autocuration,1,235,B,H,,,,8,CHEMBL615360,,,137,,Inhibitory concentration against human neutrophil elastase (HNE),,6043,,,BAO_0000357
,Heart,Rattus norvegicus,Autocuration,1,22226,F,U,,,948.0,0,CHEMBL615361,,10116.0,138,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,11140,,,BAO_0000218
,,,Autocuration,1,19640,F,H,,,,8,CHEMBL615362,,,139,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,,BAO_0000019
,,,Expert,1,19640,F,H,,,,8,CHEMBL615363,,,140,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,,BAO_0000019
,,,Autocuration,1,19640,B,H,,,,8,CHEMBL615364,,,141,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,,BAO_0000357
,,,Expert,1,19640,F,H,,,,8,CHEMBL615365,,,142,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,10543,,,BAO_0000019
524.0,,Mus musculus,Intermediate,1,80360,F,N,,,,1,CHEMBL615366,,10090.0,143,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,11365,,P338,BAO_0000219
524.0,,Mus musculus,Intermediate,1,80360,F,N,,,,1,CHEMBL615367,,10090.0,144,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,11365,,P338,BAO_0000219
554.0,,Homo sapiens,Intermediate,1,80384,F,N,,,,1,CHEMBL615368,,9606.0,145,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,11803,,PBL,BAO_0000219
,,Ovis aries,Autocuration,1,22226,F,U,,,,0,CHEMBL615369,,9940.0,146,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,11803,,,BAO_0000019
,,Ovis aries,Autocuration,1,22226,F,U,,,,0,CHEMBL615370,,9940.0,147,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,11803,,,BAO_0000019
,,,Autocuration,1,191,B,H,,,,8,CHEMBL615673,,,148,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,12278,,,BAO_0000357
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615674,,9606.0,149,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,8249,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615675,,9606.0,150,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,8249,,,BAO_0000019
635.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615676,,9606.0,151,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,8249,,CCRF-CEM,BAO_0000219
635.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615677,,9606.0,152,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,8249,,CCRF-CEM,BAO_0000219
635.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615678,,9606.0,153,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,8249,,CCRF-CEM,BAO_0000219
635.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615679,,9606.0,154,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,8249,,CCRF-CEM,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615680,,9606.0,155,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,8249,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615681,,9606.0,156,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,8249,,,BAO_0000019
,,,Autocuration,1,104290,B,H,,,,6,CHEMBL857972,,,157,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,16992,,,BAO_0000249
,,Streptococcus pyogenes,Intermediate,1,50264,F,N,,,,1,CHEMBL857899,,1314.0,158,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,10543,,,BAO_0000218
,,Human herpesvirus 3,Intermediate,1,50527,F,N,,,,1,CHEMBL615371,,10335.0,159,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,17833,,,BAO_0000218
468.0,,vericilla zoster virus,Expert,1,50527,F,N,,,,1,CHEMBL615372,,10335.0,160,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,17290,,HEL,BAO_0000218
,,vericilla zoster virus,Intermediate,1,50527,F,N,,,,1,CHEMBL615373,,10335.0,161,,Antiviral activity against 07/1 strain of VZV; ND: No data,,17290,,,BAO_0000218
,,vericilla zoster virus,Intermediate,1,50527,F,N,,,,1,CHEMBL615374,,10335.0,162,,Antiviral activity against 07/1 strain of VZV; ND=No data,,17290,,,BAO_0000218
,,escherichia cloac,Intermediate,1,50145,F,N,,,,1,CHEMBL615375,,561.0,163,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,10932,,,BAO_0000218
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615376,,,164,,Ratio of Ki at A2 to Ki at A1 receptors,,9707,,,BAO_0000019
,,Candida albicans,Expert,1,11143,B,H,,,,8,CHEMBL615377,,5476.0,165,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,2346,,,BAO_0000249
,,Candida glabrata CBS 138,Expert,1,18077,B,H,,,,8,CHEMBL615378,,284593.0,166,,"Inhibition of 1,3-beta-glucan synthase",,2205,,,BAO_0000357
832.0,,Homo sapiens,Intermediate,1,80609,F,N,,,,1,CHEMBL615379,,9606.0,167,,Inhibition of growth of 1-87 human tumor cell line,,11900,,1-87 tumor cell line,BAO_0000219
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL615380,,10116.0,168,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,14864,,,BAO_0000219
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615381,,3847.0,169,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,16474,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615382,,3847.0,170,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,16474,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615383,,3847.0,171,,% inhibition against soybean 1-lipoxygenase (SLO),,16474,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615384,,3847.0,172,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,16474,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615385,,3847.0,173,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615386,,3847.0,174,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615387,,3847.0,175,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615388,,3847.0,176,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615214,,3847.0,177,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL827087,,3847.0,178,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615215,,3847.0,179,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615216,,3847.0,180,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615217,,3847.0,181,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615218,,3847.0,182,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,3094,,,BAO_0000357
,,Glycine max,Autocuration,1,100171,B,D,,,,9,CHEMBL615219,,3847.0,183,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,3094,,,BAO_0000357
,,Mus musculus,Autocuration,1,22226,B,U,,,,0,CHEMBL615220,,10090.0,184,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,10413,,,BAO_0000019
294.0,,Mus musculus,Intermediate,1,80049,F,N,,,,1,CHEMBL615221,,10090.0,185,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,16929,,C3H 10T1/2,BAO_0000219
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL615222,,,186,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,1229,,,BAO_0000019
,,,Autocuration,1,11489,B,H,,,,8,CHEMBL615223,,,187,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,16587,,,BAO_0000357
,,,Autocuration,1,11862,B,H,,,,8,CHEMBL615224,,,188,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,16587,,,BAO_0000357
,,,Autocuration,1,11862,B,H,,,,8,CHEMBL615225,,,189,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,16587,,,BAO_0000357
,,,Autocuration,1,11489,B,H,,,,8,CHEMBL615226,,,190,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,16587,,,BAO_0000357
,,,Autocuration,1,11862,B,H,,,,8,CHEMBL615227,,,191,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,16587,,,BAO_0000357
,,Bos taurus,Expert,1,12347,F,D,,,,9,CHEMBL615228,,9913.0,192,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,8058,,,BAO_0000019
,,Rattus norvegicus,Expert,1,100120,B,D,,,,9,CHEMBL615229,,10116.0,193,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,9065,,,BAO_0000357
,Adrenal gland,Rattus norvegicus,Expert,1,100120,B,D,,,2369.0,9,CHEMBL615230,,10116.0,194,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,8865,,,BAO_0000357
,,Rattus norvegicus,Expert,1,100120,B,D,,,,9,CHEMBL615231,,10116.0,195,,Inhibition of rat adrenal 11-beta-hydroxylase,,9066,,,BAO_0000357
,,Rattus norvegicus,Expert,1,100120,B,D,,,,9,CHEMBL884520,,10116.0,196,,Inhibition of rat adrenal 11-beta-hydroxylase,,8394,,,BAO_0000357
,,Rattus norvegicus,Expert,1,100120,B,D,,,,9,CHEMBL615232,,10116.0,197,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,8394,,,BAO_0000357
,,,Autocuration,1,10328,B,H,,,,8,CHEMBL615233,,,198,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,6431,,,BAO_0000019
,,,Autocuration,1,11490,B,H,,,,8,CHEMBL827088,,,199,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,6431,,,BAO_0000357
,,,Autocuration,1,11490,B,H,,,,8,CHEMBL615234,,,200,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,6431,,,BAO_0000357
,,,Autocuration,1,11134,F,H,,,,8,CHEMBL615235,,,201,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,9295,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615236,,,202,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615237,,,203,,Compound was tested in vitro for inhibition of 12-LO human platelet,,13622,,,BAO_0000019
,,,Autocuration,1,11134,F,H,,,,8,CHEMBL615238,,,204,,Inhibitory concentration against human platelet 12-lipoxygenase,,12079,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615239,,,205,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,13622,,,BAO_0000019
,,Homo sapiens,Autocuration,1,11134,F,D,,,,9,CHEMBL615240,,9606.0,206,,Inhibitory concentration against human platelet 12-lipoxygenase,,12079,,,BAO_0000019
,,,Expert,1,11835,B,H,,,,8,CHEMBL615241,,,207,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,13500,,,BAO_0000019
,,,Expert,1,11601,B,H,,,,8,CHEMBL615242,,,208,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,13723,,,BAO_0000357
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615243,,,209,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,16474,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615244,,,210,,Inhibitory activity against human platelet 12-lipoxygenase,,1630,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615245,,,211,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,167,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615246,,,212,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,16474,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615247,,,213,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,167,,,BAO_0000019
,,,Autocuration,1,11134,B,H,,,,8,CHEMBL615248,,,214,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,16474,,,BAO_0000019
,,,Autocuration,1,11601,B,H,,,,8,CHEMBL615249,,,215,,Inhibitory activity towards porcine 12-lipoxygenase,,10091,,,BAO_0000357
,,,Autocuration,1,11601,B,H,,,,8,CHEMBL615250,,,216,,Tested for inhibition against porcine 12-LO,,11966,,,BAO_0000357
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615251,,,217,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,951,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615252,,,218,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,10997,,,BAO_0000019
,,,Expert,1,12052,B,H,,,,8,CHEMBL828340,,,219,,In vitro inhibition of rat platelet 12-lipoxygenase,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615253,,,220,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615254,,,221,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615255,,,222,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615256,,,223,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615257,,,224,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,10193,,,BAO_0000019
,,,Autocuration,1,12052,B,H,,,,8,CHEMBL615258,,,225,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,11087,,,BAO_0000019
621.0,,Homo sapiens,Intermediate,1,80007,F,N,,,,1,CHEMBL615259,,9606.0,226,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,15569,,41M,BAO_0000219
621.0,,Homo sapiens,Expert,1,80007,F,N,,,,1,CHEMBL615260,,9606.0,227,,In vitro antitumor activity against 41M cell line.,,12989,,41M,BAO_0000219
621.0,,Homo sapiens,Intermediate,1,80007,F,N,,,,1,CHEMBL615261,,9606.0,228,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,16745,,41M,BAO_0000219
621.0,,Homo sapiens,Intermediate,1,80007,F,N,,,,1,CHEMBL615262,,9606.0,229,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,15569,,41M,BAO_0000219
621.0,,Homo sapiens,Expert,1,80007,F,N,,,,1,CHEMBL615263,,9606.0,230,,In vitro antitumor activity against 41McisR cell line.,,12989,,41M,BAO_0000219
621.0,,Homo sapiens,Expert,1,80007,F,N,,,,1,CHEMBL838393,,9606.0,231,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,12989,,41M,BAO_0000219
621.0,,Homo sapiens,Intermediate,1,80007,F,N,,,,1,CHEMBL615264,,9606.0,232,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,16745,,41M,BAO_0000219
,,Homo sapiens,Expert,1,84,B,D,,,,9,CHEMBL615265,,9606.0,233,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,6210,,,BAO_0000357
,,Homo sapiens,Expert,1,68,B,D,,,,9,CHEMBL615266,,9606.0,234,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,6210,,,BAO_0000357
,,,Expert,1,68,B,H,,,,8,CHEMBL615267,,,235,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,6226,,,BAO_0000357
,,,Expert,1,10201,B,H,,,,8,CHEMBL615268,,,236,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,17855,,,BAO_0000357
,,,Expert,1,10201,B,H,,,,8,CHEMBL615269,,,237,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,17855,,,BAO_0000357
,,,Expert,1,10201,B,H,,,,8,CHEMBL615270,,,238,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,17855,,,BAO_0000357
,,,Autocuration,1,12220,B,H,,,,8,CHEMBL615271,,,239,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,10413,,,BAO_0000357
,,Escherichia coli,Autocuration,1,11303,B,H,,,,8,CHEMBL615272,,562.0,240,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,10413,,,BAO_0000357
,,Escherichia coli,Autocuration,1,11303,B,H,,,,8,CHEMBL615103,,562.0,241,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,10413,,,BAO_0000357
,,Escherichia coli,Autocuration,1,11303,B,H,,,,8,CHEMBL615104,,562.0,242,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,10413,,,BAO_0000357
,,,Autocuration,1,12220,B,H,,,,8,CHEMBL615105,,,243,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,10413,,,BAO_0000357
,,,Autocuration,1,12220,B,H,,,,8,CHEMBL872866,,,244,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,10413,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615106,,9823.0,245,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615107,,9823.0,246,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615108,,9823.0,247,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,7587,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615109,,9823.0,248,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,7587,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615110,,9823.0,249,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL840105,,9823.0,250,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615111,,9823.0,251,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615112,,9823.0,252,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615113,,9823.0,253,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615114,,9823.0,254,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615115,,9823.0,255,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,7587,,,BAO_0000357
,,Sus scrofa,Autocuration,1,11303,B,H,,,,8,CHEMBL615116,,9823.0,256,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,7587,,,BAO_0000019
,,,Autocuration,1,11303,B,H,,,,8,CHEMBL615698,,,257,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,7323,,,BAO_0000357
,,Sus scrofa,Autocuration,1,22226,B,U,,,,0,CHEMBL615699,,9823.0,258,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,7587,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22226,B,U,,,,0,CHEMBL615700,,9823.0,259,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,7587,,,BAO_0000019
,,Saccharomyces cerevisiae,Expert,1,100249,B,H,,,,8,CHEMBL615701,,4932.0,260,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,13750,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615702,,10116.0,261,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,7662,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615703,,10116.0,262,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,7662,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615704,,10116.0,263,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,7662,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL615705,,,264,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,12211,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL615706,,,265,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,12211,,,BAO_0000019
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL615707,,10141.0,266,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,12211,,,BAO_0000221
,,,Expert,1,10623,F,H,,,,8,CHEMBL615708,,,267,,Stimulatory activity of intragastric pressure was tested in the rat,,12211,,,BAO_0000019
,,,Autocuration,1,121,B,H,,,,8,CHEMBL615709,,,268,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,15453,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL615710,,10116.0,269,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,11884,,,BAO_0000218
,,,Autocuration,1,12688,F,H,,,,8,CHEMBL615711,,,270,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,7185,,,BAO_0000019
,,Homo sapiens,Expert,1,121,B,D,,,,9,CHEMBL615712,,9606.0,271,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,6876,,,BAO_0000357
,,Homo sapiens,Expert,1,121,B,D,,,,9,CHEMBL836325,,9606.0,272,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,6876,,,BAO_0000357
,,,Autocuration,1,12198,F,H,,,,8,CHEMBL615713,,,273,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,11863,,,BAO_0000019
,,,Autocuration,1,12198,B,H,,,,8,CHEMBL615714,,,274,,Inhibition constant of high-affinity 5-HT uptake,,11863,,,BAO_0000357
,,,Autocuration,1,12198,F,H,,,,8,CHEMBL615715,,,275,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,11863,,,BAO_0000019
,,,Autocuration,1,12198,F,H,,,,8,CHEMBL615716,,,276,,Maximum rate was determined for high affinity transport of 5-HT,,11863,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL615717,,,277,,Compound was tested for agonistic activity against 5-HT uptake,,4639,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL881818,,,278,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,15796,,,BAO_0000019
,,Bos taurus,Expert,1,105,B,H,,,,8,CHEMBL884540,,9913.0,279,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,15796,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615718,,10116.0,280,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,12801,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615719,,,281,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,12801,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615720,,,282,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Membranes,12120,,,BAO_0000249
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615721,,,283,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Membranes,12120,,,BAO_0000249
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615722,,,284,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,11963,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615723,,,285,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,11701,,,BAO_0000019
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615724,,,286,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615725,,,287,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615726,,,288,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615727,,,289,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,16394,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL615728,,10141.0,290,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,11574,,,BAO_0000019
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL857971,,,291,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL615729,,,292,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,15363,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL615730,,10116.0,293,,Efficacy against 5-hydroxytryptamine 2A receptor,,15363,,,BAO_0000019
,,,Expert,1,12687,F,H,,,,8,CHEMBL615731,,,294,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,15329,,,BAO_0000019
,,,Expert,1,12687,F,H,,,,8,CHEMBL615732,,,295,,Relative potency towards 5-HT2A receptor of rat tail artery,,15329,,,BAO_0000019
,,,Expert,1,12687,F,H,,,,8,CHEMBL615733,,,296,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,15329,,,BAO_0000019
,,,Expert,1,12687,F,H,,,,8,CHEMBL615734,,,297,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,15329,,,BAO_0000019
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL615735,,,298,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,15329,,,BAO_0000019
,,,Expert,1,12687,F,H,,,,8,CHEMBL615736,,,299,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,15329,,,BAO_0000019
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL615737,,10141.0,300,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,273,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL615738,,10141.0,301,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,273,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL615739,,10141.0,302,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,273,,,BAO_0000221
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL615278,,,303,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,12092,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10623,F,D,,,,9,CHEMBL615279,,10116.0,304,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,1317,,,BAO_0000019
,,,Expert,1,168,B,H,,,,8,CHEMBL615280,,,305,,Binding affinity against 5-hydroxytryptamine 4 receptor,,12409,,,BAO_0000357
,,Gallus gallus,Autocuration,1,22226,B,U,,,,0,CHEMBL615281,,9031.0,306,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,11126,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615282,,9606.0,307,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,11126,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615283,,9606.0,308,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,11126,,,BAO_0000019
649.0,,Homo sapiens,Autocuration,1,80156,B,N,,,,1,CHEMBL615284,,9606.0,309,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,11126,,HL-60,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615285,,9606.0,310,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,11126,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615286,,9606.0,311,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,11126,,,BAO_0000019
,,Homo sapiens,Autocuration,1,104703,B,D,,,,7,CHEMBL615287,,9606.0,312,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,17807,,Oocytes,BAO_0000219
,,,Intermediate,1,100256,F,S,,,,2,CHEMBL615288,,,313,,Chymotryptic inhibitory activity against 26S proteasome,,16575,,,BAO_0000220
,,,Intermediate,1,100256,B,S,,,,2,CHEMBL615289,,,314,,Inhibitory activity against 26S proteasome degradation of IkB,,15407,,,BAO_0000220
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL615290,,9606.0,315,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,10797,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL884522,,9606.0,316,,In vitro inhibition of 2780/S ovarian cancer cell line,,10797,,A2780,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615291,,9606.0,317,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,3469,,,BAO_0000019
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615292,,,318,,Association constant for binding to AATT 28-mer AATT hairpin,,16037,,,BAO_0000225
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615293,,,319,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,16037,,,BAO_0000225
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615294,,,320,,Reaction Rate Parameter for 28-mer AATT hairpin,,16037,,,BAO_0000225
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL615295,,,321,,Reaction Rate Parameter for 28-mer AATT hairpin,,16037,,,BAO_0000225
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL825021,,9606.0,322,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,16524,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615296,,9606.0,323,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,16524,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL615297,,9606.0,324,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,16524,,,BAO_0000019
,,Cricetulus griseus,Autocuration,1,22226,F,U,,,,0,CHEMBL615298,,10029.0,325,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,16758,,,BAO_0000019
,,Cricetulus griseus,Autocuration,1,22226,F,U,,,,0,CHEMBL615299,,10029.0,326,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,16758,,,BAO_0000019
,,Cricetulus griseus,Autocuration,1,22226,F,U,,,,0,CHEMBL615300,,10029.0,327,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,16758,,,BAO_0000019
,,,Autocuration,1,241,B,H,,,,8,CHEMBL615301,,,328,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,14360,,,BAO_0000357
,,Homo sapiens,Expert,1,241,B,D,,,,9,CHEMBL615302,,9606.0,329,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,14360,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615303,,10116.0,330,,Selectivity ratio of ID50 in liver and heart,,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615304,,,331,,"Selectivity, ratio of relative ID50 in liver and heart",,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615305,,,332,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615306,,,333,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000218
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615307,,,334,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000218
,,,Autocuration,1,12132,B,H,In vivo,,,8,CHEMBL615308,,,335,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000218
,,,Autocuration,1,12132,F,H,In vivo,,,8,CHEMBL615309,,,336,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000218
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615310,,,337,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615311,,,338,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,9964,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615312,,9606.0,339,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615313,,,340,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,9964,,,BAO_0000019
,,,Autocuration,1,12132,F,H,,,,8,CHEMBL615314,,,341,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,9964,,,BAO_0000019
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615315,,,342,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615316,,10116.0,343,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,9964,,,BAO_0000218
,,,Autocuration,1,12132,B,H,In vivo,,,8,CHEMBL615317,,,344,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,9964,,,BAO_0000218
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615318,,,345,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615319,,10116.0,346,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,9964,,,BAO_0000218
,,,Autocuration,1,12132,B,H,,,,8,CHEMBL615320,,,347,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000019
,,,Autocuration,1,12132,F,H,,,,8,CHEMBL615321,,,348,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,9964,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615322,,10116.0,349,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,3796,,,BAO_0000019
,,Escherichia coli,Autocuration,1,19690,B,H,,,,8,CHEMBL615323,,562.0,350,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,4251,,,BAO_0000357
,,Escherichia coli,Autocuration,1,19690,B,H,,,,8,CHEMBL615407,,562.0,351,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,4251,,,BAO_0000357
,,Escherichia coli,Autocuration,1,19690,B,H,,,,8,CHEMBL857267,,562.0,352,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,4251,,,BAO_0000357
,,Escherichia coli,Autocuration,1,19690,B,H,,,,8,CHEMBL615408,,562.0,353,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,4251,,,BAO_0000357
,,,Autocuration,1,19690,B,H,,,,8,CHEMBL615409,,,354,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,166,,,BAO_0000357
,,,Autocuration,1,19690,B,H,,,,8,CHEMBL615410,,,355,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,17861,,,BAO_0000357
,,,Autocuration,1,19690,B,H,,,,8,CHEMBL615411,,,356,,Inhibition constant against 3-dehydroquinate synthase,,166,,,BAO_0000357
,,,Autocuration,1,19690,B,H,,,,8,CHEMBL615412,,,357,,Association rate constant against 3-dehydroquinate synthase,,166,,,BAO_0000357
,,,Autocuration,1,19690,B,H,,,,8,CHEMBL615413,,,358,,Rate constant against 3-dehydroquinate synthase,,166,,,BAO_0000357
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615414,,,359,,Inhibitory activity against fuc-TVII,,3548,,,BAO_0000019
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615415,,10116.0,360,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615416,,10116.0,361,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615417,,10116.0,362,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615418,,10116.0,363,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615419,,10116.0,364,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615420,,10116.0,365,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615421,,10116.0,366,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615422,,10116.0,367,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615423,,10116.0,368,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL872868,,10116.0,369,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Microsomes,9877,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,12236,B,D,,,2107.0,9,CHEMBL615424,,10116.0,370,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Microsomes,9877,,,BAO_0000251
,,,Autocuration,1,104832,B,H,,,,4,CHEMBL825022,,,371,,Inhibitory activity against 3-phosphoglycerate kinase.,,3003,,,BAO_0000224
,,,Autocuration,1,104832,B,H,,,,4,CHEMBL615425,,,372,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,3003,,,BAO_0000224
,,,Autocuration,1,104832,B,H,,,,4,CHEMBL615426,,,373,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,3003,,,BAO_0000224
,,Homo sapiens,Expert,1,10612,B,D,,,,9,CHEMBL615427,,9606.0,374,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,17185,,,BAO_0000357
844.0,,Homo sapiens,Intermediate,1,80616,F,N,,,,1,CHEMBL615428,,9606.0,375,,Cytotoxicity on 3677 melanoma cells,,6072,,3677 melanoma cell line,BAO_0000219
844.0,,Homo sapiens,Intermediate,1,80616,F,N,,,,1,CHEMBL615429,,9606.0,376,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,6072,,3677 melanoma cell line,BAO_0000219
700.0,,Mus musculus,Intermediate,1,80617,F,N,,,,1,CHEMBL615430,,10090.0,377,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,5018,,MC-38,BAO_0000219
,,Homo sapiens,Intermediate,1,22226,F,U,,,,0,CHEMBL615431,,9606.0,378,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,2852,,,BAO_0000019
798.0,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615432,,,379,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,8663,,B16,BAO_0000218
798.0,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615433,,,380,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,8663,,B16,BAO_0000218
,,Human rhinovirus 14,Expert,1,12464,F,D,,,,9,CHEMBL615434,,12131.0,381,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,3245,,,BAO_0000019
,,Human rhinovirus sp.,Intermediate,1,50085,F,N,,,,1,CHEMBL615435,,169066.0,382,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,3245,,,BAO_0000218
,,human rhinovirus type 14,Intermediate,1,50679,F,N,,,,1,CHEMBL615436,,169066.0,383,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,3877,,,BAO_0000218
,,human rhinovirus type 14,Intermediate,1,50679,F,N,,,,1,CHEMBL615437,,169066.0,384,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,3877,,,BAO_0000218
,,Human rhinovirus 14,Expert,1,12464,F,D,,,,9,CHEMBL615438,,12131.0,385,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,,BAO_0000019
,,Human rhinovirus 14,Expert,1,12464,F,D,,,,9,CHEMBL615439,,12131.0,386,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,,BAO_0000019
,,Human rhinovirus 14,Expert,1,12464,F,D,,,,9,CHEMBL615440,,12131.0,387,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,5861,,,BAO_0000019
,,Human rhinovirus 14,Expert,1,12464,F,D,,,,9,CHEMBL615441,,12131.0,388,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,5861,,,BAO_0000019
,,Enterovirus,Intermediate,1,50665,F,N,,,,1,CHEMBL615641,,12059.0,389,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,13748,,,BAO_0000218
,,Enterovirus,Intermediate,1,50665,F,N,,,,1,CHEMBL872065,,12059.0,390,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,13748,,,BAO_0000218
,,Enterovirus,Intermediate,1,50665,F,N,,,,1,CHEMBL825023,,12059.0,391,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,13748,,,BAO_0000218
,,Enterovirus,Intermediate,1,50665,F,N,,,,1,CHEMBL615642,,12059.0,392,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,13748,,,BAO_0000218
,,Human rhinovirus B,Expert,1,12464,B,H,,,,8,CHEMBL615643,,147712.0,393,,Inhibition of human rhinovirus 3C protease,,13748,,,BAO_0000357
,,Homo sapiens,Autocuration,1,22226,B,U,,,,0,CHEMBL615644,,9606.0,394,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,17699,,,BAO_0000019
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615645,,10090.0,395,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,7145,,3EM 37,BAO_0000218
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615646,,10090.0,396,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,7145,,3EM 37,BAO_0000218
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615647,,10090.0,397,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,7145,,3EM 37,BAO_0000218
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615648,,10090.0,398,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,7145,,3EM 37,BAO_0000218
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615649,,10090.0,399,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,7145,,3EM 37,BAO_0000218
833.0,,Mus musculus,Intermediate,1,80619,F,N,,,,1,CHEMBL615650,,10090.0,400,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,7145,,3EM 37,BAO_0000218
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615651,,10090.0,401,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,5325,,3LL cell line,BAO_0000218
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615652,,10090.0,402,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,5325,,3LL cell line,BAO_0000218
847.0,,Mus musculus,Expert,1,80620,F,N,,,,1,CHEMBL615653,,10090.0,403,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,5325,,3LL cell line,BAO_0000218
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615654,,10090.0,404,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615655,,10090.0,405,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL825024,,10090.0,406,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615656,,10090.0,407,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615657,,10090.0,408,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615658,,10090.0,409,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615659,,10090.0,410,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615660,,10090.0,411,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615661,,10090.0,412,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615662,,10090.0,413,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615663,,10090.0,414,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615664,,10090.0,415,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615665,,10090.0,416,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615666,,10090.0,417,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615667,,10090.0,418,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615668,,10090.0,419,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615669,,10090.0,420,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615670,,10090.0,421,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL836739,,10090.0,422,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615671,,10090.0,423,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615672,,10090.0,424,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615791,,10090.0,425,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615792,,10090.0,426,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615793,,10090.0,427,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615794,,10090.0,428,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,16169,,3LL cell line,BAO_0000219
847.0,,Mus musculus,Intermediate,1,80620,F,N,,,,1,CHEMBL615795,,10090.0,429,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,16169,,3LL cell line,BAO_0000219
971.0,,Homo sapiens,Intermediate,1,80621,F,N,,,,1,CHEMBL615590,,9606.0,430,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,15547,,3LLD122,BAO_0000219
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615591,,,431,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,8663,,,BAO_0000218
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615592,,,432,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,8663,,,BAO_0000218
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615593,,,433,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,8663,,,BAO_0000218
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL615594,,,434,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,8663,,,BAO_0000218
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615595,,10090.0,435,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,4504,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615596,,10090.0,436,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,4504,,NIH3T3,BAO_0000219
723.0,,,Expert,1,11169,F,H,,,,8,CHEMBL615597,,,437,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,12695,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615598,,10090.0,438,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,12695,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615599,,10090.0,439,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,12695,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615600,,10090.0,440,,Effective dose against murine 3T3 fibroblasts cells,,17642,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615601,,10090.0,441,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,17642,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615602,,10090.0,442,,Cytotoxic effect on 3T3 cells,,12340,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615603,,10090.0,443,,Cytotoxic effect on 3T3 cells,,12340,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615604,,10090.0,444,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,12716,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615605,,10090.0,445,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615606,,10090.0,446,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL884526,,10090.0,447,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615607,,10090.0,448,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615608,,10090.0,449,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615609,,10090.0,450,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615682,,10090.0,451,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615683,,10090.0,452,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615684,,10090.0,453,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,17780,,NIH3T3,BAO_0000218
,,Mus musculus,Autocuration,1,104860,F,D,,,,7,CHEMBL615685,,10090.0,454,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,12751,,,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615686,,10090.0,455,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,12380,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615687,,10090.0,456,,Inhibitory activity against 3T3 cell line,,14892,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL884523,,10090.0,457,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,12695,,NIH3T3,BAO_0000219
,,,Expert,1,11169,F,H,,,,8,CHEMBL615688,,,458,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,12695,,,BAO_0000019
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615689,,10090.0,459,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,12695,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615690,,10090.0,460,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,12695,,NIH3T3,BAO_0000219
,,,Expert,1,11169,F,H,,,,8,CHEMBL615691,,,461,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,12695,,,BAO_0000019
,,,Expert,1,11169,F,H,,,,8,CHEMBL615692,,,462,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,12695,,,BAO_0000019
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615693,,10090.0,463,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,6277,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615324,,10090.0,464,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,6277,,NIH3T3,BAO_0000219
723.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL615325,,9606.0,465,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,4959,,NIH3T3,BAO_0000219
723.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL615490,,9606.0,466,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,4959,,NIH3T3,BAO_0000219
723.0,,Homo sapiens,Expert,1,188,F,D,,,,9,CHEMBL615491,,9606.0,467,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,4959,,NIH3T3,BAO_0000219
723.0,,Homo sapiens,Expert,1,188,F,D,,,,9,CHEMBL615492,,9606.0,468,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,4959,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615493,,10090.0,469,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,12082,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615494,,10090.0,470,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,12082,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615495,,10090.0,471,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,12082,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615496,,10090.0,472,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,12082,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615497,,10090.0,473,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,2643,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615498,,10090.0,474,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,11926,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,A,N,,,,1,CHEMBL615499,,10090.0,475,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,15204,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL835522,,10090.0,476,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,15992,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615500,,10090.0,477,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615501,,10090.0,478,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615502,,10090.0,479,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615503,,10090.0,480,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615504,,10090.0,481,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615505,,10090.0,482,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,16279,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Expert,1,80951,F,N,,,,1,CHEMBL615506,,10090.0,483,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,12831,,NIH3T3,BAO_0000219
723.0,,Mus musculus,Intermediate,1,80951,F,N,,,,1,CHEMBL615507,,10090.0,484,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,13497,,NIH3T3,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615508,,,485,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615509,,10090.0,486,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,13618,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615510,,10090.0,487,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,11902,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615511,,10090.0,488,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,11902,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615512,,10090.0,489,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,11902,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615513,,10090.0,490,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,14840,,3T3-L1,BAO_0000218
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615514,,10090.0,491,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,14840,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615515,,,492,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615516,,,493,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615517,,,494,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615518,,,495,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615519,,,496,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615520,,,497,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615521,,,498,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615522,,,499,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615523,,,500,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,80006,F,N,,,,1,CHEMBL615524,,,501,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,80006,F,N,,,,1,CHEMBL615525,,,502,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615526,,,503,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615527,,,504,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615528,,,505,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,80006,F,N,,,,1,CHEMBL615529,,,506,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,80006,F,N,,,,1,CHEMBL615530,,,507,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,80006,F,N,,,,1,CHEMBL615531,,,508,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615532,,,509,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615533,,,510,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615534,,,511,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,13715,,3T3-L1,BAO_0000219
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615535,,,512,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615536,,,513,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615537,,,514,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL615538,,,515,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Intermediate,1,80006,F,N,,,,1,CHEMBL836166,,,516,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,13715,,3T3-L1,BAO_0000218
620.0,,,Expert,1,11214,F,H,,,,8,CHEMBL615539,,,517,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,6411,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615540,,10090.0,518,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,6411,,3T3-L1,BAO_0000219
620.0,,,Expert,1,11214,F,H,,,,8,CHEMBL615541,,,519,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,6411,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615542,,10090.0,520,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,3966,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Intermediate,1,80006,F,N,,,,1,CHEMBL615543,,10090.0,521,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,3966,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615544,,10090.0,522,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,15556,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615545,,10090.0,523,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,5845,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615546,,10090.0,524,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,14422,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615547,,10090.0,525,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,5845,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615548,,10090.0,526,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,14508,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615549,,10090.0,527,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,14508,,3T3-L1,BAO_0000219
620.0,,Mus musculus,Expert,1,80006,F,N,,,,1,CHEMBL615550,,10090.0,528,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,14508,,3T3-L1,BAO_0000219
1118.0,,Rattus norvegicus,Intermediate,1,80622,F,N,,,,1,CHEMBL615551,,10116.0,529,,Inhibitory activity against rat fibroblast (3Y1) cell line,,6349,,3Y1 cell line,BAO_0000219
1118.0,,Rattus norvegicus,Expert,1,80622,F,N,,,,1,CHEMBL615552,,10116.0,530,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,15899,,3Y1 cell line,BAO_0000219
1118.0,,Rattus norvegicus,Expert,1,80622,F,N,,,,1,CHEMBL615553,,10116.0,531,,Cytotoxicity in 3Y1 cells.,,15899,,3Y1 cell line,BAO_0000219
1118.0,,Rattus norvegicus,Expert,1,80622,F,N,,,,1,CHEMBL615554,,10116.0,532,,Cytostatic effect in 3Y1 cells.,,15899,,3Y1 cell line,BAO_0000219
1118.0,,Rattus norvegicus,Intermediate,1,80622,F,N,,,,1,CHEMBL615555,,10116.0,533,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,15899,,3Y1 cell line,BAO_0000219
1118.0,,Rattus norvegicus,Expert,1,80622,F,N,,,,1,CHEMBL615556,,10116.0,534,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,17038,,3Y1 cell line,BAO_0000219
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615557,,,535,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,12421,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615558,,,536,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,12947,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL872066,,,537,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,12947,,,BAO_0000019
,,Sus scrofa,Expert,1,11607,B,D,,,,9,CHEMBL615559,,9823.0,538,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,4896,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615560,,,539,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,6148,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615561,,,540,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,16432,,,BAO_0000019
,,,Expert,1,11607,B,H,,,,8,CHEMBL857062,,,541,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,4978,,,BAO_0000019
,,,Expert,1,11607,B,H,,,,8,CHEMBL615562,,,542,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,4978,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615563,,,543,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,3723,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615564,,,544,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,3518,,,BAO_0000357
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615565,,,545,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,4164,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615566,,,546,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,3518,,,BAO_0000019
,,Sus scrofa,Expert,1,11607,B,D,,,,9,CHEMBL615567,,9823.0,547,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,4164,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615568,,,548,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,3518,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615569,,,549,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,3518,,,BAO_0000357
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615570,,,550,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,4978,,,BAO_0000019
,,,Autocuration,1,11607,B,H,,,,8,CHEMBL615571,,,551,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,4978,,,BAO_0000019
,,,Autocuration,1,104733,B,H,,,,4,CHEMBL615572,,,552,,Binding affinity against melatonin (MT1) receptor (pC1),,6455,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615573,,,553,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,2222,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615574,,,554,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,13020,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615575,,,555,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,13021,,,BAO_0000019
,,,Autocuration,1,10619,B,H,,,,8,CHEMBL615576,,,556,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,14532,,,BAO_0000357
,,,Autocuration,1,10619,B,H,,,,8,CHEMBL615577,,,557,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,14118,,,BAO_0000357
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615578,,,558,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,11884,,,BAO_0000221
,,,Expert,1,51,B,H,,,,8,CHEMBL615579,,,559,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,13969,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615580,,,560,,Binding affinity for 5-hydroxytryptamine 1A receptor,,13392,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615581,,,561,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,14430,,,BAO_0000019
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615582,,,562,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12248,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615583,,,563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615584,,,564,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL833691,,,565,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615585,,,566,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615586,,,567,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL884524,,,568,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615587,,,569,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615588,,,570,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,11799,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615589,,10116.0,571,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Membranes,14331,,,BAO_0000249
,Hippocampus,Bos taurus,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615442,,9913.0,572,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,11884,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615443,,,573,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,14331,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615444,,,574,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,11701,,,BAO_0000221
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615445,,,575,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,11701,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615446,,,576,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,12248,,,BAO_0000221
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615447,,,577,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,12248,,CHO,BAO_0000219
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615448,,,578,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12248,,,BAO_0000221
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615449,,,579,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,12249,,,BAO_0000221
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615450,,,580,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12248,,CHO,BAO_0000219
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615451,,,581,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,11799,,,BAO_0000221
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615452,,,582,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,634,,,BAO_0000357
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615453,,,583,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615454,,,584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615455,,,585,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615456,,,586,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL615457,,,587,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,9995,,,BAO_0000221
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615458,,,588,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,12210,,,BAO_0000218
,Hippocampus,,Expert,1,51,B,H,,,10000000.0,8,CHEMBL615459,,,589,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,13311,,,BAO_0000221
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615460,,9606.0,590,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,2331,,CHO,BAO_0000219
,,Cavia porcellus,Autocuration,1,51,F,H,,,,8,CHEMBL615461,,10141.0,591,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,1375,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,51,F,H,,,,8,CHEMBL615462,,10141.0,592,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,1375,,,BAO_0000019
,Hippocampus,Cavia porcellus,Autocuration,1,51,F,H,,,10000000.0,8,CHEMBL615463,,10141.0,593,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,11574,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615464,,10141.0,594,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,12867,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615465,,10141.0,595,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615466,,10141.0,596,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,12867,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615467,,10141.0,597,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615468,,10141.0,598,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,12867,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,51,B,H,,,2116.0,8,CHEMBL615469,,10141.0,599,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,12867,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,51,B,H,,,,8,CHEMBL615470,,10141.0,600,,Binding affinity against 5-hydroxytryptamine 1A receptor,,11574,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,51,B,H,,,,8,CHEMBL615471,,10141.0,601,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,13114,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,51,B,H,,,,8,CHEMBL615472,,10141.0,602,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,13181,,,BAO_0000357
,Hippocampus,Cavia porcellus,Autocuration,1,106,B,H,,,10000000.0,8,CHEMBL883242,,10141.0,603,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10639,,,BAO_0000221
,Hippocampus,Cavia porcellus,Autocuration,1,106,F,H,,,10000000.0,8,CHEMBL615473,,10141.0,604,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,10639,,,BAO_0000221
449.0,,Cricetulus griseus,Autocuration,1,11863,B,H,,,,8,CHEMBL615474,,10029.0,605,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,11883,,CHO,BAO_0000218
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615475,,,606,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,17785,,,BAO_0000357
308.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615476,,,607,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,1558,,HeLa,BAO_0000219
308.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615477,,,608,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,1558,,HeLa,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615478,,,609,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,15740,,,BAO_0000019
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615160,,,610,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,17624,,CHO,BAO_0000219
449.0,,,Expert,1,51,F,H,,,,8,CHEMBL615161,,,611,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615162,,,612,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615163,,,613,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,17624,,CHO,BAO_0000219
449.0,,,Expert,1,51,B,H,,,,8,CHEMBL615164,,,614,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Expert,1,51,B,H,,,,8,CHEMBL615165,,,615,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615166,,,616,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,17624,,CHO,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615167,,,617,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,14256,,,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615168,,9606.0,618,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,3445,,HeLa,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615169,,9606.0,619,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,3445,,HeLa,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615170,,9606.0,620,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,17200,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615171,,9606.0,621,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,17200,,CHO,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615694,,,622,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,15180,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615695,,,623,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,15180,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615696,,,624,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,,BAO_0000019
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615697,,,625,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL859410,,9606.0,626,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615841,,,627,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,2759,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615842,,9606.0,628,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL835003,,,629,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615843,,,630,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,2759,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615979,,9606.0,631,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615980,,,632,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,2759,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615981,,9606.0,633,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,2759,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615982,,9606.0,634,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,3445,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615983,,9606.0,635,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615984,,9606.0,636,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615985,,9606.0,637,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,5272,,,BAO_0000019
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615986,,,638,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615987,,,639,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615988,,,640,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,17624,,CHO,BAO_0000219
449.0,,,Expert,1,51,F,H,,,,8,CHEMBL615989,,,641,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615990,,,642,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615991,,,643,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615992,,,644,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615993,,,645,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,17624,,CHO,BAO_0000219
449.0,,,Expert,1,51,F,H,,,,8,CHEMBL615994,,,646,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615995,,,647,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615996,,,648,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615997,,,649,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,17624,,CHO,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615998,,,650,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615999,,,651,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616000,,,652,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,6563,,,BAO_0000019
722.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616001,,,653,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,HEK293,BAO_0000219
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616002,,9606.0,654,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,6876,,,BAO_0000019
,,,Expert,1,51,F,H,,,,8,CHEMBL616003,,,655,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,6876,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616004,,9606.0,656,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616005,,9606.0,657,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,5272,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616006,,,658,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,,BAO_0000019
,,,Expert,1,51,F,H,,,,8,CHEMBL616007,,,659,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,5548,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616008,,,660,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616009,,,661,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,5548,,,BAO_0000019
,,,Expert,1,51,F,H,,,,8,CHEMBL616010,,,662,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,5929,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616011,,9606.0,663,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,5929,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL615740,,9606.0,664,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,5929,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615741,,,665,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,16245,,,BAO_0000019
,,,Expert,1,51,F,H,,,,8,CHEMBL615742,,,666,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,5640,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615743,,,667,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,5640,,,BAO_0000019
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615744,,,668,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,14509,,CHO,BAO_0000219
449.0,,,Expert,1,51,F,H,,,,8,CHEMBL615745,,,669,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,14509,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615746,,,670,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615747,,,671,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615748,,,672,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615749,,,673,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,6563,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615750,,,674,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,6563,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616259,,9606.0,675,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,6563,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616260,,,676,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616261,,9606.0,677,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616262,,9606.0,678,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616263,,9606.0,679,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616264,,9606.0,680,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616265,,9606.0,681,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616266,,9606.0,682,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616267,,9606.0,683,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616268,,9606.0,684,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,5272,,,BAO_0000019
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616269,,9606.0,685,,Inhibition of human 5-hydroxytryptamine 1A receptor,,16146,,,BAO_0000357
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL884528,,,686,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
722.0,,,Expert,1,105,B,D,,,,9,CHEMBL616270,,,687,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,13706,,HEK293,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616271,,,688,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616272,,,689,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,CHO,BAO_0000219
,,,Expert,1,51,B,H,,,,8,CHEMBL616273,,,690,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,6861,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616274,,9606.0,691,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,17200,,,BAO_0000357
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616275,,,692,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616276,,,693,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616277,,10116.0,694,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616278,,10116.0,695,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616279,,10116.0,696,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616280,,10116.0,697,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616281,,10116.0,698,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616282,,10116.0,699,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616283,,10116.0,700,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616284,,10116.0,701,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616285,,10116.0,702,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616286,,10116.0,703,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616287,,10116.0,704,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616288,,10116.0,705,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL616289,,10116.0,706,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615610,,10116.0,707,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615611,,10116.0,708,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615612,,10116.0,709,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615613,,10116.0,710,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615614,,10116.0,711,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,12058,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL615615,,10116.0,712,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,12058,,,BAO_0000218
,,,Autocuration,1,105093,B,H,,,,4,CHEMBL615616,,,713,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,11440,,,BAO_0000019
,Hypothalamus,,Autocuration,1,11923,B,H,,,1898.0,8,CHEMBL615617,,,714,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,6238,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL615618,,,715,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,10046,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL615619,,,716,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,10046,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL615620,,,717,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10046,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL615621,,,718,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,167,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL615622,,,719,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,167,,,BAO_0000357
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL615623,,,720,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,11520,,,BAO_0000019
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL615624,,,721,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,,BAO_0000019
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL615625,,,722,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,,BAO_0000019
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL767045,,,723,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,11520,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,F,H,,,,8,CHEMBL615626,,10141.0,724,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,135,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,F,H,,,,8,CHEMBL615627,,10141.0,725,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,135,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL615628,,10141.0,726,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,11311,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL615629,,10141.0,727,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10193,,,BAO_0000357
,,Homo sapiens,Expert,1,55,B,D,,,,9,CHEMBL615630,,9606.0,728,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,12281,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL615631,,,729,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Autocuration,1,17087,F,H,,,,8,CHEMBL615632,,,730,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,12576,,,BAO_0000218
,,,Autocuration,1,17087,B,H,,,,8,CHEMBL615633,,,731,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,12281,,,BAO_0000357
,,,Autocuration,1,17087,F,H,,,,8,CHEMBL615634,,,732,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,12576,,,BAO_0000218
,,Sus scrofa,Expert,1,55,B,H,,,,8,CHEMBL615635,,9823.0,733,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,11089,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL615636,,,734,,In vitro inhibition of rat 5-Lipoxygenase,,11006,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL615637,,10116.0,735,,Inhibitory activity against 5-Lipoxygenase,,11481,,,BAO_0000357
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL615638,,,736,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,10864,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615639,,,737,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615640,,,738,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,11311,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615796,,,739,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,11311,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615845,,,740,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615846,,,741,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,11006,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615847,,,742,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,3595,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615848,,,743,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,11311,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615849,,10116.0,744,,Ratio of IC50 against 5-LO and COX,,11481,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615850,,,745,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,11006,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615851,,,746,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,11006,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL615852,,,747,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,11311,,,BAO_0000219
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL615853,,,748,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,11006,,,BAO_0000019
,Prostate gland,,Autocuration,1,120,B,H,,,2367.0,8,CHEMBL884527,,,749,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,4288,,,BAO_0000357
,,Columba livia,Autocuration,1,22226,B,U,,,,0,CHEMBL872871,,8932.0,750,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,7587,,,BAO_0000019
,,Columba livia,Autocuration,1,22226,B,U,,,,0,CHEMBL615854,,8932.0,751,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,7587,,,BAO_0000019
,,Columba livia,Autocuration,1,22226,B,U,,,,0,CHEMBL767046,,8932.0,752,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,7587,,,BAO_0000019
,,,Autocuration,1,10732,B,H,,,,8,CHEMBL615855,,,753,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,11249,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12198,F,D,,,,9,CHEMBL615856,,10116.0,754,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,8003,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12198,F,D,,,,9,CHEMBL615857,,10116.0,755,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,8003,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12198,F,D,,,,9,CHEMBL615858,,10116.0,756,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,8003,,,BAO_0000019
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615859,,,757,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,12416,,,BAO_0000221
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615860,,,758,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,16293,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,22226,B,U,,,,0,CHEMBL615861,,9986.0,759,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,22226,B,U,,,,0,CHEMBL615862,,9986.0,760,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,22226,B,U,,,,0,CHEMBL615863,,9986.0,761,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,22226,B,U,,,,0,CHEMBL615864,,9986.0,762,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,Hippocampus,,Autocuration,1,104744,B,H,,,10000000.0,4,CHEMBL615865,,,763,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,,,BAO_0000221
,Hippocampus,,Autocuration,1,104744,B,H,,,10000000.0,4,CHEMBL615866,,,764,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,,,BAO_0000221
,Hippocampus,,Autocuration,1,104744,B,H,,,10000000.0,4,CHEMBL615867,,,765,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,10085,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615868,,,766,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Membranes,9841,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615869,,10116.0,767,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,8822,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615870,,10116.0,768,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,9806,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615871,,10116.0,769,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,9806,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615872,,,770,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,8868,,,BAO_0000224
,Hippocampus,,Autocuration,1,104744,B,H,,,10000000.0,4,CHEMBL833492,,,771,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,9036,,,BAO_0000221
,Hippocampus,,Autocuration,1,104744,B,H,,,10000000.0,4,CHEMBL615873,,,772,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,11374,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615479,,,773,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,10881,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615480,,,774,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,8822,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615481,,10116.0,775,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,9806,,,BAO_0000249
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL872869,,,776,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,15463,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615482,,,777,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,15463,,,BAO_0000019
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615483,,,778,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,,,BAO_0000221
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615484,,,779,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615485,,,780,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,8569,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615486,,10116.0,781,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615487,,,782,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,4771,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615488,,,783,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615489,,,784,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615389,,,785,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615390,,,786,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,15463,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615391,,,787,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,15463,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615392,,,788,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,9098,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615393,,10116.0,789,,Affinity for 5-hydroxytryptamine 1 receptor,,3070,,,BAO_0000019
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615394,,,790,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,14542,,,BAO_0000221
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615395,,,791,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,14542,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615396,,,792,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,6398,,,BAO_0000224
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615397,,,793,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,1344,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615398,,,794,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,11963,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615399,,10116.0,795,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,8908,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615400,,,796,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,9098,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104744,B,D,,,,5,CHEMBL615401,,10116.0,797,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,8841,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL615402,,10116.0,798,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,8814,,,BAO_0000019
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615403,,,799,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,11752,,,BAO_0000019
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615404,,,800,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,11642,,,BAO_0000221
,,,Autocuration,1,104744,B,H,,,,4,CHEMBL615781,,,801,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,11642,,,BAO_0000019
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615782,,,802,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,9231,,,BAO_0000220
,Brain,,Autocuration,1,104744,B,H,,,955.0,4,CHEMBL615783,,,803,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,11351,,,BAO_0000221
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL873481,,,804,,Compound was tested for binding affinity against 5-HT1 receptor,,4639,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL615784,,,805,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,1205,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615785,,,806,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10025,,,BAO_0000357
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL615786,,,807,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,13241,,,BAO_0000249
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615787,,,808,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,16245,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615788,,,809,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,16245,,,BAO_0000218
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL767044,,,810,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,12438,,,BAO_0000019
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615789,,,811,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,16245,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615790,,,812,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,16245,,,BAO_0000218
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL615813,,,813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,15740,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL615814,,,814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,15535,,,BAO_0000219
,,,Expert,1,51,F,H,,,,8,CHEMBL615815,,,815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,15535,,,BAO_0000219
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL615816,,,816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,15535,,,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL615817,,,817,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,9888,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615818,,,818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,10085,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615819,,,819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,10085,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615820,,,820,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Membranes,17331,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615821,,10116.0,821,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,10845,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615822,,10116.0,822,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10845,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615823,,,823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,10845,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615824,,10116.0,824,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,10845,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615825,,10116.0,825,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,10845,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615826,,,826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,13730,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615827,,,827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,13508,,,BAO_0000249
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615828,,,828,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,13508,,,BAO_0000249
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615829,,,829,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615830,,,830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,4671,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615831,,,831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,13631,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615832,,,832,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,12438,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615833,,,833,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,10483,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615834,,,834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,10483,,,BAO_0000221
,,,Intermediate,1,10576,B,H,,,,8,CHEMBL615835,,,835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,12352,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615836,,,836,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,14732,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615837,,10116.0,837,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,11049,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615838,,10116.0,838,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,11049,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615839,,,839,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,13657,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL884525,,,840,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,11473,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615840,,,841,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,2014,,,BAO_0000249
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615405,,,842,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,3086,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615406,,,843,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,,BAO_0000019
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615900,,,844,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10922,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615901,,,845,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,13346,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615902,,,846,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,15311,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615903,,,847,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,10922,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615904,,,848,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,10025,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615905,,,849,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,10025,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615906,,,850,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL615907,,,851,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615908,,,852,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,12304,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615909,,,853,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,15789,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615910,,,854,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,9912,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615911,,,855,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,9912,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615912,,,856,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,9912,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615913,,,857,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,16693,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615914,,,858,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,13276,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615915,,,859,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,12678,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615916,,,860,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,11825,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615917,,,861,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,12443,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615918,,,862,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,13830,,,BAO_0000357
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615919,,,863,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,14286,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615920,,10116.0,864,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,14356,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615921,,,865,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,15306,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615922,,,866,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,15306,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL881290,,10116.0,867,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,16616,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615923,,,868,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,3651,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,F,H,,,10000000.0,8,CHEMBL615924,,,869,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,14331,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,F,H,,,10000000.0,8,CHEMBL615925,,,870,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,14331,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615926,,10116.0,871,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,14178,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615927,,10116.0,872,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,10639,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615928,,,873,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615929,,10116.0,874,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,1348,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615930,,,875,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,13605,,,BAO_0000221
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615931,,,876,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615932,,,877,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615933,,,878,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,17624,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615934,,,879,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,15267,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615935,,,880,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,16532,,,BAO_0000357
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615936,,,881,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,6563,,,BAO_0000019
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615937,,,882,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,4751,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615938,,,883,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,15463,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615797,,,884,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615798,,,885,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5640,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL872870,,,886,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,6563,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615799,,,887,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,5548,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615800,,,888,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,6347,,,BAO_0000357
722.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL615801,,,889,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,HEK293,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615802,,,890,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,13047,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615803,,,891,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,15740,,,BAO_0000357
,,,Expert,1,51,F,H,,,,8,CHEMBL835002,,,892,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,5640,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL615804,,,893,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,5640,,,BAO_0000019
308.0,,,Expert,1,51,B,H,,,,8,CHEMBL615805,,,894,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,17211,,HeLa,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615806,,,895,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,4751,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615807,,9606.0,896,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,6491,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615808,,,897,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,4707,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615809,,9606.0,898,,Binding affinity against 5-hydroxytryptamine 1A receptor,,13910,,,BAO_0000357
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615810,,,899,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,16190,,HeLa,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615811,,,900,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16633,,,BAO_0000357
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615812,,,901,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,11898,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615751,,,902,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,11898,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615752,,,903,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,14331,,,BAO_0000357
449.0,,,Expert,1,51,B,H,,,,8,CHEMBL615753,,,904,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,17624,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615754,,,905,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,17624,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615755,,,906,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,3307,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615756,,9606.0,907,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,6563,,CHO,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615757,,,908,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,14165,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615758,,,909,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,5732,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615759,,,910,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,13366,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615760,,,911,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,17626,,,BAO_0000357
308.0,,,Expert,1,51,B,H,,,,8,CHEMBL615761,,,912,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,6588,,HeLa,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL872104,,,913,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615762,,,914,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,15463,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615763,,,915,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,15463,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615764,,,916,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,14770,,,BAO_0000357
1167.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL615765,,,917,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,16245,,Cell line,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615766,,,918,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,16245,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615767,,,919,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615768,,,920,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615769,,,921,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,5548,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615770,,,922,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,6876,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615771,,,923,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,2598,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615772,,,924,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,17785,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615773,,,925,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,6013,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615774,,,926,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,5929,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615775,,,927,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16633,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615776,,,928,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,1558,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL615777,,,929,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,16026,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615778,,,930,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,12469,,,BAO_0000219
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615779,,9606.0,931,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL615780,,,932,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616298,,,933,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,3935,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616299,,,934,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,15818,,,BAO_0000357
485.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616300,,,935,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
485.0,,,Expert,1,51,F,H,,,,8,CHEMBL616301,,,936,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,13729,,CHO-K1,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616302,,,937,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,15413,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616117,,,938,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,15413,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616118,,,939,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,15413,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616119,,,940,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,15413,,,BAO_0000019
308.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616120,,9606.0,941,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,3445,,HeLa,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616121,,,942,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,15740,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616122,,,943,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,15740,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616123,,,944,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,17626,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616124,,9606.0,945,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,4234,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL616125,,,946,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,5640,,,BAO_0000357
,,Rattus norvegicus,Expert,1,51,B,H,,,,8,CHEMBL616126,,10116.0,947,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,5272,,,BAO_0000357
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616127,,,948,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,4622,,CHO,BAO_0000219
,,,Expert,1,51,B,H,,,,8,CHEMBL616128,,,949,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,17085,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616129,,,950,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,3025,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL616130,,,951,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,15315,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616131,,,952,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,15267,,,BAO_0000357
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616132,,,953,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,17158,,HeLa,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616133,,9606.0,954,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,14214,,HeLa,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616134,,,955,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,17133,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616135,,,956,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,16532,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616136,,9606.0,957,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,2391,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616137,,,958,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,14447,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL872105,,,959,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,14447,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616138,,,960,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,15086,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616139,,9606.0,961,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,13051,,,BAO_0000357
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616140,,,962,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,16026,,,BAO_0000019
,,,Expert,1,51,B,H,,,,8,CHEMBL616141,,,963,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,17085,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616142,,,964,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,17133,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616143,,,965,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,17133,,,BAO_0000357
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616144,,,966,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616145,,,967,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616012,,,968,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616013,,,969,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,17211,,HeLa,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616014,,,970,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616015,,,971,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616016,,,972,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,16394,,,BAO_0000019
,,,Autocuration,1,51,F,H,In vivo,,,8,CHEMBL616017,,,973,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,16394,,,BAO_0000218
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616018,,,974,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,16394,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616019,,,975,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,15740,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616020,,,976,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,15740,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL858018,,,977,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,15740,,,BAO_0000357
722.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616021,,,978,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,HEK293,BAO_0000219
,,,Expert,1,51,F,H,,,,8,CHEMBL616022,,,979,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,5640,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616023,,,980,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,5640,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616024,,,981,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,5640,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616025,,,982,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,5640,,,BAO_0000019
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616026,,,983,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,2759,,CHO,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616027,,,984,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,16394,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616028,,9606.0,985,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,16394,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616029,,9606.0,986,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,3445,,,BAO_0000019
449.0,,,Expert,1,51,B,H,,,,8,CHEMBL616030,,,987,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,4316,,CHO,BAO_0000219
,,,Expert,1,51,B,H,,,,8,CHEMBL616031,,,988,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,4316,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616032,,9606.0,989,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,15180,,,BAO_0000019
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616033,,9606.0,990,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,15180,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616034,,,991,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616035,,,992,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616036,,,993,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616037,,,994,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616038,,,995,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616039,,,996,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,15042,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616040,,,997,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,15042,,,BAO_0000019
308.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616041,,9606.0,998,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,HeLa,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616042,,9606.0,999,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,HeLa,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616043,,9606.0,1000,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,15180,,HeLa,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616044,,,1001,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,16245,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616045,,,1002,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,,BAO_0000019
722.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616046,,,1003,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,17296,,HEK293,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616047,,,1004,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616048,,,1005,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,2759,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL616049,,9606.0,1006,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,2759,,CHO,BAO_0000219
449.0,,,Autocuration,1,51,F,H,,,,8,CHEMBL616050,,,1007,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,2759,,CHO,BAO_0000219
,,,Expert,1,51,F,H,,,,8,CHEMBL616051,,,1008,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,15419,,,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616212,,,1009,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,15419,,,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616213,,,1010,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,16026,,,BAO_0000019
,,,Expert,1,51,B,H,In vitro,,,8,CHEMBL616214,,,1011,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,1414,,,BAO_0000219
,,,Expert,1,51,B,H,In vitro,,,8,CHEMBL616215,,,1012,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,1414,,,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616216,,,1013,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616217,,,1014,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616218,,,1015,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,5104,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616219,,,1016,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,5105,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616220,,,1017,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,16312,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL833493,,9606.0,1018,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,15180,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616221,,,1019,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,5033,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616222,,9606.0,1020,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,16909,,CHO,BAO_0000219
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616223,,,1021,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,2590,,,BAO_0000019
,,,Autocuration,1,51,F,H,,,,8,CHEMBL616224,,,1022,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,2590,,,BAO_0000019
,,,Expert,1,51,B,H,,,,8,CHEMBL616225,,,1023,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,16394,,,BAO_0000019
722.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616226,,9606.0,1024,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,4540,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616227,,,1025,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616228,,,1026,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616229,,,1027,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616230,,,1028,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616231,,,1029,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,15779,,HEK293,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616232,,,1030,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,6166,,,BAO_0000357
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616233,,,1031,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL857973,,,1032,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,4199,,HEK293,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616234,,,1033,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,15316,,,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616235,,,1034,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,14875,,,BAO_0000357
308.0,,,Expert,1,51,B,H,,,,8,CHEMBL616236,,,1035,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,14727,,HeLa,BAO_0000219
,,,Expert,1,51,B,H,,,,8,CHEMBL616237,,,1036,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,14727,,,BAO_0000019
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616238,,,1037,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,15146,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616239,,,1038,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,5213,,HEK293,BAO_0000219
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616240,,,1039,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,16429,,,BAO_0000219
308.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616241,,9606.0,1040,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,15042,,HeLa,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616242,,,1041,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616243,,,1042,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,4829,,HEK293,BAO_0000219
,,,Expert,1,51,B,D,,,,9,CHEMBL616244,,,1043,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,17200,,,BAO_0000357
,,Homo sapiens,Autocuration,1,51,B,D,,,,9,CHEMBL616245,,9606.0,1044,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,13051,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616246,,,1045,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,5486,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616247,,,1046,,Binding affinity against 5-HT1D receptor,,5254,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616248,,,1047,,Binding affinity against 5-hydroxytryptamine 1A receptor,,5254,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL616249,,,1048,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
,,Homo sapiens,Autocuration,1,10576,B,H,,,,8,CHEMBL616250,,9606.0,1049,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,13506,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616251,,,1050,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,15267,,,BAO_0000357
,,,Autocuration,1,11863,F,H,In vivo,,,8,CHEMBL616252,,,1051,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,16616,,,BAO_0000218
,,,Autocuration,1,11863,F,H,In vivo,,,8,CHEMBL616253,,,1052,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,16616,,,BAO_0000218
,,,Autocuration,1,11863,F,H,In vivo,,,8,CHEMBL616254,,,1053,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL616255,,10090.0,1054,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL832872,,10090.0,1055,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL616256,,10090.0,1056,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL616257,,10090.0,1057,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL616258,,10090.0,1058,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,16616,,,BAO_0000218
,,Mus musculus,Expert,1,11863,F,D,,,,9,CHEMBL616384,,10090.0,1059,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,16616,,,BAO_0000218
,Hippocampus,,Autocuration,1,11863,B,H,,,10000000.0,8,CHEMBL616385,,,1060,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,10297,,,BAO_0000221
,,,Expert,1,11863,B,H,,,,8,CHEMBL616386,,,1061,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,13704,,,BAO_0000357
,Hippocampus,Mus musculus,Expert,1,11863,B,D,,,10000000.0,9,CHEMBL616387,,10090.0,1062,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10297,,,BAO_0000221
,Hippocampus,,Autocuration,1,11863,B,H,,,10000000.0,8,CHEMBL616388,,,1063,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,10297,,,BAO_0000221
,Hippocampus,Mus musculus,Expert,1,11863,B,D,,,10000000.0,9,CHEMBL616389,,10090.0,1064,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,10297,,,BAO_0000221
,Hippocampus,,Autocuration,1,11863,B,H,,,10000000.0,8,CHEMBL616390,,,1065,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,10297,,,BAO_0000221
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616391,,,1066,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,217,,,BAO_0000357
,Hippocampus,Mus musculus,Expert,1,11863,B,D,,,10000000.0,9,CHEMBL616392,,10090.0,1067,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,10297,,,BAO_0000221
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616393,,9823.0,1068,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,4921,,,BAO_0000357
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616394,,9823.0,1069,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,4921,,,BAO_0000357
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616395,,9823.0,1070,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,4996,,,BAO_0000019
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616396,,9823.0,1071,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,12918,,,BAO_0000357
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL872907,,9823.0,1072,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,5333,,,BAO_0000019
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616397,,9823.0,1073,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,4437,,,BAO_0000019
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616398,,9823.0,1074,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,1742,,,BAO_0000019
,,Sus scrofa,Expert,1,51,B,H,,,,8,CHEMBL616399,,9823.0,1075,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,16688,,,BAO_0000357
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL857065,,9823.0,1076,,Binding activity radioligand.,,12861,,,BAO_0000357
,,Sus scrofa,Expert,1,51,B,H,,,,8,CHEMBL616400,,9823.0,1077,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,12861,,,BAO_0000019
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616401,,9823.0,1078,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,12861,,,BAO_0000019
,,,Expert,1,10624,B,H,,,,8,CHEMBL616402,,,1079,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,12490,,,BAO_0000019
,,Sus scrofa,Expert,1,51,B,H,,,,8,CHEMBL616403,,9823.0,1080,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,11828,,,BAO_0000019
,Hippocampus,Sus scrofa,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL616404,,9823.0,1081,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,11866,,,BAO_0000221
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616405,,9823.0,1082,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,12827,,,BAO_0000249
,,Sus scrofa,Autocuration,1,51,B,H,,,,8,CHEMBL616406,,9823.0,1083,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,12918,,,BAO_0000019
,,Sus scrofa,Expert,1,51,F,H,,,,8,CHEMBL616407,,9823.0,1084,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,12919,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,51,B,H,,,,8,CHEMBL616408,,9986.0,1085,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,13047,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616409,,10116.0,1086,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,15796,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616410,,10116.0,1087,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,3651,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616411,,,1088,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,188,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL616412,,10116.0,1089,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,16616,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,F,D,,,10000000.0,9,CHEMBL616413,,10116.0,1090,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,16616,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616414,,,1091,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616415,,10116.0,1092,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,17167,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616416,,,1093,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,14776,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616417,,,1094,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,12158,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616418,,,1095,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,13481,,,BAO_0000357
,,,Autocuration,1,10576,B,H,In vitro,,,8,CHEMBL616419,,,1096,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,13427,,,BAO_0000219
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616420,,,1097,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,10210,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616421,,,1098,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,10205,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616422,,,1099,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,10205,,,BAO_0000249
,,,Expert,1,10576,B,H,,,,8,CHEMBL616423,,,1100,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Membranes,10205,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616424,,10116.0,1101,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,12280,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616425,,,1102,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,17386,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616426,,,1103,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,13654,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616427,,,1104,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,14423,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616428,,,1105,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,15412,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616290,,,1106,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616052,,10116.0,1107,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,4101,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616053,,,1108,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,10062,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616054,,,1109,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,6238,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616055,,,1110,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,16273,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616056,,,1111,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,11139,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616057,,,1112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,16796,,,BAO_0000019
,Brain,Rattus norvegicus,Expert,1,10576,B,D,,,955.0,9,CHEMBL616058,,10116.0,1113,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,9548,,,BAO_0000221
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616059,,,1114,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,10381,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616060,,,1115,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,13408,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616061,,10116.0,1116,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,13825,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616062,,,1117,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,11147,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616063,,,1118,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,10552,,,BAO_0000249
,Striatum,,Autocuration,1,10576,B,H,,,2435.0,8,CHEMBL616064,,,1119,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,10552,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616065,,10116.0,1120,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Membranes,17136,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616066,,10116.0,1121,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Membranes,5778,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616067,,,1122,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,13481,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616068,,,1123,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,13481,,,BAO_0000221
,Hippocampus,,Intermediate,1,10576,B,H,,,10000000.0,8,CHEMBL616069,,,1124,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,13630,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616070,,,1125,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,16245,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616071,,,1126,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,14509,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616072,,,1127,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,14509,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616073,,,1128,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,14509,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616074,,,1129,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,14509,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616075,,,1130,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,14256,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616076,,,1131,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,11139,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616077,,10116.0,1132,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,11047,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616078,,10116.0,1133,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,11047,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616079,,10116.0,1134,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,11047,,,BAO_0000019
485.0,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616080,,10116.0,1135,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,2395,,CHO-K1,BAO_0000219
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616081,,,1136,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,9699,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616082,,10116.0,1137,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,12028,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616083,,,1138,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,12028,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616084,,,1139,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,5815,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616085,,,1140,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,16616,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616086,,,1141,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,5815,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616087,,,1142,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,2761,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616088,,,1143,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,13133,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616089,,,1144,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,10444,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616090,,10116.0,1145,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,13278,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616091,,,1146,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,15874,,,BAO_0000357
,Striatum,,Autocuration,1,10576,B,H,,,2435.0,8,CHEMBL616092,,,1147,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Membranes,10552,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616093,,,1148,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,11130,,,BAO_0000357
,,,Autocuration,1,10576,B,H,In vivo,,,8,CHEMBL616094,,,1149,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,11130,,,BAO_0000218
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616095,,,1150,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,14542,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616096,,10116.0,1151,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,13670,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616097,,,1152,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,9888,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616098,,10116.0,1153,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Membranes,3678,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616099,,,1154,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,11332,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616100,,,1155,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,11332,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616101,,,1156,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1185,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616102,,,1157,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,2014,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616103,,,1158,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1185,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616104,,,1159,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,14429,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616105,,,1160,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,16288,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616106,,10116.0,1161,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,5432,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616107,,,1162,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,14429,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616108,,,1163,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,13672,,,BAO_0000357
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616109,,,1164,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616110,,,1165,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,11296,,,BAO_0000357
449.0,,,Expert,1,10576,B,H,,,,8,CHEMBL616111,,,1166,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,14749,,CHO,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL616112,,,1167,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,15086,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616113,,,1168,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,13462,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616114,,,1169,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,15363,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616115,,,1170,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,15363,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616116,,,1171,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,10796,,,BAO_0000357
,Brain,,Expert,1,10576,B,H,,,955.0,8,CHEMBL615844,,,1172,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,12816,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615939,,,1173,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,13542,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615940,,,1174,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,13308,,,BAO_0000019
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL615941,,,1175,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,13541,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615942,,,1176,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615943,,,1177,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615944,,,1178,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615945,,,1179,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615946,,,1180,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615947,,,1181,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615948,,,1182,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615949,,,1183,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615950,,,1184,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615951,,,1185,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615952,,,1186,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615953,,,1187,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615954,,,1188,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,10058,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL615955,,10116.0,1189,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615956,,,1190,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL615957,,,1191,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,10058,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615958,,,1192,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,12879,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL615959,,,1193,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,11964,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615960,,,1194,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,11964,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615961,,,1195,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,11964,,,BAO_0000019
,Brain,,Expert,1,10576,B,H,,,955.0,8,CHEMBL615962,,,1196,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,9548,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615963,,,1197,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,9098,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615964,,,1198,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,9098,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615965,,,1199,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,9098,,,BAO_0000019
449.0,,,Expert,1,10576,B,H,,,,8,CHEMBL615966,,,1200,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,13248,,CHO,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL615967,,,1201,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,3147,,,BAO_0000249
,,,Expert,1,10576,B,H,,,,8,CHEMBL615968,,,1202,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,13949,,,BAO_0000019
449.0,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615969,,,1203,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,11883,,CHO,BAO_0000218
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615970,,,1204,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,11883,,,BAO_0000218
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615971,,10116.0,1205,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,11883,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615972,,,1206,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,15535,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615973,,,1207,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,15535,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615974,,,1208,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,15535,,,BAO_0000249
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL615975,,9606.0,1209,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,16372,,CHO,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL615976,,,1210,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,14608,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL872106,,10116.0,1211,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,4795,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615977,,,1212,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615978,,,1213,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616166,,,1214,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616167,,,1215,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616168,,,1216,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616169,,,1217,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616170,,,1218,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616171,,,1219,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616172,,,1220,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616173,,,1221,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616174,,,1222,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616175,,,1223,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616176,,,1224,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616177,,,1225,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616178,,,1226,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616179,,,1227,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,9742,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616180,,,1228,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,12073,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616181,,,1229,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,4101,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616182,,,1230,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,15360,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616183,,,1231,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,11576,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL615874,,,1232,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,5834,,,BAO_0000019
485.0,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615875,,10116.0,1233,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,2395,,CHO-K1,BAO_0000219
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615876,,,1234,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,1375,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615877,,,1235,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,1375,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615878,,,1236,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,3967,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615879,,,1237,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,12884,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL615880,,,1238,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,2343,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615881,,,1239,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,11511,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL615882,,10116.0,1240,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,11511,,,BAO_0000019
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615883,,,1241,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615884,,,1242,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615885,,,1243,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615886,,,1244,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615887,,,1245,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615888,,,1246,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615889,,,1247,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615890,,,1248,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615891,,,1249,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615892,,,1250,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615893,,,1251,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615894,,,1252,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615895,,,1253,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615896,,,1254,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,16394,,,BAO_0000218
,,,Autocuration,1,10576,F,H,In vivo,,,8,CHEMBL615897,,,1255,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,16394,,,BAO_0000218
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL615898,,10116.0,1256,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,16616,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL615899,,,1257,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,16796,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616291,,,1258,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,16796,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616292,,,1259,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,15629,,,BAO_0000357
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616293,,,1260,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,13241,,,BAO_0000249
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616294,,,1261,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,12073,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616295,,,1262,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,14286,,,BAO_0000249
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616296,,,1263,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,14542,,,BAO_0000221
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616297,,,1264,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616605,,,1265,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616606,,,1266,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616607,,,1267,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616608,,,1268,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616609,,,1269,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,13630,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL616610,,10116.0,1270,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616611,,,1271,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616612,,,1272,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616613,,,1273,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616614,,,1274,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616615,,,1275,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616616,,,1276,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616617,,,1277,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616618,,,1278,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616619,,,1279,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616620,,,1280,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616621,,,1281,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616622,,,1282,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,13630,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616146,,,1283,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL832873,,,1284,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616147,,,1285,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL872872,,,1286,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,13630,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616148,,,1287,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,13630,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616149,,,1288,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,9783,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616150,,,1289,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,9783,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616151,,10116.0,1290,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Membranes,14331,,,BAO_0000249
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL872873,,,1291,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,15260,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616670,,,1292,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,15260,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616671,,,1293,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,15260,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL884861,,10116.0,1294,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,16616,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616672,,,1295,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,15629,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616673,,,1296,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,15086,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616674,,,1297,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,5717,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616675,,,1298,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,12652,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616676,,,1299,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,14608,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616677,,,1300,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616678,,,1301,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616679,,10116.0,1302,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,15247,,,BAO_0000357
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616680,,,1303,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,17529,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616681,,,1304,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,14826,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616682,,,1305,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,14826,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616683,,,1306,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,13241,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616684,,,1307,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,14093,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616685,,,1308,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,14093,,,BAO_0000221
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616686,,,1309,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,14442,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616687,,,1310,,Affinity for 5-hydroxytryptamine 1A receptor site,,9919,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616688,,,1311,,Affinity for 5-hydroxytryptamine 1A receptor site,,9919,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616689,,,1312,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,11440,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616690,,,1313,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,11257,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616691,,,1314,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,10330,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616692,,10116.0,1315,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,17331,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616693,,,1316,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,16567,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616694,,10116.0,1317,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,12058,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616695,,,1318,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,9699,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616696,,,1319,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,9547,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616697,,,1320,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,10330,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616698,,,1321,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,14331,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616949,,10116.0,1322,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,14060,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616950,,,1323,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,14744,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL832875,,,1324,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,13506,,,BAO_0000357
,Brain,,Expert,1,10576,B,H,,,955.0,8,CHEMBL616951,,,1325,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,,,BAO_0000221
,Brain,,Expert,1,10576,B,H,,,955.0,8,CHEMBL616952,,,1326,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616953,,,1327,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,10062,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616954,,,1328,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,12073,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616955,,,1329,,GTPgammaS radioligand binding assay,,14875,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616956,,,1330,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,2391,,,BAO_0000357
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616957,,,1331,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,2391,,,BAO_0000019
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616958,,,1332,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,2391,,,BAO_0000019
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616959,,,1333,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,2391,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616960,,,1334,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,2391,,,BAO_0000357
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616961,,,1335,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,2391,,,BAO_0000019
308.0,,,Expert,1,106,B,H,,,,8,CHEMBL616962,,,1336,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616963,,,1337,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,17211,,HeLa,BAO_0000219
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616524,,9606.0,1338,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,6491,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616525,,,1339,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,16190,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL872908,,,1340,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,14165,,,BAO_0000019
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616526,,,1341,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,14165,,,BAO_0000019
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616527,,9606.0,1342,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,4234,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL616528,,,1343,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,6328,,,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616529,,,1344,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,14770,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616530,,,1345,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,2598,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL616531,,,1346,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,6897,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616532,,,1347,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,6897,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616533,,,1348,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,6013,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL616534,,,1349,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,5843,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL616535,,,1350,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,14454,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616536,,,1351,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616537,,,1352,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,3935,,,BAO_0000357
485.0,,,Expert,1,106,F,H,,,,8,CHEMBL616538,,,1353,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,13729,,CHO-K1,BAO_0000219
,,,Expert,1,106,F,H,,,,8,CHEMBL616539,,,1354,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,14251,,,BAO_0000019
,,,Expert,1,106,B,H,,,,8,CHEMBL616540,,,1355,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,17085,,,BAO_0000019
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616429,,,1356,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,3025,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL616430,,,1357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,15315,,,BAO_0000357
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616431,,9606.0,1358,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,14214,,,BAO_0000219
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616432,,9606.0,1359,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,3804,,,BAO_0000357
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616433,,9606.0,1360,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,2391,,,BAO_0000357
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616434,,9606.0,1361,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,4175,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616435,,,1362,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,17296,,CHO,BAO_0000219
,,,Expert,1,106,B,H,,,,8,CHEMBL616436,,,1363,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,17085,,,BAO_0000019
308.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616437,,,1364,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616438,,,1365,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,17211,,HeLa,BAO_0000219
308.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616439,,,1366,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,17211,,HeLa,BAO_0000219
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616440,,9606.0,1367,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,15926,,,BAO_0000357
485.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616441,,,1368,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,16312,,CHO-K1,BAO_0000219
,,,Expert,1,106,B,H,,,,8,CHEMBL616442,,,1369,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,5843,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616443,,,1370,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,5843,,,BAO_0000357
485.0,,,Expert,1,106,B,H,,,,8,CHEMBL616444,,,1371,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,16312,,CHO-K1,BAO_0000219
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616445,,9606.0,1372,,Binding activity against human 5-hydroxytryptamine 1B receptor,,15926,,,BAO_0000357
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616446,,9606.0,1373,,Binding activity against human 5-hydroxytryptamine 1B receptor,,15926,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616447,,9606.0,1374,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,4540,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616448,,,1375,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,6166,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616449,,,1376,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,17296,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616450,,,1377,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,17296,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL857974,,,1378,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,17296,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616451,,,1379,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616452,,,1380,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616453,,,1381,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616454,,,1382,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616455,,9606.0,1383,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,14875,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616456,,,1384,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,15146,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616457,,,1385,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,5213,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616458,,,1386,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,14818,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616459,,,1387,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,CHO,BAO_0000219
,,,Expert,1,106,F,H,,,,8,CHEMBL616460,,,1388,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,14454,,,BAO_0000019
,,,Expert,1,106,F,H,,,,8,CHEMBL616461,,,1389,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,14454,,,BAO_0000019
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616462,,,1390,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,14875,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616463,,,1391,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,14875,,CHO,BAO_0000219
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616464,,,1392,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,15250,,,BAO_0000019
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616465,,,1393,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,15250,,CHO,BAO_0000219
,,,Autocuration,1,17105,B,H,,,,8,CHEMBL832874,,,1394,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,15086,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,106,F,H,,,,8,CHEMBL616184,,9986.0,1395,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,3025,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,106,B,H,,,,8,CHEMBL616185,,9986.0,1396,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,14998,,,BAO_0000019
,,Oryctolagus cuniculus,Intermediate,1,106,B,H,,,,8,CHEMBL616186,,9986.0,1397,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,14998,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,106,B,H,,,,8,CHEMBL616187,,9986.0,1398,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,14998,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616188,,,1399,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,13969,,,BAO_0000357
,,,Intermediate,1,10577,B,D,,,,9,CHEMBL873475,,,1400,,Binding affinity for 5-hydroxytryptamine 1B receptor,,13392,,,BAO_0000357
,Striatum,Rattus norvegicus,Expert,1,10577,B,D,,,2435.0,9,CHEMBL616189,,10116.0,1401,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,3651,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616190,,,1402,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10025,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616191,,,1403,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616192,,,1404,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616193,,,1405,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616194,,,1406,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616195,,,1407,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,13863,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616196,,,1408,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,13863,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616197,,,1409,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,4622,,,BAO_0000249
,,,Intermediate,1,10576,B,H,,,,8,CHEMBL616198,,,1410,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,14911,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616199,,,1411,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,12678,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616200,,,1412,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,12678,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616201,,,1413,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,14235,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616202,,,1414,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,14949,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616203,,,1415,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,14949,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616204,,,1416,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,14949,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616205,,,1417,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,14949,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616206,,,1418,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,14949,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616207,,,1419,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,16118,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616208,,,1420,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,3268,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616209,,,1421,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,3268,,,BAO_0000249
,,,Expert,1,10576,B,H,,,,8,CHEMBL616210,,,1422,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,16117,,,BAO_0000357
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616211,,,1423,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,9783,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616504,,,1424,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,9783,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616505,,10116.0,1425,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,14356,,,BAO_0000221
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616506,,,1426,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,15740,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL872107,,,1427,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,12306,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616507,,10116.0,1428,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,13348,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616303,,,1429,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,10394,,,BAO_0000249
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616304,,,1430,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,15260,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616305,,,1431,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,,,BAO_0000221
,Hippocampus,,Intermediate,1,10576,F,H,,,10000000.0,8,CHEMBL616306,,,1432,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,15260,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616307,,,1433,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,12851,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL881829,,10116.0,1434,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,2148,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616308,,,1435,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,13134,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616309,,,1436,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,12462,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616310,,,1437,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,12462,,,BAO_0000019
449.0,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616311,,,1438,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,12462,,CHO,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL616312,,,1439,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,11933,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616313,,,1440,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,11933,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616314,,10116.0,1441,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,403,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616315,,,1442,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,15538,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616567,,,1443,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,15538,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616568,,,1444,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,15538,,,BAO_0000221
,,,Intermediate,1,10576,B,H,,,,8,CHEMBL616569,,,1445,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,12464,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616570,,,1446,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,1455,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616571,,,1447,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,12652,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616572,,,1448,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,12639,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616573,,,1449,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,13949,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616574,,10116.0,1450,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,12463,,,BAO_0000357
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616575,,,1451,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,14829,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL872108,,,1452,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,14829,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616576,,,1453,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,12092,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616577,,,1454,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,403,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616578,,,1455,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,403,,,BAO_0000249
,,,Expert,1,10576,B,H,,,,8,CHEMBL616579,,,1456,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,3967,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616580,,10116.0,1457,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,12771,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616581,,,1458,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,15086,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616582,,,1459,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,14909,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616583,,,1460,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,14949,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616584,,10116.0,1461,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,2309,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616585,,,1462,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,4170,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616586,,10116.0,1463,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,11642,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616587,,,1464,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,11642,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616588,,,1465,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,12953,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616589,,,1466,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,12953,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616590,,,1467,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,12953,,,BAO_0000221
449.0,,,Expert,1,10576,B,H,,,,8,CHEMBL616591,,,1468,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,12903,,CHO,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL616592,,,1469,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,12536,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616593,,,1470,,The inhibition activity of 5-HT1A at 1 uM,,10058,,,BAO_0000357
485.0,,,Expert,1,10576,B,H,,,,8,CHEMBL616594,,,1471,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,12902,,CHO-K1,BAO_0000219
,,,Expert,1,10576,B,H,,,,8,CHEMBL616595,,,1472,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,14057,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616596,,,1473,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,11296,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616597,,,1474,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,,,BAO_0000221
,Hippocampus,,Expert,1,10576,B,H,,,10000000.0,8,CHEMBL616598,,,1475,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,11296,,,BAO_0000221
,,Rattus norvegicus,Expert,1,10576,F,D,,,,9,CHEMBL616599,,10116.0,1476,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Membranes,16616,,,BAO_0000249
,Hippocampus,Rattus norvegicus,Expert,1,10576,F,D,,,10000000.0,9,CHEMBL616600,,10116.0,1477,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,16616,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616601,,,1478,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,16567,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616602,,,1479,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,16567,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616603,,,1480,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,16567,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616604,,,1481,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,16567,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616316,,,1482,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,17136,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616317,,,1483,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,17136,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616318,,10116.0,1484,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,16616,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616319,,,1485,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,17331,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616320,,,1486,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,17331,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616321,,10116.0,1487,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,17167,,,BAO_0000221
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616322,,,1488,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,15740,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616323,,,1489,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,15740,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616324,,,1490,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,4671,,,BAO_0000357
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616325,,,1491,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616326,,,1492,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,10058,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616327,,,1493,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,10058,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616328,,,1494,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,12073,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL858110,,,1495,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,2759,,,BAO_0000249
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616329,,,1496,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,2759,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616330,,,1497,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,2759,,,BAO_0000249
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616331,,,1498,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,2759,,,BAO_0000249
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616332,,,1499,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,2759,,,BAO_0000249
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL857063,,,1500,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616333,,,1501,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,9737,,,BAO_0000019
,,,Expert,1,10576,F,H,,,,8,CHEMBL616334,,,1502,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,5717,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616335,,,1503,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,12253,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616336,,,1504,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,14025,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616337,,,1505,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,10425,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616338,,,1506,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,14998,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616339,,,1507,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,13694,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616340,,,1508,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,13694,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616341,,,1509,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,4342,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616342,,10116.0,1510,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,12936,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616343,,10116.0,1511,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,13144,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616344,,,1512,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,13343,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616345,,,1513,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,12132,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616346,,,1514,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,15419,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616347,,,1515,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,1479,,,BAO_0000221
,,,Expert,1,10576,B,H,,,,8,CHEMBL616348,,,1516,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,14287,,,BAO_0000019
,,,Expert,1,10576,B,H,,,,8,CHEMBL616349,,,1517,,Binding affinity at 5-hydroxytryptamine 1A receptor,,13116,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10576,B,D,,,,9,CHEMBL616152,,10116.0,1518,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Membranes,2759,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616153,,,1519,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,2759,,,BAO_0000249
,,,Expert,1,10576,B,H,,,,8,CHEMBL616154,,,1520,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,14748,,,BAO_0000019
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616155,,,1521,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,12304,,,BAO_0000019
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616156,,10116.0,1522,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,12409,,,BAO_0000221
,Hippocampus,Rattus norvegicus,Expert,1,10576,B,D,,,10000000.0,9,CHEMBL616157,,10116.0,1523,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,12409,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL616158,,,1524,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,13267,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616159,,,1525,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,15194,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL616160,,,1526,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,14256,,,BAO_0000357
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616161,,,1527,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,16567,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616162,,,1528,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,15740,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL616163,,10116.0,1529,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,13278,,,BAO_0000357
,,,Expert,1,10626,B,H,,,,8,CHEMBL616164,,,1530,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,1970,,,BAO_0000249
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616165,,,1531,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,10034,,,BAO_0000221
,,Rattus norvegicus,Autocuration,1,51,B,H,,,,8,CHEMBL616355,,10116.0,1532,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,13348,,,BAO_0000019
,,,Autocuration,1,10576,F,H,,,,8,CHEMBL616356,,,1533,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,13630,,,BAO_0000019
,Brain,,Autocuration,1,10576,B,H,,,955.0,8,CHEMBL616357,,,1534,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,10862,,,BAO_0000221
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL616358,,,1535,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,12058,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616359,,,1536,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,4639,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL616360,,,1537,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,15453,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL616361,,,1538,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,4820,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616362,,,1539,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,1089,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616363,,,1540,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Brain membranes,386,,,BAO_0000249
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616364,,,1541,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,6011,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616365,,,1542,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,5014,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL616366,,,1543,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,4402,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL872906,,,1544,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,17066,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616367,,,1545,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616368,,,1546,,Binding affinity against 5-hydroxytryptamine 1A receptor,,2474,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616369,,,1547,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,4775,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616370,,9606.0,1548,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,14294,,,BAO_0000357
,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL616371,,9606.0,1549,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,14294,,,BAO_0000357
449.0,,,Autocuration,1,51,B,H,,,,8,CHEMBL616372,,,1550,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12249,,CHO,BAO_0000219
,,,Expert,1,51,B,H,,,,8,CHEMBL616373,,,1551,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,11376,,,BAO_0000219
,,,Autocuration,1,51,B,H,In vivo,,,8,CHEMBL616374,,,1552,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,2474,,,BAO_0000218
,Hippocampus,,Autocuration,1,51,B,H,,,10000000.0,8,CHEMBL616375,,,1553,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,13311,,,BAO_0000221
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616376,,,1554,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,51,B,H,,,,8,CHEMBL857064,,,1555,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,1633,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616377,,,1556,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,11866,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616378,,,1557,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616379,,,1558,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,4687,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616380,,,1559,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,16946,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616381,,,1560,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,13291,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616382,,,1561,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,14159,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616383,,,1562,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,10812,,,BAO_0000357
449.0,,Mus musculus,Expert,1,11863,B,D,,,,9,CHEMBL616350,,10090.0,1563,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,3032,,CHO,BAO_0000219
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616351,,,1564,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,16655,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616352,,,1565,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,14532,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616353,,,1566,,Binding affinity against 5-hydroxytryptamine 1A receptor,,13944,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616354,,,1567,,Binding affinity against serotonergic 5-HT1a receptor,,13033,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616508,,,1568,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,10321,,,BAO_0000357
,,Mus musculus,Expert,1,11863,B,D,,,,9,CHEMBL616559,,10090.0,1569,,Binding affinity for 5-hydroxytryptamine 1A receptor,,2968,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616560,,,1570,,Binding affinity at 5-hydroxytryptamine 1A receptor,,13964,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616561,,,1571,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,15527,,,BAO_0000357
449.0,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616562,,,1572,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12248,,CHO,BAO_0000219
449.0,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616563,,,1573,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,12249,,CHO,BAO_0000219
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616564,,,1574,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,15120,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616565,,,1575,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,13313,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616566,,,1576,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,2613,,,BAO_0000218
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616989,,,1577,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,16700,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL857975,,,1578,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,2201,,,BAO_0000357
,,Mus musculus,Expert,1,11863,B,D,,,,9,CHEMBL616990,,10090.0,1579,,Binding affinity against 5-hydroxytryptamine 1A receptor,,1274,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616991,,,1580,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,1317,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616992,,,1581,,Tested against 5-hydroxytryptamine 1A receptor,,12146,,,BAO_0000357
,,,Autocuration,1,11863,B,H,,,,8,CHEMBL616993,,,1582,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,14059,,,BAO_0000357
,,Oryctolagus cuniculus,Expert,1,106,B,H,,,,8,CHEMBL616994,,9986.0,1583,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,14025,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,106,B,H,,,,8,CHEMBL616995,,9986.0,1584,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,14025,,,BAO_0000019
722.0,,Gorilla gorilla,Intermediate,1,105571,B,D,,,,9,CHEMBL616996,,9593.0,1585,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,14447,,HEK293,BAO_0000219
,,Cavia porcellus,Autocuration,1,106,F,H,In vivo,,,8,CHEMBL616997,,10141.0,1586,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,3025,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,106,F,H,In vivo,,,8,CHEMBL616998,,10141.0,1587,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,3025,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,106,F,H,,,,8,CHEMBL616999,,10141.0,1588,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,15329,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,106,F,H,,,,8,CHEMBL617000,,10141.0,1589,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,15329,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,106,F,H,,,,8,CHEMBL617001,,10141.0,1590,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,15847,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,106,F,H,,,,8,CHEMBL858111,,10141.0,1591,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,15847,,,BAO_0000019
,,,Autocuration,1,106,F,H,,,,8,CHEMBL617002,,,1592,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,14165,,,BAO_0000019
,,,Autocuration,1,106,F,H,,,,8,CHEMBL617003,,,1593,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,14214,,,BAO_0000019
,,,Autocuration,1,106,F,H,,,,8,CHEMBL617004,,,1594,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,14214,,,BAO_0000019
,,Homo sapiens,Expert,1,106,F,D,,,,9,CHEMBL617005,,9606.0,1595,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,14214,,,BAO_0000019
485.0,,Homo sapiens,Expert,1,106,F,D,,,,9,CHEMBL616623,,9606.0,1596,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,13729,,CHO-K1,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616624,,,1597,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,3025,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL883243,,,1598,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,2391,,,BAO_0000357
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616625,,,1599,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,2391,,,BAO_0000019
449.0,,,Expert,1,106,F,H,,,,8,CHEMBL616626,,,1600,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,14956,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616627,,,1601,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,2598,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616628,,,1602,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,2598,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616629,,,1603,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,2598,,CHO,BAO_0000219
449.0,,,Autocuration,1,106,F,H,,,,8,CHEMBL616630,,,1604,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,2598,,CHO,BAO_0000219
,,,Expert,1,106,F,H,,,,8,CHEMBL616631,,,1605,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,14956,,,BAO_0000019
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616632,,,1606,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,14956,,,BAO_0000019
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616633,,9606.0,1607,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,14214,,,BAO_0000357
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616634,,,1608,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,3463,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616635,,,1609,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL885358,,9606.0,1610,,Binding affinity against 5-hydroxytryptamine 1B receptor,,16146,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,106,B,D,,,,9,CHEMBL616636,,9606.0,1611,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,14159,,CHO,BAO_0000219
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616637,,,1612,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,14158,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616638,,,1613,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,14159,,,BAO_0000357
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616639,,,1614,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616640,,,1615,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,15250,,CHO,BAO_0000219
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616641,,,1616,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,15331,,CHO,BAO_0000219
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616642,,,1617,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,15332,,CHO,BAO_0000219
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616643,,,1618,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,14956,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616644,,,1619,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616645,,,1620,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,14875,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,105,F,H,,,,8,CHEMBL616646,,9986.0,1621,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,,BAO_0000019
,,Oryctolagus cuniculus,Expert,1,105,F,H,,,,8,CHEMBL616647,,9986.0,1622,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616509,,,1623,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,16288,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616510,,,1624,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,16288,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616511,,,1625,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,16312,,,BAO_0000357
,,Bos taurus,Expert,1,105,B,H,,,,8,CHEMBL616512,,9913.0,1626,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,1348,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616513,,9913.0,1627,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,5834,,,BAO_0000357
,Striatum,Bos taurus,Autocuration,1,105,B,H,,,2435.0,8,CHEMBL616514,,9913.0,1628,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,13366,,,BAO_0000019
,,Bos taurus,Expert,1,105,B,H,,,,8,CHEMBL616515,,9913.0,1629,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,1414,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616516,,9913.0,1630,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,14998,,,BAO_0000019
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616517,,9913.0,1631,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,11473,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616518,,9913.0,1632,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,11473,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616519,,9913.0,1633,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,10639,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616520,,9913.0,1634,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,10639,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616521,,9913.0,1635,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,1375,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616522,,9913.0,1636,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,1375,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL884531,,9913.0,1637,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,16532,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616523,,9913.0,1638,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,11147,,,BAO_0000357
,Striatum,Bos taurus,Autocuration,1,105,B,H,,,2435.0,8,CHEMBL616731,,9913.0,1639,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,13366,,,BAO_0000019
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616732,,9913.0,1640,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,10444,,,BAO_0000019
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616733,,9913.0,1641,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,16532,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616734,,9913.0,1642,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,16532,,,BAO_0000357
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616735,,9913.0,1643,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,12827,,,BAO_0000249
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616736,,9913.0,1644,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,12827,,,BAO_0000249
,,Bos taurus,Expert,1,105,F,H,,,,8,CHEMBL616737,,9913.0,1645,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,,BAO_0000019
,,Bos taurus,Autocuration,1,105,B,H,,,,8,CHEMBL616738,,9913.0,1646,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,14025,,,BAO_0000019
,,Bos taurus,Expert,1,105,F,H,,,,8,CHEMBL616739,,9913.0,1647,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,,BAO_0000019
,,Bos taurus,Expert,1,105,F,H,,,,8,CHEMBL616740,,9913.0,1648,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,,BAO_0000019
,,Bos taurus,Expert,1,105,F,H,,,,8,CHEMBL616741,,9913.0,1649,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,12919,,,BAO_0000019
722.0,,Gorilla gorilla,Autocuration,1,105,B,H,,,,8,CHEMBL616742,,9593.0,1650,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,14447,,HEK293,BAO_0000219
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616743,,10141.0,1651,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,1375,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616744,,10141.0,1652,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,1375,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616745,,10141.0,1653,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,12409,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616746,,10141.0,1654,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616747,,10141.0,1655,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,12409,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616748,,10141.0,1656,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,12409,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616648,,10141.0,1657,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,12409,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616649,,10141.0,1658,,Binding affinity against 5-hydroxytryptamine 1D receptor,,11574,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616650,,10141.0,1659,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,1558,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616651,,10141.0,1660,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616652,,10141.0,1661,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616653,,10141.0,1662,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,12409,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,105570,F,D,,,,9,CHEMBL616654,,10141.0,1663,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,12409,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616655,,10141.0,1664,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,12253,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616656,,10141.0,1665,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,12936,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,105,B,H,,,,8,CHEMBL616657,,10141.0,1666,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,13181,,,BAO_0000019
,Striatum,Cavia porcellus,Intermediate,1,105570,B,D,,,2435.0,9,CHEMBL616658,,10141.0,1667,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,12409,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,105570,B,D,,,,9,CHEMBL616659,,10141.0,1668,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,10639,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL616660,,,1669,,Binding affinity against 5-hydroxytryptamine 1D receptor,,5254,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616661,,,1670,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,13051,,,BAO_0000357
,,,Expert,1,105,F,H,,,,8,CHEMBL616662,,,1671,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,3463,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616663,,,1672,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,15315,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616664,,,1673,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,6011,,,BAO_0000019
449.0,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL881820,,9606.0,1674,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,14159,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL616665,,,1675,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,14159,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616666,,,1676,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,15250,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616667,,,1677,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,15250,,CHO,BAO_0000219
449.0,,,Expert,1,105,F,H,,,,8,CHEMBL616668,,,1678,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,15331,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL616669,,9606.0,1679,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,15332,,CHO,BAO_0000219
449.0,,,Expert,1,105,F,H,,,,8,CHEMBL617040,,,1680,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,15332,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL617041,,,1681,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,3294,,CHO,BAO_0000219
449.0,,,Expert,1,105,F,H,,,,8,CHEMBL617042,,,1682,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,14158,,CHO,BAO_0000219
449.0,,,Expert,1,105,F,H,,,,8,CHEMBL617043,,,1683,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,14956,,CHO,BAO_0000219
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617044,,,1684,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,12469,,,BAO_0000019
449.0,,,Expert,1,105,F,H,,,,8,CHEMBL617045,,,1685,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,3463,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL617046,,9606.0,1686,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,15250,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL617047,,9606.0,1687,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,15250,,CHO,BAO_0000219
,,,Expert,1,105,F,H,,,,8,CHEMBL617048,,,1688,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,14956,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616897,,,1689,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,14159,,,BAO_0000019
,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL616898,,9606.0,1690,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,14159,,,BAO_0000019
449.0,,Homo sapiens,Expert,1,105,F,D,,,,9,CHEMBL858201,,9606.0,1691,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,14499,,CHO,BAO_0000219
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616899,,,1692,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,15315,,,BAO_0000019
,,,Autocuration,1,105,B,H,In vitro,,,8,CHEMBL616900,,,1693,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,3294,,,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616901,,,1694,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,3463,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616902,,,1695,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616903,,9606.0,1696,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14159,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616904,,,1697,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,14158,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616905,,,1698,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,14159,,,BAO_0000357
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616906,,,1699,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,15250,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616907,,,1700,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616908,,,1701,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15331,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616909,,9606.0,1702,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,15332,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616910,,9606.0,1703,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14499,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616911,,,1704,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,15332,,CHO,BAO_0000219
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL616912,,,1705,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,14956,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616913,,,1706,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616914,,9606.0,1707,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,6011,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616915,,,1708,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,16190,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616916,,,1709,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,14165,,,BAO_0000019
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616917,,9606.0,1710,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,4234,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616918,,,1711,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,15527,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL616919,,,1712,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,6328,,,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616920,,,1713,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL872914,,,1714,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,14770,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616921,,,1715,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,2598,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL616922,,,1716,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,6897,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616923,,,1717,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,6013,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL616924,,,1718,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,5843,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL875909,,,1719,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,14454,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616925,,,1720,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,14454,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616926,,,1721,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,14454,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616927,,,1722,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,15818,,,BAO_0000357
485.0,,,Expert,1,105,F,H,,,,8,CHEMBL616928,,,1723,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,13729,,CHO-K1,BAO_0000219
,,Homo sapiens,Expert,1,105,B,D,In vitro,,,9,CHEMBL616929,,9606.0,1724,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,6011,,,BAO_0000219
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616930,,9606.0,1725,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,4234,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL616931,,,1726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,17085,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616932,,,1727,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,3025,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL616933,,,1728,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,15315,,,BAO_0000357
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616934,,9606.0,1729,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,14214,,,BAO_0000219
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616935,,9606.0,1730,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,3804,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616936,,,1731,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,16700,,,BAO_0000357
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616937,,9606.0,1732,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,2391,,,BAO_0000357
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616938,,9606.0,1733,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,4175,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616939,,,1734,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,17085,,,BAO_0000019
,,,Expert,1,105,B,H,,,,8,CHEMBL616940,,,1735,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,17085,,,BAO_0000019
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616941,,9606.0,1736,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,15926,,,BAO_0000357
485.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616942,,,1737,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,16312,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616943,,,1738,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,16312,,CHO-K1,BAO_0000219
449.0,,,Autocuration,1,104802,B,H,,,,4,CHEMBL616944,,,1739,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,14956,,CHO,BAO_0000219
,,,Autocuration,1,105,F,H,,,,8,CHEMBL616945,,,1740,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,3294,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616946,,,1741,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616947,,,1742,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,,BAO_0000019
485.0,,,Expert,1,105,B,H,,,,8,CHEMBL616948,,,1743,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,16312,,CHO-K1,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616851,,,1744,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,5104,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616852,,,1745,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,5105,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616853,,,1746,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,14499,,,BAO_0000357
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616854,,9606.0,1747,,Binding activity against human 5-hydroxytryptamine 1D receptor,,15926,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616855,,9606.0,1748,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,4540,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616856,,,1749,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616857,,,1750,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616858,,,1751,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,6166,,,BAO_0000357
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616859,,,1752,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616860,,,1753,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,15779,,CHO,BAO_0000219
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616861,,,1754,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,17451,,HEK293,BAO_0000219
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616541,,,1755,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,17451,,HEK293,BAO_0000219
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616542,,,1756,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,17451,,HEK293,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616543,,,1757,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL616544,,9606.0,1758,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,14875,,,BAO_0000357
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616545,,,1759,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,15146,,CHO,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616546,,,1760,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,5213,,,BAO_0000357
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616547,,,1761,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,14818,,CHO,BAO_0000219
449.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL616548,,,1762,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,CHO,BAO_0000219
,,,Expert,1,105,F,H,,,,8,CHEMBL616549,,,1763,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,14454,,,BAO_0000019
,,,Expert,1,105,F,H,,,,8,CHEMBL616550,,,1764,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,14454,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL857066,,,1765,,Binding affinity against 5-HT2C receptor,,5254,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL616551,,,1766,,Binding affinity against 5-hydroxytryptamine 1D receptor,,5254,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616552,,,1767,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10639,,,BAO_0000357
,,,Autocuration,1,10577,F,H,,,,8,CHEMBL832876,,,1768,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,10639,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616553,,,1769,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,12352,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616554,,,1770,,Binding affinity towards 5-HT1B was determined,,9098,,,BAO_0000357
,,,Expert,1,10577,B,H,,,,8,CHEMBL616555,,,1771,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,14430,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616556,,,1772,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,13657,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616557,,,1773,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,13657,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616558,,,1774,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616749,,10116.0,1775,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,10639,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616750,,,1776,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,10025,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616751,,,1777,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,10025,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616752,,,1778,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,14286,,,BAO_0000249
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616753,,,1779,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,3651,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616754,,10116.0,1780,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,14178,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616755,,,1781,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,10639,,,BAO_0000019
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616756,,,1782,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,13605,,,BAO_0000019
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616757,,,1783,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,5834,,,BAO_0000019
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616758,,,1784,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,10922,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616759,,,1785,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,14286,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616760,,,1786,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,11825,,,BAO_0000357
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616761,,,1787,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,14826,,,BAO_0000019
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616762,,,1788,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,9699,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616763,,,1789,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,14423,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL872909,,,1790,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,10062,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616764,,,1791,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10062,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616765,,10116.0,1792,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,12280,,,BAO_0000357
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616766,,,1793,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,15412,,,BAO_0000357
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616767,,,1794,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,15412,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616768,,,1795,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,10062,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616769,,,1796,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,11147,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616770,,,1797,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,9547,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616771,,,1798,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,10444,,,BAO_0000019
,Striatum,,Autocuration,1,10577,B,H,,,2435.0,8,CHEMBL616772,,,1799,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,12469,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616773,,,1800,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,9098,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616774,,,1801,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,9098,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616775,,,1802,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,9699,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616776,,,1803,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10394,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616777,,,1804,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,12092,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616778,,,1805,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,16700,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616779,,10116.0,1806,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,403,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616780,,10116.0,1807,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,12771,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616781,,,1808,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,11642,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616782,,,1809,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,12953,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616783,,,1810,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,12953,,,BAO_0000357
,Striatum,,Expert,1,10577,B,H,,,2435.0,8,CHEMBL616784,,,1811,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,12953,,,BAO_0000019
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616785,,,1812,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000357
,Brain,,Autocuration,1,10577,B,H,,,955.0,8,CHEMBL857067,,,1813,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616786,,,1814,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,9737,,,BAO_0000019
,Brain,,Autocuration,1,10577,B,H,,,955.0,8,CHEMBL616787,,,1815,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616788,,,1816,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,12827,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616789,,,1817,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,5033,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616790,,10116.0,1818,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,9786,,,BAO_0000019
,,,Expert,1,10577,B,H,,,,8,CHEMBL616791,,,1819,,Binding affinity at 5-hydroxytryptamine 1B receptor,,13116,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616792,,,1820,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,16429,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10577,B,D,,,,9,CHEMBL616793,,10116.0,1821,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,12409,,,BAO_0000249
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616794,,,1822,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,15194,,,BAO_0000357
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL616795,,,1823,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,15194,,,BAO_0000357
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616796,,,1824,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,5486,,,BAO_0000019
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616797,,,1825,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,4639,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616798,,,1826,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Brain membranes,386,,,BAO_0000249
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616799,,,1827,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,2474,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616800,,,1828,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,6011,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616801,,,1829,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,5014,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616802,,,1830,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616803,,,1831,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,106,B,H,,,,8,CHEMBL857068,,,1832,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,1633,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616804,,,1833,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,1633,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616805,,,1834,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616806,,,1835,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,4687,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616807,,,1836,,Binding affinity against 5-hydroxytryptamine 1B receptor,,11574,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616808,,,1837,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,10321,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616809,,,1838,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,15527,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616810,,,1839,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,104802,B,H,,,,4,CHEMBL616811,,,1840,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,14423,,,BAO_0000224
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL616812,,9913.0,1841,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,5834,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616813,,9823.0,1842,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,11473,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616814,,9823.0,1843,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,11473,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616815,,9823.0,1844,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,10639,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616816,,9823.0,1845,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,10639,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616817,,9823.0,1846,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,14331,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616818,,9823.0,1847,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,10796,,,BAO_0000357
,,Sus scrofa,Expert,1,108,B,H,,,,8,CHEMBL616819,,9823.0,1848,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,9098,,,BAO_0000357
,,Sus scrofa,Expert,1,108,B,H,,,,8,CHEMBL616820,,9823.0,1849,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,14331,,,BAO_0000357
,,Sus scrofa,Expert,1,108,B,H,,,,8,CHEMBL616821,,9823.0,1850,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,11828,,,BAO_0000019
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL616822,,9823.0,1851,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,11866,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,108,B,H,,,,8,CHEMBL616823,,9986.0,1852,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616824,,10116.0,1853,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,188,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616825,,10116.0,1854,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,11825,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616826,,10116.0,1855,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,11825,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL616827,,10116.0,1856,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,11624,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616828,,10116.0,1857,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,11139,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616829,,10116.0,1858,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,11147,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616830,,10116.0,1859,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,10444,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL616831,,10116.0,1860,,Binding affinity against 5-hydroxytryptamine 1C receptor,,11624,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616832,,10116.0,1861,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616833,,10116.0,1862,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL616834,,10116.0,1863,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL829595,,10116.0,1864,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,11662,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616835,,10116.0,1865,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,9098,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL872910,,10116.0,1866,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,10394,,,BAO_0000249
,,,Expert,1,12689,B,H,,,,8,CHEMBL616836,,,1867,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,11933,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616837,,10116.0,1868,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,12092,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616466,,10116.0,1869,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,12253,,,BAO_0000019
722.0,,Rattus norvegicus,Autocuration,1,12689,B,D,,,,9,CHEMBL616467,,10116.0,1870,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,12253,,HEK293,BAO_0000219
,,,Autocuration,1,108,B,H,,,,8,CHEMBL616468,,,1871,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1558,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL616469,,,1872,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,2474,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL616470,,,1873,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,2474,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616471,,,1874,,Binding affinity against 5-hydroxytryptamine 1C receptor,,11574,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616472,,,1875,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1558,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616473,,,1876,,Binding affinity against 5-hydroxytryptamine 1C receptor,,13944,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616474,,,1877,,Binding affinity against serotonergic 5-HT1c receptor,,13033,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616475,,,1878,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,10321,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL616476,,,1879,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,11866,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,105,B,H,,,,8,CHEMBL616477,,9986.0,1880,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,14454,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616478,,,1881,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,11574,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616479,,,1882,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,11574,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616480,,,1883,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,13631,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL616481,,10116.0,1884,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,9630,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL616482,,10116.0,1885,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,8822,,,BAO_0000249
,Brain,Rattus norvegicus,Autocuration,1,104686,B,D,,,955.0,5,CHEMBL884713,,10116.0,1886,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,9064,,,BAO_0000221
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616483,,,1887,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,8868,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616484,,,1888,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,9064,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616485,,,1889,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,9806,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616486,,,1890,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,9098,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616487,,,1891,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,8868,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616488,,,1892,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,12765,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616489,,,1893,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616490,,,1894,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616491,,,1895,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616492,,,1896,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616493,,,1897,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616494,,,1898,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,11473,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616495,,,1899,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,11473,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616496,,,1900,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,3086,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616497,,,1901,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616498,,,1902,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,11049,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616499,,,1903,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,10639,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616500,,,1904,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,10922,,,BAO_0000019
,Brain,Rattus norvegicus,Autocuration,1,104686,B,D,,,955.0,5,CHEMBL616501,,10116.0,1905,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,9064,,,BAO_0000221
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL616502,,,1906,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,10748,,,BAO_0000221
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL884529,,,1907,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,11614,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616503,,,1908,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,11615,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616964,,,1909,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,11615,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616965,,,1910,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,11614,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616966,,,1911,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,11702,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616967,,,1912,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL616968,,10116.0,1913,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,11702,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616969,,,1914,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL884530,,,1915,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,13346,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616970,,,1916,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,10025,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616971,,,1917,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,10025,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616972,,,1918,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,10025,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616973,,,1919,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,9036,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616974,,,1920,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,9036,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616975,,,1921,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616976,,,1922,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,12304,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616977,,,1923,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,13276,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616978,,,1924,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,11825,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616979,,,1925,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,12443,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616980,,,1926,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,13830,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616981,,,1927,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Membranes,9592,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616982,,,1928,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Membranes,9592,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616983,,,1929,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,10881,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616984,,,1930,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,13605,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL616985,,10116.0,1931,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,11624,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616986,,,1932,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4101,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616987,,,1933,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,4101,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL616988,,,1934,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,15360,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617243,,,1935,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,11576,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617244,,,1936,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,5834,,,BAO_0000019
485.0,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617245,,10116.0,1937,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,CHO-K1,BAO_0000219
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617246,,,1938,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,11965,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617546,,,1939,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,3967,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617547,,,1940,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Brain membranes,11130,,,BAO_0000249
,,,Autocuration,1,104686,B,H,In vitro,,,4,CHEMBL617548,,,1941,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,13427,,,BAO_0000219
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617549,,,1942,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,9443,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617550,,,1943,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,9443,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617551,,,1944,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,11825,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617552,,,1945,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Membranes,12120,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617553,,,1946,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Membranes,12120,,,BAO_0000249
,Thoracic aorta,,Autocuration,1,104686,F,H,,,1515.0,4,CHEMBL617554,,,1947,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,11963,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617555,,,1948,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,9069,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617556,,,1949,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,8868,,,BAO_0000224
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL617557,,,1950,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL617558,,,1951,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,17200,,,BAO_0000357
,,,Expert,1,17106,B,H,,,,8,CHEMBL617559,,,1952,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,13969,,,BAO_0000357
,,,Expert,1,17106,B,D,,,,9,CHEMBL617560,,,1953,,Binding affinity for 5-hydroxytryptamine 1D receptor,,13392,,,BAO_0000357
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617561,,,1954,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1742,,,BAO_0000249
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617562,,,1955,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1742,,,BAO_0000249
,Striatum,,Autocuration,1,17106,B,H,,,2435.0,8,CHEMBL617563,,,1956,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,14331,,,BAO_0000357
,,,Autocuration,1,17106,F,H,,,,8,CHEMBL617564,,,1957,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,12861,,,BAO_0000019
,,,Expert,1,17106,B,H,,,,8,CHEMBL617565,,,1958,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,12861,,,BAO_0000019
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL856076,,,1959,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617566,,,1960,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
,,,Expert,1,17106,B,H,,,,8,CHEMBL875911,,,1961,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617567,,,1962,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,12861,,,BAO_0000019
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617568,,,1963,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,675,,,BAO_0000249
,,,Expert,1,17106,B,H,,,,8,CHEMBL617569,,,1964,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,12490,,,BAO_0000019
,,,Expert,1,17106,B,H,,,,8,CHEMBL617570,,,1965,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,11828,,,BAO_0000249
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617571,,,1966,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,11866,,,BAO_0000357
,,Sus scrofa,Autocuration,1,105,B,H,,,,8,CHEMBL617572,,9823.0,1967,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,773,,,BAO_0000357
,,Oryctolagus cuniculus,Expert,1,105,B,H,,,,8,CHEMBL617573,,9986.0,1968,,The compound was tested for intrinsic activity against 5-HT1D receptor,,13047,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,105,B,H,,,,8,CHEMBL617574,,9986.0,1969,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Oryctolagus cuniculus,Expert,1,105,B,H,,,,8,CHEMBL617575,,9986.0,1970,,The compound was tested for binding affinity against 5-HT1D receptor,,13047,,,BAO_0000357
,,,Autocuration,1,10578,B,H,,,,8,CHEMBL617576,,,1971,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,188,,,BAO_0000357
,,,Autocuration,1,10578,F,H,,,,8,CHEMBL617577,,,1972,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,10639,,,BAO_0000019
,,,Autocuration,1,10578,F,H,,,,8,CHEMBL617578,,,1973,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,12438,,,BAO_0000019
,,,Autocuration,1,10578,B,H,,,,8,CHEMBL617579,,,1974,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,12438,,,BAO_0000357
,,,Expert,1,10578,B,H,,,,8,CHEMBL617580,,,1975,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,15854,,,BAO_0000019
,,,Autocuration,1,10578,B,H,,,,8,CHEMBL617581,,,1976,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,10394,,,BAO_0000249
,,,Autocuration,1,10578,B,H,,,,8,CHEMBL617582,,,1977,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,12092,,,BAO_0000357
,,,Expert,1,10578,B,H,,,,8,CHEMBL617583,,,1978,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,3389,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617584,,,1979,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,6011,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617585,,,1980,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,4639,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL875912,,,1981,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,2474,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617586,,,1982,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,5014,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617587,,,1983,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617588,,,1984,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,11866,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL857980,,,1985,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,4687,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617589,,,1986,,Tested against 5-hydroxytryptamine 1D receptor,,12146,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617590,,,1987,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,10321,,,BAO_0000357
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL617591,,,1988,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,13267,,HEK293,BAO_0000219
,,Homo sapiens,Expert,1,105,B,D,,,,9,CHEMBL617592,,9606.0,1989,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,1274,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617593,,,1990,,,,15250,,,BAO_0000357
485.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL617594,,,1991,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL617595,,,1992,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL617596,,,1993,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,13706,,HEK293,BAO_0000219
722.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL617597,,,1994,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,13706,,HEK293,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617598,,,1995,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL872916,,,1996,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,13366,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL617599,,,1997,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,13366,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617091,,,1998,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,1558,,,BAO_0000357
485.0,,,Expert,1,105,B,H,,,,8,CHEMBL617092,,,1999,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,12902,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,B,H,,,,8,CHEMBL617093,,,2000,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617094,,,2001,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,13706,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617095,,,2002,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617096,,,2003,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617097,,,2004,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,,BAO_0000019
,,,Autocuration,1,105,F,H,,,,8,CHEMBL617098,,,2005,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,14251,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617301,,,2006,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,13313,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617302,,,2007,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,13313,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617303,,,2008,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,13366,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL617304,,,2009,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,13051,,,BAO_0000357
449.0,,,Expert,1,105,B,H,,,,8,CHEMBL617305,,,2010,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,CHO,BAO_0000219
,,Homo sapiens,Autocuration,1,105,B,D,,,,9,CHEMBL617306,,9606.0,2011,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,12469,,,BAO_0000219
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL617307,,,2012,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,5619,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,105,B,H,,,,8,CHEMBL617308,,9986.0,2013,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617309,,,2014,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,16633,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617310,,,2015,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,16633,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617311,,,2016,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,16633,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617312,,,2017,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,16633,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL617313,,,2018,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,3269,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL617314,,,2019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,12409,,,BAO_0000357
,,,Autocuration,1,106,F,H,,,,8,CHEMBL617315,,,2020,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,,BAO_0000019
722.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL617316,,,2021,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,13706,,HEK293,BAO_0000219
722.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL617317,,,2022,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,13706,,HEK293,BAO_0000219
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL617318,,,2023,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,CHO,BAO_0000219
,,,Autocuration,1,106,B,H,,,,8,CHEMBL617319,,,2024,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,,Expert,1,106,B,D,,,,9,CHEMBL617320,,,2025,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,,BAO_0000357
,,,Expert,1,106,B,D,,,,9,CHEMBL617321,,,2026,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,,BAO_0000357
,,,Expert,1,106,B,D,,,,9,CHEMBL617322,,,2027,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,13366,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616862,,,2028,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,13366,,,BAO_0000357
,,,Autocuration,1,106,B,H,,,,8,CHEMBL616863,,,2029,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,13366,,,BAO_0000357
449.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616864,,,2030,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,12469,,CHO,BAO_0000219
485.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616865,,,2031,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,106,B,H,,,,8,CHEMBL616866,,,2032,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,13706,,CHO-K1,BAO_0000219
,,,Autocuration,1,106,F,H,,,,8,CHEMBL616867,,,2033,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,13706,,,BAO_0000019
485.0,,,Expert,1,106,B,H,,,,8,CHEMBL616868,,,2034,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,12902,,CHO-K1,BAO_0000219
,,,Expert,1,105,B,H,,,,8,CHEMBL616869,,,2035,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,13051,,,BAO_0000357
449.0,,,Expert,1,106,B,H,,,,8,CHEMBL616870,,,2036,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,12903,,CHO,BAO_0000219
485.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL616871,,,2037,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,1558,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL616872,,,2038,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,1558,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL616873,,,2039,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,1558,,CHO-K1,BAO_0000219
485.0,,,Autocuration,1,105,F,H,,,,8,CHEMBL616838,,,2040,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,1558,,CHO-K1,BAO_0000219
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616839,,,2041,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,1558,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,106,B,H,,,,8,CHEMBL616840,,9986.0,2042,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616841,,,2043,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,13313,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL616842,,,2044,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,13313,,,BAO_0000357
,,,Expert,1,105,B,H,,,,8,CHEMBL857976,,,2045,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,12409,,,BAO_0000357
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616843,,,2046,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,10618,B,D,,,,9,CHEMBL616844,,9606.0,2047,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,1348,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616845,,,2048,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,1348,,,BAO_0000357
,,Homo sapiens,Expert,1,10618,B,D,,,,9,CHEMBL616846,,9606.0,2049,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,4234,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616847,,,2050,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616848,,,2051,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,10444,,,BAO_0000019
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616849,,,2052,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,3935,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL872911,,,2053,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,15818,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616850,,,2054,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,17085,,,BAO_0000019
449.0,,Homo sapiens,Expert,1,10618,B,D,,,,9,CHEMBL616699,,9606.0,2055,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,12936,,CHO,BAO_0000219
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616700,,,2056,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,6166,,,BAO_0000357
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616701,,,2057,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616702,,,2058,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616703,,,2059,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,15779,,CHO,BAO_0000219
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616704,,,2060,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,13181,,,BAO_0000357
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616705,,,2061,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,4199,,CHO,BAO_0000219
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616706,,,2062,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,14875,,,BAO_0000357
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616707,,,2063,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,15146,,CHO,BAO_0000219
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616708,,,2064,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,5213,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616709,,,2065,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,12146,,,BAO_0000357
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616710,,,2066,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,13267,,CHO,BAO_0000219
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616711,,,2067,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,14818,,CHO,BAO_0000219
449.0,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616712,,,2068,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,CHO,BAO_0000219
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616713,,,2069,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616714,,,2070,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616715,,,2071,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,14159,,,BAO_0000357
,,,Autocuration,1,10618,B,H,,,,8,CHEMBL616716,,,2072,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,16633,,,BAO_0000357
,,,Autocuration,1,279,F,H,,,,8,CHEMBL616717,,,2073,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,17085,,,BAO_0000019
,,,Expert,1,279,F,H,,,,8,CHEMBL616718,,,2074,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,17085,,,BAO_0000019
,,,Autocuration,1,279,F,H,,,,8,CHEMBL875905,,,2075,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,16209,,,BAO_0000019
,,,Autocuration,1,279,F,H,,,,8,CHEMBL616719,,,2076,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,16209,,,BAO_0000019
,,,Expert,1,279,F,H,,,,8,CHEMBL616720,,,2077,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,17085,,,BAO_0000019
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616721,,,2078,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,14159,,,BAO_0000357
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL616722,,,2079,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616723,,,2080,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL616724,,,2081,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,16190,,CHO,BAO_0000219
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616725,,,2082,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,16190,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616726,,,2083,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,16209,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616727,,,2084,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,16209,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616728,,,2085,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL616729,,,2086,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,6866,,,BAO_0000357
,,,Expert,1,279,B,H,,,,8,CHEMBL616730,,,2087,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,17085,,,BAO_0000019
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617125,,,2088,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,16312,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL857977,,,2089,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,6166,,,BAO_0000357
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617126,,,2090,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,15779,,CHO,BAO_0000219
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617127,,,2091,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,4199,,CHO,BAO_0000219
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617128,,,2092,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,14875,,,BAO_0000357
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617129,,,2093,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,15146,,CHO,BAO_0000219
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617130,,,2094,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,5213,,,BAO_0000357
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617131,,,2095,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,14818,,CHO,BAO_0000219
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617132,,,2096,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,CHO,BAO_0000219
449.0,,,Autocuration,1,279,B,H,,,,8,CHEMBL617133,,,2097,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,4829,,CHO,BAO_0000219
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617134,,,2098,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617135,,,2099,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,279,B,H,,,,8,CHEMBL617136,,,2100,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,5014,,,BAO_0000357
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617137,,,2101,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,11662,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617138,,,2102,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,11662,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617139,,,2103,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617140,,,2104,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,14093,,,BAO_0000019
,,,Autocuration,1,104686,F,H,In vivo,,,4,CHEMBL617141,,,2105,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,11200,,,BAO_0000218
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL858112,,,2106,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,,,Intermediate,1,17005,B,H,,,,8,CHEMBL617142,,,2107,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,12352,,,BAO_0000019
,,Bos taurus,Autocuration,1,22226,B,U,,,,0,CHEMBL617143,,9913.0,2108,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,13657,,,BAO_0000019
,,Bos taurus,Autocuration,1,22226,B,U,,,,0,CHEMBL617144,,9913.0,2109,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,14331,,,BAO_0000019
,,Bos taurus,Autocuration,1,22226,B,U,,,,0,CHEMBL617145,,9913.0,2110,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,14331,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617146,,,2111,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,14331,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104784,B,H,,,,4,CHEMBL617147,,10141.0,2112,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,12685,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104784,B,H,,,,4,CHEMBL617148,,10141.0,2113,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,14389,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104784,B,H,,,,4,CHEMBL617149,,10141.0,2114,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,14386,,,BAO_0000019
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617150,,,2115,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,5732,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617151,,,2116,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,16293,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617201,,,2117,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,2078,,,BAO_0000224
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL617202,,,2118,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,5486,,,BAO_0000357
,,,Autocuration,1,104826,B,H,In vivo,,,4,CHEMBL617203,,,2119,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,11820,,,BAO_0000218
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617204,,,2120,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,10297,,,BAO_0000019
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617205,,,2121,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,13704,,,BAO_0000224
,,Mus musculus,Autocuration,1,104826,B,D,,,,5,CHEMBL617206,,10090.0,2122,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,10297,,,BAO_0000019
,,,Autocuration,1,104826,B,H,In vivo,,,4,CHEMBL617207,,,2123,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,11820,,,BAO_0000218
,,Mus musculus,Autocuration,1,104826,B,D,,,,5,CHEMBL617208,,10090.0,2124,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,10297,,,BAO_0000019
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617209,,,2125,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,11555,,,BAO_0000224
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617210,,,2126,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,11555,,,BAO_0000224
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617211,,,2127,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,11555,,,BAO_0000224
,,Mus musculus,Autocuration,1,104826,B,D,,,,5,CHEMBL617212,,10090.0,2128,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,10297,,,BAO_0000019
,,Sus scrofa,Autocuration,1,104784,B,H,,,,4,CHEMBL617213,,9823.0,2129,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,16688,,,BAO_0000224
,,Sus scrofa,Autocuration,1,104784,B,H,,,,4,CHEMBL617214,,9823.0,2130,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,16688,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617215,,,2131,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,5333,,,BAO_0000221
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617216,,,2132,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,4437,,,BAO_0000221
,,Sus scrofa,Autocuration,1,17005,B,H,,,,8,CHEMBL617217,,9823.0,2133,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,5033,,,BAO_0000357
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617218,,,2134,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,15267,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL872913,,,2135,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,15267,,,BAO_0000019
,,,Autocuration,1,104826,B,H,,,,4,CHEMBL617219,,,2136,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,11820,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL873482,,,2137,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,9069,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617220,,10116.0,2138,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,9162,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617221,,,2139,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,9162,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617222,,,2140,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,9162,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL875906,,,2141,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,10428,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617223,,,2142,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,9628,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617224,,,2143,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,12704,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617225,,10116.0,2144,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,15453,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617226,,,2145,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,188,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617227,,,2146,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,10349,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617228,,,2147,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,10349,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617229,,,2148,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,8868,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617230,,,2149,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,10025,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617231,,,2150,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,10025,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617232,,,2151,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,11702,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617233,,,2152,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,11702,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617234,,,2153,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,11702,,,BAO_0000224
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617235,,,2154,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,11702,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617236,,,2155,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,11702,,,BAO_0000019
,Hippocampus,,Autocuration,1,104686,B,H,,,10000000.0,4,CHEMBL617237,,,2156,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,10085,,,BAO_0000221
,Hippocampus,,Autocuration,1,104686,B,H,,,10000000.0,4,CHEMBL617238,,,2157,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,10085,,,BAO_0000221
,Brain,Rattus norvegicus,Autocuration,1,104686,B,D,,,955.0,5,CHEMBL617239,,10116.0,2158,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,9630,,,BAO_0000221
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617240,,,2159,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,11070,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617241,,,2160,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,9841,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL875907,,,2161,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,9841,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617242,,,2162,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,13291,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617152,,,2163,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,10590,,,BAO_0000019
,Brain,Rattus norvegicus,Autocuration,1,104686,B,D,,,955.0,5,CHEMBL617153,,10116.0,2164,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,9064,,,BAO_0000221
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617154,,10116.0,2165,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Membranes,12268,,,BAO_0000249
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617155,,,2166,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,13508,,,BAO_0000221
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617156,,,2167,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,11279,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617157,,,2168,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617158,,,2169,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617159,,,2170,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617160,,,2171,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL858113,,,2172,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617247,,,2173,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,9231,,,BAO_0000220
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617248,,,2174,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,9737,,,BAO_0000019
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617249,,,2175,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,9737,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617250,,,2176,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,9737,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617251,,,2177,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,9737,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617252,,10116.0,2178,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,11828,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617006,,,2179,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,12253,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617007,,,2180,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,12253,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617008,,,2181,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,11279,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617009,,,2182,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,11866,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617010,,10116.0,2183,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,14424,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL857978,,10116.0,2184,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,15180,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617011,,10116.0,2185,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,15180,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617012,,10116.0,2186,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,9786,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617013,,,2187,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,12132,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617014,,,2188,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,5486,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617015,,,2189,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,15316,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617016,,,2190,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,16429,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617017,,,2191,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,14617,,,BAO_0000224
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617018,,,2192,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,11351,,,BAO_0000221
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617019,,,2193,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,11279,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617020,,,2194,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617021,,,2195,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617022,,,2196,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617023,,,2197,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617024,,,2198,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617025,,,2199,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,9523,,,BAO_0000019
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617026,,,2200,,Hill coefficient of compound was determined,,9523,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617027,,,2201,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,4771,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617028,,10116.0,2202,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,5033,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617029,,,2203,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,10845,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL875908,,,2204,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,10845,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617030,,,2205,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,16288,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617031,,,2206,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,16288,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617032,,,2207,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,16190,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617033,,10116.0,2208,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,12463,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617034,,,2209,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,9699,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617035,,,2210,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,9699,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617036,,,2211,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,,BAO_0000019
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617037,,,2212,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,1205,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617038,,,2213,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,11376,,,BAO_0000219
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617039,,,2214,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,11376,,,BAO_0000219
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617161,,,2215,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,4639,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617162,,,2216,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,2222,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617163,,,2217,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,1558,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617164,,,2218,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,1089,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617165,,,2219,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Brain membranes,386,,,BAO_0000249
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617166,,,2220,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,2474,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617167,,,2221,,Binding affinity towards 5-HT2 receptor,,17066,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL872912,,,2222,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,959,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617168,,,2223,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,6398,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617169,,,2224,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,11889,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617170,,,2225,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4221,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617171,,,2226,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,11026,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617172,,,2227,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,11866,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617173,,,2228,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,4221,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL617174,,,2229,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,13950,,,BAO_0000019
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617175,,,2230,,5-hydroxytryptamine 2 receptor binding affinity,,1263,,,BAO_0000224
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617176,,,2231,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,13291,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617177,,,2232,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,10812,,,BAO_0000357
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617178,,,2233,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,13020,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617179,,,2234,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,13021,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617180,,,2235,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,13020,,,BAO_0000224
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617181,,,2236,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,14532,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617182,,,2237,,Binding affinity against 5-hydroxytryptamine 2 receptor,,13944,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617183,,,2238,,Binding affinity against 5-hydroxytryptamine 2 receptor,,14331,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617184,,,2239,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,14118,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617185,,,2240,,Binding affinity against serotonergic 5-HT2 receptor,,13033,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617186,,,2241,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,10321,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617187,,,2242,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,12918,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617188,,,2243,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,15120,,,BAO_0000357
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617189,,,2244,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,2613,,,BAO_0000218
,,Homo sapiens,Autocuration,1,104784,B,D,,,,5,CHEMBL617190,,9606.0,2245,,Inhibitory activity against cloned human 5-HT2 receptor,,13378,,,BAO_0000224
449.0,,Homo sapiens,Autocuration,1,104784,B,D,,,,5,CHEMBL617191,,9606.0,2246,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,2331,,CHO,BAO_0000219
449.0,,Homo sapiens,Autocuration,1,104784,B,D,,,,5,CHEMBL617192,,9606.0,2247,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,2331,,CHO,BAO_0000219
449.0,,Homo sapiens,Autocuration,1,104784,B,D,,,,5,CHEMBL617193,,9606.0,2248,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,2331,,CHO,BAO_0000219
449.0,,Homo sapiens,Autocuration,1,104784,B,D,,,,5,CHEMBL617194,,9606.0,2249,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,2331,,CHO,BAO_0000219
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL617195,,,2250,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,4170,,,BAO_0000224
,,,Autocuration,1,104784,B,H,,,,4,CHEMBL881830,,,2251,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,15453,,,BAO_0000224
,,,Autocuration,1,17005,B,H,,,,8,CHEMBL617196,,,2252,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,1479,,,BAO_0000357
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617197,,,2253,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,11139,,,BAO_0000224
,,,Expert,1,17005,B,H,,,,8,CHEMBL617198,,,2254,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,13969,,,BAO_0000357
,,,Expert,1,17005,B,H,,,,8,CHEMBL873476,,,2255,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,13392,,,BAO_0000357
,,,Expert,1,17005,B,H,,,,8,CHEMBL617199,,,2256,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,14430,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,107,B,H,,,,8,CHEMBL617200,,10141.0,2257,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,13181,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL617484,,,2258,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617485,,,2259,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL617486,,,2260,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL858022,,,2261,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,13463,,,BAO_0000357
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617049,,,2262,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,6347,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,107,F,D,,,,9,CHEMBL617050,,9606.0,2263,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,CHO,BAO_0000219
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617051,,,2264,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,4176,,,BAO_0000219
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617052,,,2265,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,4176,,,BAO_0000219
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617053,,,2266,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,4176,,,BAO_0000219
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617054,,,2267,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,6347,,CHO,BAO_0000219
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617055,,,2268,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,6347,,CHO,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL882924,,,2269,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,15331,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617056,,9606.0,2270,,Inhibition of human 5-hydroxytryptamine 2A receptor,,16146,,,BAO_0000357
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617057,,,2271,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
,,,Expert,1,107,B,H,,,,8,CHEMBL617058,,,2272,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,13631,,,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617059,,,2273,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617060,,,2274,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,4011,,CHO,BAO_0000219
449.0,,,Expert,1,107,B,H,,,,8,CHEMBL617061,,,2275,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,4012,,CHO,BAO_0000219
307.0,,,Expert,1,107,B,H,,,,8,CHEMBL617062,,,2276,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,6366,,L929,BAO_0000219
449.0,,,Expert,1,107,B,H,,,,8,CHEMBL617063,,,2277,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,15949,,CHO,BAO_0000219
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617064,,,2278,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617065,,,2279,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,13481,,,BAO_0000019
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617066,,,2280,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,6347,,CHO,BAO_0000219
449.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617067,,,2281,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,6347,,CHO,BAO_0000219
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617068,,,2282,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617069,,,2283,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,14093,,,BAO_0000019
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617070,,,2284,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,13481,,,BAO_0000019
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617071,,,2285,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL872915,,,2286,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617072,,,2287,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,14755,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617073,,,2288,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,16441,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617074,,,2289,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,14744,,,BAO_0000357
449.0,,,Expert,1,107,B,H,,,,8,CHEMBL617075,,,2290,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,16659,,CHO,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617076,,,2291,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,3307,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617077,,9606.0,2292,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,6857,,,BAO_0000019
,,,Expert,1,107,B,H,,,,8,CHEMBL617078,,,2293,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,5635,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617079,,9606.0,2294,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,4234,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617080,,,2295,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,15527,,,BAO_0000357
449.0,,,Expert,1,107,B,H,,,,8,CHEMBL617081,,,2296,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,6588,,CHO,BAO_0000219
,,,Expert,1,107,B,H,,,,8,CHEMBL617082,,,2297,,Binding affinity towards human 5-HT2A receptor in BEK cells,,13631,,,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617083,,,2298,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,17723,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617084,,,2299,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,14770,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617085,,9606.0,2300,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,16293,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617086,,,2301,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617087,,,2302,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,12469,,,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617088,,,2303,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,15363,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617089,,,2304,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,15363,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617090,,,2305,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,16441,,,BAO_0000019
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617513,,,2306,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,8,,,BAO_0000357
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617514,,,2307,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,4176,,HEK293,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617515,,,2308,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,17085,,,BAO_0000019
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617516,,,2309,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617517,,9606.0,2310,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
449.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617518,,9606.0,2311,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,4013,,CHO,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617519,,,2312,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,5088,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617520,,9606.0,2313,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,5088,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617521,,,2314,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,5088,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617522,,9606.0,2315,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,5088,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617523,,,2316,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617524,,,2317,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617525,,,2318,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,9786,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617526,,10116.0,2319,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,9205,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617527,,,2320,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,11257,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617528,,,2321,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,9362,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617529,,,2322,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,9362,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617530,,,2323,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,10590,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617531,,,2324,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,10468,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617532,,,2325,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,13050,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617533,,,2326,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,11624,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617534,,,2327,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,10468,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617535,,,2328,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,10330,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617536,,,2329,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,10062,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617537,,,2330,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,11642,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617538,,,2331,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104686,B,H,In vitro,,,4,CHEMBL617539,,,2332,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,13427,,,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617540,,10116.0,2333,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,12280,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617541,,10116.0,2334,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,4101,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617542,,,2335,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,10062,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617543,,,2336,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,11147,,,BAO_0000224
485.0,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617544,,10116.0,2337,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,CHO-K1,BAO_0000219
485.0,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617545,,10116.0,2338,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2395,,CHO-K1,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617413,,10116.0,2339,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617414,,,2340,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,9098,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617415,,10116.0,2341,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617416,,,2342,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,9443,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617417,,,2343,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,9443,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617418,,,2344,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,9699,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617419,,,2345,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,9699,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617420,,,2346,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,9098,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617421,,10116.0,2347,,Affinity for 5-hydroxytryptamine 2 receptor,,3070,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617422,,,2348,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,9547,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617423,,,2349,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,10444,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617424,,,2350,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,14617,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617425,,,2351,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,14617,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617426,,,2352,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,11130,,,BAO_0000224
,,,Autocuration,1,104686,B,H,In vivo,,,4,CHEMBL617427,,,2353,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,11130,,,BAO_0000218
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617428,,,2354,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,14542,,,BAO_0000221
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617429,,,2355,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,2797,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617430,,,2356,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,11332,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617431,,,2357,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,11332,,,BAO_0000019
,Frontal cortex,,Autocuration,1,104686,B,H,,,1870.0,4,CHEMBL617432,,,2358,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,10752,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617433,,,2359,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,1185,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617434,,,2360,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,1185,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617435,,10116.0,2361,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,11624,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617436,,,2362,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,1344,,,BAO_0000019
,Striatum,Rattus norvegicus,Autocuration,1,104686,B,D,,,2435.0,5,CHEMBL617437,,10116.0,2363,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,15453,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617438,,,2364,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,11662,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617439,,,2365,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,11662,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617440,,,2366,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,10796,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617441,,,2367,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,9069,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL872918,,10116.0,2368,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,8814,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617442,,10116.0,2369,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,8908,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617443,,,2370,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617444,,,2371,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617445,,,2372,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617446,,,2373,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617447,,,2374,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,9098,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617448,,,2375,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617449,,,2376,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,9098,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617450,,,2377,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617451,,,2378,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617452,,,2379,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617453,,,2380,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617660,,,2381,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617661,,,2382,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617662,,,2383,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL872919,,,2384,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617663,,,2385,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617664,,,2386,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617665,,,2387,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617666,,,2388,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,9161,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617667,,,2389,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,12094,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617668,,,2390,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,12018,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617669,,,2391,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,10394,,,BAO_0000249
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617670,,,2392,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,15260,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617671,,10116.0,2393,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,11624,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617672,,,2394,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,13654,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617673,,,2395,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,9541,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617674,,,2396,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,11933,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617675,,,2397,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,15538,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617676,,,2398,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,15538,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617677,,,2399,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,15538,,,BAO_0000019
,,,Autocuration,1,104686,B,D,,,,5,CHEMBL617678,,,2400,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,8841,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617679,,,2401,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,1455,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617680,,,2402,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,1455,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617681,,,2403,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,11752,,,BAO_0000019
,Brain,,Autocuration,1,104686,B,H,,,955.0,4,CHEMBL617682,,,2404,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,11642,,,BAO_0000221
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617683,,,2405,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,12092,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617684,,,2406,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,3967,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104686,B,D,,,,5,CHEMBL617685,,10116.0,2407,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,12771,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617686,,,2408,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,11642,,,BAO_0000019
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617687,,,2409,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,11628,,,BAO_0000224
,,,Autocuration,1,104686,B,H,,,,4,CHEMBL617688,,,2410,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,13654,,,BAO_0000224
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617689,,,2411,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,,,,4,CHEMBL617690,,,2412,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,11200,,,BAO_0000019
,,,Autocuration,1,104686,F,H,In vivo,,,4,CHEMBL617691,,,2413,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,11200,,,BAO_0000218
,,,Autocuration,1,104686,F,H,In vivo,,,4,CHEMBL617692,,,2414,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,11200,,,BAO_0000218
,,,Autocuration,1,104686,F,H,In vivo,,,4,CHEMBL617693,,,2415,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,11200,,,BAO_0000218
,,,Autocuration,1,104686,F,H,In vivo,,,4,CHEMBL617694,,,2416,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,11200,,,BAO_0000218
,Brain,,Expert,1,12687,B,H,,,955.0,8,CHEMBL857985,,,2417,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,15436,,,BAO_0000221
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617695,,10116.0,2418,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617696,,,2419,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,14025,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617697,,,2420,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,4342,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617257,,10116.0,2421,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,13735,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617258,,10116.0,2422,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,5816,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617259,,,2423,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,14287,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617260,,,2424,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,15738,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617261,,10116.0,2425,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,15738,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617262,,,2426,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,15026,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617263,,,2427,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,16647,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617264,,,2428,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,16647,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617265,,10116.0,2429,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,13345,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617266,,,2430,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Membranes,1543,,,BAO_0000249
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617267,,,2431,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,12444,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617268,,,2432,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,16404,,,BAO_0000019
449.0,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617269,,,2433,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,16404,,CHO,BAO_0000219
,,,Expert,1,12687,B,H,,,,8,CHEMBL617323,,,2434,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,15577,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617324,,,2435,,Serotonergic activity of the compound.,,15577,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617325,,,2436,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,2495,,,BAO_0000249
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617326,,10116.0,2437,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,15042,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617327,,,2438,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,15026,,,BAO_0000249
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617328,,10116.0,2439,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617329,,10116.0,2440,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617330,,10116.0,2441,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,12919,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617331,,,2442,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,15194,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617332,,,2443,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,15194,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617333,,,2444,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,4820,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617334,,,2445,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,6736,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617335,,,2446,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,5163,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617336,,,2447,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,5163,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617337,,,2448,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,6011,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617338,,9606.0,2449,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,14294,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617339,,,2450,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,5014,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617340,,,2451,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,17066,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617341,,,2452,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617342,,,2453,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,6736,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617343,,,2454,,Affinity for 5-hydroxytryptamine 2A receptor,,5163,,,BAO_0000357
723.0,,,Expert,1,107,B,H,,,,8,CHEMBL617344,,,2455,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,16911,,NIH3T3,BAO_0000219
,,,Expert,1,107,B,H,,,,8,CHEMBL617345,,,2456,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,6841,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617346,,,2457,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,6119,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617347,,,2458,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,3962,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617348,,,2459,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617349,,,2460,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,107,F,H,,,,8,CHEMBL617350,,,2461,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,3962,,,BAO_0000019
,,,Expert,1,107,B,H,,,,8,CHEMBL872339,,,2462,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,1633,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617351,,,2463,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617352,,,2464,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,6576,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617353,,,2465,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,4687,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617354,,,2466,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,16946,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617355,,,2467,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,14159,,,BAO_0000357
449.0,,Mus musculus,Expert,1,107,B,H,,,,8,CHEMBL617356,,10090.0,2468,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,3032,,CHO,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617357,,,2469,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,16655,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617358,,,2470,,Binding affinity at 5-hydroxytryptamine 2A receptor,,13964,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617359,,,2471,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,16989,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617360,,,2472,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,16117,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL875913,,,2473,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,16700,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617361,,,2474,,Affinity against 5-hydroxytryptamine 2A receptor,,3269,,,BAO_0000357
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617362,,9606.0,2475,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,1274,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617363,,,2476,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,1317,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617364,,,2477,,Tested against 5-hydroxytryptamine 2A receptor,,12146,,,BAO_0000357
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617365,,,2478,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,12652,,,BAO_0000224
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617366,,,2479,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,12652,,,BAO_0000224
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617367,,,2480,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,12652,,,BAO_0000224
,,,Autocuration,1,105075,B,H,,,,4,CHEMBL617368,,,2481,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,12652,,,BAO_0000224
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617369,,,2482,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,16647,,,BAO_0000357
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617370,,9606.0,2483,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,15851,,HEK293,BAO_0000219
449.0,,Homo sapiens,Expert,1,227,F,D,,,,9,CHEMBL617371,,9606.0,2484,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,CHO,BAO_0000219
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617372,,,2485,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617373,,9606.0,2486,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,6491,,,BAO_0000357
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617374,,,2487,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617375,,,2488,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,13481,,,BAO_0000019
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617376,,,2489,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617377,,,2490,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,14093,,,BAO_0000019
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617378,,,2491,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,227,F,H,,,,8,CHEMBL617379,,,2492,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,13481,,,BAO_0000019
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617380,,,2493,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617381,,,2494,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617382,,,2495,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617383,,,2496,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,12369,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617384,,,2497,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,12369,,,BAO_0000357
,,,Expert,1,107,B,H,,,,8,CHEMBL617385,,,2498,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,12369,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617386,,,2499,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,14447,,,BAO_0000019
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617387,,,2500,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,14447,,,BAO_0000019
723.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617388,,,2501,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,NIH3T3,BAO_0000219
449.0,,,Autocuration,1,107,F,H,,,,8,CHEMBL617389,,,2502,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,107,F,D,,,,9,CHEMBL617390,,9606.0,2503,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,CHO,BAO_0000219
,,,Autocuration,1,104817,B,H,,,,4,CHEMBL617391,,,2504,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,5635,,,BAO_0000224
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617392,,,2505,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617393,,,2506,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
307.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617394,,,2507,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,5105,,L929,BAO_0000219
307.0,,,Expert,1,107,B,H,,,,8,CHEMBL617395,,,2508,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,5104,,L929,BAO_0000219
307.0,,,Expert,1,107,B,H,,,,8,CHEMBL617396,,,2509,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,5105,,L929,BAO_0000219
307.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617397,,,2510,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,5105,,L929,BAO_0000219
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617398,,,2511,,Binding affinity against 5-HT2A receptor,,5254,,,BAO_0000357
,,,Autocuration,1,107,B,H,,,,8,CHEMBL617399,,,2512,,Binding affinity against 5-hydroxytryptamine 2A receptor,,5254,,,BAO_0000357
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617400,,,2513,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,13267,,HEK293,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617401,,,2514,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,13267,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617402,,9606.0,2515,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,14157,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617403,,9606.0,2516,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,HEK293,BAO_0000219
,,,Expert,1,107,B,H,,,,8,CHEMBL617404,,,2517,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,14068,,,BAO_0000357
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL857981,,9606.0,2518,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617405,,9606.0,2519,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL617253,,9606.0,2520,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,4540,,HEK293,BAO_0000219
,,,Expert,1,107,B,H,,,,8,CHEMBL617254,,,2521,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,6166,,,BAO_0000357
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617255,,,2522,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL617256,,,2523,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616874,,,2524,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,17296,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL616875,,9606.0,2525,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,107,B,H,,,,8,CHEMBL616876,,,2526,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,14391,,HEK293,BAO_0000219
722.0,,,Expert,1,107,B,H,,,,8,CHEMBL616877,,,2527,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,15851,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL616878,,9606.0,2528,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,15851,,HEK293,BAO_0000219
722.0,,,Expert,1,107,B,H,,,,8,CHEMBL616879,,,2529,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,3832,,HEK293,BAO_0000219
722.0,,,Expert,1,107,B,H,,,,8,CHEMBL616880,,,2530,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,3833,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL616881,,9606.0,2531,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,12936,,HEK293,BAO_0000219
723.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616882,,,2532,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,17451,,NIH3T3,BAO_0000219
723.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616883,,,2533,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,NIH3T3,BAO_0000219
723.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616884,,,2534,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,NIH3T3,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616885,,,2535,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,4199,,HEK293,BAO_0000219
485.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616886,,,2536,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,1883,,CHO-K1,BAO_0000219
485.0,,,Expert,1,107,B,H,,,,8,CHEMBL616887,,,2537,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,1883,,CHO-K1,BAO_0000219
,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL616888,,9606.0,2538,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,14875,,,BAO_0000357
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616889,,,2539,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,15146,,HEK293,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616890,,,2540,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,5213,,HEK293,BAO_0000219
449.0,,Homo sapiens,Expert,1,107,B,D,,,,9,CHEMBL616891,,9606.0,2541,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,16404,,CHO,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616892,,,2542,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,107,B,H,,,,8,CHEMBL616893,,,2543,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,4829,,HEK293,BAO_0000219
723.0,,,Autocuration,1,10620,F,H,,,,8,CHEMBL616894,,,2544,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,12652,,NIH3T3,BAO_0000219
723.0,,,Expert,1,107,B,H,,,,8,CHEMBL616895,,,2545,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,4682,,NIH3T3,BAO_0000219
,,,Autocuration,1,10620,F,H,,,,8,CHEMBL616896,,,2546,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,12652,,,BAO_0000019
,,,Autocuration,1,10621,B,H,,,,8,CHEMBL617099,,,2547,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,4921,,,BAO_0000357
,,,Autocuration,1,10621,B,H,,,,8,CHEMBL617100,,,2548,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,4921,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,107,B,H,,,,8,CHEMBL884532,,9986.0,2549,,Binding affinity against rabbit aorta 5-HT2A receptor,,16312,,,BAO_0000357
,,Oryctolagus cuniculus,Expert,1,107,B,H,,,,8,CHEMBL617101,,9986.0,2550,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,14998,,,BAO_0000357
,,Oryctolagus cuniculus,Expert,1,107,B,H,,,,8,CHEMBL617102,,9986.0,2551,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,14025,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,107,B,H,,,,8,CHEMBL617103,,9986.0,2552,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Oryctolagus cuniculus,Expert,1,107,B,H,,,,8,CHEMBL617104,,9986.0,2553,,The compound was tested for binding affinity against 5-HT2A receptor,,13047,,,BAO_0000357
485.0,,,Autocuration,1,10576,B,H,,,,8,CHEMBL857979,,,2554,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,1883,,CHO-K1,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL857502,,,2555,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,13463,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617105,,,2556,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,13463,,,BAO_0000019
,Stomach,,Autocuration,1,12687,B,H,,,945.0,8,CHEMBL858021,,,2557,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,13463,,,BAO_0000019
,Stomach,Rattus norvegicus,Expert,1,12687,B,D,,,945.0,9,CHEMBL875910,,10116.0,2558,,Binding affinity for 5-HT 2A in rat stomach fundus,,13463,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617106,,,2559,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,13463,,,BAO_0000019
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL617107,,,2560,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,16326,,NIH3T3,BAO_0000219
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617108,,,2561,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,14093,,,BAO_0000019
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617109,,,2562,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,14093,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617110,,,2563,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,15740,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617111,,,2564,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,16633,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617112,,10116.0,2565,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,17200,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617113,,,2566,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617114,,,2567,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617115,,,2568,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,17133,,,BAO_0000357
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617116,,,2569,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,,BAO_0000219
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617117,,,2570,,Efficacy at 5-hydroxytryptamine 2A receptor,,15363,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617118,,,2571,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,17200,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617119,,10116.0,2572,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,17200,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617120,,10116.0,2573,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,17200,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617121,,10116.0,2574,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,,BAO_0000219
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617122,,,2575,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,17200,,,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617123,,,2576,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,17211,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617124,,,2577,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,17331,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617600,,,2578,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,13565,,,BAO_0000249
,,,Expert,1,12687,B,H,,,,8,CHEMBL617601,,,2579,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,13730,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL882923,,,2580,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,12416,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617602,,,2581,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,15295,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617603,,,2582,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,1742,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617604,,,2583,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,15295,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617605,,,2584,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,14970,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617606,,,2585,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,16693,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617607,,10116.0,2586,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,14776,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617455,,,2587,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,14286,,,BAO_0000249
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617456,,10116.0,2588,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,17200,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617457,,,2589,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,15306,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617458,,10116.0,2590,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,14178,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617459,,10116.0,2591,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,14229,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617460,,,2592,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,12884,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617461,,,2593,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,13149,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617462,,10116.0,2594,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,15295,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617463,,,2595,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,15740,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617464,,,2596,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,15185,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617465,,,2597,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,15185,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617466,,,2598,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,17529,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617467,,,2599,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,14826,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617468,,,2600,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,17211,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617469,,,2601,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,14826,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617470,,,2602,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,14093,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617471,,,2603,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,14093,,,BAO_0000019
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL617472,,,2604,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,13246,,NIH3T3,BAO_0000219
,,,Expert,1,12687,B,H,,,,8,CHEMBL617473,,,2605,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,13246,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617474,,10116.0,2606,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617475,,10116.0,2607,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,15436,,,BAO_0000019
,Brain,,Autocuration,1,12687,B,H,,,955.0,8,CHEMBL617476,,,2608,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,14442,,,BAO_0000221
,,,Expert,1,12687,B,H,,,,8,CHEMBL617477,,,2609,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,12457,,,BAO_0000357
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL617478,,,2610,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,12457,,NIH3T3,BAO_0000219
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617479,,,2611,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,14755,,,BAO_0000221
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617480,,,2612,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,4707,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617481,,,2613,,Binding affinity against 5-hydroxytryptamine 2A receptor,,13297,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617482,,,2614,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,17331,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617483,,,2615,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,4664,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621528,,,2616,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16633,,,BAO_0000357
723.0,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL621529,,10116.0,2617,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,4664,,NIH3T3,BAO_0000219
,,,Expert,1,12687,B,H,,,,8,CHEMBL621530,,,2618,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,16133,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL621531,,,2619,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,16133,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL621532,,10116.0,2620,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,14060,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL621533,,,2621,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,16326,,,BAO_0000357
449.0,,,Expert,1,12687,B,H,,,,8,CHEMBL621534,,,2622,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,16659,,CHO,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621535,,,2623,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,14776,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621536,,,2624,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,13481,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621537,,,2625,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,17386,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL621538,,10116.0,2626,,Binding affinity for 5-hydroxytryptamine 2A receptor,,6611,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621539,,,2627,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,14423,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621540,,,2628,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,15412,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621541,,,2629,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,15412,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621542,,,2630,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,6238,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL621543,,,2631,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,6648,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL621544,,,2632,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,5667,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL621545,,10116.0,2633,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,6611,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621546,,,2634,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,13481,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL621547,,,2635,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,13481,,,BAO_0000357
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL618692,,,2636,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,15558,,NIH3T3,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618693,,,2637,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,6013,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL872922,,,2638,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,16633,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618694,,,2639,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,6013,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL618695,,10116.0,2640,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,6013,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618696,,,2641,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,6013,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL618697,,,2642,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,6013,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618892,,,2643,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,6013,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618893,,,2644,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,6013,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618894,,,2645,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,16293,,,BAO_0000357
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL618895,,,2646,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,17175,,NIH3T3,BAO_0000219
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL618896,,10116.0,2647,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,13278,,,BAO_0000357
,Caudate-putamen,,Autocuration,1,12687,B,H,,,5383.0,8,CHEMBL618897,,,2648,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,3682,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618898,,,2649,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,2014,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618899,,,2650,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,2014,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618900,,,2651,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,4932,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618901,,,2652,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,4932,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618902,,,2653,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,3935,,,BAO_0000357
,Hippocampus,Rattus norvegicus,Expert,1,12687,B,D,,,10000000.0,9,CHEMBL618903,,10116.0,2654,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,5432,,,BAO_0000221
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618904,,,2655,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,15818,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618905,,,2656,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,13672,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618906,,,2657,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,13672,,,BAO_0000357
723.0,,,Expert,1,12687,B,H,,,,8,CHEMBL618907,,,2658,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,14749,,NIH3T3,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL618908,,,2659,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,13462,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617909,,,2660,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,15740,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617910,,,2661,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,16647,,,BAO_0000019
,Brain,,Autocuration,1,12687,B,H,,,955.0,8,CHEMBL617911,,,2662,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,13345,,,BAO_0000221
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL872923,,,2663,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,,BAO_0000249
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617912,,,2664,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,,BAO_0000249
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617913,,10116.0,2665,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,15535,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617914,,,2666,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,,BAO_0000249
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617915,,,2667,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,,BAO_0000249
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617916,,,2668,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,16740,,,BAO_0000249
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617917,,10116.0,2669,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,4795,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617918,,,2670,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,8,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617919,,,2671,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,8,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617920,,10116.0,2672,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,17200,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617921,,10116.0,2673,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,2148,,,BAO_0000019
,,Rattus norvegicus,Expert,1,105102,B,D,,,,5,CHEMBL617922,,10116.0,2674,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,13345,,,BAO_0000224
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617923,,,2675,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617924,,,2676,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617925,,,2677,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,17133,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617926,,10116.0,2678,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,17133,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617927,,,2679,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,16532,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617928,,,2680,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,15086,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12687,B,D,,,,9,CHEMBL617929,,10116.0,2681,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2309,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617930,,,2682,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,12953,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617931,,,2683,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,12953,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617932,,,2684,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000019
449.0,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617933,,,2685,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,16659,,CHO,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617934,,,2686,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,16740,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617935,,,2687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,16740,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617936,,,2688,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,17133,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617937,,,2689,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,17211,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617938,,,2690,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,17331,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617939,,,2691,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,16633,,,BAO_0000218
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617940,,,2692,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,16633,,,BAO_0000218
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617941,,,2693,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,16633,,,BAO_0000218
,,,Expert,1,12687,B,H,,,,8,CHEMBL617942,,,2694,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,15026,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617943,,,2695,,Ratio of pKi of 5-HT2A to that of D2 receptor,,15026,,,BAO_0000357
,,,Expert,1,105093,B,H,,,,4,CHEMBL617944,,,2696,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,16404,,,BAO_0000224
,,,Expert,1,105093,B,H,,,,4,CHEMBL617945,,,2697,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,16404,,,BAO_0000224
,,,Expert,1,105075,B,H,,,,4,CHEMBL617946,,,2698,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,16404,,,BAO_0000224
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617947,,,2699,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,16404,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617948,,,2700,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,16326,,,BAO_0000357
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL858116,,,2701,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,15847,,,BAO_0000019
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617949,,,2702,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,15847,,,BAO_0000019
,,,Autocuration,1,12687,F,H,,,,8,CHEMBL617950,,,2703,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,15329,,,BAO_0000019
,Thoracic aorta,,Expert,1,12687,F,H,,,1515.0,8,CHEMBL617951,,,2704,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,16404,,,BAO_0000019
,Thoracic aorta,,Expert,1,12687,F,H,,,1515.0,8,CHEMBL617952,,,2705,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,16404,,,BAO_0000019
,Thoracic aorta,,Autocuration,1,12687,F,H,,,1515.0,8,CHEMBL617953,,,2706,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,16404,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617954,,,2707,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Expert,1,12687,B,H,,,,8,CHEMBL617955,,,2708,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL857071,,,2709,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12861,,,BAO_0000019
,,,Expert,1,12687,B,H,,,,8,CHEMBL617270,,,2710,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,12490,,,BAO_0000019
339.0,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617271,,,2711,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,12827,,N1E-115,BAO_0000219
339.0,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617272,,,2712,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,12827,,N1E-115,BAO_0000219
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617273,,,2713,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,12918,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12687,F,D,,,,9,CHEMBL617274,,10116.0,2714,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,12919,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617275,,,2715,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,17723,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617276,,,2716,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,6013,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617277,,,2717,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,16293,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617278,,,2718,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,3857,,,BAO_0000019
,,,Expert,1,108,B,H,,,,8,CHEMBL617279,,,2719,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,3857,,,BAO_0000019
,,,Expert,1,108,B,H,,,,8,CHEMBL617280,,,2720,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,3857,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617281,,,2721,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,15363,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617282,,,2722,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,15363,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617283,,,2723,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,16441,,,BAO_0000019
,,,Expert,1,108,B,H,,,,8,CHEMBL617284,,,2724,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,16441,,,BAO_0000019
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617285,,,2725,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,4176,,HEK293,BAO_0000219
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617286,,,2726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,17085,,,BAO_0000019
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617287,,9606.0,2727,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617288,,,2728,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,5088,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617289,,,2729,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL872917,,,2730,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,5088,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617290,,,2731,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,5088,,,BAO_0000357
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617291,,,2732,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,16659,,CHO,BAO_0000219
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617292,,,2733,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,16659,,CHO,BAO_0000219
723.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617293,,,2734,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,17451,,NIH3T3,BAO_0000219
449.0,,Homo sapiens,Expert,1,108,F,D,,,,9,CHEMBL617294,,9606.0,2735,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,CHO,BAO_0000219
,,,Expert,1,108,B,H,,,,8,CHEMBL617295,,,2736,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,3857,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617296,,,2737,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617297,,,2738,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL617298,,,2739,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,5104,,CHO,BAO_0000219
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL617299,,,2740,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,5105,,CHO,BAO_0000219
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617300,,,2741,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,5105,,CHO,BAO_0000219
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617454,,,2742,,Binding affinity against 5-HT2C receptor,,5254,,,BAO_0000357
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617505,,,2743,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,13267,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617506,,9606.0,2744,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,14157,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617507,,9606.0,2745,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,12936,,HEK293,BAO_0000219
,,,Expert,1,108,B,H,,,,8,CHEMBL617508,,,2746,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,14068,,,BAO_0000357
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL857982,,9606.0,2747,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,12936,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617509,,9606.0,2748,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,4540,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617510,,9606.0,2749,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,4540,,HEK293,BAO_0000219
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617511,,,2750,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,6166,,,BAO_0000357
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617512,,,2751,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617749,,,2752,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,17296,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617750,,,2753,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617751,,,2754,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,108,B,H,,,,8,CHEMBL617752,,,2755,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,14391,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617753,,,2756,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,108,B,H,,,,8,CHEMBL617754,,,2757,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,15851,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617755,,9606.0,2758,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,15851,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617756,,,2759,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,108,B,H,,,,8,CHEMBL617757,,,2760,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,3832,,HEK293,BAO_0000219
722.0,,,Expert,1,108,B,H,,,,8,CHEMBL617758,,,2761,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,3833,,HEK293,BAO_0000219
723.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617759,,,2762,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,17451,,NIH3T3,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617760,,,2763,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,4199,,HEK293,BAO_0000219
485.0,,,Expert,1,108,B,H,,,,8,CHEMBL617761,,,2764,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,1883,,CHO-K1,BAO_0000219
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617762,,9606.0,2765,,Binding affinity against 5-hydroxytryptamine 2C receptor,,4321,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617763,,,2766,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,14875,,,BAO_0000357
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL857983,,,2767,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,15146,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617764,,,2768,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,5213,,HEK293,BAO_0000219
308.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617765,,,2769,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,16404,,HeLa,BAO_0000219
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617766,,,2770,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,13267,,,BAO_0000019
,Hippocampus,,Autocuration,1,108,F,H,,,10000000.0,8,CHEMBL617767,,,2771,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,13267,,,BAO_0000221
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617768,,,2772,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617769,,,2773,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,4829,,HEK293,BAO_0000219
,,,Autocuration,1,11864,B,H,,,,8,CHEMBL858023,,,2774,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,13463,,,BAO_0000357
,Stomach,,Autocuration,1,11864,B,H,,,945.0,8,CHEMBL617770,,,2775,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,13463,,,BAO_0000019
,Stomach,,Autocuration,1,11864,B,H,,,945.0,8,CHEMBL617771,,,2776,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,13463,,,BAO_0000019
625.0,,,Autocuration,1,11864,F,H,,,,8,CHEMBL617772,,,2777,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,12652,,A9,BAO_0000219
723.0,,,Autocuration,1,11864,B,H,,,,8,CHEMBL617773,,,2778,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,4682,,NIH3T3,BAO_0000219
723.0,,,Autocuration,1,11864,B,H,,,,8,CHEMBL617850,,,2779,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,4682,,NIH3T3,BAO_0000219
723.0,,,Autocuration,1,11864,B,H,,,,8,CHEMBL617851,,,2780,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,4682,,NIH3T3,BAO_0000219
,,,Autocuration,1,11864,F,H,,,,8,CHEMBL617852,,,2781,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,12652,,,BAO_0000019
,Stomach,Mus musculus,Autocuration,1,12689,B,H,,,945.0,8,CHEMBL858024,,10090.0,2782,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,13463,,,BAO_0000019
,Stomach,Rattus norvegicus,Expert,1,12689,B,D,,,945.0,9,CHEMBL617853,,10116.0,2783,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,13463,,,BAO_0000019
,,,Expert,1,108,B,H,,,,8,CHEMBL617854,,,2784,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,13969,,,BAO_0000357
,,Sus scrofa,Expert,1,108,B,H,,,,8,CHEMBL873477,,9823.0,2785,,Binding affinity for 5-hydroxytryptamine 2C receptor,,13392,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617855,,,2786,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,13392,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617856,,,2787,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,14430,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617857,,,2788,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,1742,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617858,,,2789,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,14286,,,BAO_0000249
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617859,,,2790,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,5619,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617860,,,2791,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,15086,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617861,,,2792,,Binding activity radioligand.,,12861,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617862,,,2793,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617863,,,2794,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,12861,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617864,,,2795,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,12827,,,BAO_0000249
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617649,,,2796,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,12827,,,BAO_0000249
,,Sus scrofa,Expert,1,108,F,H,,,,8,CHEMBL617650,,9823.0,2797,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,12919,,,BAO_0000019
,,Sus scrofa,Expert,1,108,F,H,,,,8,CHEMBL617651,,9823.0,2798,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,12919,,,BAO_0000019
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL617652,,9823.0,2799,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,16429,,,BAO_0000357
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL857072,,9823.0,2800,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,773,,,BAO_0000019
,,Sus scrofa,Autocuration,1,108,B,H,,,,8,CHEMBL617653,,9823.0,2801,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,5033,,,BAO_0000357
,,,Autocuration,1,12687,B,H,,,,8,CHEMBL617654,,,2802,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,12689,F,H,,,,8,CHEMBL617655,,,2803,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,14093,,,BAO_0000019
,,,Expert,1,12689,B,H,,,,8,CHEMBL617656,,,2804,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,14970,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617657,,,2805,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,14970,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617658,,,2806,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,14970,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL617659,,10116.0,2807,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,14178,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL617838,,10116.0,2808,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,14178,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL617839,,10116.0,2809,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Brain membranes,14229,,,BAO_0000249
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617840,,,2810,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,16532,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617841,,,2811,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,14826,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL875915,,,2812,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,17211,,,BAO_0000019
,,,Expert,1,12689,B,H,In vitro,,,8,CHEMBL617842,,,2813,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,17211,,,BAO_0000219
723.0,,,Expert,1,12689,B,H,,,,8,CHEMBL617843,,,2814,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,13246,,NIH3T3,BAO_0000219
,,,Expert,1,12689,B,H,,,,8,CHEMBL617844,,,2815,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,13246,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL617845,,,2816,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,12457,,,BAO_0000357
723.0,,,Expert,1,12689,B,H,,,,8,CHEMBL617846,,,2817,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,12457,,NIH3T3,BAO_0000219
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617847,,,2818,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,4707,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL617848,,,2819,,Binding affinity against 5-hydroxytryptamine 2C receptor,,13297,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617849,,,2820,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,16633,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL621507,,,2821,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,16133,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL621508,,,2822,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,16326,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621509,,,2823,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,14423,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621510,,,2824,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,15412,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621511,,,2825,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,15412,,,BAO_0000019
625.0,,,Expert,1,12689,B,H,,,,8,CHEMBL621512,,,2826,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,15558,,A9,BAO_0000219
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621513,,,2827,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,16633,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL621514,,,2828,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,6013,,,BAO_0000357
,,,Expert,1,12689,B,H,In vitro,,,8,CHEMBL621515,,,2829,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,17175,,,BAO_0000219
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621516,,,2830,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,12469,,,BAO_0000219
,Caudate-putamen,,Autocuration,1,12689,B,H,,,5383.0,8,CHEMBL621517,,,2831,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,3682,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621518,,,2832,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,4932,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621519,,,2833,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,4932,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621520,,,2834,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,3935,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621521,,,2835,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,15818,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621522,,,2836,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,15818,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL621523,,,2837,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,14749,,,BAO_0000219
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621524,,,2838,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,15740,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL621525,,10116.0,2839,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,17133,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL872921,,,2840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,16532,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL621526,,,2841,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,12369,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL621527,,,2842,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,12369,,,BAO_0000219
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL617865,,10116.0,2843,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,2309,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617866,,,2844,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,12953,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617867,,,2845,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617487,,,2846,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000357
,,,Expert,1,12689,B,H,,,,8,CHEMBL617488,,,2847,,Binding affinity for 5-hydroxytryptamine 2C receptor,,12953,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617489,,,2848,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,17133,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617490,,,2849,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,17211,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617491,,,2850,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,17211,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617492,,,2851,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,14025,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617493,,,2852,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,14998,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617494,,,2853,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,4342,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12689,B,D,,,,9,CHEMBL617495,,10116.0,2854,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,13735,,,BAO_0000019
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617496,,,2855,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,13181,,,BAO_0000357
485.0,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617497,,,2856,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,1883,,CHO-K1,BAO_0000219
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617498,,,2857,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,15194,,,BAO_0000357
,,,Autocuration,1,12689,B,H,,,,8,CHEMBL617499,,,2858,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,15194,,,BAO_0000357
,,,Autocuration,1,12689,F,H,,,,8,CHEMBL617500,,,2859,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,14579,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617501,,,2860,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,4639,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617502,,,2861,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,4820,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617503,,,2862,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,14442,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617504,,,2863,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,14755,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617406,,,2864,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,14744,,,BAO_0000357
,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617407,,9606.0,2865,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,6857,,,BAO_0000019
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617408,,,2866,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617409,,,2867,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,15363,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617410,,,2868,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,15363,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617411,,,2869,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,15363,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617412,,,2870,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,17085,,,BAO_0000019
,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617774,,9606.0,2871,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,17200,,,BAO_0000357
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617775,,9606.0,2872,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,15851,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617776,,9606.0,2873,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,15851,,HEK293,BAO_0000219
449.0,,Homo sapiens,Expert,1,227,F,D,,,,9,CHEMBL617777,,9606.0,2874,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,227,F,D,,,,9,CHEMBL617778,,9606.0,2875,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,6857,,CHO,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617779,,,2876,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,227,B,H,,,,8,CHEMBL617780,,,2877,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,15851,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617781,,,2878,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,15779,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617782,,9606.0,2879,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,14157,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617783,,9606.0,2880,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,4540,,HEK293,BAO_0000219
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617784,,,2881,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,6166,,,BAO_0000357
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617785,,,2882,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Expert,1,227,B,H,,,,8,CHEMBL857984,,,2883,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,14391,,HEK293,BAO_0000219
722.0,,,Expert,1,227,B,H,,,,8,CHEMBL617786,,,2884,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,3832,,HEK293,BAO_0000219
722.0,,,Expert,1,227,B,H,,,,8,CHEMBL617787,,,2885,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,3833,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617788,,9606.0,2886,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,15851,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,227,B,D,,,,9,CHEMBL617789,,9606.0,2887,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,15851,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617790,,,2888,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,4199,,HEK293,BAO_0000219
485.0,,,Expert,1,227,B,H,,,,8,CHEMBL617791,,,2889,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,1883,,CHO-K1,BAO_0000219
,,,Expert,1,227,B,H,,,,8,CHEMBL617608,,,2890,,Binding affinity against 5-hydroxytryptamine 2B receptor,,4321,,,BAO_0000357
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617609,,,2891,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,15146,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617610,,,2892,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,5213,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617611,,,2893,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617612,,,2894,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,4829,,HEK293,BAO_0000219
722.0,,,Autocuration,1,227,B,H,,,,8,CHEMBL617613,,,2895,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,4829,,HEK293,BAO_0000219
,,Oryctolagus cuniculus,Autocuration,1,227,B,H,,,,8,CHEMBL617614,,9986.0,2896,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,14025,,,BAO_0000019
,Stomach,,Expert,1,12688,B,H,,,945.0,8,CHEMBL617615,,,2897,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,13463,,,BAO_0000019
,Stomach,,Expert,1,12688,B,H,,,945.0,8,CHEMBL858114,,,2898,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,7259,,,BAO_0000357
,Stomach,,Autocuration,1,12688,B,H,,,945.0,8,CHEMBL617616,,,2899,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,7259,,,BAO_0000357
,Stomach,Rattus norvegicus,Expert,1,12688,F,D,,,945.0,9,CHEMBL617617,,10116.0,2900,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,7185,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12688,F,D,,,,9,CHEMBL875914,,10116.0,2901,,Antagonistic against 5-hydroxytryptamine 2B receptor,,7185,,,BAO_0000019
,Stomach,,Autocuration,1,12688,F,H,,,945.0,8,CHEMBL617618,,,2902,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,13267,,,BAO_0000019
,Stomach,Rattus norvegicus,Expert,1,12688,B,D,,,945.0,9,CHEMBL617619,,10116.0,2903,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,13735,,,BAO_0000357
,,,Autocuration,1,12688,F,H,,,,8,CHEMBL617620,,,2904,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,15738,,,BAO_0000019
,,,Autocuration,1,12688,F,H,,,,8,CHEMBL617621,,,2905,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,15738,,,BAO_0000019
,,,Autocuration,1,12688,F,H,,,,8,CHEMBL617622,,,2906,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,15738,,,BAO_0000019
,Stomach,Rattus norvegicus,Expert,1,12688,B,D,,,945.0,9,CHEMBL617623,,10116.0,2907,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,,,BAO_0000357
,Stomach,Rattus norvegicus,Expert,1,12688,B,D,,,945.0,9,CHEMBL617624,,10116.0,2908,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,,,BAO_0000357
,Stomach,Rattus norvegicus,Expert,1,12688,B,D,,,945.0,9,CHEMBL617625,,10116.0,2909,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,,,BAO_0000357
,Stomach,Rattus norvegicus,Expert,1,12688,B,D,,,945.0,9,CHEMBL617626,,10116.0,2910,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,12936,,,BAO_0000357
,Stomach,,Autocuration,1,12688,F,H,,,945.0,8,CHEMBL617627,,,2911,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,,,BAO_0000019
,Stomach,,Expert,1,12688,F,H,,,945.0,8,CHEMBL617628,,,2912,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,,,BAO_0000019
,Stomach,,Autocuration,1,12688,F,H,,,945.0,8,CHEMBL617629,,,2913,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,16404,,,BAO_0000019
,Stomach,,Autocuration,1,12688,F,H,,,945.0,8,CHEMBL858115,,,2914,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,16404,,,BAO_0000019
,Stomach,Rattus norvegicus,Expert,1,12688,F,D,,,945.0,9,CHEMBL617630,,10116.0,2915,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,16404,,,BAO_0000019
,Thoracic aorta,,Autocuration,1,12688,F,H,,,1515.0,8,CHEMBL617631,,,2916,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,16404,,,BAO_0000019
,,,Autocuration,1,12688,B,H,,,,8,CHEMBL617632,,,2917,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,,BAO_0000357
,,,Expert,1,12688,B,H,,,,8,CHEMBL617633,,,2918,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,7483,,,BAO_0000357
,,,Autocuration,1,12688,B,H,,,,8,CHEMBL617634,,,2919,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,,BAO_0000357
,,,Autocuration,1,12688,B,H,,,,8,CHEMBL617635,,,2920,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,7483,,,BAO_0000357
,Stomach,Rattus norvegicus,Autocuration,1,12688,F,D,,,945.0,9,CHEMBL617637,,10116.0,2922,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,16404,,,BAO_0000019
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617638,,,2923,,Binding affinity against 5-hydroxytryptamine 1A receptor,,6347,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617639,,,2924,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617640,,,2925,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617641,,,2926,,Evaluated for the binding affinity to 5-HT 2B receptor,,4687,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617642,,,2927,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,16946,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617643,,,2928,,Binding affinities against 5-hydroxytryptamine 2B receptor,,16633,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617644,,,2929,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,16633,,,BAO_0000357
,,,Autocuration,1,227,B,H,,,,8,CHEMBL617645,,,2930,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,16633,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL617646,,,2931,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,15026,,,BAO_0000357
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL617647,,9913.0,2932,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,15738,,,BAO_0000357
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL617648,,9913.0,2933,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,15738,,,BAO_0000357
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL617875,,9913.0,2934,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,15738,,,BAO_0000357
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL617876,,9913.0,2935,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,15738,,,BAO_0000357
,,Bos taurus,Expert,1,108,B,H,,,,8,CHEMBL617877,,9913.0,2936,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,16404,,,BAO_0000357
,,Bos taurus,Expert,1,108,B,H,,,,8,CHEMBL617878,,9913.0,2937,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,15026,,,BAO_0000357
,,Bos taurus,Autocuration,1,108,B,H,,,,8,CHEMBL617879,,9913.0,2938,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,15738,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,108,B,H,,,,8,CHEMBL617880,,10141.0,2939,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,16312,,,BAO_0000019
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617881,,10141.0,2940,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,5486,,,BAO_0000357
,,,Autocuration,1,51,B,H,,,,8,CHEMBL857073,,,2941,,Binding affinity against 5-HT1A receptor,,5254,,,BAO_0000357
449.0,,,Expert,1,108,F,H,,,,8,CHEMBL617882,,,2942,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,3857,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,108,F,D,,,,9,CHEMBL617883,,9606.0,2943,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,6857,,CHO,BAO_0000219
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617884,,,2944,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,4176,,,BAO_0000219
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617885,,,2945,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,6347,,CHO,BAO_0000219
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617886,,,2946,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,6347,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617887,,9606.0,2947,,Inhibition of human 5-hydroxytryptamine 2C receptor,,16146,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617888,,,2948,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617889,,,2949,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,3857,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617890,,,2950,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,5635,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617891,,,2951,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,5635,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617892,,,2952,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,5635,,,BAO_0000357
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL617893,,,2953,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,4012,,CHO,BAO_0000219
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL617894,,,2954,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,6366,,CHO,BAO_0000219
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL617895,,,2955,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,15949,,CHO,BAO_0000219
449.0,,,Autocuration,1,108,B,H,,,,8,CHEMBL617896,,,2956,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,17211,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL617897,,9606.0,2957,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,6491,,,BAO_0000357
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617898,,,2958,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617899,,,2959,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,13481,,,BAO_0000019
449.0,,Rattus norvegicus,Expert,1,108,B,H,,,,8,CHEMBL617900,,10116.0,2960,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,6347,,CHO,BAO_0000219
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617901,,,2961,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,14093,,,BAO_0000019
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617902,,,2962,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,14093,,,BAO_0000019
,,,Autocuration,1,108,F,H,,,,8,CHEMBL617903,,,2963,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,13481,,,BAO_0000019
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617904,,,2964,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617905,,,2965,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,14442,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617906,,,2966,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,14442,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617907,,,2967,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,14755,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL617908,,,2968,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,14744,,,BAO_0000357
449.0,,,Expert,1,108,B,H,,,,8,CHEMBL620617,,,2969,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,16659,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL620618,,9606.0,2970,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,6857,,,BAO_0000019
,,,Expert,1,108,B,H,,,,8,CHEMBL620619,,,2971,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,5635,,,BAO_0000357
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL620620,,9606.0,2972,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,4234,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620621,,,2973,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,16209,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL872920,,10116.0,2974,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Membranes,5778,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620622,,,2975,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,5094,,,BAO_0000223
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL620623,,10116.0,2976,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,809,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620624,,,2977,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,1578,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620625,,,2978,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,809,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620626,,,2979,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,12469,,,BAO_0000219
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621307,,,2980,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,14290,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621308,,,2981,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,14290,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621309,,,2982,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,10609,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621310,,,2983,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,10609,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621311,,,2984,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,10609,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621502,,,2985,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,15253,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621503,,,2986,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,15253,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621504,,,2987,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Membranes,11683,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621505,,,2988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,12092,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL621506,,,2989,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,1946,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619781,,,2990,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,11623,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619782,,,2991,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,11623,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619783,,,2992,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,14788,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619784,,10116.0,2993,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,5432,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619785,,,2994,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,14826,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619786,,,2995,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,2222,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619787,,,2996,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,11963,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL872925,,,2997,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,14145,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619788,,,2998,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,17819,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619789,,,2999,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,10394,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619790,,,3000,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,10394,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619791,,,3001,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,15034,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619792,,,3002,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,691,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619793,,,3003,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Membranes,12092,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619794,,10116.0,3004,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,11752,,,BAO_0000223
,Brain,,Autocuration,1,104698,B,H,,,955.0,6,CHEMBL619795,,,3005,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,11752,,,BAO_0000221
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619796,,,3006,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,301,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620448,,,3007,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,16532,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620449,,,3008,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,16532,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620450,,,3009,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,12092,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620451,,,3010,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,11684,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620631,,,3011,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,11684,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620632,,,3012,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,12953,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620633,,,3013,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,12953,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620634,,,3014,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,12953,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620635,,,3015,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,12861,,,BAO_0000019
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620636,,,3016,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620637,,,3017,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620638,,,3018,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620639,,,3019,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620640,,,3020,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620641,,,3021,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620642,,,3022,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620643,,,3023,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620644,,,3024,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620645,,,3025,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620646,,,3026,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620647,,,3027,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620648,,,3028,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620649,,,3029,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620650,,,3030,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620651,,,3031,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL872875,,,3032,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL620652,,,3033,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL620653,,,3034,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,10609,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL857076,,,3035,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,12861,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL620654,,10116.0,3036,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,12861,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620655,,,3037,,Binding activity radioligand.,,12861,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620656,,,3038,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Brain membranes,10728,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620657,,,3039,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Brain membranes,10728,,,BAO_0000249
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620658,,,3040,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,5163,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620659,,,3041,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,5163,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620660,,,3042,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,6011,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620661,,,3043,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,5014,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620662,,,3044,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,5635,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL620663,,,3045,,Affinity for 5-hydroxytryptamine 2C receptor,,5163,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620664,,,3046,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,6841,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL620665,,,3047,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,6119,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620666,,,3048,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620667,,,3049,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,1633,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL620668,,,3050,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,1633,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620669,,,3051,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,108,B,H,,,,8,CHEMBL620670,,,3052,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,6576,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620671,,,3053,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,4687,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620672,,,3054,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,12146,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620673,,,3055,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,12146,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620674,,,3056,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,16946,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620675,,,3057,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,14159,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL620676,,,3058,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,16700,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL621382,,,3059,,Affinity against 5-hydroxytryptamine 2C receptor,,3269,,,BAO_0000357
,,Homo sapiens,Expert,1,108,B,D,,,,9,CHEMBL621383,,9606.0,3060,,Binding affinity against 5-hydroxytryptamine 2C receptor,,1274,,,BAO_0000357
,,,Autocuration,1,108,B,H,,,,8,CHEMBL621384,,,3061,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,1317,,,BAO_0000357
,,Bos taurus,Autocuration,1,144,B,H,,,,8,CHEMBL621385,,9913.0,3062,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,5834,,,BAO_0000357
,,Bos taurus,Autocuration,1,144,B,H,,,,8,CHEMBL617989,,9913.0,3063,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,11147,,,BAO_0000357
,,Cavia porcellus,Expert,1,104714,F,H,,,,4,CHEMBL617990,,10141.0,3064,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,14145,,,BAO_0000019
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL875085,,10141.0,3065,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10561,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617991,,10141.0,3066,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,15847,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617992,,10141.0,3067,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,15847,,,BAO_0000019
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617993,,10141.0,3068,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,10561,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617994,,10141.0,3069,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,11454,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617995,,10141.0,3070,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617996,,10141.0,3071,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617997,,10141.0,3072,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617998,,10141.0,3073,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL617999,,10141.0,3074,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618000,,10141.0,3075,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,4639,,,BAO_0000019
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617815,,10141.0,3076,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,15253,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617816,,10141.0,3077,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,15253,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617817,,10141.0,3078,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,11963,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617818,,10141.0,3079,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,1946,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617819,,10141.0,3080,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,1946,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,104714,B,H,,,,4,CHEMBL617820,,10141.0,3081,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,12045,,,BAO_0000223
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617821,,10141.0,3082,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617822,,10141.0,3083,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617823,,10141.0,3084,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,273,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617824,,10141.0,3085,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,188,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617825,,10141.0,3086,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,12919,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617826,,10141.0,3087,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,12918,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617827,,10141.0,3088,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617828,,10141.0,3089,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617829,,10141.0,3090,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,1559,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617830,,10141.0,3091,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,1559,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617831,,10141.0,3092,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,1559,,,BAO_0000221
,Ileum,Cavia porcellus,Autocuration,1,104714,B,H,,,2116.0,4,CHEMBL617832,,10141.0,3093,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,14424,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,22226,B,U,,,,0,CHEMBL617833,,10141.0,3094,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,13181,,,BAO_0000019
,,,Autocuration,1,51,B,H,,,,8,CHEMBL617834,,,3095,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,5486,,,BAO_0000357
,,Homo sapiens,Expert,1,104714,B,D,,,,5,CHEMBL617835,,9606.0,3096,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,6491,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL617836,,,3097,,Binding affinity towards 5-HT3 receptor,,6013,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL617837,,,3098,,Binding activity radioligand.,,12861,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620392,,,3099,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,12861,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620393,,,3100,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,5104,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620394,,,3101,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,5105,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620395,,,3102,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,5104,,,BAO_0000223
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL620396,,,3103,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,3935,,,BAO_0000019
433.0,,,Expert,1,105030,B,H,,,,4,CHEMBL620582,,,3104,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,13657,,NG108-15,BAO_0000219
,,,Autocuration,1,105030,B,H,In vivo,,,4,CHEMBL620583,,,3105,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,10369,,,BAO_0000218
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620584,,,3106,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,10369,,,BAO_0000019
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620585,,,3107,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,12918,,,BAO_0000224
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620586,,,3108,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,12918,,,BAO_0000224
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620587,,,3109,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,10369,,,BAO_0000019
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620588,,,3110,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,773,,,BAO_0000019
,,,Autocuration,1,105030,F,H,,,,4,CHEMBL620589,,,3111,,5-hydroxytryptamine 3 receptor agonism in mouse,,12918,,,BAO_0000218
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL620590,,,3112,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,10561,,,BAO_0000219
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617956,,,3113,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,12827,,,BAO_0000019
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617957,,,3114,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,12827,,,BAO_0000019
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617958,,,3115,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,12918,,,BAO_0000224
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617959,,,3116,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,273,,,BAO_0000219
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617960,,,3117,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,273,,,BAO_0000219
,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617961,,,3118,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,10561,,,BAO_0000224
,,,Autocuration,1,105030,B,H,In vitro,,,4,CHEMBL617962,,,3119,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,5033,,,BAO_0000219
339.0,,,Autocuration,1,105030,B,H,,,,4,CHEMBL617963,,,3120,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,16429,,N1E-115,BAO_0000219
,,,Autocuration,1,11765,B,H,,,,8,CHEMBL617964,,,3121,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,10322,,,BAO_0000019
,,,Autocuration,1,11765,B,H,,,,8,CHEMBL617965,,,3122,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,14331,,,BAO_0000219
,,Mus musculus,Autocuration,1,10630,B,D,,,,9,CHEMBL617966,,10090.0,3123,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,13462,,,BAO_0000357
,,,Autocuration,1,17106,B,H,,,,8,CHEMBL857074,,,3124,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,12861,,,BAO_0000019
,,Sus scrofa,Autocuration,1,144,B,H,,,,8,CHEMBL617967,,9823.0,3125,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,15086,,,BAO_0000357
,,Sus scrofa,Autocuration,1,144,B,H,,,,8,CHEMBL617968,,9823.0,3126,,Binding activity radioligand.,,12861,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,104714,B,H,,,,4,CHEMBL617969,,9986.0,3127,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,10561,,,BAO_0000223
,,Oryctolagus cuniculus,Autocuration,1,104714,B,H,,,,4,CHEMBL617970,,9986.0,3128,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,10561,,,BAO_0000223
,,Oryctolagus cuniculus,Autocuration,1,104714,B,H,,,,4,CHEMBL617971,,9986.0,3129,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,10561,,,BAO_0000223
,,Oryctolagus cuniculus,Autocuration,1,104714,B,H,,,,4,CHEMBL617972,,9986.0,3130,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,10561,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617973,,9986.0,3131,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617974,,9986.0,3132,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,,BAO_0000019
,Ileum,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,2116.0,4,CHEMBL617975,,9986.0,3133,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,273,,,BAO_0000221
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617976,,9986.0,3134,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617977,,9986.0,3135,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617978,,9986.0,3136,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,273,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,104714,F,H,,,,4,CHEMBL617979,,9986.0,3137,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,273,,,BAO_0000019
449.0,,Oryctolagus cuniculus,Autocuration,1,104714,B,H,,,,4,CHEMBL617980,,9986.0,3138,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,13047,,CHO,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617981,,10116.0,3139,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,1650,,,BAO_0000019
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL617982,,,3140,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,16288,,,BAO_0000019
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL617983,,,3141,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,16288,,,BAO_0000357
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617984,,10116.0,3142,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,10254,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617985,,,3143,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,14532,,,BAO_0000019
,Heart,,Autocuration,1,104698,F,H,In vivo,,948.0,6,CHEMBL617986,,,3144,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,13392,,,BAO_0000218
,Heart,,Autocuration,1,104698,F,H,,,948.0,6,CHEMBL617987,,,3145,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,13392,,,BAO_0000019
,Heart,,Autocuration,1,104698,F,H,,,948.0,6,CHEMBL617988,,,3146,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,13392,,,BAO_0000019
,Heart,,Autocuration,1,104698,F,H,,,948.0,6,CHEMBL617792,,,3147,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,13392,,,BAO_0000019
,Heart,,Autocuration,1,104698,F,H,,,948.0,6,CHEMBL617793,,,3148,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,13392,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617794,,,3149,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,13392,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617795,,,3150,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,13392,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617796,,,3151,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,13392,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617797,,,3152,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,13392,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,F,D,In vivo,,,7,CHEMBL617798,,10116.0,3153,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,1089,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617799,,,3154,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,1089,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,104698,F,D,In vivo,,,7,CHEMBL617800,,10116.0,3155,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,104698,F,D,,,,7,CHEMBL617801,,10116.0,3156,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,11454,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,F,D,In vivo,,,7,CHEMBL617802,,10116.0,3157,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,12205,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,104698,F,D,,,,7,CHEMBL617803,,10116.0,3158,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,1089,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617804,,,3159,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,5094,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617805,,10116.0,3160,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,2622,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617806,,,3161,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,245,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617807,,,3162,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,14788,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617808,,,3163,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,14788,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617809,,,3164,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,3020,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617810,,,3165,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,1742,,,BAO_0000019
,Brain,,Autocuration,1,104698,B,H,,,955.0,6,CHEMBL617811,,,3166,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,17394,,,BAO_0000249
,Brain,,Autocuration,1,104698,B,H,,,955.0,6,CHEMBL617812,,,3167,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,17394,,,BAO_0000221
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617813,,,3168,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,17394,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617814,,,3169,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,14286,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617698,,,3170,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,14178,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617699,,10116.0,3171,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,14178,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617700,,10116.0,3172,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,14178,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617701,,10116.0,3173,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,14178,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617702,,,3174,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,15034,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617703,,,3175,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Membranes,1089,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617704,,10116.0,3176,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,1089,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617705,,,3177,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,16532,,,BAO_0000223
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL617706,,10116.0,3178,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,12801,,,BAO_0000223
433.0,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617707,,,3179,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,15194,,NG108-15,BAO_0000219
433.0,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617708,,,3180,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,15194,,NG108-15,BAO_0000219
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617709,,,3181,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,15194,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617710,,,3182,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,15194,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL882925,,,3183,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,15194,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL617711,,,3184,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,15194,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617712,,,3185,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,10610,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,F,D,,,,7,CHEMBL617713,,10116.0,3186,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,10355,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617714,,,3187,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,691,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617715,,,3188,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,10611,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617716,,,3189,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,12801,,,BAO_0000218
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617717,,,3190,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,10609,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617718,,,3191,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617719,,,3192,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617720,,,3193,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,11454,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,104698,F,D,In vivo,,,7,CHEMBL617721,,10116.0,3194,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617722,,,3195,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617723,,,3196,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617724,,,3197,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617725,,,3198,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617726,,,3199,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617727,,,3200,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617728,,,3201,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617729,,,3202,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617730,,,3203,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617731,,,3204,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617732,,,3205,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617733,,,3206,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617734,,,3207,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL872874,,,3208,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617735,,,3209,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617736,,,3210,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617737,,,3211,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617738,,,3212,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617739,,,3213,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617740,,,3214,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617741,,,3215,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617742,,,3216,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617743,,,3217,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617744,,,3218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617745,,,3219,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,11454,,,BAO_0000218
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617746,,,3220,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,670,,,BAO_0000218
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL617747,,,3221,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,670,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL617748,,,3222,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,10321,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL618909,,,3223,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,10321,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL618910,,,3224,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,10321,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL618911,,,3225,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,10321,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL618912,,,3226,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,10321,,,BAO_0000218
,,,Autocuration,1,104698,F,H,In vivo,,,6,CHEMBL618913,,,3227,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,10322,,,BAO_0000218
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL618914,,,3228,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,15412,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL618915,,,3229,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,15412,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL618916,,10116.0,3230,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,15412,,,BAO_0000223
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL618917,,,3231,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,15412,,,BAO_0000019
,Hippocampus,,Intermediate,1,104698,B,D,,,10000000.0,7,CHEMBL618918,,,3232,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,15412,,,BAO_0000221
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL618919,,10116.0,3233,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,15412,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL618920,,10116.0,3234,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,17394,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618921,,,3235,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,12457,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618922,,,3236,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,12457,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618923,,,3237,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,12205,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618924,,,3238,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,14532,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618925,,,3239,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,1122,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618926,,,3240,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,5094,,,BAO_0000019
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL618927,,10141.0,3241,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL618928,,10141.0,3242,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL618929,,10141.0,3243,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL618930,,10141.0,3244,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL618931,,10141.0,3245,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619594,,10141.0,3246,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619595,,10141.0,3247,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619596,,10141.0,3248,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,13961,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619755,,10141.0,3249,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,13961,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619756,,10141.0,3250,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619757,,10141.0,3251,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619758,,10141.0,3252,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619759,,10141.0,3253,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619760,,10141.0,3254,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619761,,10141.0,3255,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619762,,10141.0,3256,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619763,,10141.0,3257,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,14290,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL617868,,10141.0,3258,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,14290,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL617869,,10141.0,3259,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,15034,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL882926,,10141.0,3260,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,,,BAO_0000249
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617870,,10141.0,3261,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,,,BAO_0000249
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617871,,10141.0,3262,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,5399,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617872,,10141.0,3263,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,17394,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617873,,10141.0,3264,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,17394,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL617874,,10141.0,3265,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,17394,,,BAO_0000357
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619067,,10141.0,3266,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,13961,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619068,,10141.0,3267,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,13961,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619069,,10141.0,3268,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,13961,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619070,,10141.0,3269,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,16946,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619071,,10141.0,3270,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,16946,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,F,D,,,,9,CHEMBL619072,,10141.0,3271,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,15034,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,20033,F,D,,,,9,CHEMBL619073,,10141.0,3272,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,15034,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,20033,F,D,,,,9,CHEMBL619074,,10141.0,3273,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,12918,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619075,,10141.0,3274,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,16946,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL619076,,10141.0,3275,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,17394,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL619077,,10141.0,3276,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,15034,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL619078,,10141.0,3277,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,,,BAO_0000249
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL619079,,10141.0,3278,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,5094,,,BAO_0000249
,Ileum,Cavia porcellus,Intermediate,1,20033,B,D,,,2116.0,9,CHEMBL619080,,10141.0,3279,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,17358,,,BAO_0000221
,,Cavia porcellus,Expert,1,20033,B,D,,,,9,CHEMBL619081,,10141.0,3280,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,12953,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619082,,10141.0,3281,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619083,,10141.0,3282,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,12953,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619084,,10141.0,3283,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,12953,,,BAO_0000357
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL859397,,10141.0,3284,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,273,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619085,,10141.0,3285,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,12918,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619086,,10141.0,3286,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,12919,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619087,,10141.0,3287,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,273,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619088,,10141.0,3288,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,273,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619089,,10141.0,3289,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,13181,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,168,B,H,,,,8,CHEMBL619090,,10141.0,3290,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,13181,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,F,D,,,,9,CHEMBL619091,,10141.0,3291,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,15034,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619092,,10141.0,3292,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,5033,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619093,,10141.0,3293,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,1980,,,BAO_0000019
722.0,,Cavia porcellus,Autocuration,1,168,B,H,,,,8,CHEMBL619094,,10141.0,3294,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,13181,,HEK293,BAO_0000219
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619095,,10141.0,3295,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,14287,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL857988,,10141.0,3296,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,1317,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619096,,10141.0,3297,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,15316,,,BAO_0000357
,Striatum,Cavia porcellus,Intermediate,1,20033,B,D,,,2435.0,9,CHEMBL619097,,10141.0,3298,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,16429,,,BAO_0000357
,Hippocampus,Cavia porcellus,Intermediate,1,20033,B,D,,,10000000.0,9,CHEMBL619098,,10141.0,3299,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,14818,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619751,,10141.0,3300,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,15194,,,BAO_0000357
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619752,,10141.0,3301,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,15194,,,BAO_0000357
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL875096,,10141.0,3302,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,13961,,,BAO_0000221
,,,Autocuration,1,108,B,H,,,,8,CHEMBL619004,,,3303,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,5486,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL619005,,,3304,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL619006,,,3305,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,17085,,,BAO_0000019
308.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL619007,,,3306,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,4199,,HeLa,BAO_0000219
,,,Autocuration,1,168,B,H,,,,8,CHEMBL619008,,,3307,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,15146,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL619009,,,3308,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,5213,,,BAO_0000357
308.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL619010,,,3309,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,4829,,HeLa,BAO_0000219
,,,Autocuration,1,10622,B,H,,,,8,CHEMBL619011,,,3310,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,17358,,,BAO_0000357
,,,Autocuration,1,10622,B,H,,,,8,CHEMBL619012,,,3311,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,17358,,,BAO_0000357
,,,Autocuration,1,10622,B,H,,,,8,CHEMBL619013,,,3312,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,16946,,,BAO_0000219
,,,Autocuration,1,10622,B,H,,,,8,CHEMBL619014,,,3313,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,17358,,,BAO_0000357
,Cardiac atrium,,Autocuration,1,11249,F,H,,,2081.0,8,CHEMBL857503,,,3314,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,268,,,BAO_0000019
,Cardiac atrium,,Autocuration,1,11249,F,H,,,2081.0,8,CHEMBL619015,,,3315,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,268,,,BAO_0000019
,,,Autocuration,1,11249,B,H,,,,8,CHEMBL619016,,,3316,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,15086,,,BAO_0000357
,Hippocampus,,Autocuration,1,11249,B,H,,,10000000.0,8,CHEMBL619017,,,3317,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,14875,,,BAO_0000221
,Hippocampus,Sus scrofa,Autocuration,1,168,B,H,,,10000000.0,8,CHEMBL619018,,9823.0,3318,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,13267,,,BAO_0000221
,,Oryctolagus cuniculus,Autocuration,1,168,B,H,,,,8,CHEMBL619019,,9986.0,3319,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,13047,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10623,B,D,,,,9,CHEMBL619020,,10116.0,3320,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,1650,,,BAO_0000357
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619021,,,3321,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,567,,,BAO_0000019
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619022,,,3322,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,17358,,,BAO_0000357
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619023,,,3323,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,188,,,BAO_0000357
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619024,,,3324,,lntrinsic activity relative to 5-HT receptor,,670,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619025,,,3325,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,204,,,BAO_0000019
,,,Expert,1,10623,F,H,,,,8,CHEMBL619026,,,3326,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,1946,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619027,,,3327,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,6398,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619028,,,3328,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,6398,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619029,,,3329,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,17358,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619030,,,3330,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,6398,,,BAO_0000019
,,,Expert,1,10623,B,H,,,,8,CHEMBL619031,,,3331,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,11752,,,BAO_0000357
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619032,,,3332,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,809,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10623,B,D,,,,9,CHEMBL619033,,10116.0,3333,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,14178,,,BAO_0000357
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619034,,,3334,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,567,,,BAO_0000357
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619035,,,3335,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,1946,,,BAO_0000357
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619036,,,3336,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,1946,,,BAO_0000357
,,Rattus norvegicus,Expert,1,10623,B,D,,,,9,CHEMBL619037,,10116.0,3337,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,13961,,,BAO_0000019
,Striatum,,Autocuration,1,10623,B,H,,,2435.0,8,CHEMBL619038,,,3338,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,6238,,,BAO_0000249
,,,Autocuration,1,10623,B,H,,,,8,CHEMBL619039,,,3339,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,14290,,,BAO_0000249
,,,Expert,1,10623,B,H,,,,8,CHEMBL619040,,,3340,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,14290,,,BAO_0000249
,Striatum,Rattus norvegicus,Expert,1,10623,B,D,,,2435.0,9,CHEMBL619041,,10116.0,3341,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,809,,,BAO_0000019
,Striatum,,Autocuration,1,10623,B,H,,,2435.0,8,CHEMBL619042,,,3342,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,1578,,,BAO_0000019
,Striatum,,Expert,1,10623,B,H,,,2435.0,8,CHEMBL619043,,,3343,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,16709,,,BAO_0000249
,Striatum,,Expert,1,10623,B,H,,,2435.0,8,CHEMBL619044,,,3344,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,1946,,,BAO_0000019
,Striatum,,Expert,1,10623,B,H,,,2435.0,8,CHEMBL619045,,,3345,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,15253,,,BAO_0000249
,Striatum,,Expert,1,10623,B,H,,,2435.0,8,CHEMBL619046,,,3346,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,4535,,,BAO_0000249
,,,Expert,1,10623,B,H,,,,8,CHEMBL619047,,,3347,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,13961,,,BAO_0000249
,Brain,,Autocuration,1,10623,F,H,,,955.0,8,CHEMBL619048,,,3348,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,17358,,,BAO_0000221
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL859398,,,3349,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,15847,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619049,,,3350,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,15847,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL857886,,,3351,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,670,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL619050,,,3352,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,670,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL620591,,,3353,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,1317,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10623,B,D,,,,9,CHEMBL620592,,10116.0,3354,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,12936,,,BAO_0000357
,Striatum,,Expert,1,10623,B,H,,,2435.0,8,CHEMBL620593,,,3355,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,4535,,,BAO_0000249
,,Rattus norvegicus,Expert,1,10623,F,D,,,,9,CHEMBL620594,,10116.0,3356,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,14424,,,BAO_0000019
,,,Expert,1,10623,F,H,,,,8,CHEMBL875079,,,3357,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,14424,,,BAO_0000019
,,,Expert,1,10623,F,H,,,,8,CHEMBL620595,,,3358,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,14424,,,BAO_0000019
,,Rattus norvegicus,Expert,1,10623,F,D,,,,9,CHEMBL620596,,10116.0,3359,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,14424,,,BAO_0000019
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL620597,,,3360,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,14424,,,BAO_0000019
,,,Expert,1,10623,F,H,,,,8,CHEMBL620598,,,3361,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,14424,,,BAO_0000019
,,,Expert,1,10623,F,H,,,,8,CHEMBL620599,,,3362,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,14424,,,BAO_0000218
,,,Autocuration,1,10623,F,H,,,,8,CHEMBL620600,,,3363,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,14424,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,168,F,H,,,,8,CHEMBL620601,,10116.0,3364,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,1980,,,BAO_0000019
,,,Autocuration,1,168,F,H,,,,8,CHEMBL620602,,,3365,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,4639,,,BAO_0000019
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620603,,,3366,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620604,,,3367,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620605,,,3368,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620606,,,3369,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,1558,,,BAO_0000357
,,,Autocuration,1,168,F,H,,,,8,CHEMBL620607,,,3370,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,,BAO_0000019
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620608,,,3371,,In vitro binding affinity towards 5-HT4 receptor was determined,,16117,,,BAO_0000357
,,,Autocuration,1,168,F,H,,,,8,CHEMBL620609,,,3372,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,,BAO_0000019
,,,Autocuration,1,168,F,H,,,,8,CHEMBL620610,,,3373,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,17358,,,BAO_0000019
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620611,,,3374,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620612,,,3375,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620613,,,3376,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,17358,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620614,,,3377,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,17358,,,BAO_0000357
,,,Expert,1,168,B,H,,,,8,CHEMBL620615,,,3378,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,1274,,,BAO_0000357
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL857075,,,3379,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Brain membranes,10728,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620616,,,3380,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Brain membranes,11695,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619411,,,3381,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Brain membranes,11695,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619412,,,3382,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,12490,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619413,,10116.0,3383,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,11828,,,BAO_0000019
,Hippocampus,,Autocuration,1,104698,B,H,,,10000000.0,6,CHEMBL619414,,,3384,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,12253,,,BAO_0000221
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619415,,,3385,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,10561,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619416,,,3386,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,10561,,,BAO_0000019
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL619417,,,3387,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,14432,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619418,,10116.0,3388,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,12936,,,BAO_0000223
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619419,,10116.0,3389,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,1274,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619420,,,3390,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,1980,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619421,,,3391,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,670,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619422,,10116.0,3392,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,968,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619423,,,3393,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,14287,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL875080,,,3394,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,567,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619424,,,3395,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,13267,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619425,,,3396,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,14826,,,BAO_0000249
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619426,,,3397,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,15194,,,BAO_0000223
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL619427,,,3398,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,15194,,,BAO_0000223
,,Rattus norvegicus,Autocuration,1,104698,B,D,,,,7,CHEMBL619645,,10116.0,3399,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,10394,,,BAO_0000223
,,,Expert,1,10576,B,D,,,,9,CHEMBL619646,,,3400,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,13657,,,BAO_0000249
,Brain,,Autocuration,1,12020,F,H,,,955.0,8,CHEMBL619647,,,3401,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,1879,,,BAO_0000221
,,,Autocuration,1,12020,F,H,,,,8,CHEMBL619648,,,3402,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,1879,,,BAO_0000019
,,,Autocuration,1,12020,F,H,,,,8,CHEMBL619165,,,3403,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,1879,,,BAO_0000019
,,,Autocuration,1,12020,F,H,In vivo,,,8,CHEMBL620719,,,3404,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,204,,,BAO_0000218
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL872924,,,3405,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,1879,,,BAO_0000019
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL620720,,,3406,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,1879,,,BAO_0000357
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL620721,,,3407,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,1879,,,BAO_0000019
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL620722,,,3408,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,1879,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620723,,,3409,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,10641,,,BAO_0000019
,,,Autocuration,1,12020,B,H,,,,8,CHEMBL620724,,,3410,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,773,,,BAO_0000019
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL620725,,,3411,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,11952,,,BAO_0000249
,,Rattus norvegicus,Autocuration,1,12020,F,D,,,,9,CHEMBL620726,,10116.0,3412,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,14145,,,BAO_0000019
,,,Expert,1,144,B,H,,,,8,CHEMBL620727,,,3413,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620728,,,3414,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,6398,,,BAO_0000223
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL620729,,,3415,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,10321,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL858288,,,3416,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,511,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620730,,,3417,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,4639,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620731,,,3418,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,4639,,,BAO_0000223
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL620732,,10141.0,3419,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618042,,10141.0,3420,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618043,,10141.0,3421,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,4639,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618044,,,3422,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,1558,,,BAO_0000223
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL618045,,,3423,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,268,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618046,,,3424,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,2474,,,BAO_0000223
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL618047,,,3425,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL875084,,,3426,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL618048,,,3427,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618049,,,3428,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,5067,,,BAO_0000223
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL619764,,,3429,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL619765,,,3430,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL619766,,,3431,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619767,,,3432,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,5067,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619768,,,3433,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,5067,,,BAO_0000223
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL619769,,,3434,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,5067,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619770,,,3435,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,5067,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619771,,,3436,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,5067,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619772,,,3437,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,14331,,,BAO_0000219
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619773,,,3438,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,5067,,,BAO_0000223
433.0,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619774,,,3439,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,6179,,NG108-15,BAO_0000219
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL875083,,,3440,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,4265,,,BAO_0000019
433.0,,,Autocuration,1,104714,B,H,,,,4,CHEMBL620718,,,3441,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,4265,,NG108-15,BAO_0000219
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618127,,,3442,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,17358,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618128,,,3443,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,17358,,,BAO_0000223
,,,Autocuration,1,104714,B,H,In vitro,,,4,CHEMBL618129,,,3444,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,13628,,,BAO_0000219
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618130,,,3445,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,4612,,,BAO_0000223
,,,Autocuration,1,104714,F,H,,,,4,CHEMBL618131,,,3446,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,17358,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618132,,10141.0,3447,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618133,,10141.0,3448,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618134,,10141.0,3449,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,4639,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618135,,10141.0,3450,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,4639,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618136,,,3451,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,511,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618137,,,3452,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,1479,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618138,,,3453,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,1317,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618139,,,3454,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,12146,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618140,,,3455,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,12146,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618141,,,3456,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,13969,,,BAO_0000223
,,,Expert,1,108,B,H,,,,8,CHEMBL873478,,,3457,,Binding affinity for 5-hydroxytryptamine 2C receptor,,13392,,,BAO_0000357
,,,Autocuration,1,104698,B,H,,,,6,CHEMBL618142,,,3458,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,13392,,,BAO_0000223
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618143,,,3459,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,14159,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618144,,,3460,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,1558,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618145,,,3461,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,16655,,,BAO_0000357
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618146,,,3462,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,13020,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618147,,,3463,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,13021,,,BAO_0000223
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618148,,,3464,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,13020,,,BAO_0000223
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618149,,,3465,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,10321,,,BAO_0000019
,,,Autocuration,1,144,B,H,,,,8,CHEMBL872927,,,3466,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,15818,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618150,,,3467,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,15818,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618151,,,3468,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,17358,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL875094,,,3469,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,2222,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618152,,,3470,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,10322,,,BAO_0000019
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618153,,,3471,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,16117,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618888,,,3472,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,144,F,H,,,,8,CHEMBL618889,,,3473,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,17358,,,BAO_0000019
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618890,,,3474,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,16700,,,BAO_0000357
,,,Autocuration,1,144,B,H,,,,8,CHEMBL618891,,,3475,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,1980,,,BAO_0000019
,,,Autocuration,1,144,B,H,,,,8,CHEMBL619054,,,3476,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,1980,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL619055,,,3477,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,12409,,,BAO_0000223
,,,Autocuration,1,144,B,H,,,,8,CHEMBL619056,,,3478,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,4365,,,BAO_0000357
,,,Autocuration,1,144,F,H,,,,8,CHEMBL619057,,,3479,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,4365,,,BAO_0000019
,,,Autocuration,1,144,B,H,,,,8,CHEMBL619058,,,3480,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,4365,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12020,F,D,,,,9,CHEMBL619059,,10116.0,3481,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,6769,,Oocytes,BAO_0000219
,,Rattus norvegicus,Expert,1,12020,F,D,,,,9,CHEMBL619060,,10116.0,3482,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,6769,,Oocytes,BAO_0000219
,,Rattus norvegicus,Expert,1,12020,F,D,,,,9,CHEMBL875095,,10116.0,3483,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,6769,,Oocytes,BAO_0000219
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619061,,10141.0,3484,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,809,,,BAO_0000221
,Ileum,Cavia porcellus,Intermediate,1,20033,F,D,,,2116.0,9,CHEMBL619062,,10141.0,3485,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,809,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,F,D,,,,9,CHEMBL619063,,10141.0,3486,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,14290,,,BAO_0000019
,Ileum,Cavia porcellus,Intermediate,1,20033,B,D,,,2116.0,9,CHEMBL619064,,10141.0,3487,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,17358,,,BAO_0000221
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL619065,,10141.0,3488,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,17358,,,BAO_0000357
,Ileum,Cavia porcellus,Intermediate,1,20033,B,D,,,2116.0,9,CHEMBL619066,,10141.0,3489,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,17358,,,BAO_0000221
,Ileum,,Autocuration,1,10209,B,H,,,2116.0,8,CHEMBL619775,,,3490,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,17386,,,BAO_0000221
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619776,,,3491,,Affinity against 5-hydroxytryptamine 7 receptor,,3269,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,104841,B,H,,,,4,CHEMBL619777,,10141.0,3492,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,7721,,,BAO_0000224
,,Cavia porcellus,Autocuration,1,104841,B,H,,,,4,CHEMBL619778,,10141.0,3493,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,7721,,,BAO_0000224
,Ileum,Cavia porcellus,Autocuration,1,104841,B,H,,,2116.0,4,CHEMBL619779,,10141.0,3494,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,9117,,,BAO_0000221
,,Cavia porcellus,Autocuration,1,104841,B,H,,,,4,CHEMBL619780,,10141.0,3495,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,7721,,,BAO_0000224
,,Cavia porcellus,Autocuration,1,104841,B,H,,,,4,CHEMBL619166,,10141.0,3496,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,7721,,,BAO_0000224
,,Cavia porcellus,Autocuration,1,104841,F,H,,,,4,CHEMBL619167,,10141.0,3497,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,15796,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,104841,F,H,,,,4,CHEMBL619168,,10141.0,3498,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,15796,,,BAO_0000019
,Cardiac atrium,Homo sapiens,Expert,1,168,B,D,,,2081.0,9,CHEMBL619169,,9606.0,3499,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,15650,,,BAO_0000219
,Cardiac atrium,Homo sapiens,Expert,1,168,B,D,,,2081.0,9,CHEMBL619170,,9606.0,3500,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,15650,,,BAO_0000219
,,Homo sapiens,Autocuration,1,104841,F,D,,,,5,CHEMBL619171,,9606.0,3501,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,6866,,,BAO_0000019
,Cardiac atrium,Homo sapiens,Expert,1,168,F,D,,,2081.0,9,CHEMBL619172,,9606.0,3502,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,15650,,,BAO_0000219
,,Mus musculus,Autocuration,1,22226,B,U,,,,0,CHEMBL619173,,10090.0,3503,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,10063,,,BAO_0000019
,,Mus musculus,Autocuration,1,22226,B,U,,,,0,CHEMBL619174,,10090.0,3504,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,12665,,,BAO_0000019
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619175,,,3505,,5-hydroxytryptamine receptor binding affinity was determined in rats,,7504,,,BAO_0000019
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619176,,,3506,,Binding affinity at rat 5-hydroxytryptamine receptor.,,7504,,,BAO_0000224
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619177,,,3507,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,7038,,,BAO_0000019
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619178,,,3508,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,7626,,,BAO_0000224
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619179,,,3509,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,7626,,,BAO_0000224
,Stomach,,Autocuration,1,104705,F,H,,,945.0,4,CHEMBL619180,,,3510,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,7185,,,BAO_0000019
,Stomach,,Autocuration,1,104705,F,H,,,945.0,4,CHEMBL619181,,,3511,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,7185,,,BAO_0000019
,,,Autocuration,1,104705,F,H,,,,4,CHEMBL619182,,,3512,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,7185,,,BAO_0000019
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619183,,,3513,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,6960,,,BAO_0000224
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619184,,,3514,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,6960,,,BAO_0000224
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL619185,,,3515,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,12416,,,BAO_0000221
,,,Expert,1,12198,B,H,,,,8,CHEMBL619186,,,3516,,Binding affinity for rat 5-hydroxytryptamine transporter.,,15753,,,BAO_0000357
,,,Autocuration,1,104705,B,H,,,,4,CHEMBL619187,,,3517,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,8062,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619188,,10116.0,3518,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,9036,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619189,,10116.0,3519,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,15067,,,BAO_0000224
,Brain,Rattus norvegicus,Expert,1,12198,F,D,,,955.0,9,CHEMBL619190,,10116.0,3520,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,15753,,,BAO_0000019
,Cerebellum,Rattus norvegicus,Expert,1,12198,F,D,,,2037.0,9,CHEMBL619191,,10116.0,3521,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,15753,,,BAO_0000221
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619192,,10116.0,3522,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,15295,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619193,,10116.0,3523,,Percent binding affinity against 5-hydroxytryptamine receptor,,6347,,,BAO_0000224
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL619194,,,3524,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,6763,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619195,,10116.0,3525,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,12092,,,BAO_0000224
,,Rattus norvegicus,Autocuration,1,104705,B,D,,,,5,CHEMBL619196,,10116.0,3526,,Affinity against 5-hydroxytryptamine receptor was determined,,1579,,,BAO_0000224
,Stomach,Rattus norvegicus,Autocuration,1,104705,B,D,,,945.0,5,CHEMBL619197,,10116.0,3527,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,1579,,,BAO_0000019
,,Homo sapiens,Expert,1,121,B,D,In vitro,,,9,CHEMBL619198,,9606.0,3528,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,5963,,,BAO_0000219
,,Homo sapiens,Expert,1,121,B,D,In vitro,,,9,CHEMBL875081,,9606.0,3529,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,5963,,,BAO_0000219
,,,Autocuration,1,18065,B,H,,,,8,CHEMBL884712,,,3530,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,5030,,,BAO_0000357
,,,Expert,1,121,B,H,,,,8,CHEMBL884710,,,3531,,Inhibition of 5-hydroxytryptamine reuptake,,15796,,,BAO_0000357
,,,Autocuration,1,18065,F,H,,,,8,CHEMBL619199,,,3532,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,15413,,,BAO_0000019
,,,Autocuration,1,18065,F,H,,,,8,CHEMBL619200,,,3533,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,15413,,,BAO_0000019
,,,Autocuration,1,18065,F,H,,,,8,CHEMBL619201,,,3534,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,15413,,,BAO_0000019
,,,Autocuration,1,18065,F,H,,,,8,CHEMBL619202,,,3535,,Tested for 5-hydroxytryptamine receptor uptake,,12409,,,BAO_0000019
449.0,,Homo sapiens,Expert,1,51,B,D,,,,9,CHEMBL619203,,9606.0,3536,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,16909,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,51,F,D,,,,9,CHEMBL619204,,9606.0,3537,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,16909,,,BAO_0000019
,,Homo sapiens,Autocuration,1,10576,B,H,,,,8,CHEMBL619205,,9606.0,3538,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,15629,,,BAO_0000249
,,,Autocuration,1,10576,B,H,,,,8,CHEMBL619206,,,3539,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,15629,,,BAO_0000357
,,,Expert,1,10576,B,H,,,,8,CHEMBL619207,,,3540,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,15629,,,BAO_0000249
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL619208,,,3541,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL619209,,,3542,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL619210,,,3543,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL619211,,,3544,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL619212,,,3545,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620681,,,3546,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620682,,,3547,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620683,,,3548,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620684,,,3549,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620685,,,3550,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,10034,,,BAO_0000019
,Striatum,,Autocuration,1,10825,F,H,,,2435.0,8,CHEMBL620686,,,3551,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620687,,,3552,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620688,,,3553,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620689,,,3554,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620690,,,3555,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620691,,,3556,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620692,,,3557,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL620693,,,3558,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,10034,,,BAO_0000019
,,,Expert,1,168,B,H,,,,8,CHEMBL620694,,,3559,,Binding affinity against 5-hydroxytryptamine 4 receptor,,1274,,,BAO_0000357
,,,Autocuration,1,168,F,H,,,,8,CHEMBL857986,,,3560,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,17358,,,BAO_0000019
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620695,,,3561,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,14532,,,BAO_0000357
,,,Expert,1,168,B,H,,,,8,CHEMBL620696,,,3562,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,16989,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620697,,,3563,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,17200,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620698,,,3564,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,15779,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620699,,,3565,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,15779,,,BAO_0000357
,,,Autocuration,1,168,B,H,,,,8,CHEMBL620700,,,3566,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,15779,,,BAO_0000357
643.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL620701,,,3567,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,15650,,COS-7,BAO_0000219
643.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL875082,,,3568,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,15650,,COS-7,BAO_0000219
643.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL620702,,,3569,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,15650,,COS-7,BAO_0000219
643.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL620703,,,3570,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,15650,,COS-7,BAO_0000219
673.0,,,Autocuration,1,168,B,H,,,,8,CHEMBL620704,,,3571,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,17046,,C6,BAO_0000219
673.0,,,Expert,1,168,B,H,,,,8,CHEMBL620705,,,3572,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,17046,,C6,BAO_0000219
673.0,,,Expert,1,168,B,H,,,,8,CHEMBL620706,,,3573,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,15650,,C6,BAO_0000219
673.0,,,Expert,1,168,B,H,,,,8,CHEMBL620707,,,3574,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,17046,,C6,BAO_0000219
,,,Expert,1,10624,B,H,,,,8,CHEMBL620708,,,3575,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,105,B,H,,,,8,CHEMBL620709,,,3576,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,17200,,,BAO_0000357
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL620710,,9606.0,3577,,Binding affinity against 5-hydroxytryptamine 5A receptor,,16146,,,BAO_0000357
449.0,,,Autocuration,1,10624,B,H,,,,8,CHEMBL620711,,,3578,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL620712,,9606.0,3579,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,6491,,,BAO_0000357
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL620713,,9606.0,3580,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL620714,,9606.0,3581,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL620715,,9606.0,3582,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,4234,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL620716,,,3583,,Binding affinity towards 5-HT5A receptor,,6013,,,BAO_0000357
,,,Expert,1,10624,B,H,,,,8,CHEMBL620717,,,3584,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,17175,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL618072,,,3585,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,15818,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL857987,,,3586,,Binding affinity towards cloned human 5-HT5A receptor was determined,,6166,,,BAO_0000357
722.0,,,Autocuration,1,10624,B,H,,,,8,CHEMBL618073,,,3587,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10624,B,H,,,,8,CHEMBL618074,,,3588,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10624,B,H,,,,8,CHEMBL618075,,,3589,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,5213,,HEK293,BAO_0000219
,,Mus musculus,Expert,1,10625,B,D,,,,9,CHEMBL618076,,10090.0,3590,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,17066,,,BAO_0000357
,,Mus musculus,Expert,1,10625,B,D,,,,9,CHEMBL618077,,10090.0,3591,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,17066,,,BAO_0000357
,,Mus musculus,Expert,1,10625,B,D,,,,9,CHEMBL618078,,10090.0,3592,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,17066,,,BAO_0000357
,,Mus musculus,Expert,1,10625,B,D,,,,9,CHEMBL881821,,10090.0,3593,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,17066,,,BAO_0000357
,,Mus musculus,Expert,1,10625,B,D,,,,9,CHEMBL618079,,10090.0,3594,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,17066,,,BAO_0000357
,,,Expert,1,10625,B,H,,,,8,CHEMBL618080,,,3595,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,17175,,,BAO_0000357
722.0,,,Autocuration,1,10576,B,H,,,,8,CHEMBL618081,,,3596,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,16190,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10626,B,H,,,,8,CHEMBL618082,,,3597,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,16190,,HEK293,BAO_0000219
,,,Expert,1,10624,B,H,,,,8,CHEMBL618083,,,3598,,Binding affinity towards 5-HT5a receptor,,4820,,,BAO_0000357
,,Homo sapiens,Expert,1,10624,B,D,,,,9,CHEMBL618084,,9606.0,3599,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,17066,,,BAO_0000357
,,,Expert,1,10624,B,H,,,,8,CHEMBL618085,,,3600,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,17066,,,BAO_0000357
,,,Expert,1,10624,B,H,,,,8,CHEMBL618086,,,3601,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,17175,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL875092,,,3602,,Binding affinities against 5-hydroxytryptamine 5A receptor,,16633,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL618087,,,3603,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,16633,,,BAO_0000357
,,,Autocuration,1,10624,B,H,,,,8,CHEMBL872926,,,3604,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,16700,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,104714,F,H,,,,4,CHEMBL618088,,10141.0,3605,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,4639,,,BAO_0000019
,,,Autocuration,1,104714,B,H,,,,4,CHEMBL618089,,,3606,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,5486,,,BAO_0000223
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618090,,9606.0,3607,,Inhibition of human 5-hydroxytryptamine 6 receptor,,16146,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618091,,9606.0,3608,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,17273,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618092,,,3609,,Inhibition against human 5-hydroxytryptamine 6 receptor,,17687,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618093,,9606.0,3610,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,6491,,,BAO_0000357
308.0,,,Expert,1,10627,B,H,,,,8,CHEMBL618094,,,3611,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,16190,,HeLa,BAO_0000219
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618095,,9606.0,3612,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL875093,,9606.0,3613,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618096,,9606.0,3614,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618118,,9606.0,3615,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618119,,9606.0,3616,,Binding affinity against 5-hydroxytryptamine 6 receptor,,3555,,,BAO_0000357
,,,Expert,1,10627,B,H,,,,8,CHEMBL618120,,,3617,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,5808,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618121,,,3618,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,6013,,,BAO_0000357
722.0,,,Expert,1,10627,B,H,,,,8,CHEMBL618122,,,3619,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,15818,,HEK293,BAO_0000219
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618123,,,3620,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,16209,,,BAO_0000357
722.0,,,Expert,1,10627,B,H,,,,8,CHEMBL618124,,,3621,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,3935,,HEK293,BAO_0000219
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618125,,,3622,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,15818,,,BAO_0000357
722.0,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618126,,9606.0,3623,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,3805,,HEK293,BAO_0000219
,,,Expert,1,10627,B,H,,,,8,CHEMBL618236,,,3624,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,16441,,,BAO_0000019
,,,Expert,1,10627,B,H,,,,8,CHEMBL618237,,,3625,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,16441,,,BAO_0000019
643.0,,,Expert,1,10627,B,H,,,,8,CHEMBL618238,,,3626,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,6786,,COS-7,BAO_0000219
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL618239,,9606.0,3627,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,4234,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618240,,,3628,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,17085,,,BAO_0000019
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL618241,,,3629,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,17200,,,BAO_0000357
722.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL859399,,,3630,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,17451,,HEK293,BAO_0000219
,,,Autocuration,1,10627,F,H,,,,8,CHEMBL618242,,,3631,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,3935,,,BAO_0000019
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL857991,,,3632,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,5033,,,BAO_0000357
,,,Expert,1,10627,B,H,,,,8,CHEMBL619951,,,3633,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,4540,,,BAO_0000357
308.0,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL619952,,9606.0,3634,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,4540,,HeLa,BAO_0000219
308.0,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL619953,,9606.0,3635,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,4540,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL619954,,,3636,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,17296,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL619955,,,3637,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,17296,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL619956,,,3638,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,17296,,HeLa,BAO_0000219
449.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL619957,,,3639,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,15779,,CHO,BAO_0000219
722.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL619958,,,3640,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620627,,,3641,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620628,,,3642,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,15779,,HEK293,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620629,,,3643,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,15779,,HeLa,BAO_0000219
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620630,,,3644,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,6166,,,BAO_0000357
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620782,,,3645,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,17451,,HeLa,BAO_0000219
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620783,,,3646,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,15316,,,BAO_0000357
,,,Expert,1,10627,B,H,,,,8,CHEMBL620784,,,3647,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,4199,,,BAO_0000357
308.0,,,Expert,1,10627,B,H,,,,8,CHEMBL620785,,,3648,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,15146,,HeLa,BAO_0000219
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL857992,,,3649,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,5213,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620786,,,3650,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,16429,,,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620787,,,3651,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,14818,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620788,,,3652,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,4829,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620789,,,3653,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,4829,,HeLa,BAO_0000219
308.0,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620790,,,3654,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,4829,,HeLa,BAO_0000219
449.0,,,Autocuration,1,10628,B,H,,,,8,CHEMBL620791,,,3655,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
,,,Autocuration,1,10628,B,H,,,,8,CHEMBL620792,,,3656,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,14423,,,BAO_0000019
,,,Autocuration,1,10628,B,H,,,,8,CHEMBL620793,,,3657,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,15086,,,BAO_0000357
,,,Autocuration,1,10628,B,H,,,,8,CHEMBL620794,,,3658,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,4342,,,BAO_0000357
308.0,,Homo sapiens,Autocuration,1,10627,B,D,,,,9,CHEMBL620795,,9606.0,3659,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,16190,,HeLa,BAO_0000219
,,,Expert,1,10627,B,H,,,,8,CHEMBL620796,,,3660,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,4820,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620797,,,3661,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,4639,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,F,D,,,,9,CHEMBL620798,,9606.0,3662,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,17066,,,BAO_0000019
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620799,,,3663,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,6011,,,BAO_0000357
,,,Expert,1,10627,B,H,,,,8,CHEMBL620800,,,3664,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620801,,,3665,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL875100,,,3666,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,5014,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620802,,,3667,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,10627,F,H,,,,8,CHEMBL620803,,,3668,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,17066,,,BAO_0000019
,,,Expert,1,10627,F,H,,,,8,CHEMBL620804,,,3669,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,17066,,,BAO_0000019
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620805,,,3670,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620806,,,3671,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,4687,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620807,,,3672,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,16946,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620808,,,3673,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,16946,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620809,,,3674,,Binding affinities against 5-hydroxytryptamine 6 receptor,,16633,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620810,,,3675,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,16633,,,BAO_0000357
,,Homo sapiens,Expert,1,10627,B,D,,,,9,CHEMBL620811,,9606.0,3676,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620812,,,3677,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,16700,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620813,,,3678,,Affinity against 5-hydroxytryptamine 6 receptor,,3269,,,BAO_0000357
,,,Autocuration,1,10627,B,H,,,,8,CHEMBL620814,,,3679,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,5486,,,BAO_0000357
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL620815,,9606.0,3680,,Inhibition of human 5-hydroxytryptamine 7 receptor,,16146,,,BAO_0000357
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620816,,,3681,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,5014,,HEK293,BAO_0000219
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620817,,,3682,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,15463,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620818,,,3683,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,3805,,,BAO_0000357
722.0,,,Expert,1,10209,B,H,,,,8,CHEMBL620819,,,3684,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,5014,,HEK293,BAO_0000219
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL620820,,9606.0,3685,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,6491,,,BAO_0000357
449.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620821,,,3686,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,16190,,CHO,BAO_0000219
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL620822,,9606.0,3687,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL620823,,9606.0,3688,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL620824,,9606.0,3689,,Binding affinity against 5-hydroxytryptamine 7 receptor,,3555,,,BAO_0000357
449.0,,,Expert,1,10209,B,H,,,,8,CHEMBL620825,,,3690,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,6588,,CHO,BAO_0000219
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL872930,,,3691,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,15463,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620826,,,3692,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,6013,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620827,,,3693,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,16209,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620828,,,3694,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,3935,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620829,,,3695,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,15818,,,BAO_0000357
722.0,,,Expert,1,10209,B,H,,,,8,CHEMBL620830,,,3696,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,5014,,HEK293,BAO_0000219
,,,Expert,1,10209,B,H,,,,8,CHEMBL620831,,,3697,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,16441,,,BAO_0000019
,,,Expert,1,10209,B,H,,,,8,CHEMBL620832,,,3698,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,16441,,,BAO_0000019
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL621548,,9606.0,3699,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,4234,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL621549,,,3700,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,17085,,,BAO_0000019
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL621550,,,3701,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,17200,,,BAO_0000357
449.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL621551,,,3702,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,17451,,CHO,BAO_0000219
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL621552,,,3703,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,17085,,,BAO_0000019
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL857077,,,3704,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,5104,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL618158,,,3705,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,5104,,,BAO_0000357
643.0,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL618159,,9606.0,3706,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,5033,,COS-7,BAO_0000219
643.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL875101,,,3707,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,5486,,COS-7,BAO_0000219
722.0,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL618160,,9606.0,3708,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,4540,,HEK293,BAO_0000219
,,,Expert,1,10209,B,H,,,,8,CHEMBL618161,,,3709,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,6166,,,BAO_0000357
722.0,,,Expert,1,10209,B,H,,,,8,CHEMBL618162,,,3710,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,17342,,HEK293,BAO_0000219
,,,Expert,1,10209,B,H,,,,8,CHEMBL618163,,,3711,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,17342,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL618164,,,3712,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,17296,,,BAO_0000357
,,,Expert,1,10209,B,H,,,,8,CHEMBL618165,,,3713,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,16429,,,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL618166,,,3714,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL857989,,,3715,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619888,,,3716,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619889,,,3717,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619890,,,3718,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,15779,,HEK293,BAO_0000219
449.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619891,,,3719,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,17451,,CHO,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619892,,,3720,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,4199,,HEK293,BAO_0000219
722.0,,,Expert,1,10209,B,D,,,,9,CHEMBL619893,,,3721,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,4199,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619894,,,3722,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,4199,,HEK293,BAO_0000219
722.0,,,Intermediate,1,10209,B,D,,,,9,CHEMBL619895,,,3723,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,3680,,HEK293,BAO_0000219
,,,Intermediate,1,10209,B,D,,,,9,CHEMBL619896,,,3724,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,3680,,,BAO_0000357
643.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619897,,,3725,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,15316,,COS-7,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619898,,,3726,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,15146,,HEK293,BAO_0000219
722.0,,,Expert,1,10209,B,H,,,,8,CHEMBL619899,,,3727,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,5213,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619900,,,3728,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,5213,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL619901,,9606.0,3729,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620580,,,3730,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620581,,,3731,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,14818,,HEK293,BAO_0000219
722.0,,,Autocuration,1,10209,B,H,,,,8,CHEMBL620733,,,3732,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,4829,,HEK293,BAO_0000219
,,Homo sapiens,Autocuration,1,10209,B,D,,,,9,CHEMBL620734,,9606.0,3733,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,17200,,,BAO_0000357
,,Mus musculus,Expert,1,10022,B,D,,,,9,CHEMBL620735,,10090.0,3734,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,17066,,,BAO_0000357
,,Oryctolagus cuniculus,Autocuration,1,10209,B,H,,,,8,CHEMBL620736,,9986.0,3735,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,14025,,,BAO_0000019
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620737,,,3736,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,15250,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620738,,,3737,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620739,,,3738,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620740,,,3739,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620741,,,3740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620742,,,3741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620743,,,3742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620744,,,3743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620745,,,3744,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620746,,,3745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620747,,,3746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620748,,,3747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620749,,,3748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,16372,,CHO,BAO_0000219
,,,Expert,1,11923,B,H,,,,8,CHEMBL620750,,,3749,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,Rattus norvegicus,Expert,1,11923,B,D,,,,9,CHEMBL620751,,10116.0,3750,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,17066,,,BAO_0000357
,,,Expert,1,11923,B,H,,,,8,CHEMBL620752,,,3751,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,17386,,,BAO_0000357
,,,Autocuration,1,11923,B,H,,,,8,CHEMBL872929,,,3752,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,14423,,,BAO_0000019
,,Rattus norvegicus,Expert,1,11923,B,D,,,,9,CHEMBL620753,,10116.0,3753,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,15874,,,BAO_0000357
,,Rattus norvegicus,Expert,1,11923,B,D,,,,9,CHEMBL620754,,10116.0,3754,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,15874,,,BAO_0000357
449.0,,Rattus norvegicus,Expert,1,11923,B,D,,,,9,CHEMBL620755,,10116.0,3755,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,16372,,CHO,BAO_0000219
,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620756,,,3756,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,4622,,,BAO_0000357
,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620757,,,3757,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,15086,,,BAO_0000357
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620758,,,3758,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620759,,,3759,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620760,,,3760,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,16372,,CHO,BAO_0000219
449.0,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620761,,,3761,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,16372,,CHO,BAO_0000219
,Ileum,,Autocuration,1,11923,F,H,,,2116.0,8,CHEMBL620762,,,3762,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,17386,,,BAO_0000221
,Ileum,,Autocuration,1,11923,F,H,,,2116.0,8,CHEMBL620763,,,3763,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,17386,,,BAO_0000221
,Ileum,,Autocuration,1,11923,F,H,,,2116.0,8,CHEMBL620764,,,3764,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,17386,,,BAO_0000221
,,Rattus norvegicus,Expert,1,11923,B,D,,,,9,CHEMBL857990,,10116.0,3765,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Membranes,5831,,,BAO_0000249
,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620765,,,3766,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,4342,,,BAO_0000357
,,,Expert,1,11923,B,H,,,,8,CHEMBL620766,,,3767,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,17319,,,BAO_0000357
,Hypothalamus,,Expert,1,11923,B,H,,,1898.0,8,CHEMBL620767,,,3768,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,17342,,,BAO_0000019
,,,Autocuration,1,11923,B,H,,,,8,CHEMBL620768,,,3769,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,17342,,,BAO_0000357
,Hypothalamus,,Expert,1,11923,B,H,,,1898.0,8,CHEMBL619051,,,3770,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,3680,,,BAO_0000249
,,,Expert,1,11923,B,H,,,,8,CHEMBL619052,,,3771,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,3680,,,BAO_0000357
722.0,,Rattus norvegicus,Expert,1,11923,F,D,,,,9,CHEMBL619053,,10116.0,3772,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,17319,,HEK293,BAO_0000219
722.0,,Rattus norvegicus,Expert,1,11923,F,D,,,,9,CHEMBL619703,,10116.0,3773,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,17319,,HEK293,BAO_0000219
722.0,,Rattus norvegicus,Autocuration,1,11923,F,D,,,,9,CHEMBL619704,,10116.0,3774,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,17319,,HEK293,BAO_0000219
,,,Expert,1,10209,B,H,,,,8,CHEMBL619851,,,3775,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,4820,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619852,,,3776,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,4639,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619853,,,3777,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,6011,,,BAO_0000357
,,Homo sapiens,Expert,1,10209,B,D,,,,9,CHEMBL619854,,9606.0,3778,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,,Expert,1,10209,B,H,,,,8,CHEMBL619855,,,3779,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619856,,,3780,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,17515,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619857,,,3781,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,4373,,,BAO_0000357
,,,Expert,1,10209,F,H,,,,8,CHEMBL619858,,,3782,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,17066,,,BAO_0000019
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619859,,,3783,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619860,,,3784,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,4373,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619861,,,3785,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,4687,,,BAO_0000357
,,,Expert,1,10209,B,H,,,,8,CHEMBL619862,,,3786,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,17342,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619863,,,3787,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,16946,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619864,,,3788,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,16946,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL872928,,,3789,,Binding affinities against 5-hydroxytryptamine 7 receptor,,16633,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619865,,,3790,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,16633,,,BAO_0000357
,,,Expert,1,10209,B,H,,,,8,CHEMBL619866,,,3791,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,17066,,,BAO_0000357
,,,Autocuration,1,10209,B,H,,,,8,CHEMBL619867,,,3792,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,16700,,,BAO_0000357
,Ileum,,Autocuration,1,10209,B,H,,,2116.0,8,CHEMBL619868,,,3793,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,17386,,,BAO_0000221
,,,Autocuration,1,55,F,H,,,,8,CHEMBL619869,,,3794,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,14080,,,BAO_0000019
,,Homo sapiens,Expert,1,55,F,D,,,,9,CHEMBL619870,,9606.0,3795,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,14080,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619871,,,3796,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,409,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619872,,,3797,,In vitro inhibition of human recombinant lipoxygenase enzyme,,409,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619873,,,3798,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,409,,,BAO_0000357
,Blood,,Expert,1,55,B,H,,,178.0,8,CHEMBL619874,,,3799,,Inhibition of 5-lipoxygenase in human whole blood.,,11090,,,BAO_0000357
,Blood,,Expert,1,55,B,H,,,178.0,8,CHEMBL619875,,,3800,,Inhibition of 5-lipoxygenase in human whole blood.,,11090,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619876,,,3801,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,948,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619877,,,3802,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,948,,,BAO_0000357
,,,Expert,1,55,F,H,,,,8,CHEMBL619878,,,3803,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,13622,,,BAO_0000219
,Blood,,Autocuration,1,55,F,H,,,178.0,8,CHEMBL619879,,,3804,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,13622,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619880,,,3805,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,9637,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619881,,,3806,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,11320,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL619882,,,3807,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,11320,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619883,,,3808,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,6838,,,BAO_0000357
,Blood,Homo sapiens,Expert,1,55,B,D,,,178.0,9,CHEMBL619884,,9606.0,3809,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,17667,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL619885,,,3810,,In vitro potency against human 5-Lipoxygenase,,12703,,,BAO_0000357
,,Homo sapiens,Expert,1,55,F,D,,,,9,CHEMBL619886,,9606.0,3811,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,14312,,,BAO_0000019
,Blood,,Autocuration,1,55,F,H,,,178.0,8,CHEMBL619887,,,3812,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,14312,,,BAO_0000019
,,,Autocuration,1,55,F,H,,,,8,CHEMBL875097,,,3813,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,5364,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618001,,,3814,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618002,,,3815,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618003,,,3816,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618004,,,3817,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618005,,,3818,,Inhibition of human 5-lipoxygenase in human cells,,12365,,,BAO_0000219
,,,Expert,1,55,B,H,,,,8,CHEMBL618006,,,3819,,Inhibition of human neutrophil 5-lipoxygenase,,10603,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL875086,,,3820,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,10501,,,BAO_0000019
,Blood,,Expert,1,55,B,H,,,178.0,8,CHEMBL618007,,,3821,,Inhibition of 5-lipoxygenase from human whole blood,,12281,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618008,,,3822,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,2567,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618009,,,3823,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,2567,,,BAO_0000219
,,,Expert,1,55,B,H,,,,8,CHEMBL618010,,,3824,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,10193,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618011,,,3825,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL618012,,,3826,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,13623,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL882927,,,3827,,Tested against 5-lipoxygenase,,12780,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618013,,,3828,,Tested for activity against 5-Lipoxygenase (5-LO),,12780,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618014,,,3829,,Tested for activity against 5-lipoxygenase,,12780,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618015,,,3830,,Tested for inhibition of 5-HPETE production by human 5-LO,,11966,,,BAO_0000357
,,,Autocuration,1,55,F,H,,,,8,CHEMBL618016,,,3831,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,5364,,,BAO_0000019
,,,Expert,1,55,B,H,,,,8,CHEMBL618017,,,3832,,Inhibition of Human 5-lipoxygenase,,13165,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618018,,,3833,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,5364,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL875087,,,3834,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618019,,,3835,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618020,,,3836,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,14863,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618021,,,3837,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,14863,,,BAO_0000019
,Blood,,Autocuration,1,55,B,H,,,178.0,8,CHEMBL618022,,,3838,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,11087,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618023,,,3839,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,455,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618024,,,3840,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL873950,,,3841,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,10319,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618025,,,3842,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618026,,,3843,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618027,,,3844,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618028,,,3845,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,951,,,BAO_0000219
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618029,,,3846,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,951,,,BAO_0000219
,,,Expert,1,55,B,H,,,,8,CHEMBL618030,,,3847,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,9859,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL618031,,,3848,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,9859,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618032,,,3849,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,9859,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618033,,,3850,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,2567,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618034,,,3851,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,10193,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL875088,,,3852,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,10193,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618035,,,3853,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,949,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618036,,,3854,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,949,,,BAO_0000019
,,,Expert,1,55,B,H,,,,8,CHEMBL618037,,,3855,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,10603,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL618038,,,3856,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,10603,,,BAO_0000357
,,,Autocuration,1,55,F,H,,,,8,CHEMBL618761,,,3857,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,10603,,,BAO_0000019
,,,Expert,1,55,B,H,,,,8,CHEMBL618762,,,3858,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,10603,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL618763,,,3859,,Inhibition of lipoxygenase at the concentration of 1 uM,,10603,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618764,,,3860,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,10193,,,BAO_0000357
,,Homo sapiens,Expert,1,55,B,D,,,,9,CHEMBL618765,,9606.0,3861,,Inhibition of 5-Lipoxygenase (5-LOX),,14580,,,BAO_0000357
,,,Expert,1,17087,B,H,,,,8,CHEMBL618766,,,3862,,Inhibition of 5-lipoxygenase in mouse macrophages.,,11090,,,BAO_0000357
,,,Expert,1,17087,B,H,,,,8,CHEMBL618767,,,3863,,Inhibition of 5-lipoxygenase in mouse macrophages.,,11090,,,BAO_0000357
,,,Autocuration,1,17087,B,H,,,,8,CHEMBL619380,,,3864,,Inhibitory activity against lipoxygenase-2 in mice,,6339,,,BAO_0000357
,,,Expert,1,17087,B,H,,,,8,CHEMBL619381,,,3865,,Inhibitory activity against murine lipoxygenase-2.,,6339,,,BAO_0000357
,,Mus musculus,Expert,1,17087,B,D,,,,9,CHEMBL619382,,10090.0,3866,,Inhibition of 5-lipoxygenase from mouse macrophage,,12281,,,BAO_0000357
,,,Autocuration,1,17087,B,H,,,,8,CHEMBL619383,,,3867,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,11311,,,BAO_0000357
,,Sus scrofa,Autocuration,1,55,B,H,,,,8,CHEMBL619384,,9823.0,3868,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,11089,,,BAO_0000019
,,Sus scrofa,Autocuration,1,55,B,H,,,,8,CHEMBL619385,,9823.0,3869,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,10091,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,55,B,H,,,,8,CHEMBL882928,,9986.0,3870,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,14352,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL619386,,10116.0,3871,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619387,,,3872,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619388,,,3873,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619389,,,3874,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,13329,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619390,,,3875,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,13329,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619391,,,3876,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619392,,,3877,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619393,,,3878,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,11311,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619394,,,3879,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,11311,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619395,,,3880,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,105,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619396,,,3881,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,105,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619397,,,3882,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,9138,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619398,,,3883,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,9138,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619399,,,3884,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,9138,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619400,,,3885,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,14427,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619401,,,3886,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,13329,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619402,,,3887,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,13329,,,BAO_0000019
663.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL619403,,10116.0,3888,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,14427,,RBL-2H3,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619404,,,3889,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,14427,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619405,,,3890,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,14427,,,BAO_0000357
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619406,,,3891,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,10293,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL619407,,10116.0,3892,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,338,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619408,,,3893,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,303,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619409,,,3894,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,303,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619410,,,3895,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619753,,,3896,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619754,,,3897,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,137,,RBL-1,BAO_0000219
,,,Expert,1,12166,B,H,,,,8,CHEMBL619903,,,3898,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,11481,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL619904,,,3899,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,11481,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL619905,,,3900,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,9029,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619906,,,3901,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,1701,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619907,,,3902,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,1701,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619908,,,3903,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,1701,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619909,,,3904,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,1701,,,BAO_0000019
702.0,,,Expert,1,12166,F,H,,,,8,CHEMBL619910,,,3905,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,13358,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL882929,,,3906,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,1175,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619911,,,3907,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,8797,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619912,,,3908,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,8797,,,BAO_0000019
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL619913,,10116.0,3909,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,577,,,BAO_0000357
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619914,,,3910,,In vitro inhibitory activity against RBL-1 5-LO,,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619915,,,3911,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619916,,,3912,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,9295,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619917,,,3913,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,9295,,,BAO_0000218
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619918,,,3914,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,9295,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619919,,,3915,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,216,,,BAO_0000218
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL883710,,,3916,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,11090,,RBL-1,BAO_0000219
,Blood,,Autocuration,1,12166,B,H,,,178.0,8,CHEMBL619920,,,3917,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,11090,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619921,,,3918,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,10091,,,BAO_0000357
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL619922,,,3919,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,10274,,,BAO_0000019
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL619923,,,3920,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,13622,,,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619924,,,3921,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,12118,,RBL-1,BAO_0000219
,,,Expert,1,12166,B,H,,,,8,CHEMBL619925,,,3922,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,12576,,,BAO_0000357
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619926,,,3923,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,9546,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619927,,,3924,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,9521,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619928,,,3925,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,10626,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619929,,,3926,,In vitro inhibition of RBL-1 5-lipoxygenase,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875089,,,3927,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619930,,,3928,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619931,,,3929,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619932,,,3930,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619933,,,3931,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619934,,,3932,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619935,,,3933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619936,,,3934,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619937,,,3935,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619938,,,3936,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619939,,,3937,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619940,,,3938,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875090,,,3939,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619941,,,3940,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619942,,,3941,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL883711,,,3942,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619943,,,3943,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619944,,,3944,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619945,,,3945,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619946,,,3946,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619947,,,3947,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619948,,,3948,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,9225,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619949,,,3949,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,9225,,RBL-1,BAO_0000219
,,,Expert,1,12166,B,H,,,,8,CHEMBL619950,,,3950,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,9401,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618050,,,3951,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,10325,,,BAO_0000019
663.0,,,Expert,1,12166,F,H,,,,8,CHEMBL875091,,,3952,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,1556,,RBL-2H3,BAO_0000219
663.0,,,Expert,1,12166,F,H,,,,8,CHEMBL618051,,,3953,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,1556,,RBL-2H3,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618052,,10116.0,3954,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,961,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618053,,,3955,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,6838,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL618054,,,3956,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,10325,,,BAO_0000019
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618055,,10116.0,3957,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,9209,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL618056,,,3958,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,11520,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618057,,,3959,,In vitro inhibitory activity against 5-lipoxygenase was determined,,137,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618058,,,3960,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,4717,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL618059,,,3961,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,10636,,RBL-1,BAO_0000219
,,Rattus norvegicus,Expert,1,12166,F,D,,,,9,CHEMBL618060,,10116.0,3962,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,14312,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618061,,,3963,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,1203,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618062,,,3964,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,1203,,,BAO_0000019
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL618063,,,3965,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,13622,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618064,,,3966,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,9793,,,BAO_0000357
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618065,,10116.0,3967,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,1143,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618066,,10116.0,3968,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,11854,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618067,,,3969,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618068,,,3970,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,3595,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618069,,10116.0,3971,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,10501,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL618070,,,3972,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,RBL-1,BAO_0000219
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL618071,,,3973,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,10034,,,BAO_0000019
,Limbic system,,Autocuration,1,10825,F,H,,,349.0,8,CHEMBL619247,,,3974,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,10034,,,BAO_0000019
,,,Autocuration,1,10825,F,H,,,,8,CHEMBL619248,,,3975,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,10034,,,BAO_0000019
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL619249,,,3976,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,,,BAO_0000221
,Hippocampus,,Autocuration,1,10576,B,H,,,10000000.0,8,CHEMBL619250,,,3977,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,10046,,,BAO_0000221
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL619251,,,3978,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,10046,,,BAO_0000019
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,,,178.0,8,CHEMBL619252,,9615.0,3979,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,12079,,,BAO_0000019
,Blood,,Autocuration,1,55,F,H,,,178.0,8,CHEMBL619253,,,3980,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,12079,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619254,,,3981,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Expert,1,17140,B,H,,,,8,CHEMBL619255,,,3982,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,12338,,,BAO_0000219
,,,Expert,1,17140,B,H,,,,8,CHEMBL619256,,,3983,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,12143,,,BAO_0000219
,,,Autocuration,1,17140,B,H,,,,8,CHEMBL875418,,,3984,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,12143,,,BAO_0000219
,,,Expert,1,17140,B,H,,,,8,CHEMBL619257,,,3985,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,12143,,,BAO_0000219
,,,Autocuration,1,17140,B,H,,,,8,CHEMBL619258,,,3986,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,12143,,,BAO_0000219
,,,Expert,1,17140,B,H,,,,8,CHEMBL619259,,,3987,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,12365,,,BAO_0000357
,,,Expert,1,17140,B,H,,,,8,CHEMBL619260,,,3988,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,13500,,,BAO_0000357
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619261,,9615.0,3989,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619263,,9615.0,3990,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619264,,9615.0,3991,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619265,,9615.0,3992,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619266,,9615.0,3993,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619902,,9615.0,3994,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620058,,9615.0,3995,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620059,,9615.0,3996,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620060,,9615.0,3997,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620061,,9615.0,3998,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620062,,9615.0,3999,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620063,,9615.0,4000,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620064,,9615.0,4001,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620065,,9615.0,4002,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620066,,9615.0,4003,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620067,,9615.0,4004,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620068,,9615.0,4005,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620069,,9615.0,4006,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620070,,9615.0,4007,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620071,,9615.0,4008,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620072,,9615.0,4009,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620036,,9615.0,4010,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL857702,,9615.0,4011,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620037,,9615.0,4012,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620038,,9615.0,4013,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620039,,9615.0,4014,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620040,,9615.0,4015,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620041,,9615.0,4016,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620042,,9615.0,4017,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620043,,9615.0,4018,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620044,,9615.0,4019,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620045,,9615.0,4020,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620046,,9615.0,4021,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620047,,9615.0,4022,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620048,,9615.0,4023,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL857703,,9615.0,4024,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620049,,9615.0,4025,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620050,,9615.0,4026,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL620051,,9615.0,4027,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619213,,9615.0,4028,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619214,,9615.0,4029,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619804,,9615.0,4030,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619805,,9615.0,4031,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619806,,9615.0,4032,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619807,,9615.0,4033,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,Blood,Canis lupus familiaris,Autocuration,1,55,F,H,In vivo,,178.0,8,CHEMBL619808,,9615.0,4034,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL619809,,9615.0,4035,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL619810,,9615.0,4036,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL619811,,9615.0,4037,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL620769,,9615.0,4038,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL620770,,9615.0,4039,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL620771,,9615.0,4040,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL620772,,9615.0,4041,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,3595,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,55,B,H,,,,8,CHEMBL620773,,9615.0,4042,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,3595,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL620774,,10141.0,4043,,Ability to inhibit 5-lipoxygenase in guinea pig,,9203,,,BAO_0000357
,,Cavia porcellus,Expert,1,55,B,H,,,,8,CHEMBL620775,,10141.0,4044,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,82,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL620776,,10141.0,4045,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,11090,,,BAO_0000357
,Blood,Cavia porcellus,Autocuration,1,55,B,H,,,178.0,8,CHEMBL620777,,10141.0,4046,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,12832,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL620778,,10141.0,4047,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,1065,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL620779,,10141.0,4048,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,1065,,,BAO_0000357
,,Cavia porcellus,Expert,1,55,B,H,,,,8,CHEMBL621500,,10141.0,4049,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,,BAO_0000019
,,Cavia porcellus,Expert,1,55,B,H,,,,8,CHEMBL621501,,10141.0,4050,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618098,,10141.0,4051,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,12832,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618099,,10141.0,4052,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10504,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618100,,10141.0,4053,,Inhibitory activity against 5-lipoxygenase,,7788,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618101,,10141.0,4054,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,10001,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618102,,10141.0,4055,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,10193,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618103,,10141.0,4056,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,13243,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618104,,10141.0,4057,,Inhibitory activity uM,,13243,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL883712,,10141.0,4058,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,969,,,BAO_0000219
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618105,,10141.0,4059,,Inhibitory activity against 5-lipoxygenase at 10 uM,,10001,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618106,,10141.0,4060,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,7788,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618107,,10141.0,4061,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,10001,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618108,,10141.0,4062,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,10193,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618109,,10141.0,4063,,Inhibitory activity uM,,13243,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618110,,10141.0,4064,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,13243,,,BAO_0000357
,,Cavia porcellus,Expert,1,55,B,H,,,,8,CHEMBL618111,,10141.0,4065,,Inhibitory activity uM,,13243,,,BAO_0000357
,,Cavia porcellus,Autocuration,1,55,F,H,,,,8,CHEMBL618112,,10141.0,4066,,Inhibitory activity uM,,13243,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618113,,10141.0,4067,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,10504,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,55,B,H,,,,8,CHEMBL618114,,10141.0,4068,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,7788,,,BAO_0000357
,Ileum,Cavia porcellus,Expert,1,55,F,H,,,2116.0,8,CHEMBL620871,,10141.0,4069,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,10546,,,BAO_0000221
,,,Autocuration,1,55,B,H,,,,8,CHEMBL620872,,,4070,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL620873,,,4071,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,13183,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL620874,,,4072,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,2578,,,BAO_0000357
,,,Expert,1,55,B,H,,,,8,CHEMBL620875,,,4073,,In vitro inhibition of human 5-Lipoxygenase.,,12780,,,BAO_0000357
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620876,,10116.0,4074,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620877,,10116.0,4075,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL857854,,10116.0,4076,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620878,,10116.0,4077,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620879,,10116.0,4078,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620880,,10116.0,4079,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620881,,10116.0,4080,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620882,,10116.0,4081,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620883,,10116.0,4082,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620884,,10116.0,4083,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620885,,10116.0,4084,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620886,,10116.0,4085,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620887,,10116.0,4086,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618039,,10116.0,4087,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618040,,10116.0,4088,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618041,,10116.0,4089,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618216,,10116.0,4090,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618217,,10116.0,4091,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618218,,10116.0,4092,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618219,,10116.0,4093,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618220,,10116.0,4094,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618221,,10116.0,4095,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618222,,10116.0,4096,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618223,,10116.0,4097,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618224,,10116.0,4098,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618225,,10116.0,4099,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618226,,10116.0,4100,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618227,,10116.0,4101,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618228,,10116.0,4102,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618229,,10116.0,4103,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618230,,10116.0,4104,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618231,,10116.0,4105,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618232,,10116.0,4106,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618233,,10116.0,4107,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618234,,10116.0,4108,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618235,,10116.0,4109,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618115,,10116.0,4110,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618116,,10116.0,4111,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL618117,,10116.0,4112,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619968,,10116.0,4113,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619969,,10116.0,4114,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619970,,10116.0,4115,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619971,,10116.0,4116,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619972,,10116.0,4117,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619973,,10116.0,4118,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619974,,10116.0,4119,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619975,,10116.0,4120,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,7411,,,BAO_0000251
,,Rattus norvegicus,Autocuration,1,22226,B,U,,,,0,CHEMBL619976,,10116.0,4121,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619977,,10116.0,4122,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619978,,10116.0,4123,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619979,,10116.0,4124,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619980,,10116.0,4125,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619981,,10116.0,4126,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,7411,,,BAO_0000251
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619982,,9606.0,4127,,In vitro inhibition of 7226/S myeloma cancer cell line,,10797,,RPMI-8226,BAO_0000219
993.0,,Homo sapiens,Intermediate,1,80698,F,N,,,,1,CHEMBL619983,,9606.0,4128,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,6881,,BEL-7404 tumor cell line,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL620031,,9606.0,4129,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,3838,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL620032,,9606.0,4130,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,3838,,786-0,BAO_0000219
505.0,,Cricetulus griseus,Expert,1,81264,F,N,,,,1,CHEMBL620033,,10029.0,4131,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,12981,,V79,BAO_0000219
505.0,,Cricetulus griseus,Expert,1,81264,F,N,,,,1,CHEMBL620034,,10029.0,4132,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,12981,,V79,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL620035,,10116.0,4133,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL618318,,10116.0,4134,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL618319,,10116.0,4135,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL618320,,10116.0,4136,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL618321,,10116.0,4137,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
1119.0,,Rattus norvegicus,Intermediate,1,80635,F,N,,,,1,CHEMBL883118,,10116.0,4138,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,7653,,7800C1 cell line,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL883795,,9606.0,4139,,In vitro antitumor activity against renal 786-0 tumor cell lines,,17229,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618322,,9606.0,4140,,Cytotoxic activity against 786-0 Renal cancer cell line,,12858,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618323,,9606.0,4141,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,16325,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618324,,9606.0,4142,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,16325,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618325,,9606.0,4143,,In vitro antitumor activity against human renal 786-0 cell line,,5858,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL875416,,9606.0,4144,,Inhibition of Renal cancer in 786-0 cancer cell lines,,16325,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618326,,9606.0,4145,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,14696,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL618327,,9606.0,4146,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,3786,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619215,,9606.0,4147,,inhibition of the growth of renal cancer(786-0) cell line,,14696,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619216,,9606.0,4148,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,14769,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619217,,9606.0,4149,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,15354,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619218,,9606.0,4150,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,14255,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619219,,9606.0,4151,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,14255,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619220,,9606.0,4152,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,14255,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619221,,9606.0,4153,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,14696,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619222,,9606.0,4154,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,12016,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL857454,,9606.0,4155,,Compound was tested for growth inhibitory activity against 786-0 cell line,,2597,,786-0,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619223,,,4156,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,12526,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619224,,,4157,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,12526,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619225,,,4158,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,14799,,,BAO_0000019
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619226,,,4159,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3595,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619227,,,4160,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,3595,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619228,,,4161,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,12767,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619229,,,4162,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,10997,,,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619230,,,4163,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,11388,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619231,,,4164,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,167,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619232,,,4165,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,167,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL619233,,,4166,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,13744,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619234,,,4167,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,1630,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619235,,,4168,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,1630,,,BAO_0000357
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL619236,,10116.0,4169,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,969,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619237,,,4170,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,13621,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619238,,,4171,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,10089,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL619239,,,4172,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,10193,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619240,,,4173,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,11966,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875417,,,4174,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12251,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619241,,,4175,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,211,,RBL-1,BAO_0000219
,,,Expert,1,12166,F,H,,,,8,CHEMBL619242,,,4176,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,12251,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL883796,,,4177,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,12495,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619243,,,4178,,Tested for its inhibitory activity against 5-lipoxygenase,,414,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619244,,,4179,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,414,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL619245,,,4180,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,10325,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619246,,,4181,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,11966,,,BAO_0000019
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619984,,,4182,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619985,,,4183,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,165,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619986,,,4184,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL619987,,,4185,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,165,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619988,,,4186,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,11311,,,BAO_0000218
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619989,,,4187,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,11311,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619990,,,4188,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,11311,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619991,,,4189,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619992,,,4190,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,11311,,,BAO_0000219
,,,Autocuration,1,12166,B,H,In vivo,,,8,CHEMBL619993,,,4191,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,11311,,,BAO_0000218
663.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL619994,,,4192,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
663.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL619995,,,4193,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619996,,,4194,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,11311,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619997,,,4195,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,11732,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619998,,,4196,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,11732,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL619999,,,4197,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,11087,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620000,,,4198,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,11087,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620001,,,4199,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,11087,,RBL-1,BAO_0000219
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL620002,,10116.0,4200,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,11087,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620003,,,4201,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,496,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,F,H,,,,8,CHEMBL620004,,,4202,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,13986,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL874063,,,4203,,Compound was evaluated for the inhibition of 5-lipoxygenase,,11520,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620005,,,4204,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,10293,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620006,,,4205,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,303,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620007,,,4206,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,303,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620008,,,4207,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,9247,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL620009,,10116.0,4208,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620010,,,4209,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620011,,,4210,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620677,,,4211,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620678,,,4212,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620679,,,4213,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,9247,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620680,,,4214,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,9247,,RBL-1,BAO_0000219
,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL620838,,10116.0,4215,,Inhibitory activity against 5-lipoxygenase at 10 uM,,11481,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620839,,,4216,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,105,,,BAO_0000357
,,,Expert,1,12166,B,H,,,,8,CHEMBL620840,,,4217,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,9029,,,BAO_0000357
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL620841,,,4218,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,1175,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620842,,,4219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,12118,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620843,,,4220,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,12118,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620844,,,4221,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,12118,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620845,,,4222,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,9225,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620846,,,4223,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,9401,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL873951,,,4224,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,137,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620847,,,4225,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,137,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620848,,,4226,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4717,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620849,,,4227,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,3595,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620850,,,4228,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,10501,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620851,,,4229,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,10501,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620852,,,4230,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,10501,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875098,,,4231,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL620853,,10116.0,4232,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,14799,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620854,,,4233,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,14799,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620855,,,4234,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,3595,,RBL-1,BAO_0000219
702.0,,,Expert,1,12166,B,H,,,,8,CHEMBL839884,,,4235,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,3595,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620856,,,4236,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620857,,,4237,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,12526,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620858,,,4238,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620859,,,4239,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620860,,,4240,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,10193,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620861,,,4241,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,10193,,,BAO_0000019
,,,Expert,1,12166,B,H,,,,8,CHEMBL620862,,,4242,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,9138,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620863,,,4243,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,9138,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620864,,,4244,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,11966,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620865,,,4245,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,165,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620866,,,4246,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,165,,RBL-1,BAO_0000219
663.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620867,,,4247,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
663.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620868,,,4248,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
663.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620869,,,4249,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
,,,Autocuration,1,12166,F,H,,,,8,CHEMBL873952,,,4250,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,11311,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875099,,,4251,,The compound was tested for inhibition of isolated 5-lipoxygenase,,11311,,,BAO_0000357
663.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620870,,,4252,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,11311,,RBL-2H3,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618261,,,4253,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,11087,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618262,,,4254,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,11087,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619428,,,4255,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,11087,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619429,,,4256,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,11087,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL619430,,,4257,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,11087,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620017,,,4258,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,496,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620018,,,4259,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,496,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620019,,,4260,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620020,,,4261,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620021,,,4262,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620022,,,4263,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620023,,,4264,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620024,,,4265,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620025,,,4266,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620026,,,4267,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,13986,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,F,H,,,,8,CHEMBL620027,,,4268,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,13986,,RBL-1,BAO_0000219
,,Rattus norvegicus,Expert,1,12166,F,D,,,,9,CHEMBL620028,,10116.0,4269,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,13986,,,BAO_0000019
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620029,,,4270,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,10193,,,BAO_0000357
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL620030,,,4271,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,9295,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL875415,,,4272,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,4717,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618256,,,4273,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4717,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618257,,,4274,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,11854,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618258,,,4275,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,11854,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618259,,,4276,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,11854,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618260,,,4277,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,10193,,,BAO_0000019
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618215,,,4278,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618390,,,4279,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618391,,,4280,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618392,,,4281,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,9295,,RBL-1,BAO_0000219
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618393,,,4282,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,165,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618394,,,4283,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,11311,,,BAO_0000219
702.0,,Homo sapiens,Expert,1,12166,B,H,,,,8,CHEMBL618395,,9606.0,4284,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,10489,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL618396,,10116.0,4285,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,10489,,RBL-1,BAO_0000219
702.0,,Rattus norvegicus,Expert,1,12166,B,D,,,,9,CHEMBL858253,,10116.0,4286,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,10489,,RBL-1,BAO_0000219
,,Rattus norvegicus,Autocuration,1,12166,B,D,,,,9,CHEMBL618397,,10116.0,4287,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,14799,,,BAO_0000019
,,Glycine max,Autocuration,1,12054,B,H,,,,8,CHEMBL618398,,3847.0,4288,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,9295,,,BAO_0000357
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL618399,,,4289,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,16811,,,BAO_0000019
,,,Expert,1,55,B,H,,,,8,CHEMBL618400,,,4290,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,168,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618401,,,4291,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,6309,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618402,,,4292,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,6309,,,BAO_0000357
702.0,,,Autocuration,1,55,B,H,,,,8,CHEMBL876400,,,4293,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,3092,,RBL-1,BAO_0000219
,,,Expert,1,55,B,H,,,,8,CHEMBL618403,,,4294,,Inhibitory activity against 5-lipoxygenase.,,168,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618404,,,4295,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,168,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618405,,,4296,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,168,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618406,,,4297,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,168,,,BAO_0000357
,,,Expert,1,55,F,H,,,,8,CHEMBL618407,,,4298,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,12338,,,BAO_0000019
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618408,,,4299,,Tested for the inhibitory activity against 5-lipoxygenase,,4501,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618409,,,4300,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,1132,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618410,,,4301,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,2117,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618411,,,4302,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,168,,,BAO_0000357
,,,Autocuration,1,55,B,H,,,,8,CHEMBL618412,,,4303,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,168,,,BAO_0000357
702.0,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618413,,,4304,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,13575,,RBL-1,BAO_0000219
,,,Autocuration,1,12166,B,H,,,,8,CHEMBL618414,,,4305,,,,11089,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618415,,,4306,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,216,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618416,,,4307,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,13165,,,BAO_0000019
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL876401,,,4308,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,3278,,,BAO_0000357
,,,Expert,1,10102,B,H,,,,8,CHEMBL618417,,,4309,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,3278,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618418,,,4310,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,11966,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618419,,,4311,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,175,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618420,,,4312,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,175,,,BAO_0000357
,,,Autocuration,1,10102,B,H,,,,8,CHEMBL618421,,,4313,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,13449,,,BAO_0000357
,,,Autocuration,1,11238,B,H,,,,8,CHEMBL618422,,,4314,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,12014,,,BAO_0000019
,,,Autocuration,1,11238,B,H,,,,8,CHEMBL618423,,,4315,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,12014,,,BAO_0000019
,,,Autocuration,1,11238,B,H,,,,8,CHEMBL618424,,,4316,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,12014,,,BAO_0000019
,,,Intermediate,1,100284,B,S,,,,2,CHEMBL618425,,,4317,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,99,,,BAO_0000220
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL618426,,9606.0,4318,,The dark toxicity against 543 human galactophore carcinoma cells,,4349,,,BAO_0000019
390.0,,Homo sapiens,Expert,1,80623,F,N,,,,1,CHEMBL618427,,9606.0,4319,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,4071,,Panel (56 tumour cell lines),BAO_0000219
345.0,,Homo sapiens,Expert,1,80008,F,N,,,,1,CHEMBL618428,,9606.0,4320,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,17589,,5637,BAO_0000219
345.0,,Homo sapiens,Intermediate,1,80008,F,N,,,,1,CHEMBL618429,,9606.0,4321,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,15002,,5637,BAO_0000219
345.0,,Homo sapiens,Intermediate,1,80008,F,N,,,,1,CHEMBL618430,,9606.0,4322,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,13958,,5637,BAO_0000219
345.0,,Homo sapiens,Expert,1,80008,F,N,,,,1,CHEMBL618431,,9606.0,4323,,Growth inhibition against human 5637 cell lines,,17589,,5637,BAO_0000219
345.0,,Homo sapiens,Expert,1,80008,F,N,,,,1,CHEMBL883799,,9606.0,4324,,Antitumor activity against human bladder carcinoma 5637 cells.,,16748,,5637,BAO_0000219
345.0,,Homo sapiens,Intermediate,1,80008,F,N,,,,1,CHEMBL618432,,9606.0,4325,,Antitumor activity against human bladder carcinoma 5637 cells,,16747,,5637,BAO_0000219
345.0,,Homo sapiens,Intermediate,1,80008,F,N,,,,1,CHEMBL618433,,9606.0,4326,,Antitumor activity against human bladder carcinoma 5637 cells,,16747,,5637,BAO_0000219
,,Bos taurus,Expert,1,10443,B,D,,,,9,CHEMBL618434,,9913.0,4327,,In vitro inhibition of bovine trypsin(Trp).,,15285,,,BAO_0000357
407.0,,Cercopithecidae,Expert,1,240,B,H,,,,8,CHEMBL618435,,9527.0,4328,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,3726,,CV-1,BAO_0000219
,,,Autocuration,1,10577,B,H,,,,8,CHEMBL876402,,,4329,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,5033,,,BAO_0000357
,,,Autocuration,1,104698,F,H,,,,6,CHEMBL618436,,,4330,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,11756,,,BAO_0000019
,,,Autocuration,1,22226,F,U,In vivo,,,0,CHEMBL618437,,,4331,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,11953,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,20033,B,D,,,,9,CHEMBL618438,,10141.0,4332,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,5033,,,BAO_0000357
,,Rattus norvegicus,Expert,1,17045,A,H,,,,8,CHEMBL883800,,10116.0,4333,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,11347,,,BAO_0000251
,,Rattus norvegicus,Expert,1,17045,A,H,,,,8,CHEMBL618439,,10116.0,4334,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,11347,,,BAO_0000251
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL618440,,,4335,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,1229,,,BAO_0000019
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL618441,,,4336,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,1229,,,BAO_0000019
,,Trypanosoma brucei,Expert,1,11938,B,H,,,,8,CHEMBL618442,,5691.0,4337,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,17588,,,BAO_0000019
,,Trypanosoma brucei,Autocuration,1,11938,B,H,,,,8,CHEMBL618443,,5691.0,4338,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,17588,,,BAO_0000019
,,Ovis aries,Expert,1,11938,B,H,,,,8,CHEMBL619158,,9940.0,4339,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,17588,,,BAO_0000019
,,Ovis aries,Autocuration,1,11938,B,H,,,,8,CHEMBL620974,,9940.0,4340,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,17588,,,BAO_0000019
,,,Autocuration,1,11938,B,H,,,,8,CHEMBL620975,,,4341,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,16485,,,BAO_0000357
,,Homo sapiens,Intermediate,1,22226,F,U,,,,0,CHEMBL620976,,9606.0,4342,,Average inhibitory concentration against 60 human cell lines was reported,,4337,,,BAO_0000019
,,Homo sapiens,Expert,1,22226,F,U,,,,0,CHEMBL620977,,9606.0,4343,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,4112,,,BAO_0000019
542.0,,Homo sapiens,Intermediate,1,80315,F,N,,,,1,CHEMBL620978,,9606.0,4344,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,16160,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
542.0,,Homo sapiens,Intermediate,1,80315,F,N,,,,1,CHEMBL620979,,9606.0,4345,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,16160,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
542.0,,,Expert,1,80315,F,N,,,,1,CHEMBL620980,,,4346,,In vitro mean growth inhibitory activity against 60-cell panel,,17376,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
542.0,,,Expert,1,80315,F,N,,,,1,CHEMBL620981,,,4347,,In vitro mean growth lethal concentration against 60-cell panel,,17376,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
542.0,,,Expert,1,80315,F,N,,,,1,CHEMBL620982,,,4348,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,17376,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
542.0,,,Expert,1,80315,F,N,,,,1,CHEMBL620983,,,4349,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,17376,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219
,,,Autocuration,1,104775,F,H,,,,4,CHEMBL620984,,,4350,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,3241,,,BAO_0000019
,,,Autocuration,1,104775,F,H,,,,4,CHEMBL620985,,,4351,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,3241,,,BAO_0000019
,,,Expert,1,275,B,H,,,,8,CHEMBL620986,,,4352,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,3725,,,BAO_0000357
,,Plasmodium falciparum,Expert,1,50425,F,N,,,,1,CHEMBL620987,,5833.0,4353,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,10805,,,BAO_0000218
,,Plasmodium falciparum,Expert,1,50425,F,N,,,,1,CHEMBL620988,,5833.0,4354,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,10805,,,BAO_0000218
,,Plasmodium falciparum,Expert,1,50425,F,N,,,,1,CHEMBL620989,,5833.0,4355,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,10805,,,BAO_0000218
,,Plasmodium falciparum,Expert,1,50425,F,N,,,,1,CHEMBL620990,,5833.0,4356,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,10805,,,BAO_0000218
,,Plasmodium falciparum,Intermediate,1,50425,F,N,,,,1,CHEMBL620991,,5833.0,4357,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,10805,,,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL620992,,10090.0,4358,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL620993,,10090.0,4359,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL620994,,10090.0,4360,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL620995,,10090.0,4361,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL620996,,10090.0,4362,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL875581,,10090.0,4363,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,10144,,6C3HED,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL620997,,10090.0,4364,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL620998,,10090.0,4365,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL620999,,10090.0,4366,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621000,,10090.0,4367,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621001,,10090.0,4368,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621002,,10090.0,4369,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621003,,10090.0,4370,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621004,,10090.0,4371,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621005,,10090.0,4372,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621006,,10090.0,4373,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL621007,,10090.0,4374,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL621008,,10090.0,4375,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,10144,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL621009,,10090.0,4376,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,10144,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL857705,,10090.0,4377,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,10144,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL619828,,10090.0,4378,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,10144,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL619829,,10090.0,4379,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL619830,,10090.0,4380,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL619831,,10090.0,4381,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL619832,,10090.0,4382,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,,,,0,CHEMBL619833,,10090.0,4383,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,,,,0,CHEMBL619834,,10090.0,4384,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,,,,0,CHEMBL619835,,10090.0,4385,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,10685,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,,,,0,CHEMBL619836,,10090.0,4386,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,10685,,,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL619837,,10090.0,4387,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,8831,,6C3HED,BAO_0000218
,,,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL619838,,,4388,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,11704,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619839,,10090.0,4389,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,11704,,,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,In vivo,,,1,CHEMBL619840,,10090.0,4390,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,10685,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,In vivo,,,1,CHEMBL619841,,10090.0,4391,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,10685,,6C3HED,BAO_0000218
850.0,,Mus musculus,Expert,1,80628,F,N,,,,1,CHEMBL857704,,10090.0,4392,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,11368,,6C3HED,BAO_0000218
850.0,,Mus musculus,Intermediate,1,80628,F,N,,,,1,CHEMBL619842,,10090.0,4393,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,11368,,6C3HED,BAO_0000218
850.0,,Mus musculus,Expert,1,80628,F,N,,,,1,CHEMBL619843,,10090.0,4394,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,11368,,6C3HED,BAO_0000218
,,Staphylococcus aureus,Autocuration,1,22226,B,U,,,,0,CHEMBL619844,,1280.0,4395,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,17763,,,BAO_0000019
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL857855,,10116.0,4396,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619845,,10116.0,4397,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619846,,10116.0,4398,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619847,,10116.0,4399,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL619848,,10116.0,4400,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620893,,10116.0,4401,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620894,,10116.0,4402,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620895,,10116.0,4403,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620896,,10116.0,4404,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620897,,10116.0,4405,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620898,,10116.0,4406,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,7411,,,BAO_0000251
,Liver,Rattus norvegicus,Autocuration,1,22226,B,U,,,2107.0,0,CHEMBL620899,,10116.0,4407,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,7411,,,BAO_0000251
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620900,,9527.0,4408,,The apparent total plasma clearance in monkey,,347,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620901,,9527.0,4409,,Compound was evaluated for Hepatic clearance in monkey,,3341,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620902,,9527.0,4410,,Lower clearance in monkey (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620903,,9527.0,4411,,Plasma clearance in rhesus monkey,,4514,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620904,,9527.0,4412,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620905,,9527.0,4413,,Plasma clearance of compound was determined in monkey,,6821,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620906,,9527.0,4414,,Plasma clearance was calculated in rhesus monkey,,6057,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875420,,9527.0,4415,,Plasma clearance in rhesus monkey,,5145,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620907,,9527.0,4416,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620908,,9527.0,4417,,Plasma clearance was evaluated in rhesus,,5472,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620909,,9527.0,4418,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620910,,9527.0,4419,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620911,,9527.0,4420,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620912,,9527.0,4421,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620913,,9527.0,4422,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,17509,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620914,,9527.0,4423,,Cmax in monkey after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620915,,9527.0,4424,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,5668,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620916,,9527.0,4425,,Cmax in cynomolgus monkey by iv administration,,5922,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620917,,9527.0,4426,,Cmax in cynomolgus monkey by po administration,,5922,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620918,,9527.0,4427,,Cmax value evaluated in monkey,,6078,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620919,,9527.0,4428,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620920,,9527.0,4429,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,3249,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620921,,9527.0,4430,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,3249,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620922,,9527.0,4431,,Maximal plasma concentration in squirrel monkeys,,5553,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620923,,9527.0,4432,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620924,,9527.0,4433,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,6227,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620925,,9527.0,4434,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620926,,9527.0,4435,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620927,,9527.0,4436,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620928,,9527.0,4437,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620929,,9527.0,4438,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,5355,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL620930,,9527.0,4439,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,6221,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620931,,9527.0,4440,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,167,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620932,,9527.0,4441,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,167,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620933,,9443.0,4442,,Absolute bioavailability was evaluated in monkey,,4257,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620934,,9443.0,4443,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,6221,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620935,,9443.0,4444,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,17667,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620936,,9544.0,4445,,Bioavailability of compound was determined in rhesus monkey,,17267,,,BAO_0000218
,,marmosets,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620937,,38020.0,4446,,Bioavailability determined after oral administration in marmoset,,4256,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620938,,9541.0,4447,,Oral bioavailability in cynomolgus monkey,,4256,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620939,,9443.0,4448,,Bioavailability in monkey (p.o.) at 2.0 mpk,,17853,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620940,,9443.0,4449,,Bioavailability was evaluated after oral administration in monkey,,16365,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620941,,9541.0,4450,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620942,,9544.0,4451,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620943,,9544.0,4452,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620944,,9443.0,4453,,Bioavailability of the compound was determined in monkey,,17592,,,BAO_0000218
,,Saimiri sciureus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620945,,9521.0,4454,,Bioavailability in squirrel monkey (dose 5 mg/kg),,1399,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620946,,9443.0,4455,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4809,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620947,,9443.0,4456,,Oral bioavailability in monkey,,3341,,,BAO_0000218
,,Saimiri sciureus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620948,,9521.0,4457,,Compound was tested for bioavailability in squirrel monkey,,64,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620949,,9544.0,4458,,Oral bioavailability in Rhesus monkey,,5005,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620950,,9544.0,4459,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,5005,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620951,,9541.0,4460,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,5237,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620952,,9541.0,4461,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,5237,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875421,,9443.0,4462,,Oral bioavailability in monkey (dose 5 mg/kg),,5302,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620953,,9443.0,4463,,Oral bioavailability of compound at 5 mg/kg in monkey,,17667,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873491,,9615.0,4464,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,6161,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL620954,,9615.0,4465,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,6161,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL620955,,9615.0,4466,,Plasma half life determined,,3854,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL618097,,9615.0,4467,,Plasma half life in dog,,993,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL618268,,9615.0,4468,,Plasma half-life in Beagle dogs,,4514,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL618269,,9615.0,4469,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,5334,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL618270,,9615.0,4470,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,5334,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618271,,9615.0,4471,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873493,,9615.0,4472,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621031,,9615.0,4473,,Tested for the half life period in dog,,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621032,,9615.0,4474,,Tested for the half life period in dog at dosage of 10 mpk,,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621033,,9615.0,4475,,The compound was tested for half life in dog,,3880,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621034,,9615.0,4476,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621035,,9615.0,4477,,The half life was determined,,3880,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621036,,9615.0,4478,,The plasma half-life in dogs,,3918,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621037,,9615.0,4479,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619812,,9615.0,4480,,Half life in dog,,17796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619813,,9615.0,4481,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873335,,9615.0,4482,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619814,,9615.0,4483,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Mustela putorius furo,Expert,1,50506,A,N,In vivo,,,1,CHEMBL619815,,9669.0,4484,,Cmax in ferrets after 30 mg/kg oral dose,,6113,,,BAO_0000218
,,Mustela putorius furo,Expert,1,50506,F,N,In vivo,,,1,CHEMBL619816,,9669.0,4485,,Emesis in ferrets at 30 mg/kg oral dose,,6113,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619817,,9541.0,4486,,Bioavailability in cynomolgus monkey,,17796,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL619818,,9541.0,4487,,Volume of distribution in cynomolgus,,17796,,,BAO_0000218
,Plasma,Cavia porcellus,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619819,,10141.0,4488,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,5308,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL619820,,10141.0,4489,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,4877,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL875419,,10141.0,4490,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,4876,,,BAO_0000218
,Plasma,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL619821,,10141.0,4491,,AUC in guinea pig after 3mg/kg oral dose,,4878,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619822,,10141.0,4492,,Bioavailability in guinea pig was tested,,5308,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619823,,10141.0,4493,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,4877,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619824,,10141.0,4494,,Tested for the oral bioavailability of the compound,,4876,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619825,,10141.0,4495,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,4876,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619826,,10141.0,4496,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,5308,,,BAO_0000218
,Lung,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL619827,,10141.0,4497,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,4877,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618167,,10141.0,4498,,Cmax in guinea pig after 3mg/kg oral dose,,4878,,,BAO_0000218
,Blood,Cavia porcellus,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL618168,,10141.0,4499,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,Brain,Cavia porcellus,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL618169,,10141.0,4500,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL618170,,10141.0,4501,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,Intestine,Cavia porcellus,Autocuration,1,22224,A,U,,,160.0,0,CHEMBL618171,,10141.0,4502,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,Kidney,Cavia porcellus,Autocuration,1,22224,A,U,,,2113.0,0,CHEMBL618172,,10141.0,4503,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,Liver,Cavia porcellus,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL618173,,10141.0,4504,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL618174,,10141.0,4505,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,Spleen,Cavia porcellus,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL875408,,10141.0,4506,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,5689,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL839827,,10141.0,4507,,Elimination T1/2 in Guinea pig (PO dose),,14465,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL618175,,10141.0,4508,,Partition coefficient was measured as -log (counts per min ),,5689,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618176,,10141.0,4509,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,611,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618177,,10141.0,4510,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,611,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618178,,10141.0,4511,,Elimination T1/2 in Guinea pig (PO dose),,14465,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618179,,10141.0,4512,,"Tested for the half life period of the compound, intravenously",,4876,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL873489,,10141.0,4513,,Half-life was measured,,5689,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,,,,0,CHEMBL618180,,10141.0,4514,,The time required for onset of inotropy after addition of a single dose of delta F75,,7515,,,BAO_0000019
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618181,,10141.0,4515,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,17667,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618182,,10141.0,4516,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,17667,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618183,,10029.0,4517,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,4727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618184,,10090.0,4518,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618185,,10090.0,4519,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618186,,10090.0,4520,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618187,,10090.0,4521,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618188,,10090.0,4522,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL875409,,10090.0,4523,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618189,,10090.0,4524,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL618190,,10090.0,4525,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL618191,,10090.0,4526,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL618192,,10090.0,4527,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL618193,,10090.0,4528,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL618194,,10090.0,4529,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL618195,,10090.0,4530,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL618196,,10090.0,4531,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL618197,,10090.0,4532,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL618198,,10090.0,4533,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL618199,,10090.0,4534,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL618200,,10090.0,4535,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL618201,,10090.0,4536,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL618202,,10090.0,4537,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL618203,,10090.0,4538,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL618204,,10090.0,4539,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL618205,,10090.0,4540,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL618206,,10090.0,4541,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL618207,,10090.0,4542,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL618208,,10090.0,4543,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL618932,,10090.0,4544,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL618933,,10090.0,4545,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL618934,,10090.0,4546,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL618935,,10090.0,4547,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL618936,,10090.0,4548,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL618937,,10090.0,4549,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL618938,,10090.0,4550,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL619104,,10090.0,4551,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL619105,,10090.0,4552,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL619106,,10090.0,4553,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL619107,,10090.0,4554,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL875410,,10090.0,4555,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,3655,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL619108,,10090.0,4556,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,3655,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL619109,,10090.0,4557,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,3655,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619110,,10090.0,4558,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL619111,,10090.0,4559,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619112,,10090.0,4560,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619113,,10090.0,4561,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619114,,10090.0,4562,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL619115,,10090.0,4563,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,17764,,,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619116,,9606.0,4564,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,3830,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619117,,9606.0,4565,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,3829,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619118,,9606.0,4566,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,2040,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619119,,9606.0,4567,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619120,,9606.0,4568,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619121,,9606.0,4569,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619122,,9606.0,4570,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619123,,9606.0,4571,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619124,,9606.0,4572,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619125,,9606.0,4573,,Compound was evaluated for cytotoxicity against A2780 cell line,,2859,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL875411,,9606.0,4574,,In vitro inhibitory activity against human tumor cell line A2780,,5618,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619126,,9606.0,4575,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619127,,9606.0,4576,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619128,,9606.0,4577,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619129,,9606.0,4578,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619130,,9606.0,4579,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,2113,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619131,,9606.0,4580,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,2113,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619132,,9606.0,4581,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,16745,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619133,,9606.0,4582,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619134,,9606.0,4583,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619135,,9606.0,4584,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,15684,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619136,,9606.0,4585,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,2040,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619137,,9606.0,4586,,Relative resistance factor in A2780 cisplatin-resistant line,,2040,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL883713,,9606.0,4587,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,16165,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL875412,,9606.0,4588,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,16165,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619138,,9606.0,4589,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,A2780,BAO_0000218
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619262,,9606.0,4590,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,16597,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619139,,9606.0,4591,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,3992,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619140,,9606.0,4592,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,10553,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619141,,9606.0,4593,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619142,,9606.0,4594,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619143,,9606.0,4595,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619144,,9606.0,4596,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619145,,9606.0,4597,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619146,,9606.0,4598,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619147,,9606.0,4599,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,15569,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619148,,9606.0,4600,,Antiproliferative effect of compound on A2780/DX cell line,,17420,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619149,,9606.0,4601,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,17420,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619150,,9606.0,4602,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,15099,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619151,,9606.0,4603,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,15099,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL883794,,9606.0,4604,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,17672,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619152,,9606.0,4605,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,17672,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619153,,9606.0,4606,,In vitro cytotoxicity against A2780ADR cell line,,17270,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619154,,9606.0,4607,,In vitro cytotoxicity against A2780CIS cell line,,17270,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619155,,9606.0,4608,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,5574,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619156,,9606.0,4609,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,2113,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619157,,9606.0,4610,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619797,,9606.0,4611,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,A2780,BAO_0000219
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619798,,9544.0,4612,,Oral bioavailability of compound in rhesus macaques,,17839,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619799,,9443.0,4613,,Oral bioavailability in monkey,,6821,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619800,,9443.0,4614,,Oral bioavailability evaluated in monkey,,6078,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619801,,9443.0,4615,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,6535,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619802,,9544.0,4616,,Oral bioavailability in Rhesus monkey,,4449,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619803,,9544.0,4617,,Oral bioavailability was calculated in rhesus monkey,,6057,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619965,,9541.0,4618,,Oral bioavailability in cynomolgus monkey,,5922,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619966,,9443.0,4619,,Oral bioavailability in monkey,,5940,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619967,,9443.0,4620,,Oral bioavailability in monkey,,6265,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620073,,9443.0,4621,,Oral bioavailability in monkey (dose 1 mg/kg),,6265,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620074,,9443.0,4622,,Oral bioavailability in monkey (dose 5 mg/kg),,6265,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620075,,9443.0,4623,,Oral bioavailability in monkey,,5940,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620076,,9443.0,4624,,Oral bioavailability in monkey,,5940,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620077,,9544.0,4625,,Oral bioavailability in rhesus monkey,,4514,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620078,,9544.0,4626,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,5546,,,BAO_0000218
,,Saimiri sciureus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620079,,9521.0,4627,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,5553,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620080,,9443.0,4628,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620081,,9544.0,4629,,Oral bioavailability in Rhesus monkey,,5472,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620082,,9544.0,4630,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,5668,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620083,,9443.0,4631,,Oral bioavailability in monkey at 10 mg/kg of the compound,,5711,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620084,,9544.0,4632,,Bioavailability in Rhesus monkey,,5145,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620085,,9527.0,4633,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL874595,,9527.0,4634,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL873352,,9527.0,4635,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,3249,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620086,,9527.0,4636,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,3249,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620087,,9527.0,4637,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620088,,9527.0,4638,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620089,,9527.0,4639,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620090,,9527.0,4640,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620091,,9527.0,4641,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620092,,9527.0,4642,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620093,,9527.0,4643,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620094,,9527.0,4644,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620095,,9527.0,4645,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Microsomes,14294,,,BAO_0000251
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620096,,9527.0,4646,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620097,,9527.0,4647,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620098,,9527.0,4648,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620099,,9527.0,4649,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620100,,9527.0,4650,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620101,,9527.0,4651,,Elimination Half-life of compound was determined in monkey,,6821,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620102,,9527.0,4652,,Half life of compound was determined in rhesus monkey,,17267,,,BAO_0000019
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL620103,,9527.0,4653,,Half life in monkey plasma,,5819,,,BAO_0000366
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL620104,,9527.0,4654,,Half life in monkey plasma; Not detected,,5819,,,BAO_0000366
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL874596,,9527.0,4655,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL873490,,9527.0,4656,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,17509,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620105,,9527.0,4657,,Terminal half life of the compound.,,1399,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620780,,9527.0,4658,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620781,,9527.0,4659,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL620956,,9527.0,4660,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,Urine,Cercopithecidae,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL620957,,9527.0,4661,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,Urine,Cercopithecidae,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL620958,,9527.0,4662,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620959,,9527.0,4663,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620960,,9527.0,4664,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,6221,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620961,,9527.0,4665,,Volume of distribution was evaluated in rhesus,,5472,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620962,,10029.0,4666,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,4727,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620963,,10029.0,4667,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,4727,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620964,,10029.0,4668,,Bioavailability in hamster was determined,,4727,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620965,,10029.0,4669,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,4727,,,BAO_0000218
,,Cricetulus griseus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620966,,10029.0,4670,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,4727,,,BAO_0000218
,Blood,Cricetulus griseus,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL620967,,10029.0,4671,,Half life of compound was determined in hamster blood,,4727,,,BAO_0000221
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL620968,,9823.0,4672,,Michaelis-Menten constant of the compound.,,1452,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL874597,,9823.0,4673,,Vmax value was measured at 0 uM concentration of silyl ether.,,1452,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL620969,,9823.0,4674,,Vmax value was measured at 10 uM concentration of silyl ether.,,1452,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL620970,,9823.0,4675,,Vmax value was measured at 5 uM concentration of silyl ether.,,1452,,,BAO_0000019
,,Homo sapiens,Expert,1,235,B,D,,,,9,CHEMBL620971,,9606.0,4676,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,11706,,,BAO_0000357
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620972,,9606.0,4677,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,1916,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620973,,9606.0,4678,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,17791,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618243,,9606.0,4679,,Active metabolite of ifosfamide determined in humans; A-Active,,7766,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618244,,9606.0,4680,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,6567,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618245,,9606.0,4681,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,6567,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618246,,9606.0,4682,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,6567,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618247,,9606.0,4683,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,6567,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618248,,9606.0,4684,,Compound was evaluated for oral bioavailability in human,,17791,,,BAO_0000218
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618249,,9606.0,4685,,Metabolite of ifosfamide determined in urine; NF-Not found,,7766,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618250,,9606.0,4686,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL874598,,9606.0,4687,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618251,,9606.0,4688,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618252,,9606.0,4689,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618253,,9606.0,4690,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618254,,9606.0,4691,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618255,,9606.0,4692,,Percent of compound in healthy individuals (Group D),,6852,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL618983,,9606.0,4693,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,4397,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618984,,9606.0,4694,,Binding towards human plasma protein at 10 uM,,17409,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618985,,9606.0,4695,,Binding towards human plasma protein at 100 uM,,17409,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618986,,9606.0,4696,,Human plasma protein binding activity was determined,,17176,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618987,,9606.0,4697,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,15444,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618988,,9606.0,4698,,Percent binding of compound towards human plasma protein was determined,,17267,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618989,,9606.0,4699,,Plasma clearance in human liver microsomes,Microsomes,5944,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618990,,9606.0,4700,,In vitro intrinsic clearance in human liver microsome,Microsomes,5668,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618991,,9606.0,4701,,In vitro intrinsic clearance in human liver microsome,Microsomes,5669,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL876725,,9606.0,4702,,In vitro microsome metabolism clearance in human was determined,Microsomes,5041,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL618992,,9606.0,4703,,In vitro microsome metabolism clearance in human was determined; High,Microsomes,5041,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL618993,,9606.0,4704,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Microsomes,5041,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618994,,9606.0,4705,,Pharmacokinetic property (clearance) in human liver microsome,Microsomes,5676,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618995,,9606.0,4706,,Plasma clearance in human liver microsomes,Microsomes,5944,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618996,,9606.0,4707,,In vitro clearance in human liver microsomes,Microsomes,17538,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618997,,9606.0,4708,,Intrinsic clearance in human liver microsomes was determined,Microsomes,6331,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618998,,9606.0,4709,,Intrinsic clearance in human liver microsomes was determined,Microsomes,5948,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618999,,9606.0,4710,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,5965,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620223,,9606.0,4711,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,1916,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620224,,9606.0,4712,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,5965,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620225,,9606.0,4713,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,1299,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620226,,9606.0,4714,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,1299,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL620227,,9606.0,4715,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL876726,,9606.0,4716,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL620228,,9606.0,4717,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL620229,,9606.0,4718,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620230,,10090.0,4719,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620231,,10090.0,4720,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620232,,10090.0,4721,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620233,,10090.0,4722,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620234,,10090.0,4723,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,14294,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620235,,10090.0,4724,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,14294,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620236,,10090.0,4725,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,14294,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL620237,,10090.0,4726,,In vitro metabolic potential in mouse liver microsomes,,6251,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620238,,10090.0,4727,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,17582,,,BAO_0000218
,Adrenal gland,Mus musculus,Intermediate,1,50594,A,N,,,2369.0,1,CHEMBL620239,,10090.0,4728,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,17811,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL620240,,10090.0,4729,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,17811,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL620241,,10090.0,4730,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,17811,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL876727,,10090.0,4731,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,17811,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL620242,,10090.0,4732,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,17811,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620243,,10090.0,4733,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,17811,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620244,,10090.0,4734,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,5288,,,BAO_0000218
,Serum,Mus musculus,Intermediate,1,50594,A,N,,,1977.0,1,CHEMBL620245,,10090.0,4735,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,2717,,,BAO_0000218
,Serum,Mus musculus,Intermediate,1,50594,A,N,,,1977.0,1,CHEMBL620246,,10090.0,4736,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,2717,,,BAO_0000218
,Serum,Mus musculus,Intermediate,1,50594,A,N,,,1977.0,1,CHEMBL620247,,10090.0,4737,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,2717,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL620248,,10090.0,4738,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,17753,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL873497,,10090.0,4739,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,17753,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL620249,,10090.0,4740,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620250,,10090.0,4741,,Half life after intraperitoneal administration in mice at 18 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620251,,10090.0,4742,,Half life after intraperitoneal administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620252,,10090.0,4743,,Half life after intraperitoneal administration in mice at 25 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620253,,10090.0,4744,,Half life after intraperitoneal administration in mice at 26 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL620254,,10090.0,4745,,Half life after intravenous administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620255,,10090.0,4746,,Half life after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620256,,10090.0,4747,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876728,,10090.0,4748,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620257,,10090.0,4749,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620258,,10090.0,4750,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620259,,10090.0,4751,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,4890,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620260,,10090.0,4752,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,429,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL620261,,10090.0,4753,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620262,,10090.0,4754,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620263,,10090.0,4755,,Half life at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620264,,10090.0,4756,,Half life in ob/ob mice,,6619,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620265,,10090.0,4757,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,4066,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620266,,10090.0,4758,,Half-life was measured in mouse,,4239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620267,,10090.0,4759,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619364,,10090.0,4760,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,8999,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619365,,10090.0,4761,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,8999,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL619366,,10090.0,4762,,T2 in brain of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL619367,,10090.0,4763,,T2 in kidney of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL619368,,10090.0,4764,,T2 in liver of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL619369,,10090.0,4765,,T2 in lungs of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL876729,,10090.0,4766,,T2 in spleen of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619370,,10090.0,4767,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619371,,10090.0,4768,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,4890,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619372,,10090.0,4769,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,429,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620012,,10090.0,4770,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,429,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620013,,10090.0,4771,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,5969,,,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL620014,,9606.0,4772,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL620015,,9606.0,4773,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621010,,9606.0,4774,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621011,,9606.0,4775,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621012,,9606.0,4776,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621013,,9606.0,4777,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,16913,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621014,,9606.0,4778,,In vitro cytotoxicity against A2780TAX cell line,,17270,,A2780,BAO_0000219
481.0,,Homo sapiens,Intermediate,1,80017,F,N,,,,1,CHEMBL618154,,9606.0,4779,,In vitro inhibitory activity against human tumor cell line A2780cis,,5618,,A2780cisR,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618155,,9606.0,4780,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,17777,,A2780,BAO_0000219
481.0,,Homo sapiens,Intermediate,1,80017,F,N,,,,1,CHEMBL618156,,9606.0,4781,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,16112,,A2780cisR,BAO_0000219
481.0,,Homo sapiens,Intermediate,1,80017,F,N,,,,1,CHEMBL618157,,9606.0,4782,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,15748,,A2780cisR,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618328,,9606.0,4783,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,6633,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618329,,9606.0,4784,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,16930,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618330,,9606.0,4785,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,17496,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618331,,9606.0,4786,,In vitro antitumor activity against A2780cisR cell line.,,12989,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618332,,9606.0,4787,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,4840,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618333,,9606.0,4788,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,12989,,A2780,BAO_0000219
481.0,,Homo sapiens,Intermediate,1,80017,F,N,,,,1,CHEMBL618334,,9606.0,4789,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,16745,,A2780cisR,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618335,,9606.0,4790,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,16597,,A2780,BAO_0000219
,,Rattus norvegicus,Expert,1,11736,B,D,,,,9,CHEMBL618336,,10116.0,4791,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,16547,,,BAO_0000019
,,,Expert,1,11736,F,H,,,,8,CHEMBL618337,,,4792,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,16547,,,BAO_0000019
,,Rattus norvegicus,Expert,1,11736,F,D,,,,9,CHEMBL618338,,10116.0,4793,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,16547,,,BAO_0000019
722.0,,Homo sapiens,Expert,1,278,F,D,,,,9,CHEMBL618339,,9606.0,4794,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,15856,,HEK293,BAO_0000219
722.0,,Homo sapiens,Expert,1,278,F,D,,,,9,CHEMBL618340,,9606.0,4795,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,15856,,HEK293,BAO_0000219
,,Mus musculus,Expert,1,11831,B,D,,,,9,CHEMBL618341,,10090.0,4796,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,16547,,,BAO_0000019
,,,Expert,1,11831,F,H,,,,8,CHEMBL618342,,,4797,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,16547,,,BAO_0000019
,,Mus musculus,Expert,1,11831,F,D,,,,9,CHEMBL618343,,10090.0,4798,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,16547,,,BAO_0000019
,,,Expert,1,280,B,H,,,,8,CHEMBL621038,,,4799,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,17402,,,BAO_0000357
574.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL621039,,9606.0,4800,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,11746,,T-cells,BAO_0000219
574.0,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL621040,,9606.0,4801,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,11746,,T-cells,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621041,,9606.0,4802,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,5455,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621042,,9606.0,4803,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,2068,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621043,,9606.0,4804,,In vitro antitumor activity against A375cell line extracted form melanoma,,2683,,A-375,BAO_0000219
455.0,,Homo sapiens,Expert,1,80018,F,N,,,,1,CHEMBL621044,,9606.0,4805,,Inhibition of cell growth in (A375) melan cell line,,15313,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621045,,9606.0,4806,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,13739,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621046,,9606.0,4807,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,13739,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL621047,,9606.0,4808,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,14750,,A-375,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621048,,9606.0,4809,,Antiproliferative activity measured against A427 human lung carcinoma,,14777,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL883798,,9606.0,4810,,Antiproliferative activity measured against A427 human lung carcinoma,,14777,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621049,,9606.0,4811,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,17672,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621050,,9606.0,4812,,Inhibition of large cell lung carcinoma (A427),,14368,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621051,,9606.0,4813,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,14368,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621052,,9606.0,4814,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,13866,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621053,,9606.0,4815,,Inhibitory concentration in human lung carcinoma A427 cell line,,2545,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL621054,,9606.0,4816,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,2545,,A-427,BAO_0000219
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621055,,9527.0,4817,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL876398,,9527.0,4818,,Tested for volume of distribution upon iv administration to african green monkey,,4578,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621056,,9527.0,4819,,Volume of distribution in monkey,,17592,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621057,,9544.0,4820,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,5005,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621058,,9544.0,4821,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,5005,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621059,,9527.0,4822,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,5922,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621060,,9527.0,4823,,The distribution volume after intravenous administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621061,,9527.0,4824,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621062,,9527.0,4825,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621063,,9527.0,4826,,Volume displacement was calculated in rhesus monkey,,6057,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621064,,9527.0,4827,,Volume of distribution in steady state was determined in rhesus monkey,,5145,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621065,,9527.0,4828,,Volume of distribution of compound was determined in monkey,,6821,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621066,,9527.0,4829,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621067,,9527.0,4830,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621068,,9527.0,4831,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL876399,,9527.0,4832,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621069,,9527.0,4833,,Volume distribution in monkey after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621070,,9527.0,4834,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621071,,9527.0,4835,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621072,,9527.0,4836,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618209,,9527.0,4837,,Oral systemic bioavailability upon iv administration to african green monkey,,4578,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618210,,9527.0,4838,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618211,,9527.0,4839,,Baboon plasma free fraction. ,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618212,,9527.0,4840,,Area under the curve was calculated in rhesus monkey after iv administration,,6057,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618213,,9527.0,4841,,Area under the curve was calculated in rhesus monkey after peroral administration,,6057,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618214,,9527.0,4842,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,17853,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL873492,,9527.0,4843,,Half life period in monkey after 5 mg/kg dose,,5302,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618272,,9527.0,4844,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,4257,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618273,,9527.0,4845,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,4257,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL618274,,9527.0,4846,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,13501,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618275,,9527.0,4847,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,5394,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618276,,9527.0,4848,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618277,,9527.0,4849,,Compound was evaluated for terminal half life in monkey,,3341,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618278,,9527.0,4850,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,3045,,,BAO_0000218
,Plasma,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL618279,,9544.0,4851,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,5005,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618280,,9527.0,4852,,Half life of compound was determined in squirrel monkey,,4847,,,BAO_0000019
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618281,,9541.0,4853,,Half life after iv administration in cynomolgus monkey,,4256,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL618282,,9527.0,4854,,Half life in monkey plasma after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618283,,9527.0,4855,,Half life was calculated in rhesus monkey,,6057,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618284,,9527.0,4856,,Half life in monkey,,17592,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618285,,9527.0,4857,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618286,,9527.0,4858,,Half life was evaluated in rhesus,,5472,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618287,,9527.0,4859,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,6221,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618288,,9527.0,4860,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,5668,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL876393,,9527.0,4861,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4809,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618289,,9527.0,4862,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618290,,9527.0,4863,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,5553,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618291,,9527.0,4864,,Half-life was calculated in monkey,,6078,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618292,,9527.0,4865,,Half-life in Squirrel monkey,,5147,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618293,,9527.0,4866,,Half-life in rhesus monkey,,5145,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618294,,9527.0,4867,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618295,,9527.0,4868,,Half-life period after intravenous administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618296,,9527.0,4869,,Half-life period after oral administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618297,,9527.0,4870,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,5355,,,BAO_0000218
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618298,,9606.0,4871,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618299,,9606.0,4872,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618300,,9606.0,4873,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618301,,9606.0,4874,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618302,,9606.0,4875,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL876394,,9606.0,4876,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618303,,9606.0,4877,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618304,,9606.0,4878,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,7766,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618305,,9606.0,4879,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,1916,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618306,,9606.0,4880,,Oral bioavailability in human,,16643,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618307,,9606.0,4881,,Compound was tested for human plasma protein binding,,17248,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618308,,9606.0,4882,,Compound was tested for human plasma protein binding; Not determined,,17248,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618309,,9606.0,4883,,Protein binding activity of compound in human plasma; % Free,,6241,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618310,,9606.0,4884,,Unbound fraction (plasma),,17716,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL873353,,9606.0,4885,,Half life for the hydrolysis of compound in human blood serum,,17605,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618311,,9606.0,4886,,Half life period in human plasma using phosphate buffer (0.08 M),,17625,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618312,,9606.0,4887,,Half life period in human plasma using phosphate buffer (0.1 M),,17625,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618313,,9606.0,4888,,Half-life in human plasma was determined,,17747,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618314,,9606.0,4889,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,15613,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618315,,9606.0,4890,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,354,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618316,,9606.0,4891,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,3741,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618317,,9606.0,4892,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,3741,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620138,,9606.0,4893,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,3741,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL858280,,9606.0,4894,,Partition coefficient (logP),,17599,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620139,,9606.0,4895,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,5486,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620140,,9606.0,4896,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Microsomes,5600,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620141,,9606.0,4897,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,14294,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620142,,9606.0,4898,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,14294,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620143,,9606.0,4899,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,14294,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620144,,9606.0,4900,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620145,,9606.0,4901,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Microsomes,14294,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620146,,9606.0,4902,,Metabolism of compound in human microsomes; Trace,Microsomes,14294,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL620147,,9606.0,4903,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Microsomes,6260,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL620148,,9606.0,4904,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Microsomes,6187,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL620149,,9606.0,4905,,In vitro metabolic potential in human liver microsomes,Microsomes,6251,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL876412,,9606.0,4906,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,3246,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619352,,9606.0,4907,,Tested for human plasma protein binding of the compound; Not tested,,17313,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619353,,9606.0,4908,,Compound was tested for percent protein binding (PB) in human,,6227,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619354,,9606.0,4909,,Protein binding in human plasma,,5530,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619355,,9606.0,4910,,Permeability coefficient (B to A) in Caco-2 cell,,6108,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619356,,9606.0,4911,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,6108,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619357,,9606.0,4912,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,2774,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619358,,9606.0,4913,,In vitro rate of absorption observed as Caco-2 permeability in humans,,16643,,,BAO_0000019
495.0,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619359,,9606.0,4914,,Cellular permeability of compound was determined in Caco-2 cells; High,,17582,,Caco-2,BAO_0000219
495.0,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619360,,9606.0,4915,,Permeability in Caco-2 cells of compound,,6838,,Caco-2,BAO_0000219
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619361,,9606.0,4916,,Permeability coefficient (A to B) in Caco-2 cell,,6108,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619362,,9606.0,4917,,Permeability coefficient (B to A) in Caco-2 cell,,6108,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619363,,9606.0,4918,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,6108,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618942,,9606.0,4919,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,2146,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618943,,9606.0,4920,,Compound was tested for protein binding in human plasma,,4514,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618944,,9606.0,4921,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,6108,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL618945,,9606.0,4922,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,7766,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618946,,10090.0,4923,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876413,,10090.0,4924,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,3277,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618947,,10090.0,4925,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,3802,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL618948,,10090.0,4926,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,2862,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL618949,,10090.0,4927,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL618950,,10090.0,4928,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618951,,10090.0,4929,,Tmax after oral administration at 30 mg/kg in ICR mouse,,5781,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618952,,10090.0,4930,,Tmax after peroral administration in mice at 2.4 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618953,,10090.0,4931,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,4066,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL618954,,10090.0,4932,,Tmax in brain of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL618955,,10090.0,4933,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL618956,,10090.0,4934,,Tmax in liver of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL618957,,10090.0,4935,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL618958,,10090.0,4936,,Tmax in mice at 18 uM/kg i.p. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL618959,,10090.0,4937,,Tmax in mice at 23 uM/kg i.v. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL618960,,10090.0,4938,,Tmax in mice at 25 uM/kg i.p. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL876723,,10090.0,4939,,Tmax in mice at 26 uM/kg i.p. administration,,17764,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618961,,10090.0,4940,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618962,,10090.0,4941,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618963,,10090.0,4942,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618964,,10090.0,4943,,Tmax value in IRC mice,,5951,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618965,,10090.0,4944,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618966,,10090.0,4945,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL618967,,10090.0,4946,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,429,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL618968,,10090.0,4947,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,429,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL618969,,10090.0,4948,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,4066,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618970,,10090.0,4949,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618971,,10090.0,4950,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618972,,10090.0,4951,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618973,,10090.0,4952,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618974,,10090.0,4953,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618975,,10090.0,4954,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618976,,10090.0,4955,,Vd in mice,,5980,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618977,,10090.0,4956,,Volume of distribution in mouse,,17592,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876724,,10090.0,4957,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618978,,10090.0,4958,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618979,,10090.0,4959,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618980,,10090.0,4960,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618981,,10090.0,4961,,Pharmacokinetic property (vdss) was measured in mouse,,4239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618982,,10090.0,4962,,Value distribution upon iv administration in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620150,,10090.0,4963,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620151,,10090.0,4964,,Volume of distribution was evaluated in mice after intravenous administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620152,,10090.0,4965,,Volume of distribution was evaluated in mice after oral administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620153,,10090.0,4966,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876395,,10090.0,4967,,Steady state volume of distribution was determined in mice,,5727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620154,,10090.0,4968,,Volume distribution (steady state) of compound was determined in mouse,,17852,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620155,,10090.0,4969,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620156,,10090.0,4970,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620157,,10090.0,4971,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL620158,,10090.0,4972,,Biodistribution of compound (oxidized form) in in kidney tissue,,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL620159,,10090.0,4973,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL620160,,10090.0,4974,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL620161,,10090.0,4975,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL620162,,9606.0,4976,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,10708,,A-427,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL620163,,9606.0,4977,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,16597,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL620833,,9606.0,4978,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,16062,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL876396,,9606.0,4979,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,16062,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL620834,,9606.0,4980,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,16958,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL620835,,9606.0,4981,,Inhibition of A431 human carcinoma cell proliferation,,6700,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL620836,,9606.0,4982,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,17226,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL620837,,9606.0,4983,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,6828,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621017,,9606.0,4984,,In vitro cytotoxicity against epidermoid carcinoma cell line,,12314,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621018,,9606.0,4985,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,13412,,A-431,BAO_0000218
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621019,,9606.0,4986,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,13299,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621020,,9606.0,4987,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,17420,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621021,,9606.0,4988,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,13678,,A-431,BAO_0000219
500.0,,,Expert,1,9,F,H,,,,8,CHEMBL621022,,,4989,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,14171,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621023,,9606.0,4990,,Tested for antiproliferative activity against human A431 cells,,6333,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621024,,9606.0,4991,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,2356,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621025,,9606.0,4992,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,15578,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621026,,9606.0,4993,,Inhibition of A431 cell proliferation,,5126,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621027,,9606.0,4994,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,6844,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL876397,,9606.0,4995,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,6844,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL883797,,9606.0,4996,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,4925,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621028,,9606.0,4997,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,4925,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621029,,9606.0,4998,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,13978,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621030,,9606.0,4999,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,16786,,A-431,BAO_0000219
500.0,,,Expert,1,9,F,H,,,,8,CHEMBL621147,,,5000,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,13412,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621148,,9606.0,5001,,In vivo antiproliferative activity against A431 cell line,,17824,,A-431,BAO_0000218
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621149,,9606.0,5002,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,12751,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621150,,9606.0,5003,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,12380,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621151,,9606.0,5004,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,4959,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621152,,9606.0,5005,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,6333,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621153,,9606.0,5006,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,6333,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL884000,,9606.0,5007,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,6333,,A-431,BAO_0000219
,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621154,,9606.0,5008,,Inhibition of EGFR overexpressing A431 cell proliferation,,5296,,,BAO_0000019
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL621155,,9606.0,5009,,Inhibition of A431 cell proliferation,,12624,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621156,,9606.0,5010,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,14926,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621157,,9606.0,5011,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,14926,,A-431,BAO_0000219
500.0,,,Expert,1,9,F,H,,,,8,CHEMBL621158,,,5012,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,14926,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621159,,9606.0,5013,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,15144,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621160,,9606.0,5014,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,15144,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621161,,9606.0,5015,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,5245,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621162,,9606.0,5016,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,5245,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621163,,9606.0,5017,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5245,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621164,,9606.0,5018,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,5245,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621165,,9606.0,5019,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,5245,,A-431,BAO_0000219
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619159,,9527.0,5020,,Half-life period in cynomolgus monkey,,5922,,,BAO_0000019
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL619160,,9527.0,5021,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,1116,,,BAO_0000366
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619161,,9527.0,5022,,Longer half-life in monkey (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619162,,9527.0,5023,,Plasma half life in monkey,,993,,,BAO_0000366
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619163,,9527.0,5024,,Plasma half-life in rhesus monkey,,4514,,,BAO_0000366
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL619164,,9527.0,5025,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL619320,,9527.0,5026,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,5334,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619321,,9527.0,5027,,Tested for half life upon iv administration to african green monkey,,4578,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL873336,,9527.0,5028,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619322,,9527.0,5029,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619323,,9527.0,5030,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL619324,,9527.0,5031,,The time for peak concentration value after oral administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619325,,9527.0,5032,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL876411,,9527.0,5033,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619326,,9527.0,5034,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619327,,9527.0,5035,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619328,,9527.0,5036,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619329,,9527.0,5037,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619330,,9527.0,5038,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619331,,9527.0,5039,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619332,,9527.0,5040,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619333,,9527.0,5041,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619334,,9527.0,5042,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619335,,9527.0,5043,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619336,,9527.0,5044,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619337,,9527.0,5045,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619338,,9527.0,5046,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,11271,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL619339,,9527.0,5047,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,11271,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619340,,10116.0,5048,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,5809,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL873496,,10116.0,5049,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL619341,,10116.0,5050,,AUC value in rat after IV administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL619342,,10116.0,5051,,AUC value in rat after oral administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619343,,10116.0,5052,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619344,,10116.0,5053,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619345,,10116.0,5054,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL619346,,10116.0,5055,,Vc value in rat after IV administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619347,,10116.0,5056,,Half life period in rat after IV administration at a dose of 10 mg/kg,,3546,,,BAO_0000218
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL619348,,9557.0,5057,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL619349,,9557.0,5058,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL619350,,9557.0,5059,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL619351,,9557.0,5060,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL875953,,9557.0,5061,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL621716,,9557.0,5062,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL621717,,9557.0,5063,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,10625,,,BAO_0000019
,,Papio hamadryas,Autocuration,1,22224,A,U,,,,0,CHEMBL621718,,9557.0,5064,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,10625,,,BAO_0000019
,,beagle,Autocuration,1,22224,A,U,,,,0,CHEMBL621719,,9615.0,5065,,Area under curve after 1 mpk peroral administration to beagles,,3510,,,BAO_0000019
,,beagle,Autocuration,1,22224,A,U,,,,0,CHEMBL621720,,9615.0,5066,,Area under curve after 2 mpk peroral administration to beagles,,3510,,,BAO_0000019
,,beagle,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621721,,9615.0,5067,,Cmax value after 1 mpk peroral administration to beagles,,3510,,,BAO_0000218
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL621722,,9606.0,5068,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL621723,,9606.0,5069,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL621724,,9606.0,5070,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623443,,9606.0,5071,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623444,,9606.0,5072,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623445,,9606.0,5073,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,7766,,,BAO_0000019
,Urine,Homo sapiens,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623446,,9606.0,5074,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,7766,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623447,,9606.0,5075,,Metabolic stability observed at 30 min after administration in human liver microsomes,Microsomes,16643,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL623448,,9606.0,5076,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL623449,,9606.0,5077,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,6852,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL623450,,9606.0,5078,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,6852,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623451,,9606.0,5079,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Microsomes,6567,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL623452,,9606.0,5080,,Metabolic stability (% remaining at 30 mins) in human S9.,,6570,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL623453,,9606.0,5081,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,6570,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623454,,9606.0,5082,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Microsomes,5237,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623455,,9606.0,5083,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Microsomes,5237,,,BAO_0000251
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL624371,,9606.0,5084,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Microsomes,5237,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624372,,9606.0,5085,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,5202,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624373,,9606.0,5086,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,5481,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624374,,9606.0,5087,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,5481,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624556,,9606.0,5088,,The percent remaining in human plasma after 30 min was determined,,3956,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624557,,9606.0,5089,,Conversion rate of the prodrug in human plasma,,5074,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624558,,9606.0,5090,,Conversion rate of the prodrug in human plasma; ND means no data,,5074,,,BAO_0000366
,Blood,Homo sapiens,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL624559,,9606.0,5091,,Half life of compound was determined in human blood,,4727,,,BAO_0000221
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624560,,9606.0,5092,,Half life of compound was determined in man with once daily dosing,,5965,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL624561,,9606.0,5093,,Half life in human microsomes,Microsomes,5732,,,BAO_0000251
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624562,,9606.0,5094,,Half life in human plasma,,5819,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624563,,9606.0,5095,,Half life in human plasma; Not detected,,5819,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624564,,9606.0,5096,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,1916,,,BAO_0000218
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL624565,,9606.0,5097,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Microsomes,6597,,,BAO_0000251
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL875152,,9606.0,5098,,Half-life in human plasma,,5229,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624566,,9606.0,5099,,Half-life of the parent prodrug in plasma,,5229,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL873805,,9606.0,5100,,In vitro half life in human plasma was determined,,2192,,,BAO_0000366
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL624567,,9606.0,5101,,The compound was tested In Vitro for half life in human liver microsomes.,Microsomes,3032,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624568,,9606.0,5102,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,1916,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624569,,9606.0,5103,,Observed volume of distribution,,17716,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624570,,9606.0,5104,,Oral bioavailability in human,,15778,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624571,,9606.0,5105,,Tested for human plasma protein binding of the compound,,17313,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624572,,9606.0,5106,,"First order rate constant, k was determined in human plasma",,4231,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624573,,9606.0,5107,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,4755,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL875153,,9606.0,5108,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,4755,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL624574,,9606.0,5109,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Microsomes,16907,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624575,,9606.0,5110,,The compound was tested for the plasma binding in human,,10839,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL624576,,9606.0,5111,,Plasma protein binding (human),,10839,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL624577,,9606.0,5112,,Compound was evaluated for half-life in human liver microsomes,Microsomes,3199,,,BAO_0000251
,Blood,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,178.0,0,CHEMBL624578,,9606.0,5113,,Half life measured in vitro for its stability in human blood,,1345,,,BAO_0000221
,Serum,Homo sapiens,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL622796,,9606.0,5114,,Half life in human serum,,4297,,,BAO_0000019
,Serum,Homo sapiens,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL622797,,9606.0,5115,,Half life in human serum; ND=not determined,,4297,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL622798,,9606.0,5116,,Half life were determined in CEM-SS cell extract in decomposition step 1,,4297,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL622799,,9606.0,5117,,Half life were determined in CEM-SS cell extract in decomposition step 2,,4297,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL622800,,9606.0,5118,,Half life of the in human plasma,,4231,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL622801,,9606.0,5119,,Half life period in human hepatic S9 fraction was determined,S9,5633,,,BAO_0000220
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL622802,,9606.0,5120,,Half life period in human liver microsome was determined,Microsomes,5633,,,BAO_0000251
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL622803,,9606.0,5121,,Half life period was determined; 6-7,,17791,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL875154,,9606.0,5122,,Half life period was evaluated in human,,17791,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL622804,,9606.0,5123,,Half life time in human plasma,,3160,,,BAO_0000366
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622805,,10090.0,5124,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622611,,10090.0,5125,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622612,,10090.0,5126,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL875160,,10090.0,5127,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL622613,,10090.0,5128,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL622614,,10090.0,5129,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622615,,10090.0,5130,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622616,,10090.0,5131,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622617,,10090.0,5132,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL622618,,10090.0,5133,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL622619,,10090.0,5134,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL622620,,10090.0,5135,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622621,,10090.0,5136,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622622,,10090.0,5137,,Biodistribution of compound (oxidized form) in blood tissue,,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622623,,10090.0,5138,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622624,,10090.0,5139,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622625,,10090.0,5140,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622626,,10090.0,5141,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622627,,10090.0,5142,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622628,,10090.0,5143,,Biodistribution of compound (oxidized form) in brain tissue of mice,,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622629,,10090.0,5144,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622630,,10090.0,5145,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622631,,10090.0,5146,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622632,,10090.0,5147,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622633,,10090.0,5148,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622634,,10090.0,5149,,Biodistribution of compound (oxidized form) in heart tissue of mice,,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622635,,10090.0,5150,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL875161,,10090.0,5151,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622636,,10090.0,5152,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL623335,,10090.0,5153,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL623336,,10090.0,5154,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623337,,10090.0,5155,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623338,,10090.0,5156,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623339,,10090.0,5157,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623524,,10090.0,5158,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623525,,10090.0,5159,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623526,,10090.0,5160,,Biodistribution of compound (oxidized form) in liver tissue,,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623527,,10090.0,5161,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623528,,10090.0,5162,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL624615,,9606.0,5163,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,5245,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621672,,9606.0,5164,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5245,,A-431,BAO_0000219
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL621673,,,5165,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL621674,,,5166,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,16289,,A-431,BAO_0000218
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL884002,,9606.0,5167,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,16093,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621850,,9606.0,5168,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,16825,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL621851,,9606.0,5169,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,4848,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621852,,9606.0,5170,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,14827,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL621853,,9606.0,5171,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,14827,,A-431,BAO_0000219
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL621854,,,5172,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL621855,,,5173,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623724,,,5174,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623725,,,5175,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623726,,,5176,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,16289,,A-431,BAO_0000218
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL623727,,9606.0,5177,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,16289,,A-431,BAO_0000219
500.0,,,Expert,1,9,F,H,,,,8,CHEMBL623728,,,5178,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,16289,,A-431,BAO_0000219
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623729,,,5179,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623730,,,5180,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,16289,,A-431,BAO_0000218
500.0,,,Expert,1,80852,F,N,,,,1,CHEMBL623731,,,5181,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,16289,,A-431,BAO_0000218
500.0,,Mus musculus,Expert,1,80852,F,N,,,,1,CHEMBL623732,,10090.0,5182,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,A-431,BAO_0000218
500.0,,Mus musculus,Expert,1,80852,F,N,,,,1,CHEMBL623733,,10090.0,5183,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,A-431,BAO_0000218
500.0,,Mus musculus,Expert,1,80852,F,N,,,,1,CHEMBL623734,,10090.0,5184,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,A-431,BAO_0000218
500.0,,Mus musculus,Expert,1,80852,F,N,,,,1,CHEMBL623735,,10090.0,5185,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,14555,,A-431,BAO_0000218
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL623736,,9606.0,5186,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,1937,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL623737,,9606.0,5187,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,13739,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL623738,,9606.0,5188,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,3558,,A-431,BAO_0000219
500.0,,Homo sapiens,Intermediate,1,80852,F,N,,,,1,CHEMBL875168,,9606.0,5189,,Dose giving a 50% decrease in the living cell number (A437 cells),,3558,,A-431,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL623739,,9606.0,5190,,In vitro inhibitory concentration against proliferation of A459 cell line.,,17686,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623740,,9606.0,5191,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,5305,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624424,,9606.0,5192,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,3614,,A549,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624425,,9606.0,5193,,In vitro antitumor activity against renal A498 tumor cell lines,,17229,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624426,,9606.0,5194,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,15935,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624427,,9606.0,5195,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,15935,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624428,,9606.0,5196,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,15560,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624429,,9606.0,5197,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,13891,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624620,,9606.0,5198,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,13891,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624621,,9606.0,5199,,Cytotoxicity on kidney carcinoma (A-498) cell line,,13788,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624622,,9606.0,5200,,Compound was evaluated against Human cell line renal A498,,15403,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624623,,9606.0,5201,,Compound was tested for inhibition of A498 human renal cancer cell line,,1009,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL874365,,9606.0,5202,,Growth inhibitory activity against A498 human cancer cell line,,1043,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624624,,9606.0,5203,,In vitro antitumor activity against human renal A498 cell line,,5858,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624625,,9606.0,5204,,In vitro cytotoxic activity against renal (A498) cell line,,5958,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624626,,9606.0,5205,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,5506,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624627,,9606.0,5206,,Tested for cytostatic activity against renal A498 cell line,,12781,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL883157,,9606.0,5207,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,14399,,A498,BAO_0000219
624.0,,Homo sapiens,Expert,1,80021,F,N,,,,1,CHEMBL624628,,9606.0,5208,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,5958,,A498,BAO_0000219
,,beagle,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624629,,9615.0,5209,,Cmax value after 2 mpk peroral administration to beagles,,3510,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623551,,9615.0,5210,,Bioavailability,,3510,beagle,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623552,,9615.0,5211,,Bioavailability after 1 mpk peroral administration to beagles,,3510,beagle,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623553,,9615.0,5212,,Bioavailability after 2 mpk peroral administration to beagles,,3510,beagle,,BAO_0000218
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623554,,9913.0,5213,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,3085,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623555,,9913.0,5214,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,3085,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623556,,9913.0,5215,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,3085,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623557,,9913.0,5216,,Solubility against bovine alpha-chymotrypsin,,9372,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623558,,9913.0,5217,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,3085,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623559,,9913.0,5218,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,3085,,,BAO_0000019
,Spleen,Bos taurus,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL623560,,9913.0,5219,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,1469,,,BAO_0000221
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623561,,9913.0,5220,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,4297,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623562,,9913.0,5221,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,4297,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623563,,9913.0,5222,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,17585,,,BAO_0000019
,Spleen,Bos taurus,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL623564,,9913.0,5223,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,1336,,,BAO_0000221
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL873806,,9913.0,5224,,Half life in presence of 2 mg/mL BSA at pH 8.8,,3085,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623565,,9913.0,5225,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,2857,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623566,,9913.0,5226,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,2857,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623567,,9913.0,5227,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,2857,,,BAO_0000019
,,Bos taurus,Autocuration,1,22224,A,U,,,,0,CHEMBL623568,,9913.0,5228,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,1540,,,BAO_0000019
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623569,,9615.0,5229,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,6316,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623570,,9615.0,5230,,AUC after administration at 100 mg/kg/day in dogs,,17594,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624254,,9615.0,5231,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,4953,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624255,,9615.0,5232,,AUC value after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624256,,9615.0,5233,,AUC value after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624257,,9615.0,5234,,AUC value after administration of 4 mg/Kg oral dose in dog,,2959,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624258,,9615.0,5235,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875277,,9615.0,5236,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,5356,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622667,,9615.0,5237,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,16807,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622668,,9615.0,5238,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622669,,9615.0,5239,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622670,,9615.0,5240,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622671,,9615.0,5241,,Area under curve determined in dogs after oral administration of 10 mg/kg,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622672,,9615.0,5242,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5802,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,A,N,,,,1,CHEMBL622673,,9615.0,5243,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,A,N,,,,1,CHEMBL622674,,9615.0,5244,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622675,,9615.0,5245,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622676,,9615.0,5246,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622677,,9615.0,5247,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622678,,9615.0,5248,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622679,,9615.0,5249,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,4186,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622680,,9615.0,5250,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5007,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622681,,9615.0,5251,,Area under curve was determine after peroral administration at 10 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875278,,9615.0,5252,,Area under curve was determine after peroral administration at 5 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622682,,9615.0,5253,,Area under curve was determined,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622683,,9615.0,5254,,Area under curve in dogs,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622684,,9615.0,5255,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,3771,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622685,,9615.0,5256,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,3771,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622686,,9615.0,5257,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,3771,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618344,,9615.0,5258,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875582,,9615.0,5259,,Area under curve value in dog at a dose of 5 mg/kg,,5302,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618345,,9615.0,5260,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618346,,9615.0,5261,,Area under curve was determined after 0.3 mg/kg po administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618347,,9615.0,5262,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618348,,9615.0,5263,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,4368,,,BAO_0000218
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618349,,9606.0,5264,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,5318,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618350,,9606.0,5265,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5318,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618351,,9606.0,5266,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,5318,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618352,,9606.0,5267,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,5318,,,BAO_0000019
,Blood,Homo sapiens,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL873494,,9606.0,5268,,Time taken to reduce 50% of the concentration of compound in blood plasma,,14518,,,BAO_0000221
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618353,,9606.0,5269,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,2209,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618354,,9606.0,5270,,Half life in human plasma,,6787,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL875583,,9606.0,5271,,Half life in human plasma was reported,,4898,,,BAO_0000366
,Serum,Homo sapiens,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL618355,,9606.0,5272,,Half life in human serum,,6072,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618356,,9606.0,5273,,Half life upon exposure to human plasma,,16907,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL618357,,9606.0,5274,,t1/2 in human microsomes,Microsomes,5656,,,BAO_0000251
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618358,,9606.0,5275,,Half life period in 80% human plasma at 37 degree Centigrade,,4755,,,BAO_0000366
,Zone of skin,Homo sapiens,Autocuration,1,22224,A,U,,,14.0,0,CHEMBL618359,,9606.0,5276,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,17503,,,BAO_0000221
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL618360,,9606.0,5277,,Half-life measured in in vitro Cathepsin B assay in human plasma,,12357,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618361,,9606.0,5278,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,3076,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618362,,9606.0,5279,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Microsomes,6410,,,BAO_0000251
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618363,,9606.0,5280,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,3741,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618364,,9606.0,5281,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,3741,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL875584,,9606.0,5282,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,3741,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618365,,9606.0,5283,,Half-life in the CEM cell extracts,,1540,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL873495,,9606.0,5284,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,2905,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618366,,9606.0,5285,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,2905,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618367,,9606.0,5286,,Half-life was determined,,5523,,,BAO_0000019
,Blood,Homo sapiens,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL618368,,9606.0,5287,,Half-life (human blood stability),,1499,,,BAO_0000221
,Blood,Homo sapiens,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL618369,,9606.0,5288,,Half-life (human blood stability); no data,,1499,,,BAO_0000221
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618370,,9606.0,5289,,Half-life in human plasma,,17065,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618371,,9606.0,5290,,CYP3A4 metabolism half-life (t1/2),,6861,,,BAO_0000019
,Blood,Homo sapiens,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL618372,,9606.0,5291,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,1499,,,BAO_0000221
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL618373,,9606.0,5292,,In vitro half life in human plasma,,530,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL618374,,9606.0,5293,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,1116,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL618375,,9606.0,5294,,In vitro hydrolysis in human plasma,,6695,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,1969.0,0,CHEMBL618376,,9606.0,5295,,In vitro hydrolysis in human plasma; no data,,6695,,,BAO_0000366
,Liver,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL618377,,9606.0,5296,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Microsomes,10,,,BAO_0000251
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618378,,9606.0,5297,,Plasma half life in human,,993,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618379,,9606.0,5298,,Stability after incubation with human plasma (at 37 degree C),,15429,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618380,,9606.0,5299,,T1/2 was evaluated in human plasma,,1675,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618381,,9606.0,5300,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,2209,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL618382,,9606.0,5301,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,2209,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL618383,,9606.0,5302,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5318,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL618384,,9606.0,5303,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,2412,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL618385,,9606.0,5304,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,2412,,,BAO_0000019
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619099,,9606.0,5305,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,2906,,,BAO_0000366
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619100,,9606.0,5306,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,2906,,,BAO_0000366
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619101,,9606.0,5307,,Time taken for 50% to be consumed by serum PON1 was determined,,5495,,,BAO_0000019
,,Homo sapiens,Autocuration,1,22224,A,U,,,,0,CHEMBL619102,,9606.0,5308,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,5495,,,BAO_0000019
,Liver,Homo sapiens,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL619103,,9606.0,5309,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,4397,,,BAO_0000251
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL619268,,10095.0,5310,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL619269,,10095.0,5311,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL619270,,10095.0,5312,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL619271,,10095.0,5313,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL875585,,10095.0,5314,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL619272,,10095.0,5315,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,,BAO_0000218
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619273,,9606.0,5316,,Compound tested for growth inhibition of renal cancer cell line 786-0,,6058,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619274,,9606.0,5317,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,17708,,786-0,BAO_0000219
391.0,,Homo sapiens,Expert,1,80640,F,N,,,,1,CHEMBL619275,,9606.0,5318,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,14017,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619276,,9606.0,5319,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,16818,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619277,,9606.0,5320,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,16818,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619278,,9606.0,5321,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,16818,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619279,,9606.0,5322,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,11970,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL858458,,9606.0,5323,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,12400,,786-0,BAO_0000219
391.0,,Homo sapiens,Expert,1,80640,F,N,,,,1,CHEMBL619280,,9606.0,5324,,Cytotoxic effect on renal cancer line 786-0,,12888,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619281,,9606.0,5325,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,15300,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619282,,9606.0,5326,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,14769,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619283,,9606.0,5327,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,15895,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619284,,9606.0,5328,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,17376,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619285,,9606.0,5329,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,14882,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619286,,9606.0,5330,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,14882,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619287,,9606.0,5331,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,15176,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL857455,,9606.0,5332,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,12696,,786-0,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL883801,,9606.0,5333,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,2496,,786-0,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619288,,9606.0,5334,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619289,,9606.0,5335,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619290,,9606.0,5336,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619291,,9606.0,5337,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619292,,9606.0,5338,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619293,,9606.0,5339,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619294,,9606.0,5340,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619295,,9606.0,5341,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619296,,9606.0,5342,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,11831,,791T cell line,BAO_0000219
972.0,,Homo sapiens,Intermediate,1,80641,F,N,,,,1,CHEMBL619297,,9606.0,5343,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,11831,,791T cell line,BAO_0000219
391.0,,Homo sapiens,Intermediate,1,80640,F,N,,,,1,CHEMBL619298,,9606.0,5344,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,12782,,786-0,BAO_0000219
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL619299,,,5345,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,1229,,,BAO_0000019
741.0,,Homo sapiens,Expert,1,80433,F,N,,,,1,CHEMBL619300,,9606.0,5346,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,15313,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Expert,1,80433,F,N,,,,1,CHEMBL619301,,9606.0,5347,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,15313,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619302,,9606.0,5348,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,11544,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619303,,9606.0,5349,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619304,,9606.0,5350,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL857706,,9606.0,5351,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619305,,9606.0,5352,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619306,,9606.0,5353,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619307,,9606.0,5354,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619308,,9606.0,5355,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619309,,9606.0,5356,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL619310,,9606.0,5357,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619311,,9606.0,5358,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,14769,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619312,,9606.0,5359,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,15354,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619313,,9606.0,5360,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,17445,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619314,,9606.0,5361,,In vitro inhibitory concentration against renal cancer cell line A498,,4337,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619959,,9606.0,5362,,Cytotoxicity against A 498 tumor cell line,,15277,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619960,,9606.0,5363,,In vitro antitumor activity against A498 human cancer cell line,,4812,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619961,,9606.0,5364,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,4812,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619962,,9606.0,5365,,Inhibitory dose required against A498 human tumor cell lines,,4995,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL875586,,9606.0,5366,,Anticancer activity against one renal cancer (A498 cell line),,5847,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619963,,9606.0,5367,,In vitro cytotoxicity against melanoma A498 cell line,,6557,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619964,,9606.0,5368,,Compound was tested for growth inhibitory activity against A498 cell line,,2597,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620108,,9606.0,5369,,Compound tested for growth inhibition of renal cancer cell line A498,,6058,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620109,,9606.0,5370,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,17708,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620110,,9606.0,5371,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,15176,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620111,,9606.0,5372,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,15300,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620112,,9606.0,5373,,Tested for cytotoxicity against A498 cell lines in renal cancer,,11970,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620113,,9606.0,5374,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,12400,,A498,BAO_0000219
624.0,,Homo sapiens,Expert,1,80021,F,N,,,,1,CHEMBL620114,,9606.0,5375,,Cytotoxic effect on renal cancer lines A498,,12888,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620115,,9606.0,5376,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,3030,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620116,,9606.0,5377,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,14769,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620117,,9606.0,5378,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,17376,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620118,,9606.0,5379,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,16558,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620119,,9606.0,5380,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,5194,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL620120,,9606.0,5381,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,10708,,A498,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620121,,9606.0,5382,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,16880,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620122,,9606.0,5383,,Antitumor activity against A549 human lung carcinoma cell line,,10196,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620123,,9606.0,5384,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,10196,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620124,,9606.0,5385,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,10196,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620125,,9606.0,5386,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,12083,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620126,,9606.0,5387,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,16464,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL883027,,9606.0,5388,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620127,,9606.0,5389,,In vitro cytotoxic activity against human lung A549 cell line,,16470,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620128,,9606.0,5390,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,16470,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620129,,9606.0,5391,,In vitro cytotoxic activity against human lung A549 cell line),,16470,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620130,,9606.0,5392,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,16470,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620131,,9606.0,5393,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,16582,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620132,,9606.0,5394,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,15935,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620133,,9606.0,5395,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,15935,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620134,,9606.0,5396,,Inhibition of A549 human lung carcinoma cell proliferation,,16597,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620135,,9606.0,5397,,Inhibitory activity against A549 lung adenocarcinoma cell line,,17376,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620136,,9606.0,5398,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,16496,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620137,,9606.0,5399,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,16152,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620268,,9606.0,5400,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,16152,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620269,,9606.0,5401,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620270,,9606.0,5402,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,2288,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620271,,9606.0,5403,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,17350,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620272,,9606.0,5404,,Inhibition of A549 cancer cell proliferation,,4090,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620273,,9606.0,5405,,Inhibition of A549 cancer cell proliferation (Not tested),,4090,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620274,,9606.0,5406,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,17350,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620275,,9606.0,5407,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,4197,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620276,,9606.0,5408,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,17072,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620277,,9606.0,5409,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,17072,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620278,,9606.0,5410,,Cytotoxicity against Renal cell lines A549 was determined,,5194,,A549,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620279,,9615.0,5411,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,4257,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620280,,9615.0,5412,,Area under curve was determined in dog after oral administration at 1 mg/kg,,6123,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620281,,9615.0,5413,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620282,,9615.0,5414,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621134,,9615.0,5415,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,8833,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621135,,9615.0,5416,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,8833,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621136,,9615.0,5417,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,8833,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621137,,9615.0,5418,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,8833,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621138,,9615.0,5419,,Area under plasma concentration time curve in dog upon oral administration,,17657,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL875587,,9615.0,5420,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,17650,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621139,,9615.0,5421,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,1977,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621140,,9615.0,5422,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,1977,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621141,,9615.0,5423,,Area under the curve for the compound was obtained when tested in dog,,3132,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621142,,9615.0,5424,,Area under the curve at a dose of 1 mg/kg,,5473,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621143,,9615.0,5425,,Area under the curve at a dose of 1 mg/kg (oral),,5474,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621144,,9615.0,5426,,Area under the curve at i.v. dose of 0.2 mg/kg,,5474,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621145,,9615.0,5427,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621146,,9615.0,5428,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622567,,9615.0,5429,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622568,,9615.0,5430,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622569,,9615.0,5431,,Compound was evaluated for area under the curve in dog blood.,,2877,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622570,,9615.0,5432,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,5444,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL622571,,9615.0,5433,,AUC in dog after oral dose (1 mg/kg),,5130,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622572,,9615.0,5434,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,6265,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622573,,9615.0,5435,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,4657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622574,,9615.0,5436,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,16367,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622575,,9615.0,5437,,Pharmacokinetic parameter AUC after oral administration to dogs,,16367,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622576,,9615.0,5438,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622577,,9615.0,5439,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622578,,9615.0,5440,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622579,,9615.0,5441,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,6241,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622580,,9615.0,5442,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622581,,9615.0,5443,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622582,,9615.0,5444,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622583,,9615.0,5445,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622584,,9615.0,5446,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,6641,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622585,,9615.0,5447,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622586,,9615.0,5448,,Compound was evaluated for oral bioavailability in dog; 90-100,,17791,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623281,,9615.0,5449,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,17655,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623282,,9615.0,5450,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,17655,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623283,,9615.0,5451,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,6596,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623284,,9615.0,5452,,Oral bioavailability in dog,,3880,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623285,,9615.0,5453,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,16367,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623463,,9615.0,5454,,Plasma protein binding towards dog plasma at 10 uM,,17409,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL875952,,9615.0,5455,,Plasma protein binding towards dog plasma at 100 uM,,17409,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621705,,9615.0,5456,,Bioavailability in dog (dose 4 mg/kg p.o.),,2959,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621706,,9615.0,5457,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,13501,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621707,,9615.0,5458,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621708,,9615.0,5459,,Bioavailability in dogs,,15145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621709,,9615.0,5460,,Bioavailability,,4219,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621710,,9615.0,5461,,Oral bioavailability in dog (dose 10 mg/kg),,17538,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621711,,9615.0,5462,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,17538,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621712,,9615.0,5463,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621713,,9615.0,5464,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,17650,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621714,,9615.0,5465,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,3132,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL621715,,10095.0,5466,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,Liver,Mus sp.,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623717,,10095.0,5467,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,Liver,Mus sp.,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623718,,10095.0,5468,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,,BAO_0000218
,Liver,Mus sp.,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623719,,10095.0,5469,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL623720,,10095.0,5470,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL623721,,10095.0,5471,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,Muscle tissue,Mus sp.,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL623722,,10095.0,5472,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,Muscle tissue,Mus sp.,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL623723,,10095.0,5473,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,,BAO_0000218
,Muscle tissue,Mus sp.,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL618543,,10095.0,5474,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,Spleen,Mus sp.,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL618544,,10095.0,5475,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,Spleen,Mus sp.,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL875155,,10095.0,5476,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL618545,,10095.0,5477,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL618546,,10095.0,5478,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL623529,,10095.0,5479,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL623530,,10095.0,5480,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,2413,,,BAO_0000218
,,Mus sp.,Autocuration,1,22224,A,U,,,,0,CHEMBL621764,,10095.0,5481,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,2413,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621765,,9527.0,5482,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,17827,,,BAO_0000019
,Cerebellum,Cercopithecidae,Autocuration,1,22224,A,U,,,2037.0,0,CHEMBL621766,,9527.0,5483,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,17827,,,BAO_0000019
,Frontal cortex,Cercopithecidae,Autocuration,1,22224,A,U,,,1870.0,0,CHEMBL621767,,9527.0,5484,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,17827,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621768,,9527.0,5485,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,17827,,,BAO_0000019
,Striatum,Cercopithecidae,Autocuration,1,22224,A,U,,,2435.0,0,CHEMBL621769,,9527.0,5486,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,17827,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621770,,9527.0,5487,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,17827,,,BAO_0000019
,Cerebellum,Cercopithecidae,Autocuration,1,22224,A,U,,,2037.0,0,CHEMBL621771,,9527.0,5488,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,17827,,,BAO_0000019
,Frontal cortex,Cercopithecidae,Autocuration,1,22224,A,U,,,1870.0,0,CHEMBL621772,,9527.0,5489,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,17827,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621773,,9527.0,5490,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,17827,,,BAO_0000019
,Striatum,Cercopithecidae,Autocuration,1,22224,A,U,,,2435.0,0,CHEMBL621774,,9527.0,5491,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,17827,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621775,,9527.0,5492,,Compound was evaluated for oral bioavailability in rats,,17791,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621776,,9527.0,5493,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,17667,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621777,,9527.0,5494,,Half life period was evaluated in monkey,,17791,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875162,,9527.0,5495,,Half-life in rhesus monkeys by intravenous administration of dose,,110,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL621778,,10090.0,5496,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,5781,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL621779,,10090.0,5497,,AUC after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622479,,10090.0,5498,,AUC value was determined after oral administration,,17718,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622480,,10090.0,5499,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,4573,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622481,,10090.0,5500,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,3277,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622482,,10090.0,5501,,Area under curve by ioral administration in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622483,,10090.0,5502,,Area under curve by iv administration in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622484,,10090.0,5503,,Area under curve at 0-8 hr in IRC mice after peroral administration,,5951,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622641,,10090.0,5504,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622642,,10090.0,5505,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622643,,10090.0,5506,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622644,,10090.0,5507,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,17729,,,BAO_0000218
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL622645,,9606.0,5508,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL622646,,9606.0,5509,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL621238,,9606.0,5510,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL621239,,9606.0,5511,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL621240,,9606.0,5512,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL621241,,9606.0,5513,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL621242,,9606.0,5514,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620350,,9606.0,5515,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620351,,9606.0,5516,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620352,,9606.0,5517,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620353,,9606.0,5518,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620354,,9606.0,5519,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620355,,9606.0,5520,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620356,,9606.0,5521,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620357,,9606.0,5522,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620358,,9606.0,5523,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Expert,1,80433,F,N,,,,1,CHEMBL620359,,9606.0,5524,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,9424,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620360,,9606.0,5525,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,11544,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620361,,9606.0,5526,,Cytotoxicity of compound against 8226/DOX1V cells,,17378,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620362,,9606.0,5527,,Cytotoxicity of compound against 8226/S cells,,17378,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620363,,9606.0,5528,,Inhibitory concentration against 8226 myeloma cancer cell line,,17079,,RPMI-8226,BAO_0000219
741.0,,Homo sapiens,Intermediate,1,80433,F,N,,,,1,CHEMBL620364,,9606.0,5529,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,17079,,RPMI-8226,BAO_0000219
854.0,,Homo sapiens,Intermediate,1,80647,F,N,,,,1,CHEMBL620365,,9606.0,5530,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,13466,,833K,BAO_0000219
854.0,,Homo sapiens,Intermediate,1,80647,F,N,,,,1,CHEMBL620366,,9606.0,5531,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,13466,,833K,BAO_0000219
854.0,,Homo sapiens,Expert,1,80647,F,N,,,,1,CHEMBL620367,,9606.0,5532,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,2392,,833K,BAO_0000219
854.0,,Homo sapiens,Intermediate,1,80647,F,N,,,,1,CHEMBL620368,,9606.0,5533,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,2392,,833K,BAO_0000219
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL620369,,,5534,,Inhibitory activity against caspase-1,,6608,,,BAO_0000019
,,Enterococcus faecalis,Autocuration,1,45,B,H,,,,8,CHEMBL620370,,1351.0,5535,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,10199,,,BAO_0000357
705.0,,Homo sapiens,Intermediate,1,80648,F,N,,,,1,CHEMBL620371,,9606.0,5536,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,17749,,8701-BC,BAO_0000219
705.0,,Homo sapiens,Intermediate,1,80648,F,N,,,,1,CHEMBL620372,,9606.0,5537,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,17749,,8701-BC,BAO_0000219
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL876492,,,5538,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,1229,,,BAO_0000019
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL620373,,,5539,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,1229,,,BAO_0000019
,,,Intermediate,1,22226,F,U,,,,0,CHEMBL620374,,,5540,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,1229,,,BAO_0000019
,,,Autocuration,1,22226,B,U,,,,0,CHEMBL620375,,,5541,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,6390,,,BAO_0000019
,,Streptococcus pyogenes,Autocuration,1,22226,F,U,,,,0,CHEMBL857902,,1314.0,5542,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,16219,,,BAO_0000019
,,Streptococcus pyogenes,Autocuration,1,22226,F,U,,,,0,CHEMBL620376,,1314.0,5543,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,16219,,,BAO_0000019
,,,Autocuration,1,11922,B,H,,,,8,CHEMBL620377,,,5544,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,17043,,,BAO_0000357
324.0,,Homo sapiens,Intermediate,1,81115,F,N,,,,1,CHEMBL620378,,9606.0,5545,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,6929,,KB ,BAO_0000219
324.0,,Homo sapiens,Intermediate,1,81115,A,N,,,,1,CHEMBL620379,,9606.0,5546,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,6929,,KB ,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL620380,,9606.0,5547,,In vitro cytotoxicity of compound was tested against 9KB cells.,,7083,,,BAO_0000219
392.0,,Rattus norvegicus,Intermediate,1,80653,F,N,,,,1,CHEMBL884006,,10116.0,5548,,Cytotoxic concentration against 9L cells was determined on day 3,,12446,,9L,BAO_0000219
392.0,,Rattus norvegicus,Expert,1,80653,F,N,,,,1,CHEMBL620381,,10116.0,5549,,Tested in vitro for anticancer activity against 9L cells,,15345,,9L,BAO_0000219
392.0,,Rattus norvegicus,Expert,1,80653,F,N,,,,1,CHEMBL620382,,10116.0,5550,,Tested in vitro for anticancer activity against 9L cells; Not determined,,15345,,9L,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620383,,9606.0,5551,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,6301,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876493,,9606.0,5552,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,4833,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620384,,9606.0,5553,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,4833,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620385,,9606.0,5554,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,4833,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620386,,9606.0,5555,,Cytotoxicity against human lung carcinoma A549 cell line,,13330,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,25,F,D,,,,9,CHEMBL620387,,9606.0,5556,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,17517,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,25,F,D,,,,9,CHEMBL621404,,9606.0,5557,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,17517,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621405,,9606.0,5558,,"In vitro growth inhibition of A549, lung carcinoma",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621406,,9606.0,5559,,"In vitro growth inhibition of A549, lung carcinoma.",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621407,,9606.0,5560,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,5228,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621408,,9606.0,5561,,Cytotoxic activity against human lung cancer A549 cell line was determined,,5351,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL885345,,9606.0,5562,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,12198,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621409,,9606.0,5563,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,13891,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL876034,,9606.0,5564,,Cytotoxicity in A549 (human carcinoma) cell line.,,5677,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621410,,9606.0,5565,,Cytotoxicity on lung carcinoma (A-549) cell line,,13788,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621411,,9606.0,5566,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,13384,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621412,,9606.0,5567,,Effective dose of compound against replication of A549 cell line was evaluated,,6726,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621413,,9606.0,5568,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,3455,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621414,,9606.0,5569,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,5726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621415,,9606.0,5570,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,5726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621416,,9606.0,5571,,The compound was evaluated for antiproliferative activity against A549 cell line,,3936,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621417,,9606.0,5572,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,14991,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621418,,9606.0,5573,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,5243,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621419,,9606.0,5574,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,12858,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621420,,9606.0,5575,,Growth inhibition against A549 cell line was evaluated,,6776,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL875823,,9606.0,5576,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,16558,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621421,,9606.0,5577,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,4583,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621422,,9606.0,5578,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,13514,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL884014,,9606.0,5579,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,15166,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621423,,9606.0,5580,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,13873,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621424,,9606.0,5581,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,6447,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621425,,9606.0,5582,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,2068,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621426,,9606.0,5583,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,1863,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621427,,9606.0,5584,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,13873,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621428,,9606.0,5585,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,13873,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621429,,9606.0,5586,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,13873,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621430,,9606.0,5587,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,579,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621431,,9606.0,5588,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,579,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621432,,9606.0,5589,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,4584,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621433,,9606.0,5590,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL875824,,9606.0,5591,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621434,,9606.0,5592,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621435,,9606.0,5593,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621436,,9606.0,5594,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,14188,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621437,,9606.0,5595,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,14188,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621438,,9606.0,5596,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,15354,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621439,,9606.0,5597,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,14253,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621440,,9606.0,5598,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,13873,,A549,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621441,,9615.0,5599,,Oral bioavailability in dog (conscious),,3043,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621442,,9615.0,5600,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,3045,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621443,,9615.0,5601,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,3022,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621444,,9615.0,5602,,Oral bioavailability in dog,,4453,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625133,,9615.0,5603,,Oral bioavailability in dog,,1696,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625134,,9615.0,5604,,Oral bioavailability in dog,,5045,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625135,,9615.0,5605,,Oral bioavailability in dog (fasted),,5356,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625136,,9615.0,5606,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625137,,9615.0,5607,,Oral bioavailability in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625138,,9615.0,5608,,Oral bioavailability in dog,,1475,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625139,,9615.0,5609,,Percent bioavailability in dog,,3788,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL872264,,9615.0,5610,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625140,,9615.0,5611,,Oral bioavailability in dog,,13397,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624436,,9615.0,5612,,The compound was evaluated for bioavailability in dogs; 34-44,,2137,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624437,,9615.0,5613,,Bioavailability in dog (dose 4 mg/kg p.o.),,2959,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL872261,,9615.0,5614,,Oral bioavailability in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624438,,9615.0,5615,,8 hour trough Blood level in dog was measured after administration of compound,,6084,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL624439,,9615.0,5616,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624440,,9615.0,5617,,C24 after oral administration at 5 mg/kg,,6316,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624441,,9615.0,5618,,Clearance after oral and iv dosing in dogs,,5238,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624442,,9615.0,5619,,Clearance of the drug was measured in the plasma of dog,,17796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624443,,9615.0,5620,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624444,,9615.0,5621,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,5654,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624445,,9615.0,5622,,Clearance of compound was determined in dogs,,6621,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624446,,9615.0,5623,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,6505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624447,,9615.0,5624,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5802,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624448,,9615.0,5625,,Plasma clearance in dog was determined,,17267,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624449,,9615.0,5626,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624450,,9615.0,5627,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875942,,9615.0,5628,,Plasma clearance in dog after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624451,,9615.0,5629,,Plasma clearance in dogs,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624452,,9615.0,5630,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624453,,9615.0,5631,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,5199,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624454,,9615.0,5632,,Plasma clearance after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624455,,9615.0,5633,,Plasma clearance after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624456,,9615.0,5634,,Plasma administration to dogs,,16367,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624457,,9615.0,5635,,Plasma clearance was determined,,5505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624458,,9615.0,5636,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,6215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624459,,9615.0,5637,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,Liver,Homo sapiens,Intermediate,1,102164,A,S,In vitro,,2107.0,2,CHEMBL624460,,9606.0,5638,,Intrinsic clearance in human liver microsomes,Microsomes,5007,,,BAO_0000251
,Liver,Homo sapiens,Intermediate,1,102164,A,S,In vitro,,2107.0,2,CHEMBL624461,,9606.0,5639,,Intrinsic clearance in human liver microsomes,Microsomes,5007,,,BAO_0000251
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875943,,9615.0,5640,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624462,,9615.0,5641,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624463,,9615.0,5642,,Clearance in dog (dose 1 mg/kg i.v.),,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624464,,9615.0,5643,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,6221,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624465,,9615.0,5644,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5007,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624466,,9615.0,5645,,Plasma clearance after peroral administration at 10 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624467,,9615.0,5646,,Plasma clearance after peroral administration at 5 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624468,,9615.0,5647,,Plasma clearance after peroral administration at 5 mg/kg in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624469,,9615.0,5648,,Plasma clearance was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624470,,9615.0,5649,,Plasma clearance was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624471,,9615.0,5650,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624472,,9615.0,5651,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622775,,9615.0,5652,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622776,,9615.0,5653,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622777,,9615.0,5654,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622778,,9615.0,5655,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622779,,9615.0,5656,,Clearance by intravenous administration of 1.2 mg/kg in dog,,4368,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622780,,9615.0,5657,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,4305,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622781,,9615.0,5658,,Clearance value was evaluated in dog plasma,,1918,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622782,,9615.0,5659,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,6005,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622783,,9615.0,5660,,Compound was tested for plasma clearance in dog,,4839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622784,,9615.0,5661,,Pharmacokinetic property (Plasma clearance) was measured in dog,,4239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622785,,10090.0,5662,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622786,,10090.0,5663,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622787,,10090.0,5664,,Area under curve value in mouse at a dose of 10 mg/kg,,5302,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875949,,10090.0,5665,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622788,,10090.0,5666,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,,,,1,CHEMBL622789,,10090.0,5667,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,,,,1,CHEMBL622790,,10090.0,5668,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,,,,1,CHEMBL622791,,10090.0,5669,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,,,,1,CHEMBL622792,,10090.0,5670,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622793,,10090.0,5671,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622794,,10090.0,5672,,Area under curve was determined for the compound at 24 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622795,,10090.0,5673,,Area under curve was determined for the compound at 40 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621803,,10090.0,5674,,Area under curve was determined for the compound at 5 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621804,,10090.0,5675,,Area under the curve for the compound is obtained at dose 25 mg/kg,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621805,,10090.0,5676,,Area under the curve for the compound was obtained when tested in mouse,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621806,,10090.0,5677,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621807,,10090.0,5678,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621808,,10090.0,5679,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621809,,10090.0,5680,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,4066,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621810,,10090.0,5681,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875164,,10090.0,5682,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,14239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621811,,10090.0,5683,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,14239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621812,,10090.0,5684,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,4890,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621813,,10090.0,5685,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,429,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621814,,10090.0,5686,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,429,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621815,,10090.0,5687,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621816,,10090.0,5688,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621817,,10090.0,5689,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621818,,10090.0,5690,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621819,,10090.0,5691,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621820,,10090.0,5692,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621821,,10090.0,5693,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621822,,10090.0,5694,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,6178,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619474,,10090.0,5695,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,6178,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619475,,10090.0,5696,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,6619,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619476,,10090.0,5697,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,6619,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619477,,10090.0,5698,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619478,,10090.0,5699,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619479,,10090.0,5700,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619480,,10090.0,5701,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619481,,10090.0,5702,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,3192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619482,,10090.0,5703,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,3192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619483,,10090.0,5704,,Area under the curve was evaluated in mice after intravenous administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619484,,10090.0,5705,,Area under the curve was evaluated in mice after oral administration,,2675,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL619485,,10090.0,5706,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL619486,,10090.0,5707,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619487,,10090.0,5708,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619488,,10090.0,5709,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL620106,,10090.0,5710,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
392.0,,,Intermediate,1,80653,F,N,,,,1,CHEMBL620107,,,5711,,The compound was tested in vitro for anticancer activity against 9L cells,,15345,,9L,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL620283,,10116.0,5712,,Anti proliferation activity determined; Weak effect,,2181,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL875176,,10116.0,5713,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,2181,,,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL620284,,10116.0,5714,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,2181,,,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL623515,,10116.0,5715,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,2181,,,BAO_0000219
,,Mus musculus,Autocuration,1,22226,F,U,,,,0,CHEMBL623516,,10090.0,5716,,The cytotoxic activity was in vitro tested by 9PS assay method,,10486,,,BAO_0000019
,,Mus musculus,Autocuration,1,22226,F,U,,,,0,CHEMBL623517,,10090.0,5717,,The cytotoxic activity was in vitro tested by 9PS assay method.,,10486,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL857878,,,5718,,Partition coefficient (logD6.5),,15508,,,BAO_0000019
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL623518,,9606.0,5719,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,5242,,A2780,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL624195,,9606.0,5720,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,16167,,A-375,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL624196,,9606.0,5721,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,4782,,A-431,BAO_0000219
500.0,,Homo sapiens,Expert,1,9,F,D,,,,9,CHEMBL624197,,9606.0,5722,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,16093,,A-431,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL624198,,9606.0,5723,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,2596,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL621287,,9606.0,5724,,in vitro cytotoxicity against A 498 cancer cell line,,2596,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL621288,,9606.0,5725,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,3239,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL876496,,9606.0,5726,,Cytotoxic activity against A 498 renal cancer cell lines.,,1847,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL621289,,9606.0,5727,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,10553,,A498,BAO_0000219
,,Staphylococcus aureus,Autocuration,1,22226,F,U,,,,0,CHEMBL621290,,1280.0,5728,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,16219,,,BAO_0000019
,,Staphylococcus aureus,Autocuration,1,22226,F,U,,,,0,CHEMBL621291,,1280.0,5729,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,16219,,,BAO_0000019
,,Staphylococcus aureus,Autocuration,1,22226,F,U,,,,0,CHEMBL621292,,1280.0,5730,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,16219,,,BAO_0000019
,,Staphylococcus aureus,Autocuration,1,22226,F,U,,,,0,CHEMBL621293,,1280.0,5731,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,16219,,,BAO_0000019
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621294,,9606.0,5732,,Inhibitory concentration required against A 549 lung cancer cell line,,4782,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621295,,9606.0,5733,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,11805,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884007,,9606.0,5734,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,11805,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621296,,9606.0,5735,,In vitro cytotoxicity against lung cancer A 549 cell lines,,2007,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621297,,9606.0,5736,,Compound was tested for its cytotoxicity against A 549 cell line,,4594,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL839828,,9606.0,5737,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,6018,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620397,,9606.0,5738,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,6018,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620398,,9606.0,5739,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,3599,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620399,,9606.0,5740,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,2551,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620400,,9606.0,5741,,In vitro inhibition of A549 (human lung cancer) cell growth.,,16132,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620401,,9606.0,5742,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,16132,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620402,,9606.0,5743,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,2551,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620403,,9606.0,5744,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,2551,,A549,BAO_0000219
,,,Autocuration,1,22226,F,U,,,,0,CHEMBL620404,,,5745,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,11913,,,BAO_0000218
,,,Autocuration,1,104694,F,H,In vivo,,,4,CHEMBL620405,,,5746,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,12621,,,BAO_0000218
,,,Autocuration,1,104694,F,H,In vivo,,,4,CHEMBL620406,,,5747,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,12621,,,BAO_0000218
,,,Autocuration,1,104694,F,H,In vivo,,,4,CHEMBL620407,,,5748,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,12621,,,BAO_0000218
,,,Autocuration,1,104694,F,H,In vivo,,,4,CHEMBL620408,,,5749,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,12621,,,BAO_0000218
,,,Autocuration,1,104694,F,H,In vivo,,,4,CHEMBL620409,,,5750,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,12621,,,BAO_0000218
624.0,,Homo sapiens,Expert,1,80021,F,N,,,,1,CHEMBL620410,,9606.0,5751,,Inhibition of A-498 human Renal cell proliferation,,3600,,A498,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL620411,,10116.0,5752,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,1796,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL620412,,10116.0,5753,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,1796,,,BAO_0000019
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL876596,,10116.0,5754,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,1796,,,BAO_0000019
622.0,,Homo sapiens,Expert,1,80012,F,N,,,,1,CHEMBL620413,,9606.0,5755,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,16464,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL620414,,9606.0,5756,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL620415,,9606.0,5757,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A 172,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620416,,9606.0,5758,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,13617,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620417,,9606.0,5759,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,4584,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620418,,9606.0,5760,,Cytotoxic activity evaluated against A549 tumor cells,,13799,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620419,,9606.0,5761,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,16726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620420,,9606.0,5762,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,16109,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620421,,9606.0,5763,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,16109,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620422,,9606.0,5764,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,15474,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620423,,9606.0,5765,,Cytotoxicity of compound against A549 cell line,,6851,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620424,,9606.0,5766,,Cytotoxicity against human lung cell carcinoma A549 cell line,,17534,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620425,,9606.0,5767,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,2621,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620426,,9606.0,5768,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,830,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620427,,9606.0,5769,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,14255,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620428,,9606.0,5770,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,14255,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620429,,9606.0,5771,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,1590,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620430,,9606.0,5772,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,6146,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL839887,,9606.0,5773,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,17427,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620431,,9606.0,5774,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,5280,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884010,,9606.0,5775,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,16786,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620538,,9606.0,5776,,In vitro cytotoxicity against A549 (human lung cancer),,5895,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620539,,9606.0,5777,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,14297,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623373,,9606.0,5778,,In vivo antiproliferative activity against A549 cell line,,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623374,,9606.0,5779,,Inhibition of non-small-cell lung adenocarcinoma (A549),,14368,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623375,,9606.0,5780,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,14368,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623376,,9606.0,5781,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,14254,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623377,,9606.0,5782,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,15897,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623378,,9606.0,5783,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,13866,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623379,,9606.0,5784,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,13370,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623380,,9606.0,5785,,Inhibitory activity against A549 lung cancer cell line,,4862,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623381,,9606.0,5786,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,4862,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623382,,9606.0,5787,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,4862,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623383,,9606.0,5788,,Inhibitory concentration against A549 (lung cancer) cell line,,15970,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL623384,,9606.0,5789,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,17713,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623385,,9606.0,5790,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,4833,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL623386,,9606.0,5791,,Activity against A549 cancer cell line.,,13736,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884105,,9606.0,5792,,The compound was evaluated for cytotoxicity against A549 cell line,,4312,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623387,,9606.0,5793,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621568,,9606.0,5794,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621569,,9606.0,5795,,Growth inhibitory activity was measured for human A549 tumor cell line.,,14717,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621570,,9606.0,5796,,Inhibitory activity against A549 lung cancer cell line,,4634,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621571,,9606.0,5797,,Inhibitory activity against A549 cell line; inactive,,1149,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621572,,9606.0,5798,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621573,,9606.0,5799,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621574,,9606.0,5800,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5421,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621575,,9606.0,5801,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,3320,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621576,,9606.0,5802,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,3320,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621577,,9606.0,5803,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,3320,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621578,,9606.0,5804,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,3320,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621579,,9606.0,5805,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,3320,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621580,,9606.0,5806,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,5726,,A549,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621581,,9615.0,5807,,Plasma clearance (in vivo) in mongrel dogs was determined,,17800,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621582,,9615.0,5808,,Plasma clearance was measured in dog,,5985,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621583,,9615.0,5809,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,5530,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621584,,9615.0,5810,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,5530,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621585,,9615.0,5811,,Tested for plasma clearance in dog,,4839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621586,,9615.0,5812,,The compound was tested for clearance in dog plasma.,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875835,,9615.0,5813,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,4838,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621587,,9615.0,5814,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,4137,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621588,,9615.0,5815,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,5017,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,In vitro,,2107.0,1,CHEMBL621589,,9615.0,5816,,In vitro clearance in dog liver microsomes,Microsomes,17538,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621590,,9615.0,5817,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,6161,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621591,,9615.0,5818,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,6161,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621592,,9615.0,5819,,Plasma clearance in dog,,1696,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621593,,9615.0,5820,,Clearance rate in dog,,6762,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621594,,9615.0,5821,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,5932,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621595,,9615.0,5822,,Clearance in dogs,,6305,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621596,,9615.0,5823,,Plasma clearance in dogs,,4942,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621597,,9615.0,5824,,Plasma clearance was determined,,4219,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621598,,9615.0,5825,,Lower clearance in dog (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621599,,9615.0,5826,,Plasma clearance in Beagle dogs,,4514,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875836,,9615.0,5827,,Plasma clearance (Clp) in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621600,,9615.0,5828,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621601,,9615.0,5829,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618474,,9615.0,5830,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618475,,9615.0,5831,,Plasma clearance of compound was determined in dog,,6821,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624524,,9615.0,5832,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624525,,9615.0,5833,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624526,,9615.0,5834,,Plasma clearance in dog was determined,,5374,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624527,,9615.0,5835,,Plasma clearance was calculated in dog,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624528,,9615.0,5836,,Plasma clearance at the dose of 2 mg/kg in dog,,4727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624529,,9615.0,5837,,Plasma clearance in dog,,5145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624530,,9615.0,5838,,Plasma clearance in dog,,17657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624531,,9615.0,5839,,Plasma clearance in dog; Unable to calculate,,17657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624532,,9615.0,5840,,Plasma clearance in rhesus monkey,,5145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624533,,9615.0,5841,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624534,,9615.0,5842,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624535,,9615.0,5843,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624536,,9615.0,5844,,Plasma clearance was evaluated in dog,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624537,,9615.0,5845,,Plasma clearance was evaluated in dog; Not tested,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624538,,9615.0,5846,,Plasma clearance was evaluated in rhesus,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624539,,9615.0,5847,,Plasma clearance was evaluated in rhesus; Not tested,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624540,,9615.0,5848,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624541,,9615.0,5849,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624542,,9615.0,5850,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624543,,9615.0,5851,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624544,,9615.0,5852,,Clearance value at a dose of 0.2 mg/kg i.v.,,5474,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL624545,,9615.0,5853,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,6316,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624546,,9615.0,5854,,Cmax after oral dose of compound at 3 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875957,,9615.0,5855,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624547,,9615.0,5856,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5802,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624548,,9615.0,5857,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624549,,9615.0,5858,,Cmax in dog after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL624550,,9615.0,5859,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621613,,9615.0,5860,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,6505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621614,,9615.0,5861,,Cmax was determine after peroral administration at 10 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623431,,9615.0,5862,,Cmax was determine after peroral administration at 5 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623432,,9615.0,5863,,Cmax was determine after peroral administration at 5 mg/kg in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623433,,9615.0,5864,,Cmax after 0.3 mg/kg po administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623434,,9615.0,5865,,Cmax after peroral administration in dogs at 2.4 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623435,,9615.0,5866,,Cmax in dog after oral administration at 1 mg/kg,,6123,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623436,,9615.0,5867,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,6123,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875958,,9615.0,5868,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,6757,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623437,,9615.0,5869,,Cmax value after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL623438,,10090.0,5870,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL623439,,10090.0,5871,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL623440,,10090.0,5872,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL623441,,10090.0,5873,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL623442,,10090.0,5874,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623469,,10090.0,5875,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623470,,10090.0,5876,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623471,,10090.0,5877,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL623472,,10090.0,5878,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL623473,,10090.0,5879,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL623474,,10090.0,5880,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623475,,10090.0,5881,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623476,,10090.0,5882,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623477,,10090.0,5883,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL621896,,10090.0,5884,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL621897,,10090.0,5885,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL621898,,10090.0,5886,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621899,,10090.0,5887,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621900,,10090.0,5888,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621901,,10090.0,5889,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL621902,,10090.0,5890,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL621903,,10090.0,5891,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL622587,,10090.0,5892,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL620285,,10090.0,5893,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL875285,,10090.0,5894,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL620286,,10090.0,5895,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620287,,10090.0,5896,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620288,,10090.0,5897,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620289,,10090.0,5898,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL620290,,10090.0,5899,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL620291,,10090.0,5900,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,160.0,1,CHEMBL620292,,10090.0,5901,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL620293,,10090.0,5902,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL620294,,10090.0,5903,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618614,,10090.0,5904,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL618615,,10090.0,5905,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL618616,,10090.0,5906,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
622.0,,Homo sapiens,Expert,1,80012,F,N,,,,1,CHEMBL618617,,9606.0,5907,,Cytotoxicity against A-172 human tumor cell lines,,2036,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL618618,,9606.0,5908,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,2357,,A 172,BAO_0000219
623.0,,Homo sapiens,Intermediate,1,80014,F,N,,,,1,CHEMBL618619,,9606.0,5909,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,1457,,A204,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618620,,9606.0,5910,,Tested for antiproliferative activity against A-2780 tumoral cell line,,4379,,A2780,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL618621,,9606.0,5911,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,1093,,A-375,BAO_0000219
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL618622,,9606.0,5912,,Tested in vitro against A-375 cell line human melanoma,,12152,,A-375,BAO_0000219
797.0,,Homo sapiens,Expert,1,80019,F,N,,,,1,CHEMBL618623,,9606.0,5913,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,16464,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618624,,9606.0,5914,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A-427,BAO_0000219
797.0,,Homo sapiens,Expert,1,80019,F,N,,,,1,CHEMBL618625,,9606.0,5915,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,16582,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618626,,9606.0,5916,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,16464,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618627,,9606.0,5917,,Antitumor activity on A-427 lung carcinoma cell lines,,10413,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618628,,9606.0,5918,,Cytotoxic activity against human A-427 lung tumor cell line,,6418,,A-427,BAO_0000219
797.0,,Homo sapiens,Expert,1,80019,F,N,,,,1,CHEMBL618629,,9606.0,5919,,In vitro antitumor effects against human A-427 cell lines.,,17134,,A-427,BAO_0000219
797.0,,Homo sapiens,Expert,1,80019,F,N,,,,1,CHEMBL618630,,9606.0,5920,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,16132,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618631,,9606.0,5921,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,16132,,A-427,BAO_0000219
797.0,,Homo sapiens,Intermediate,1,80019,F,N,,,,1,CHEMBL618632,,9606.0,5922,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,16780,,A-427,BAO_0000219
500.0,,Homo sapiens,Expert,1,80852,F,N,,,,1,CHEMBL618633,,9606.0,5923,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,4085,,A-431,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619315,,9606.0,5924,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,1276,,A498,BAO_0000219
624.0,,Homo sapiens,Expert,1,80021,F,N,,,,1,CHEMBL619316,,9606.0,5925,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,3498,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619317,,9606.0,5926,,Cytotoxicity against human kidney carcinoma A-498cell lines,,1169,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619318,,9606.0,5927,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,4450,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619319,,9606.0,5928,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,3311,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619739,,9606.0,5929,,Antitumor cytotoxic activity against A-498 cell line was determined,,4461,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619740,,9606.0,5930,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,3311,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL883158,,9606.0,5931,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,3311,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL884012,,9606.0,5932,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,1457,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619741,,9606.0,5933,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,3664,,A498,BAO_0000219
624.0,,Homo sapiens,Intermediate,1,80021,F,N,,,,1,CHEMBL619742,,9606.0,5934,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,15895,,A498,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876610,,9606.0,5935,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,11843,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619743,,9606.0,5936,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,11843,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619744,,9606.0,5937,,In vitro antiproliferative activity against human A-549 NSCL cell line,,17705,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619745,,9606.0,5938,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,17705,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619746,,9606.0,5939,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619747,,9606.0,5940,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619748,,9606.0,5941,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619749,,9606.0,5942,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619750,,9606.0,5943,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624014,,9606.0,5944,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624015,,9606.0,5945,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,4369,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL885344,,9606.0,5946,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,4787,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623224,,9606.0,5947,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,4787,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL623225,,9606.0,5948,,Cytotoxic activity against A-549 cell line,,6513,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622698,,9606.0,5949,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,6690,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622699,,9606.0,5950,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,6690,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL622700,,9606.0,5951,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,12263,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622701,,9606.0,5952,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,1054,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622702,,9606.0,5953,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,1359,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622703,,9606.0,5954,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,3547,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL622704,,9606.0,5955,,Cytotoxic activity towards A-549 cells,,5771,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622705,,9606.0,5956,,"In vitro percent inhibition of A549, lung carcinoma.",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622706,,9606.0,5957,,"In vitro percent inhibition of A549, lung carcinoma",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622707,,9606.0,5958,,"In vitro percent inhibition of A549, lung carcinoma.",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622708,,9606.0,5959,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,14425,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622709,,9606.0,5960,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,5280,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622710,,9606.0,5961,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,15176,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622711,,9606.0,5962,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,15300,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622712,,9606.0,5963,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622713,,9606.0,5964,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622714,,9606.0,5965,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622715,,9606.0,5966,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622716,,9606.0,5967,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,17824,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622717,,9606.0,5968,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,17824,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622718,,9606.0,5969,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,17528,,A549,BAO_0000218
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL622719,,9606.0,5970,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,6870,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622720,,9606.0,5971,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,6870,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622721,,9606.0,5972,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,6870,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622722,,9606.0,5973,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,6870,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876030,,9606.0,5974,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,16726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620206,,9606.0,5975,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,6170,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620207,,9606.0,5976,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,6583,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620208,,9606.0,5977,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,6583,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620209,,9606.0,5978,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,6583,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620210,,9606.0,5979,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,6583,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621639,,9606.0,5980,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,6583,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621640,,9606.0,5981,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,17321,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621641,,9606.0,5982,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,17528,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL621642,,9606.0,5983,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,12888,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621643,,9606.0,5984,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,4312,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621644,,9606.0,5985,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,4312,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL621645,,9606.0,5986,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,4312,,A549,BAO_0000219
646.0,,Mus musculus,Intermediate,1,80682,F,N,,,,1,CHEMBL621646,,10090.0,5987,,In vitro antiproliferative activity against A549 cell line,,17737,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621647,,,5988,,Synergism with indomethacin in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621648,,,5989,,Synergism with tolmetin in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621649,,,5990,,Synergism with sulindac in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621650,,,5991,,Antagonism of indomethacin in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621651,,,5992,,Antagonism of sulindac in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621652,,,5993,,Antagonism of tolmetin in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621653,,,5994,,Synergism with indomethacin in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621654,,,5995,,Synergism with sulindac in A549 cells,,6630,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL621655,,,5996,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,6630,,A549,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621656,,9615.0,5997,,Cmax value after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621657,,9615.0,5998,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621658,,9615.0,5999,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621659,,9615.0,6000,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621660,,9615.0,6001,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,5944,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621661,,9615.0,6002,,Cmax value after administration of 4 mg/Kg oral dose in dog,,2959,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621662,,9615.0,6003,,Cmax value in dog,,6241,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621663,,9615.0,6004,,Cmax value in dogs after oral administration at 1 mg/kg,,6241,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621664,,9615.0,6005,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,2652,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621665,,9615.0,6006,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,1806,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621666,,9615.0,6007,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,1806,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621667,,9615.0,6008,,Concentration maxima after oral dosing in dogs,,1021,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876738,,9615.0,6009,,Concentration maxima after oral dosing in dogs; not available,,1021,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621668,,9615.0,6010,,Concentration maxima after oral dosing in dogs; not available,,1021,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621669,,9615.0,6011,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621670,,9615.0,6012,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621671,,9615.0,6013,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622360,,9615.0,6014,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622361,,9615.0,6015,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,5444,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622362,,9615.0,6016,,Cmax in dog plasma after oral dose (1 mg/kg),,5130,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622363,,9615.0,6017,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,3249,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622364,,9615.0,6018,,Maximal plasma concentration at a dose of 1 mg/kg,,5473,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622365,,9615.0,6019,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,5474,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622533,,9615.0,6020,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,4657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622534,,9615.0,6021,,Maximum concentration of compound in dog was evaluated.,,3031,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622535,,9615.0,6022,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876739,,9615.0,6023,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,4186,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622536,,9615.0,6024,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5007,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622537,,9615.0,6025,,Maximum concentration obtained in dog plasma was determined,,3132,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622538,,9615.0,6026,,Maximum concentration was determined,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL627867,,9615.0,6027,,Maximum concentration at the dose of 2 mg/kg in dog,,4727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL627868,,9615.0,6028,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627869,,9615.0,6029,,Maximum concentration was evaluated in dog plasma,,1918,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL627870,,9615.0,6030,,Maximum concentration was evaluated after 75 min after administration in dog,,3045,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627871,,9615.0,6031,,Maximum plasma concentration determined in dog after oral administration of 17b,,9579,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627872,,9615.0,6032,,Maximum plasma concentration determined in dog after oral administration of 2b,,9579,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627873,,9615.0,6033,,Maximum plasma concentration in dog,,933,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627874,,9615.0,6034,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,17839,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627875,,9615.0,6035,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,17839,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627876,,9615.0,6036,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,17839,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627877,,9615.0,6037,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,17839,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627878,,9615.0,6038,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627879,,9615.0,6039,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,16367,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL875355,,9615.0,6040,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627880,,9615.0,6041,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627881,,9615.0,6042,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,5199,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627882,,9615.0,6043,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,17650,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627883,,9615.0,6044,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,6679,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628526,,9615.0,6045,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,5356,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628527,,9615.0,6046,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,5356,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628528,,9615.0,6047,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,6227,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628529,,9615.0,6048,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,6227,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628530,,9615.0,6049,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,6227,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625243,,9615.0,6050,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,6227,,,BAO_0000218
,Plasma,Canis lupus familiaris,Expert,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625244,,9615.0,6051,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625245,,9615.0,6052,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,4368,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625246,,9615.0,6053,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,6265,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL625247,,10090.0,6054,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1088.0,1,CHEMBL625248,,10090.0,6055,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,7767,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1088.0,1,CHEMBL625249,,10090.0,6056,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,7767,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1088.0,1,CHEMBL625250,,10090.0,6057,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,7767,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625251,,10090.0,6058,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,17811,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875356,,10090.0,6059,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,17811,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625252,,10090.0,6060,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,17827,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL625253,,10090.0,6061,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625254,,10090.0,6062,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625255,,10090.0,6063,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625256,,10090.0,6064,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,17827,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL625257,,10090.0,6065,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,17827,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL625258,,10090.0,6066,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625259,,10090.0,6067,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625260,,10090.0,6068,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625261,,10090.0,6069,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625262,,10090.0,6070,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622639,,10090.0,6071,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622640,,10090.0,6072,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,17257,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622812,,10090.0,6073,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,17257,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622813,,10090.0,6074,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,17257,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622814,,10090.0,6075,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,17257,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622815,,10090.0,6076,,Time at maximum activity in mice (Radiolabeled compound),,17827,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625342,,10090.0,6077,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625343,,10090.0,6078,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL877591,,10090.0,6079,,Binding towards mouse plasma protein at 10 uM,,17409,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625344,,10090.0,6080,,Binding towards mouse plasma protein at 100 uM,,17409,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625345,,10090.0,6081,,Bioavailability was evaluated in mice after intravenous administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625346,,10090.0,6082,,Bioavailability was evaluated in mice after oral administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625347,,10090.0,6083,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625348,,10090.0,6084,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625349,,10090.0,6085,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625350,,10090.0,6086,,Oral bioavailability in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL882952,,10090.0,6087,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL625351,,10090.0,6088,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL625352,,10090.0,6089,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL877592,,10090.0,6090,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL625353,,10090.0,6091,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL625354,,10090.0,6092,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL626019,,10090.0,6093,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL626020,,10090.0,6094,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL626021,,10090.0,6095,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL626022,,10090.0,6096,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL626192,,10090.0,6097,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626193,,9606.0,6098,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,1276,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL626194,,9606.0,6099,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,3498,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626195,,9606.0,6100,,Cytotoxicity against human lung carcinoma A-549 cell lines,,1169,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626196,,9606.0,6101,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,4450,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626197,,9606.0,6102,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626198,,9606.0,6103,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626199,,9606.0,6104,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626200,,9606.0,6105,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626201,,9606.0,6106,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626202,,9606.0,6107,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626203,,9606.0,6108,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,358,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL626204,,9606.0,6109,,In vitro cytotoxicity against A-549 human lung cancer cells,,15167,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624701,,9606.0,6110,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,4139,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624702,,9606.0,6111,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,833,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624703,,9606.0,6112,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624704,,9606.0,6113,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,12373,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624705,,9606.0,6114,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,637,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624706,,9606.0,6115,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,14867,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624707,,9606.0,6116,,Antitumor cytotoxic activity against A-549 cell line was determined,,4461,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624708,,9606.0,6117,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,5406,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624709,,9606.0,6118,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,4457,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL884107,,9606.0,6119,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,1386,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624710,,9606.0,6120,,Antitumoral activity was assayed against A-549 cell line,,3265,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624711,,9606.0,6121,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,2359,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624712,,9606.0,6122,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,4457,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624713,,9606.0,6123,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,12454,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624714,,9606.0,6124,,Compound was tested for inhibition of cell growth of A-549 cells,,1481,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624715,,9606.0,6125,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,1750,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624716,,9606.0,6126,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,5065,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619505,,9606.0,6127,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,808,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619506,,9606.0,6128,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,16364,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619507,,9606.0,6129,,Cytotoxic activity against A-549 cell lines.,,1847,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619508,,9606.0,6130,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,1747,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619509,,9606.0,6131,,Cytotoxicity against human A549 non small cell lung cell lines,,1003,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619510,,9606.0,6132,,Inhibition of cell growth in (A-549) lung cell line,,15313,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619511,,9606.0,6133,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,3122,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619512,,9606.0,6134,,In vitro antitumor activity against A-549 tumor cells.,,16049,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619513,,9606.0,6135,,In vitro antitumor effects against human A-549 cell lines.,,17134,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619514,,9606.0,6136,,In vitro cytotoxic activity of compound against A-549 cell line,,6406,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619515,,9606.0,6137,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,627,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619516,,9606.0,6138,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,12307,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884005,,9606.0,6139,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,17861,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619517,,9606.0,6140,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,6682,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619518,,9606.0,6141,,Inhibitory concentration of compound against A-549 cell line,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619519,,9606.0,6142,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,2454,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876489,,9606.0,6143,,cytotoxic activity against leukemia (A-549) cancer cell line,,14709,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619520,,9606.0,6144,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619521,,9606.0,6145,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,15718,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619522,,9606.0,6146,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619523,,9606.0,6147,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619524,,9606.0,6148,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619525,,9606.0,6149,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,17130,,A549,BAO_0000219
646.0,,,Intermediate,1,80682,F,N,,,,1,CHEMBL619526,,,6150,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,6630,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619527,,9606.0,6151,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,16726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619528,,9606.0,6152,,Cytotoxicity against A549 cells; No cytotoxicity,,17846,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619529,,9606.0,6153,,Cytotoxicity against human lung carcinoma (A549) cell lines,,3415,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619530,,9606.0,6154,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,3415,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876490,,9606.0,6155,,In vitro anticancer activity against human lung (A549) cell line,,5609,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619531,,9606.0,6156,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619532,,9606.0,6157,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619533,,9606.0,6158,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619534,,9606.0,6159,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620164,,9606.0,6160,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620165,,9606.0,6161,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620166,,9606.0,6162,,Inhibition of A549 human lung tumor cell proliferation,,16295,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620167,,9606.0,6163,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,16825,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL620168,,9606.0,6164,,In vitro cytotoxicity against human tumor cell line A549,,3439,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620338,,9606.0,6165,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,10870,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620339,,9606.0,6166,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,4845,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620340,,9606.0,6167,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,5822,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620341,,9606.0,6168,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,5822,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876491,,9606.0,6169,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,5822,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620342,,9606.0,6170,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620343,,9606.0,6171,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620344,,9606.0,6172,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620345,,9606.0,6173,,In vitro anticancer activity against human lung (A549) cell line,,5609,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620346,,9606.0,6174,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,4644,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620347,,9606.0,6175,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,4644,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620348,,9606.0,6176,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,4644,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620349,,9606.0,6177,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,4644,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL618667,,9606.0,6178,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,5822,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL618668,,9606.0,6179,,Percentage inhibition of human lung carcinoma (A549) cell lines,,3415,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876031,,9606.0,6180,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,16726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL618759,,9606.0,6181,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL618760,,9606.0,6182,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619000,,9606.0,6183,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619001,,9606.0,6184,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619002,,9606.0,6185,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619003,,9606.0,6186,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619597,,9606.0,6187,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619598,,9606.0,6188,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619599,,9606.0,6189,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619600,,9606.0,6190,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619601,,9606.0,6191,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,16726,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619602,,9606.0,6192,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619603,,9606.0,6193,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619604,,9606.0,6194,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619605,,9606.0,6195,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619606,,9615.0,6196,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876032,,9615.0,6197,,Pharmacokinetic activity (Cmax) in dog,,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619607,,9615.0,6198,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,4809,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619608,,9615.0,6199,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619609,,9615.0,6200,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,6251,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL619610,,9615.0,6201,,Cmax in dog plasma after 30mg/kg oral dose,,5932,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL619611,,9615.0,6202,,Tested for the peak blood level in dog,,4273,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619612,,9615.0,6203,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619613,,9615.0,6204,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,5313,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL619614,,9615.0,6205,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,6221,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619615,,9615.0,6206,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619616,,9615.0,6207,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,167,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL619617,,9615.0,6208,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,6241,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619618,,9615.0,6209,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,344,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL876033,,9615.0,6210,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,344,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619619,,9615.0,6211,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,344,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619620,,9615.0,6212,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,2189,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL619621,,9615.0,6213,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,2189,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL619622,,9615.0,6214,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,2189,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL618874,,9615.0,6215,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,2189,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618875,,9615.0,6216,,Absolute bioavailability was evaluated in dog,,4257,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618876,,9615.0,6217,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,6221,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618877,,9615.0,6218,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,6215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618878,,9615.0,6219,,Bioavailability in dog,,17267,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618879,,9615.0,6220,,Bioavailability in dog,,6621,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618880,,9615.0,6221,,Bioavailability after intravenous administration in dogs,,3854,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618881,,9615.0,6222,,Bioavailability after peroral administration in dogs,,3854,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618882,,9615.0,6223,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,5007,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624226,,9615.0,6224,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,4333,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL624227,,9615.0,6225,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,4333,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624228,,9615.0,6226,,Bioavailability,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624229,,9615.0,6227,,Bioavailability,,5199,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624230,,9615.0,6228,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,4368,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624231,,9615.0,6229,,Bioavailability in dog,,3771,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624232,,9615.0,6230,,Bioavailability in dog,,4953,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625127,,9615.0,6231,,Bioavailability in dog,,5064,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625128,,9615.0,6232,,Bioavailability in dog,,17657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621675,,9615.0,6233,,Bioavailability in dog,,17796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621676,,9615.0,6234,,Bioavailability in dog (p.o.) at 2.0 mpk,,17853,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621677,,9615.0,6235,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621678,,9615.0,6236,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621679,,9615.0,6237,,Bioavailability in dog,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621680,,9615.0,6238,,Bioavailability was evaluated after oral administration in dog,,16365,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621681,,9615.0,6239,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876740,,9615.0,6240,,Bioavailability was evaluated in dog,,1918,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621682,,9615.0,6241,,Bioavailability in dog,,4239,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621683,,9615.0,6242,,Bioavailability in dog,,6505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621684,,9615.0,6243,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,5334,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621685,,9615.0,6244,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,5334,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621686,,9615.0,6245,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,4809,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621687,,9615.0,6246,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621688,,9615.0,6247,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,6005,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621689,,9615.0,6248,,Bioavailability of compound in dog was determined after peroral administration,,17804,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621690,,9615.0,6249,,Oral bioavailability in dog,,3184,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621691,,9615.0,6250,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,1806,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875941,,9615.0,6251,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,1806,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621692,,9615.0,6252,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,1806,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621693,,9615.0,6253,,Bioavailability in dog,,4839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621694,,9615.0,6254,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,5017,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621695,,10090.0,6255,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621696,,10090.0,6256,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621697,,10090.0,6257,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621698,,10090.0,6258,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623420,,10090.0,6259,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623421,,10090.0,6260,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623422,,10090.0,6261,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623423,,10090.0,6262,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623424,,10090.0,6263,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623425,,10090.0,6264,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623426,,10090.0,6265,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623427,,10090.0,6266,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623428,,10090.0,6267,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL875947,,10090.0,6268,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623429,,10090.0,6269,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623430,,10090.0,6270,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL622588,,10090.0,6271,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL622589,,10090.0,6272,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL622751,,10090.0,6273,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL622752,,10090.0,6274,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,846,,,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622753,,10090.0,6275,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622647,,10090.0,6276,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875163,,10090.0,6277,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622648,,10090.0,6278,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622649,,10090.0,6279,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622650,,10090.0,6280,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622651,,10090.0,6281,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622652,,10090.0,6282,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622653,,10090.0,6283,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622654,,10090.0,6284,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL622655,,10090.0,6285,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL622656,,10090.0,6286,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL622657,,10090.0,6287,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL622658,,10090.0,6288,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL622659,,10090.0,6289,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL624630,,10090.0,6290,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL624631,,10090.0,6291,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL624632,,10090.0,6292,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624633,,9606.0,6293,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624634,,9606.0,6294,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624635,,9606.0,6295,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624636,,9606.0,6296,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,17130,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL857055,,9606.0,6297,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,3263,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624637,,9606.0,6298,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624638,,9606.0,6299,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL874366,,9606.0,6300,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624639,,9606.0,6301,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL624640,,9606.0,6302,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624641,,9606.0,6303,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624642,,9606.0,6304,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624643,,9606.0,6305,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624644,,9606.0,6306,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL624645,,9606.0,6307,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,6663,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619445,,9606.0,6308,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,3983,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL839886,,9606.0,6309,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,11141,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619446,,9606.0,6310,,Cytotoxic activity of compound against A-549 tumor cell line.,,5076,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619447,,9606.0,6311,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,3311,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619448,,9606.0,6312,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,3311,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619449,,9606.0,6313,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,3311,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619450,,9606.0,6314,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,5076,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619451,,9606.0,6315,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,4150,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619452,,9606.0,6316,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,2150,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619453,,9606.0,6317,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,4644,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL874367,,9606.0,6318,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,263,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619454,,9606.0,6319,,Cytotoxic concentration against A-549 tumor cells.,,11333,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619455,,9606.0,6320,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,11333,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619456,,9606.0,6321,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,15895,,A549,BAO_0000219
,,Acinetobacter baumannii,Expert,1,50191,F,N,,,,1,CHEMBL619457,,470.0,6322,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,16677,,,BAO_0000218
,,Acinetobacter calcoaceticus,Intermediate,1,50192,F,N,,,,1,CHEMBL619458,,471.0,6323,,Activity against Acinetobacter calcoaceticus (AC54),,10624,,,BAO_0000218
,,Aspergillus flavus,Expert,1,50274,F,N,,,,1,CHEMBL619459,,5059.0,6324,,In vitro antifungal activity against Aspergillus flavus CM74,,16717,,,BAO_0000218
,,Aspergillus flavus,Expert,1,50274,F,N,,,,1,CHEMBL619460,,5059.0,6325,,In vitro antifungal activity against Aspergillus flavus CM74,,16717,,,BAO_0000218
,,Aspergillus fumigatus,Intermediate,1,50416,F,N,,,,1,CHEMBL619461,,746128.0,6326,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,5513,,,BAO_0000218
,,Aspergillus fumigatus,Intermediate,1,50416,F,N,,,,1,CHEMBL619462,,746128.0,6327,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,15962,,,BAO_0000218
,,Aspergillus fumigatus,Intermediate,1,50416,F,N,,,,1,CHEMBL620388,,746128.0,6328,,Antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,,BAO_0000218
,,Aspergillus fumigatus,Intermediate,1,50416,F,N,,,,1,CHEMBL620389,,746128.0,6329,,Antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,,BAO_0000218
,,Aspergillus fumigatus,Intermediate,1,50416,F,N,,,,1,CHEMBL620390,,746128.0,6330,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,15962,,,BAO_0000218
,,Aspergillus fumigatus,Expert,1,50416,F,N,,,,1,CHEMBL620391,,746128.0,6331,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,16717,,,BAO_0000218
,,Aspergillus fumigatus,Expert,1,50416,F,N,,,,1,CHEMBL621073,,746128.0,6332,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,16717,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL621074,,1655.0,6333,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,8117,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL621075,,1656.0,6334,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,8117,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL619554,,6277.0,6335,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,15472,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL619555,,6277.0,6336,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,15472,,,BAO_0000218
,,Aggregatibacter actinomycetemcomitans,Intermediate,1,50169,F,N,,,,1,CHEMBL619556,,714.0,6337,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,16443,,,BAO_0000218
,,Aggregatibacter actinomycetemcomitans,Intermediate,1,50169,F,N,,,,1,CHEMBL619557,,714.0,6338,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,16443,,,BAO_0000218
,,Aggregatibacter actinomycetemcomitans,Intermediate,1,50169,F,N,,,,1,CHEMBL619558,,714.0,6339,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,16443,,,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619559,,9606.0,6340,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619560,,9606.0,6341,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619561,,9606.0,6342,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619562,,9606.0,6343,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619563,,9606.0,6344,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL857457,,9606.0,6345,,GI values against A549 cells (lung cancer),,16381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619564,,9606.0,6346,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,17206,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619565,,9606.0,6347,,Inhibitory activity against A549 human adenocarcinoma,,16325,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619566,,9606.0,6348,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,10708,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619567,,9606.0,6349,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,10708,,A549,BAO_0000218
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619568,,9606.0,6350,,Inhibitory activity against A549 lung adenocarcinoma cell line,,17376,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619569,,9606.0,6351,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,17376,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619570,,9606.0,6352,,Cytotoxicity against human A549 lung cells,,17488,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619571,,9606.0,6353,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,17404,,A549,BAO_0000218
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619572,,9606.0,6354,,Growth inhibition of A549 (human lung carcinoma) cell line.,,10958,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619573,,9606.0,6355,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,17099,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619574,,9606.0,6356,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,17099,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619575,,9606.0,6357,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,4096,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL619576,,9606.0,6358,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,4096,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619577,,9606.0,6359,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,4096,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619578,,9606.0,6360,,In vitro inhibitory activity against A549 tumor cell culture,,2525,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884009,,9606.0,6361,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,2525,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619579,,9606.0,6362,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,5302,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619580,,9606.0,6363,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,16325,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619581,,9606.0,6364,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,16939,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619582,,9606.0,6365,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,17229,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619583,,9606.0,6366,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,17380,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL876502,,9606.0,6367,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,17380,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619584,,9606.0,6368,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,1903,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619585,,9606.0,6369,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,3838,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619586,,9606.0,6370,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,14696,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619587,,9606.0,6371,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,3838,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619588,,9606.0,6372,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,1522,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619589,,9606.0,6373,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,12400,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619590,,9606.0,6374,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,14696,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619591,,9606.0,6375,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,14769,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619592,,9606.0,6376,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,14696,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL619593,,9606.0,6377,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,1888,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620217,,9606.0,6378,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,12016,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620218,,9606.0,6379,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,6058,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620219,,9606.0,6380,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,17708,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL620220,,9606.0,6381,,Antitumor activity against A549/ATCC cell line,,12301,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL625141,,9606.0,6382,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,11970,,A549,BAO_0000219
646.0,,Homo sapiens,Expert,1,80682,F,N,,,,1,CHEMBL625142,,9606.0,6383,,In vitro cytotoxicity against A549/ATCC cell line.,,11818,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL625143,,9606.0,6384,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,12400,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL625144,,9606.0,6385,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,3381,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL622474,,9606.0,6386,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,17376,,A549,BAO_0000219
646.0,,Homo sapiens,Intermediate,1,80682,F,N,,,,1,CHEMBL884104,,9606.0,6387,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,10708,,A549,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL622475,,9606.0,6388,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,2964,,,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL622476,,9615.0,6389,,Compound was tested for oral bioavailability in dogs,,5005,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875831,,9615.0,6390,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,6229,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622477,,9615.0,6391,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,6229,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622478,,9615.0,6392,,Oral bioavailability in dog,,5374,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623172,,9615.0,6393,,Compound was tested for the oral bioavailability in dog; No availability,,5374,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623173,,9615.0,6394,,Oral bioavailability in dog (dose 5 mg/kg),,6265,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623174,,9615.0,6395,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,5654,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623175,,9615.0,6396,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,5654,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623340,,9615.0,6397,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,16456,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623341,,9615.0,6398,,Oral bioavailability in dog (dose 5 mg/kg),,5302,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623342,,9615.0,6399,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,3624,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623343,,9615.0,6400,,Oral bioavailability of active FTIs in dogs,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623344,,9615.0,6401,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,5802,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,A,N,In vivo,,,1,CHEMBL623345,,9615.0,6402,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875832,,9615.0,6403,,Oral bioavailability in dog,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623346,,9615.0,6404,,Oral bioavailability in dog,,6762,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623347,,9615.0,6405,,Oral bioavailability in dog,,6821,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623348,,9615.0,6406,,Oral bioavailability of compound was determined in dog; Not tested,,6821,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623349,,9615.0,6407,,Oral bioavailability in dog,,5210,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623350,,9615.0,6408,,Oral bioavailability (10 mg/kg) was determined in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623351,,9615.0,6409,,Oral bioavailability,,761,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623352,,9615.0,6410,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,761,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623353,,9615.0,6411,,Oral bioavailability administered in solution in rats,,761,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875833,,9615.0,6412,,Oral bioavailability after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623354,,9615.0,6413,,Oral bioavailability at a dose of 1 mg/kg in dogs,,5474,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623355,,9615.0,6414,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623356,,9615.0,6415,,Oral bioavailability in Dog; ND = not determined,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623357,,9615.0,6416,,Oral bioavailability in dog,,3352,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623358,,9615.0,6417,,Oral bioavailability in dog,,6168,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623359,,9615.0,6418,,Oral bioavailability in dog,,5988,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623360,,9615.0,6419,,Oral bioavailability in dog,,4942,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623361,,9615.0,6420,,Oral bioavailability in dogs; No data,,4942,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623362,,9615.0,6421,,Oral bioavailability measured in dogs,,14541,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623363,,9615.0,6422,,Oral bioavailability in dog,,4449,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623364,,9615.0,6423,,Oral bioavailability was calculated in dog,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875834,,9615.0,6424,,Oral bioavailability after 0.3 mg/kg po administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623365,,9615.0,6425,,Oral bioavailability in dog (i.v. dosing),,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623366,,9615.0,6426,,Oral bioavailability in dog,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623367,,9615.0,6427,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,5546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623368,,9615.0,6428,,Oral bioavailability in Beagle dogs,,4514,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623369,,9615.0,6429,,Oral bioavailability in dog,,3624,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623370,,9615.0,6430,,Oral bioavailability in dog,,3854,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623371,,9615.0,6431,,Oral bioavailability in dog,,5836,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623372,,9615.0,6432,,Oral bioavailability in dog,,5940,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621351,,9615.0,6433,,Oral bioavailability in dog,,6168,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621352,,9615.0,6434,,Oral bioavailability in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621353,,9615.0,6435,,Oral bioavailability in dog,,6251,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621354,,9615.0,6436,,Oral bioavailability in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621355,,9615.0,6437,,Oral bioavailability in dog,,6647,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621356,,9615.0,6438,,Oral bioavailability in dog,,5940,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621357,,9615.0,6439,,Oral bioavailability in dog,,933,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621358,,9615.0,6440,,Oral bioavailability in dog,,5210,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621359,,9615.0,6441,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621360,,9615.0,6442,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,6641,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621361,,9615.0,6443,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621362,,9615.0,6444,,Oral bioavailability in dog,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621363,,9615.0,6445,,Oral bioavailability in dog,,5985,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621364,,9615.0,6446,,Oral bioavailability in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621166,,9615.0,6447,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,5530,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621167,,9615.0,6448,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,5530,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621168,,9615.0,6449,,Oral bioavailability (F) in dogs,,6305,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621169,,9615.0,6450,,Oral bioavailability in dog,,5210,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875950,,9615.0,6451,,Bioavailability in dog,,5238,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621170,,9615.0,6452,,Oral bioavailability in dog (dose 10 mg/kg),,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621171,,9615.0,6453,,Oral bioavailability after peroral administration at 5 mpk in Dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621172,,9615.0,6454,,Oral bioavailability in dog (dose 5 mg/kg),,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621173,,9615.0,6455,,Oral bioavailability in dog (dose 10 mg/kg),,6084,,,BAO_0000218
42.0,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL621174,,10090.0,6456,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL621175,,10090.0,6457,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621176,,10090.0,6458,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621177,,10090.0,6459,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621178,,10090.0,6460,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621179,,10090.0,6461,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621180,,10090.0,6462,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL875951,,10090.0,6463,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL621181,,10090.0,6464,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL621182,,10090.0,6465,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL621183,,10090.0,6466,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL621184,,10090.0,6467,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621185,,10090.0,6468,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621186,,10090.0,6469,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621187,,10090.0,6470,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621188,,10090.0,6471,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621189,,10090.0,6472,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL621190,,10090.0,6473,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL618520,,10090.0,6474,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL621739,,10090.0,6475,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL621740,,10090.0,6476,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL621741,,10090.0,6477,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621742,,10090.0,6478,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621743,,10090.0,6479,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621744,,10090.0,6480,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621745,,10090.0,6481,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621746,,10090.0,6482,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621747,,10090.0,6483,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621748,,10090.0,6484,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621749,,10090.0,6485,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621750,,10090.0,6486,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621751,,10090.0,6487,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL621752,,10090.0,6488,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL621753,,10090.0,6489,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL875955,,10090.0,6490,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL621754,,10090.0,6491,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Heart,Mus musculus,Intermediate,1,50594,A,N,,,948.0,1,CHEMBL621755,,10090.0,6492,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL621756,,10090.0,6493,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL624199,,10090.0,6494,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL624200,,10090.0,6495,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL624375,,10090.0,6496,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL624376,,10090.0,6497,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL624377,,10090.0,6498,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL624378,,10090.0,6499,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
,,aeinetobacter anitrotap,Intermediate,1,50067,F,N,,,,1,CHEMBL857901,,107673.0,6500,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,,BAO_0000218
,,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,1,50067,F,N,,,,1,CHEMBL875274,,107673.0,6501,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,,BAO_0000218
,,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,1,50067,F,N,,,,1,CHEMBL624379,,107673.0,6502,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,,BAO_0000218
,,aeinetobacter anitrotap,Intermediate,1,50067,F,N,,,,1,CHEMBL624380,,107673.0,6503,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,12269,,,BAO_0000218
,,Acinetobacter calcoaceticus,Intermediate,1,50192,F,N,,,,1,CHEMBL624381,,471.0,6504,,Activity against Acinetobacter calcoaceticus (AC54),,10624,,,BAO_0000218
,,Anolis carolinensis,Intermediate,1,50714,F,N,,,,1,CHEMBL624382,,28377.0,6505,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,17216,,,BAO_0000218
,,Anolis carolinensis,Intermediate,1,50714,F,N,,,,1,CHEMBL624383,,28377.0,6506,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,17216,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624384,,1655.0,6507,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624385,,1655.0,6508,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624386,,1655.0,6509,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624387,,1655.0,6510,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624388,,1655.0,6511,,Plaque bactericidal index against Actinomyces naeslundii 631,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624389,,1655.0,6512,,Plaque bactericidal index against Actinomyces naeslundii N/9,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL624390,,1655.0,6513,,Plaque bactericidal index against Actinomyces naeslundii B74,,9560,,,BAO_0000218
,,Actinomyces naeslundii,Intermediate,1,50296,F,N,,,,1,CHEMBL875275,,1655.0,6514,,Plaque bactericidal index against Actinomyces naeslundii N/3,,9560,,,BAO_0000218
,,Artemia salina,Intermediate,1,50056,F,N,,,,1,CHEMBL624391,,85549.0,6515,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,114,,,BAO_0000218
,,Artemia salina,Intermediate,1,50056,F,N,,,,1,CHEMBL623636,,85549.0,6516,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,114,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623637,,6253.0,6517,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623638,,6253.0,6518,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623639,,6253.0,6519,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623640,,6253.0,6520,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623641,,6253.0,6521,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623642,,6253.0,6522,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623643,,6253.0,6523,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623644,,6253.0,6524,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623645,,6253.0,6525,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623646,,6253.0,6526,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623647,,6253.0,6527,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,10841,,,BAO_0000218
,,Ascaris suum,Intermediate,1,50532,F,N,,,,1,CHEMBL623648,,6253.0,6528,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,10841,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623649,,1656.0,6529,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,8117,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623650,,1656.0,6530,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,8117,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623651,,1656.0,6531,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,9560,,,BAO_0000218
,,Actinomyces viscosus,Expert,1,50366,F,N,,,,1,CHEMBL623652,,1656.0,6532,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623653,,1656.0,6533,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623654,,1656.0,6534,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623655,,1656.0,6535,,Plaque bactericidal index against Actinomyces viscosus 8A06,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623656,,1656.0,6536,,Plaque bactericidal index against Actinomyces viscosus M-100,,9560,,,BAO_0000218
,,Actinomyces viscosus,Expert,1,50366,F,N,,,,1,CHEMBL623657,,1656.0,6537,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623658,,1656.0,6538,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623659,,1656.0,6539,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623660,,1656.0,6540,,Plaque bactericidal index against Actinomyces viscosus 626,,9560,,,BAO_0000218
,,Actinomyces viscosus,Intermediate,1,50366,F,N,,,,1,CHEMBL623661,,1656.0,6541,,Plaque bactericidal index against Actinomyces viscosus T14V,,9560,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL875281,,6277.0,6542,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL623662,,6277.0,6543,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL623663,,6277.0,6544,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL623664,,6277.0,6545,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL623665,,6277.0,6546,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
165.0,,Homo sapiens,Intermediate,1,80023,F,N,,,,1,CHEMBL621856,,9606.0,6547,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,10708,,A673,BAO_0000219
645.0,,Homo sapiens,Intermediate,1,80661,F,N,,,,1,CHEMBL620432,,9606.0,6548,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,10708,,A704,BAO_0000219
,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL620433,,10116.0,6549,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,416,,,BAO_0000219
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL620434,,10090.0,6550,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,14354,,A9,BAO_0000219
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL620435,,10090.0,6551,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,14354,,A9,BAO_0000219
625.0,,Homo sapiens,Intermediate,1,80024,F,N,,,,1,CHEMBL620436,,9606.0,6552,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,5116,,A9,BAO_0000219
625.0,,Homo sapiens,Intermediate,1,80024,F,N,,,,1,CHEMBL876597,,9606.0,6553,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,5116,,A9,BAO_0000219
874.0,,Homo sapiens,Expert,1,81037,F,N,,,,1,CHEMBL620437,,9606.0,6554,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,15694,,Human ovarian carcinoma cell line,BAO_0000219
625.0,,Mus musculus,Expert,1,80024,F,N,,,,1,CHEMBL620438,,10090.0,6555,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,13038,,A9,BAO_0000219
625.0,,Mus musculus,Expert,1,80024,F,N,,,,1,CHEMBL620439,,10090.0,6556,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,13038,,A9,BAO_0000219
625.0,,Mus musculus,Expert,1,80024,F,N,,,,1,CHEMBL619657,,10090.0,6557,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,10923,,A9,BAO_0000219
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL619658,,10090.0,6558,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,10923,,A9,BAO_0000219
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL619659,,10090.0,6559,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,10923,,A9,BAO_0000219
,,,Expert,1,10649,F,H,,,,8,CHEMBL619660,,,6560,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,10923,,,BAO_0000019
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL619661,,10090.0,6561,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,10923,,A9,BAO_0000219
625.0,,Mus musculus,Intermediate,1,80024,F,N,,,,1,CHEMBL619662,,10090.0,6562,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,10923,,A9,BAO_0000219
975.0,,Cricetulus griseus,Intermediate,1,80663,F,N,,,,1,CHEMBL619663,,10029.0,6563,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,8158,,AA6,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL619664,,9606.0,6564,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,15494,,,BAO_0000219
,,Homo sapiens,Autocuration,1,22226,F,U,,,,0,CHEMBL619665,,9606.0,6565,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,15494,,,BAO_0000219
974.0,,Homo sapiens,Intermediate,1,80662,F,N,,,,1,CHEMBL883244,,9606.0,6566,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,12348,,AA5,BAO_0000219
974.0,,Homo sapiens,Intermediate,1,80662,F,N,,,,1,CHEMBL884011,,9606.0,6567,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,12348,,AA5,BAO_0000219
974.0,,Homo sapiens,Intermediate,1,80662,F,N,,,,1,CHEMBL619666,,9606.0,6568,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,2726,,AA5,BAO_0000219
379.0,,Homo sapiens,Intermediate,1,80566,F,N,,,,1,CHEMBL619667,,9606.0,6569,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,2726,,U-937,BAO_0000219
274.0,,Cricetulus griseus,Intermediate,1,80578,F,N,,,,1,CHEMBL619668,,10029.0,6570,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,10747,,UV4,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL619669,,10029.0,6571,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,11005,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL876608,,10029.0,6572,,Average intracellular compound concentration when the hypoxic SER=1.6,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619670,,10029.0,6573,,Average intracellular compound concentration when the hypoxic SER=1.6.,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619671,,10029.0,6574,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619672,,10029.0,6575,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619673,,10029.0,6576,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619674,,10029.0,6577,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,13436,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619675,,10029.0,6578,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,13435,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619676,,10029.0,6579,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,13302,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL619677,,10029.0,6580,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL619678,,10029.0,6581,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL619679,,10029.0,6582,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,A,N,,,,1,CHEMBL619680,,10029.0,6583,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,12878,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL621457,,10029.0,6584,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,12878,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL876609,,10029.0,6585,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,14367,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL621458,,10029.0,6586,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,14367,,CHO-AA8,BAO_0000219
185.0,,hampster,Expert,1,80089,F,N,,,,1,CHEMBL621459,,36483.0,6587,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,12398,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL621460,,10029.0,6588,,Aerobic growth inhibition in Chinese hamster cell line AA8,,12878,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL621461,,10029.0,6589,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,13820,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL621462,,10029.0,6590,,Inhibition of growth under aerobic conditions in AA8 cells,,13436,,CHO-AA8,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621463,,9615.0,6591,,Oral bioavailability in dog (dose 10 mg/kg),,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621464,,9615.0,6592,,Oral bioavailability in dog at 10 mg/kg of the compound,,5711,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621465,,9615.0,6593,,Oral bioavailability in dog (dose 5 uM/kg),,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621466,,9615.0,6594,,Oral bioavailability in dog (dose 5 uM/kg),,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621467,,9615.0,6595,,Oral bioavailability in dog (mongrel),,17800,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621468,,9615.0,6596,,Oral bioavailability in dog (dose 10 mg/kg),,3994,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,F,N,In vivo,,,1,CHEMBL876734,,9615.0,6597,,Oral bioavailability in dog (dose 10 mg/kg),,3994,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618476,,9615.0,6598,,Bioavailability in dog,,5145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618477,,9615.0,6599,,Bioavailability in dog (dose 1 mg/kg i.v.),,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618478,,9615.0,6600,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618479,,9615.0,6601,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618480,,9615.0,6602,,Bioavailability in dog,,4273,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618481,,9615.0,6603,,Bioavailability in dog (dose 3-10 mg/kg),,12500,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL618482,,9615.0,6604,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,12500,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618483,,9615.0,6605,,Oral bioavailability in dog,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618484,,9615.0,6606,,Oral bioavailability in dog,,3880,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618485,,9615.0,6607,,Bioavailability in dog,,4838,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618486,,9615.0,6608,,oral bioavailability was measured in dogs,,15600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618487,,9615.0,6609,,Compound was tested for plasma protein binding in dog; Not determined,,17248,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618488,,9615.0,6610,,Compound was tested for plasma protein binding of dog,,17248,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL876735,,9615.0,6611,,Compound was tested for plasma protein binding of dog; Not determined,,17248,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618489,,9615.0,6612,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,17443,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618490,,9615.0,6613,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,4186,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618491,,9615.0,6614,,Half life was determined,,3749,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618492,,9615.0,6615,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,3249,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL873354,,9615.0,6616,,Half life was evaluated in dog,,3022,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618493,,9615.0,6617,,Half life was determined,,3749,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618494,,9615.0,6618,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,Heart,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,948.0,1,CHEMBL618495,,9615.0,6619,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,Kidney,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,2113.0,1,CHEMBL618496,,9615.0,6620,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,2107.0,1,CHEMBL618497,,9615.0,6621,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,Lung,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,2048.0,1,CHEMBL618498,,9615.0,6622,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,Spleen,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,2106.0,1,CHEMBL618499,,9615.0,6623,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,2517,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL876736,,9615.0,6624,,LogP in dog,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618500,,9615.0,6625,,Partition coefficient (logP),,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL857831,,9615.0,6626,,Partition coefficient in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618501,,9615.0,6627,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618502,,9615.0,6628,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,4809,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618503,,9615.0,6629,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618504,,9615.0,6630,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,14294,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618505,,9615.0,6631,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,14294,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618506,,9615.0,6632,,Metabolism of compound in dog S9 microsomes; Trace,,14294,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2107.0,1,CHEMBL618507,,9615.0,6633,,In vitro metabolic potential in dog liver microsomes,,6251,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876737,,9615.0,6634,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,3748,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618508,,9615.0,6635,,Oral bioavailability in dog,,2713,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618509,,9615.0,6636,,Oral bioavailability in dog,,6512,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618510,,9615.0,6637,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618511,,9615.0,6638,,The compound was tested for bioavailability in dogs,,3749,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618512,,9615.0,6639,,The compound was tested for oral bioavailability in dogs,,3749,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618513,,9615.0,6640,,Oral bioavailability in dog,,6742,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618514,,9615.0,6641,,Compound was tested for percent protein binding (PB) in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620052,,9615.0,6642,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,6874,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL620053,,9615.0,6643,,Compound was evaluated for plasma clearance.,,2877,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL620054,,9615.0,6644,,The compound was tested for plasma clearance in dog,,12500,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL620055,,9615.0,6645,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL620056,,9615.0,6646,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2107.0,1,CHEMBL620057,,9615.0,6647,,In vitro relative rate of metabolism was determined in dog liver microsomes,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618939,,9615.0,6648,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618940,,9615.0,6649,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618941,,9615.0,6650,,Half life after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL624473,,10090.0,6651,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL624474,,10090.0,6652,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL624475,,10090.0,6653,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624476,,10090.0,6654,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623478,,10090.0,6655,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623479,,10090.0,6656,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623480,,10090.0,6657,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,6599,,CCRF S-180,BAO_0000218
42.0,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623481,,10090.0,6658,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,6599,,CCRF S-180,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL623482,,10090.0,6659,,C2 in brain of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL623483,,10090.0,6660,,C2 in kidney of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL623484,,10090.0,6661,,C2 in liver of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,,,2048.0,1,CHEMBL623485,,10090.0,6662,,C2 in lungs of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL623486,,10090.0,6663,,C2 in spleen of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623487,,10090.0,6664,,Plasma clearance in mouse,,17852,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623488,,10090.0,6665,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623489,,10090.0,6666,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL875157,,10090.0,6667,,Clearance was evaluated in mice after intravenous administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623490,,10090.0,6668,,Clearance was evaluated in mice after oral administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623491,,10090.0,6669,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,4239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623492,,10090.0,6670,,Plasma clearance of compound was determined at 40 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623493,,10090.0,6671,,Plasma clearance of at 24 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623494,,10090.0,6672,,Plasma clearance at 24 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623495,,10090.0,6673,,Plasma clearance at 5 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623496,,10090.0,6674,,Plasma clearance in mice,,5727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623497,,10090.0,6675,,Plasma clearance value upon iv administration in mouse,,2862,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623498,,10090.0,6676,,Total plasma clearance in mice,,5980,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623499,,10090.0,6677,,Clearance in mouse,,17592,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623500,,10090.0,6678,,Clearance value was determined,,17718,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623501,,10090.0,6679,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,,Intermediate,1,22229,P,U,,,,0,CHEMBL875158,,,6680,,Calculated partition coefficient (clogP),,17384,,,BAO_0000100
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623502,,10090.0,6681,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623503,,10090.0,6682,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623504,,10090.0,6683,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623505,,10090.0,6684,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623506,,10090.0,6685,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623507,,10090.0,6686,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623508,,10090.0,6687,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623509,,10090.0,6688,,Cmax after oral administration at 30 mg/kg in ICR mouse,,5781,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL875159,,10090.0,6689,,Cmax after peroral administration in mice at 2.4 uM/kg,,17764,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL623510,,10090.0,6690,,Cmax in brain of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL623511,,10090.0,6691,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623512,,10090.0,6692,,Cmax in liver of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623513,,10090.0,6693,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL623514,,10090.0,6694,,Cmax in mice at 18 uM/kg i.p. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL622609,,10090.0,6695,,Cmax in mice at 23 uM/kg i.v. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL622610,,10090.0,6696,,Cmax in mice at 24 uM/kg i.p. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL621823,,10090.0,6697,,Cmax in mice at 25 uM/kg i.p. administration,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,In vivo,,,1,CHEMBL621824,,10090.0,6698,,Cmax in mice at 26 uM/kg i.p. administration,,17764,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL621825,,10090.0,6699,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,17641,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621826,,10090.0,6700,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621827,,10090.0,6701,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621828,,10090.0,6702,,Cmax value was determined,,5727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621829,,10090.0,6703,,Cmax value in IRC mice,,5951,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621830,,10090.0,6704,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL621831,,10090.0,6705,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,5506,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL621832,,10090.0,6706,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,14239,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL624579,,10090.0,6707,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,4890,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624580,,10090.0,6708,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,429,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL624581,,6277.0,6709,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL624582,,6277.0,6710,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
,,Acanthocheilonema viteae,Intermediate,1,50535,F,N,,,,1,CHEMBL624583,,6277.0,6711,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,10986,,,BAO_0000218
455.0,,Homo sapiens,Intermediate,1,80018,F,N,,,,1,CHEMBL624584,,9606.0,6712,,Inhibitory activity against human tumor cell line A0375 melanoma.,,13227,,A-375,BAO_0000219
,,Rattus norvegicus,Expert,1,12512,B,D,,,,9,CHEMBL624585,,10116.0,6713,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Brain membranes,4481,,,BAO_0000249
,,Homo sapiens,Expert,1,114,F,D,,,,9,CHEMBL875165,,9606.0,6714,,Forskolin-induced cAMP production at human A1 adenosine receptor,,16931,,,BAO_0000019
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619490,,,6715,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619491,,,6716,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL619492,,,6717,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL619493,,,6718,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619494,,,6719,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619495,,,6720,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619496,,,6721,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,Homo sapiens,Expert,1,114,F,D,,,,9,CHEMBL619497,,9606.0,6722,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619498,,,6723,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619499,,,6724,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL619500,,,6725,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619501,,,6726,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL619502,,,6727,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619503,,,6728,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL619504,,,6729,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL621298,,,6730,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL621299,,,6731,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL621300,,,6732,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
449.0,,,Autocuration,1,114,F,H,,,,8,CHEMBL621301,,,6733,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,3850,,CHO,BAO_0000219
449.0,,,Expert,1,114,F,H,,,,8,CHEMBL621302,,,6734,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,3850,,CHO,BAO_0000219
164.0,,Oryctolagus cuniculus,Intermediate,1,80013,F,N,,,,1,CHEMBL621303,,9986.0,6735,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,12680,,A10,BAO_0000219
164.0,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL621304,,10116.0,6736,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,1313,,A10,BAO_0000219
164.0,,Rattus norvegicus,Autocuration,1,22226,F,U,,,,0,CHEMBL621305,,10116.0,6737,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,1313,,A10,BAO_0000219
164.0,,Rattus norvegicus,Intermediate,1,80013,F,N,,,,1,CHEMBL621306,,10116.0,6738,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,17567,,A10,BAO_0000219
164.0,,Rattus norvegicus,Intermediate,1,80013,F,N,,,,1,CHEMBL618444,,10116.0,6739,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,17567,,A10,BAO_0000219
164.0,,Rattus norvegicus,Intermediate,1,80013,F,N,,,,1,CHEMBL618445,,10116.0,6740,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,11819,,A10,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618446,,10029.0,6741,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,13436,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618447,,10029.0,6742,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618448,,10029.0,6743,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,12651,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618449,,10029.0,6744,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,13300,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618637,,10029.0,6745,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,15296,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618638,,10029.0,6746,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,15328,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618639,,10029.0,6747,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,13302,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL618640,,10029.0,6748,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,14367,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL618641,,10029.0,6749,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,17002,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618642,,10029.0,6750,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,13436,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL618643,,10029.0,6751,,Inhibitory activity against aerobic growth of AA8 cells.,,13435,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL884013,,10029.0,6752,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL622723,,10029.0,6753,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622724,,10029.0,6754,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,10503,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL622725,,10029.0,6755,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,15090,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL622726,,10029.0,6756,,Cytotoxicity against AA8 cell line,,10368,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622727,,10029.0,6757,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,12651,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL622728,,10029.0,6758,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622729,,10029.0,6759,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,A,N,,,,1,CHEMBL622730,,10029.0,6760,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,12687,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622731,,10029.0,6761,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,1890,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622732,,10029.0,6762,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10747,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Intermediate,1,80089,F,N,,,,1,CHEMBL622733,,10029.0,6763,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,10747,,CHO-AA8,BAO_0000219
,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL622734,,10029.0,6764,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,11616,,,BAO_0000218
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL622735,,10029.0,6765,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,11616,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618746,,10029.0,6766,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618747,,10029.0,6767,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL620540,,10029.0,6768,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL620541,,10029.0,6769,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL620542,,10029.0,6770,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL620543,,10029.0,6771,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618832,,10029.0,6772,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,3471,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL618833,,10029.0,6773,,Concentration required to reduce AA8 cell survival by 10%,,11616,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618834,,10029.0,6774,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,2656,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618835,,10029.0,6775,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618836,,10029.0,6776,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618837,,10029.0,6777,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618838,,10029.0,6778,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618839,,10029.0,6779,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,16156,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618840,,10029.0,6780,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,2656,,CHO-AA8,BAO_0000219
,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618841,,10029.0,6781,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,11005,,,BAO_0000019
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618842,,10029.0,6782,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,11942,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL618843,,10029.0,6783,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,2128,,CHO-AA8,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618844,,9615.0,6784,,Half life period after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618845,,9615.0,6785,,Half life period after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618846,,9615.0,6786,,Half life was measured after oral 2b administration (tested in 6 dogs),,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618847,,9615.0,6787,,Half life was measured in dog after oral 17b administration,,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618848,,9615.0,6788,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618849,,9615.0,6789,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,9579,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618850,,9615.0,6790,,Tmax value after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618851,,9615.0,6791,,Tmax value after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873815,,9615.0,6792,,Compound was evaluated for its half life when administered intravenously in dog,,3184,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL618852,,9615.0,6793,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,5017,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618853,,9615.0,6794,,Elimination Half-life of compound was determined in dog,,6821,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618854,,9615.0,6795,,Half life of compound in dog following oral administration,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618855,,9615.0,6796,,Half life of compound was determined in dog,,17267,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,,,178.0,1,CHEMBL618856,,9615.0,6797,,Half life of compound was determined in dog blood,,4727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875827,,9615.0,6798,,Half life after oral and iv dosing in dogs,,5238,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618857,,9615.0,6799,,Half life in dogs in hours,,4942,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618858,,9615.0,6800,,Half life on i.v. administration of 2 mg/kg was measured in dog,,6505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618859,,9615.0,6801,,t1/2 in dog after oral dose (1 mg/kg),,5130,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618860,,9615.0,6802,,Half life was evaluated in dog,,1475,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618861,,9615.0,6803,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,17804,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622539,,9615.0,6804,,Half life period of compound was determined after peroral administration at 2 mg/kg,,17804,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622540,,9615.0,6805,,Half life period (10 mg/kg) was determined in dog,,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873803,,9615.0,6806,,Half life period (10 mg/kg) was determined in dog,,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873804,,9615.0,6807,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624311,,9615.0,6808,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624312,,9615.0,6809,,Half life period in dog,,6084,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624313,,9615.0,6810,,Half life period in dogs after oral administration at 1 mg/kg,,6241,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624314,,9615.0,6811,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624315,,9615.0,6812,,Half-life of compound was determined in dogs,,6621,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624316,,9615.0,6813,,Half-life in dog plasma,,1696,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624317,,9615.0,6814,,Half-life in mongrel dogs was determined,,17800,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624318,,9615.0,6815,,Half-life in dog upon oral administration,,17657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624319,,9615.0,6816,,Half-life in dog upon oral administration; Unable to calculate,,17657,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624496,,9615.0,6817,,Half-life was measured in dog,,4239,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624497,,9615.0,6818,,Half-life was measured in dog,,5985,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624498,,9615.0,6819,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,9932,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624499,,9615.0,6820,,Oral half life was determined,,5199,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL624500,,9615.0,6821,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,5199,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL624501,,9615.0,6822,,Plasma half life was evaluated,,1475,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623666,,9615.0,6823,,Plasma half life was evaluated in Dog,,1475,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623667,,9615.0,6824,,Plasma half life was evaluated in dog,,1475,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623668,,9615.0,6825,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,6316,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623669,,9615.0,6826,,Tested for the half life value in dog,,4883,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623670,,9615.0,6827,,Maximum time at the dose of 2 mg/kg in dog,,4727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623671,,9615.0,6828,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL875945,,9615.0,6829,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL623672,,9615.0,6830,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623673,,9615.0,6831,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,6265,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623674,,9615.0,6832,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,4809,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623675,,9615.0,6833,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,5983,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL872526,,9615.0,6834,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,5313,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623676,,9615.0,6835,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,5313,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623677,,9615.0,6836,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,17650,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623678,,9615.0,6837,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,5199,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL623679,,9615.0,6838,,Time taken for maximum plasma concentration in dog,,933,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623680,,9615.0,6839,,Time to reach Cmax after oral administration to dogs,,16367,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623681,,9615.0,6840,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623682,,9615.0,6841,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,6316,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623683,,9615.0,6842,,Tmax after peroral administration (1 mg/kg) was determined in dog,,6215,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,A,N,In vivo,,,1,CHEMBL623684,,9615.0,6843,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622745,,9615.0,6844,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622746,,9615.0,6845,,Tmax after peroral administration in dogs at 2.4 uM/kg,,17764,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622747,,10090.0,6846,,In vivo Cmax in mice at dose of 100 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622748,,10090.0,6847,,In vivo Cmax in mice at dose of 50 mg/kg,,5969,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622749,,10090.0,6848,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,4573,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL622750,,10090.0,6849,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,3277,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623411,,10090.0,6850,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL875946,,10090.0,6851,,Maximum concentration obtained in mouse plasma was determined,,3132,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623412,,10090.0,6852,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,3132,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623413,,10090.0,6853,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623414,,10090.0,6854,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,17729,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623415,,10090.0,6855,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,17729,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623416,,10090.0,6856,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,17729,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623417,,10090.0,6857,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,17728,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623418,,10090.0,6858,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,17728,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623419,,10090.0,6859,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622816,,10090.0,6860,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,4066,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623313,,10090.0,6861,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,6178,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623314,,10090.0,6862,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,6178,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876788,,10090.0,6863,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623315,,10090.0,6864,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623316,,10090.0,6865,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623317,,10090.0,6866,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623319,,10090.0,6868,,Cmax in male mice after 2 mg/kg oral dose,,5961,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623320,,10090.0,6869,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,6137,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623321,,10090.0,6870,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,3802,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623322,,10090.0,6871,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,3535,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623323,,10090.0,6872,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,3535,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623324,,10090.0,6873,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,3535,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623325,,10090.0,6874,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,3535,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623326,,10090.0,6875,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,3535,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623327,,10090.0,6876,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,3535,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL623328,,10090.0,6877,,Maximum concentration in plasma upon oral administration in mouse,,2862,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL623329,,10090.0,6878,,Maximum plasma concentration was evaluated in mice after oral administration,,2675,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623330,,10090.0,6879,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL876789,,10090.0,6880,,Dose at which the compound induced fecal excretion in mice,,5399,,,BAO_0000218
164.0,,Rattus norvegicus,Expert,1,80013,F,N,,,,1,CHEMBL623333,,10116.0,6893,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,11819,,A10,BAO_0000219
164.0,,Rattus norvegicus,Expert,1,80013,F,N,,,,1,CHEMBL623334,,10116.0,6894,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,11819,,A10,BAO_0000219
164.0,,Rattus norvegicus,Expert,1,80013,F,N,,,,1,CHEMBL627536,,10116.0,6895,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,11819,,A10,BAO_0000219
164.0,,Rattus norvegicus,Expert,1,80013,F,N,,,,1,CHEMBL627537,,10116.0,6896,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,11819,,A10,BAO_0000219
164.0,,Rattus norvegicus,Intermediate,1,80013,F,N,,,,1,CHEMBL627538,,10116.0,6897,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,16361,,A10,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL884106,,9606.0,6898,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,2288,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625294,,9606.0,6899,,Anticancer activity against human ovarian carcinoma A121 cells,,10404,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625295,,9606.0,6900,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,14790,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625296,,9606.0,6901,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,14790,,A121,BAO_0000219
393.0,,Homo sapiens,Expert,1,80655,F,N,,,,1,CHEMBL625297,,9606.0,6902,,Growth inhibition of human ovarian carcinoma (A121) cell line,,14253,,A121,BAO_0000219
393.0,,Homo sapiens,Expert,1,80655,F,N,,,,1,CHEMBL625298,,9606.0,6903,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,13617,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625960,,9606.0,6904,,Cytotoxicity against human A121 ovarian cells,,1003,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625961,,9606.0,6905,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,830,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL625962,,9606.0,6906,,In vitro cytotoxicity against human ovarian carcinoma A21,,12307,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL624717,,9606.0,6907,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,14254,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL624718,,9606.0,6908,,Inhibitory activity of compound against human A121 ovarian cell line.,,13370,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL624719,,9606.0,6909,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,14790,,A121,BAO_0000219
393.0,,Homo sapiens,Intermediate,1,80655,F,N,,,,1,CHEMBL624720,,9606.0,6910,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,3614,,A121,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL624721,,9606.0,6911,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,2664,,A 172,BAO_0000219
622.0,,Homo sapiens,Expert,1,80012,F,N,,,,1,CHEMBL624722,,9606.0,6912,,In vitro cytotoxicity against A172 human tumor cell lines.,,2037,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL877597,,9606.0,6913,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,14539,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL624723,,9606.0,6914,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,2836,,A 172,BAO_0000219
622.0,,Homo sapiens,Intermediate,1,80012,F,N,,,,1,CHEMBL624724,,9606.0,6915,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,10708,,A 172,BAO_0000219
,,Canis lupus familiaris,Autocuration,1,104729,B,H,,,,4,CHEMBL624725,,9615.0,6916,,Association constant against A2 adenosine receptor,,8975,,,BAO_0000224
1085.0,,fish,Intermediate,1,80656,F,N,,,,1,CHEMBL624726,,,6917,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,7645,,A2,BAO_0000219
,,Rattus norvegicus,Autocuration,1,104713,B,D,,,,5,CHEMBL857535,,10116.0,6918,,Ratio of Ki for adenosine A2 and A1 receptor binding,,11377,,,BAO_0000224
623.0,,Homo sapiens,Expert,1,80014,F,N,,,,1,CHEMBL624727,,9606.0,6919,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,13528,,A204,BAO_0000219
623.0,,Homo sapiens,Expert,1,80014,F,N,,,,1,CHEMBL624728,,9606.0,6920,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,10160,,A204,BAO_0000219
404.0,,Homo sapiens,Intermediate,1,80015,F,N,,,,1,CHEMBL624729,,9606.0,6921,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,15144,,A2058,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624730,,9606.0,6922,,Growth inhibition against Human squamous cell line(A 253),,13160,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624731,,9606.0,6923,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,12898,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624732,,9606.0,6924,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,13069,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL883245,,9606.0,6925,,Growth inhibition of A253 cell lines.,,15984,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624733,,9606.0,6926,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,15564,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624734,,9606.0,6927,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,15564,,A253 cell line,BAO_0000219
973.0,,Homo sapiens,Intermediate,1,80657,F,N,,,,1,CHEMBL624735,,9606.0,6928,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,15564,,A253 cell line,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621780,,9606.0,6929,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,4720,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL877598,,9606.0,6930,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,16112,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621781,,9606.0,6931,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,16597,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621782,,9606.0,6932,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,16378,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621783,,9606.0,6933,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,16085,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621784,,9606.0,6934,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,16317,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621785,,9606.0,6935,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,15748,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621968,,9606.0,6936,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,16597,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621969,,9606.0,6937,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,16597,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621970,,9606.0,6938,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,16597,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621971,,9606.0,6939,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621972,,9606.0,6940,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL884108,,9606.0,6941,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,15608,,A2780,BAO_0000219
,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623826,,10029.0,6942,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,15296,,,BAO_0000019
185.0,,Cricetulus griseus,Autocuration,1,22224,A,U,,,,0,CHEMBL623827,,10029.0,6943,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,10251,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623828,,10029.0,6944,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,10251,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623829,,10029.0,6945,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,10251,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623830,,10029.0,6946,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,10251,,CHO-AA8,BAO_0000219
,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623831,,10029.0,6947,,Growth inhibition against CHO-derived cell line AA8,,11858,,,BAO_0000019
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623832,,10029.0,6948,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,11858,,CHO-AA8,BAO_0000219
185.0,,hampster,Expert,1,80089,F,N,,,,1,CHEMBL623833,,36483.0,6949,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,11616,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL623834,,10029.0,6950,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,11616,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623835,,10029.0,6951,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623836,,10029.0,6952,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,11396,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Autocuration,1,22224,F,U,,,,0,CHEMBL623837,,10029.0,6953,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,10518,,CHO-AA8,BAO_0000219
185.0,,Cricetulus griseus,Expert,1,80089,F,N,,,,1,CHEMBL623838,,10029.0,6954,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,11616,,CHO-AA8,BAO_0000219
,,,Autocuration,1,12675,F,H,,,,8,CHEMBL623839,,,6955,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,14837,,,BAO_0000019
,,,Autocuration,1,12675,F,H,,,,8,CHEMBL623840,,,6956,,Number of binding sites (n) of isolated serum protein AAG,,14837,,,BAO_0000019
,,,Intermediate,1,22222,B,M,,,,3,CHEMBL623841,,,6957,,Association constant for binding to AATT duplex,,16037,,,BAO_0000225
416.0,,Homo sapiens,Expert,1,100090,F,N,,,,1,CHEMBL623842,,9606.0,6958,,Inhibition of ABAE human fibroblast cell proliferation,,16597,,ABAE,BAO_0000219
1064.0,,Mus musculus,Intermediate,1,80668,F,N,,,,1,CHEMBL623843,,10090.0,6959,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,8831,,AC755,BAO_0000218
,,Oryctolagus cuniculus,Expert,1,102444,F,D,,,,9,CHEMBL618669,,9986.0,6960,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,13419,,,BAO_0000218
,,Oryctolagus cuniculus,Expert,1,102444,F,D,In vivo,,,9,CHEMBL618670,,9986.0,6961,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,13419,,,BAO_0000218
,,,Autocuration,1,69,B,H,,,,8,CHEMBL618671,,,6962,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,15778,,,BAO_0000357
,,,Autocuration,1,69,B,H,,,,8,CHEMBL618672,,,6963,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,15778,,,BAO_0000357
978.0,,Homo sapiens,Intermediate,1,80669,F,N,,,,1,CHEMBL618673,,9606.0,6964,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,12988,,ACH-2 cell line,BAO_0000219
978.0,,Homo sapiens,Intermediate,1,80669,F,N,,,,1,CHEMBL618674,,9606.0,6965,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,ACH-2 cell line,BAO_0000219
998.0,,Human immunodeficiency virus 1,Autocuration,1,22224,F,U,,,,0,CHEMBL618675,,11676.0,6966,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,12988,,T cell line,BAO_0000219
998.0,,Human immunodeficiency virus 1,Autocuration,1,22224,F,U,,,,0,CHEMBL618676,,11676.0,6967,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,T cell line,BAO_0000219
998.0,,Human immunodeficiency virus 1,Autocuration,1,22224,F,U,,,,0,CHEMBL618677,,11676.0,6968,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,12988,,T cell line,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618678,,9606.0,6969,,Inhibition of growth of renal cancer ACHN cell line,,11843,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618679,,9606.0,6970,,Inhibition of growth of ACHN renal cancer cell line,,16939,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618680,,9606.0,6971,,Inhibitory concentration required against ACHN renal cancer cell line,,4782,,ACHN,BAO_0000219
626.0,,Homo sapiens,Expert,1,80025,F,N,,,,1,CHEMBL618681,,9606.0,6972,,Concentration required to inhibit growth of human renal (ACHN) cell line,,6310,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618682,,9606.0,6973,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,6310,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618683,,9606.0,6974,,Cytotoxic activity against ACHN Renal cancer cell line,,12858,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618684,,9606.0,6975,,Cytotoxicity evaluation against ACHN renal cancer cells,,17380,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618685,,9606.0,6976,,In vitro antitumor activity against human renal ACHN cell line,,5858,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL876499,,9606.0,6977,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,3838,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618686,,9606.0,6978,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,3838,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618687,,9606.0,6979,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,5406,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618688,,9606.0,6980,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,4071,,ACHN,BAO_0000219
626.0,,Homo sapiens,Expert,1,80025,F,N,,,,1,CHEMBL618689,,9606.0,6981,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,4071,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618690,,9606.0,6982,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,4071,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL618691,,9606.0,6983,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,15002,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619373,,9606.0,6984,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,14769,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL884008,,9606.0,6985,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,13958,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619374,,9606.0,6986,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,1665,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619375,,9606.0,6987,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,15354,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619376,,9606.0,6988,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,15354,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619377,,9606.0,6989,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,13978,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL619378,,9606.0,6990,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,6798,,ACHN,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL872527,,9615.0,6991,,Tmax value after administration of 4 mg/Kg oral dose in dog,,2959,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL876500,,9615.0,6992,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,9932,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619379,,9615.0,6993,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619538,,9615.0,6994,,Volume distribution after 15 mg/kg iv dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619539,,9615.0,6995,,Volume distribution after 30 mg/kg po dose in Dogs,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619540,,9615.0,6996,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619541,,9615.0,6997,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,4305,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619542,,9615.0,6998,,Volume of distribution was evaluated in dog,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619543,,9615.0,6999,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,A,N,,,,1,CHEMBL619544,,9615.0,7000,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619545,,9615.0,7001,,The compound was tested for volume of distribution in dog,,12500,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619546,,9615.0,7002,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619547,,9615.0,7003,,Vd (1 mg/kg) was determined in dog (in vivo),,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619548,,9615.0,7004,,Vd in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619549,,9615.0,7005,,Volume distribution was determined,,4219,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619550,,9615.0,7006,,Volume of distribution in dog,,1696,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876501,,9615.0,7007,,Volume of distribution by as 4 fold increase by iv administration in dogs,,5542,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619551,,9615.0,7008,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,5199,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619552,,9615.0,7009,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619553,,9615.0,7010,,Volume distribution at the dose of 2 mg/kg in dog,,4727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618722,,9615.0,7011,,Steady state volume of distribution was determined,,16367,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618723,,9615.0,7012,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618724,,9615.0,7013,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618725,,9615.0,7014,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618726,,9615.0,7015,,Bioavailability in dog (dose 1 mg/kg i.v.),,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618727,,9615.0,7016,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,5334,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624233,,9615.0,7017,,Pharmacokinetic property (vdss) was measured in dog,,4239,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624234,,9615.0,7018,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624235,,9615.0,7019,,Vdss was determined after iv 0.1 mg/kg administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624236,,9615.0,7020,,Volume displacement was calculated in dog,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624237,,9615.0,7021,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,5654,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624238,,9615.0,7022,,Volume distribution constant was determined,,5505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624239,,9615.0,7023,,Volume distribution at a dose of 1 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875829,,9615.0,7024,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624240,,9615.0,7025,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624241,,9615.0,7026,,Volume distribution (Vdss) was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624242,,9615.0,7027,,Volume distribution (Vdss) was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624243,,9615.0,7028,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624244,,9615.0,7029,,Volume of distribution in steady state was determined in dog,,5145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624245,,9615.0,7030,,Volume of distribution of compound was determined in dog,,6821,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624246,,9615.0,7031,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,4137,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624247,,9615.0,7032,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,5334,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624248,,9615.0,7033,,Volume of distribution (Vdss) was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624249,,9615.0,7034,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624250,,9615.0,7035,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624251,,9615.0,7036,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624252,,9615.0,7037,,Maximum rate of depolarization of the upstroke of the action potential,,11659,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624253,,9615.0,7038,,Steady state volume distribution in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624950,,9615.0,7039,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,5474,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624951,,9615.0,7040,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,1466,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875830,,9615.0,7041,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624952,,9615.0,7042,,Volume distribution in dog after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624953,,9615.0,7043,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,17764,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624954,,9615.0,7044,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,6215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624955,,9615.0,7045,,Vss on i.v. administration of 2 mg/kg was measured in dog,,6505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624956,,9615.0,7046,,Vss was determined,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625129,,9615.0,7047,,Vss in dog,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625130,,9615.0,7048,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625131,,9615.0,7049,,Volume distribution in dogs,,4942,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625132,,9615.0,7050,,Volume of distribution in dog,,17796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL872263,,9615.0,7051,,Tested for the oral bioavailability in dog,,4883,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624336,,10090.0,7060,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,17837,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624337,,10090.0,7061,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624338,,10090.0,7062,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624339,,10090.0,7063,,Bioavailability was measured in mouse,,4239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624340,,10090.0,7064,,Bioavailability in mouse,,17592,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624341,,10090.0,7065,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624342,,10090.0,7066,,Bioavailability in mouse,,2801,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624343,,10090.0,7067,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,2801,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624344,,10090.0,7068,,Oral bioavailability in mouse,,17718,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624345,,10090.0,7069,,Oral availability at 50 mg/kg po in male mice,,5727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624346,,10090.0,7070,,Oral bioavailability in mouse (dose 10 mg/kg),,5302,,,BAO_0000218
,,Mus musculus,Expert,1,50594,A,N,In vivo,,,1,CHEMBL624347,,10090.0,7071,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL624348,,10090.0,7072,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,5961,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622754,,10090.0,7074,,Oral bioavailability in mouse,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622755,,10090.0,7075,,Oral bioavailability in vivo in mice;ND=Not determined,,6091,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622756,,10090.0,7076,,Oral bioavailability in mouse at 10 mg/kg of the compound,,5711,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622757,,10090.0,7077,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622758,,10090.0,7078,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622759,,10090.0,7079,,Tested for bioavailability of the compound,,3802,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL622760,,10090.0,7080,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,3802,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622761,,10090.0,7081,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,14029,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622762,,10090.0,7082,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,14029,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622763,,10090.0,7083,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,14029,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622764,,10090.0,7084,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,14029,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622765,,10090.0,7085,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,14029,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,F,N,,,,1,CHEMBL622766,,10090.0,7086,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622767,,10090.0,7087,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,17753,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622768,,10090.0,7088,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,17753,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL875948,,10090.0,7089,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622769,,10090.0,7090,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622770,,10090.0,7091,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622771,,10090.0,7092,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622772,,10090.0,7093,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622773,,10090.0,7094,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622774,,10090.0,7095,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL621725,,10090.0,7096,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL621726,,10090.0,7097,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,10107,,,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621727,,9606.0,7098,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,15608,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622413,,9606.0,7099,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,3290,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622414,,9606.0,7100,,Compound was evaluated for cytotoxicity against A2780 cell line,,2859,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622415,,9606.0,7101,,Inhibition of A2780 cell clonogenic assay,,15688,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL884001,,9606.0,7102,,Cytotoxic effect on ovarian cancer cell line (A2780),,5642,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622416,,9606.0,7103,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,6633,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622417,,9606.0,7104,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,3906,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622590,,9606.0,7105,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,6788,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622591,,9606.0,7106,,Antiproliferative activity against human A2780 cells,,17582,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622592,,9606.0,7107,,Inhibition of human A2780 cell proliferation,,17764,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622593,,9606.0,7108,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,17764,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622594,,9606.0,7109,,Inhibition of human A2780 cell proliferation (No data),,17764,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622595,,9606.0,7110,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,2815,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622596,,9606.0,7111,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,16930,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622597,,9606.0,7112,,Growth inhibition against A2780 wild-type ovarian cell lines,,17777,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622598,,9606.0,7113,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,17777,,A2780,BAO_0000219
,,Homo sapiens,Autocuration,1,104766,F,D,,,,5,CHEMBL622599,,9606.0,7114,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,16936,,,BAO_0000019
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622600,,9606.0,7115,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,13759,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622601,,9606.0,7116,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,13759,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622602,,9606.0,7117,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,13759,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622603,,9606.0,7118,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,13759,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622604,,9606.0,7119,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,15292,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622605,,9606.0,7120,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,15292,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL622606,,9606.0,7121,,In vitro inhibition of human ovarian cell line A2780,,15069,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619463,,9606.0,7122,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,15069,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619464,,9606.0,7123,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,14073,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619465,,9606.0,7124,,Concentration required to inhibit A2780-cell growth by 50%,,14553,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619466,,9606.0,7125,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,13040,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619467,,9606.0,7126,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,6891,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619468,,9606.0,7127,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,15569,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619469,,9606.0,7128,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,14190,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL619470,,9606.0,7129,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,15014,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619471,,9606.0,7130,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,15014,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619472,,9606.0,7131,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,17496,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL619473,,9606.0,7132,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,13617,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL874368,,9606.0,7133,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,13617,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL884003,,9606.0,7134,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,13617,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622690,,9606.0,7135,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,13617,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622691,,9606.0,7136,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,17672,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL622692,,9606.0,7137,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,4544,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL623406,,9606.0,7138,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,4544,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL884004,,9606.0,7139,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,16317,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL623407,,9606.0,7140,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,15099,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL623408,,9606.0,7141,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,13978,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL623409,,9606.0,7142,,In vitro antitumor activity against A2780 cell line.,,12989,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL623410,,9606.0,7143,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,5574,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL623576,,9606.0,7144,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,13528,,A2780,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623577,,9606.0,7145,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,12782,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623578,,9606.0,7146,,The IC50 value was measured on ACHN cell line in renal tumor type.,,14255,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623579,,9606.0,7147,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,16364,,ACHN,BAO_0000219
626.0,,Homo sapiens,Expert,1,80025,F,N,,,,1,CHEMBL623580,,9606.0,7148,,In vitro lethal concentration against most sensitive ACHN cell line,,17376,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623581,,9606.0,7149,,Tested for cytotoxic activity against renal cancer ACHN cell line,,12016,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL857456,,9606.0,7150,,Compound tested for growth inhibition of renal cancer cell line ACHN,,6058,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623582,,9606.0,7151,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,17708,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623583,,9606.0,7152,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,15176,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623584,,9606.0,7153,,In vitro anticancer activity against ACHN renal cancer cell line,,2806,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623585,,9606.0,7154,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,15300,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623586,,9606.0,7155,,Percent selectivity was evaluated in renal ACHN cell lines,,16364,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623587,,9606.0,7156,,In vitro inhibitory activity against renal ACHN cancer cell line,,13859,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL875279,,9606.0,7157,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,11970,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623588,,9606.0,7158,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,2450,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623589,,9606.0,7159,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,12696,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623590,,9606.0,7160,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,12400,,ACHN,BAO_0000219
626.0,,Homo sapiens,Expert,1,80025,F,N,,,,1,CHEMBL623591,,9606.0,7161,,Cytotoxic effect on renal cancer line ACHN,,12888,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623592,,9606.0,7162,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,3156,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623593,,9606.0,7163,,In vitro inhibition of Renal Cancer ACHN cell lines,,3381,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL623594,,9606.0,7164,,Antitumor activity against human renal adenocarcinoma ACHN cells,,16747,,ACHN,BAO_0000219
626.0,,Homo sapiens,Expert,1,80025,F,N,,,,1,CHEMBL621833,,9606.0,7165,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,16748,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621834,,9606.0,7166,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,12062,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621835,,9606.0,7167,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,14769,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621836,,9606.0,7168,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,15895,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621837,,9606.0,7169,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,17376,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL875280,,9606.0,7170,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,14882,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621838,,9606.0,7171,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,14882,,ACHN,BAO_0000219
626.0,,Homo sapiens,Intermediate,1,80025,F,N,,,,1,CHEMBL621839,,9606.0,7172,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,15661,,ACHN,BAO_0000219
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621840,,,7173,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,9680,,,BAO_0000019
,,,Autocuration,1,10647,F,H,,,,8,CHEMBL621841,,,7174,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,14579,,,BAO_0000019
468.0,,Cytomegalovirus,Expert,1,50529,F,N,,,,1,CHEMBL622979,,10358.0,7175,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,17290,,HEL,BAO_0000218
,,Cytomegalovirus,Intermediate,1,50529,F,N,,,,1,CHEMBL876595,,10358.0,7176,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,17290,,,BAO_0000218
,,,Autocuration,1,12159,B,H,,,,8,CHEMBL620221,,,7177,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,15891,,,BAO_0000357
,,,Autocuration,1,12159,B,H,,,,8,CHEMBL620222,,,7178,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,15890,,,BAO_0000357
979.0,,Bos taurus,Intermediate,1,80670,F,N,,,,1,CHEMBL620506,,9913.0,7179,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,3801,,ADDP cell line,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,F,N,,,,1,CHEMBL620507,,10090.0,7180,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,9222,,ADJ/PC6,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,F,N,,,,1,CHEMBL620508,,10090.0,7181,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,9222,,ADJ/PC6,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,F,N,,,,1,CHEMBL620509,,10090.0,7182,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,7257,,ADJ/PC6,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,F,N,,,,1,CHEMBL620510,,10090.0,7183,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,7257,,ADJ/PC6,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,A,N,,,,1,CHEMBL620511,,10090.0,7184,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,7257,,ADJ/PC6,BAO_0000219
980.0,,Mus musculus,Intermediate,1,80671,F,N,,,,1,CHEMBL620512,,10090.0,7185,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,8084,,ADJ/PC6,BAO_0000219
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL620513,,10090.0,7186,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,14943,,,BAO_0000019
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL620514,,10090.0,7187,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,14943,,,BAO_0000019
,,Mus musculus,Autocuration,1,22224,F,U,,,,0,CHEMBL620515,,10090.0,7188,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,14943,,,BAO_0000019
,,Bacillus subtilis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620516,,1423.0,7189,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,10524,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL620517,,9615.0,7190,,AUC value in dog after IV administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL620518,,9615.0,7191,,AUC value in dog after oral administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL620519,,9615.0,7192,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621386,,9615.0,7193,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621387,,9615.0,7194,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621388,,9615.0,7195,,Compound was evaluated for its clearance when administered intravenously in dog,,3184,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621389,,9615.0,7196,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621390,,9615.0,7197,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,4809,,,BAO_0000218
,,,Intermediate,1,22229,P,U,,,,0,CHEMBL621391,,,7198,,Calculated partition coefficient (clogP),,4219,,,BAO_0000100
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621392,,9615.0,7199,,Half life in dog,,3748,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621393,,9615.0,7200,,Time taken for EC90 was determined when tested in dog,,3132,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621394,,9615.0,7201,,Half life (iv) was determined,,4219,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2107.0,1,CHEMBL621395,,9615.0,7202,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621396,,9615.0,7203,,Area under the curve was calculated in dog after iv administration,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621397,,9615.0,7204,,Area under the curve was calculated in dog after peroral administration,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621398,,9615.0,7205,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,17853,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618818,,9615.0,7206,,pKa was evaluated in dog,,3639,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618819,,9615.0,7207,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,14541,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618820,,9615.0,7208,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873810,,9615.0,7209,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876606,,9615.0,7210,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,2652,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618821,,9615.0,7211,,Compound was evaluated for the half-life (t 1/2) in hours,,3624,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL618822,,9615.0,7212,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL618823,,9615.0,7213,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,1337,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618824,,9615.0,7214,,Half life after intravenous administration of 1 mg/kg in dog,,4709,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618825,,9615.0,7215,,Half life was measured in dog,,15660,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618826,,9615.0,7216,,Half life period in dog after 5 mg/kg dose,,5302,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618827,,9615.0,7217,,Half life period was evaluated in dog; 4-4.8,,17791,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618828,,9615.0,7218,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL618829,,9615.0,7219,,Half-life was determined in dog after a3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618830,,9615.0,7220,,Half-life was determined,,3771,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618831,,9615.0,7221,,Half life in dogs,,6305,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL619489,,9615.0,7222,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,13501,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619649,,9615.0,7223,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876607,,9615.0,7224,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,3045,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619650,,9615.0,7225,,Compound was evaluated for the half life period after oral administration in conscious dog.,,3043,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619651,,9615.0,7226,,Compound was tested for half life in dog,,4839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619652,,9615.0,7227,,Compound was tested for its half life in dog,,4839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619653,,9615.0,7228,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5802,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619654,,9615.0,7229,,Half life of compound in dog was determined,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619655,,9615.0,7230,,Half life (iv) was determined,,4219,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,,,178.0,1,CHEMBL619656,,9615.0,7231,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,13966,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL873812,,9615.0,7232,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,3994,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,F,N,In vivo,,1969.0,1,CHEMBL621365,,9615.0,7233,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,3994,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621366,,9615.0,7234,,Half life in dog,,4453,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621367,,9615.0,7235,,Half life in dog plasma,,6535,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621368,,9615.0,7236,,Half life in dog plasma after administration of 0.25 mg/kg iv,,6535,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621369,,9615.0,7237,,Half life in dog plasma after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621370,,9615.0,7238,,Half life in dog plasma was determined at dose 10 mg/kg,,3132,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621371,,9615.0,7239,,Half life in dog was determined,,5374,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621372,,9615.0,7240,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5007,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621373,,9615.0,7241,,Half life upon exposure to human plasma,,16907,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621374,,9615.0,7242,,Half life was calculated in dog,,6057,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621375,,9615.0,7243,,Half life was determined,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621376,,9615.0,7244,,Half life was determined,,5473,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619624,,9615.0,7245,,Half life by intravenous administration of 1.2 mg/kg in dog,,4368,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875840,,9615.0,7246,,Half life in dog,,6448,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619625,,9615.0,7247,,Half life in dog after intra venous administration of the compound,,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619626,,9615.0,7248,,Half life in dog after intra venous administration of the compound; ND means Not determined,,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619627,,9615.0,7249,,Half life in dog after po administration of the compound,,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873817,,9615.0,7250,,Half life in dog after po administration of the compound; ND means Not determined,,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619628,,9615.0,7251,,Half life in dog at the single oral dose of 1 mg/kg,,6265,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619629,,9615.0,7252,,Half life in dogs,,5006,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619630,,9615.0,7253,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,5356,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL619631,,9615.0,7254,,Half life in rat,,405,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL619632,,9615.0,7255,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,6642,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL619633,,10090.0,7256,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL875841,,10090.0,7257,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL619634,,10090.0,7258,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL619635,,10090.0,7259,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL619636,,10090.0,7260,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619637,,10090.0,7261,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619638,,10090.0,7262,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619639,,10090.0,7263,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619640,,10090.0,7264,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619641,,10090.0,7265,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619642,,10090.0,7266,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Gut,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000004.0,1,CHEMBL619643,,10090.0,7267,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL619644,,10090.0,7268,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621112,,10090.0,7269,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621113,,10090.0,7270,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621114,,10090.0,7271,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621115,,10090.0,7272,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621116,,10090.0,7273,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL621117,,10090.0,7274,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621118,,10090.0,7275,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621119,,10090.0,7276,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621120,,10090.0,7277,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621757,,10090.0,7278,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621758,,10090.0,7279,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621759,,10090.0,7280,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621760,,10090.0,7281,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621761,,10090.0,7282,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621762,,10090.0,7283,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621763,,10090.0,7284,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624502,,10090.0,7285,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624503,,10090.0,7286,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624504,,10090.0,7287,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624505,,10090.0,7288,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624506,,10090.0,7289,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624507,,9606.0,7290,,In vitro cytotoxicity against A2780 (human ovarian cancer),,5895,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624508,,9606.0,7291,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,6338,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624509,,9606.0,7292,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,15163,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624510,,9606.0,7293,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,15163,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL875956,,9606.0,7294,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,15000,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL839885,,9606.0,7295,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,15000,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL624511,,9606.0,7296,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,14729,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624512,,9606.0,7297,,In vitro cytotoxicity against A2780 cell line,,17270,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624513,,9606.0,7298,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,5685,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL624514,,9606.0,7299,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,3563,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618547,,9606.0,7300,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,17753,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618548,,9606.0,7301,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,16317,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618549,,9606.0,7302,,Inhibition of tubulin polymerization in analogy of ca.,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618550,,9606.0,7303,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,3801,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618551,,9606.0,7304,,Cytotoxic effect in ovarian cancer cell line (A2780),,6181,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618552,,9606.0,7305,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,5318,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618553,,9606.0,7306,,Tested for the cytotoxicity in A2780 ovarian cell line,,4840,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618554,,9606.0,7307,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,15748,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618555,,9606.0,7308,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,15748,,A2780,BAO_0000219
481.0,,,Intermediate,1,80017,F,N,,,,1,CHEMBL618556,,,7309,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,15748,,A2780cisR,BAO_0000219
481.0,,,Intermediate,1,80017,F,N,,,,1,CHEMBL618557,,,7310,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,15748,,A2780cisR,BAO_0000219
481.0,,,Intermediate,1,80017,F,N,,,,1,CHEMBL618558,,,7311,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,15748,,A2780cisR,BAO_0000219
481.0,,,Intermediate,1,80017,F,N,,,,1,CHEMBL618559,,,7312,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,15748,,A2780cisR,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618560,,9606.0,7313,,In vivo log of cells killed after administration of compound in A2780 cell line,,17753,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,In vivo,,,1,CHEMBL618561,,9606.0,7314,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,17753,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618562,,9606.0,7315,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618563,,9606.0,7316,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618564,,9606.0,7317,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618565,,9606.0,7318,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618566,,9606.0,7319,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,17528,,A2780,BAO_0000218
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL618567,,9606.0,7320,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,6633,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618568,,9606.0,7321,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,15000,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL618569,,9606.0,7322,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,17528,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621857,,9606.0,7323,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621858,,9606.0,7324,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621859,,9606.0,7325,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621860,,9606.0,7326,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621861,,9606.0,7327,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Expert,1,81034,F,N,,,,1,CHEMBL621862,,9606.0,7328,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621863,,9606.0,7329,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621864,,9606.0,7330,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621865,,9606.0,7331,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,16936,,A2780,BAO_0000219
478.0,,Mus musculus,Intermediate,1,81034,F,N,,,,1,CHEMBL621866,,10090.0,7332,,In vitro antiproliferative activity against A2780 cell line,,17737,,A2780,BAO_0000219
478.0,,Mus musculus,Expert,1,81034,F,N,,,,1,CHEMBL621867,,10090.0,7333,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,17764,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL621868,,9606.0,7334,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,3830,,A2780,BAO_0000219
478.0,,Homo sapiens,Intermediate,1,81034,F,N,,,,1,CHEMBL875282,,9606.0,7335,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,3829,,A2780,BAO_0000219
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621869,,9615.0,7336,,Vc value in dog after IV administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621870,,9615.0,7337,,Half life period in dog after IV administration at a dose of 5 mg/kg,,3546,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621871,,9527.0,7338,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,5668,,,BAO_0000019
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL621243,,9527.0,7339,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,Plasma,Cercopithecidae,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL621244,,9527.0,7340,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621245,,9541.0,7341,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,4256,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621246,,9541.0,7342,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,4256,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621247,,9541.0,7343,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,4256,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618386,,10116.0,7344,,Oral Bioavailability in rat,,4256,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618387,,9527.0,7345,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618388,,9527.0,7346,,Area under curve value in monkey at a dose of 5 mg/kg,,5302,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618389,,9527.0,7347,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,4257,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618574,,9527.0,7348,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,5355,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618575,,9527.0,7349,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,5355,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618576,,9527.0,7350,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,5355,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618577,,9527.0,7351,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,6078,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL876487,,9527.0,7352,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,6078,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618578,,9527.0,7353,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618579,,9527.0,7354,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618580,,9527.0,7355,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,2661,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618581,,9527.0,7356,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,5394,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618582,,9527.0,7357,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,4397,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618583,,9527.0,7358,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,17509,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618584,,9527.0,7359,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,17509,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618585,,9527.0,7360,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,6641,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618586,,9527.0,7361,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618587,,9527.0,7362,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618588,,9527.0,7363,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,3443,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618589,,9527.0,7364,,Binding towards monkey plasma protein at 10 uM,,17409,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL618590,,9527.0,7365,,Binding towards monkey plasma protein at 100 uM,,17409,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL872262,,9527.0,7366,,Apparent bioavailability in squirrel monkey was determined,,1052,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618591,,9527.0,7367,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,13501,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618592,,9443.0,7368,,Bioavailability in monkey (dose 2 mg/kg),,17509,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL876488,,9527.0,7369,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,5394,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618593,,9527.0,7370,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,,monkey,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618594,,9443.0,7371,,Bioavailability in monkey (i.d. dosing),,11219,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL618595,,9527.0,7372,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,3045,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,,,,0,CHEMBL621469,,9527.0,7373,,Clearance of the drug was measured in cynomolgus,,17796,,,BAO_0000019
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621470,,9527.0,7374,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,1399,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621471,,9527.0,7375,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,2661,,,BAO_0000218
,Plasma,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621472,,9544.0,7376,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,5005,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621473,,9527.0,7377,,Plasma clearance in rhesus monkey was determined,,17267,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621474,,9527.0,7378,,Plasma clearance in monkey after administration of 1 mg/kg iv,,6535,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621475,,9527.0,7379,,Plasma clearance in cynomolgus monkey,,5922,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621476,,9527.0,7380,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,6221,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624290,,9527.0,7381,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,5668,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624291,,9527.0,7382,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624292,,9527.0,7383,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624293,,9527.0,7384,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,5355,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624294,,9527.0,7385,,Tested for Clearance upon iv administration to african green monkey,,4578,,,BAO_0000218
,,Cercopithecidae,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624295,,9527.0,7386,,Clearance in monkey,,17592,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624296,,9615.0,7387,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6641,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624297,,9615.0,7388,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,6642,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624298,,9615.0,7389,,Half life was evaluated after intravenous administration to dogs,,16367,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624299,,9615.0,7390,,Half life was evaluated in dog,,5472,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624300,,9615.0,7391,,Half life was evaluated in dog,,5474,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624301,,9615.0,7392,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,5654,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624302,,9615.0,7393,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876026,,9615.0,7394,,Half life period after intravenous administration in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624303,,9615.0,7395,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,6221,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624304,,9615.0,7396,,Half life period at a dose of 1 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624305,,9615.0,7397,,Half life period was determine after peroral administration at 10 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624306,,9615.0,7398,,Half life period was determine after peroral administration at 5 mpk in dog,,5668,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624307,,9615.0,7399,,Half life period was determined,,3854,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624308,,9615.0,7400,,Half life period was determined,,5505,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624309,,9615.0,7401,,Half life period by iv administration in dog at a dose of 6 mg/kg,,6251,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624310,,9615.0,7402,,Half life period was evaluated in dog,,1918,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625003,,9615.0,7403,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625004,,9615.0,7404,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,4809,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625005,,9615.0,7405,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,6215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873813,,9615.0,7406,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,4527,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625006,,9615.0,7407,,Half-life after oral dose of compound at 3 mg/kg in dogs,,17594,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625007,,9615.0,7408,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL876027,,9615.0,7409,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625008,,9615.0,7410,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,17839,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625009,,9615.0,7411,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,17839,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL625010,,9615.0,7412,,Half-life of compound in plasma of dog was determined,,5210,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625011,,9615.0,7413,,Half-life of compound was determined in dogs,,5210,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621553,,9615.0,7414,,Half-life after administration of 4 mg/Kg oral dose in dog,,2959,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621554,,9615.0,7415,,Half-life after intravenous administration of 1 mg/kg/h in dog,,4137,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621555,,9615.0,7416,,Half-life in Dog,,5064,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621556,,9615.0,7417,,Half-life in Dog,,5147,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621557,,9615.0,7418,,Half-life in dog,,5145,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621558,,9615.0,7419,,Half-life in dog after oral administration at 1 mg/kg,,6123,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621559,,9615.0,7420,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,6123,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621560,,9615.0,7421,,Half-life in dogs,,4333,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL876028,,9615.0,7422,,Half-life in dogs; ND indicates not determined,,4333,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621561,,9615.0,7423,,Half-life in plasma of dog,,12500,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL621562,,9615.0,7424,,Half-life in plasma of dog at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621563,,9615.0,7425,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,6005,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621564,,9615.0,7426,,Half-life was measured in dog after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621565,,9615.0,7427,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,17650,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621566,,9615.0,7428,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,5530,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL621567,,9615.0,7429,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,5530,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622978,,9615.0,7430,,Half-life of the compound after 0.3 mg/kg po administration in dog,,5600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL873814,,9615.0,7431,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623219,,9615.0,7432,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624477,,9615.0,7433,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,6039,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624478,,9615.0,7434,,t1/2 in dog,,6227,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624479,,9615.0,7435,,Half-life period measured in dogs,,14541,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL624480,,9615.0,7436,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623595,,9615.0,7437,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,4521,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623596,,9615.0,7438,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vitro,,1969.0,1,CHEMBL623597,,9615.0,7439,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,1116,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623598,,9615.0,7440,,In vivo half life period was calculated at 1 mg/kg in dog,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623599,,9615.0,7441,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,5444,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623600,,9615.0,7442,,Longer half-life in dog (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623601,,9615.0,7443,,Oral bioavailability in dog (dose 5 uM/kg),,4353,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623602,,9615.0,7444,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623603,,9615.0,7445,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,16452,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623604,,9615.0,7446,,Bioavailability in dog (dose 1 mg/kg i.v.),,16452,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623605,,10090.0,7447,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623606,,10090.0,7448,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623607,,10090.0,7449,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623608,,10090.0,7450,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623609,,10090.0,7451,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL623610,,10090.0,7452,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623611,,10090.0,7453,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623612,,10090.0,7454,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623613,,10090.0,7455,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623614,,10090.0,7456,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623615,,10090.0,7457,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623616,,10090.0,7458,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL623617,,10090.0,7459,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL875944,,10090.0,7460,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623618,,10090.0,7461,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623619,,10090.0,7462,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623620,,10090.0,7463,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623621,,10090.0,7464,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623622,,10090.0,7465,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL623623,,10090.0,7466,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL623624,,10090.0,7467,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618521,,10090.0,7468,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618522,,10090.0,7469,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618523,,10090.0,7470,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618524,,10090.0,7471,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL618525,,10090.0,7472,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL624586,,10090.0,7473,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624587,,10090.0,7474,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624588,,10090.0,7475,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624589,,10090.0,7476,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624590,,10090.0,7477,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624591,,10090.0,7478,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624592,,10090.0,7479,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,10107,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL624593,,10090.0,7480,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,10107,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624594,,10116.0,7481,,Oral bioavailability in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624595,,10116.0,7482,,Tested for the bioavailability in rat,,4950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624596,,10116.0,7483,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,5328,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624597,,10116.0,7484,,Bioavailability in rat,,406,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624598,,10116.0,7485,,Bioavailability in rat,,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624599,,10116.0,7486,,Bioavailability in rat (dose 3-10 mg/kg),,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875166,,10116.0,7487,,Bioavailability in rat,,5247,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624600,,10116.0,7488,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624601,,10116.0,7489,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624602,,10116.0,7490,,Half life after oral administration was determined in rats at 6 mg/kg,,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624603,,10116.0,7491,,Half life was determined,,6484,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624604,,10116.0,7492,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,3249,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624605,,10116.0,7493,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,6281,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624606,,10116.0,7494,,Half life in rats,,3307,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624607,,10116.0,7495,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,12058,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624608,,10116.0,7496,,Hill coefficient of the compound,,8833,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624609,,10116.0,7497,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624610,,10116.0,7498,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624611,,10116.0,7499,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624612,,10116.0,7500,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL875167,,10116.0,7501,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624613,,10116.0,7502,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,3193,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624614,,10116.0,7503,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,3193,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624392,,10116.0,7504,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,5960,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624393,,10116.0,7505,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624394,,10116.0,7506,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624395,,10116.0,7507,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624396,,10116.0,7508,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624397,,10116.0,7509,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL624398,,10116.0,7510,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL624399,,10116.0,7511,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL624400,,10116.0,7512,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL624401,,10116.0,7513,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL624402,,10116.0,7514,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624403,,10116.0,7515,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624404,,10116.0,7516,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624405,,10116.0,7517,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL624406,,10116.0,7518,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL624407,,10116.0,7519,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL624408,,10116.0,7520,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL618644,,10116.0,7521,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL618645,,10116.0,7522,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL618646,,10116.0,7523,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL618647,,10116.0,7524,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL618648,,10116.0,7525,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL618649,,10116.0,7526,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL618650,,10116.0,7527,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL618651,,10116.0,7528,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL876497,,10116.0,7529,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL618652,,10116.0,7530,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL618653,,10116.0,7531,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL618654,,10116.0,7532,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618655,,10116.0,7533,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,6351,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618656,,10116.0,7534,,Compound was tested for solubility in water,,1465,,,BAO_0000218
,,,Intermediate,1,22229,P,U,,,,0,CHEMBL618657,,,7535,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,5182,,,BAO_0000100
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618658,,10116.0,7536,,Solubility was determined,,17847,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618659,,10116.0,7537,,solubility in water (ug/mL) at 37 degree C.,,15339,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618660,,10116.0,7538,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,5202,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618661,,10116.0,7539,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,1088,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL873807,,10116.0,7540,,Half life in rats,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618662,,10116.0,7541,,Half life in Dawley rat,,5353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618663,,10116.0,7542,,Half life period after 3 mg/kg iv administration,,2864,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618664,,10116.0,7543,,Half life period after 3 mg/kg iv administration in rat,,2864,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618665,,10116.0,7544,,Half life period after 3 mg/kg iv administration in the rat,,2864,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876498,,10116.0,7545,,Half life period in female Sprague-Dawley rats,,6362,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618666,,10116.0,7546,,Half life period in rat,,6249,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620440,,10116.0,7547,,Half-life in rats was determined,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620441,,10116.0,7548,,Half-life in rats with metabolic oxidation,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620442,,10116.0,7549,,Half-life in rats,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620443,,10116.0,7550,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620444,,10116.0,7551,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620445,,10116.0,7552,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620446,,10116.0,7553,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,17260,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL620447,,10116.0,7554,,Biological half-life measured in plasma of rat,,2879,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621129,,10116.0,7555,,Biological half-life measured in plasma of rat; 22-25,,2879,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621130,,10116.0,7556,,Biological half-life measured in plasma of rat; 9-16,,2879,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873808,,10116.0,7557,,Compound was evaluated for its half life when administered intravenously in rat,,3184,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876598,,10116.0,7558,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,4891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621131,,10116.0,7559,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621132,,10116.0,7560,,Half life (T1/2) after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621133,,10116.0,7561,,Half life of compound after iv administration of 20 mg/kg dose in rat,,4413,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,,1,CHEMBL621312,,10116.0,7562,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621313,,10116.0,7563,,Half life of compound was determined in rat,,17267,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621314,,10116.0,7564,,Half life of compound was determined in rat blood,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621315,,10116.0,7565,,Half life at 1 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621316,,10116.0,7566,,Half life at 10 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621317,,10116.0,7567,,Half life in rats,,401,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621318,,10116.0,7568,,Half life in rats in hours,,4942,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621319,,10116.0,7569,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,17735,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621377,,10116.0,7570,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,6056,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621378,,10116.0,7571,,Half life was determined,,5213,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876599,,10116.0,7572,,Half life after i.v. administration,,6616,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621379,,10116.0,7573,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,5937,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621380,,10116.0,7574,,Half life in rat plasma,,5819,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621381,,10116.0,7575,,Half life in rat plasma; Not detected,,5819,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618515,,10116.0,7576,,Half life in rats,,6803,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618516,,10116.0,7577,,Half life period of compound was determined after peroral administration,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618517,,10116.0,7578,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618518,,10116.0,7579,,Half life period in rat,,5948,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618519,,10116.0,7580,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618698,,10116.0,7581,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618862,,10116.0,7582,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618863,,10116.0,7583,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618864,,10116.0,7584,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618865,,10116.0,7585,,Half life time in rat the dose of 2 mg/kg,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618866,,10116.0,7586,,Half-life 24 hr after 10 mg/kg iv administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618867,,10116.0,7587,,Half-life 24 hr after 2 mg/kg iv administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875828,,10116.0,7588,,Half-life consistent with the observed metabolic steady state in rats,,6597,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618868,,10116.0,7589,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,17735,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618869,,10116.0,7590,,Half-life for oxidative metabolic stability was determined using male human,,6597,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618870,,10116.0,7591,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,17670,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL618871,,10116.0,7592,,Half-life in rat plasma,,1696,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL618872,,10116.0,7593,,Half-life in rat plasma was determined,,1742,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL873816,,10116.0,7594,,Half-life in rats was determined,,17800,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL618873,,,7595,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,12923,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621602,,,7596,,Area under curve after oral dose of 0.1 mg//kg,,11954,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621603,,,7597,,Area under curve after oral dose of 0.3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621604,,,7598,,Area under curve after oral dose of 1 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621605,,,7599,,Area under curve after oral dose of 10 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621606,,,7600,,Area under curve after oral dose of 23.4 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621607,,,7601,,Area under curve after oral dose of 3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621608,,,7602,,Area under curve after oral dose of 3.87 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621609,,,7603,,Area under curve was determined,,5237,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621610,,,7604,,Area under curve at a dose of 10 mg/kg,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621611,,10116.0,7605,,Area under curve was determined; ND=No data,,5237,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621612,,10116.0,7606,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622308,,10116.0,7607,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622309,,10116.0,7608,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622310,,10116.0,7609,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622311,,10116.0,7610,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622312,,10116.0,7611,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622931,,10116.0,7612,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622932,,10116.0,7613,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622736,,10116.0,7614,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622737,,10116.0,7615,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622738,,10116.0,7616,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622739,,10116.0,7617,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622740,,10116.0,7618,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622741,,10116.0,7619,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622742,,10116.0,7620,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622743,,10116.0,7621,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,14793,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL622744,,10090.0,7622,,AUC in mice,,11637,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624134,,,7623,,Area under curve was measured from the graph obtained from concentration Vs time,,11149,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624135,,,7624,,Area under curve value of compound per hour after oral administration,,10016,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624136,,10116.0,7625,,Area under curve was determined after oral administration in rats,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624137,,10116.0,7626,,Area under curve was determined after oral administration in rats; No data,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624320,,10116.0,7627,,Area under curve was determined after oral administration in rats;No data,,17796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624321,,9615.0,7628,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,12923,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624322,,10116.0,7629,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624323,,10116.0,7630,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624324,,10116.0,7631,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624325,,10116.0,7632,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624326,,10116.0,7633,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624327,,10116.0,7634,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624328,,10116.0,7635,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,15372,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL627848,,9615.0,7636,,Area under curve was determined in Dogs after peroral administration,,14169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627849,,10116.0,7637,,Area under curve was determined in Rats after peroral administration,,14169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627850,,10116.0,7638,,Area under curve was determined in carotid blood of rat when administered intradermally,,14258,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627851,,10116.0,7639,,Area under curve was determined in portal blood of rat when administered intradermally,,14258,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627852,,10090.0,7640,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627853,,10090.0,7641,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627854,,10090.0,7642,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627855,,10090.0,7643,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627856,,10090.0,7644,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875339,,10090.0,7645,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627857,,10090.0,7646,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,15011,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627858,,10116.0,7647,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,11195,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627859,,10116.0,7648,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL627860,,10116.0,7649,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL627019,,10116.0,7650,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL627020,,10116.0,7651,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627021,,10116.0,7652,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL627022,,10116.0,7653,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627023,,10116.0,7654,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL627024,,10116.0,7655,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL627025,,10116.0,7656,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL627026,,10116.0,7657,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627027,,10116.0,7658,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL627028,,10116.0,7659,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL627029,,10116.0,7660,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL627030,,10116.0,7661,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL627031,,10116.0,7662,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627032,,10116.0,7663,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL627033,,10116.0,7664,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627034,,10116.0,7665,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL627035,,10116.0,7666,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL627036,,10116.0,7667,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL875340,,10116.0,7668,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL627037,,10116.0,7669,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL627038,,10116.0,7670,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL627039,,10116.0,7671,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL627040,,10116.0,7672,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL624663,,10116.0,7673,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL625963,,10116.0,7674,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL876799,,10116.0,7675,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,10130,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626133,,10116.0,7676,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626134,,10116.0,7677,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626135,,10116.0,7678,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,6295,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626136,,10116.0,7679,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,6296,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626137,,10116.0,7680,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,6296,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626138,,10116.0,7681,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,6295,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626139,,10116.0,7682,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,6296,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626140,,10116.0,7683,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626141,,10116.0,7684,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626142,,10116.0,7685,,C24h in rat p.o. at 20 mg/kg concentration,,17686,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627930,,10116.0,7686,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627931,,10116.0,7687,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627932,,10116.0,7688,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627933,,10116.0,7689,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627934,,10116.0,7690,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627935,,10116.0,7691,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627936,,10116.0,7692,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627937,,10116.0,7693,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627938,,10116.0,7694,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627939,,10116.0,7695,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627940,,10116.0,7696,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627941,,10116.0,7697,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL876800,,10116.0,7698,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627942,,10116.0,7699,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627943,,10116.0,7700,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627944,,10116.0,7701,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627945,,10116.0,7702,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628584,,10116.0,7703,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628585,,10116.0,7704,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628586,,10116.0,7705,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628587,,10116.0,7706,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628588,,10116.0,7707,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628589,,10116.0,7708,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625304,,10116.0,7709,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625305,,10116.0,7710,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625306,,10116.0,7711,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625307,,10116.0,7712,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625308,,10116.0,7713,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627740,,10116.0,7714,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627741,,10116.0,7715,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627742,,10116.0,7716,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627743,,10116.0,7717,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627744,,10116.0,7718,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627745,,10116.0,7719,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627746,,10116.0,7720,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627747,,10116.0,7721,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL876810,,10116.0,7722,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627748,,10116.0,7723,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627749,,10116.0,7724,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627750,,10116.0,7725,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618728,,10116.0,7726,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618729,,10116.0,7727,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618730,,10116.0,7728,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618731,,10116.0,7729,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618732,,10116.0,7730,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618733,,10116.0,7731,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618734,,10116.0,7732,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618735,,10116.0,7733,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL876602,,10116.0,7734,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618736,,10116.0,7735,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618737,,10116.0,7736,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618738,,10116.0,7737,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618739,,10116.0,7738,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618740,,10116.0,7739,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618741,,10116.0,7740,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618742,,10116.0,7741,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL618743,,10116.0,7742,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL618744,,10116.0,7743,,Half-life from rat plasma at a single oral dose of 25 mg/kg,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618745,,10116.0,7744,,Half-life in male rat,,5610,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620479,,10116.0,7745,,Half-life in rat after peroral administration at 10 mg/kg concentration,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620480,,10116.0,7746,,Half-life in rat after peroral administration at 5 mg/kg concentration,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620481,,10116.0,7747,,Half-life in rat at a dose of 3 mg/kg,,17771,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620482,,10116.0,7748,,Half-life was evaluated in rats,,1974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876603,,10116.0,7749,,Half-life was measured in rat,,4239,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620483,,10116.0,7750,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,6681,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620484,,10116.0,7751,,Half-life period in rats after intravenous administration at 5 mg/kg,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620485,,10116.0,7752,,Half-life period in rat at 10 mg/kg,,6046,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620486,,10116.0,7753,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620487,,10116.0,7754,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620488,,10116.0,7755,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620489,,10116.0,7756,,Half-life time in rat the dose of 2 mg/kg,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620490,,10116.0,7757,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,1088,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620491,,10116.0,7758,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,5610,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL876604,,10116.0,7759,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,3032,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620492,,10116.0,7760,,Oral half life was determined,,5199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620493,,10116.0,7761,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620494,,10116.0,7762,,Pharmacokinetic property (t1/2) in rat,,4408,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL620495,,10116.0,7763,,Plasma elimination half-life was determined,,2552,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL620496,,10116.0,7764,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,5199,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL620497,,10116.0,7765,,Plasma half life was observed after intravenous administration in rat,,15662,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL620498,,10116.0,7766,,Plasma half-life was determined,,1465,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL620499,,10116.0,7767,,Plasma half-life following oral administration in Fisher rats,,1446,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL620500,,10116.0,7768,,Plasma half-life in rat,,6824,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL873809,,10116.0,7769,,Plasmatic Half-life after intravenous administration to rat,,17533,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620501,,10116.0,7770,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620502,,10116.0,7771,,Terminal half life after intravenous administration (1 mg/kg) in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620503,,10116.0,7772,,Terminal half life in Rat at a oral dose of 5 mg/kg,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620504,,10116.0,7773,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,2463,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876605,,10116.0,7774,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,4883,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620505,,10116.0,7775,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,4883,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL873811,,10116.0,7776,,plasma half life was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,,1,CHEMBL624016,,10116.0,7777,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624017,,10116.0,7778,,Half life of compound determined in rat,,4576,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624018,,10116.0,7779,,Mean residence time determined in rat,,4576,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624019,,10116.0,7780,,Plasma half life determined in rat,,4576,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624020,,10116.0,7781,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624201,,10116.0,7782,,Compound was evaluated for pharmacokinetic parameter maximum time period,,4891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL872528,,10116.0,7783,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624202,,10116.0,7784,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624203,,10116.0,7785,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624350,,10116.0,7786,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621320,,10116.0,7787,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621321,,10116.0,7788,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621322,,10116.0,7789,,Maximum time (Tmax) required to reach Cmax in rats,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621323,,10116.0,7790,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621324,,10116.0,7791,,Maximum time of clearance of compound in rats after peroral administration,,6571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621325,,10116.0,7792,,Maximum time at the dose of 2 mg/kg in rat,,4727,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL875837,,10116.0,7793,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,17651,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621326,,10116.0,7794,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621327,,10116.0,7795,,Tmax in Guinea pig (PO dose),,14465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621328,,10116.0,7796,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621329,,10116.0,7797,,Pharmacokinetic parameter (Tmax) in rat,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621330,,10116.0,7798,,Pharmacokinetic parameter (Tmax) was estimated,,5022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621331,,10116.0,7799,,Pharmacokinetic property (Tmax) in rat,,4408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621332,,10116.0,7800,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621333,,10116.0,7801,,T max in Rat at a oral dose of 5 mg/kg,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621334,,10116.0,7802,,T max was determined at 10 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621335,,10090.0,7803,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,15011,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621336,,9615.0,7804,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,14180,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621337,,10116.0,7805,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,14180,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621338,,9615.0,7806,,Area under curve was measured after i.v. administration into Beagle dog.,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875838,,9615.0,7807,,Area under curve was measured after iv administration into Beagle dog,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621339,,9615.0,7808,,Area under curve was measured after po administration into Beagle dog,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621340,,9615.0,7809,,Area under curve was measured after po administration into Beagle dog.,,14599,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621341,,,7810,,Area under curve was measured at peroral dose of 3 mg/kg,,15675,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621342,,,7811,,Area under curve was measured by using concentration Vs time,,12706,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621343,,,7812,,Area under curve was measured by using concentration Vs time; not tested,,12706,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621344,,10090.0,7813,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,9750,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621345,,10090.0,7814,,Area under curve(AUC) was measured in mice after oral administration.,,9750,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621346,,,7815,,Area under curve(AUC) value of the compound,,14691,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL621347,,,7816,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,14691,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621348,,9615.0,7817,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,14691,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL621349,,,7818,,Area under curve(carotid artery) was determined by the availability in blood,,2939,,,BAO_0000019
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL621350,,,7819,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,2939,,,BAO_0000019
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL875839,,,7820,,Area under curve(carotid artery) was determined by the availability in blood; No data,,2939,,,BAO_0000019
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL620211,,,7821,,Area under curve(portal vein) was determined by the availability in blood,,2939,,,BAO_0000019
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL620212,,,7822,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,2939,,,BAO_0000019
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL620213,,,7823,,Area under curve(portal vein) was determined by the availability in blood; No data,,2939,,,BAO_0000019
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,,,1969.0,1,CHEMBL620214,,9544.0,7824,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,9552,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,,,1969.0,1,CHEMBL620215,,9544.0,7825,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,9552,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,,,1969.0,1,CHEMBL620216,,9544.0,7826,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,9552,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL620888,,9615.0,7827,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,9552,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL620889,,9615.0,7828,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,9552,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL620890,,,7829,,Area under plasma concentration vs time curve observed in rats for 0-3 h,,9552,,,BAO_0000019
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL620891,,10116.0,7830,,Area under plasma time curve determined in male rat,,11911,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL620892,,,7831,,Area under the MAP curve measured over 5 min.,,16618,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621079,,10090.0,7832,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,14387,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL621080,,10090.0,7833,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,14387,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621081,,9615.0,7834,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,,,,1,CHEMBL621082,,10026.0,7835,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621083,,10116.0,7836,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621084,,9615.0,7837,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,14339,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621085,,9615.0,7838,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,14339,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621086,,9615.0,7839,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,14339,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621087,,9615.0,7840,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,10524,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622607,,9615.0,7841,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,9994,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622608,,9615.0,7842,,Serum AUC in marmosets (IV dose),,11325,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624481,,,7843,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,12536,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624482,,,7844,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,12536,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624483,,,7845,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,12536,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624484,,,7846,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,12536,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624485,,,7847,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,12536,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624486,,10116.0,7848,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,15556,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624487,,,7849,,Area under the curve for the compound was calculated.,,2809,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624488,,,7850,,Area under the curve in concentration/ time,,9511,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624489,,10116.0,7851,,Area under the curve administered intraintestinal in rats.,,12818,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625184,,10116.0,7852,,Area under the curve administered intravenously in rats.,,12818,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625185,,,7853,,Area under the curve during intravenous administration,,15118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875954,,,7854,,Area under the curve during intravenous administration; Not determined,,15118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625186,,,7855,,Area under the curve during systemic administration,,15118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625187,,,7856,,Area under the curve during systemic administration; Not determined,,15118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625188,,,7857,,Area under the curve was calculated for the compound.,,2632,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625189,,9615.0,7858,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,14346,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625190,,9615.0,7859,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621733,,10116.0,7860,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621734,,10116.0,7861,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621735,,10116.0,7862,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,11149,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621736,,10116.0,7863,,Clearance of the drug was measured in the plasma of rat; No data,,17796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL621737,,10116.0,7864,,The pharmacokinetic parameter plasma clearance in vivo in rats,,5247,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621738,,10116.0,7865,,Plasma clearance at the dose of 2 mg/kg in rat,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622806,,10116.0,7866,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623519,,10116.0,7867,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623520,,10116.0,7868,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623521,,10116.0,7869,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,17065,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623522,,10116.0,7870,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,17671,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623523,,10116.0,7871,,Clearance rate in rat,,6672,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623690,,10116.0,7872,,Clearance rate in rat,,6673,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623691,,10116.0,7873,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623692,,10116.0,7874,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623693,,10116.0,7875,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623694,,10116.0,7876,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623695,,10116.0,7877,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,4413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623696,,10116.0,7878,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623697,,10116.0,7879,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,2661,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623698,,9544.0,7880,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,5005,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623699,,10116.0,7881,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623700,,10116.0,7882,,Mean (%CV) PK parameters for CL(mL/min/kg).,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623701,,10116.0,7883,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,3747,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623702,,10116.0,7884,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623703,,10116.0,7885,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623704,,10116.0,7886,,Plasma clearance in rat was determined,,17267,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623705,,10116.0,7887,,Plasma clearance in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623706,,10116.0,7888,,Plasma clearance in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623707,,10116.0,7889,,Plasma clearance was determined,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623708,,10116.0,7890,,Plasma clearance in rat,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623709,,10116.0,7891,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,5937,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623710,,10116.0,7892,,Plasma clearance in rat by iv administration,,5871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623711,,10116.0,7893,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,5874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623712,,10116.0,7894,,Plasma clearance in rat p.o.,,6504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623713,,10116.0,7895,,Plasma clearance in rats,,6803,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623714,,10116.0,7896,,Plasma clearance was determined; ND denotes no data,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623715,,10116.0,7897,,Plasma clearance was determined; ND denotes not determined,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623716,,10116.0,7898,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622980,,10116.0,7899,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,5199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622981,,10116.0,7900,,Plasma administration to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622982,,10116.0,7901,,Plasma clearance of the compound in female Sprague-Dawley rats,,6362,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622983,,10116.0,7902,,Plasma clearance was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622984,,10116.0,7903,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,6215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622985,,10116.0,7904,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623631,,10116.0,7905,,plasma clearance was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623632,,10116.0,7906,,In vivo CL/F determined,,4723,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623633,,10116.0,7907,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623634,,10116.0,7908,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623635,,10116.0,7909,,Compound was tested for the lower blood clearance in rat,,5213,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621195,,10116.0,7910,,Evaluated for the low clearance in rat (in vivo),,4687,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621196,,10116.0,7911,,Pharmacokinetic property (CLb)of the compound was determined in rat,,3371,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875287,,10116.0,7912,,Rapid clearance after intravenous administration in rat was determined,,4690,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621197,,10116.0,7913,,Clearance measured in rat,,5702,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621198,,10116.0,7914,,Compound was evaluated for plasma clearance in rat,,740,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621199,,10116.0,7915,,Low plasma clearance was calculated in rat,,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621200,,10116.0,7916,,Pharmacokinetic property (Clp) in rat,,5789,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621201,,10116.0,7917,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621202,,10116.0,7918,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621203,,10116.0,7919,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621204,,10116.0,7920,,Plasma clearance after IV dosing at 1 mg/kg in rat,,6518,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621205,,10116.0,7921,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621206,,10116.0,7922,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621207,,10116.0,7923,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621208,,10116.0,7924,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621209,,10116.0,7925,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL876484,,10116.0,7926,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621210,,10116.0,7927,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621211,,10116.0,7928,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621212,,10116.0,7929,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621213,,10116.0,7930,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621214,,10116.0,7931,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621215,,10116.0,7932,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621216,,10116.0,7933,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621217,,10116.0,7934,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621218,,10116.0,7935,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621219,,10116.0,7936,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621220,,10116.0,7937,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621221,,10116.0,7938,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621222,,10116.0,7939,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621223,,10116.0,7940,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL876485,,10116.0,7941,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621224,,10116.0,7942,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621225,,10116.0,7943,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621226,,10116.0,7944,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621227,,10116.0,7945,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621228,,10116.0,7946,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621229,,10116.0,7947,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621230,,10116.0,7948,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621231,,10116.0,7949,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621232,,10116.0,7950,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621233,,10116.0,7951,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621234,,10116.0,7952,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621235,,10116.0,7953,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621236,,10116.0,7954,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621237,,10116.0,7955,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL876486,,10116.0,7956,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622436,,10116.0,7957,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622437,,10116.0,7958,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622438,,10116.0,7959,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622439,,10116.0,7960,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622440,,10116.0,7961,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622441,,10116.0,7962,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622442,,10116.0,7963,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622443,,10116.0,7964,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622444,,10116.0,7965,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622445,,10116.0,7966,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622446,,10116.0,7967,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622447,,10116.0,7968,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622448,,10116.0,7969,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622449,,10116.0,7970,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622450,,10116.0,7971,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622451,,10116.0,7972,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622452,,10116.0,7973,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622453,,10116.0,7974,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622454,,10116.0,7975,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622455,,10116.0,7976,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL876024,,10116.0,7977,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,9866,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622456,,10116.0,7978,,T max was determined at 3 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622457,,10116.0,7979,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622458,,10116.0,7980,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622459,,10116.0,7981,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL873343,,10116.0,7982,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622460,,10116.0,7983,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,15022,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622461,,10116.0,7984,,Time for maximum plasma concentration determined in rat,,4576,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622462,,10116.0,7985,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,6681,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622463,,10116.0,7986,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622464,,10116.0,7987,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622465,,10116.0,7988,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622466,,10116.0,7989,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622467,,10116.0,7990,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,16365,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622468,,10116.0,7991,,Time of maximum plasma concentration in rat,,6824,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL876025,,10116.0,7992,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,6685,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622469,,10116.0,7993,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,6685,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622470,,10116.0,7994,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622471,,10116.0,7995,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,15662,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622472,,10116.0,7996,,Time required to reach maximum concentration in rat plasma,,1742,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622473,,10116.0,7997,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,2774,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624282,,10116.0,7998,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,5199,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624283,,10116.0,7999,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,12873,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624284,,10116.0,8000,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,12873,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624285,,10116.0,8001,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624286,,10116.0,8002,,Time to reach Cmax after oral administration to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624287,,10116.0,8003,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624288,,10116.0,8004,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,216,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624289,,10116.0,8005,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,6410,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL873344,,10116.0,8006,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619623,,10116.0,8007,,Tmax after peroral administration (10 mg/kg) was determined in rat,,6215,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,,1,CHEMBL621399,,10116.0,8008,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621400,,10116.0,8009,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621401,,10116.0,8010,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,17670,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621402,,10116.0,8011,,Tmax was determined,,1465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621403,,10116.0,8012,,Tmax was determined,,2552,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621121,,10116.0,8013,,Tmax after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL872525,,10116.0,8014,,Tmax after peroral administration in rats at 2.4 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621122,,10116.0,8015,,Tmax in male rat,,5610,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621123,,10116.0,8016,,Tmax in rat at 10 mg/kg,,6046,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621124,,10116.0,8017,,Tmax in rat by po administration at a dose of 40 mg/kg,,5874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621125,,10116.0,8018,,Tmax in rats,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621126,,10116.0,8019,,Tmax was measured in rats after peroral administration at 5 mg/kg,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621127,,10116.0,8020,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,1908,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621128,,10116.0,8021,,Tmax value after administration of 20 mg/Kg oral dose in rat,,2959,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618263,,10116.0,8022,,Tmax value at a dose of 10 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618264,,10116.0,8023,,Tmax value at a dose of 100 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618265,,10116.0,8024,,Tmax value at a dose of 50 mg/kg in male SD rats,,6757,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL618266,,10116.0,8025,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618267,,10116.0,8026,,time required to reach maximum concentration (Cmax) after oral administration in rat,,15662,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL618450,,10116.0,8027,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,429,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL618451,,10116.0,8028,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618452,,10116.0,8029,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL618453,,10116.0,8030,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,3173,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL618454,,10116.0,8031,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,3173,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL618455,,10116.0,8032,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,3173,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618456,,10116.0,8033,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618457,,10116.0,8034,,Compound distribution in rat tissues was determined,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618458,,10116.0,8035,,Volume of distribution was evaluated in rat,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618459,,10116.0,8036,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876733,,10116.0,8037,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL618460,,9615.0,8038,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618461,,10116.0,8039,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL618462,,,8040,,Area under the curve was determined after oral administration (300 uM/Kg),,15469,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618463,,10116.0,8041,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618464,,10116.0,8042,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618465,,10116.0,8043,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618466,,10116.0,8044,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618467,,10116.0,8045,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618468,,10116.0,8046,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL618469,,9615.0,8047,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,12935,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL618470,,9615.0,8048,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,12935,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL618471,,,8049,,Plasma drug AUC in rat (PO dose),,14813,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618472,,10090.0,8050,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,15792,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL618473,,,8051,,Area under was determined at a dose of 30 mg/kg,,3579,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL621699,,9669.0,8052,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,12487,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621700,,10116.0,8053,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,12487,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621701,,10116.0,8054,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,12487,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL621702,,9669.0,8055,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,12487,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621703,,9615.0,8056,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,12487,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL621704,,9615.0,8057,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,12487,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624259,,10116.0,8058,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624260,,10116.0,8059,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624430,,10116.0,8060,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624431,,10116.0,8061,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624432,,10116.0,8062,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624433,,10116.0,8063,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624434,,10116.0,8064,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,12902,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624435,,10116.0,8065,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,12902,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618570,,10090.0,8066,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618571,,10090.0,8067,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618572,,10090.0,8068,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618573,,10090.0,8069,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619267,,10090.0,8070,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619431,,10090.0,8071,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619432,,10090.0,8072,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619433,,10090.0,8073,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,12745,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619434,,,8074,,AUC in mice after oral dose (50 mg/kg),,13298,,,BAO_0000218
,Serum,Mus musculus,Intermediate,1,50594,A,N,,,1977.0,1,CHEMBL619435,,10090.0,8075,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,12226,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL619436,,,8076,,AUC (0-4 hr) ug/ml/h,,12634,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL619437,,10116.0,8077,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,14810,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL619438,,,8078,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,13889,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL619439,,10090.0,8079,,Compound was evaluated for Area under curve in mice,,10018,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL619440,,10116.0,8080,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8758,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL619441,,,8081,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8758,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL619442,,10116.0,8082,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,8758,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875156,,,8083,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,2249,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL619443,,,8084,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,2249,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL619444,,,8085,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,2249,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623464,,,8086,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,2249,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623465,,10090.0,8087,,Compound was evaluated for area under curve when administered through oral route in mouse,,15115,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623466,,10116.0,8088,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623467,,10116.0,8089,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623468,,10116.0,8090,,Plasma clearance in rat,,6249,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622660,,10116.0,8091,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,2463,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622661,,10116.0,8092,,Plasma clearance rate in Sprague-Dawley rats,,4969,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,,1,CHEMBL622662,,10116.0,8093,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622663,,10116.0,8094,,Pharmacokinetic property (total body clearance) in rat,,3457,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622664,,10116.0,8095,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622665,,10116.0,8096,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,6295,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622666,,10116.0,8097,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,6296,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621615,,10116.0,8098,,Cl in rat i.v. at 2 mg/kg concentration,,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621616,,10116.0,8099,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621617,,10116.0,8100,,Clearance was determined,,5503,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621618,,10116.0,8101,,Clearance by intravenous administration of 3.4 mg/kg in rat,,4368,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621619,,10116.0,8102,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,6005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621620,,10116.0,8103,,Clearance rate after i.v. administration in rats,,5031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621786,,10116.0,8104,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621787,,10116.0,8105,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621788,,10116.0,8106,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621789,,10116.0,8107,,Clearance (Cl) after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621790,,10116.0,8108,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,17804,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621791,,10116.0,8109,,Compound was tested for plasma clearance in rat,,4839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL621792,,10116.0,8110,,In vitro microsome metabolism clearance in rat was determined,Microsomes,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL621793,,10116.0,8111,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Microsomes,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621794,,10116.0,8112,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621795,,10116.0,8113,,In vivo plasma clearance was determined,,5496,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621796,,10116.0,8114,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,5739,,,BAO_0000218
401.0,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621797,,10116.0,8115,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,5676,,Hepatocyte,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621798,,10116.0,8116,,Pharmacokinetic property (Plasma clearance) was measured in rat,,4239,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621799,,10116.0,8117,,Pharmacokinetic property (clearance) in rat i.v.,,5676,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621800,,10116.0,8118,,"Plasma Clearance was evaluated in rats, iv",,1918,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621801,,10116.0,8119,,Plasma clearance (in vivo) in rats was determined,,17800,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621802,,10116.0,8120,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,6056,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618596,,10116.0,8121,,Plasma clearance was determined,,5496,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618597,,10116.0,8122,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618598,,10116.0,8123,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618599,,10116.0,8124,,Plasma clearance in rats,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618600,,10116.0,8125,,Plasma clearance rate determined in rat,,4576,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618601,,10116.0,8126,,Plasma clearance was determined in rat,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618602,,10116.0,8127,,Plasma clearance was determined,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618603,,10116.0,8128,,Plasma clearance value in rat,,5948,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,Ex vivo,,2107.0,1,CHEMBL618604,,10116.0,8129,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,6125,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618605,,10116.0,8130,,Clearance in rat,,4839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618606,,10116.0,8131,,Total body clearance in rat i.v. at 2 mg/kg concentration,,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618607,,10116.0,8132,,Clearance of compound in rats after intravenous administration,,6571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618608,,10116.0,8133,,Clearance after iv administration to rats,,3364,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618609,,10116.0,8134,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618610,,10116.0,8135,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618611,,10116.0,8136,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618612,,10116.0,8137,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618613,,10116.0,8138,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621076,,10116.0,8139,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621077,,10116.0,8140,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621078,,10116.0,8141,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,17670,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621251,,10116.0,8142,,Clearance in rat,,5970,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621252,,10116.0,8143,,Clearance in rat after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621253,,10116.0,8144,,Clearance in rat.,,4590,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621254,,10116.0,8145,,Clearance rate following an oral dose of 20 mg/kg in rats,,6193,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621255,,10116.0,8146,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,2832,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621256,,10116.0,8147,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,1052,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621257,,10116.0,8148,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621258,,10116.0,8149,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621259,,10116.0,8150,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621260,,10116.0,8151,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL876494,,10116.0,8152,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621261,,10116.0,8153,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621262,,10116.0,8154,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621263,,10116.0,8155,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,9866,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621264,,10116.0,8156,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621265,,10116.0,8157,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621266,,10116.0,8158,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621267,,10116.0,8159,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621268,,10116.0,8160,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621269,,10116.0,8161,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621270,,10116.0,8162,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621271,,10116.0,8163,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621272,,10116.0,8164,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621273,,10116.0,8165,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621274,,10116.0,8166,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL876495,,10116.0,8167,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621275,,10116.0,8168,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621276,,10116.0,8169,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621277,,10116.0,8170,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621278,,10116.0,8171,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621279,,10116.0,8172,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,9866,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621280,,10116.0,8173,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621281,,10116.0,8174,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621282,,10116.0,8175,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621283,,10116.0,8176,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621284,,10116.0,8177,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621285,,10116.0,8178,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL621286,,10116.0,8179,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL623220,,10116.0,8180,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL623221,,10116.0,8181,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,9866,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL876029,,10116.0,8182,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,9866,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL623222,,10116.0,8183,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,9866,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL623223,,10116.0,8184,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,9866,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL621445,,10116.0,8185,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,9866,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL621446,,10116.0,8186,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL621447,,10116.0,8187,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL619681,,10116.0,8188,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL619682,,10116.0,8189,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL619683,,10116.0,8190,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL619684,,10116.0,8191,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL619685,,10116.0,8192,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL619686,,10116.0,8193,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL619687,,10116.0,8194,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL619688,,10116.0,8195,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL619689,,10116.0,8196,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL619690,,10116.0,8197,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL619691,,10116.0,8198,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619692,,10116.0,8199,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,,,,1,CHEMBL619693,,10116.0,8200,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619694,,10116.0,8201,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,1908,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619695,,10116.0,8202,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619696,,10116.0,8203,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,4891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619697,,10116.0,8204,,Compound was evaluated for volume of distribution in rat,,740,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619698,,10116.0,8205,,Steady state volume distribution was determined; steady state(ss),,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619699,,10116.0,8206,,Steady state volume of distribution after iv administration to rats,,3364,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619700,,10116.0,8207,,Steady state volume of distribution dosing at 3 mg/kg iv,,2552,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619701,,10116.0,8208,,The compound was evaluated for volume of distribution in rat,,406,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL619702,,10116.0,8209,,The compound was tested for volume of distribution in rat,,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620335,,10116.0,8210,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620336,,10116.0,8211,,Volume distribution (VD) after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620337,,10116.0,8212,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,17671,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620520,,10116.0,8213,,Volume distribution in rat,,1094,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620521,,10116.0,8214,,Volume distribution in rat,,5833,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875825,,10116.0,8215,,Volume distribution in rat after peroral administration at 10 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620522,,10116.0,8216,,Volume distribution in rat after peroral administration at 5 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620523,,10116.0,8217,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,6005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620524,,10116.0,8218,,Volume of distribution in rat.,,1696,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620525,,10116.0,8219,,Volume of distribution in rat,,6672,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620526,,10116.0,8220,,Volume of distribution in rat,,6673,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620527,,10116.0,8221,,Volume of distribution in rat by iv administration,,5871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620528,,10116.0,8222,,Volume of distribution in rats,,6803,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620529,,10116.0,8223,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,5199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620530,,10116.0,8224,,Volume distribution at the dose of 2 mg/kg in rat,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620531,,10116.0,8225,,Steady state volume of distribution was determined,,16367,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL620532,,9544.0,8226,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL620533,,10116.0,8227,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL620534,,10116.0,8228,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620535,,10116.0,8229,,Mean (%CV) PK parameters for Vdss(mL/kg).,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875826,,10116.0,8230,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620536,,10116.0,8231,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620537,,10116.0,8232,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618526,,10116.0,8233,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618527,,10116.0,8234,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,5739,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618528,,10116.0,8235,,Pharmacokinetic property (Vdss) in rat,,5789,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618529,,10116.0,8236,,Pharmacokinetic property (vdss) was measured in rat,,4239,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618530,,10116.0,8237,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618531,,10116.0,8238,,Volume of distribution in rat,,6642,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618532,,10116.0,8239,,The pharmacokinetic parameter volume of distribution in vivo in rats,,5247,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,,1,CHEMBL618533,,10116.0,8240,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618534,,10116.0,8241,,Vdss in rat i.v. at 2 mg/kg concentration,,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618535,,10116.0,8242,,Volume distribution after intravenous administration (1 mg/kg) in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618536,,10116.0,8243,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618537,,10116.0,8244,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618538,,10116.0,8245,,Volume distribution at a dose of 10 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618539,,10116.0,8246,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618540,,10116.0,8247,,Volume distribution was calculated in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618541,,10116.0,8248,,Volume distribution was determined,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618542,,10116.0,8249,,Volume of distribution after intravenous administration was evaluated in rat,,2938,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622544,,10116.0,8250,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622545,,10116.0,8251,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622546,,10116.0,8252,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622547,,10116.0,8253,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622548,,10116.0,8254,,Volume of distribution in steady state was determined in rat,,5145,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622549,,10116.0,8255,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,6467,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622550,,10116.0,8256,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,6467,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622551,,10090.0,8257,,Compound was evaluated for area under curve when administered through oral route to mouse,,15115,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622552,,10116.0,8258,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8758,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622553,,10116.0,8259,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,8758,,,BAO_0000218
,,,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL622554,,,8260,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,8267,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622555,,9615.0,8261,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,8267,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622556,,10090.0,8262,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,14239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622557,,10090.0,8263,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,14239,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL622558,,10090.0,8264,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL622559,,10090.0,8265,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,10754,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622560,,9615.0,8266,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,10754,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622561,,10116.0,8267,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,14681,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622562,,10116.0,8268,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,14681,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622563,,10116.0,8269,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,14681,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622564,,,8270,,Concentration of compound in Central nervous system,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622565,,,8271,,Concentration of compound in Central nervous system; Not detectable,,13118,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622566,,10090.0,8272,,"Concentration of diester in the blood, following oral administration in mice",,13318,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624515,,10090.0,8273,,"Concentration of monoester in the blood, following oral administration in mice",,13318,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624516,,10090.0,8274,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,13318,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624517,,,8275,,Evaluated for Pharmacokinetic property: Area under the curve,,15692,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624518,,10090.0,8276,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624519,,9541.0,8277,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624520,,9541.0,8278,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624521,,9541.0,8279,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624522,,9541.0,8280,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624523,,9541.0,8281,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624409,,9541.0,8282,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624410,,9541.0,8283,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL624411,,9541.0,8284,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623531,,9541.0,8285,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623532,,9541.0,8286,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623533,,9541.0,8287,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623534,,9541.0,8288,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623535,,10090.0,8289,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623536,,10090.0,8290,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623537,,10090.0,8291,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623538,,10090.0,8292,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623539,,10090.0,8293,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623540,,10090.0,8294,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623541,,10090.0,8295,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623542,,10090.0,8296,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623543,,10090.0,8297,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623544,,10090.0,8298,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623545,,10090.0,8299,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623546,,10090.0,8300,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,14839,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623547,,10116.0,8301,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623548,,10116.0,8302,,High i.v. clearance in Dawley rats,,6827,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL623549,,10116.0,8303,,In vitro clearance in rat liver microsomes,Microsomes,17538,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL623550,,10116.0,8304,,Intrinsic clearance in rat liver microsomes was determined,Microsomes,6331,,,BAO_0000218
401.0,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL875276,,10116.0,8305,,Intrinsic clearance in rat hepatocytes was determined,,5948,,Hepatocyte,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621872,,10116.0,8306,,Plasma Clearance was determined,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621873,,10116.0,8307,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621874,,10116.0,8308,,Plasma clearance in rat.,,1696,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621875,,10116.0,8309,,Plasma clearance in rats,,6597,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621876,,10116.0,8310,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,347,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621877,,10116.0,8311,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621878,,10116.0,8312,,Plasma clearance was measured in rat,,2879,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621879,,10116.0,8313,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,4883,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621880,,10116.0,8314,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,5328,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621881,,10116.0,8315,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,5160,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621882,,10116.0,8316,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875283,,10116.0,8317,,Total clearance at 1 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621883,,10116.0,8318,,Total clearance at 10 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621884,,10116.0,8319,,Clearance in rat,,6596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621885,,10116.0,8320,,Plasma clearance rate determined in rats,,4796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621886,,10116.0,8321,,Clearance of compound in rat was evaluated,,6850,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621887,,10116.0,8322,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,5932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621888,,10116.0,8323,,Pharmacokinetic property (blood clearance) in rat,,3371,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621889,,10116.0,8324,,Plasma clearance in rat,,2083,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621890,,10116.0,8325,,Plasma clearance in rats,,4942,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL621891,,10116.0,8326,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Microsomes,6838,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621892,,10116.0,8327,,Clearance in Dawley rat,,5353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621893,,10116.0,8328,,Clearance rat,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621894,,10116.0,8329,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621895,,10116.0,8330,,Clearance rat; Not determined,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875284,,10116.0,8331,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618699,,10116.0,8332,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618700,,10116.0,8333,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618701,,10116.0,8334,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,6211,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL876600,,10116.0,8335,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618702,,10116.0,8336,,Clearance of compound in rat after 1 mg/kg i.v. administration,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618703,,10116.0,8337,,Compound was evaluated for Hepatic clearance in rat,,3341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618704,,10116.0,8338,,In vivo clearance after 5 mg/kg dose,,4891,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL618705,,10116.0,8339,,Compound was tested for plasma clearance in rats,,1094,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618706,,10116.0,8340,,Hepatic clearance after intravenous administration was evaluated in rat,,2938,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618707,,10116.0,8341,,Lower clearance in rat (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL618708,,10116.0,8342,,Pharmacokinetic parameter expressed as plasma clearance in rat,,6049,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618709,,10116.0,8343,,Pharmacokinetic property (Clp) in rat,,5789,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618710,,10116.0,8344,,Plasma clearance in Sprague-Dawley rats,,4514,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618711,,10116.0,8345,,Plasma clearance (Clp) in rat,,6448,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618712,,10116.0,8346,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618713,,10116.0,8347,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618714,,10116.0,8348,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618715,,10116.0,8349,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618716,,10116.0,8350,,Plasma clearance in rat was determined,,1742,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876601,,10116.0,8351,,Plasma clearance measured in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618717,,10116.0,8352,,Plasma clearance was calculated in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618718,,10116.0,8353,,Plasma clearance in rat,,5145,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618719,,10116.0,8354,,Plasma clearance in rat,,5833,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618720,,10116.0,8355,,Plasma clearance in rat,,6453,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618721,,10116.0,8356,,Plasma clearance in rat,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621477,,10116.0,8357,,Plasma clearance in rats,,6305,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621478,,10116.0,8358,,Plasma clearance in rat,,6642,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621479,,10116.0,8359,,Plasma clearance was evaluated in rat,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621480,,10116.0,8360,,Plasma clearance was evaluated in rat; Not tested,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621481,,10116.0,8361,,Plasma clearance rate was determined for the compound in rat,,5144,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621482,,10116.0,8362,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621483,,10116.0,8363,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621484,,10116.0,8364,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,6685,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621485,,10116.0,8365,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL621486,,10116.0,8366,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621487,,10116.0,8367,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621488,,10116.0,8368,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621489,,10116.0,8369,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621490,,10116.0,8370,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL621491,,10116.0,8371,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621492,,10116.0,8372,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621493,,10116.0,8373,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621494,,10116.0,8374,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621495,,10116.0,8375,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621496,,10116.0,8376,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621497,,10116.0,8377,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621498,,10116.0,8378,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621499,,10116.0,8379,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL618634,,10116.0,8380,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL618635,,10116.0,8381,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL618636,,10116.0,8382,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL619737,,10116.0,8383,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL619738,,10116.0,8384,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624329,,10116.0,8385,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624330,,10116.0,8386,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624331,,10116.0,8387,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624332,,10116.0,8388,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624333,,10116.0,8389,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624334,,10116.0,8390,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624335,,10116.0,8391,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL620016,,10116.0,8392,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL620169,,10116.0,8393,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL620170,,10116.0,8394,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL620171,,10116.0,8395,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL620172,,10116.0,8396,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL620173,,10116.0,8397,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL620174,,10116.0,8398,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL620175,,10116.0,8399,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL620176,,10116.0,8400,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL620177,,10116.0,8401,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL620178,,10116.0,8402,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL620179,,10116.0,8403,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620180,,10116.0,8404,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620181,,10116.0,8405,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620182,,10116.0,8406,,Volume of distribution of compound in rats after intravenous administration,,6571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620183,,10116.0,8407,,Volume of distribution in rat,,6453,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620184,,10116.0,8408,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620185,,10116.0,8409,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620186,,10116.0,8410,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620187,,10116.0,8411,,Volume of distribution was determined in Dawley rat,,5353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620188,,10116.0,8412,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620189,,10116.0,8413,,Volume of distribution was reported in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620190,,10116.0,8414,,Volumes of distribution in rat after peroral administration,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620191,,10116.0,8415,,Volumes of distribution in rat after po administration,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620192,,10116.0,8416,,Volumes of distribution in rat after po administration; Not determined,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620193,,10116.0,8417,,Pharmacokinetic property (Volume) in rat i.v.,,5676,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620194,,10116.0,8418,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876730,,10116.0,8419,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,17670,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620195,,10116.0,8420,,Volume distribution in rat after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620196,,10116.0,8421,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620197,,10116.0,8422,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,4883,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620198,,10116.0,8423,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620199,,10116.0,8424,,Volume of distribution in rats,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620200,,10116.0,8425,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620201,,10116.0,8426,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620202,,10116.0,8427,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620203,,10116.0,8428,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620204,,10116.0,8429,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620205,,10116.0,8430,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624664,,10116.0,8431,,Pharmacokinetic parameter (Vss) in rat,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624665,,10116.0,8432,,Pharmacokinetic property (Volume) in rat i.v.,,5676,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624666,,10116.0,8433,,Pharmacokinetic property (Vss) in rat,,5948,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624667,,10116.0,8434,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624668,,10116.0,8435,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624669,,10116.0,8436,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624670,,10116.0,8437,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624671,,10116.0,8438,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624672,,10116.0,8439,,Steady state volume distribution in rat,,6448,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624673,,10116.0,8440,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624674,,10116.0,8441,,Steady state volume of distribution determined in rat,,4576,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624675,,10116.0,8442,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621728,,10116.0,8443,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621729,,10116.0,8444,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621730,,10116.0,8445,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621731,,10116.0,8446,,Volume distribution in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621732,,10116.0,8447,,Volume distribution in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621908,,10116.0,8448,,Volume in steady state distribution value was determined,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875347,,10116.0,8449,,Volume in steady state distribution value was determined; ND denotes no data,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621909,,10116.0,8450,,Volume in steady state distribution value was determined; ND denotes not determined,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621910,,10116.0,8451,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,17065,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621911,,10116.0,8452,,Volume of distribution at steady state was evaluated in rats,,6597,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621912,,10116.0,8453,,Volume of distribution at steady state was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621913,,10116.0,8454,,Volume of distribution in steady state was determined in rat,,6485,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621914,,10116.0,8455,,Volume of distribution in steady state was determined in rat,,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621915,,10116.0,8456,,Volume of distribution after i.v. administration,,6616,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621916,,10116.0,8457,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,1916,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621917,,10090.0,8458,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL621918,,10090.0,8459,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL621919,,10090.0,8460,,Biodistribution of compound (oxidized form) in spleen tissue,,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL621920,,10090.0,8461,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL621921,,10090.0,8462,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL622401,,10090.0,8463,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL875348,,10090.0,8464,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL622402,,10090.0,8465,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622403,,10090.0,8466,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,16438,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL622404,,10090.0,8467,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622405,,10090.0,8468,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622406,,10090.0,8469,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL622407,,10090.0,8470,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622408,,10090.0,8471,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622409,,10090.0,8472,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL622410,,10090.0,8473,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL622411,,10090.0,8474,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL627864,,10090.0,8475,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,16438,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL627865,,10090.0,8476,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL627866,,10090.0,8477,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,16438,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL627751,,10090.0,8478,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL627752,,10090.0,8479,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL627753,,10090.0,8480,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,16438,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL627754,,10090.0,8481,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,16438,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627755,,10090.0,8482,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,12467,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627756,,10090.0,8483,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627757,,10090.0,8484,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627758,,10090.0,8485,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627759,,10090.0,8486,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627760,,10090.0,8487,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,In vivo,,955.0,1,CHEMBL627761,,10090.0,8488,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL876811,,10090.0,8489,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL627762,,10090.0,8490,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL627763,,10090.0,8491,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL627764,,10090.0,8492,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL627765,,10090.0,8493,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL627766,,10090.0,8494,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL627767,,10090.0,8495,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL627768,,10090.0,8496,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL628422,,10090.0,8497,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL628423,,10090.0,8498,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628424,,10116.0,8499,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,5089,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628425,,10116.0,8500,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,5089,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628426,,10116.0,8501,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,4257,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628427,,10116.0,8502,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626938,,10116.0,8503,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626939,,10116.0,8504,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,6141,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626940,,10116.0,8505,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626941,,10116.0,8506,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626942,,10116.0,8507,,Plasma clearance was reported in Sprague-Dawley rat,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876812,,10116.0,8508,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626943,,10116.0,8509,,Plasma clearance of compound in rats was evaluated,,6848,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626944,,10116.0,8510,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,6848,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626945,,10116.0,8511,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,6467,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626946,,10116.0,8512,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,6467,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626856,,10116.0,8513,,Plasma clearance rate in Sprague-Dawley rats,,4956,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626857,,10116.0,8514,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,5529,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626858,,10116.0,8515,,The compound was evaluated for plasma clearance in rat,,406,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627018,,10116.0,8516,,Total plasma clearance in rat,,17655,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625331,,10116.0,8517,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,3293,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625332,,10116.0,8518,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,4075,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877590,,10116.0,8519,,C max was determined at 10 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625333,,10116.0,8520,,C max was determined at 3 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625334,,10116.0,8521,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,17594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625335,,10116.0,8522,,Cmax after single intravenous bolus of 1 mg/kg in rats,,17594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625336,,10116.0,8523,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,4762,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625337,,10116.0,8524,,Cmax 24 hr after 10 mg/kg oral administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625338,,10116.0,8525,,Cmax 24 hr after 2 mg/kg oral administration in rats,,17509,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625339,,10116.0,8526,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625340,,10116.0,8527,,Cmax in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625341,,10116.0,8528,,Cmax in rat after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622687,,10116.0,8529,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,3169,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622688,,10116.0,8530,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,6515,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622689,,10116.0,8531,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,11149,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL620295,,10116.0,8532,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,11149,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620296,,10116.0,8533,,Cmax after 10 mg/kg oral administration in rat,,17858,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620297,,10116.0,8534,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620298,,10116.0,8535,,Cmax after IV dosing at 1 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620299,,10116.0,8536,,Cmax after oral administration at 20 mpk in rats,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620300,,10116.0,8537,,Cmax after oral administration at 20 mpk in rats; Not performed.,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620301,,10116.0,8538,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620302,,10116.0,8539,,Cmax after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620303,,10116.0,8540,,Cmax after oral administration at a dose of 2 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620304,,10116.0,8541,,Cmax after oral administration at a dose of 4 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620305,,10116.0,8542,,Cmax in rats after 20 mg/kg oral dose,,6113,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620306,,10116.0,8543,,Cmax after peroral administration in rats at 2.4 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620307,,10116.0,8544,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620308,,10116.0,8545,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620309,,10116.0,8546,,Cmax by administering at 20 mg/kg p.o. in rats,,6402,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620310,,10116.0,8547,,Cmax in male rat,,5610,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620311,,10116.0,8548,,Cmax in rat,,5207,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620312,,10116.0,8549,,Cmax in rat,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620313,,10116.0,8550,,Cmax in rat,,6504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620314,,10116.0,8551,,Cmax in rat at 10 mg/kg,,6046,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620315,,10116.0,8552,,Cmax in rat at the dose of 1 mg/kg i.v.,,6504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620316,,10116.0,8553,,Cmax in rat by po administration at a dose of 40 mg/kg,,5874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620317,,10116.0,8554,,Cmax in rat p.o. at 20 mg/kg concentration,,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620318,,10116.0,8555,,Cmax in rats,,5836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620319,,10116.0,8556,,Cmax in rats,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620320,,10116.0,8557,,Cmax was evaluated after 20 uM/kg of peroral administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620321,,10116.0,8558,,Cmax was measured in rats after peroral administration at 3 mg/kg,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620322,,10116.0,8559,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,1908,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620323,,10116.0,8560,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Frontal cortex,Rattus norvegicus,Intermediate,1,50597,A,N,,,1870.0,1,CHEMBL620324,,10116.0,8561,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Frontal cortex,Rattus norvegicus,Intermediate,1,50597,A,N,,,1870.0,1,CHEMBL620325,,10116.0,8562,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL620326,,10116.0,8563,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL620327,,10116.0,8564,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620328,,10116.0,8565,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620329,,10116.0,8566,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Midbrain,Rattus norvegicus,Intermediate,1,50597,A,N,,,1891.0,1,CHEMBL620330,,10116.0,8567,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Midbrain,Rattus norvegicus,Intermediate,1,50597,A,N,,,1891.0,1,CHEMBL875286,,10116.0,8568,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620331,,10116.0,8569,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620332,,10116.0,8570,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL620333,,10116.0,8571,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL620334,,10116.0,8572,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,13950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621015,,10116.0,8573,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621016,,10116.0,8574,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621191,,10116.0,8575,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621192,,10116.0,8576,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621193,,10116.0,8577,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL621194,,10116.0,8578,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624204,,10116.0,8579,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624205,,10116.0,8580,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624206,,10116.0,8581,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624207,,10116.0,8582,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624208,,10116.0,8583,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624209,,10116.0,8584,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624210,,10116.0,8585,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624211,,10116.0,8586,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624212,,10116.0,8587,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624213,,10116.0,8588,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL876611,,10116.0,8589,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624214,,10116.0,8590,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624215,,10116.0,8591,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624216,,10116.0,8592,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624217,,10116.0,8593,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624218,,10116.0,8594,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624219,,10116.0,8595,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624220,,10116.0,8596,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624221,,10116.0,8597,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624222,,10116.0,8598,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624223,,10116.0,8599,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624224,,10116.0,8600,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624225,,10116.0,8601,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622420,,10116.0,8602,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622421,,10116.0,8603,,Volume of steady state distribution after i.v. administration in rats,,5031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622422,,10116.0,8604,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,6215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622423,,10116.0,8605,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,17671,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622424,,10116.0,8606,,Vss was determined,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622425,,10116.0,8607,,Vss in rat,,6596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876612,,10116.0,8608,,Vss was evaluated after 10 uM/kg of intra arterial administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622426,,10116.0,8609,,volume of distribution at steady state was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622427,,10116.0,8610,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622428,,10116.0,8611,,Pharmacokinetic (PK) parameter Vz in rat,,5874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622429,,10116.0,8612,,Volume distribution in rats,,4942,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622430,,10116.0,8613,,Volume of distribution in rat; No data,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622431,,10116.0,8614,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,Ileum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2116.0,1,CHEMBL622432,,10116.0,8615,,% absorption predicted from in vitro rat ileum transport studies,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622433,,10116.0,8616,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622434,,10116.0,8617,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622435,,10116.0,8618,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618748,,10116.0,8619,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618749,,10116.0,8620,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618750,,10116.0,8621,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618751,,10116.0,8622,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618752,,10116.0,8623,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,13569,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618753,,10116.0,8624,,Oral bioavailability in rat,,4576,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL618754,,10116.0,8625,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,750,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618755,,10116.0,8626,,Oral bioavailability in rat,,750,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618756,,10116.0,8627,,Oral bioavailability in rat,,4590,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618757,,10116.0,8628,,Oral bioavailability in rat,,1716,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618758,,10116.0,8629,,Bioavailability in rat,,1974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621088,,10116.0,8630,,Oral bioavailability in rat (dose 30 mg/kg),,4502,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621089,,10116.0,8631,,Pharmacokinetic property (cLogP) in rat,,3371,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,F,N,,,178.0,1,CHEMBL621090,,10116.0,8632,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,9099,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,F,N,,,178.0,1,CHEMBL621091,,10116.0,8633,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,9099,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876731,,10116.0,8634,,Clearance in rat.,,4590,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621092,,10116.0,8635,,Compound was evaluated for its clearance when administered intravenously in rat,,3184,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621093,,10116.0,8636,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621094,,10116.0,8637,,Blood: Brain distribution ratio is determined in rat,,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621095,,10116.0,8638,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621096,,10116.0,8639,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,4199,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL621097,,10116.0,8640,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL621098,,10116.0,8641,,Percent dose excreted in 0-48 hours administered ip to male rat,,7449,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL621099,,10116.0,8642,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL621100,,10116.0,8643,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL621101,,10116.0,8644,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL621102,,10116.0,8645,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2037.0,1,CHEMBL876732,,10116.0,8646,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621103,,10116.0,8647,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621104,,10116.0,8648,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621105,,10116.0,8649,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621106,,10116.0,8650,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621107,,10116.0,8651,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621108,,10116.0,8652,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621109,,10116.0,8653,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621110,,10090.0,8654,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL621111,,10090.0,8655,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622541,,10090.0,8656,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622542,,10090.0,8657,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL622543,,10090.0,8658,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624412,,10090.0,8659,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624413,,10090.0,8660,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL624414,,10090.0,8661,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624415,,10090.0,8662,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624416,,10090.0,8663,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624417,,10090.0,8664,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624418,,10090.0,8665,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624419,,10090.0,8666,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL624420,,10090.0,8667,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL624421,,10090.0,8668,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL624422,,10090.0,8669,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL624423,,10090.0,8670,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL625123,,10090.0,8671,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL625124,,10090.0,8672,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2385.0,1,CHEMBL625125,,10090.0,8673,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL625126,,10090.0,8674,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL626947,,10090.0,8675,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL626948,,10090.0,8676,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL626949,,10090.0,8677,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL626950,,10090.0,8678,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL626951,,10090.0,8679,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626952,,10090.0,8680,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626953,,10090.0,8681,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626954,,10090.0,8682,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626955,,10090.0,8683,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626956,,10090.0,8684,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL626957,,10090.0,8685,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626958,,10090.0,8686,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626959,,10090.0,8687,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626960,,10090.0,8688,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626961,,10090.0,8689,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL627589,,10090.0,8690,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL627590,,10090.0,8691,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,17208,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627591,,10090.0,8692,,Time taken for EC90 was determined when tested in mouse,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627592,,10090.0,8693,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627593,,10090.0,8694,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,16597,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627594,,10090.0,8695,,Half life in mice,,5727,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876813,,10090.0,8696,,Half life period in mouse after 10 mg/Kg dose,,5302,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627595,,10090.0,8697,,Half life period in mouse after 10 mg/kg dose,,5302,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627596,,10090.0,8698,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6348,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627597,,10116.0,8699,,Cmax value at 5 mg/kg po was determined in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627598,,10116.0,8700,,Cmax value evaluated in rat,,6078,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL627599,,10116.0,8701,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,5206,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627600,,10116.0,8702,,Cmax value after administration of 20 mg/Kg oral dose in rat,,2959,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627601,,10116.0,8703,,Cmax value at 1 mg/kg po in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627776,,10116.0,8704,,Cmax value at 5 mg/kg po in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627777,,10116.0,8705,,Cmax value at a dose of 10 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627778,,10116.0,8706,,Cmax value at a dose of 100 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627779,,10116.0,8707,,Cmax value at a dose of 50 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876814,,10116.0,8708,,Cmax value in rats at 10 mg/kg,,17617,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627780,,10116.0,8709,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,1445,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627781,,10116.0,8710,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,6082,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627782,,10116.0,8711,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,1446,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627783,,10116.0,8712,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,5407,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627784,,10116.0,8713,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,2690,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627785,,10116.0,8714,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627786,,10116.0,8715,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,2661,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627787,,10116.0,8716,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,4891,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627788,,10116.0,8717,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,2807,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626579,,10116.0,8718,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,2807,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626580,,10116.0,8719,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,2807,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876815,,10116.0,8720,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,3634,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626581,,10116.0,8721,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,1881,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626582,,10116.0,8722,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,1881,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626583,,10116.0,8723,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626205,,10116.0,8724,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626206,,10116.0,8725,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626207,,10116.0,8726,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623882,,10116.0,8727,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623883,,10116.0,8728,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623884,,10116.0,8729,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,17582,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623885,,10116.0,8730,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,3032,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623886,,10116.0,8731,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,6295,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623887,,10116.0,8732,,Maximal concentration in rat was determined,,6619,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623888,,10116.0,8733,,Maximal concentration after i.v. administration,,6616,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623889,,10116.0,8734,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,3249,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623890,,10116.0,8735,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,17791,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623891,,10116.0,8736,,Cmax in rat plasma after oral dose (50 mg/Kg),,17791,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623892,,10116.0,8737,,Maximal plasma concentration was determined.,,1360,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623893,,10116.0,8738,,Maximal plasma drug concentration was determined,,2552,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877616,,10116.0,8739,,Maximal concentration in rats after peroral administration,,6571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623894,,10116.0,8740,,Maximum concentration in rat after 2 mg/kg peroral administration,,6570,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623895,,10116.0,8741,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,6567,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623896,,10116.0,8742,,Maximum concentration of compound in rat was evaluated.,,3031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623897,,10116.0,8743,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,3436,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623898,,10116.0,8744,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,3436,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623899,,10116.0,8745,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,2083,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623900,,10116.0,8746,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,3436,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623901,,10116.0,8747,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623902,,10116.0,8748,,Maximum concentration was evaluated in rats,,1974,,,BAO_0000218
,Cerebrospinal fluid,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1359.0,1,CHEMBL623903,,10116.0,8749,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,3307,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623904,,10116.0,8750,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,3307,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL877617,,10116.0,8751,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623905,,10116.0,8752,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,1500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623906,,10116.0,8753,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,1500,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623907,,10116.0,8754,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623908,,10116.0,8755,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623909,,10116.0,8756,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623910,,10116.0,8757,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623911,,10116.0,8758,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623912,,10116.0,8759,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624616,,10116.0,8760,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624617,,10116.0,8761,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624618,,10116.0,8762,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624619,,10116.0,8763,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624794,,10116.0,8764,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624795,,10116.0,8765,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623921,,10116.0,8766,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623922,,10116.0,8767,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623923,,10116.0,8768,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623924,,10116.0,8769,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623925,,10116.0,8770,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623926,,10116.0,8771,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623927,,10116.0,8772,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623928,,10116.0,8773,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623929,,10116.0,8774,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623930,,10116.0,8775,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL623931,,10116.0,8776,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622165,,10116.0,8777,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621249,,10116.0,8778,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621250,,10116.0,8779,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621448,,10116.0,8780,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621449,,10116.0,8781,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621450,,10116.0,8782,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621451,,10116.0,8783,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621452,,10116.0,8784,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621453,,10116.0,8785,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621454,,10116.0,8786,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621455,,10116.0,8787,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL621456,,10116.0,8788,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625145,,10116.0,8789,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL875847,,10116.0,8790,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625146,,10116.0,8791,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625147,,10116.0,8792,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625148,,10116.0,8793,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625149,,10116.0,8794,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625150,,10116.0,8795,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625151,,10116.0,8796,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625152,,10116.0,8797,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625153,,10116.0,8798,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625154,,10116.0,8799,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL625155,,10116.0,8800,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625156,,10116.0,8801,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624354,,10116.0,8802,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL624355,,10116.0,8803,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL624356,,10116.0,8804,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL624357,,10116.0,8805,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,,,10000000.0,1,CHEMBL624358,,10116.0,8806,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL624359,,10116.0,8807,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL624360,,10116.0,8808,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL624361,,10116.0,8809,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL624362,,10116.0,8810,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL624363,,10116.0,8811,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624364,,10116.0,8812,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624365,,10116.0,8813,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624366,,10116.0,8814,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624367,,10116.0,8815,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624368,,10116.0,8816,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624369,,10116.0,8817,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624370,,10116.0,8818,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625069,,10116.0,8819,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625070,,10116.0,8820,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626051,,10116.0,8821,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626052,,10116.0,8822,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626053,,10116.0,8823,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626054,,10116.0,8824,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626055,,10116.0,8825,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626056,,10116.0,8826,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626057,,10116.0,8827,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625193,,10116.0,8828,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625194,,10116.0,8829,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625195,,10116.0,8830,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625196,,10116.0,8831,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625197,,10116.0,8832,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625198,,10116.0,8833,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627929,,10116.0,8834,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627074,,10116.0,8835,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627075,,10116.0,8836,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627076,,10116.0,8837,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627077,,10116.0,8838,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627078,,10116.0,8839,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627079,,10116.0,8840,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL873824,,10090.0,8841,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,4573,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627080,,10090.0,8842,,Half life in mouse plasma was determined at dose 25 mg/kg,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627081,,10090.0,8843,,Half life was determined,,17718,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627082,,10090.0,8844,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627083,,10090.0,8845,,Half-life in male mice after 1 mg/kg intravenous dose,,5961,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL627085,,10090.0,8847,,Half life in mice plasma,,17731,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627086,,10090.0,8848,,Half life in mouse,,17592,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627087,,10090.0,8849,,Half life in mouse plasma at dose 25 mg/kg,,3132,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627088,,10090.0,8850,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627089,,10090.0,8851,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627090,,10090.0,8852,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,17729,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627091,,10090.0,8853,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,3277,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627092,,10090.0,8854,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL876785,,10090.0,8855,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,3760,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627093,,10090.0,8856,,Half-life by iv administration in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627094,,10090.0,8857,,Half-life by oral administration in mouse,,2862,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627095,,10090.0,8858,,Half-life in mice,,5980,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL627096,,10090.0,8859,,Half-life using mouse brain homogenate,,6159,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627097,,10090.0,8860,,Half-life was measured in mice,,6254,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627098,,10090.0,8861,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,,,178.0,1,CHEMBL627099,,10090.0,8862,,Half-life period was determined in mouse blood,,1574,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL627100,,10090.0,8863,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,56,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL627101,,10090.0,8864,,Plasma half life in mouse,,993,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627102,,10090.0,8865,,Stability of the peptide in the presence of mouse serum,,6652,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627103,,10090.0,8866,,Terminal half life of compound was determined in mouse,,17852,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627104,,10090.0,8867,,Terminal half life was evaluated in mice after intravenous administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627105,,10090.0,8868,,Terminal half life was evaluated in mice after oral administration,,2675,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL876786,,10090.0,8869,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,499,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL873825,,10090.0,8870,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,499,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627106,,10090.0,8871,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,499,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626336,,10090.0,8872,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,14239,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL877462,,10090.0,8873,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626337,,10090.0,8874,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,5506,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626338,,10090.0,8875,,Half life after intraperitoneal administration of 100 mg/kg in mice,,17734,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626339,,10090.0,8876,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626340,,10090.0,8877,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625377,,10090.0,8878,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625378,,10090.0,8879,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,17728,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625379,,10090.0,8880,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,17728,,,BAO_0000218
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL625380,,9823.0,8881,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL625381,,9823.0,8882,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Microsomes,14294,,,BAO_0000251
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL625382,,9823.0,8883,,Stability to porcine renal DHP-I,,6056,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL873828,,9823.0,8884,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,1317,,,BAO_0000218
,,Sus scrofa,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625383,,9823.0,8885,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,1317,,,BAO_0000218
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL625384,,9823.0,8886,,Half-life of the parent prodrug in porcine esterase solution,,5229,,,BAO_0000019
,,Sus scrofa,Autocuration,1,22224,A,U,,,,0,CHEMBL625385,,9823.0,8887,,"First order rate constant, k was determined in in pig liver Esterase",,4231,,,BAO_0000019
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL625386,,9823.0,8888,,Half life of the in pig liver Esterase,,4231,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623571,,9823.0,8889,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,5318,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623572,,9823.0,8890,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,5318,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623573,,9823.0,8891,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,5318,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623574,,9823.0,8892,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,3305,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623575,,9823.0,8893,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,3305,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623749,,9823.0,8894,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,2842,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623750,,9823.0,8895,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,2842,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,In vitro,,2107.0,0,CHEMBL623751,,9823.0,8896,,Half-life in vitro in pig liver,,889,,,BAO_0000221
,Liver,Sus scrofa,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL623752,,9823.0,8897,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,1904,,,BAO_0000221
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623753,,10116.0,8898,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623754,,10116.0,8899,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,2774,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623755,,10116.0,8900,,Maximum concentration in rat plasma was determined,,1742,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623756,,10116.0,8901,,Maximum concentration in rats,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623757,,10116.0,8902,,Maximum concentration in rats at 1-2 hours,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623758,,10116.0,8903,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,2081,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623759,,10116.0,8904,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,3307,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623760,,10116.0,8905,,Maximum concentration at the dose of 2 mg/kg in rat,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623761,,10116.0,8906,,Maximum concentration was evaluated in rats,,6597,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623762,,10116.0,8907,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,16365,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL877594,,10116.0,8908,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,16365,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623763,,10116.0,8909,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,16365,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623764,,10116.0,8910,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,16365,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623765,,10116.0,8911,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,16365,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623766,,10116.0,8912,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,2591,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623767,,10116.0,8913,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,2591,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623768,,10116.0,8914,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,2591,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623769,,10116.0,8915,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623770,,10116.0,8916,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623771,,10116.0,8917,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623772,,10116.0,8918,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623773,,10116.0,8919,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623774,,10116.0,8920,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623775,,10116.0,8921,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623776,,10116.0,8922,,Cmax in rat (PO dose),,14465,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622191,,10116.0,8923,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622192,,10116.0,8924,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622193,,10116.0,8925,,Maximum plasma concentration determined in rat,,4576,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622194,,10116.0,8926,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,12873,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622195,,10116.0,8927,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,12873,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622196,,10116.0,8928,,Maximum plasma concentration in rat,,6824,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622197,,10116.0,8929,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,17065,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622198,,10116.0,8930,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,2932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622199,,10116.0,8931,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,2932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622200,,10116.0,8932,,Maximum plasma concentration of compound was measured in rat,,2879,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622201,,10116.0,8933,,Maximum plasma concentration after 20 mg/kg oral administration in rat,,2864,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623990,,10116.0,8934,,Maximum plasma concentration after oral administration to rats,,16367,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623991,,10116.0,8935,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623992,,10116.0,8936,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,17717,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623993,,10116.0,8937,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623994,,10116.0,8938,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,17717,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,1969.0,1,CHEMBL623995,,10116.0,8939,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,1969.0,1,CHEMBL623996,,10116.0,8940,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,1969.0,1,CHEMBL623997,,10116.0,8941,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623998,,10116.0,8942,,Maximum plasma concentration dosed orally in rats,,4516,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623999,,10116.0,8943,,Maximum plasma concentration dosed orally in rats after 6 hours,,4516,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624000,,10116.0,8944,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,4516,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624001,,10116.0,8945,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,5199,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624002,,10116.0,8946,,Maximum plasma concentration in rat after po administration,,17538,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624003,,10116.0,8947,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,6685,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL624004,,10116.0,8948,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,6685,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624005,,10116.0,8949,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624006,,10116.0,8950,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624007,,10116.0,8951,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624008,,10116.0,8952,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624009,,10116.0,8953,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL874387,,10116.0,8954,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624010,,10116.0,8955,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624011,,10116.0,8956,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624012,,10116.0,8957,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624013,,10116.0,8958,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624736,,10116.0,8959,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624737,,10116.0,8960,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624738,,10116.0,8961,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624739,,10116.0,8962,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624740,,10116.0,8963,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624896,,10116.0,8964,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624897,,10116.0,8965,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624108,,10116.0,8966,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624109,,10116.0,8967,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624110,,10116.0,8968,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624111,,10116.0,8969,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624112,,10116.0,8970,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624113,,10116.0,8971,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL619709,,10116.0,8972,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL619710,,10116.0,8973,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619711,,10116.0,8974,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619712,,10116.0,8975,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619713,,10116.0,8976,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619714,,10116.0,8977,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619715,,10116.0,8978,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619716,,10116.0,8979,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619717,,10116.0,8980,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619718,,10116.0,8981,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619719,,10116.0,8982,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL875329,,10116.0,8983,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619720,,10116.0,8984,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619721,,10116.0,8985,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619722,,10116.0,8986,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619723,,10116.0,8987,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619724,,10116.0,8988,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619725,,10116.0,8989,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619726,,10116.0,8990,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619727,,10116.0,8991,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619728,,10116.0,8992,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL619729,,10116.0,8993,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL619730,,10116.0,8994,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL619731,,10116.0,8995,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL619732,,10116.0,8996,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL619733,,10116.0,8997,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL619734,,10116.0,8998,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL619735,,10116.0,8999,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL875330,,10116.0,9000,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL628465,,10116.0,9001,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL628466,,10116.0,9002,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL628467,,10116.0,9003,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628468,,10116.0,9004,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628469,,10116.0,9005,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628470,,10116.0,9006,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628471,,10116.0,9007,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628472,,10116.0,9008,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL625191,,10116.0,9009,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL625192,,10116.0,9010,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL875337,,10116.0,9011,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,11977,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL626341,,10116.0,9012,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL626342,,10116.0,9013,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL621943,,10116.0,9014,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621944,,10116.0,9015,,Half life in rats,,3748,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621945,,10116.0,9016,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621946,,10116.0,9017,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,4871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621947,,10116.0,9018,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,4871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621948,,10116.0,9019,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,4872,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621949,,10116.0,9020,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,4872,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621950,,10116.0,9021,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,5413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621951,,10116.0,9022,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,5413,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL621952,,10116.0,9023,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,15272,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL621953,,10116.0,9024,,Stability (%) in rat liver microsomes,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621954,,10116.0,9025,,Area under curve was calculated after intravenous administration,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621955,,10116.0,9026,,Area under the curve was calculated after iv administration in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621956,,10116.0,9027,,Area under the curve was calculated in rat after peroral administration,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621957,,10116.0,9028,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,6211,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621958,,10116.0,9029,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621959,,10116.0,9030,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621960,,10116.0,9031,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621961,,10116.0,9032,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,17853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621962,,10116.0,9033,,p value of the compound,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL876787,,10116.0,9034,,p value of the compound,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621963,,10116.0,9035,,p value of the compound,,15765,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL622637,,10116.0,9036,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL622638,,10116.0,9037,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL626561,,10116.0,9038,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,F,U,,,,0,CHEMBL626562,,9986.0,9039,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,7991,,,BAO_0000019
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL626563,,9986.0,9040,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,429,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL626564,,9986.0,9041,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,429,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626565,,9986.0,9042,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,6253,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626566,,9986.0,9043,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,6253,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626567,,9986.0,9044,,Clearance rate in rabbits,,3615,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626568,,9986.0,9045,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,4059,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626569,,9986.0,9046,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626570,,9986.0,9047,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626571,,9986.0,9048,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626572,,9986.0,9049,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,429,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626573,,9986.0,9050,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,4059,,,BAO_0000218
,Liver,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL626574,,9986.0,9051,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Microsomes,9659,,,BAO_0000251
,Liver,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL626575,,9986.0,9052,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Microsomes,9659,,,BAO_0000251
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL626576,,9986.0,9053,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,3639,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL626577,,9986.0,9054,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,3639,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626578,,9986.0,9055,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,3639,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625263,,9986.0,9056,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625264,,9986.0,9057,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625265,,9986.0,9058,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL625266,,9986.0,9059,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,14294,,,BAO_0000251
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL876796,,9986.0,9060,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Microsomes,14294,,,BAO_0000251
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625267,,9986.0,9061,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,429,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL625268,,9986.0,9062,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,5124,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL625269,,9986.0,9063,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,5124,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL624689,,9986.0,9064,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,5124,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624690,,9986.0,9065,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,429,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL624691,,9986.0,9066,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,429,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL624692,,9986.0,9067,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,429,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624693,,9986.0,9068,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,4059,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624694,,9986.0,9069,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,4137,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL877596,,9986.0,9070,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,11672,,,BAO_0000221
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL624695,,9986.0,9071,,Time within which only 10% of the drug was degraded,,12886,,,BAO_0000019
,Liver,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,2107.0,0,CHEMBL624696,,9986.0,9072,,Half life period in rabbit liver homogenate,,3853,,,BAO_0000221
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,,,,0,CHEMBL624697,,9986.0,9073,,Half life value in rabbits,,3615,,,BAO_0000019
,Blood,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL624698,,9986.0,9074,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,6253,,,BAO_0000218
,Blood,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL624699,,9986.0,9075,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,6253,,,BAO_0000218
,,Oryctolagus cuniculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624700,,9986.0,9076,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,6077,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622903,,10116.0,9077,,AUC 0-8 hr value in rats at 10 mg/kg,,17617,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622904,,10116.0,9078,,AUC after administration at 2000 mg/kg/day in rats,,17594,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622905,,10116.0,9079,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,6149,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622906,,10116.0,9080,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,17260,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622907,,10116.0,9081,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,17260,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622908,,10116.0,9082,,AUC in rat after oral administration at 10.5 mg/kg dose,,6644,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622909,,10116.0,9083,,AUC in rat after oral administration at 11.2 mg/kg dose,,6644,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622910,,10116.0,9084,,AUC in rat after oral administration at 9.7 mg/kg dose,,6644,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622911,,10116.0,9085,,AUC in rat brain after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622912,,10116.0,9086,,AUC in rat p.o.,,6504,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622913,,10116.0,9087,,AUC in rat p.o. at 20 mg/kg concentration,,17686,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622914,,10116.0,9088,,AUC in rat plasma after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622915,,10116.0,9089,,AUC in rats,,216,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622916,,10116.0,9090,,AUC value after IV dose at a dose of 5 mg/kg in rats.,,1908,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622917,,10116.0,9091,,AUC value after oral dose at a dose of 10 mg/kg in rats.,,1908,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622918,,10116.0,9092,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,6685,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622919,,10116.0,9093,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,216,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622920,,10116.0,9094,,Maximum plasma concentration was evaluated in rat,,6049,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622921,,10116.0,9095,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,2463,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622922,,10116.0,9096,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,6679,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622923,,10116.0,9097,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,6681,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL877604,,10116.0,9098,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622924,,10116.0,9099,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,6410,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622925,,10116.0,9100,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622926,,10116.0,9101,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,16366,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623625,,10116.0,9102,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,6227,,,BAO_0000218
,Plasma,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623626,,10116.0,9103,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623627,,10116.0,9104,,Maximum plasma drug concentration was determined,,1465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623628,,10116.0,9105,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,4368,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623629,,10116.0,9106,,Mean peak plasma concentration was observed after intravenous administration in rat,,15662,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623630,,10116.0,9107,,Mean peak plasma concentration was observed after oral administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623804,,10116.0,9108,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623805,,10116.0,9109,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,5355,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623806,,10116.0,9110,,Peak oral plasma concentration was determined in rats by oral administration,,1567,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623807,,10116.0,9111,,Peak plasma concentration (Cmax) was determined,,4026,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623808,,10116.0,9112,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,6193,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623809,,10116.0,9113,,Peak plasma concentration (Cmax) in rats,,4026,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623810,,10116.0,9114,,Peak plasma concentration at 1 mg/kg peroral administration,,6485,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623811,,10116.0,9115,,Peak plasma concentration in rat,,17655,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623812,,10116.0,9116,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877605,,10116.0,9117,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,5394,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623813,,10116.0,9118,,Pharmacokinetic property (Cmax) in rat,,4408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623814,,10116.0,9119,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623815,,10116.0,9120,,Cmax in rat after 3mg/kg oral dose,,4878,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623816,,10116.0,9121,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,5862,Sprague-Dawley,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623145,,10116.0,9122,,Cmax in rats after 20 mg/kg oral dose,,4517,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623146,,10116.0,9123,,Cmax in rat plasma after 30mg/kg oral dose,,5932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623147,,10116.0,9124,,Plasma concentration after oral administration of 100 mg/kg to rats,,5436,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623042,,10116.0,9125,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623043,,10116.0,9126,,Tested for the Cmax in rat at 10 mg/kg per orally,,4950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623044,,10116.0,9127,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623045,,10116.0,9128,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623046,,10116.0,9129,,Bioavailability as oral Cmax in rats at 30 mins,,3360,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623226,,10116.0,9130,,Bioavailability as oral Cmax in rats at 6hr,,3360,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623227,,10116.0,9131,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623228,,10116.0,9132,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623229,,10116.0,9133,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,15022,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623230,,10116.0,9134,,The maximum plasma levels for the compounds were determined by LC-MS.,,5160,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623231,,10116.0,9135,,mean peak plasma concentration was observed after intravenous administration in rat,,15662,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623232,,10116.0,9136,,mean peak plasma concentration was observed after oral administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623233,,10116.0,9137,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623234,,10116.0,9138,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,3535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623235,,10116.0,9139,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,3535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623236,,10116.0,9140,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,3535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623237,,10116.0,9141,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,3535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623238,,10116.0,9142,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,3535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623239,,10116.0,9143,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,3535,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623240,,10116.0,9144,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,5005,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,,,1898.0,1,CHEMBL623241,,10116.0,9145,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,6326,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,,,1898.0,1,CHEMBL623242,,10116.0,9146,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,6326,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874394,,10116.0,9147,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,6326,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623243,,10116.0,9148,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,6326,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623244,,10116.0,9149,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623245,,10116.0,9150,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623246,,10116.0,9151,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623247,,10116.0,9152,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623248,,10116.0,9153,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623249,,10116.0,9154,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625072,,10116.0,9155,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625073,,10116.0,9156,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625074,,10116.0,9157,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625075,,10116.0,9158,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625076,,10116.0,9159,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625077,,10116.0,9160,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625078,,10116.0,9161,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL874395,,10116.0,9162,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625079,,10116.0,9163,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625080,,10116.0,9164,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625081,,10116.0,9165,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625082,,10116.0,9166,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625083,,10116.0,9167,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625084,,10116.0,9168,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625085,,10116.0,9169,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625086,,10116.0,9170,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625087,,10116.0,9171,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625088,,10116.0,9172,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622205,,10116.0,9173,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622206,,10116.0,9174,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622207,,10116.0,9175,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622366,,10116.0,9176,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622367,,10116.0,9177,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL875331,,10116.0,9178,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622368,,10116.0,9179,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622369,,10116.0,9180,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622370,,10116.0,9181,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622371,,10116.0,9182,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622372,,10116.0,9183,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622373,,10116.0,9184,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622374,,10116.0,9185,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622375,,10116.0,9186,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622376,,10116.0,9187,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622377,,10116.0,9188,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622378,,10116.0,9189,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622379,,10116.0,9190,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622380,,10116.0,9191,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622381,,10116.0,9192,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622382,,10116.0,9193,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622383,,10116.0,9194,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL875332,,10116.0,9195,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL622384,,10116.0,9196,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL622385,,10116.0,9197,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,,,945.0,1,CHEMBL622386,,10116.0,9198,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,6175,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622387,,10116.0,9199,,The compound was tested for the plasma binding in rat,,10839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622388,,10116.0,9200,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622389,,10116.0,9201,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622390,,10116.0,9202,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622391,,10116.0,9203,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622392,,10116.0,9204,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622393,,10116.0,9205,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,16459,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622394,,10116.0,9206,,Plasma level at 2 hr after administration of the compound,,3278,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622395,,10116.0,9207,,plasma level at 2 hr after administration of the compound,,3278,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL622396,,10116.0,9208,,Stability in rat serum measured as % recovery at 1 min,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624894,,10116.0,9209,,Stability in rat serum measured as % recovery at 10 min,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624895,,10116.0,9210,,Stability in rat serum measured as % recovery at 10 mins,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624058,,10116.0,9211,,Stability in rat serum measured as % recovery at 2 hr,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624059,,10116.0,9212,,Stability in rat serum measured as % recovery at 3 min,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624060,,10116.0,9213,,Stability in rat serum measured as % recovery at 3 mins,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624061,,10116.0,9214,,Stability in rat serum measured as % recovery at 5 min,,4684,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL624062,,10116.0,9215,,Stability in rat serum measured as % recovery at 5 mins,,4684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624063,,10116.0,9216,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624064,,10116.0,9217,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL624065,,10116.0,9218,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,723,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL624066,,10116.0,9219,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877490,,10116.0,9220,,Half life tested in mature male rat at a dose of 30 mg/kg,,5160,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874442,,10116.0,9221,,Half life after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626890,,10116.0,9222,,Half life period after administration (30 mg/kg) in rat,,5633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626891,,10116.0,9223,,Half life period in rat after 5 mg/Kg dose,,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626892,,10116.0,9224,,Half life period in rat after 5 mg/kg dose,,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626893,,10116.0,9225,,Half life period was determined,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626894,,10116.0,9226,,Half life period was evaluated in rat,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626895,,10116.0,9227,,Half life period was evaluated in rat; 0.5-1.0,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626896,,10116.0,9228,,Half life period was evaluated in rat; 5.9-7.5,,17791,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626897,,10116.0,9229,,Half-life in rat plasma,,14512,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626898,,10116.0,9230,,Half-life time in rat was determined,,6230,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626899,,10116.0,9231,,Terminal half-life after iv administration to rats,,3364,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626900,,10116.0,9232,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,6874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626901,,10116.0,9233,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,857,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626902,,10116.0,9234,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,858,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626903,,10116.0,9235,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,858,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874443,,10116.0,9236,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626904,,10116.0,9237,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626905,,10116.0,9238,,Half life in rats,,6305,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL873830,,10116.0,9239,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,13501,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626906,,10116.0,9240,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,17594,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL631076,,10116.0,9241,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631077,,10116.0,9242,,Biological half-life was measured in plasma of rats,,2932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631078,,10116.0,9243,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,17065,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631079,,10116.0,9244,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631080,,10116.0,9245,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,2713,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631081,,10116.0,9246,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631239,,10116.0,9247,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,2661,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631240,,10116.0,9248,,Compound was evaluated for plasma half life in rat,,740,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631241,,10116.0,9249,,AUC value at a dose of 5 mg/kg (p.o.) in rats,,6597,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631242,,10116.0,9250,,AUC value after administration of 20 mg/Kg oral dose in rat,,2959,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631243,,10116.0,9251,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,17594,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL874444,,10116.0,9252,,AUC0-96 after administration at 50 mg/kg,,17596,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631244,,10116.0,9253,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,17594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631245,,10116.0,9254,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,3293,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627162,,10116.0,9255,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627163,,10116.0,9256,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,6757,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627164,,10116.0,9257,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,6757,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL627165,,10116.0,9258,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627166,,10116.0,9259,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627167,,10116.0,9260,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,5979,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627822,,10116.0,9261,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627823,,10116.0,9262,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627824,,10116.0,9263,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627825,,10116.0,9264,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,5355,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627826,,10116.0,9265,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,5633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627827,,10116.0,9266,,Area under curve (Pharmacokinetic property) was determined,,1716,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627828,,10116.0,9267,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,1716,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627829,,10116.0,9268,,Area under curve after intravenous administration (1 mg/kg) in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627830,,10116.0,9269,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627831,,10116.0,9270,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627832,,10116.0,9271,,Area under curve in male SD rats was observed after oral administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627833,,10116.0,9272,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,4413,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,,,,1,CHEMBL627834,,10116.0,9273,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,,,,1,CHEMBL628004,,10116.0,9274,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628005,,10116.0,9275,,Area under curve at 5 mg/kg po was determined in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628006,,10116.0,9276,,Area under curve in Rat at a oral dose of 5 mg/kg,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628007,,10116.0,9277,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,4186,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625676,,10116.0,9278,,Area under curve was determined,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631309,,10116.0,9279,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,17858,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631310,,10116.0,9280,,Area under curve after intravenous administration at 3 mg/kg,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631311,,10116.0,9281,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,6106,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631312,,10116.0,9282,,Area under curve at 4 hr in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631313,,10116.0,9283,,Area under curve at a dose of 30 mg/kg,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631314,,10116.0,9284,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631315,,10116.0,9285,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631316,,10116.0,9286,,Area under curve for a 2-mpk po dose in SD rats,,5862,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631317,,10116.0,9287,,Area under curve in SD rats,,5862,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874471,,10116.0,9288,,Area under curve in rat after oral administration at 13 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631318,,10116.0,9289,,Area under curve in rat by po administration at 0-24 hr,,5871,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631319,,10116.0,9290,,Area under curve in rat plasma,,5919,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631320,,10116.0,9291,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631321,,10116.0,9292,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631322,,10116.0,9293,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,10,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631323,,10116.0,9294,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,11149,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631324,,10116.0,9295,,Area under curve value in rat at a dose of 5 mg/kg,,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631325,,10116.0,9296,,Area under curve was determined after oral administration in rats,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631326,,10116.0,9297,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631327,,10116.0,9298,,Area under curve was determined after peroral administration in rat,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631328,,10116.0,9299,,Area under curve was determined at a dose 30 mpk administered orally.,,5375,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631329,,10116.0,9300,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627217,,10116.0,9301,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,4368,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626352,,10116.0,9302,,Area under curve was determined in male rat,,5610,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626353,,10116.0,9303,,Area under curve was determined in rat after PO administration,,5833,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626354,,10116.0,9304,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,4257,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626355,,10116.0,9305,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,5937,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626356,,10116.0,9306,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,5932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626357,,10116.0,9307,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,5932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626358,,10116.0,9308,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626359,,10116.0,9309,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626360,,10116.0,9310,,Peak plasma concentration in rat at a dose of 3 mg/kg,,17771,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626361,,10116.0,9311,,Plasma concentration at 2 hr in rats was evaluated.,,1628,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626362,,10116.0,9312,,Plasma concentration at 2 hr in rats was evaluated; Not available,,1628,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626363,,10116.0,9313,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626970,,10116.0,9314,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626971,,10116.0,9315,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626972,,10116.0,9316,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626973,,10116.0,9317,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626974,,10116.0,9318,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL874592,,10116.0,9319,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626975,,10116.0,9320,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626976,,10116.0,9321,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626977,,10116.0,9322,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626978,,10116.0,9323,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626979,,10116.0,9324,,PK study was carried to determine the relative absorption ranking in rat.,,16427,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626980,,10116.0,9325,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,4689,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626981,,10116.0,9326,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,11450,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626982,,10116.0,9327,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,11450,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626983,,10116.0,9328,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,11450,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622522,,10116.0,9329,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,11450,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622523,,10116.0,9330,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,11450,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622524,,10116.0,9331,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622525,,10116.0,9332,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622526,,10116.0,9333,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL619849,,10116.0,9334,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL619850,,10116.0,9335,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL623864,,10116.0,9336,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,11450,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL623865,,10116.0,9337,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL623866,,10116.0,9338,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL623867,,10116.0,9339,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL877615,,10116.0,9340,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL623868,,10116.0,9341,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL623869,,10116.0,9342,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,11450,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL623870,,10116.0,9343,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL623871,,10116.0,9344,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL623872,,10116.0,9345,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622129,,10116.0,9346,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622130,,10116.0,9347,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622131,,10116.0,9348,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622132,,10116.0,9349,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622133,,10116.0,9350,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622134,,10116.0,9351,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622135,,10116.0,9352,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622136,,10116.0,9353,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL622137,,10116.0,9354,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL622138,,10116.0,9355,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623017,,10116.0,9356,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623018,,10116.0,9357,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623019,,10116.0,9358,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623020,,10116.0,9359,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623021,,10116.0,9360,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623022,,10116.0,9361,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623023,,10116.0,9362,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623024,,10116.0,9363,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623025,,10116.0,9364,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620545,,10116.0,9365,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620546,,10116.0,9366,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620547,,10116.0,9367,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620548,,10116.0,9368,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620549,,10116.0,9369,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620550,,10116.0,9370,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620551,,10116.0,9371,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620552,,10116.0,9372,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620553,,10116.0,9373,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620554,,10116.0,9374,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL875845,,10116.0,9375,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620555,,10116.0,9376,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620556,,10116.0,9377,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620557,,10116.0,9378,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620558,,10116.0,9379,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL620559,,10116.0,9380,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622939,,10116.0,9381,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622940,,10116.0,9382,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622941,,10116.0,9383,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622942,,10116.0,9384,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622943,,10116.0,9385,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622944,,10116.0,9386,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622945,,10116.0,9387,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622946,,10116.0,9388,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622947,,10116.0,9389,,Compound was evaluated for terminal half life in rat,,3341,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622948,,10116.0,9390,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,3634,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622949,,10116.0,9391,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,3634,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622950,,10116.0,9392,,Compound was tested for its half life in rat,,4839,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,22224,A,U,In vivo,,1969.0,0,CHEMBL622951,,9544.0,9393,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,5005,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,22224,A,U,,,1969.0,0,CHEMBL622952,,10116.0,9394,,Compound was tested for its plasma half life in Sprague Dawley rats,,5005,,,BAO_0000366
,Plasma,Rattus norvegicus,Intermediate,1,22224,A,U,,,1969.0,0,CHEMBL622953,,10116.0,9395,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,5005,,,BAO_0000366
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL873818,,10116.0,9396,,Compound was tested for plasma half-life period in rat,,1094,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622954,,10116.0,9397,,Elimination half life after i.v. administration of compound in rats,,5031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622955,,10116.0,9398,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875229,,10116.0,9399,,Elimination half-life after IV dosing at 1 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622956,,10116.0,9400,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622957,,10116.0,9401,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,6518,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622958,,10116.0,9402,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,5408,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622959,,10116.0,9403,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,5408,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622960,,10116.0,9404,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,5408,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622961,,10116.0,9405,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622962,,10116.0,9406,,Evaluated for the half life in rat (in vivo),,4687,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622963,,10116.0,9407,,Hafl life in rat,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622964,,10116.0,9408,,Hafl life rat,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622965,,10116.0,9409,,Hafl life rat,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622966,,10116.0,9410,,Hafl life rat; Not determined,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622967,,10116.0,9411,,Hafl life rat; Not determined,,6641,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622968,,10116.0,9412,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622969,,10116.0,9413,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL875327,,10116.0,9414,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628638,,10116.0,9415,,Half life in rat after 1 mg/kg i.v. administration,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628639,,10116.0,9416,,Half life in rat after 2 mg/kg peroral administration,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625840,,10116.0,9417,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625841,,10116.0,9418,,Half life of 10 mg/kg oral dose determined in rats,,4722,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625842,,10116.0,9419,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625843,,10116.0,9420,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625844,,10116.0,9421,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873822,,10116.0,9422,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625845,,10116.0,9423,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627059,,10116.0,9424,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627060,,10116.0,9425,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627061,,10116.0,9426,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627709,,10116.0,9427,,Half life of compound at 5 mg/kg after po administration was determined in rat,,4762,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627710,,10116.0,9428,,Half life of compound determined after intravenous administration to rat,,5327,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627711,,10116.0,9429,,Half life of compound was determined in rat,,4847,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627712,,10116.0,9430,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627713,,10116.0,9431,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627714,,10116.0,9432,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627889,,9541.0,9433,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,4256,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627890,,10116.0,9434,,Half life determined in rat by intravenous administration,,4256,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627891,,10116.0,9435,,Half life determined in rats after iv administration,,4722,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627892,,10116.0,9436,,Half life in rat plasma after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627893,,10116.0,9437,,Half life in rat plasma after administration of 2 mg/kg iv,,6535,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627894,,10116.0,9438,,Half life in rat plasma was determined,,1435,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627895,,10116.0,9439,,Half life in rat plasma was determined; NA means not applicable,,1435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627896,,10116.0,9440,,Half life in rat was tested,,5206,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627897,,10116.0,9441,,Half life measured in rat plasma,,6080,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627898,,10116.0,9442,,Half life recorded in rats,,4449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627899,,10116.0,9443,,Half life was calculated,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL873823,,10116.0,9444,,Half life was calculated in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627900,,10116.0,9445,,Half life was determined,,3747,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627901,,10116.0,9446,,Half life after 10 mg/kg oral administration in rat,,17858,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627902,,10116.0,9447,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627903,,10116.0,9448,,Half life after administering orally a dose of 30 mg/kg,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627904,,10116.0,9449,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,5031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627905,,10116.0,9450,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,4722,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627906,,10116.0,9451,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627907,,10116.0,9452,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876783,,10116.0,9453,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627908,,10116.0,9454,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627909,,10116.0,9455,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,17065,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627910,,10116.0,9456,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,1353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627911,,10116.0,9457,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,1353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627912,,10116.0,9458,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,1353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627913,,10116.0,9459,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,1353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627914,,10116.0,9460,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,1353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627915,,10116.0,9461,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627916,,10116.0,9462,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627917,,10116.0,9463,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627918,,10116.0,9464,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,6056,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627919,,10116.0,9465,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627920,,10116.0,9466,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627921,,10116.0,9467,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627922,,10116.0,9468,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876784,,10116.0,9469,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627923,,10116.0,9470,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626208,,10116.0,9471,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626209,,10116.0,9472,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626210,,10116.0,9473,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627994,,10116.0,9474,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,2463,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627995,,10116.0,9475,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627996,,10116.0,9476,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,4075,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627997,,10116.0,9477,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,5394,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627998,,10116.0,9478,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628640,,10116.0,9479,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628641,,10116.0,9480,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628642,,10116.0,9481,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628643,,10116.0,9482,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628644,,10116.0,9483,,Compound was tested for area under curve in rat,,2591,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628645,,10116.0,9484,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,6567,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628646,,10116.0,9485,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,6211,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628647,,10116.0,9486,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,5529,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628648,,10116.0,9487,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625358,,10116.0,9488,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625359,,10116.0,9489,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625360,,10116.0,9490,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,5408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625361,,10116.0,9491,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625362,,10116.0,9492,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625363,,10116.0,9493,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625364,,10116.0,9494,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,4796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625365,,10116.0,9495,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625366,,10116.0,9496,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625367,,10116.0,9497,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625368,,10116.0,9498,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,11450,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625369,,10116.0,9499,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,11450,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625370,,10116.0,9500,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,11450,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625371,,10116.0,9501,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,11450,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625372,,10116.0,9502,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,11450,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625373,,10116.0,9503,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625374,,10116.0,9504,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL877593,,10116.0,9505,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625375,,10116.0,9506,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625376,,10116.0,9507,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL621973,,10116.0,9508,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,11450,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL621974,,10116.0,9509,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL621975,,10116.0,9510,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622166,,10116.0,9511,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622167,,10116.0,9512,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622168,,10116.0,9513,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622169,,10116.0,9514,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,11450,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL622170,,10116.0,9515,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622171,,10116.0,9516,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622172,,10116.0,9517,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622173,,10116.0,9518,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622174,,10116.0,9519,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622175,,10116.0,9520,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622176,,10116.0,9521,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622177,,10116.0,9522,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622178,,10116.0,9523,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622179,,10116.0,9524,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622180,,10116.0,9525,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,11450,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622181,,10116.0,9526,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622182,,10116.0,9527,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622183,,10116.0,9528,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622184,,10116.0,9529,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622185,,10116.0,9530,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622186,,10116.0,9531,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622187,,10116.0,9532,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625002,,10116.0,9533,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622090,,10116.0,9534,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622091,,10116.0,9535,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622092,,10116.0,9536,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622093,,10116.0,9537,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622094,,10116.0,9538,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622095,,10116.0,9539,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622264,,10116.0,9540,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL622265,,10116.0,9541,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL622266,,10116.0,9542,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL622267,,10116.0,9543,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL622268,,10116.0,9544,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL622269,,10116.0,9545,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625071,,10116.0,9546,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621621,,10116.0,9547,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621622,,10116.0,9548,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621623,,10116.0,9549,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621624,,10116.0,9550,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621625,,10116.0,9551,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621626,,10116.0,9552,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621627,,10116.0,9553,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621628,,10116.0,9554,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL875328,,10116.0,9555,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621629,,10116.0,9556,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621630,,10116.0,9557,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621631,,10116.0,9558,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621632,,10116.0,9559,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621633,,10116.0,9560,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621634,,10116.0,9561,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621635,,10116.0,9562,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621636,,10116.0,9563,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621637,,10116.0,9564,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL621638,,10116.0,9565,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618883,,10116.0,9566,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL618884,,10116.0,9567,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628627,,10116.0,9568,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628628,,10116.0,9569,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628629,,10116.0,9570,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628630,,10116.0,9571,,Half life after administering orally a dose of 3 mg/kg,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628631,,10116.0,9572,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628632,,10116.0,9573,,Half life after administering intravenously a dose of 1 mg/kg,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628633,,10116.0,9574,,Half life after oral dosing in rats,,526,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628634,,10116.0,9575,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627789,,10116.0,9576,,Half life by intravenous administration of 3.4 mg/kg in rat,,4368,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627790,,10116.0,9577,,Half life in rat,,3371,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627791,,10116.0,9578,,Half life in rat,,6448,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627792,,10116.0,9579,,Half life in rat,,6453,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627793,,10116.0,9580,,Half life in rat after intravenous administration of the compound,,4353,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627794,,10116.0,9581,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,4353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627795,,10116.0,9582,,Half life in rat after po administration of the compound,,4353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627796,,10116.0,9583,,Half life in rat after po administration of the compound; ND means Not determined,,4353,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL875335,,10116.0,9584,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,4353,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627797,,10116.0,9585,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,4353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627798,,10116.0,9586,,Half life in rat i.v.,,5789,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627799,,10116.0,9587,,Half life in rat i.v. at 2 mg/kg concentration,,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627800,,10116.0,9588,,Half life in rats,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627801,,10116.0,9589,,Half life in rats after intravenous administration,,484,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627802,,10116.0,9590,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,6467,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,,,,1,CHEMBL627803,,10116.0,9591,,Half life in rat,,6642,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873820,,10116.0,9592,,Half life was evaluated after intravenous administration to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627804,,10116.0,9593,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,1369,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627805,,10116.0,9594,,Half life was evaluated in rat,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627806,,10116.0,9595,,Half life was evaluated in rat,,6049,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627107,,10116.0,9596,,Half life was evaluated in rat; Not tested,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627108,,10116.0,9597,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627109,,10116.0,9598,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,11149,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627110,,10116.0,9599,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,11149,,,BAO_0000218
,,Primates,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627111,,9443.0,9600,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,2891,,,BAO_0000218
,,Primates,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627112,,9443.0,9601,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627113,,10116.0,9602,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL627114,,10116.0,9603,,Half life was measured in rat at dose of 30 mg/kg by po administration,,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627115,,10116.0,9604,,Half life (t1/2) was determined,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627116,,10116.0,9605,,Half life period at a dose of 10 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627117,,10116.0,9606,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627118,,10116.0,9607,,Half life period was determined,,5503,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627119,,10116.0,9608,,Half life period after intravenous administration at 20 mpk in rats,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627120,,10116.0,9609,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626922,,10116.0,9610,,Half life period after intravenous administration in rat,,6109,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626923,,10116.0,9611,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626924,,10116.0,9612,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,5654,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626925,,10116.0,9613,,Half life period in 80% rat plasma at 37 degree Centigrade,,4755,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626926,,10116.0,9614,,Half life period in SD rats,,5862,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626927,,10116.0,9615,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626928,,10116.0,9616,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626929,,10116.0,9617,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626930,,10116.0,9618,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,1515,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626931,,10116.0,9619,,Half life period in rat,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626932,,10116.0,9620,,Half life period in rat,,6103,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626933,,10116.0,9621,,Half life period in rat,,6317,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873826,,10116.0,9622,,Half life period in rat after oral administration at 10.5 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626934,,10116.0,9623,,Half life period in rat after oral administration at 11.2 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626935,,10116.0,9624,,Half life period in rat after oral administration at 13 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626936,,10116.0,9625,,Half life period in rat after oral administration at 9.7 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626937,,10116.0,9626,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625906,,10116.0,9627,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,6295,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625907,,10116.0,9628,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,6296,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625908,,10116.0,9629,,PK study was carried to determine AUC (area under curve) value in rat,,16427,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625909,,10116.0,9630,,Pharmacokinetic parameter AUC after intravenous administration to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625910,,10116.0,9631,,Pharmacokinetic parameter AUC after oral administration to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625911,,10116.0,9632,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625912,,10116.0,9633,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626538,,10116.0,9634,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876794,,10116.0,9635,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626539,,10116.0,9636,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626540,,10116.0,9637,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626541,,10116.0,9638,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,5394,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626542,,10116.0,9639,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,5394,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626543,,10116.0,9640,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626544,,10116.0,9641,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626545,,10116.0,9642,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626546,,10116.0,9643,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626547,,10116.0,9644,,Pharmacokinetic parameter area under curve was reported,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626548,,10116.0,9645,,Pharmacokinetic property (AUC) in rat,,4408,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626549,,10116.0,9646,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626550,,10116.0,9647,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,4397,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626551,,10116.0,9648,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,4397,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623777,,10116.0,9649,,Pharmacokinetic property was determined,,5491,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623778,,10116.0,9650,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,5491,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623779,,10116.0,9651,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,5491,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL623780,,10116.0,9652,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,4199,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622015,,10116.0,9653,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,4199,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622016,,10116.0,9654,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622017,,10116.0,9655,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,5173,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622018,,10116.0,9656,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,5173,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622019,,10116.0,9657,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,5173,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622020,,10116.0,9658,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,5173,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622021,,10116.0,9659,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622022,,10116.0,9660,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622023,,10116.0,9661,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,5327,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622024,,10116.0,9662,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,6681,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622693,,10116.0,9663,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622694,,10116.0,9664,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622695,,10116.0,9665,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622696,,10116.0,9666,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622697,,10116.0,9667,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622874,,10116.0,9668,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,6619,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622875,,10116.0,9669,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,6619,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622876,,10116.0,9670,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,10363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622877,,10116.0,9671,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,4796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622878,,10116.0,9672,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622879,,10116.0,9673,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877602,,10116.0,9674,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,4839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622880,,10116.0,9675,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622881,,10116.0,9676,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622882,,10116.0,9677,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622883,,10116.0,9678,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622884,,10116.0,9679,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,11450,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL622885,,10116.0,9680,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,11450,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622886,,10116.0,9681,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622887,,10116.0,9682,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,8151,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622888,,10116.0,9683,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,8151,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622889,,10116.0,9684,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622890,,10116.0,9685,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622891,,10116.0,9686,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL877603,,10116.0,9687,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622892,,10116.0,9688,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622893,,10116.0,9689,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622894,,10116.0,9690,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622895,,10116.0,9691,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622896,,10116.0,9692,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,8677,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622897,,10116.0,9693,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622898,,10116.0,9694,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622899,,10116.0,9695,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622900,,10116.0,9696,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL624114,,10116.0,9697,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL624115,,10116.0,9698,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL624116,,10116.0,9699,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL624117,,10116.0,9700,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL624118,,10116.0,9701,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL624119,,10116.0,9702,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL624120,,10116.0,9703,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624121,,10116.0,9704,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624122,,10116.0,9705,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624123,,10116.0,9706,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624124,,10116.0,9707,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624125,,10116.0,9708,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624126,,10116.0,9709,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624127,,10116.0,9710,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624128,,10116.0,9711,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL624129,,10116.0,9712,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL624130,,10116.0,9713,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL622340,,10116.0,9714,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL622341,,10116.0,9715,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622342,,10116.0,9716,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622343,,10116.0,9717,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622344,,10116.0,9718,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622345,,10116.0,9719,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622346,,10116.0,9720,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622347,,10116.0,9721,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622348,,10116.0,9722,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622349,,10116.0,9723,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622350,,10116.0,9724,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622351,,10116.0,9725,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622352,,10116.0,9726,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622353,,10116.0,9727,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622354,,10116.0,9728,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622355,,10116.0,9729,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622356,,10116.0,9730,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622357,,10116.0,9731,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622358,,10116.0,9732,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622359,,10116.0,9733,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874393,,10116.0,9734,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622872,,10116.0,9735,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622873,,10116.0,9736,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623047,,10116.0,9737,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623048,,10116.0,9738,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623049,,10116.0,9739,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623050,,10116.0,9740,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623051,,10116.0,9741,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623052,,10116.0,9742,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626343,,10116.0,9743,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626344,,10116.0,9744,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626345,,10116.0,9745,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626346,,10116.0,9746,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626347,,10116.0,9747,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626348,,10116.0,9748,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626349,,10116.0,9749,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,16434,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626350,,10116.0,9750,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626351,,10116.0,9751,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627650,,10116.0,9752,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL627651,,10116.0,9753,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627652,,10116.0,9754,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627653,,10116.0,9755,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,16435,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627654,,10116.0,9756,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627835,,10116.0,9757,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627836,,10116.0,9758,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627837,,10116.0,9759,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627838,,10116.0,9760,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875338,,10116.0,9761,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627839,,10116.0,9762,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627840,,10116.0,9763,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627841,,10116.0,9764,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627842,,10116.0,9765,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627843,,10116.0,9766,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627844,,10116.0,9767,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627845,,10116.0,9768,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627846,,10116.0,9769,,Half life period in rat by iv administration at a dose of 3 mg/kg,,5874,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627847,,10116.0,9770,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL873821,,10116.0,9771,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626079,,10116.0,9772,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626080,,10116.0,9773,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,1515,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626081,,10116.0,9774,,Half life period was evaluated in rat plasma,,5491,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL875344,,10116.0,9775,,Half life period was evaluated in rat plasma; Not tested,,5491,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626082,,10116.0,9776,,Half life period was evaluated in rats,,1918,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626250,,10116.0,9777,,"Half life period was evaluated in rats, iv",,1918,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626251,,10116.0,9778,,Half life period after intravenous administration at 5 mg/kg in rat,,6113,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626252,,10116.0,9779,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,5546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626253,,10116.0,9780,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,5553,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626254,,10116.0,9781,,Half life stability of compound was evaluated in rat plasma,,4188,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626255,,10116.0,9782,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,6215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626256,,10116.0,9783,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,6141,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626257,,10116.0,9784,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626258,,10116.0,9785,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,5182,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626259,,10116.0,9786,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626260,,10116.0,9787,,Half in rat i.v.,,5789,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875345,,10116.0,9788,,Half period in rat after intravenous administration,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626261,,10116.0,9789,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,17594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL626262,,10116.0,9790,,Half-life measured in in vitro Cathepsin B assay in rat liver,,12357,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626263,,10116.0,9791,,Half-life of compound was determined in rats,,5210,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625270,,10116.0,9792,,Half-life at 10 mg/kg in rat upon intravenous administration,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625271,,10116.0,9793,,Half-life determined in rat,,6672,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625272,,10116.0,9794,,Half-life determined in rat,,6673,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625273,,10116.0,9795,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625274,,10116.0,9796,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,3741,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625275,,10116.0,9797,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,17671,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625276,,10116.0,9798,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,4910,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625277,,10116.0,9799,,Half-life in rat plasma,,17537,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625278,,10116.0,9800,,Half-life in rat plasma was determined,,4965,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625279,,10116.0,9801,,Half-life in rat plasma; Not tested,,17537,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL625280,,10116.0,9802,,Half-life in rat serum,,6124,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL876797,,10116.0,9803,,Half-life in rat serum; na is not available,,6124,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625281,,10116.0,9804,,Half-life was calculated in rat,,6078,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL873827,,10116.0,9805,,Half-life was calculated in rat plasma,,17668,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625282,,10116.0,9806,,Half-life was determined,,3185,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625283,,10116.0,9807,,Half-life was determined,,4883,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625284,,10116.0,9808,,Half-life after administration of 20 mg/Kg oral dose in rat,,2959,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625285,,10116.0,9809,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,4029,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625286,,10116.0,9810,,Half-life after intravenous administration in female rat,,4029,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625287,,10116.0,9811,,Half-life after intravenous administration in male rat,,4029,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625288,,10116.0,9812,,Half-life after intravenous dose in rat,,6180,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625289,,10116.0,9813,,Half-life in a rat liver homogenate preparation,,1557,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625290,,10116.0,9814,,Half-life in plasma of rat,,12500,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL876798,,10116.0,9815,,Half-life in plasma of rat at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625291,,10116.0,9816,,Half-life in rat,,5064,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625292,,10116.0,9817,,Half-life in rat,,5145,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625293,,10116.0,9818,,Half-life in rat,,5147,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622832,,10116.0,9819,,Half-life in rat,,5833,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622833,,10116.0,9820,,Half-life in rat,,6596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622834,,10116.0,9821,,Half-life in rat,,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622835,,10116.0,9822,,Half-life in rat after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622836,,10116.0,9823,,Half-life in rat after po administration at a dose of 10 mg/kg,,17538,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622837,,10116.0,9824,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,17538,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622838,,10116.0,9825,,Half-life in rat at 3 mg/kg dose administered intravenously,,10,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622839,,10116.0,9826,,Half-life in rat brain homogenate,,17669,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622840,,10116.0,9827,,Half-life in rat plasma,,17065,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622841,,10116.0,9828,,Half-life in rats,,4333,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622842,,10116.0,9829,,Half-life in Dawley rats,,6827,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,1969.0,1,CHEMBL622843,,10116.0,9830,,Half-life in vitro in rat plasma,,889,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,1969.0,1,CHEMBL622844,,10116.0,9831,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,889,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622845,,10116.0,9832,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,3747,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622846,,10116.0,9833,,The area under the curve of compound was measured at the dose of 100 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622847,,10116.0,9834,,The area under the curve of compound was measured at the dose of 300 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622848,,10116.0,9835,,The area under the curve of compound was measured at the dose of 30 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622849,,10116.0,9836,,Bioavailability as oral AUC in rats,,3360,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622850,,10116.0,9837,,The plasma concentration versus time curve (AUC) was determined,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876807,,10116.0,9838,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622851,,10116.0,9839,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622852,,10116.0,9840,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622853,,10116.0,9841,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622854,,10116.0,9842,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622855,,10116.0,9843,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,17411,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622856,,10116.0,9844,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622857,,10116.0,9845,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622858,,10116.0,9846,,AUC in rat after po administration at a dose of 10 mg/kg,,17538,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622859,,10116.0,9847,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622860,,10116.0,9848,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622861,,10116.0,9849,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622862,,10116.0,9850,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622863,,10116.0,9851,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623817,,10116.0,9852,,Area under curve value 6 hr after po administration in rat,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623818,,10116.0,9853,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623819,,10116.0,9854,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623820,,10116.0,9855,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623821,,10116.0,9856,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,17717,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL623822,,10116.0,9857,,AUC normalized for dose (AUCN) in rat,,6642,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623823,,10116.0,9858,,Area under curve in rat after p.o. administration,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623824,,10116.0,9859,,Area under curve in rat after p.o. administration,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623825,,10116.0,9860,,Area under curve in rat after p.o. administration; Not determined,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622070,,10116.0,9861,,Area under curve in rat after peroral administration,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622071,,10116.0,9862,,Area under curve (carotid artery) value of the compound,,3603,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622072,,10116.0,9863,,Bioavailability expressed as the area under curve of rat carotid artery,,3550,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622073,,10116.0,9864,,Area under curve in male SD rats was observed after intravenous administration in rat,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622074,,10116.0,9865,,Area under curve of the compound was determined,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622075,,10116.0,9866,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,5407,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622076,,10116.0,9867,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,17752,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622077,,10116.0,9868,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622078,,10116.0,9869,,Area under curve (portal vein) value of the compound,,3603,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622079,,10116.0,9870,,Bioavailability expressed as the area under curve of rat portal vein,,3550,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622080,,10116.0,9871,,Area Under plasma concentration time curve in rat upon peroral administration,,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877612,,10116.0,9872,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622081,,10116.0,9873,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622082,,10116.0,9874,,Compound was evaluated for oral bioavailability in rats,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622083,,10116.0,9875,,Compound was evaluated for oral bioavailability in rats after iv administration,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622084,,10116.0,9876,,Compound was evaluated for oral bioavailability in rats; 30-80,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622085,,10116.0,9877,,Compound was evaluated for oral bioavailability in rats; 50-60,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622086,,10116.0,9878,,Compound was evaluated for oral bioavailability in rats; no data,,17791,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622087,,10116.0,9879,,Compound was evaluated for oral bioavailability in rats; peptide,,17791,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622088,,10116.0,9880,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,7768,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622089,,10116.0,9881,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,7768,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL623685,,10116.0,9882,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,7768,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL623686,,10116.0,9883,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,7768,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL623687,,10116.0,9884,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL623688,,10116.0,9885,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL623689,,10116.0,9886,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Stomach,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,945.0,1,CHEMBL622485,,10116.0,9887,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622486,,10116.0,9888,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL877613,,10116.0,9889,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622487,,10116.0,9890,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622488,,10116.0,9891,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622489,,10116.0,9892,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,8677,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622490,,10116.0,9893,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,6899,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622491,,10116.0,9894,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,6899,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622492,,10116.0,9895,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,6899,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622493,,10116.0,9896,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,6899,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622494,,10116.0,9897,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,6899,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL622495,,10116.0,9898,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622496,,10116.0,9899,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,6899,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622497,,10116.0,9900,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,6899,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622498,,10116.0,9901,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,2189,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624918,,10116.0,9902,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,2189,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624919,,10116.0,9903,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,2189,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624920,,10116.0,9904,,Biodistribution of compound in rat blood after 5 min of administration,,10839,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624921,,10116.0,9905,,Biodistribution of compound in rat blood after 5 min of administration.,,10839,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL624922,,10116.0,9906,,Biodistribution of compound in rat brain after 5 min of administration,,10839,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL624923,,10116.0,9907,,Biodistribution of compound in rat heart after 5 min of administration,,10839,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL624924,,10116.0,9908,,Biodistribution of compound in rat heart after 5 min of administration.,,10839,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL624925,,10116.0,9909,,Biodistribution of compound in rat kidney after 5 min of administration,,10839,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL624926,,10116.0,9910,,Biodistribution of compound in rat kidney after 5 min of administration.,,10839,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL624927,,10116.0,9911,,Biodistribution of compound in rat liver after 5 min of administration,,10839,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL874402,,10116.0,9912,,Biodistribution of compound in rat liver after 5 min of administration.,,10839,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624928,,10116.0,9913,,Biodistribution of compound in rat lung after 5 min of administration,,10839,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624929,,10116.0,9914,,Biodistribution of compound in rat lung after 5 min of administration.,,10839,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624930,,10116.0,9915,,Biodistribution of compound in rat muscle after 5 min of administration,,10839,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624931,,10116.0,9916,,Biodistribution of compound in rat muscle after 5 min of administration.,,10839,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624932,,10116.0,9917,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624933,,10116.0,9918,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624934,,10116.0,9919,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624935,,10116.0,9920,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624936,,10116.0,9921,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624937,,10116.0,9922,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL624938,,10116.0,9923,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL624939,,10116.0,9924,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624940,,10116.0,9925,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874403,,10116.0,9926,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,4043,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624941,,10116.0,9927,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,1446,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624942,,10116.0,9928,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,9971,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624943,,10116.0,9929,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,9971,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624944,,10116.0,9930,,% Bioavailability after 1 day of the drug administration in rats,,5765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624945,,10116.0,9931,,% Bioavailability after 4 day of the drug administration in rats,,5765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624946,,10116.0,9932,,Absolute bioavailability was evaluated in rat,,4257,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624947,,10116.0,9933,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624948,,10116.0,9934,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624949,,10116.0,9935,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,13091,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622025,,10116.0,9936,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,13091,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622026,,10116.0,9937,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,13091,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622027,,10116.0,9938,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,13091,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622028,,10116.0,9939,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,13091,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622029,,10116.0,9940,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,13091,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622208,,10116.0,9941,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,13091,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622209,,10116.0,9942,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,13091,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622210,,10116.0,9943,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622211,,10116.0,9944,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622212,,10116.0,9945,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622213,,10116.0,9946,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874404,,10116.0,9947,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620452,,10116.0,9948,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620453,,10116.0,9949,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL620454,,10116.0,9950,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624067,,10116.0,9951,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624068,,10116.0,9952,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,13091,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,,,992.0,1,CHEMBL624069,,10116.0,9953,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,13091,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,,,992.0,1,CHEMBL624070,,10116.0,9954,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,13091,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,,,992.0,1,CHEMBL624071,,10116.0,9955,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,13091,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL624072,,10116.0,9956,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,13091,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL624073,,10116.0,9957,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,13091,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL624788,,10116.0,9958,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,13091,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL624789,,10116.0,9959,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624790,,10116.0,9960,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624791,,10116.0,9961,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624792,,10116.0,9962,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624793,,10116.0,9963,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL877491,,10116.0,9964,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624957,,10116.0,9965,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624958,,10116.0,9966,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,13091,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624959,,10116.0,9967,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,13091,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624960,,10116.0,9968,,Dissociation constant was determined,,11977,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624961,,10116.0,9969,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624962,,10116.0,9970,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624963,,10116.0,9971,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624964,,10116.0,9972,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,4755,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624965,,10116.0,9973,,LogP value was evaluated in the in situ rat gut perfusion assay,,589,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624966,,10116.0,9974,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624967,,10116.0,9975,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,5031,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624968,,10116.0,9976,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624969,,10116.0,9977,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,F,N,,,,1,CHEMBL624970,,10116.0,9978,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,2862,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624971,,10116.0,9979,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624972,,10116.0,9980,,Half-life was evaluated after 20 uM/kg of peroral administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624973,,10116.0,9981,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,6005,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL624974,,10116.0,9982,,Half-life was evaluated in plasma of rat,,2938,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624975,,10116.0,9983,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877492,,10116.0,9984,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624976,,10116.0,9985,,Half-life was measured in rat after an iv dose of 1 mg/kg,,6062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624977,,10116.0,9986,,Half-life period of compound in rats after peroral administration,,6571,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626848,,10116.0,9987,,Half-life period of compound was measured in rat plasma.,,3136,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626849,,10116.0,9988,,Half-life period of compound was measured in rat plasma; ND is not determined,,3136,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626850,,10116.0,9989,,Half-life period of compound was measured in rat plasma; not determined,,3136,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626851,,10116.0,9990,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626852,,10116.0,9991,,Half-life period in rat by iv administration,,5871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626853,,10116.0,9992,,Half-life period in rats following intravenous administration at 2 mg/kg,,6077,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626854,,10116.0,9993,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627486,,10116.0,9994,,Half-life period was determined for the compound in rat,,5144,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627487,,10116.0,9995,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,4498,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627488,,10116.0,9996,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,4498,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627489,,10116.0,9997,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,1908,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627490,,10116.0,9998,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,6211,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873829,,10116.0,9999,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,5529,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627655,,10116.0,10000,,Half-life was determined in rat at a dose of 1 mpk i.v.,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625994,,10116.0,10001,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625995,,10116.0,10002,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,6444,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625996,,10116.0,10003,,Half-life in rat,,5207,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,1969.0,1,CHEMBL625850,,10116.0,10004,,In vitro half life in rat plasma,,530,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,1969.0,1,CHEMBL625851,,10116.0,10005,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,1116,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL625852,,10116.0,10006,,In vitro half life in rat,,3219,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625853,,10116.0,10007,,In vivo half life period after intravenous administration in rat,,6109,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625854,,10116.0,10008,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874450,,10116.0,10009,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625855,,10116.0,10010,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625856,,10116.0,10011,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625857,,10116.0,10012,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873831,,10116.0,10013,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625858,,10116.0,10014,,Longer half-life in rat (i.v.) at 0.5 mpk,,17853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625859,,10116.0,10015,,Longer half-life in rat (p.o.) at 2.0 mpk,,17853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625860,,10116.0,10016,,Pharmacokinetic property (half life) in rat,,3457,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625861,,10116.0,10017,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625862,,10116.0,10018,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625863,,10116.0,10019,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625864,,10116.0,10020,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625865,,10116.0,10021,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,5739,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625866,,10116.0,10022,,Pharmacokinetic half time was determined intravenously in rats.,,15765,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625867,,10116.0,10023,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,6567,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625868,,10116.0,10024,,Plasma half life of hydrolysis of the compound,,2448,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625869,,10116.0,10025,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,5423,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL874451,,10116.0,10026,,Plasma half life period was calculated in rat,,4853,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625870,,10116.0,10027,,Plasma half-life in Sprague-Dawley rats,,4514,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625871,,10116.0,10028,,Plasma half-life in Sprague-Dawley rats; Not determined,,4514,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625872,,10116.0,10029,,Plasma half-life in rats,,1500,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625873,,10116.0,10030,,Plasma half-life in rats; <MQL,,1500,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625874,,10116.0,10031,,Plasma half-life period (0-8 h) was determined,,5334,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL625875,,10116.0,10032,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,5334,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625876,,10116.0,10033,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL631258,,10116.0,10034,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,5334,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631259,,10116.0,10035,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,4956,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL631260,,10116.0,10036,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,4956,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631261,,10116.0,10037,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,7768,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631262,,10116.0,10038,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,7768,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631263,,10116.0,10039,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631264,,10116.0,10040,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631265,,10116.0,10041,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631266,,10116.0,10042,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631267,,10116.0,10043,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631268,,10116.0,10044,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631269,,10116.0,10045,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631270,,10116.0,10046,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631271,,10116.0,10047,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631272,,10116.0,10048,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631273,,10116.0,10049,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631274,,10116.0,10050,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631275,,10116.0,10051,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626984,,10116.0,10052,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,7768,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626985,,10116.0,10053,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626986,,10116.0,10054,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626987,,10116.0,10055,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626988,,10116.0,10056,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626989,,10116.0,10057,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626990,,10116.0,10058,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626991,,10116.0,10059,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,7768,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626992,,10116.0,10060,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626993,,10116.0,10061,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL874593,,10116.0,10062,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626994,,10116.0,10063,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626995,,10116.0,10064,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626190,,10116.0,10065,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626191,,10116.0,10066,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,7768,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626364,,10116.0,10067,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626365,,10116.0,10068,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626366,,10116.0,10069,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626367,,10116.0,10070,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626368,,10116.0,10071,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626369,,10116.0,10072,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,7768,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626370,,10116.0,10073,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626371,,10116.0,10074,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,4498,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626372,,10116.0,10075,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,4498,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626373,,10116.0,10076,,Bioavailability after a dose of 10 mg/kg p.o.,,3603,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626374,,10116.0,10077,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,6215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626375,,10116.0,10078,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626376,,10116.0,10079,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,5710,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626377,,10116.0,10080,,Bioavailability in rat po was determined,,5676,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626378,,10116.0,10081,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,17667,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626379,,10116.0,10082,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,17667,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626380,,10116.0,10083,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,6848,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626381,,10116.0,10084,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,6848,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626382,,10116.0,10085,,Bioavailability in rat,,17267,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626383,,10116.0,10086,,Bioavailability in rat (Sprague-Dawley) (female),,6362,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874652,,10116.0,10087,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,17671,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626384,,10116.0,10088,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,17671,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626385,,10116.0,10089,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,4333,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626386,,10116.0,10090,,Bioavailability in rat at an oral dose of 2 mg/kg,,6077,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626387,,10116.0,10091,,Bioavailability in rat,,3278,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626388,,10116.0,10092,,Bioavailability in rat,,5964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626389,,10116.0,10093,,Bioavailability in rat,,4884,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626390,,10116.0,10094,,Bioavailability in rat,,4905,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626391,,10116.0,10095,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,4884,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626392,,10116.0,10096,,Bioavailability in rat,,6850,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626393,,10116.0,10097,,Oral bioavailability in rat,,2864,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623026,,10116.0,10098,,Bioavailability was determined in rat,,5780,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623027,,10116.0,10099,,Bioavailability,,1465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623028,,10116.0,10100,,Bioavailability,,5199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623029,,10116.0,10101,,Bioavailability in rat after 1 day dosing,,5765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623030,,10116.0,10102,,Bioavailability in rat after 4 day dosing,,5765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623031,,10116.0,10103,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623032,,10116.0,10104,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623033,,10116.0,10105,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623034,,10116.0,10106,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,6518,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623035,,10116.0,10107,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,2083,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623036,,10116.0,10108,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,17260,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623037,,10116.0,10109,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,4956,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623038,,10116.0,10110,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,4368,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL874385,,10116.0,10111,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,17752,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623039,,10116.0,10112,,Bioavailability in rat (Fisher) (fasted),,1446,,,BAO_0000218
,,Primates,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL623040,,9443.0,10113,,Bioavailability in monkey after po administration of 10 mg/kg dose,,2891,,,BAO_0000218
,,Primates,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL623041,,9443.0,10114,,Oral bioavailability in monkey (dose 10 mg/kg),,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623741,,10116.0,10115,,Bioavailability in rat,,6672,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623742,,10116.0,10116,,Bioavailability in rat,,6673,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623743,,10116.0,10117,,Bioavailability in rat,,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623744,,10116.0,10118,,Bioavailability in rat,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623745,,10116.0,10119,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,17853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623746,,10116.0,10120,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,4521,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623747,,10116.0,10121,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,4940,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL623748,,10116.0,10122,,Bioavailability in rat after po administration of 30 mg/kg dose,,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL623916,,10116.0,10123,,Bioavailability in rat after po administration of 30 mg/kg dose,,2891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623917,,10116.0,10124,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,4521,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623918,,10116.0,10125,,Bioavailability in rat (dose 2 mg/kg i.v.),,17686,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874386,,10116.0,10126,,Bioavailability in rat,,17796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623919,,10116.0,10127,,Bioavailability in rat; Only traces detected in rat plasma,,17796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623920,,10116.0,10128,,Bioavailability in rat,,5064,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623148,,10116.0,10129,,Bioavailability upon oral administration of compound,,5147,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623149,,10116.0,10130,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,1916,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623150,,10116.0,10131,,Bioavailability in rat,,6049,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623151,,10116.0,10132,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,1445,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623152,,10116.0,10133,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,1445,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,F,N,,,,1,CHEMBL623153,,10116.0,10134,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,2862,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,F,N,,,,1,CHEMBL623154,,10116.0,10135,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,2862,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623155,,10116.0,10136,,In vitro and metabolic stability was determined,,4194,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623156,,10116.0,10137,,In vitro metabolic stability in rat hepatocytes,,4194,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623157,,10116.0,10138,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,5486,,,BAO_0000218
401.0,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL623158,,10116.0,10139,,Metabolic rate for compound was observed in rat hepatocytes,,17582,,Hepatocyte,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623159,,10116.0,10140,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,5600,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874390,,10116.0,10141,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,14294,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623160,,10116.0,10142,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,14294,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623161,,10116.0,10143,,Metabolism of compound in rat S9 microsomes; Trace,,14294,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623162,,10116.0,10144,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,17847,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623163,,10116.0,10145,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623164,,10116.0,10146,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623165,,10116.0,10147,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623166,,10116.0,10148,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624983,,10116.0,10149,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624984,,10116.0,10150,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624985,,10116.0,10151,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622970,,10116.0,10152,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622971,,10116.0,10153,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622972,,10116.0,10154,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622973,,10116.0,10155,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622974,,10116.0,10156,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622975,,10116.0,10157,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622976,,10116.0,10158,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622977,,10116.0,10159,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624351,,10116.0,10160,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624352,,10116.0,10161,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624353,,10116.0,10162,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622397,,10116.0,10163,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622398,,10116.0,10164,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622399,,10116.0,10165,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622400,,10116.0,10166,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628428,,10116.0,10167,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628590,,10116.0,10168,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628591,,10116.0,10169,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628592,,10116.0,10170,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628593,,10116.0,10171,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875333,,10116.0,10172,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628594,,10116.0,10173,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,11020,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628595,,10116.0,10174,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,4969,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628596,,10116.0,10175,,Stability in rat plasma was determined,,6737,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628597,,10116.0,10176,,Stability in rat plasma was determined; ND= no data,,6737,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628598,,10116.0,10177,,Tested for plasma half life period in rat (0-8 hr),,5089,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628599,,10116.0,10178,,Tested for plasma half life period in rat (0-8 hr); Not determined,,5089,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628600,,10116.0,10179,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628601,,10116.0,10180,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628602,,10116.0,10181,,Tested for the half life in rat,,4950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL628603,,10116.0,10182,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,2412,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL628604,,10116.0,10183,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,2412,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL628605,,10116.0,10184,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,2412,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL628606,,10116.0,10185,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,2412,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL628607,,10116.0,10186,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,2412,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628608,,10116.0,10187,,The biological half life the compound was measured at the dose of 100 umol/kg,,15022,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628609,,10116.0,10188,,The biological half life the compound was measured at the dose of 30 umol/kg,,15022,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628610,,10116.0,10189,,The compound was evaluated for plasma half life period in rat,,406,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL873819,,10116.0,10190,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628611,,10116.0,10191,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628612,,10116.0,10192,,The pharmacokinetic parameter half-life period in vivo in rats,,5247,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628613,,10116.0,10193,,"The pharmacokinetic property, Half-life was determined",,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628614,,10116.0,10194,,"The pharmacokinetic property, Half-life in rat in vivo",,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628615,,10116.0,10195,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628616,,10116.0,10196,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,5041,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627924,,10116.0,10197,,The plasma half life period in rats,,3918,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL627925,,10116.0,10198,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,2906,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627926,,10116.0,10199,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,6467,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627927,,10116.0,10200,,t1/2 (apparent elimination)of the compound was determined,,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627928,,10116.0,10201,,t1/2 value in rat,,3788,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627539,,10116.0,10202,,Half life in rat,,17796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL876790,,10116.0,10203,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL858186,,10116.0,10204,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627540,,10116.0,10205,,Half-life period in fasted rats,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627541,,10116.0,10206,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627715,,10116.0,10207,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627716,,10116.0,10208,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,429,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627717,,10116.0,10209,,Maximum time required to achieve Cmax was determined in rat,,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627718,,10116.0,10210,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627719,,10116.0,10211,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627720,,10116.0,10212,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627721,,10116.0,10213,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627722,,10116.0,10214,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627723,,10116.0,10215,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626058,,10116.0,10216,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626059,,10116.0,10217,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626060,,10116.0,10218,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626061,,10116.0,10219,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876791,,10116.0,10220,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626062,,10116.0,10221,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,4723,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626063,,10116.0,10222,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626064,,10116.0,10223,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626065,,10116.0,10224,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626066,,10116.0,10225,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,17720,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626067,,10116.0,10226,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626068,,10116.0,10227,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626069,,10116.0,10228,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626070,,10116.0,10229,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626071,,10116.0,10230,,Percent total excretion of N-methoxyacetaminophen glucuronide,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626072,,10116.0,10231,,Percent total excretion of N-methoxyacetaminophen sulfate,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626073,,10116.0,10232,,Percent total excretion of acetaminophen,,7449,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626741,,10116.0,10233,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,7768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626742,,10116.0,10234,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,17655,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626743,,10116.0,10235,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,17735,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876792,,10116.0,10236,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626744,,10116.0,10237,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,17735,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626745,,10116.0,10238,,Compound was tested for antidiuretic activity in rats,,7116,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626746,,10116.0,10239,,AUC in rat after 3mg/kg oral dose,,4878,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626747,,10116.0,10240,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626748,,10116.0,10241,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626749,,10116.0,10242,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,16367,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626750,,10116.0,10243,,Oral Bioavailability was determined,,16366,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626751,,10116.0,10244,,Oral bioavailability in rat,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626913,,10116.0,10245,,Oral bioavailability in rat; Not performed.,,4426,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626914,,10116.0,10246,,Bioavailability,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626915,,10116.0,10247,,Bioavailability was determined; ND denotes no data,,5041,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626916,,10116.0,10248,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,1500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626917,,10116.0,10249,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,1500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626918,,10116.0,10250,,Binding towards rat plasma protein at 10 uM,,17409,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626919,,10116.0,10251,,Binding towards rat plasma protein at 100 uM,,17409,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626920,,10116.0,10252,,Bioavailability in rat (dose 20 mg/kg p.o.),,2959,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621976,,10116.0,10253,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,13501,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877599,,10116.0,10254,,Bioavailability in rat after 5 mg/kg oral gavage,,6567,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621977,,10116.0,10255,,Bioavailability in rat,,6571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621978,,10116.0,10256,,Bioavailability in rat (dose 1 mg/kg i.v.),,6715,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621979,,10116.0,10257,,Bioavailability in rat (dose 3 mg/kg p.o.),,6715,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621980,,10116.0,10258,,Oral bioavailability in rat,,2932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621981,,10116.0,10259,,Bioavailability of the compound in rats after administration of 30 mg/kg,,4171,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621982,,10116.0,10260,,Bioavailability after administration of 10 mg/kg in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL882953,,10116.0,10261,,Bioavailability after administration of 2 mg/kg in rats,,17509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621983,,10116.0,10262,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,4527,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621984,,10116.0,10263,,Bioavailability in dogs was determined; high,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621985,,10116.0,10264,,Bioavailability in monkey after intravenous administration at 1 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621986,,10116.0,10265,,Bioavailability in monkey after peroral administration at 10 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621987,,10116.0,10266,,Bioavailability in rat after intravenous administration at 1 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,,1,CHEMBL877600,,10116.0,10267,,Bioavailability in rat after intravenous administration at 2 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621988,,10116.0,10268,,Bioavailability in rat after peroral administration at 30 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,In vivo,,,1,CHEMBL621989,,10116.0,10269,,Bioavailability in rat after peroral administration at at 100 mpk,,6659,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621990,,10116.0,10270,,Bioavailability in rats was evaluated,,6597,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621991,,10116.0,10271,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,1202,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621992,,10116.0,10272,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,1202,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621993,,10116.0,10273,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,1202,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621994,,10116.0,10274,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,1202,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621995,,10116.0,10275,,Bioavailability in rat,,5207,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621996,,10116.0,10276,,Bioavailability in rat,,5970,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621997,,10116.0,10277,,Oral bioavailability in rat (dose 10 mg/kg),,17538,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621998,,10116.0,10278,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,17538,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621999,,10116.0,10279,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,1466,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622000,,10116.0,10280,,Oral bioavailability in rat,,2879,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622001,,10116.0,10281,,Bioavailability was measured in rat after oral administration; 2-4,,2879,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622002,,10116.0,10282,,Bioavailability was measured in rat after oral administration; 3-7,,2879,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622003,,10116.0,10283,,Bioavailability in rat (intraduodenal administration),,3777,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877601,,10116.0,10284,,Bioavailability in rat (intraduodenal administration),,3777,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624871,,10116.0,10285,,Oral bioavailability in rat,,3777,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622004,,10116.0,10286,,Oral bioavailability in rat,,3777,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL882954,,10116.0,10287,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,5423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622005,,10116.0,10288,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622006,,10116.0,10289,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,16365,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622007,,10116.0,10290,,Bioavailability was measured in rat,,4239,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622008,,10116.0,10291,,Bioavailability was reported,,5438,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622009,,10116.0,10292,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622010,,10116.0,10293,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622011,,10116.0,10294,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622012,,10116.0,10295,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622013,,10116.0,10296,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,4199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622014,,10116.0,10297,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,4890,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624749,,10116.0,10298,,Bioavailability was determined at 3 mg/kg po dose in rats,,2792,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624750,,10116.0,10299,,Oral bioavailability in rat (dose 2 mg/kg),,5529,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624751,,10116.0,10300,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624752,,10116.0,10301,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624753,,10116.0,10302,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,6685,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624754,,10116.0,10303,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,6005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624755,,10116.0,10304,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624756,,10116.0,10305,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624757,,10116.0,10306,,Bioavailability in rat,,6103,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624758,,10116.0,10307,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622270,,10116.0,10308,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,6410,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622271,,10116.0,10309,,Bioavailability in rat (Sprague-Dawley),,5353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622272,,10116.0,10310,,Bioavailability in rat at the dose of 2 mg/kg,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622273,,10116.0,10311,,Oral bioavailability in rat,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622274,,10116.0,10312,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,5809,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622275,,10116.0,10313,,Bioavailability value of compound in rats was determined after peroral administration,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622276,,10116.0,10314,,Oral bioavailability in rat (dose 20 mg/kg),,3634,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622277,,10116.0,10315,,Oral bioavailability in rat,,3341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622278,,10116.0,10316,,Oral bioavailability in rat (dose 5 mg/kg),,2690,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622279,,10116.0,10317,,Oral bioavailability in rat,,3184,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622280,,10116.0,10318,,Oral bioavailability in rat,,740,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624083,,10116.0,10319,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,1806,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624084,,10116.0,10320,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,4891,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624085,,10116.0,10321,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,3634,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624086,,10116.0,10322,,Compound was tested for bioavailability in rats,,64,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624087,,10116.0,10323,,Bioavailability in rat,,4839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624088,,10116.0,10324,,Oral bioavailability in rat,,1094,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL624089,,9544.0,10325,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,22224,A,U,In vivo,,,0,CHEMBL624090,,10116.0,10326,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,5005,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624091,,10116.0,10327,,Evaluated for the bioavailability in rat (in vivo),,4687,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624092,,10116.0,10328,,F value of compound in rats was determined after peroral administration,,17804,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624093,,10116.0,10329,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624094,,10116.0,10330,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624095,,10116.0,10331,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624096,,10116.0,10332,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,5974,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624097,,10116.0,10333,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,1088,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624098,,10116.0,10334,,Maximum fall in carotid flow in rat,,1742,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874392,,10116.0,10335,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,4689,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624099,,10116.0,10336,,Oral bioavailability in rat (dose 5 mg/kg),,2463,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624100,,10116.0,10337,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624101,,10116.0,10338,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,5654,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624102,,10116.0,10339,,Oral bioavailability in rat (male Wistar),,6874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624103,,10116.0,10340,,Oral bioavailability after administration (30 mg/kg) in rat; good,,5633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624104,,10116.0,10341,,Oral bioavailability at the dose of 2 mg/kg in rat,,5496,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624105,,10116.0,10342,,Oral bioavailability determined in rats,,2358,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624106,,10116.0,10343,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,16456,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624107,,10116.0,10344,,Oral bioavailability in rat (dose single 10 mg/kg),,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623943,,10116.0,10345,,Oral bioavailability in rat (dose single 10 mg/kg),,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623944,,10116.0,10346,,Oral bioavailability in rat (dose 5 mg/kg,,5302,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623945,,10116.0,10347,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623946,,10116.0,10348,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623947,,10116.0,10349,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623948,,10116.0,10350,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623949,,10116.0,10351,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623950,,10116.0,10352,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874398,,10116.0,10353,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623951,,10116.0,10354,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623952,,10116.0,10355,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623953,,10116.0,10356,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623954,,10116.0,10357,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623955,,10116.0,10358,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623956,,10116.0,10359,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627807,,10116.0,10360,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627808,,10116.0,10361,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627809,,10116.0,10362,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627810,,10116.0,10363,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627811,,10116.0,10364,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627812,,10116.0,10365,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627813,,10116.0,10366,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627814,,10116.0,10367,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875336,,10116.0,10368,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627815,,10116.0,10369,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627816,,10116.0,10370,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627817,,10116.0,10371,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627818,,10116.0,10372,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627819,,10116.0,10373,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627820,,10116.0,10374,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627821,,10116.0,10375,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628464,,10116.0,10376,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626239,,10116.0,10377,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626240,,10116.0,10378,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626241,,10116.0,10379,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626242,,10116.0,10380,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626243,,10116.0,10381,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626244,,10116.0,10382,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626907,,10116.0,10383,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626908,,10116.0,10384,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626909,,10116.0,10385,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626910,,10116.0,10386,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,11020,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL875342,,10116.0,10387,,Percent total excretion of acetaminophen cysteine conjugate,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626911,,10116.0,10388,,Percent total excretion of acetaminophen glucuronide,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL626912,,10116.0,10389,,Percent total excretion of acetaminophen sulfate,,7449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,F,N,,,,1,CHEMBL627065,,10116.0,10390,,Percent total excretion of acetaminophen-mercapturic acid,,7449,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627066,,10116.0,10391,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,3172,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627067,,10116.0,10392,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,16456,,,BAO_0000218
,Muscle tissue,ratrat,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627068,,8656.0,10393,,Biodistribution of compound in rat muscle after 5 min of administration,,10839,,,BAO_0000218
,Muscle tissue,ratrat,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627069,,8656.0,10394,,Biodistribution of compound in rat muscle after 5 min of administration.,,10839,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627070,,9940.0,10395,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627071,,9940.0,10396,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627072,,9940.0,10397,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627073,,9940.0,10398,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625387,,9940.0,10399,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Ovis aries,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625388,,9940.0,10400,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,Plasma,Ovis aries,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL625389,,9940.0,10401,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,Plasma,Ovis aries,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL875343,,9940.0,10402,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,5334,,,BAO_0000218
,,Serpentes,Intermediate,1,50497,A,N,,,,1,CHEMBL876795,,8570.0,10403,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,1735,,,BAO_0000218
,,Serpentes,Intermediate,1,50497,A,N,,,,1,CHEMBL626552,,8570.0,10404,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,1469,,,BAO_0000218
,,Serpentes,Intermediate,1,50497,A,N,,,,1,CHEMBL626553,,8570.0,10405,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,1336,,,BAO_0000218
,Plasma,Homo sapiens,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL626554,,9606.0,10406,,The human biological plasma half life of the compound,,12403,,,BAO_0000366
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626555,,10116.0,10407,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626556,,10116.0,10408,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626557,,10116.0,10409,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626558,,10116.0,10410,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626559,,10116.0,10411,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626560,,10116.0,10412,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876803,,10116.0,10413,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627964,,10116.0,10414,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627965,,10116.0,10415,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627966,,10116.0,10416,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627967,,10116.0,10417,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627968,,10116.0,10418,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627969,,10116.0,10419,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,8004,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627970,,10116.0,10420,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,8004,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627971,,10116.0,10421,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,8004,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627972,,10116.0,10422,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,8004,,,BAO_0000218
,,Homo sapiens,Expert,1,180,B,D,,,,9,CHEMBL856029,,9606.0,10423,,Dissociation constant against binding to human cyclophilin A,,15917,,,BAO_0000357
,,Bos taurus,Expert,1,11591,B,H,,,,8,CHEMBL627973,,9913.0,10424,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,12396,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627974,,,10425,,-Log C was determined by performing the electroshock minimum test,,7065,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627975,,,10426,,-Log C was determined by performing the foot shock test,,7065,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627976,,,10427,,-Log C was determined by performing the incl screen test,,7065,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627977,,,10428,,-Log C was determined by performing the maximum electroshock test,,7065,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627978,,,10429,,-Log C was determined by performing the pentylenetetrazole test,,7065,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627979,,,10430,,Tested for experimental arotinoid inhibitory dose,,12415,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL876804,,,10431,,Negative log transformed activity,,10256,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627980,,,10432,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,7991,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,50512,A,N,,,,1,CHEMBL627981,,10141.0,10433,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,14342,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,,,,1,CHEMBL627982,,10141.0,10434,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,14342,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,,,,1,CHEMBL627983,,10141.0,10435,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,14342,,,BAO_0000218
,Ileum,Cavia porcellus,Intermediate,1,50512,A,N,,,2116.0,1,CHEMBL627984,,10141.0,10436,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,14342,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL627985,,,10437,,Solubility in water was determined; values expressed as -log,,6047,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627986,,,10438,,Ratio of Kcat to that of Km was determined,,17269,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627987,,,10439,,Observed first order rate constant,,10026,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627988,,,10440,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,14583,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627989,,10116.0,10441,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627990,,10116.0,10442,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,2661,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876805,,10116.0,10443,,Oral Bioavailability after administration of 10 mg/kg in male rat,,4029,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627991,,10116.0,10444,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,17735,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627992,,10116.0,10445,,Oral bioavailability in rat,,4576,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627993,,10116.0,10446,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,17582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622817,,10116.0,10447,,Oral bioavailability at 1 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622818,,10116.0,10448,,Oral bioavailability at 10 mg/kg was determined in rat,,17651,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622819,,10116.0,10449,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,17670,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL872267,,10116.0,10450,,Oral bioavailability in rat,,5045,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622820,,10116.0,10451,,Oral bioavailability in rat,,1696,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622821,,10116.0,10452,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,17764,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622822,,10116.0,10453,,Oral bioavailability in rat,,6448,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622823,,10116.0,10454,,Oral bioavailability in rat,,6596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622824,,10116.0,10455,,Oral bioavailability in rat,,17547,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622825,,10116.0,10456,,Oral bioavailability in rat at a dose of 3 mg/kg,,17771,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622901,,10116.0,10457,,Oral bioavailability in rat after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622902,,10116.0,10458,,Oral bioavailability in rat,,4558,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621844,,10116.0,10459,,Oral bioavailability in rat,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621845,,10116.0,10460,,Oral bioavailability in Dawley rats,,6827,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621846,,10116.0,10461,,Oral bioavailability,,4026,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621847,,10116.0,10462,,Oral bioavailability in rat (dose 30 mg/kg),,10,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877609,,10116.0,10463,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621848,,10116.0,10464,,Bioavailability in rat (dose 3 mg/kg i.v.),,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL621849,,10116.0,10465,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622030,,10116.0,10466,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622031,,10116.0,10467,,Percent oral bioavailability determined in rats,,4796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622032,,10116.0,10468,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,4883,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622033,,10116.0,10469,,The compound was evaluated for bioavailability in rats; 32-51,,2137,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622034,,10116.0,10470,,Bioavailability in rat (dose 20 mg/kg p.o.),,2959,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622035,,10116.0,10471,,Oral bioavailability in rat,,1361,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL882966,,10116.0,10472,,Bioavailability percent in rat at the dose of 2 mg/kg,,4727,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622036,,10116.0,10473,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,16423,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622037,,10116.0,10474,,Oral bioavailability in rat,,5206,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622038,,10116.0,10475,,Oral bioavailability in rat,,6448,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622039,,10116.0,10476,,Bioavailability in rats,,17723,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622040,,10116.0,10477,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622041,,10116.0,10478,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622042,,10116.0,10479,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622043,,10116.0,10480,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622044,,10116.0,10481,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL622045,,10116.0,10482,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL622046,,10116.0,10483,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL622047,,10116.0,10484,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL877610,,10116.0,10485,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622048,,10116.0,10486,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622049,,10116.0,10487,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622050,,10116.0,10488,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622051,,10116.0,10489,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622052,,10116.0,10490,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622053,,10116.0,10491,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622054,,10116.0,10492,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622055,,10116.0,10493,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622056,,10116.0,10494,,Oral bioavailability in rats was determined; High,,5237,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622057,,10116.0,10495,,Oral bioavailability in the rat was determined,,5503,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628008,,10116.0,10496,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,15765,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622058,,10116.0,10497,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,15660,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622059,,10116.0,10498,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622060,,10116.0,10499,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622061,,10116.0,10500,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622062,,10116.0,10501,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,5978,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622063,,10116.0,10502,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,5656,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,,1,CHEMBL877611,,10116.0,10503,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,3598,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622064,,10116.0,10504,,Oral bioavailability of compound in Sprague Dawley rats,,4216,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622065,,10116.0,10505,,Oral bioavailability of compound in rat,,17839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622066,,10116.0,10506,,Oral bioavailability in rat (dose 2 mg/kg),,6570,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622067,,10116.0,10507,,Oral bioavailability of compound in rat was determined,,5334,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622068,,10116.0,10508,,Oral bioavailability of compound in rats,,6886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622069,,10116.0,10509,,Oral bioavailability of compound was determined in rats,,5210,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624796,,10116.0,10510,,Oral bioavailability at a dose of 30 mg/kg in rats,,4170,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624797,,10116.0,10511,,Oral bioavailability in rat (dose 10 mg/kg),,6028,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623053,,10116.0,10512,,Oral bioavailability in rat (dose 10 mg/kg),,6028,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623054,,10116.0,10513,,Oral bioavailability evaluated in rat,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623055,,10116.0,10514,,Oral bioavailability in fasted rat,,6168,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623056,,10116.0,10515,,Oral bioavailability in fed rat,,6168,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623057,,10116.0,10516,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,5160,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623058,,10116.0,10517,,Oral bioavailability in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623059,,10116.0,10518,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623060,,10116.0,10519,,Oral bioavailability in rat after administration of 10 mg/kg po,,6535,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623061,,10116.0,10520,,Oral bioavailability in rat,,4194,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623062,,10116.0,10521,,Oral bioavailability in rat,,6230,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623063,,10116.0,10522,,Oral bioavailability in rat,,6619,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623064,,10116.0,10523,,Oral bioavailability in rat,,17607,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623065,,10116.0,10524,,Oral bioavailability in ratrs,,4942,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623066,,10116.0,10525,,Oral bioavailability in rat,,4942,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623067,,10116.0,10526,,Oral bioavailability in rat,,6646,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623068,,10116.0,10527,,Oral bioavailability in rats was determined; High,,5237,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623069,,10116.0,10528,,Oral bioavailability in rat,,6646,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623070,,10116.0,10529,,Oral bioavailability in rat,,4449,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623071,,10116.0,10530,,Oral bioavailability was calculated in rat,,6057,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623072,,10116.0,10531,,Oral bioavailability,,2552,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623073,,10116.0,10532,,Oral bioavailability,,5496,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623074,,10116.0,10533,,Oral bioavailability,,6484,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623075,,10116.0,10534,,Oral bioavailability,,6485,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623076,,10116.0,10535,,Oral bioavailability after i.v. administration,,6616,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623077,,10116.0,10536,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,4969,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623078,,10116.0,10537,,Oral bioavailability in rat (Sprague-Dawley),,5862,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623079,,10116.0,10538,,Oral bioavailability in Sprague-Dawley rats,,4514,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623080,,10116.0,10539,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,4514,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623081,,10116.0,10540,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,4514,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623082,,10116.0,10541,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,5546,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874400,,10116.0,10542,,Oral bioavailability in fasted rat,,6168,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623083,,10116.0,10543,,Oral bioavailability in fed rat,,6168,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623084,,10116.0,10544,,Oral bioavailability in rat,,3624,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623085,,10116.0,10545,,Oral bioavailability in rat,,5213,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623086,,10116.0,10546,,Oral bioavailability in rat,,5496,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623087,,10116.0,10547,,Oral bioavailability in rat,,5553,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623088,,10116.0,10548,,Oral bioavailability in rat,,5833,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623089,,10116.0,10549,,Oral bioavailability in rat,,5836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623090,,10116.0,10550,,Oral bioavailability in rat,,5865,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623091,,10116.0,10551,,Oral bioavailability in rat,,5960,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623092,,10116.0,10552,,Oral bioavailability in rat,,6249,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623093,,10116.0,10553,,Oral bioavailability in rat,,6448,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874401,,10116.0,10554,,Oral bioavailability in rat,,6453,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623094,,10116.0,10555,,Oral bioavailability in rat,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623095,,10116.0,10556,,Oral bioavailability in rat,,17607,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623096,,10116.0,10557,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624913,,10116.0,10558,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,5939,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624914,,10116.0,10559,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,6281,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624915,,10116.0,10560,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,5874,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624916,,10116.0,10561,,Oral bioavailability in rat; Not measured,,5213,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624917,,10116.0,10562,,Oral bioavailability in rat,,4964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625157,,10116.0,10563,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,11020,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625158,,10116.0,10564,,In vitro metabolic potential in rat liver microsomes,,6251,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625159,,10116.0,10565,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,1568,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625160,,10116.0,10566,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,3032,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625161,,10116.0,10567,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,3748,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625162,,10116.0,10568,,Oral bioavailability in rat,,401,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625163,,10116.0,10569,,Oral bioavailability in rat,,6512,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625164,,10116.0,10570,,Oral bioavailability in rats at 10 mg/kg,,17617,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625165,,10116.0,10571,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6679,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625166,,10116.0,10572,,Oral bioavailability in rat,,6742,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625167,,10116.0,10573,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,589,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625168,,10116.0,10574,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,589,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625169,,10116.0,10575,,Plasma clearance of the compound,,3185,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626264,,10116.0,10576,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,17596,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626265,,10116.0,10577,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,2713,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626266,,10116.0,10578,,The compound was tested for plasma clearance in rat,,12500,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626267,,10116.0,10579,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,12500,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626268,,10116.0,10580,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,2713,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626269,,10116.0,10581,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,1446,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626270,,10116.0,10582,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,6227,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626271,,10116.0,10583,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,4709,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626272,,10116.0,10584,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626273,,10116.0,10585,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875346,,10116.0,10586,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626274,,10116.0,10587,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,5510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626275,,10116.0,10588,,Compound was tested for protein binding in rat plasma,,4514,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624646,,10116.0,10589,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,2713,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624647,,10116.0,10590,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,2713,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624648,,10116.0,10591,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,5340,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624649,,10116.0,10592,,Area under curve ratio was determined (po/iv) in rat,,12058,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624650,,10116.0,10593,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,11195,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624651,,10116.0,10594,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,11195,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624652,,10116.0,10595,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,11195,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624653,,10116.0,10596,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,6495,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624654,,10116.0,10597,,Ratio of AUCbrain to AUCplasma,,6078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624655,,10116.0,10598,,Ratio of brain to plasma,,5656,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624656,,10116.0,10599,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624657,,10116.0,10600,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624658,,10116.0,10601,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624659,,10116.0,10602,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624660,,10116.0,10603,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624661,,10116.0,10604,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,10130,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624662,,10116.0,10605,,Steady state brain :blood ratio was determined,,5213,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625199,,10116.0,10606,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625200,,10116.0,10607,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625201,,10116.0,10608,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625202,,10116.0,10609,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,4910,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625203,,10116.0,10610,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,2083,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625204,,10116.0,10611,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,2082,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625205,,10116.0,10612,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,2082,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625206,,10116.0,10613,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,6351,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625207,,,10614,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,14583,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625208,,,10615,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,14583,,,BAO_0000019
495.0,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL625209,,9606.0,10616,,In vivo absorption in Caco-2 cell line monolayers was determined,,4608,,Caco-2,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625210,,,10617,,Calculated partition coefficient (clogP),,13668,,,BAO_0000100
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625211,,10116.0,10618,,Area under curve was determine after peroral administration at 10 mpk in Rat,,5669,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,,,,1,CHEMBL625212,,9544.0,10619,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625213,,10116.0,10620,,Area under curve was determine after peroral administration at 160 mpk in Rat,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625214,,10116.0,10621,,Area under curve was determine after peroral administration at 20 mpk in Rat,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874542,,10116.0,10622,,Area under curve was determine after peroral administration at 50 mpk in Rat,,5669,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625215,,,10623,,Calculated partition coefficient (clogP) (AlogP),,6472,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625216,,,10624,,Activated partial thromboplastin time measured,,15106,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL625217,,,10625,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,15207,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL625218,,,10626,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,15207,,,BAO_0000100
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL622864,,9615.0,10627,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,13941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622865,,10116.0,10628,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,13941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622866,,10116.0,10629,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,13941,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL622867,,9615.0,10630,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,13941,,,BAO_0000218
,Plasma,Cavia porcellus,Intermediate,1,50512,A,N,,,1969.0,1,CHEMBL876808,,10141.0,10631,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,15240,,,BAO_0000218
,Brain,,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL627725,,,10632,,AUC in brain,,10655,,,BAO_0000019
,Serum,,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL627726,,,10633,,AUC in serum,,10655,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627727,,,10634,,AUC was determined,,6504,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627728,,,10635,,AUC of the compound.,,10615,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627729,,,10636,,AUC value (0-4 hr),,10353,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627730,,,10637,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,14907,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627731,,,10638,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,14907,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627732,,,10639,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,14907,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL627733,,,10640,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,14907,,,BAO_0000019
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627734,,10116.0,10641,,AUC(area under curve) was determined after intravenous administration in rats,,16359,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL627735,,10116.0,10642,,AUC(area under curve) was determined after oral administration in rats,,16359,,,BAO_0000218
,Plasma,Cavia porcellus,Intermediate,1,50512,A,N,,,1969.0,1,CHEMBL627736,,10141.0,10643,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,15240,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL876809,,10116.0,10644,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,15240,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627737,,,10645,,Area Under Curve after oral dosing of 100 uM/Kg,,15469,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627738,,,10646,,Area Under Curve after oral dosing of 30 uM/Kg,,15469,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627739,,,10647,,Area Under Curve was measured by ploting the graph between concentration verses time,,13520,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626143,,9615.0,10648,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,17025,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL626144,,314293.0,10649,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,17025,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL626145,,9986.0,10650,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,17025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626146,,10116.0,10651,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,17025,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626147,,10116.0,10652,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,12032,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626148,,,10653,,Area under curve (AUC) was determined,,10291,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626149,,,10654,,Area under curve (AUC) following ip administration at 1 mg/kg,,5767,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626150,,,10655,,Area under curve (AUC) was determined; ND is Not determined,,1434,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626151,,9615.0,10656,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,14925,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626152,,9615.0,10657,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,14925,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626153,,9615.0,10658,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,14925,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626154,,,10659,,Area under curve (AUR) was determined,,1434,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626155,,,10660,,Area under curve at 1 uM/dg administered intravenously,,11883,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626156,,,10661,,Area under curve at 10 uM/dg administered perorally,,11883,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626157,,,10662,,Area under curve at 2 uM/dg administered intravenously,,11883,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626158,,,10663,,Area under curve at 20 uM/dg administered perorally,,11883,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626159,,9615.0,10664,,Area under curve at a peroral dose of 3 mg/kg in dog,,15233,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626160,,10116.0,10665,,Area under curve at a peroral dose of 3 mg/kg in rat,,15233,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626161,,9615.0,10666,,Area under curve at an iv dose of 1 mg/kg in dog,,15233,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626162,,10116.0,10667,,Area under curve at an iv dose of 1 mg/kg in rat,,15233,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626163,,,10668,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,12978,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626164,,,10669,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,12978,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626165,,10090.0,10670,,Area under curve measured as conc vs time after intravenous administration to mice.,,11355,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626166,,10090.0,10671,,Area under curve measured as conc vs time after peroral administration to mice.,,11355,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626167,,9615.0,10672,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,12923,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626168,,9615.0,10673,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,12923,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL877463,,9615.0,10674,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,12923,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626169,,9615.0,10675,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,12923,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626170,,10116.0,10676,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626171,,10116.0,10677,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626172,,10116.0,10678,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL626173,,10116.0,10679,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626174,,10116.0,10680,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626175,,10116.0,10681,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626176,,10116.0,10682,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626177,,10116.0,10683,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622499,,10116.0,10684,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622500,,10116.0,10685,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622501,,10116.0,10686,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622502,,10116.0,10687,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622503,,10116.0,10688,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL877614,,10116.0,10689,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624839,,10116.0,10690,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624840,,10116.0,10691,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624841,,10116.0,10692,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL624842,,10116.0,10693,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624843,,10116.0,10694,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624844,,10116.0,10695,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL624845,,10116.0,10696,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL621904,,10116.0,10697,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,17738,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL621905,,10116.0,10698,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,11195,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL874382,,10116.0,10699,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,11195,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL621906,,10116.0,10700,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,11195,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL621907,,10116.0,10701,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,11195,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622096,,10116.0,10702,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,11195,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL622097,,10116.0,10703,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,11195,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622098,,10116.0,10704,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,11195,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622099,,10116.0,10705,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,11195,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622100,,10116.0,10706,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,11195,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622101,,10116.0,10707,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,11195,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622102,,10116.0,10708,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,11195,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622103,,10116.0,10709,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,11195,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622104,,10116.0,10710,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,11195,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622105,,10116.0,10711,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,11195,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622106,,10116.0,10712,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,11195,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622107,,10116.0,10713,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,11195,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622108,,10116.0,10714,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,11195,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622109,,10116.0,10715,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,11195,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL622110,,10116.0,10716,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,11195,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL622111,,10116.0,10717,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,11195,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL874383,,10116.0,10718,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,11195,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL622112,,10116.0,10719,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,11195,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL622113,,10116.0,10720,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,11195,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL622114,,10116.0,10721,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,11195,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622115,,10116.0,10722,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,11195,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622116,,10116.0,10723,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,11195,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622117,,10116.0,10724,,Oral bioavailability in rat,,6193,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622118,,10116.0,10725,,Oral bioavailability in rat,,6803,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622119,,10116.0,10726,,Oral bioavailability in rats at 6 mg/kg,,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622120,,10116.0,10727,,Oral bioavailability in rat (dose 6 mg/kg),,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622121,,10116.0,10728,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,6647,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622122,,10116.0,10729,,Oral bioavailability in rat,,6640,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622123,,10116.0,10730,,Oral bioavailability in rat,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622124,,10116.0,10731,,Oral bioavailability in rat,,6641,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622125,,10116.0,10732,,Bioavailability in rat,,6642,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622126,,10116.0,10733,,Oral bioavailability,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620455,,10116.0,10734,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,6141,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620456,,10116.0,10735,,Oral bioavailability in rat,,4390,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620457,,10116.0,10736,,Oral bioavailability in rat,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620458,,10116.0,10737,,Oral bioavailability was evaluated; Not tested,,5472,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620459,,10116.0,10738,,Oral bioavailability,,5438,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620460,,10116.0,10739,,Oral bioavailability in rat by oral dosing,,4883,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620461,,10116.0,10740,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,1908,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620462,,10116.0,10741,,Oral bioavailability in rat (Sprague-Dawley),,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620463,,10116.0,10742,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620464,,10116.0,10743,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620465,,10116.0,10744,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620466,,10116.0,10745,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620467,,10116.0,10746,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620468,,10116.0,10747,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,4853,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620469,,10116.0,10748,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620470,,10116.0,10749,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,12873,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620471,,10116.0,10750,,Oral bioavailability in rat,,3169,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620472,,10116.0,10751,,Oral bioavailability in rat,,6305,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620473,,10116.0,10752,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,4762,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620474,,10116.0,10753,,Oral bioavailability in rat,,17847,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620475,,10116.0,10754,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,6211,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620476,,10116.0,10755,,Oral bioavailability in rat,,6011,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620477,,10116.0,10756,,Oral bioavailability in rat,,6317,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620478,,10116.0,10757,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618768,,10116.0,10758,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618769,,10116.0,10759,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618770,,10116.0,10760,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,6644,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618771,,10116.0,10761,,Oral bioavailability (dose 20 mg/kg p.o.),,6113,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618772,,10116.0,10762,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,5937,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618773,,10116.0,10763,,Oral bioavailability in rat at 10 mg/kg of the compound,,5711,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875842,,10116.0,10764,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618774,,10116.0,10765,,Bioavailability in rat (dose 3 mg/kg i.v.),,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618775,,10116.0,10766,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618776,,10116.0,10767,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,17717,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618777,,10116.0,10768,,Percent bioavailability (F) in rats after iv administration,,4722,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618778,,10116.0,10769,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,4722,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618779,,10116.0,10770,,Bioavailability in rat (dose 5 uM/kg p.o.),,4353,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618780,,10116.0,10771,,Oral bioavailability,,15662,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618781,,10116.0,10772,,Bioavailability in rat (dose 2 mg/kg p.o.),,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618782,,10116.0,10773,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,4756,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618783,,10116.0,10774,,Oral bioavailability in rat (dose 20 mg/kg),,3436,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618784,,10116.0,10775,,Oral bioavailability in rat,,17800,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618785,,10116.0,10776,,Percent oral bioavailability evaluated in rat,,15762,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618786,,10116.0,10777,,Oral bioavailability in rat,,5089,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618787,,10116.0,10778,,Percent oral bioavailability in rat; Not determined,,5089,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618788,,10116.0,10779,,Oral bioavailability in rat,,3185,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618789,,10116.0,10780,,Bioavailability in rat,,5145,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618790,,10116.0,10781,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,3457,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618791,,10116.0,10782,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,3457,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875843,,10116.0,10783,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,5983,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL618792,,10116.0,10784,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,5739,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623395,,10116.0,10785,,Cmax at a dose of 30 mg/kg in rat,,3579,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623396,,314293.0,10786,,Cmax in monkeys at a dose of 1 mg/kg,,17788,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623397,,10116.0,10787,,Cmax in rat,,14956,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623398,,10116.0,10788,,Cmax in rats at a dose of 1 mg/kg,,17788,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623399,,10090.0,10789,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,9750,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623400,,,10790,,"Cmax value at a dose of 12.7 uM/kg, po",,12767,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623401,,,10791,,"Cmax value at a dose of 6.3 uM/kg, iv",,12767,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623402,,,10792,,"Cmax value at a dose of 7.1 uM/kg, iv",,12767,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623403,,,10793,,Cmax value of compound was determined after 1 hr,,12703,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623404,,,10794,,Cmax value of the compound,,15778,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625997,,10116.0,10795,,Cmax value administered intraintestinal in rats.,,12818,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625998,,10116.0,10796,,Cmax value administered perorally was determined in rat; Not determined,,14964,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625999,,,10797,,Cmax value at the dose of 2.3 mg/kg,,15808,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626000,,,10798,,Cmax value at the dose of 5 mg/kg,,15808,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626001,,,10799,,Cmax value in the period of 8 hr after dosing. ,,15778,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626002,,,10800,,Cmax value at a oral dose of 20 mg/kg; Not tested,,3715,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626003,,,10801,,Cmax value at a oral dose of 20 mg/kg,,3715,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626004,,10116.0,10802,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,1446,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL626005,,10141.0,10803,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,15240,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626006,,10116.0,10804,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,15240,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626007,,10116.0,10805,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,14810,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL626008,,10090.0,10806,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,14239,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,2107.0,1,CHEMBL626009,,9615.0,10807,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,12555,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626010,,9615.0,10808,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626011,,10090.0,10809,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626012,,10090.0,10810,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626013,,10090.0,10811,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL626014,,10090.0,10812,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,10754,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL877496,,10090.0,10813,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,10754,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,F,N,In vivo,,,1,CHEMBL626015,,9615.0,10814,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,14600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,F,N,In vivo,,,1,CHEMBL626016,,9615.0,10815,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,14600,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,F,N,In vivo,,,1,CHEMBL626017,,9615.0,10816,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,14600,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626018,,9615.0,10817,,Bioavailability as maximal plasma concentration in dogs,,13543,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626692,,9615.0,10818,,Bioavailability as maximal plasma concentration in dogs,,13543,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626693,,10116.0,10819,,Bioavailability as maximal plasma concentration in rats,,13543,,,BAO_0000218
,Plasma,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626694,,10116.0,10820,,Bioavailability as maximal plasma concentration in rats,,13543,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626695,,9615.0,10821,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,14600,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626696,,9615.0,10822,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,14600,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626697,,9615.0,10823,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,14600,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626859,,9615.0,10824,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,14600,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626860,,9615.0,10825,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,14600,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,178.0,1,CHEMBL626861,,9615.0,10826,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,14600,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626296,,10116.0,10827,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,14681,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626297,,,10828,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,15905,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626298,,,10829,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,15905,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626299,,10116.0,10830,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,13304,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626300,,10116.0,10831,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626301,,10116.0,10832,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626962,,10116.0,10833,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626963,,10116.0,10834,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626964,,10116.0,10835,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,15137,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,1969.0,1,CHEMBL626965,,9541.0,10836,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL626966,,10090.0,10837,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL626967,,10090.0,10838,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,1969.0,1,CHEMBL626968,,9541.0,10839,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,14839,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626969,,10116.0,10840,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL627126,,10116.0,10841,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631276,,10116.0,10842,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631277,,10116.0,10843,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631278,,10116.0,10844,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL874457,,10116.0,10845,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631279,,10116.0,10846,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631280,,10116.0,10847,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631281,,10116.0,10848,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631968,,10116.0,10849,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631969,,10116.0,10850,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631970,,10116.0,10851,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631971,,10116.0,10852,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL631972,,10116.0,10853,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL630435,,10116.0,10854,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL630436,,10116.0,10855,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL630437,,10116.0,10856,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL630438,,10116.0,10857,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,8418,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL630439,,10116.0,10858,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630440,,10116.0,10859,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630441,,10116.0,10860,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630442,,10116.0,10861,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625234,,10116.0,10862,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625235,,10116.0,10863,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625236,,10116.0,10864,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625237,,10116.0,10865,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626125,,10116.0,10866,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626126,,10116.0,10867,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626127,,10116.0,10868,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626128,,10116.0,10869,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626129,,10116.0,10870,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626130,,10116.0,10871,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626131,,10116.0,10872,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626132,,10116.0,10873,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626752,,10116.0,10874,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626753,,10116.0,10875,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626754,,10116.0,10876,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,8418,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626755,,10116.0,10877,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626756,,10116.0,10878,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626757,,10116.0,10879,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626758,,10116.0,10880,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626759,,10116.0,10881,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626760,,10116.0,10882,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,8418,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626394,,9615.0,10883,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626395,,9615.0,10884,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626396,,9615.0,10885,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626397,,9615.0,10886,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626398,,9615.0,10887,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626399,,9615.0,10888,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874653,,10116.0,10889,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626400,,10116.0,10890,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626401,,10116.0,10891,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626402,,10116.0,10892,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626403,,10116.0,10893,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626404,,10116.0,10894,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626405,,10116.0,10895,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625529,,10116.0,10896,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625530,,10116.0,10897,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625531,,10116.0,10898,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625532,,10116.0,10899,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625533,,10116.0,10900,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875474,,10116.0,10901,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625534,,10116.0,10902,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625535,,10116.0,10903,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625536,,10116.0,10904,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625537,,10116.0,10905,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625538,,10116.0,10906,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625539,,10116.0,10907,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625540,,10116.0,10908,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625541,,10116.0,10909,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625542,,10116.0,10910,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625543,,10116.0,10911,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625544,,10116.0,10912,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625545,,9615.0,10913,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625546,,9615.0,10914,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625547,,9615.0,10915,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625548,,9615.0,10916,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625549,,9615.0,10917,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625550,,9615.0,10918,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625551,,9615.0,10919,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875475,,9615.0,10920,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625552,,9615.0,10921,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625553,,9615.0,10922,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625554,,9615.0,10923,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625555,,9615.0,10924,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625556,,9615.0,10925,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624986,,9615.0,10926,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624987,,9615.0,10927,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624988,,9615.0,10928,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624989,,9615.0,10929,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624990,,9615.0,10930,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL874391,,9615.0,10931,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624991,,9615.0,10932,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624992,,9615.0,10933,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624993,,9615.0,10934,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624994,,9615.0,10935,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624995,,9615.0,10936,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624996,,9615.0,10937,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624997,,9615.0,10938,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624998,,9615.0,10939,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624999,,9615.0,10940,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL882955,,9615.0,10941,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625000,,9615.0,10942,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625001,,9615.0,10943,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625089,,9615.0,10944,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625090,,9615.0,10945,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625091,,9615.0,10946,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625092,,9615.0,10947,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625093,,9615.0,10948,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625094,,9615.0,10949,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL625095,,9615.0,10950,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625096,,9615.0,10951,,Compound was evaluated for its bioavailability in the dogs,,2249,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625097,,10116.0,10952,,Compound was evaluated for its bioavailability in the rats,,2249,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL882956,,,10953,,Compound was evaluated for oral bioavailability,,17515,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625098,,10116.0,10954,,Compound was evaluated for percentage of Oral bioavailability in rats,,14541,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625099,,10141.0,10955,,Bioavailability in guinea pig,,12797,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625100,,10116.0,10956,,Compound was evaluated for the oral bioavailability in rat,,12797,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625101,,9615.0,10957,,Compound was evaluated for the oral bioavailability in dog,,12797,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874396,,10116.0,10958,,Compound was evaluated for the oral bioavailability in rat,,12797,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL625102,,9615.0,10959,,Bioavailability in dog (dosed i.v.),,11727,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625103,,9615.0,10960,,Compound was tested for in vivo bioavailability in dog,,13249,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,In vivo,,,1,CHEMBL625104,,10026.0,10961,,Compound was tested for in vivo bioavailability in hamsters,,13249,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625105,,314293.0,10962,,Compound was tested for in vivo bioavailability in monkey,,13249,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625106,,10116.0,10963,,Compound was tested for in vivo bioavailability in rat,,13249,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625107,,10090.0,10964,,Oral bioavailability in mouse,,9552,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625108,,10090.0,10965,,Compound was tested for percent of oral bioavailability in mice; 56-74,,9552,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625109,,10090.0,10966,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,14839,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625110,,9541.0,10967,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,14839,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625111,,9541.0,10968,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625112,,10090.0,10969,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL875334,,10090.0,10970,,Oral bioavailability in nude mice,,14839,,,BAO_0000218
,,Primates,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628617,,9443.0,10971,,Bioavailability in monkey (i.d. dosing),,11219,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628618,,10116.0,10972,,Bioavailability in rat,,9552,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628619,,,10973,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,11732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628620,,,10974,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,11732,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL628621,,9541.0,10975,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL628622,,9541.0,10976,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,14839,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL628623,,9541.0,10977,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,14839,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,1969.0,1,CHEMBL628624,,9541.0,10978,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL628625,,10090.0,10979,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,1969.0,1,CHEMBL628626,,9541.0,10980,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627041,,10090.0,10981,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627042,,10090.0,10982,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627043,,10090.0,10983,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,14839,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL627044,,,10984,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,13932,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL627045,,10090.0,10985,,Cmax in mouse plasma,,11637,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL627046,,,10986,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,11637,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627047,,10116.0,10987,,Maximal plasma concentration in rat,,13960,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627048,,10116.0,10988,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,15905,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627049,,10116.0,10989,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627050,,10116.0,10990,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627051,,10116.0,10991,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627052,,10116.0,10992,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627053,,10116.0,10993,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627054,,10116.0,10994,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,14062,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627055,,10090.0,10995,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627056,,10090.0,10996,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627057,,10090.0,10997,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627058,,10090.0,10998,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626211,,10090.0,10999,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,15011,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626212,,,11000,,Maximum Concentration of the compound.,,10291,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626213,,9615.0,11001,,Maximum Concentration was measured after iv administration into Beagle dog,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626214,,9615.0,11002,,Maximum Concentration was measured after iv administration into Beagle dog.,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626215,,9615.0,11003,,Maximum Concentration was measured after po administration into Beagle dog,,14599,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626216,,9615.0,11004,,Maximum Concentration was measured after po administration into Beagle dog.,,14599,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626217,,,11005,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,12767,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626218,,,11006,,Maximum blood level reached after an iv dose of 12.2 uM/kg,,12767,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626219,,,11007,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,12767,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626220,,,11008,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,12767,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626221,,,11009,,Maximum blood level reached after an oral dose of 5.0 mg/kg,,12767,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626222,,,11010,,Maximum blood level reached at dose of 10.6 uM/kg orally,,12767,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL626223,,10141.0,11011,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,14706,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL626224,,10141.0,11012,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,14706,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL626225,,10116.0,11013,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL626226,,10116.0,11014,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,14793,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL626227,,10116.0,11015,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,14793,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL626228,,10116.0,11016,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626229,,10116.0,11017,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626921,,10116.0,11018,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876793,,10116.0,11019,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,14793,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625309,,10116.0,11020,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,,Bacillus subtilis,Intermediate,1,50278,A,N,In vivo,,,1,CHEMBL625310,,1423.0,11021,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,10524,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625311,,314293.0,11022,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,11871,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625312,,10116.0,11023,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,11871,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625313,,,11024,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,3437,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625314,,10090.0,11025,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,12038,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625315,,10116.0,11026,,Maximum concentration in male rats after iv administration of 20 mg/kg,,12038,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625316,,10116.0,11027,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625317,,10116.0,11028,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625318,,10116.0,11029,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625319,,10116.0,11030,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625320,,10116.0,11031,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625321,,10116.0,11032,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625322,,10116.0,11033,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL876801,,10116.0,11034,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625323,,10116.0,11035,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625324,,10116.0,11036,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625325,,10116.0,11037,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625326,,10116.0,11038,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625327,,10116.0,11039,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,8418,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625328,,10116.0,11040,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625329,,10116.0,11041,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625330,,10116.0,11042,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627774,,10116.0,11043,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627775,,10116.0,11044,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627949,,10116.0,11045,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627950,,10116.0,11046,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627951,,10116.0,11047,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627952,,10116.0,11048,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627953,,10116.0,11049,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627954,,10116.0,11050,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627955,,10116.0,11051,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627956,,10116.0,11052,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL876802,,10116.0,11053,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627957,,10116.0,11054,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627958,,10116.0,11055,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627959,,10116.0,11056,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627960,,10116.0,11057,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627961,,10116.0,11058,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,8418,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627962,,10116.0,11059,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627963,,10116.0,11060,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624759,,10116.0,11061,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624760,,10116.0,11062,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624761,,10116.0,11063,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877607,,10116.0,11064,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624762,,10116.0,11065,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624763,,10116.0,11066,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624764,,10116.0,11067,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624765,,10116.0,11068,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624766,,10116.0,11069,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624767,,9615.0,11070,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624768,,9615.0,11071,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624769,,9615.0,11072,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624770,,9615.0,11073,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624771,,9615.0,11074,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624772,,9615.0,11075,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624773,,10116.0,11076,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624774,,10116.0,11077,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624775,,10116.0,11078,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624776,,10116.0,11079,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624777,,10116.0,11080,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624778,,10116.0,11081,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624779,,10116.0,11082,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624780,,10116.0,11083,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624781,,10116.0,11084,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877608,,10116.0,11085,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624782,,10116.0,11086,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624783,,10116.0,11087,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624784,,10116.0,11088,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624785,,10116.0,11089,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624786,,10116.0,11090,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624787,,10116.0,11091,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628676,,10116.0,11092,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621842,,10116.0,11093,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL621843,,10116.0,11094,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623873,,10116.0,11095,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623874,,10116.0,11096,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623875,,10116.0,11097,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623876,,10116.0,11098,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623877,,9615.0,11099,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623878,,9615.0,11100,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623879,,9615.0,11101,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623880,,9615.0,11102,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623881,,9615.0,11103,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623957,,9615.0,11104,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623958,,9615.0,11105,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623959,,9615.0,11106,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623960,,9615.0,11107,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623961,,9615.0,11108,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL623962,,9615.0,11109,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624676,,9615.0,11110,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624677,,9615.0,11111,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624678,,9615.0,11112,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624679,,9615.0,11113,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624680,,9615.0,11114,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624849,,,11115,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,11732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624850,,,11116,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,11732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL874399,,,11117,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,11732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624851,,,11118,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,11732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624852,,,11119,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,11732,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624853,,10116.0,11120,,Oral bioavailability in rat (dose 10 mg/kg),,13359,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624854,,10116.0,11121,,Oral bioavailability in rat (Sprague-Dawley),,16618,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624855,,10116.0,11122,,Oral bioavailability in rat,,13960,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624856,,10116.0,11123,,Oral bioavailability in rats was determined in vivo,,13917,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL882957,,9615.0,11124,,Oral bioavailability in dog,,14266,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL624857,,314293.0,11125,,Oral bioavailability of compound in monkey,,12359,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622202,,10116.0,11126,,Oral bioavailability of compound in rat,,12359,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622203,,10116.0,11127,,Bioavailability in rat of PMEA prodrug,,12359,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625522,,10116.0,11128,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,12359,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622868,,9544.0,11129,,Serum conc at 3 hours following 25 mg/kg dose,,10791,,,BAO_0000218
,Urine,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,1088.0,0,CHEMBL622869,,9544.0,11130,,Urine conc 0-5 hours following 25 mg/kg dose,,10791,,,BAO_0000218
,Urine,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,1088.0,0,CHEMBL622870,,9544.0,11131,,Urine conc 0-24 hours following 25 mg/kg dose,,10791,,,BAO_0000218
,,Chlorocebus aethiops,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622871,,9534.0,11132,,Oral bioavailability in African green monkeys; 20-25,,138,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL620560,,9541.0,11133,,Oral bioavailability in cynomolgus monkey.,,14521,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620561,,9615.0,11134,,Oral bioavailability in dog,,13953,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL620562,,9615.0,11135,,Oral bioavailability in dog at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,In vivo,,,1,CHEMBL620563,,10026.0,11136,,Oral bioavailability in hamster at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL620564,,10116.0,11137,,Oral bioavailability in rat at 10 mg/kg oral dose,,12836,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL872265,,10116.0,11138,,Oral bioavailability in rat,,14521,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620565,,10116.0,11139,,Oral bioavailability in rat,,13953,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620566,,9347.0,11140,,Oral bioavailability,,6799,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620567,,,11141,,Oral bioavailability was determined; range 49-102%,,11311,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL620568,,9615.0,11142,,Oral bioavailability was determined in dogs,,4013,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620569,,10116.0,11143,,Oral bioavailability in rat,,4013,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620570,,9347.0,11144,,Oral bioavailability,,17591,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620571,,,11145,,Oral bioavailability was determined; Not orally available,,17591,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL620572,,10090.0,11146,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,15011,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620573,,10090.0,11147,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,15011,,,BAO_0000218
,,Mus musculus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620574,,10090.0,11148,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,15011,,,BAO_0000218
,,Macaca mulatta,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620575,,9544.0,11149,,Oral bioavailability in Rhesus monkey,,9552,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620576,,9615.0,11150,,Oral bioavailability in dog (female mongrel),,9552,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875846,,,11151,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,3639,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620577,,9615.0,11152,,Oral bioavailability in dog,,13397,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620578,,,11153,,Percentage Bioavailability was evaluated.,,3031,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL620579,,10116.0,11154,,Bioavailability in rat administered i.d.,,12818,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL621248,,9347.0,11155,,Bioavailability,,4847,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625390,,9615.0,11156,,Bioavailability in dog (male Beagle) i.v. administration,,12421,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625391,,10116.0,11157,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,11966,,,BAO_0000218
,,Primates,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL872266,,9443.0,11158,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,11218,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625392,,10116.0,11159,,Oral bioavailability in rat (Sprague-Dawley) (male),,13129,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625393,,10116.0,11160,,The oral bioavailability was measured on rats after oral administration,,12350,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625394,,10116.0,11161,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,2231,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,,1,CHEMBL625395,,9544.0,11162,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,2231,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625396,,10116.0,11163,,Bioavailability in rat (dose 10 mg/kg i.d.),,12187,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625397,,9615.0,11164,,Bioavailability in dog (male Beagle) i.v. administration,,12421,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625398,,10090.0,11165,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL625399,,10090.0,11166,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Cerebellum,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2037.0,1,CHEMBL626074,,10090.0,11167,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626075,,10090.0,11168,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626076,,10116.0,11169,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,2231,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,1969.0,1,CHEMBL626077,,9544.0,11170,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,2231,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL626078,,10116.0,11171,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,12178,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL625846,,,11172,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,12178,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL625847,,,11173,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,12178,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,In vivo,,,1,CHEMBL625848,,10116.0,11174,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,15633,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625849,,10116.0,11175,,Maximum concentration of compound in plasma administered orally to rats,,14258,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626023,,9615.0,11176,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,14224,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626024,,9615.0,11177,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,14224,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626025,,9615.0,11178,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,14224,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626026,,,11179,,Maximum concentration after 10 mg/kg by oral administration,,5566,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626027,,,11180,,Maximum concentration at a dose of 1.5 mg/kg,,16935,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626028,,,11181,,Maximum concentration at a dose of 2.0 mg/kg,,16935,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626029,,9615.0,11182,,Maximum concentration in dog plasma,,14224,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626030,,,11183,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,12536,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626031,,,11184,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,12536,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626032,,,11185,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,12536,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626033,,,11186,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,12536,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626034,,,11187,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,12536,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626035,,9615.0,11188,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,9994,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626036,,,11189,,Maximum concentration in plasma at Tmax,,1434,,,BAO_0000218
,Plasma,Canis lupus familiaris,Expert,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626037,,9615.0,11190,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,12836,,,BAO_0000218
,Plasma,Cricetinae,Intermediate,1,100712,A,N,In vivo,,1969.0,1,CHEMBL626038,,10026.0,11191,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,12836,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626039,,10116.0,11192,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,12836,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626040,,10116.0,11193,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,12545,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Intermediate,1,50592,A,N,In vivo,,1969.0,1,CHEMBL626041,,9986.0,11194,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,13856,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626042,,,11195,,Maximum concentration was calculated,,3550,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626043,,,11196,,Maximum concentration was calculated.,,2632,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626044,,,11197,,Maximum concentration at a peroral dose of 10 mg/kg,,5566,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626045,,,11198,,Maximum concentration of the drug at 10 uM/dg administered perorally,,11883,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626046,,,11199,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,11883,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626047,,9615.0,11200,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,14122,,,BAO_0000218
,Plasma,Cricetinae,Intermediate,1,100712,A,N,In vivo,,1969.0,1,CHEMBL626048,,10026.0,11201,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,14122,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626049,,10116.0,11202,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,14122,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626050,,10116.0,11203,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,12542,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL874541,,9615.0,11204,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,12542,,,BAO_0000218
,Plasma,Cricetinae,Intermediate,1,100712,A,N,In vivo,,1969.0,1,CHEMBL622826,,10026.0,11205,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,12542,,,BAO_0000218
,Plasma,Cricetinae,Intermediate,1,100712,A,N,In vivo,,1969.0,1,CHEMBL622827,,10026.0,11206,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,12542,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622828,,10116.0,11207,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,12542,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622829,,10116.0,11208,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,14080,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL876806,,10116.0,11209,,Maximum concentration reached following intravenous administration in male rat,,11911,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL622830,,9615.0,11210,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,13204,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622831,,10116.0,11211,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,13204,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626794,,9615.0,11212,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626795,,10116.0,11213,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626796,,10116.0,11214,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626797,,10116.0,11215,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626798,,10116.0,11216,,Maximum drug concentration is determined after oral dosing in rats.,,14127,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626799,,9615.0,11217,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,14339,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626800,,9615.0,11218,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,14339,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626801,,,11219,,Maximum plasma concentration,,13494,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL876816,,10116.0,11220,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,14925,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626802,,10116.0,11221,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,14474,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626803,,9615.0,11222,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,14474,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626804,,,11223,,Maximum plasma concentration following oral administration of 30 umol/kg,,13917,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626805,,10116.0,11224,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,9796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626309,,10116.0,11225,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626310,,10116.0,11226,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626311,,10116.0,11227,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626312,,10116.0,11228,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL626313,,10116.0,11229,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL626314,,10116.0,11230,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL626315,,10116.0,11231,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL626316,,10116.0,11232,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL626317,,10116.0,11233,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,9796,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626318,,10116.0,11234,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626319,,10116.0,11235,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626320,,10116.0,11236,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875053,,10116.0,11237,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626321,,10116.0,11238,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626322,,10116.0,11239,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626323,,10116.0,11240,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626324,,10116.0,11241,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626325,,10116.0,11242,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626326,,10116.0,11243,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626327,,10116.0,11244,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,8363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626328,,10116.0,11245,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,8363,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626329,,10116.0,11246,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626330,,10116.0,11247,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626331,,10116.0,11248,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626332,,10116.0,11249,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626333,,10116.0,11250,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626334,,10116.0,11251,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626335,,10116.0,11252,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624798,,10116.0,11253,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624799,,10116.0,11254,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624800,,10116.0,11255,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624801,,10116.0,11256,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624802,,10116.0,11257,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624803,,10116.0,11258,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624804,,10116.0,11259,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624805,,10116.0,11260,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL624806,,10116.0,11261,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624807,,10116.0,11262,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624808,,10116.0,11263,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624809,,10116.0,11264,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624810,,10116.0,11265,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877618,,10116.0,11266,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624811,,10116.0,11267,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624812,,10116.0,11268,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624813,,10116.0,11269,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624814,,10116.0,11270,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624815,,10116.0,11271,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624816,,10116.0,11272,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624817,,10116.0,11273,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624818,,9615.0,11274,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624819,,9615.0,11275,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624820,,9615.0,11276,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624821,,9615.0,11277,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624822,,9615.0,11278,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624823,,9615.0,11279,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Escherichia coli,Intermediate,1,50212,A,N,,,,1,CHEMBL624824,,562.0,11280,,Observed diffusion coefficient in organic solvent for Escherichia coli,,15599,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624825,,10116.0,11281,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624826,,10116.0,11282,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,Cardiac atrium,Rattus norvegicus,Intermediate,1,50597,A,N,,,2081.0,1,CHEMBL876817,,10116.0,11283,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Cardiac atrium,Rattus norvegicus,Intermediate,1,50597,A,N,,,2081.0,1,CHEMBL624827,,10116.0,11284,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624828,,10116.0,11285,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624829,,10116.0,11286,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624830,,10116.0,11287,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624831,,10116.0,11288,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,Cardiac atrium,Rattus norvegicus,Intermediate,1,50597,A,N,,,2081.0,1,CHEMBL624832,,10116.0,11289,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Cardiac atrium,Rattus norvegicus,Intermediate,1,50597,A,N,,,2081.0,1,CHEMBL624833,,10116.0,11290,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624834,,10116.0,11291,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624835,,10116.0,11292,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL624836,,10116.0,11293,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,9614,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL624837,,10116.0,11294,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,9614,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL624838,,10116.0,11295,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL622188,,10116.0,11296,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,9071,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL622189,,10116.0,11297,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL622190,,10116.0,11298,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,9071,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL625170,,10116.0,11299,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,9071,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625171,,10116.0,11300,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625172,,10116.0,11301,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL625173,,10116.0,11302,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,9071,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625174,,10116.0,11303,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625175,,10116.0,11304,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,9071,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL625176,,10116.0,11305,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,9071,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625177,,10116.0,11306,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625178,,10116.0,11307,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,9071,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625179,,10116.0,11308,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,9071,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL625180,,10116.0,11309,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,9071,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625181,,,11310,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,10677,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL625182,,10090.0,11311,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,9750,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625183,,10116.0,11312,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875848,,10116.0,11313,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622260,,10116.0,11314,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622261,,10116.0,11315,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622262,,10116.0,11316,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622263,,10116.0,11317,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL622418,,10116.0,11318,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622419,,10116.0,11319,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623388,,10090.0,11320,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL623389,,10090.0,11321,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623390,,10090.0,11322,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623391,,10090.0,11323,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL623392,,10090.0,11324,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Cerebellum,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2037.0,1,CHEMBL623393,,10090.0,11325,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623394,,10090.0,11326,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618885,,10090.0,11327,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL618886,,10090.0,11328,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL618887,,10090.0,11329,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619535,,10090.0,11330,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL619536,,10090.0,11331,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Cerebellum,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2037.0,1,CHEMBL619537,,10090.0,11332,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619705,,10090.0,11333,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619706,,10090.0,11334,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL619707,,10090.0,11335,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL619708,,10090.0,11336,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625219,,10090.0,11337,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL625220,,10090.0,11338,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Cerebellum,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2037.0,1,CHEMBL625221,,10090.0,11339,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625222,,10090.0,11340,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625223,,10090.0,11341,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL625224,,10090.0,11342,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625225,,10090.0,11343,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,13256,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625226,,10116.0,11344,,Biodistribution in Rat blood after 24 hours of iv administration,,8829,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625227,,10116.0,11345,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,8829,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625228,,10116.0,11346,,Biodistribution in Rat blood after 30 minutes of iv administration,,8829,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL875354,,10116.0,11347,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625229,,10116.0,11348,,Biodistribution in Rat blood after 5 minutes of iv administration,,8829,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625230,,10116.0,11349,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625231,,10116.0,11350,,Biodistribution in Rat heart after 24 hours of iv administration,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625900,,10116.0,11351,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625901,,10116.0,11352,,Biodistribution in Rat heart after 30 minutes of iv administration,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625902,,10116.0,11353,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625903,,10116.0,11354,,Biodistribution in Rat heart after 5 minutes of iv administration,,8829,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625904,,10116.0,11355,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625905,,10116.0,11356,,Biodistribution in Rat liver after 24 hours of iv administration,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627861,,10116.0,11357,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627862,,10116.0,11358,,Biodistribution in Rat liver after 30 minutes of iv administration,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627863,,10116.0,11359,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627769,,10116.0,11360,,Biodistribution in Rat liver after 30 minutes of iv administration,,8829,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL627770,,9615.0,11361,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,13249,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL627771,,9541.0,11362,,Cmax in cynomolgus monkey (PO dose),,13622,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627772,,10116.0,11363,,Cmax in rat (PO dose),,13622,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627773,,10116.0,11364,,Cmax in rat (PO dose),,13622,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621922,,10116.0,11365,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,13494,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621923,,10116.0,11366,,Cmax in rat plasma after oral dose (10 mg/kg),,12170,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621924,,,11367,,Cmax in plasma after oral dose (10 mg/kg),,12170,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621925,,9615.0,11368,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,17025,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621926,,314293.0,11369,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,17025,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Intermediate,1,50592,A,N,In vivo,,1969.0,1,CHEMBL621927,,9986.0,11370,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,17025,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621928,,10116.0,11371,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,17025,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621929,,10116.0,11372,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,14187,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL621930,,10090.0,11373,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,14816,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621931,,10116.0,11374,,Maximum plasma concentration after oral dosing in rat,,17820,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621932,,,11375,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621933,,,11376,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621934,,9615.0,11377,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,14691,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL621935,,9615.0,11378,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,14691,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL621936,,10116.0,11379,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,13375,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621937,,,11380,,Maximum plasma concentration was determined,,6236,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621938,,,11381,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621939,,,11382,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621940,,,11383,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621941,,,11384,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL621942,,,11385,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626178,,,11386,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626179,,,11387,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626180,,,11388,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626181,,10116.0,11389,,Plasma Cmax in rat (PO dose),,13622,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626182,,10116.0,11390,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626183,,10116.0,11391,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626184,,10116.0,11392,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,15372,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626185,,10116.0,11393,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626186,,9615.0,11394,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,14925,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL877589,,9615.0,11395,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,14925,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626187,,,11396,,Maximum concentration of the drug at 1 uM/dg administered intravenously,,11883,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626188,,,11397,,Maximum concentration of the drug at 20 uM/dg administered perorally,,11883,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626189,,,11398,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL626855,,,11399,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL623781,,,11400,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL623782,,,11401,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623783,,10116.0,11402,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,16360,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623784,,9615.0,11403,,Cmax in dog plasma after 1mg/kg oral dose,,3673,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623785,,9615.0,11404,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,14431,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623786,,10116.0,11405,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,14431,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623787,,10116.0,11406,,Oral maximum concentration in rat,,14964,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623788,,10116.0,11407,,Oral maximum concentration in rat,,14964,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623789,,10090.0,11408,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,14209,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL623790,,10090.0,11409,,Peak concentration in blood after intravenous administration to mice,,11355,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL623791,,10090.0,11410,,Peak concentration in blood after peroral administration to mice,,11355,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623792,,10116.0,11411,,Peak concentration in rat plasma was determined,,11966,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623793,,314293.0,11412,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL623794,,10090.0,11413,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623795,,10116.0,11414,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623796,,10116.0,11415,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623797,,10116.0,11416,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623798,,10116.0,11417,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623799,,10116.0,11418,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624490,,10116.0,11419,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624491,,10116.0,11420,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624492,,10116.0,11421,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624493,,10116.0,11422,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL877595,,10116.0,11423,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624494,,10116.0,11424,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624495,,10116.0,11425,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,,,160.0,1,CHEMBL624681,,10116.0,11426,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624682,,10116.0,11427,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624683,,10116.0,11428,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624684,,10116.0,11429,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624685,,10116.0,11430,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624686,,10116.0,11431,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624687,,10116.0,11432,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624688,,10116.0,11433,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627161,,10116.0,11434,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622127,,10116.0,11435,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622128,,10116.0,11436,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874384,,10116.0,11437,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624898,,10116.0,11438,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624899,,10116.0,11439,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624900,,10116.0,11440,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624901,,10116.0,11441,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624902,,10116.0,11442,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624903,,10116.0,11443,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624904,,10116.0,11444,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624905,,10116.0,11445,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624906,,10116.0,11446,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624907,,10116.0,11447,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624908,,10116.0,11448,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624909,,10116.0,11449,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624910,,10116.0,11450,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624911,,10116.0,11451,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL874388,,10116.0,11452,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL624912,,10116.0,11453,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL622930,,10116.0,11454,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623121,,10116.0,11455,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623122,,10116.0,11456,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623123,,10116.0,11457,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623124,,10116.0,11458,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623125,,10116.0,11459,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623126,,10116.0,11460,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623127,,10116.0,11461,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623128,,10116.0,11462,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623129,,10116.0,11463,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623130,,10116.0,11464,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623131,,10116.0,11465,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623132,,10116.0,11466,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623133,,10116.0,11467,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623134,,10116.0,11468,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874389,,10116.0,11469,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623135,,10116.0,11470,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623136,,10116.0,11471,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623137,,10116.0,11472,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623138,,10116.0,11473,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623139,,10116.0,11474,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL623140,,10116.0,11475,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623141,,10116.0,11476,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623142,,10116.0,11477,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623143,,10116.0,11478,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL623144,,10090.0,11479,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,14571,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623405,,10116.0,11480,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,14571,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624074,,10116.0,11481,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624075,,10116.0,11482,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624076,,10116.0,11483,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624077,,10116.0,11484,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624078,,10116.0,11485,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624079,,10116.0,11486,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624261,,10116.0,11487,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624262,,10116.0,11488,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624263,,10116.0,11489,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624264,,10116.0,11490,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624265,,10116.0,11491,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624266,,10116.0,11492,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624267,,10116.0,11493,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624268,,10116.0,11494,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875227,,10116.0,11495,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624269,,10116.0,11496,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624270,,10116.0,11497,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624271,,10116.0,11498,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624272,,10116.0,11499,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624273,,10116.0,11500,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,8319,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624274,,10116.0,11501,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624275,,10116.0,11502,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624276,,10116.0,11503,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624277,,10116.0,11504,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,12038,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624278,,,11505,,% dose converted to 2-amino-5-chlorophenyl sulfate,,14314,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624279,,,11506,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,14314,,,BAO_0000019
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL624280,,10116.0,11507,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,11488,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL624281,,10116.0,11508,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,11488,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL622933,,10116.0,11509,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,11488,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL622934,,10116.0,11510,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,11488,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622935,,10116.0,11511,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL622936,,10116.0,11512,,Biodistribution in Rat liver after 5 minutes of iv administration,,8829,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL875228,,10116.0,11513,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622937,,10116.0,11514,,Biodistribution in Rat lung after 24 hours of iv administration,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622938,,10116.0,11515,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL619736,,10116.0,11516,,Biodistribution in Rat lung after 30 minutes of iv administration,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625117,,10116.0,11517,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625118,,10116.0,11518,,Biodistribution in Rat lung after 5 minutes of iv administration,,8829,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625119,,10116.0,11519,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,8829,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL625120,,10116.0,11520,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,14972,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625121,,10116.0,11521,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,14972,,,BAO_0000218
,Thalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000006.0,1,CHEMBL625122,,10116.0,11522,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,14972,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL622204,,10116.0,11523,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL877503,,10116.0,11524,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627127,,10116.0,11525,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Hippocampus,,Autocuration,1,22224,A,U,In vivo,,10000000.0,0,CHEMBL627128,,,11526,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Hippocampus,,Autocuration,1,22224,A,U,In vivo,,10000000.0,0,CHEMBL627129,,,11527,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Hippocampus,,Autocuration,1,22224,A,U,In vivo,,10000000.0,0,CHEMBL627130,,,11528,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL627131,,10116.0,11529,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL627132,,10116.0,11530,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL627133,,10116.0,11531,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL627134,,10116.0,11532,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL627135,,10116.0,11533,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL627136,,10116.0,11534,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628435,,10116.0,11535,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628436,,10116.0,11536,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628437,,10116.0,11537,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL628438,,10116.0,11538,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL628439,,10116.0,11539,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL628440,,10116.0,11540,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628441,,10116.0,11541,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628442,,10116.0,11542,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628443,,10116.0,11543,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628444,,10116.0,11544,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628445,,10116.0,11545,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL877504,,10116.0,11546,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL628446,,10116.0,11547,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL626874,,10116.0,11548,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL626875,,10116.0,11549,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL626876,,10116.0,11550,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL626877,,10116.0,11551,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL626878,,10116.0,11552,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL626879,,10116.0,11553,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626880,,314293.0,11554,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL626881,,10090.0,11555,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626882,,10116.0,11556,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,8918,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626883,,9615.0,11557,,Peak plasma concentration was measured in dogs,,14470,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626884,,10116.0,11558,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626885,,10116.0,11559,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,14886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626886,,10116.0,11560,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,14886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626887,,10116.0,11561,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,14886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626888,,10116.0,11562,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626889,,9615.0,11563,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,13465,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626761,,314293.0,11564,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,13465,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626762,,9615.0,11565,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,13465,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626763,,9615.0,11566,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,13465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626764,,10116.0,11567,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,13465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626765,,10116.0,11568,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,13465,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626766,,9615.0,11569,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,13465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626767,,10116.0,11570,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,13465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626768,,10116.0,11571,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,13465,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626769,,9615.0,11572,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,13465,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL874463,,9615.0,11573,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,13465,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626770,,314293.0,11574,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,13465,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626771,,314293.0,11575,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,13465,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626772,,10116.0,11576,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,13465,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL626773,,9541.0,11577,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,14731,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626774,,10090.0,11578,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,14731,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626775,,9615.0,11579,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,13376,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626776,,9615.0,11580,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,13376,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626777,,10116.0,11581,,Maximum concentration (Cmax) in rat when administered orally,,14443,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626778,,314293.0,11582,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,13465,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626779,,10116.0,11583,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,16359,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626780,,10116.0,11584,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,16359,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626781,,,11585,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,15618,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL632164,,10116.0,11586,,Pharmacokinetic profile Cmax was evaluated in rats,,14554,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL632165,,9615.0,11587,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,11537,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL632166,,10090.0,11588,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,11537,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL632167,,9615.0,11589,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,11537,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL632168,,10090.0,11590,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,11537,,,BAO_0000218
,Plasma,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL632169,,10116.0,11591,,Cmax in rat plasma,,2021,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL632170,,9615.0,11592,,Cmax in dog plasma after 30mg/kg oral dose,,5932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL632171,,10116.0,11593,,Cmax in rat plasma after 30mg/kg oral dose,,5932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL632172,,10116.0,11594,,Plasma level in rats at 30 mg/kg,,17320,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL632173,,10090.0,11595,,Tested for maximum plasma concentration in mice,,15831,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL632174,,10116.0,11596,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL632175,,10116.0,11597,,The Cmax values in female wistar rats.,,14941,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL632176,,9615.0,11598,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,15343,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL632177,,10116.0,11599,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,15343,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL632178,,10116.0,11600,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,14856,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL632179,,10116.0,11601,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,13129,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL632180,,10116.0,11602,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,13098,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL632181,,10116.0,11603,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,13098,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL632182,,10116.0,11604,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,13098,,,BAO_0000218
,Blood,Mus musculus,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL632183,,10090.0,11605,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,15478,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL632184,,9615.0,11606,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874470,,10116.0,11607,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631302,,10116.0,11608,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631303,,10116.0,11609,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631304,,10116.0,11610,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631305,,10116.0,11611,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631306,,10116.0,11612,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631307,,10116.0,11613,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631308,,10116.0,11614,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625557,,10116.0,11615,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625558,,10116.0,11616,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625559,,10116.0,11617,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625560,,10116.0,11618,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625561,,10116.0,11619,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625562,,10116.0,11620,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL875320,,10116.0,11621,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625563,,10116.0,11622,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL625564,,10116.0,11623,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL625565,,10116.0,11624,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL625566,,10116.0,11625,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL625567,,10116.0,11626,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL625568,,10116.0,11627,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL628217,,10116.0,11628,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL628218,,10116.0,11629,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL628219,,10116.0,11630,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL628220,,10116.0,11631,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,8684,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628221,,,11632,,Distribution in the blood after 120 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628222,,,11633,,Distribution in the blood after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628223,,,11634,,Distribution in the blood after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628224,,,11635,,Distribution in the blood after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628225,,,11636,,Distribution in the blood after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628226,,,11637,,Distribution in the blood after 90 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628227,,,11638,,Distribution in the bone after 120 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875481,,,11639,,Distribution in the bone after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628228,,,11640,,Distribution in the bone after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628229,,,11641,,Distribution in the bone after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628230,,,11642,,Distribution in the bone after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628231,,,11643,,Distribution in the bone after 90 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628232,,,11644,,Distribution in the heart after 120 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628233,,,11645,,Distribution in the heart after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628234,,,11646,,Distribution in the heart after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628235,,,11647,,Distribution in the heart after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628236,,,11648,,Distribution in the heart after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628237,,,11649,,Distribution in the heart after 90 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628238,,,11650,,Distribution in the kidneys after 120 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628239,,,11651,,Distribution in the kidneys after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628240,,,11652,,Distribution in the kidneys after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628241,,,11653,,Distribution in the kidneys after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628242,,,11654,,Distribution in the kidneys after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875482,,,11655,,Distribution in the kidneys after 90 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628243,,,11656,,Distribution in the liver after 120 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628244,,,11657,,Distribution in the liver after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628245,,,11658,,Distribution in the liver after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628246,,,11659,,Distribution in the liver after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628247,,,11660,,Distribution in the liver after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628248,,,11661,,Distribution in the liver after 90 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628249,,,11662,,Distribution in the lung after 120 min of intravenous administration,,8926,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625452,,10090.0,11663,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625453,,10090.0,11664,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625454,,10090.0,11665,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,14839,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623844,,10090.0,11666,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,14839,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623845,,10116.0,11667,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,12178,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623846,,10116.0,11668,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,12178,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623847,,,11669,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,12178,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623848,,9541.0,11670,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,12186,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623849,,9541.0,11671,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,12186,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623850,,9541.0,11672,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,12186,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623851,,9541.0,11673,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,12186,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL623852,,314293.0,11674,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,12187,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL624551,,9669.0,11675,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,12187,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL624552,,9669.0,11676,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL624553,,314293.0,11677,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL624554,,314293.0,11678,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,12187,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624555,,10116.0,11679,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,12187,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624741,,10116.0,11680,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,12187,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624742,,9615.0,11681,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,14122,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,,,,1,CHEMBL624743,,10026.0,11682,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,14122,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877606,,10116.0,11683,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,14122,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624744,,,11684,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL624745,,,11685,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL624746,,,11686,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL624747,,,11687,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,13391,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624748,,,11688,,Oral absorption expressed as Area under curve was determined,,16360,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622504,,9615.0,11689,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,3673,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622505,,9615.0,11690,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,14122,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,,,,1,CHEMBL622506,,10026.0,11691,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,14122,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,,,,1,CHEMBL622507,,10026.0,11692,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,14122,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622508,,10116.0,11693,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,14122,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622509,,,11694,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,13889,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622510,,10116.0,11695,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622511,,10116.0,11696,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,17279,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL622512,,9541.0,11697,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,14548,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL622513,,9541.0,11698,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,14548,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL622514,,9541.0,11699,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,14548,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622515,,9615.0,11700,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,14548,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622516,,9615.0,11701,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,14548,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622517,,10116.0,11702,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,14548,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622518,,10116.0,11703,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,14548,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622519,,10116.0,11704,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,14548,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL622520,,10116.0,11705,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL622521,,10116.0,11706,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL625113,,10090.0,11707,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL625114,,10116.0,11708,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL874397,,10116.0,11709,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625115,,10116.0,11710,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625116,,10116.0,11711,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL623932,,10116.0,11712,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL623933,,10116.0,11713,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL623934,,10116.0,11714,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL623935,,10116.0,11715,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL623936,,10116.0,11716,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,14608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL623937,,10116.0,11717,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,14608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL623938,,10116.0,11718,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,14608,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623939,,10090.0,11719,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623940,,10090.0,11720,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623941,,10090.0,11721,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627216,,10090.0,11722,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623942,,10090.0,11723,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL618793,,10090.0,11724,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL618794,,10090.0,11725,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL618795,,10090.0,11726,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618796,,10090.0,11727,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618797,,10090.0,11728,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618798,,10090.0,11729,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618799,,10090.0,11730,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618800,,10090.0,11731,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618801,,10090.0,11732,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618802,,10090.0,11733,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL618803,,10090.0,11734,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618804,,10090.0,11735,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618805,,10090.0,11736,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618806,,10090.0,11737,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618807,,10090.0,11738,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618808,,10090.0,11739,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL618809,,10090.0,11740,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL618810,,10090.0,11741,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL618811,,10090.0,11742,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,15383,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL875844,,10090.0,11743,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,15383,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL618812,,10090.0,11744,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL618813,,10090.0,11745,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618814,,10090.0,11746,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618815,,10090.0,11747,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618816,,10090.0,11748,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL618817,,10090.0,11749,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL620544,,10090.0,11750,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626230,,10116.0,11751,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626231,,10116.0,11752,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626232,,10116.0,11753,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,15341,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626233,,9615.0,11754,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,14906,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626234,,10116.0,11755,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,14906,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL875341,,10116.0,11756,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,14906,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL626235,,9606.0,11757,,The maximum plasma concentration (100 mg/kg) administered orally in human,,14215,,,BAO_0000218
,Plasma,Callithrix,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626236,,9481.0,11758,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,14215,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL626237,,314293.0,11759,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,14215,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626238,,9615.0,11760,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,14215,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL622412,,9606.0,11761,,The maximum plasma concentration (200 mg/kg) administered orally in human,,14215,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623114,,10116.0,11762,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,14215,,,BAO_0000218
,Plasma,Callithrix,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623115,,9481.0,11763,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,14215,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623116,,314293.0,11764,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,14215,,,BAO_0000218
,Plasma,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623117,,9615.0,11765,,The maximum plasma concentration (30 mg/kg) administered orally in dog,,14215,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL623118,,9606.0,11766,,The maximum plasma concentration (400 mg/kg) administered orally in human,,14215,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623119,,10116.0,11767,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,14215,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623120,,10116.0,11768,,The maximum plasma concentration (50 mg/kg) administered orally in rat,,14215,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL623286,,9606.0,11769,,The maximum plasma concentration (800 mg/kg) administered orally in human,,14215,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623287,,10116.0,11770,,The maximum plasma concentration was measured on rats,,14067,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623288,,10116.0,11771,,The maximum plasma concentration was measured on rats after oral administration,,12350,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623289,,10116.0,11772,,Plasma drug Cmax in rat (PO dose),,14813,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623290,,,11773,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,12536,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623291,,9615.0,11774,,maximum Plasma concentration in Dog was determined after Peroral administration,,14169,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623292,,10116.0,11775,,maximum Plasma concentration in Rats was determined after Peroral administration,,14169,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL623293,,9615.0,11776,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,15604,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623294,,314293.0,11777,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,15604,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL623295,,10116.0,11778,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,15604,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL623296,,10090.0,11779,,maximum concentration was measured when administered through oral route in mice,,14387,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875349,,10090.0,11780,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,15115,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL623297,,314293.0,11781,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,15115,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL623298,,314293.0,11782,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,15115,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL623299,,314293.0,11783,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,15115,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623300,,10116.0,11784,,Pharmacokinetic parameter was evaluated in rats,,16359,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623301,,10090.0,11785,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,12829,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623302,,10090.0,11786,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,12829,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623303,,10090.0,11787,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,12829,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623304,,10090.0,11788,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,12829,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623305,,10090.0,11789,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,12829,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL623306,,10116.0,11790,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL623307,,10116.0,11791,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,15137,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL623308,,10116.0,11792,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,15137,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,,,1969.0,1,CHEMBL623309,,10090.0,11793,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,15137,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623310,,10090.0,11794,,Plasma Concentration after 120 min of oral administration to mice,,13509,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623311,,10090.0,11795,,Plasma Concentration after 30 min of oral administration to mice,,13509,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL623312,,9541.0,11796,,Plasma Concentration after 60 min of oral administration to mice,,13509,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL875350,,10090.0,11797,,Plasma Concentration after 60 min of oral administration to mice; Not determined,,13509,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL628635,,10090.0,11798,,Plasma Concentration after 90 min of oral administration to mice,,13509,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628636,,10116.0,11799,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628637,,10116.0,11800,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628058,,10116.0,11801,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,12064,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628059,,10116.0,11802,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,10677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628060,,10116.0,11803,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,10677,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628061,,,11804,,Distribution in the lung after 15 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628062,,,11805,,Distribution in the lung after 30 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628063,,,11806,,Distribution in the lung after 5 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628064,,,11807,,Distribution in the lung after 60 min of intravenous administration,,8926,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628065,,,11808,,Distribution in the lung after 90 min of intravenous administration,,8926,,,BAO_0000019
,Muscle tissue,,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL628066,,,11809,,Distribution in the muscle after 120 min of intravenous administration,,8926,,,BAO_0000019
,Muscle tissue,,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL628067,,,11810,,Distribution in the muscle after 15 min of intravenous administration,,8926,,,BAO_0000019
,Muscle tissue,Mus musculus,Intermediate,1,50594,A,N,,,2385.0,1,CHEMBL874646,,10090.0,11811,,Distribution in the muscle after 30 min of intravenous administration,,8926,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL628068,,,11812,,Distribution in the muscle after 5 min of intravenous administration,,8926,,,BAO_0000019
,Muscle tissue,,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL628069,,,11813,,Distribution in the muscle after 60 min of intravenous administration,,8926,,,BAO_0000019
,Muscle tissue,,Autocuration,1,22224,A,U,,,2385.0,0,CHEMBL628070,,,11814,,Distribution in the muscle after 90 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628071,,,11815,,Distribution in the spleen after 120 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628072,,,11816,,Distribution in the spleen after 15 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628073,,,11817,,Distribution in the spleen after 30 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628074,,,11818,,Distribution in the spleen after 5 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628075,,,11819,,Distribution in the spleen after 60 min of intravenous administration,,8926,,,BAO_0000019
,Spleen,,Autocuration,1,22224,A,U,,,2106.0,0,CHEMBL628076,,,11820,,Distribution in the spleen after 90 min of intravenous administration,,8926,,,BAO_0000019
,Adrenal cortex,Rattus norvegicus,Intermediate,1,50597,A,N,,,1235.0,1,CHEMBL628077,,10116.0,11821,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,7570,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628078,,10116.0,11822,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,7570,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628079,,10116.0,11823,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,7570,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,,,992.0,1,CHEMBL628080,,10116.0,11824,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,7570,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL628081,,10116.0,11825,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,7570,,,BAO_0000218
,Adrenal cortex,Rattus norvegicus,Intermediate,1,50597,A,N,,,1235.0,1,CHEMBL628082,,10116.0,11826,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,7570,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL874647,,10116.0,11827,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,7570,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL626406,,10116.0,11828,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,7570,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,,,992.0,1,CHEMBL626407,,10116.0,11829,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,7570,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626408,,10116.0,11830,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,7570,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626409,,10116.0,11831,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626410,,10116.0,11832,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626411,,10116.0,11833,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626412,,10116.0,11834,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626413,,10116.0,11835,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626414,,10116.0,11836,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626415,,10116.0,11837,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626416,,10116.0,11838,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627062,,10116.0,11839,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627063,,10116.0,11840,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627064,,10116.0,11841,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627227,,10116.0,11842,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627228,,10116.0,11843,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627229,,10116.0,11844,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625792,,10116.0,11845,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625793,,10116.0,11846,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625794,,10116.0,11847,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,8608,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625795,,10116.0,11848,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,8608,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625796,,10090.0,11849,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,13792,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625797,,9615.0,11850,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,13376,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625798,,9615.0,11851,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,13376,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875613,,,11852,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625799,,,11853,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625800,,,11854,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625801,,,11855,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625802,,,11856,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625803,,,11857,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625804,,,11858,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,14380,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622530,,,11859,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,14380,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622531,,10090.0,11860,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622532,,10090.0,11861,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623176,,10090.0,11862,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623177,,10090.0,11863,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623178,,10090.0,11864,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623179,,10090.0,11865,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623180,,10090.0,11866,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623181,,10090.0,11867,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624131,,10090.0,11868,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624132,,10090.0,11869,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624133,,10090.0,11870,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624846,,10090.0,11871,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624847,,10090.0,11872,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL624848,,10090.0,11873,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625012,,10090.0,11874,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625013,,10090.0,11875,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625014,,10090.0,11876,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625015,,10090.0,11877,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625016,,10090.0,11878,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625017,,10090.0,11879,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625018,,10090.0,11880,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625019,,10090.0,11881,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625020,,10090.0,11882,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625021,,10090.0,11883,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,13701,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625022,,10116.0,11884,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625023,,10090.0,11885,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,14731,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL625024,,9541.0,11886,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,14731,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL627626,,9541.0,11887,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,14731,,,BAO_0000218
,Brain,,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL627627,,,11888,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,13758,,,BAO_0000218
,Serum,,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL627628,,,11889,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,13758,,,BAO_0000218
,Brain,,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL627629,,,11890,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,13758,,,BAO_0000218
,Serum,,Autocuration,1,22224,A,U,,,1977.0,0,CHEMBL627630,,,11891,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,13758,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627631,,,11892,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,16359,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629515,,,11893,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,16359,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL629516,,10090.0,11894,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL629517,,10090.0,11895,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL629518,,10090.0,11896,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL877499,,10090.0,11897,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629519,,10090.0,11898,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629520,,10090.0,11899,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629521,,10090.0,11900,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,15383,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629522,,10090.0,11901,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629523,,10090.0,11902,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629524,,10090.0,11903,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629525,,10090.0,11904,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629526,,10090.0,11905,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629527,,10090.0,11906,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629528,,10090.0,11907,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629529,,10090.0,11908,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629530,,10090.0,11909,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629531,,10090.0,11910,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL628656,,10090.0,11911,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL628657,,10090.0,11912,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,14439,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628658,,10116.0,11913,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628659,,10116.0,11914,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL877500,,10116.0,11915,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628660,,10116.0,11916,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628661,,10116.0,11917,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628662,,10116.0,11918,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628663,,10116.0,11919,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628664,,10116.0,11920,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628665,,10116.0,11921,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628666,,10116.0,11922,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628667,,10116.0,11923,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628668,,10116.0,11924,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628669,,10116.0,11925,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628670,,10116.0,11926,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL628671,,10116.0,11927,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL628672,,10116.0,11928,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL630300,,10116.0,11929,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL629787,,10116.0,11930,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL629788,,10116.0,11931,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629789,,10116.0,11932,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629790,,10116.0,11933,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629791,,10116.0,11934,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629792,,10116.0,11935,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629793,,10116.0,11936,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629794,,10116.0,11937,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874459,,10116.0,11938,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,10677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629795,,10116.0,11939,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,10677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629796,,10116.0,11940,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,10677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629797,,10116.0,11941,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,10677,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629798,,10116.0,11942,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,10677,,,BAO_0000218
,Adrenal gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2369.0,1,CHEMBL629799,,10116.0,11943,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Adrenal gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2369.0,1,CHEMBL629800,,10116.0,11944,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Adrenal gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2369.0,1,CHEMBL629801,,10116.0,11945,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Adrenal gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2369.0,1,CHEMBL629802,,10116.0,11946,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,10911,,,BAO_0000218
,Adrenal gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2369.0,1,CHEMBL629803,,10116.0,11947,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL629804,,10116.0,11948,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL629805,,10116.0,11949,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL629806,,10116.0,11950,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL629807,,10116.0,11951,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL629808,,10116.0,11952,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629809,,10116.0,11953,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629810,,10116.0,11954,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629811,,10116.0,11955,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629812,,10116.0,11956,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629813,,10116.0,11957,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL874460,,10116.0,11958,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629814,,10116.0,11959,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629815,,10116.0,11960,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629816,,10116.0,11961,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629817,,10116.0,11962,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626643,,10116.0,11963,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626644,,10116.0,11964,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626806,,10116.0,11965,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL626807,,10116.0,11966,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627261,,10116.0,11967,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627262,,10116.0,11968,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627263,,10116.0,11969,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627264,,10116.0,11970,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627265,,10116.0,11971,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627266,,10116.0,11972,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627267,,10116.0,11973,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627268,,10116.0,11974,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627269,,10116.0,11975,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627270,,10116.0,11976,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627271,,10116.0,11977,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627946,,10116.0,11978,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875472,,10116.0,11979,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627947,,10116.0,11980,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627948,,10116.0,11981,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628113,,10116.0,11982,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628114,,10116.0,11983,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628115,,10116.0,11984,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628116,,10116.0,11985,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628117,,10116.0,11986,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628118,,10116.0,11987,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628119,,10116.0,11988,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628120,,10116.0,11989,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628121,,10116.0,11990,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628122,,10116.0,11991,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627297,,10116.0,11992,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627298,,10116.0,11993,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627299,,10116.0,11994,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627300,,10116.0,11995,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627301,,10116.0,11996,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627302,,10116.0,11997,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627303,,10116.0,11998,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627304,,10116.0,11999,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627305,,10116.0,12000,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627306,,10116.0,12001,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623982,,10116.0,12002,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623983,,10116.0,12003,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623984,,10116.0,12004,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623985,,10116.0,12005,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623986,,10116.0,12006,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623987,,10116.0,12007,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623988,,10116.0,12008,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623989,,10116.0,12009,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622215,,10116.0,12010,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622216,,10116.0,12011,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877481,,10116.0,12012,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,8608,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622217,,,12013,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,16359,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622218,,10090.0,12014,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,13701,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622219,,10116.0,12015,,Pharmacokinetic profile AUC was evaluated in rats,,14554,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622220,,,12016,,Pharmacokinetic property (Area under curve),,6241,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622221,,9615.0,12017,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,11537,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622222,,10090.0,12018,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,11537,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL622223,,9615.0,12019,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,11537,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622224,,10090.0,12020,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,11537,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622225,,,12021,,Plasma concentration (AUC) was determined,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622226,,,12022,,Plasma concentration (AUC) was determined; Not detectable,,13118,,,BAO_0000019
,,Cavia porcellus,Intermediate,1,50512,A,N,,,,1,CHEMBL624154,,10141.0,12023,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,9562,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624155,,10116.0,12024,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,10363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624156,,10116.0,12025,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,10363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624157,,10116.0,12026,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,10363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624158,,10116.0,12027,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,10363,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624159,,10116.0,12028,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624160,,10116.0,12029,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624161,,10116.0,12030,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624162,,10116.0,12031,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,12504,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624163,,9615.0,12032,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,13317,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624164,,10116.0,12033,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624165,,10116.0,12034,,The AUC(0-infinity) values in female wistar rats.,,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624166,,10116.0,12035,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624167,,10116.0,12036,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,15078,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624168,,10116.0,12037,,The AUC(0-t)values in female wistar rats.,,14941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624169,,10116.0,12038,,The Area under the concentration time curve of compound was measured on rats,,14067,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL624170,,9606.0,12039,,The area under curve (100 mg/kg) administered orally in humans,,14215,,,BAO_0000218
,,Callithrix,Autocuration,1,22224,A,U,,,,0,CHEMBL624171,,9481.0,12040,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,14215,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL624172,,314293.0,12041,,The area under curve (12.5 mg/kg) administered intravenously in monkey,,14215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624173,,9615.0,12042,,The area under curve (15 mg/kg) administered intravenously in dog,,14215,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL877488,,9606.0,12043,,The area under curve (200 mg/kg) administered orally in humans,,14215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624174,,10116.0,12044,,The area under curve (25 mg/kg) administered intravenously in rat,,14215,,,BAO_0000218
,,Callithrix,Autocuration,1,22224,A,U,,,,0,CHEMBL624175,,9481.0,12045,,The area under curve (25 mg/kg) administered orally in marmoset,,14215,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL624176,,314293.0,12046,,The area under curve (25 mg/kg) administered orally in monkey,,14215,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624177,,9615.0,12047,,The area under curve (30 mg/kg) administered orally in dog,,14215,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL624178,,9606.0,12048,,The area under curve (400 mg/kg) administered orally in humans,,14215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624179,,10116.0,12049,,The area under curve (50 mg/kg) administered orally in fasted rat,,14215,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627689,,10116.0,12050,,The area under curve (50 mg/kg) administered orally in rat,,14215,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL627690,,9606.0,12051,,The area under curve (800 mg/kg) administered orally in humans,,14215,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627691,,,12052,,The compound was evaluated for area under the curve,,11324,,,BAO_0000019
,,Callithrix,Autocuration,1,22224,A,U,,,,0,CHEMBL627692,,9481.0,12053,,The compound was evaluated for area under the curve in marmosets,,11324,,,BAO_0000019
,,Callithrix,Autocuration,1,22224,A,U,,,,0,CHEMBL627693,,9481.0,12054,,The compound was evaluated for area under the curve in marmosets,,11324,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627694,,10116.0,12055,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,13875,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627695,,10116.0,12056,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,13875,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627696,,,12057,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,13875,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627697,,10116.0,12058,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,13875,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627698,,10116.0,12059,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,13875,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627699,,10116.0,12060,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,13875,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627700,,10116.0,12061,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,13807,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627701,,10116.0,12062,,Total drug exposure is determined after oral dosing in rats.,,14127,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627702,,,12063,,Total drug exposure (5 mg/kg) when administered intravenously,,15116,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627703,,,12064,,Total drug exposure (5 mg/kg) when administered orally,,15116,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL626873,,314293.0,12065,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,15604,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629583,,10116.0,12066,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,15604,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629584,,9615.0,12067,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,15604,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629585,,9615.0,12068,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,15604,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629586,,10116.0,12069,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL629587,,10116.0,12070,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629588,,10116.0,12071,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629589,,10116.0,12072,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629590,,10116.0,12073,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629591,,10116.0,12074,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629592,,10116.0,12075,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629593,,10116.0,12076,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL629594,,10116.0,12077,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL629595,,10116.0,12078,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL630290,,10116.0,12079,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627137,,10116.0,12080,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627138,,10116.0,12081,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627139,,10116.0,12082,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627140,,10116.0,12083,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627141,,10116.0,12084,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627142,,10116.0,12085,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627143,,10116.0,12086,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL874449,,10116.0,12087,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627144,,10116.0,12088,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627145,,10116.0,12089,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627146,,10116.0,12090,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627147,,10116.0,12091,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627148,,10116.0,12092,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627149,,10116.0,12093,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL632160,,10116.0,12094,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL632161,,10116.0,12095,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL632162,,10116.0,12096,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL632163,,10116.0,12097,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL874469,,10116.0,12098,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627182,,10116.0,12099,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627183,,10116.0,12100,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627184,,10116.0,12101,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627185,,10116.0,12102,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627186,,10116.0,12103,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627187,,10116.0,12104,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627188,,10116.0,12105,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627189,,10116.0,12106,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627190,,10116.0,12107,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627191,,10116.0,12108,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627192,,10116.0,12109,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627193,,10116.0,12110,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL874590,,10116.0,12111,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627194,,10116.0,12112,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627195,,10116.0,12113,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,992.0,1,CHEMBL627196,,10116.0,12114,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,992.0,1,CHEMBL627197,,10116.0,12115,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,992.0,1,CHEMBL627198,,10116.0,12116,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,992.0,1,CHEMBL627199,,10116.0,12117,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,10911,,,BAO_0000218
,Female gonad,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,992.0,1,CHEMBL627200,,10116.0,12118,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627201,,10116.0,12119,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627202,,10116.0,12120,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627203,,10116.0,12121,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627204,,10116.0,12122,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627205,,10116.0,12123,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627206,,10116.0,12124,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627207,,10116.0,12125,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627208,,10116.0,12126,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL627209,,10116.0,12127,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL627210,,10116.0,12128,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL627211,,10116.0,12129,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL627212,,10116.0,12130,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL627213,,10116.0,12131,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL626599,,10116.0,12132,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL626600,,10116.0,12133,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL626601,,10116.0,12134,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,10911,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627484,,,12135,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,8081,,,BAO_0000019
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,,,1969.0,1,CHEMBL627485,,9541.0,12136,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,17248,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,,,1969.0,1,CHEMBL628147,,9541.0,12137,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,17248,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,,,1969.0,1,CHEMBL628148,,9541.0,12138,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,17248,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL628149,,9615.0,12139,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,17248,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL628150,,9615.0,12140,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,17248,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL628318,,9615.0,12141,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,17248,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL628319,,9615.0,12142,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,17248,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL875609,,9615.0,12143,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,15592,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628320,,,12144,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628321,,,12145,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628322,,,12146,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628323,,,12147,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628324,,,12148,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628325,,,12149,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,7040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628326,,,12150,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,7040,,,BAO_0000019
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL628327,,9615.0,12151,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,9614,,,BAO_0000218
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL628328,,9615.0,12152,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,9614,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,,,178.0,1,CHEMBL628329,,9615.0,12153,,"Concentration of compound in blood of dog 1, after administering intravenously",,9614,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628330,,10116.0,12154,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628331,,10116.0,12155,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628332,,10116.0,12156,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628333,,10116.0,12157,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628334,,10116.0,12158,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628335,,10116.0,12159,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628336,,10116.0,12160,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628337,,10116.0,12161,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628338,,10116.0,12162,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL875610,,10116.0,12163,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628339,,10116.0,12164,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628340,,10116.0,12165,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628341,,10116.0,12166,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622214,,10116.0,12167,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623167,,10116.0,12168,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623168,,10116.0,12169,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623169,,10116.0,12170,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,8608,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL623170,,10116.0,12171,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627224,,10116.0,12172,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL875634,,10116.0,12173,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627225,,10116.0,12174,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627226,,10116.0,12175,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626083,,10116.0,12176,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626084,,10116.0,12177,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626085,,10116.0,12178,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626086,,10116.0,12179,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626087,,10116.0,12180,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626088,,10116.0,12181,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626089,,10116.0,12182,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626090,,10116.0,12183,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626091,,10116.0,12184,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626092,,10116.0,12185,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626093,,10116.0,12186,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626094,,10116.0,12187,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626095,,10116.0,12188,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,8608,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL626096,,10116.0,12189,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,8608,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL626097,,314293.0,12190,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,15604,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626098,,10116.0,12191,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,15604,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL626099,,,12192,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,1806,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL626100,,,12193,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,1806,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL626101,,9615.0,12194,,AUC 0-inf in dog,,17237,,,BAO_0000218
,Plasma,Cavia porcellus,Intermediate,1,50512,A,N,,,1969.0,1,CHEMBL626102,,10141.0,12195,,AUC 0-inf in guinea pig,,17237,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1969.0,1,CHEMBL626103,,9615.0,12196,,AUC 0-t in dog,,17237,,,BAO_0000218
,Plasma,Cavia porcellus,Intermediate,1,50512,A,N,,,1969.0,1,CHEMBL628391,,10141.0,12197,,AUC 0-t in guinea pig,,17237,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628392,,10116.0,12198,,The compound was tested for brain to plasma partition in rat,,15194,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628393,,10116.0,12199,,The compound was tested for brain to plasma partition in rat.,,15194,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,,,178.0,0,CHEMBL628394,,,12200,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,8787,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628395,,9615.0,12201,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628396,,314293.0,12202,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL628397,,9986.0,12203,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628398,,10116.0,12204,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,,,,1,CHEMBL628399,,9544.0,12205,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,4236,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628400,,9615.0,12206,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,15343,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874907,,10116.0,12207,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,15343,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628401,,,12208,,Area under curve of the compound was determined,,17720,,,BAO_0000019
,Plasma,Simiiformes,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL628402,,314293.0,12209,,AUC in monkeys at a dose of 1 mg/kg,,17788,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628403,,10116.0,12210,,AUC in rats at a dose of 1 mg/kg,,17788,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628404,,,12211,,Compound was evaluated for the overall absorbance loss at pH of 2,,8778,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628405,,,12212,,Compound was evaluated for the overall absorbance loss at pH of 4,,8778,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628406,,,12213,,Compound was evaluated for the overall absorbance loss at pH of 7,,8778,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628407,,10116.0,12214,,Compound was evaluated for its absorption in the rats,,2249,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628408,,10116.0,12215,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,8881,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629171,,10116.0,12216,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,8881,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629172,,10116.0,12217,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,8881,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629173,,10116.0,12218,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,8881,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629174,,10116.0,12219,,In vitro percent permeability into rat ileum,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629175,,10116.0,12220,,In vitro percent permeability into rat ileum; Range is 10-17,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629176,,10116.0,12221,,In vitro percent permeability into rat ileum; Range is 10-18,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629177,,10116.0,12222,,In vitro percent permeability into rat ileum; Range is 10-19,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629178,,10116.0,12223,,In vitro percent permeability into rat ileum; Range is 12-15,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631869,,10116.0,12224,,In vitro percent permeability into rat ileum; Range is 13-19,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631870,,10116.0,12225,,In vitro percent permeability into rat ileum; Range is 14-17,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631871,,10116.0,12226,,In vitro percent permeability into rat ileum; Range is 15-18,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631872,,10116.0,12227,,In vitro percent permeability into rat ileum; Range is 2-5,,15286,,,BAO_0000218
,Ileum,,Autocuration,1,22224,A,U,,,2116.0,0,CHEMBL875775,,,12228,,In vitro percent permeability into rat ileum; Range is 23-42,,15286,,,BAO_0000221
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631873,,10116.0,12229,,In vitro percent permeability into rat ileum; Range is 28-36,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631874,,10116.0,12230,,In vitro percent permeability into rat ileum; Range is 29-35,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631875,,10116.0,12231,,In vitro percent permeability into rat ileum; Range is 46-66,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631876,,10116.0,12232,,In vitro percent permeability into rat ileum; Range is 50-68,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631877,,10116.0,12233,,In vitro percent permeability into rat ileum; Range is 78-81,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631878,,10116.0,12234,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631879,,10116.0,12235,,In vitro percent permeability into rat ileum; nd indicates not detected,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631880,,10116.0,12236,,In vitro percent permeability into rat ileum; nt indicates not detected,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631881,,10116.0,12237,,In vitro percent permeability into rat ileum; nt indicates not tested,,15286,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631882,,10116.0,12238,,Compound was tested for oral absorption in bile-duct cannulated rats,,13770,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630749,,10116.0,12239,,Compound was tested for oral absorption in bile-duct cannulated rats.,,13770,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL630750,,9606.0,12240,,Oral absorption using Caco-2 cell monolayers.,,5202,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL630253,,9606.0,12241,,Percent of the drug absorbed after administration to humans was determined,,14920,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL630254,,10116.0,12242,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL630255,,10116.0,12243,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL630256,,10116.0,12244,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,14103,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL875781,,10116.0,12245,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL630257,,10116.0,12246,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL630258,,10116.0,12247,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,13751,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630259,,10116.0,12248,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,15807,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL630260,,10116.0,12249,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,15807,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,,,2435.0,1,CHEMBL630261,,10116.0,12250,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,15807,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630262,,10116.0,12251,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630263,,10116.0,12252,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630264,,10116.0,12253,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630265,,10116.0,12254,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630266,,10116.0,12255,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,14950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630267,,10116.0,12256,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,14950,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630268,,10116.0,12257,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630269,,10116.0,12258,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630270,,10116.0,12259,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,14950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL630141,,10116.0,12260,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,14950,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL630142,,10116.0,12261,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,14950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL630143,,10116.0,12262,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,14950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL630144,,10116.0,12263,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,14950,,,BAO_0000218
,Prostate gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2367.0,1,CHEMBL630145,,10116.0,12264,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,14950,,,BAO_0000218
,Prostate gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2367.0,1,CHEMBL630146,,10116.0,12265,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630147,,10116.0,12266,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630148,,10116.0,12267,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630149,,10116.0,12268,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,14950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL630150,,10116.0,12269,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,14950,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL630151,,10116.0,12270,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,14950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL632031,,10116.0,12271,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,14950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL632032,,10116.0,12272,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632033,,10116.0,12273,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632034,,10116.0,12274,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,14950,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL632035,,10116.0,12275,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,14950,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632036,,10116.0,12276,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,14950,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL632037,,10116.0,12277,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,14950,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL632038,,10116.0,12278,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL632039,,10116.0,12279,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL632040,,10116.0,12280,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL632041,,10116.0,12281,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,8631,,,BAO_0000218
,Blood,Canis lupus familiaris,Intermediate,1,50588,A,N,,,178.0,1,CHEMBL632042,,9615.0,12282,,"Concentration of compound in blood of dog 2, after administering intravenously",,9614,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL632043,,9615.0,12283,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,9614,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL632044,,9615.0,12284,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,9614,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2107.0,1,CHEMBL632045,,9615.0,12285,,"Concentration of compound in liver of dog 1, after administering intravenously",,9614,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2107.0,1,CHEMBL632046,,9615.0,12286,,"Concentration of compound in liver of dog 2, after administering intravenously",,9614,,,BAO_0000218
,Lung,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2048.0,1,CHEMBL632047,,9615.0,12287,,"Concentration of compound in lung of dog 1, after administering intravenously",,9614,,,BAO_0000218
,Lung,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2048.0,1,CHEMBL632048,,9615.0,12288,,"Concentration of compound in lung of dog 2, after administering intravenously",,9614,,,BAO_0000218
,Muscle tissue,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2385.0,1,CHEMBL632049,,9615.0,12289,,"Concentration of compound in muscle of dog 1, after administering intravenously",,9614,,,BAO_0000218
,Muscle tissue,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2385.0,1,CHEMBL876418,,9615.0,12290,,"Concentration of compound in muscle of dog 2, after administering intravenously",,9614,,,BAO_0000218
,Spleen,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2106.0,1,CHEMBL632050,,9615.0,12291,,"Concentration of compound in spleen of dog 1,after administering intravenously",,9614,,,BAO_0000218
,Spleen,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2106.0,1,CHEMBL632051,,9615.0,12292,,"Concentration of compound in spleen of dog 2, after administering intravenously",,9614,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL632052,,,12293,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,10353,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL632053,,,12294,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,10353,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632054,,,12295,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,10353,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL632055,,,12296,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,10353,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL631181,,,12297,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,10353,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631182,,,12298,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631183,,,12299,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631184,,,12300,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629774,,,12301,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629775,,,12302,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL876549,,,12303,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628172,,,12304,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628173,,,12305,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628174,,,12306,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628175,,,12307,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628176,,,12308,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628177,,,12309,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628178,,,12310,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628179,,,12311,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628180,,,12312,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628181,,,12313,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628182,,,12314,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628183,,,12315,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628184,,,12316,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628185,,,12317,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875617,,,12318,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628186,,,12319,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628187,,,12320,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628188,,,12321,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628189,,,12322,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628190,,,12323,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628191,,,12324,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626513,,,12325,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,9196,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626514,,10116.0,12326,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626515,,10116.0,12327,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626516,,10116.0,12328,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626517,,10116.0,12329,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626518,,10116.0,12330,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626519,,10116.0,12331,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626520,,10116.0,12332,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626521,,10116.0,12333,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626522,,10116.0,12334,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626523,,10116.0,12335,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626524,,10116.0,12336,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626688,,10116.0,12337,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626689,,10116.0,12338,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626690,,10116.0,12339,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626691,,10116.0,12340,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL627319,,10116.0,12341,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL624052,,10116.0,12342,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,8608,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL624053,,10116.0,12343,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,8608,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624054,,10116.0,12344,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624055,,10116.0,12345,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624056,,10116.0,12346,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL624057,,10116.0,12347,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622281,,10116.0,12348,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622282,,10116.0,12349,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622283,,10116.0,12350,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622284,,10116.0,12351,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622285,,10116.0,12352,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL622286,,10116.0,12353,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,8085,,,BAO_0000218
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL622287,,,12354,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,7657,,,BAO_0000100
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622288,,10090.0,12355,,Partition coefficient (logD7.4),,8935,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622289,,10090.0,12356,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622290,,10090.0,12357,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,13792,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622291,,10090.0,12358,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622292,,10090.0,12359,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,13792,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622293,,10090.0,12360,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL622294,,10090.0,12361,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,13792,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL622295,,10090.0,12362,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,13792,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,,,955.0,1,CHEMBL622296,,10116.0,12363,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,13792,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL874409,,10116.0,12364,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622297,,10116.0,12365,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622298,,10116.0,12366,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622299,,10116.0,12367,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622300,,10116.0,12368,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622301,,10116.0,12369,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622302,,10116.0,12370,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622303,,10116.0,12371,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622304,,10116.0,12372,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622305,,10116.0,12373,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL622306,,10116.0,12374,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626864,,10116.0,12375,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626865,,10116.0,12376,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626866,,10116.0,12377,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626867,,10116.0,12378,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626868,,10116.0,12379,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626869,,10116.0,12380,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626870,,10116.0,12381,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626871,,10116.0,12382,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626872,,10116.0,12383,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL632185,,10116.0,12384,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,14103,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL632186,,10116.0,12385,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,14103,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629310,,,12386,,Amount of acetic acid produced by the compound,,12904,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629311,,,12387,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,12904,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629312,,10116.0,12388,,Log of (Cbrain/Cblood) in rats,,9663,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629313,,,12389,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,7652,,,BAO_0000221
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629314,,,12390,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,7652,,,BAO_0000221
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629315,,,12391,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,7652,,,BAO_0000221
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL629316,,,12392,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,7652,,,BAO_0000219
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629317,,,12393,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,7652,,,BAO_0000221
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629318,,,12394,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL877497,,,12395,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629319,,,12396,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629320,,,12397,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629496,,,12398,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629497,,,12399,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629498,,,12400,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629499,,,12401,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629500,,,12402,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629501,,,12403,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629502,,,12404,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,7652,,,BAO_0000019
,,,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL629503,,,12405,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,8267,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629504,,9615.0,12406,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,8267,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629505,,,12407,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,14479,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629506,,,12408,,Compound was evaluated for total body clearance,,17515,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629507,,,12409,,Compound was evaluated for volume of distribution at steady state,,17515,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL877498,,,12410,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,8142,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629508,,,12411,,Percentage of the diamine which is monoprotonated at pH 7.4,,14849,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629509,,,12412,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,7653,,,BAO_0000019
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629510,,10116.0,12413,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629511,,10116.0,12414,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629512,,10116.0,12415,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629513,,10116.0,12416,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629514,,10116.0,12417,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628447,,10116.0,12418,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628448,,10116.0,12419,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628449,,10116.0,12420,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631119,,10116.0,12421,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631120,,10116.0,12422,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631121,,10116.0,12423,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL874458,,10116.0,12424,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631122,,10116.0,12425,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631123,,10116.0,12426,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631124,,10116.0,12427,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631125,,10116.0,12428,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631290,,10116.0,12429,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631291,,10116.0,12430,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631292,,10116.0,12431,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631293,,10116.0,12432,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631294,,10116.0,12433,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631295,,10116.0,12434,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631296,,10116.0,12435,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,8631,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631297,,10116.0,12436,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,8631,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631298,,,12437,,Maximum biodistribution (Bmax) was determined.,,10263,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631299,,10090.0,12438,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,12364,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631300,,10090.0,12439,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,12364,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631301,,10090.0,12440,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,12364,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630291,,10090.0,12441,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,12364,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630292,,,12442,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630293,,,12443,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630294,,,12444,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630295,,,12445,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630296,,,12446,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626782,,,12447,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626783,,,12448,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626784,,,12449,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626785,,,12450,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626786,,,12451,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626787,,,12452,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626788,,,12453,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625927,,,12454,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625928,,10116.0,12455,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625929,,10116.0,12456,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625930,,10116.0,12457,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625931,,10116.0,12458,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627230,,10116.0,12459,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627231,,10116.0,12460,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627232,,10116.0,12461,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627233,,10116.0,12462,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL875470,,10116.0,12463,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627234,,10116.0,12464,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627235,,10116.0,12465,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627236,,10116.0,12466,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627237,,10116.0,12467,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627238,,10116.0,12468,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627239,,10116.0,12469,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627240,,10116.0,12470,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627241,,10116.0,12471,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627242,,10116.0,12472,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627243,,10116.0,12473,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627244,,10116.0,12474,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627245,,10116.0,12475,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627246,,10116.0,12476,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627247,,10116.0,12477,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627248,,10116.0,12478,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627249,,10116.0,12479,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625569,,10116.0,12480,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625570,,10116.0,12481,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625571,,10116.0,12482,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625572,,10116.0,12483,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625573,,10116.0,12484,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625574,,10116.0,12485,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626245,,10116.0,12486,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626246,,10116.0,12487,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626247,,,12488,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626248,,,12489,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626249,,,12490,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626420,,,12491,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626421,,,12492,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626422,,,12493,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626423,,,12494,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626424,,,12495,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626425,,9615.0,12496,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,12023,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875476,,10116.0,12497,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,12023,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL626426,,9541.0,12498,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,12023,,,BAO_0000218
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL626427,,,12499,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,10580,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL626428,,,12500,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,10580,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626429,,,12501,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,16032,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL625025,,,12502,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,16032,,,BAO_0000019
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625026,,10116.0,12503,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625027,,10116.0,12504,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL874410,,10116.0,12505,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625028,,10116.0,12506,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625029,,10116.0,12507,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625030,,10116.0,12508,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625031,,10116.0,12509,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625032,,10116.0,12510,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625033,,10116.0,12511,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL625034,,10116.0,12512,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624872,,10116.0,12513,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624873,,10116.0,12514,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624874,,10116.0,12515,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624875,,10116.0,12516,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624876,,10116.0,12517,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624877,,10116.0,12518,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624878,,10116.0,12519,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624879,,10116.0,12520,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624880,,10116.0,12521,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624881,,10116.0,12522,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL624882,,10116.0,12523,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624883,,10116.0,12524,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624884,,10116.0,12525,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624885,,10116.0,12526,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624886,,10116.0,12527,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624887,,10116.0,12528,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624888,,10116.0,12529,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624889,,10116.0,12530,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL624890,,10116.0,12531,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL621964,,10116.0,12532,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL621965,,10116.0,12533,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL621966,,10116.0,12534,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL621967,,10116.0,12535,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL622164,,10116.0,12536,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623097,,,12537,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,7653,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623098,,,12538,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,7653,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623099,,,12539,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,7653,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623100,,,12540,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,7653,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628673,,10116.0,12541,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628674,,10116.0,12542,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628675,,10116.0,12543,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627644,,10116.0,12544,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627645,,10116.0,12545,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627646,,10116.0,12546,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627647,,10116.0,12547,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627648,,10116.0,12548,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,9104,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627649,,10116.0,12549,,Free level in rat plasma,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628313,,,12550,,Level reaching in blood plasma of rat or human was determined,,6614,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628314,,10116.0,12551,,Log (Cbrain/Cblood) in rats,,9663,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628315,,,12552,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,17658,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628316,,,12553,,Mean percentage of compound transport through membrane; expressed as membrane transport,,17658,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628317,,,12554,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,14314,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628473,,,12555,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,7385,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628474,,,12556,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,7385,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628475,,,12557,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,7385,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628476,,,12558,,Net water uptake by a carrier mediated transport (%cm) mechanism,,1329,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628477,,314293.0,12559,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,12187,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL628478,,9669.0,12560,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,12187,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL628479,,9669.0,12561,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628480,,314293.0,12562,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628481,,314293.0,12563,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,12187,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628482,,10116.0,12564,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,12187,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628483,,10116.0,12565,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,12187,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628484,,10116.0,12566,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,9278,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628485,,10116.0,12567,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,9278,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,,,1969.0,1,CHEMBL628486,,9541.0,12568,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,9278,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,,,1969.0,1,CHEMBL628487,,9606.0,12569,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,9278,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628488,,10116.0,12570,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,9278,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628489,,10116.0,12571,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,9278,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628490,,10116.0,12572,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,9278,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL628491,,9541.0,12573,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,12186,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,,,,1,CHEMBL877507,,9541.0,12574,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,12186,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628492,,,12575,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,12186,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628493,,314293.0,12576,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,12041,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628494,,314293.0,12577,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,12041,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL628495,,314293.0,12578,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,12041,,,BAO_0000019
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL628496,,9606.0,12579,,Permeability in Caco-2 assay at 10E-6,,6737,,,BAO_0000218
,Brain,,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL628497,,,12580,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,13758,,,BAO_0000218
,Brain,,Autocuration,1,22224,A,U,,,955.0,0,CHEMBL628498,,,12581,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,13758,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628499,,,12582,,Plasma protein binding was determined,,5676,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627656,,,12583,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627657,,,12584,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626808,,,12585,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626809,,,12586,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626810,,,12587,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626811,,,12588,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874465,,,12589,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626812,,,12590,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626813,,,12591,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626814,,,12592,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,14793,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626815,,,12593,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,14000,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628566,,,12594,,Partition coefficient (logP),,5948,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL628567,,,12595,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,13824,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL628568,,,12596,,Calculated partition coefficient (clogP),,10778,,,BAO_0000100
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628569,,9615.0,12597,,C max in dog,,17237,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL628570,,10141.0,12598,,C max in guinea pig,,17237,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628571,,,12599,,C max value was evaluated,,2809,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628572,,,12600,,Cmax value after oral dose of 0.1 mg//kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628573,,,12601,,Cmax value after oral dose of 0.3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628574,,,12602,,Cmax value after oral dose of 1 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628575,,,12603,,Cmax value after oral dose of 10 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628576,,,12604,,Cmax value after oral dose of 23.4 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628577,,,12605,,Cmax value after oral dose of 3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628578,,,12606,,Cmax value after oral dose of 3.87 mg/kg,,11954,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL874466,,9615.0,12607,,Cmax value in female Beagle dogs,,12768,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628579,,10116.0,12608,,Cmax value in male rats,,12768,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL628580,,10116.0,12609,,Cmax value in rat plasma when administered 20 mg/kg perorally,,12780,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628581,,9615.0,12610,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,15592,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL628582,,9615.0,12611,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,15592,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628583,,9615.0,12612,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL625782,,314293.0,12613,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL625783,,9986.0,12614,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625784,,10116.0,12615,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,,,1969.0,1,CHEMBL625785,,9544.0,12616,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,4236,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625786,,10116.0,12617,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,15791,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874467,,,12618,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,11149,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625787,,9615.0,12619,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,15592,,,BAO_0000218
,,Human immunodeficiency virus,Intermediate,1,50677,A,N,,,,1,CHEMBL625964,,12721.0,12620,,cytotoxicity against HIV protease enzyme.,,15778,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625965,,10090.0,12621,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,12745,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625966,,10090.0,12622,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,12745,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625967,,9615.0,12623,,The plasma clearance in dog.,,13941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625968,,10116.0,12624,,The plasma clearance in rat.,,13941,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625969,,10116.0,12625,,Clearance from plasma in male Sprague-Dawley rats,,16449,,,BAO_0000218
,Plasma,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,1969.0,1,CHEMBL625970,,9541.0,12626,,Clearance from plasma in male cynomolgus monkeys,,16449,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625971,,9615.0,12627,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,14224,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625972,,9615.0,12628,,Clearance of compound in dog plasma,,14224,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL625973,,9606.0,12629,,Clearance of compound in human plasma,,14224,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625974,,9615.0,12630,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,14317,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625975,,9615.0,12631,,Clearance of compound when administered intravenously as an individual dose to a single dog.,,14317,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625976,,9615.0,12632,,"Clearance (10 mg/kg, intravenously) in dog plasma",,14224,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625977,,9615.0,12633,,Clearance value in dog,,17237,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL625978,,10141.0,12634,,Clearance value in guinea pig,,17237,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL874468,,10116.0,12635,,Clearance values in rats after iv administration.,,14187,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL625421,,,12636,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,4806,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,In vivo,,,1,CHEMBL625422,,9986.0,12637,,In vivo clearance (5 mg/kg) was determined in rabbits,,15025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625423,,10116.0,12638,,Plasma Clearance rate was determined for the compound in rats,,13197,,,BAO_0000218
,,Saimiri,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625424,,9520.0,12639,,Plasma Clearance rate was determined for the compound in squirrel monkeys,,13197,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625425,,10116.0,12640,,Plasma clearance in rat,,13960,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625426,,,12641,,Plasma clearance of the compound,,17820,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL625427,,10141.0,12642,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,14706,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL625428,,10141.0,12643,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,14706,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625429,,,12644,,Plasma clearance was determined,,6504,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625430,,9615.0,12645,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,14925,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625431,,10116.0,12646,,Plasma clearance rate was determined for the compound in rats,,13197,,,BAO_0000218
,,Saimiri,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627307,,9520.0,12647,,Plasma clearance rate was determined for the compound in squirrel monkeys,,13197,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627308,,,12648,,Slow clearance (CL) was determined,,3437,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627309,,,12649,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627310,,,12650,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627311,,,12651,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627312,,,12652,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627313,,,12653,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627314,,,12654,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627315,,,12655,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627316,,,12656,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627317,,,12657,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627318,,,12658,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627999,,,12659,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628000,,,12660,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628001,,,12661,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628002,,,12662,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625610,,,12663,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625611,,,12664,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625612,,,12665,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625613,,,12666,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875479,,,12667,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625614,,,12668,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625615,,,12669,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,9196,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626302,,,12670,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,9196,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626303,,10116.0,12671,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL627420,,10116.0,12672,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,8374,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627421,,10116.0,12673,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625695,,10116.0,12674,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625696,,10116.0,12675,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,13477,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL875606,,10090.0,12676,,Distribution of compound in mice brain was measured after 1 hr,,10009,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL625697,,10090.0,12677,,Distribution of compound in mice brain was measured after 24 hr r,,10009,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL625698,,10090.0,12678,,Distribution of compound in mice brain was measured after 2 hr,,10009,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL625699,,10090.0,12679,,Distribution of compound in mice brain was measured after 3 hr,,10009,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL625700,,10090.0,12680,,Distribution of compound in mice brain was measured after 6 hr,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625701,,10090.0,12681,,Distribution of compound in mice liver was measured after 1 hr,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625702,,10090.0,12682,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625703,,10090.0,12683,,Distribution of compound in mice liver was measured after 2 hr,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625704,,10090.0,12684,,Distribution of compound in mice liver was measured after 3 hr,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625705,,10090.0,12685,,Distribution of compound in mice liver was measured after 6 hr,,10009,,,BAO_0000218
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL625706,,9615.0,12686,,Distribution in dog adrenal medulla 30 min after administration.,,8170,,,BAO_0000218
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL625707,,9615.0,12687,,Distribution in dog adrenal medulla 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625708,,9615.0,12688,,Distribution in female dog Ovary 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625709,,9615.0,12689,,Distribution in female dog Ovary 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624180,,9615.0,12690,,Distribution in female dog adipose 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624181,,9615.0,12691,,Distribution in female dog adipose 72 hours after administration.,,8170,,,BAO_0000218
,Adrenal cortex,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1235.0,1,CHEMBL624182,,9615.0,12692,,Distribution in female dog adrenal cortex 72 hours after administration.,,8170,,,BAO_0000218
,Adrenal cortex,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1235.0,1,CHEMBL624183,,9615.0,12693,,Distribution in female dog adrenal cortex 72 hours after administration.,,8170,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624184,,10116.0,12694,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL877489,,10116.0,12695,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624185,,10116.0,12696,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624186,,10116.0,12697,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624187,,10116.0,12698,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL624188,,10116.0,12699,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624189,,10116.0,12700,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624190,,10116.0,12701,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624191,,10116.0,12702,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624192,,10116.0,12703,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624193,,10116.0,12704,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624194,,10116.0,12705,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624891,,10116.0,12706,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624892,,10116.0,12707,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL624893,,10116.0,12708,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL627632,,10116.0,12709,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627633,,10116.0,12710,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627634,,10116.0,12711,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627635,,10116.0,12712,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627636,,10116.0,12713,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626816,,10116.0,12714,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626817,,10116.0,12715,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626818,,10116.0,12716,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626819,,10116.0,12717,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626820,,10116.0,12718,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626821,,10116.0,12719,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626822,,10116.0,12720,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626823,,10116.0,12721,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626824,,10116.0,12722,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626825,,10116.0,12723,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626826,,10116.0,12724,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626827,,10116.0,12725,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626828,,10116.0,12726,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626829,,10116.0,12727,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL626830,,10116.0,12728,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627150,,10116.0,12729,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627151,,10116.0,12730,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627152,,10116.0,12731,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627153,,10116.0,12732,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627154,,,12733,,Rate of acetate production by the compound was determined,,12904,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627155,,,12734,,Rate of acetate production by the compound was determined; Not determined,,12904,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627156,,,12735,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,3730,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627157,,,12736,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,3627,,,BAO_0000019
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL627158,,9986.0,12737,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,13799,,,BAO_0000218
,Plasma,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1969.0,1,CHEMBL627159,,9986.0,12738,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,13799,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627160,,10090.0,12739,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,13799,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628540,,10116.0,12740,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,13799,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628541,,10116.0,12741,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,13799,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628542,,10116.0,12742,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,13799,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL628543,,,12743,,Solubility after at a pH 1.2,,6629,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL628544,,,12744,,Solubility after at pH 1.2,,6629,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL628545,,,12745,,Solubility after injection of water,,6629,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628546,,,12746,,Statistical significance of IC 50 values; Expressed as R value,,14000,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874455,,,12747,,Systemic availability with respect to methyldopa was determined,,8267,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628547,,10116.0,12748,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,13799,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL628548,,10116.0,12749,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,13799,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628549,,9986.0,12750,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628550,,9986.0,12751,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628551,,9986.0,12752,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628552,,9986.0,12753,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628553,,9986.0,12754,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628554,,9986.0,12755,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628555,,9986.0,12756,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628556,,9986.0,12757,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,7132,,,BAO_0000218
,Kidney,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,2113.0,1,CHEMBL628557,,9986.0,12758,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628558,,9986.0,12759,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628559,,9986.0,12760,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628560,,9986.0,12761,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL874456,,9986.0,12762,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628561,,9986.0,12763,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL628562,,9986.0,12764,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628563,,9986.0,12765,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628564,,9986.0,12766,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL628565,,9986.0,12767,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL631248,,9986.0,12768,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL631249,,9986.0,12769,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,7132,,,BAO_0000218
,Kidney,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,2113.0,1,CHEMBL627214,,9986.0,12770,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL874591,,9986.0,12771,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL627215,,9986.0,12772,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL625471,,9986.0,12773,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,7132,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL625472,,9986.0,12774,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,7132,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL625473,,9986.0,12775,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,7132,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625474,,9615.0,12776,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,13317,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625475,,9615.0,12777,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625476,,10116.0,12778,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625477,,10116.0,12779,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,15341,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625478,,10116.0,12780,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,15341,,,BAO_0000218
,esophageal tunica muscularis mucosae,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL625479,,10116.0,12781,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,12801,,,BAO_0000218
,esophageal tunica muscularis mucosae,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,,1,CHEMBL625480,,10116.0,12782,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,12801,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625481,,10116.0,12783,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,14856,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625482,,10116.0,12784,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625483,,10116.0,12785,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625484,,10116.0,12786,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,14062,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625485,,10116.0,12787,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,14062,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625486,,9615.0,12788,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,14346,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625487,,10116.0,12789,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625488,,10116.0,12790,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625489,,10116.0,12791,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625490,,10116.0,12792,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL625491,,9615.0,12793,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,14346,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625492,,10116.0,12794,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,14346,,,BAO_0000218
,Plasma,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1969.0,1,CHEMBL625493,,9606.0,12795,,plasma clearance in human,,15711,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625494,,10116.0,12796,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,14886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625495,,10116.0,12797,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,14886,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625496,,10116.0,12798,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,14886,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625497,,,12799,,1-Octanol/water partition coefficient measured at 7.4,,4115,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625498,,,12800,,Calculated partition coefficient (clogP),,13733,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625499,,,12801,,Partition coefficient (logP),,12102,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625500,,,12802,,Calculated partition coefficient (clogP),,12676,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625501,,,12803,,Calculated partition coefficient (clogP),,13733,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625502,,,12804,,Calculated partition coefficient (clogP),,13740,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625503,,,12805,,Calculated partition coefficient (clogP) (relative to BAY K 8644),,12766,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625504,,,12806,,Calculated partition coefficient (clogP),,2764,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625505,,,12807,,Calculated partition coefficient (clogP),,12355,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625506,,,12808,,Calculated partition coefficient of the compound,,11314,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625507,,,12809,,Partition coefficient (logP),,12706,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625508,,,12810,,Calculated partition coefficient (clogP),,12645,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625509,,,12811,,Calculated partition coefficient (clogP),,13668,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625510,,,12812,,Calculated partition coefficient (clogP),,12819,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL883125,,,12813,,Calculated partition coefficient (clogP),,13668,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625511,,,12814,,Calculated partition coefficient (clogP),,13017,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874650,,,12815,,Partition coefficient of the compound,,2448,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625512,,,12816,,Partition coefficient of the compound,,11526,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625513,,,12817,,Partition coefficient of compound was determined,,12426,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625514,,,12818,,Partition coefficient was determined,,2448,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625515,,,12819,,Calculated partition coefficient (clogP),,12001,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625516,,,12820,,partition coefficient of compound was determined,,12426,,,BAO_0000100
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625517,,9615.0,12821,,The total body administered intravenously in dog,,13204,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625518,,10116.0,12822,,The total body administered intravenously in rats,,13204,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625519,,10090.0,12823,,Time taken for the administration to female NIH mice weighing 25-30 g.,,13889,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625520,,,12824,,Time taken for the administration,,13889,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL874651,,9615.0,12825,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625521,,314293.0,12826,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,In vivo,,,1,CHEMBL623171,,9986.0,12827,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623853,,10116.0,12828,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,17025,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623854,,,12829,,Plasma clearance for the compound was determined.,,15067,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL874405,,,12830,,CLog P value of the compound,,3091,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL623855,,,12831,,Calculated partition coefficient (clogP),,15592,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL623856,,,12832,,Calculated partition coefficient (clogP),,14738,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL623857,,,12833,,ClogP value of the compound; nd ='no data',,14738,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL623858,,,12834,,ClogP value of the compound; nd ='not determined',,14738,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL623859,,,12835,,CLog P was determined,,6076,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL839829,,,12836,,Calculated partition coefficient (clogP),,17840,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623860,,,12837,,CLogP was calculated,,13589,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623861,,,12838,,CLogP value was determined,,17655,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623862,,,12839,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,5867,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL874406,,,12840,,Calculated partition coefficient (clogP),,5867,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL623863,,,12841,,Calculated partition coefficient (clogP),,10783,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624021,,,12842,,Calculated partition coefficient (clogP),,14849,,,BAO_0000100
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL624022,,9615.0,12843,,Distribution in female dog adrenal medulla 24 hours after administration.,,8170,,,BAO_0000218
,Adrenal medulla,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1236.0,1,CHEMBL624023,,9615.0,12844,,Distribution in female dog adrenal medulla 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624024,,9615.0,12845,,Distribution in female dog bile 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624025,,9615.0,12846,,Distribution in female dog bile 72 hr after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624026,,9615.0,12847,,Distribution in female dog blood 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624027,,9615.0,12848,,Distribution in female dog blood 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624028,,9615.0,12849,,Distribution in female dog heart 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624029,,9615.0,12850,,Distribution in female dog heart 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624030,,9615.0,12851,,Distribution in female dog kidney 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624031,,9615.0,12852,,Distribution in female dog kidney 72 hours after administration.,,8170,,,BAO_0000218
,Intestine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,160.0,1,CHEMBL624032,,9615.0,12853,,Distribution in female dog large intestine 24 hours after administration.,,8170,,,BAO_0000218
,Intestine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,160.0,1,CHEMBL874407,,9615.0,12854,,Distribution in female dog large intestine 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624033,,9615.0,12855,,Distribution in female dog liver 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624034,,9615.0,12856,,Distribution in female dog liver 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624035,,9615.0,12857,,Distribution in female dog lung 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624036,,9615.0,12858,,Distribution in female dog lung 72 hours after administration.,,8170,,,BAO_0000218
,Muscle tissue,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2385.0,1,CHEMBL624037,,9615.0,12859,,Distribution in female dog muscle 24 hours after administration.,,8170,,,BAO_0000218
,Muscle tissue,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2385.0,1,CHEMBL624038,,9615.0,12860,,Distribution in female dog muscle 72 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624039,,9615.0,12861,,Distribution in female dog pancreas 24 hours after administration.,,8170,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624040,,9615.0,12862,,Distribution in female dog pancreas 72 hours after administration.,,8170,,,BAO_0000218
,Intestine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,160.0,1,CHEMBL624041,,9615.0,12863,,Distribution in female dog small intestine 24 hours after administration.,,8170,,,BAO_0000218
,Intestine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,160.0,1,CHEMBL624042,,9615.0,12864,,Distribution in female dog small intestine 72 hours after administration.,,8170,,,BAO_0000218
,Spleen,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2106.0,1,CHEMBL624043,,9615.0,12865,,Distribution in female dog spleen 24 hours after administration.,,8170,,,BAO_0000218
,Spleen,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2106.0,1,CHEMBL624044,,9615.0,12866,,Distribution in female dog spleen 72 hours after administration.,,8170,,,BAO_0000218
,Stomach,Canis lupus familiaris,Intermediate,1,50588,A,N,,,945.0,1,CHEMBL624045,,9615.0,12867,,Distribution in female dog stomach 24 hours after administration.,,8170,,,BAO_0000218
,Stomach,Canis lupus familiaris,Intermediate,1,50588,A,N,,,945.0,1,CHEMBL624046,,9615.0,12868,,Distribution in female dog stomach 72 hours after administration.,,8170,,,BAO_0000218
,Thyroid gland,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2046.0,1,CHEMBL624047,,9615.0,12869,,Distribution in female dog thyroid 24 hours after administration.,,8170,,,BAO_0000218
,Thyroid gland,Canis lupus familiaris,Intermediate,1,50588,A,N,,,2046.0,1,CHEMBL624048,,9615.0,12870,,Distribution in female dog thyroid 72 hours after administration.,,8170,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL874408,,9615.0,12871,,Distribution in female dog urine 24 hours after administration.,,8170,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL624049,,9615.0,12872,,Distribution in female dog urine 72 hr after administration.,,8170,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL624050,,,12873,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,14283,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624051,,,12874,,Plasma concentration at 7 hr after intravenous dosing,,5623,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623278,,10116.0,12875,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623279,,10116.0,12876,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623280,,10116.0,12877,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623963,,10116.0,12878,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623964,,10116.0,12879,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623965,,10116.0,12880,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623966,,10116.0,12881,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874415,,10116.0,12882,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623967,,10116.0,12883,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623968,,10116.0,12884,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623969,,10116.0,12885,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628409,,10116.0,12886,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628410,,10116.0,12887,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628411,,10116.0,12888,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628412,,10116.0,12889,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,13477,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628413,,,12890,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,12553,,,BAO_0000019
,Plasma,,Autocuration,1,22224,A,U,,,1969.0,0,CHEMBL628414,,,12891,,The concentration in plasmat; Not determined,,14548,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628415,,10116.0,12892,,Tissue level at 10 mg/kg/po in wistar rats in blood,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628416,,10116.0,12893,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628417,,10116.0,12894,,Tissue level at 10 mg/kg/po in wistar rats in heart,,14393,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL874908,,10116.0,12895,,Tissue level at 10 mg/kg/po in wistar rats in liver,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628418,,10116.0,12896,,Tissue level at 10 mg/kg/po in wistar rats in plasma,,14393,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL628419,,10116.0,12897,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628420,,10116.0,12898,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,14393,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628421,,,12899,,Water solubility at 37 degree C.,,1629,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626726,,,12900,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626727,,,12901,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,8194,,,BAO_0000100
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626728,,10116.0,12902,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626729,,10116.0,12903,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626730,,10116.0,12904,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626731,,10116.0,12905,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL626732,,10116.0,12906,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626733,,10116.0,12907,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626734,,10116.0,12908,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626735,,10116.0,12909,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL874909,,10116.0,12910,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,,,948.0,1,CHEMBL626736,,10116.0,12911,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL626737,,10116.0,12912,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL630999,,10116.0,12913,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL631000,,10116.0,12914,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL631001,,10116.0,12915,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,,,2113.0,1,CHEMBL631002,,10116.0,12916,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631003,,10116.0,12917,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631004,,10116.0,12918,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631005,,10116.0,12919,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631006,,10116.0,12920,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631007,,10116.0,12921,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL631008,,10116.0,12922,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL631009,,10116.0,12923,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL631010,,10116.0,12924,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL631011,,10116.0,12925,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,,,2048.0,1,CHEMBL631012,,10116.0,12926,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL630271,,10116.0,12927,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL630272,,10116.0,12928,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL630273,,10116.0,12929,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL630274,,10116.0,12930,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,,,2046.0,1,CHEMBL630275,,10116.0,12931,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875782,,10116.0,12932,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630276,,10116.0,12933,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630277,,10116.0,12934,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630278,,10116.0,12935,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630279,,10116.0,12936,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,8594,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630280,,,12937,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,8151,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630281,,,12938,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,8151,,,BAO_0000019
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630282,,9986.0,12939,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,7132,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630283,,9986.0,12940,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,7132,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630284,,,12941,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,5797,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630285,,,12942,,Alkylating activity was determined,,7849,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630286,,,12943,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),Microsomes,14220,,,BAO_0000251
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630069,,9986.0,12944,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,8650,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630070,,9986.0,12945,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,8650,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630071,,9986.0,12946,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,8650,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL630072,,9986.0,12947,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,8650,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL875110,,9986.0,12948,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,8650,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630073,,10116.0,12949,,Compound was tested for antidiuretic activity in rats,,7116,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630074,,,12950,,Compound was tested for inactivation kinetic values,,14131,,,BAO_0000019
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL630075,,,12951,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,7415,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630076,,,12952,,Dissociation rate calculated from the first-order equation using the t1/2 value,,13178,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL630077,,,12953,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,8815,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL630078,,,12954,,Aqueous solubility was measured,,1450,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL630079,,,12955,,Aqueous solubility was measured at a pH 4,,1450,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL630080,,,12956,,Aqueous solubility (pH 7),,1450,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL630081,,,12957,,Aqueous solubility was measured at a pH 9,,1450,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630082,,,12958,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,12711,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630083,,,12959,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,12711,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630084,,,12960,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,12711,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL629198,,,12961,,Aqueous solubility of the compound,,15032,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL629199,,,12962,,Aqueous solubility at 37 degree Celsius at pH 7.38,,9964,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL629200,,,12963,,Aqueous solubility in pH 7.4 phosphate buffer,,14962,,,BAO_0000100
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629201,,9615.0,12964,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,12487,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629202,,9615.0,12965,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,12487,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL875111,,9606.0,12966,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL629203,,9606.0,12967,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL629204,,9606.0,12968,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL629205,,9606.0,12969,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL629206,,9606.0,12970,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631185,,,12971,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,10026,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631186,,10116.0,12972,,Compound was evaluated for the average bile flow rat in rats,,7415,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL631187,,9986.0,12973,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,17025,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,,1,CHEMBL631188,,9986.0,12974,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,17025,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL876419,,,12975,,Average half life period was determined,,10184,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631189,,,12976,,Average half life period was determined,,10184,,,BAO_0000019
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL631190,,10298.0,12977,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL631191,,10298.0,12978,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL631192,,10298.0,12979,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632400,,10298.0,12980,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL630564,,10298.0,12981,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL630565,,10298.0,12982,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL630566,,10298.0,12983,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL631229,,10298.0,12984,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL631230,,10298.0,12985,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,8613,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL876428,,,12986,,Calculated partition coefficient (clogP),,6030,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631231,,,12987,,Calculated partition coefficient (clogP),,6147,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631232,,,12988,,Calculated partition coefficient (clogP) (MacLogP),,14556,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631233,,,12989,,Hydrophilicity was determined,,768,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631234,,,12990,,Calculated partition coefficient (clogP),,14452,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL883126,,,12991,,Increased absorption was determined,,5237,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL631235,,,12992,,Lipophilicity value was evaluated,,14378,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL631236,,,12993,,Log P value of the compound.,,14418,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631237,,,12994,,Partition coefficient of compound was determined,,5249,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631238,,,12995,,Calculated partition coefficient (clogP),,14621,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL876429,,,12996,,Calculated partition coefficient (clogP),,12542,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631414,,,12997,,Partition coefficient was measured by medchem software; Not calculated,,12542,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL631415,,,12998,,Partition coefficient was measured by octanol-water using standard shake-flask method,,12542,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631416,,,12999,,Calculated partition coefficient (clogP),,15462,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631417,,,13000,,Partition coefficient (logP),,14884,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631418,,,13001,,Calculated partition coefficient (clogP),,16526,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631419,,,13002,,The Octanol/Water partition coefficient CLogP,,13693,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631420,,,13003,,The pharmacokinetic parameter C Log p was reported,,13693,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631421,,,13004,,Calculated partition coefficient (clogP),,13779,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631422,,,13005,,Calculated partition coefficient (clogP),,14772,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL631423,,,13006,,Calculated partition coefficient (clogP),,14393,,,BAO_0000100
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL876430,,10116.0,13007,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL631424,,10116.0,13008,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,14793,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL631425,,9615.0,13009,,Compound was administered intravenously in dog to evaluate plasma clearance values,,13744,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL631426,,314293.0,13010,,Compound was administered intravenously in monkey to evaluate plasma clearance values,,13744,,,BAO_0000218
,Plasma,Mus musculus,Intermediate,1,50594,A,N,In vivo,,1969.0,1,CHEMBL631427,,10090.0,13011,,Compound was administered intravenously in mouse to evaluate plasma clearance values,,13744,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL631428,,9615.0,13012,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,13207,,,BAO_0000218
,Liver,Macaca mulatta,Intermediate,1,50797,A,N,In vitro,,2107.0,1,CHEMBL631429,,9544.0,13013,,Intrinsic clearance in Rhesus liver microsome,Microsomes,5669,,,BAO_0000218
,Liver,Canis lupus familiaris,Intermediate,1,50588,A,N,In vitro,,2107.0,1,CHEMBL631430,,9615.0,13014,,Intrinsic clearance in dog liver microsome,Microsomes,5669,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vitro,,2107.0,1,CHEMBL631431,,10116.0,13015,,Intrinsic clearance in rat liver microsome,Microsomes,5669,,,BAO_0000218
,Plasma,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,1969.0,1,CHEMBL631432,,9544.0,13016,,Low plasma clearance was calculated in rhesus monkey,,4853,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL631433,,9615.0,13017,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,16452,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL631434,,,13018,,Plasma clearance after intravenous dose of 0.3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL631435,,,13019,,Plasma clearance after intravenous dose of 1 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL631436,,,13020,,Plasma clearance after intravenous dose of 3 mg/kg,,11954,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL631437,,,13021,,Plasma clearance after intravenous dose of 3.87 mg/kg,,11954,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631438,,10116.0,13022,,Plasma clearance after peroral administration at 10 mpk in Rat,,5669,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,,1,CHEMBL876431,,9544.0,13023,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,5669,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL631439,,9615.0,13024,,Plasma clearance after peroral administration at 10 mpk in dog,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631440,,10116.0,13025,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,13662,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631441,,,13026,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,8272,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631442,,,13027,,Critical Micellar concentration was determined,,13410,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626525,,,13028,,Critical Micellar concentration of the compound. was determined,,13410,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627168,,,13029,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,12628,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875618,,,13030,,Critical micellar concentration was measured in water by the dye solubilization method,,9675,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL626612,,,13031,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,12628,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626613,,,13032,,CMR value (relative to BAY K 8644),,12766,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626614,,,13033,,Carbamoylating activity was determined,,7849,,,BAO_0000019
,,Simiiformes,Autocuration,1,22224,A,U,,,,0,CHEMBL626615,,314293.0,13034,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,12187,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626616,,,13035,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,2040,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626617,,,13036,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,2040,,,BAO_0000019
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626618,,9615.0,13037,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,14180,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626619,,10116.0,13038,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,14180,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626620,,9615.0,13039,,"Clearance rate at 0.46 mg/kg, iv, in dogs",,14474,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626621,,10116.0,13040,,"Clearance rate at 5.5 mg/kg, iv, in rat",,14474,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL626622,,9541.0,13041,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,14548,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL626623,,9541.0,13042,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,14548,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626624,,9615.0,13043,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,14548,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626625,,10116.0,13044,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,14548,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,Ex vivo,,2107.0,1,CHEMBL626626,,10116.0,13045,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,6125,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626627,,,13046,,Tested for the total clearance of the compound,,6874,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626628,,9615.0,13047,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,15343,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626629,,,13048,,Total body clearance was determined,,6236,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626630,,10116.0,13049,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626631,,10116.0,13050,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,11510,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626632,,,13051,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626633,,,13052,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626634,,,13053,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626635,,,13054,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626636,,,13055,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,8194,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626637,,,13056,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,8194,,,BAO_0000100
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL626638,,4754.0,13057,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL626639,,4754.0,13058,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL626640,,4754.0,13059,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL626641,,4754.0,13060,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL627272,,4754.0,13061,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL627273,,4754.0,13062,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL627441,,4754.0,13063,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL628355,,4754.0,13064,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL628356,,4754.0,13065,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL628357,,4754.0,13066,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL628358,,4754.0,13067,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,13273,,,BAO_0000218
,,Pneumocystis carinii,Intermediate,1,50339,A,N,,,,1,CHEMBL622307,,4754.0,13068,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,13273,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622527,,,13069,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622528,,,13070,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622529,,,13071,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622992,,,13072,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622993,,,13073,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,13118,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622994,,,13074,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,13118,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622995,,10116.0,13075,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,10633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622996,,10116.0,13076,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,10633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622997,,10116.0,13077,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,10633,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622998,,10116.0,13078,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,10633,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622999,,,13079,,Cp max following ip administration at 1 mg/kg,,5767,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623000,,,13080,,Maximum concentration in plasma was reported at 0.5 hour,,3302,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL623001,,,13081,,Maximum concentration in plasma was reported at 2 hour,,3302,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL623002,,10090.0,13082,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,12467,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL623003,,,13083,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,11778,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623004,,,13084,,Steady state concentration was evaluated,,4321,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623005,,,13085,,Partition coefficient (logP),,14884,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623006,,,13086,,Partition coefficient (logD7.4),,15234,,,BAO_0000019
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL623007,,10116.0,13087,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,14198,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL623008,,10116.0,13088,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,14198,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL876654,,10116.0,13089,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623009,,10116.0,13090,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623010,,10116.0,13091,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,14198,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL623011,,10116.0,13092,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,14198,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL623012,,10116.0,13093,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,14198,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623013,,,13094,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,8151,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623014,,,13095,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,8151,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623015,,,13096,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,8151,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL623016,,,13097,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,8151,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL624858,,,13098,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,8151,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624859,,10116.0,13099,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624860,,10116.0,13100,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624861,,10116.0,13101,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624862,,10116.0,13102,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL624863,,10116.0,13103,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,8151,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876655,,10116.0,13104,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,8151,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624864,,9615.0,13105,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624865,,9615.0,13106,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624866,,9615.0,13107,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,6996,,,BAO_0000218
,,Canis lupus familiaris,Expert,1,50588,F,N,,,,1,CHEMBL624867,,9615.0,13108,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL624868,,9615.0,13109,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628450,,9615.0,13110,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628451,,9615.0,13111,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628452,,9615.0,13112,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628453,,9615.0,13113,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628454,,9615.0,13114,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628455,,9615.0,13115,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628456,,9615.0,13116,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628457,,9615.0,13117,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL877505,,9615.0,13118,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628458,,9615.0,13119,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628459,,9615.0,13120,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628460,,9615.0,13121,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628461,,9615.0,13122,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,6996,,,BAO_0000218
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL628462,,,13123,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL628463,,9615.0,13124,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,6996,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,F,N,,,,1,CHEMBL625666,,10116.0,13125,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,6996,,,BAO_0000218
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL625667,,,13126,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,6996,,,BAO_0000218
,,Rattus norvegicus,Expert,1,50597,A,N,,,,1,CHEMBL625668,,10116.0,13127,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625669,,10116.0,13128,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,6996,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625670,,,13129,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,7114,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625671,,10116.0,13130,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,7114,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL625672,,10298.0,13131,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL625673,,10298.0,13132,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL625674,,10298.0,13133,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL625675,,10298.0,13134,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627637,,10298.0,13135,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627638,,10298.0,13136,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627639,,10298.0,13137,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627640,,10298.0,13138,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627641,,10298.0,13139,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL627642,,10298.0,13140,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL877506,,10298.0,13141,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,8613,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627275,,10090.0,13142,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,8613,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL627643,,9669.0,13143,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL631246,,9669.0,13144,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL631247,,9669.0,13145,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL629532,,9669.0,13146,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL629533,,9669.0,13147,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL629534,,9669.0,13148,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,11219,,,BAO_0000218
,,Mustela putorius furo,Intermediate,1,50506,A,N,,,,1,CHEMBL629535,,9669.0,13149,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,11219,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625932,,,13150,,Pharmacokinetic parameter :drug bound to plasma was reported,,14837,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625933,,,13151,,compound was evaluated for drug bound in plasma,,14837,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625934,,10116.0,13152,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,15343,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,,,,0,CHEMBL625935,,9347.0,13153,,Bioavailability,,13761,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625936,,10116.0,13154,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,14810,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625937,,10116.0,13155,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,14810,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL625938,,9615.0,13156,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,13249,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL625939,,10116.0,13157,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,9267,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL625940,,10116.0,13158,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,9267,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL874464,,10116.0,13159,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,9267,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL625941,,10116.0,13160,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,9267,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL625942,,10116.0,13161,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,9267,,,BAO_0000218
,Bile,Rattus norvegicus,Intermediate,1,50597,A,N,,,1970.0,1,CHEMBL625943,,10116.0,13162,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,9267,,,BAO_0000218
,Serum,Homo sapiens,Intermediate,1,50587,A,N,,,1977.0,1,CHEMBL625944,,9606.0,13163,,In vitro protein binding in human serum at 5 ug/ml,,15549,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625945,,,13164,,Serum protein binding ability was measured,,10929,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625946,,,13165,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,15444,,,BAO_0000019
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625947,,9615.0,13166,,Oral bioavailability in dog,,12860,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625948,,10116.0,13167,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,12170,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625949,,,13168,,Absolute oral bioavailability at an iv dose of 14 mg/kg,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625950,,,13169,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,15173,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625951,,9347.0,13170,,Oral bioavailability (dose 15 mg/kg i.v.),,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625952,,,13171,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625953,,,13172,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625954,,,13173,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL882959,,,13174,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,15173,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625955,,9615.0,13175,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,11767,,,BAO_0000218
,,Mustela putorius furo,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625956,,9669.0,13176,,Bioavailability in ferret,,11219,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL625957,,9541.0,13177,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,12186,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625958,,10116.0,13178,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625959,,10116.0,13179,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626642,,10116.0,13180,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631330,,10116.0,13181,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631331,,10116.0,13182,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631332,,10116.0,13183,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631333,,10116.0,13184,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632018,,10116.0,13185,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632019,,10116.0,13186,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632020,,10116.0,13187,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632021,,10116.0,13188,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632022,,10116.0,13189,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632023,,10116.0,13190,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632024,,10116.0,13191,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874472,,10116.0,13192,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632025,,10116.0,13193,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632026,,10116.0,13194,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632027,,10116.0,13195,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632028,,10116.0,13196,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626430,,10116.0,13197,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626431,,10116.0,13198,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626432,,10116.0,13199,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626433,,10116.0,13200,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626434,,10116.0,13201,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627280,,10116.0,13202,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627281,,10116.0,13203,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627282,,10116.0,13204,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,11510,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627283,,,13205,,Total body clearance was measured at given dose,,7199,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627284,,,13206,,Total body clearance was measured at given dose.,,7199,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627285,,10116.0,13207,,Metabolic clearance from the body in rat,,7095,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627286,,,13208,,Renal clearance from the body,,7095,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL875477,,10116.0,13209,,Renal clearance from the body in rat,,7095,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627287,,10116.0,13210,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,12528,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL627288,,9615.0,13211,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,12528,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627289,,10116.0,13212,,Total clearance from the body in rat,,7095,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627290,,10116.0,13213,,Clearance into cortex from rat plasma or PBS,,14223,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627291,,,13214,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,13569,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627292,,,13215,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,13569,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627293,,,13216,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,13569,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627294,,,13217,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,13569,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875478,,,13218,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,13569,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627295,,,13219,,Clearance was determined,,13979,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL627296,,10090.0,13220,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,14315,,,BAO_0000218
,,Oryctolagus cuniculus,Intermediate,1,50592,A,N,In vivo,,,1,CHEMBL626119,,9986.0,13221,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,14315,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626120,,10116.0,13222,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,14315,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626121,,10116.0,13223,,Clearance in rat after iv dose (100 ug/kg),,12174,,,BAO_0000218
,,Cavia porcellus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626122,,10141.0,13224,,Clearance in guinea pig,,12797,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626123,,10116.0,13225,,Compound was evaluated for clearance in rat,,12797,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL623456,,9615.0,13226,,Compound was evaluated for the clearance in dog,,12797,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623457,,10116.0,13227,,Compound was evaluated for the clearance in rat,,12797,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623458,,10116.0,13228,,Compound was tested in vivo for clearance after iv administration in the rat,,11500,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623459,,,13229,,IV clearance determined at an iv dose of 14 mg/kg,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875484,,,13230,,IV clearance determined at an iv dose of 15.2 mg/kg,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623460,,,13231,,IV clearance determined at an iv dose of 15 mg/kg,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623461,,,13232,,IV clearance determined at an peroral dose of 30 mg/kg.,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL623462,,,13233,,IV clearance determined at an peroral dose of 30.2 mg/kg.,,15173,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627386,,,13234,,IV clearance determined at an peroral dose of 30.3 mg/kg.,,15173,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627387,,10116.0,13235,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,14198,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627388,,10116.0,13236,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,14198,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627389,,10116.0,13237,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,14198,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627390,,10116.0,13238,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,14198,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627391,,10116.0,13239,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627392,,10116.0,13240,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,14198,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL627393,,10116.0,13241,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,14198,,,BAO_0000218
,Trachea,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,3126.0,1,CHEMBL627394,,10116.0,13242,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,14198,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627395,,10116.0,13243,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,14198,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL875485,,10116.0,13244,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627396,,10116.0,13245,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627397,,10116.0,13246,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,14198,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL627398,,10116.0,13247,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,14198,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL627399,,10116.0,13248,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,14198,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627400,,10116.0,13249,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,14198,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627401,,10116.0,13250,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,14198,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627402,,10116.0,13251,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,14198,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL627403,,10116.0,13252,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,14198,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL627404,,10116.0,13253,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623101,,10116.0,13254,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,14198,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL877480,,10116.0,13255,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,14198,,,BAO_0000218
,Trachea,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,3126.0,1,CHEMBL623102,,10116.0,13256,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,14198,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL623103,,10116.0,13257,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,14198,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL623104,,10116.0,13258,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623105,,10116.0,13259,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623106,,10116.0,13260,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,14198,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL623107,,10116.0,13261,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,14198,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL623108,,10116.0,13262,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,14198,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL623109,,10116.0,13263,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,14198,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL623110,,10116.0,13264,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,14198,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL623111,,10116.0,13265,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,14198,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625060,,10116.0,13266,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,14198,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625061,,10116.0,13267,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625062,,10116.0,13268,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,14198,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625063,,10116.0,13269,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,14198,,,BAO_0000218
,Trachea,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,3126.0,1,CHEMBL625064,,10116.0,13270,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,14198,,,BAO_0000218
,Bone,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000001.0,1,CHEMBL625065,,10116.0,13271,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,14198,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL625066,,10116.0,13272,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625067,,10116.0,13273,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625068,,10116.0,13274,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,14198,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL622159,,10116.0,13275,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,14198,,,BAO_0000218
,Intestine,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,160.0,1,CHEMBL622160,,10116.0,13276,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,14198,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL622161,,10116.0,13277,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,14198,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL622162,,10116.0,13278,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,14198,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL622163,,10116.0,13279,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,14198,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622313,,10116.0,13280,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,14198,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622314,,10116.0,13281,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,14198,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622315,,10116.0,13282,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,14198,,,BAO_0000218
,Trachea,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,3126.0,1,CHEMBL622316,,10116.0,13283,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,14198,,,BAO_0000218
,,Escherichia coli,Intermediate,1,50212,A,N,,,,1,CHEMBL877486,,562.0,13284,,Normal diffusion coefficient in water for Escherichia coli,,15599,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622317,,,13285,,Average max percent decrease in RVR (renal vascular resistance) was determined,,8204,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622318,,,13286,,Average max percent decrease in RVR (renal vascular resistance) was determined.,,8204,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622319,,,13287,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622320,,,13288,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622321,,,13289,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622322,,,13290,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622323,,,13291,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,7114,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL622324,,10116.0,13292,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,7114,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622325,,9615.0,13293,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622326,,9615.0,13294,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL877487,,9615.0,13295,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622327,,9615.0,13296,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622328,,9615.0,13297,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622329,,9615.0,13298,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622330,,9615.0,13299,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622331,,9615.0,13300,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622332,,9615.0,13301,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622333,,9615.0,13302,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL627658,,314293.0,13303,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630428,,314293.0,13304,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630429,,314293.0,13305,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630430,,314293.0,13306,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630431,,314293.0,13307,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL630432,,10116.0,13308,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL630433,,10116.0,13309,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL630434,,10116.0,13310,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629372,,10116.0,13311,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629553,,10116.0,13312,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629554,,10116.0,13313,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL874447,,10116.0,13314,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629555,,10116.0,13315,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629556,,10116.0,13316,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629557,,10116.0,13317,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629558,,10116.0,13318,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629559,,10116.0,13319,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629560,,10116.0,13320,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629561,,9615.0,13321,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629562,,9615.0,13322,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629563,,9615.0,13323,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629564,,9615.0,13324,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629565,,9615.0,13325,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629566,,9615.0,13326,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629567,,9615.0,13327,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629568,,9615.0,13328,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629569,,9615.0,13329,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL629570,,9615.0,13330,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL629571,,314293.0,13331,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,8133,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629572,,10116.0,13332,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,12170,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629573,,10116.0,13333,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,12170,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629574,,9347.0,13334,,Bioavailability (dose 20 mg/kg),,4985,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629575,,9615.0,13335,,Bioavailability in dog,,15145,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL874448,,10116.0,13336,,Bioavailability in rat (Sprague-Dawley) (male),,14080,,,BAO_0000218
,,Primates,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629576,,9443.0,13337,,Bioavailability in monkey (dose 10 mg/kg i.d.),,11219,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629577,,10116.0,13338,,Bioavailability in rat,,15145,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629578,,10116.0,13339,,Bioavailability in rat,,15145,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629579,,9615.0,13340,,Bioavailability in dog (dose 3.0 mg/kg p.o.),,1202,,,BAO_0000218
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL882958,,9615.0,13341,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,1202,,,BAO_0000218
,,Pan troglodytes,Intermediate,1,50505,A,N,In vivo,,,1,CHEMBL629580,,9598.0,13342,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,1202,,,BAO_0000218
,,Eutheria,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629581,,9347.0,13343,,Bioavailability,,4026,,,BAO_0000218
,,Saimiri,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629582,,9520.0,13344,,Bioavailability in squirrel monkey,,1492,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628522,,9615.0,13345,,Bioavailability was evaluated in dog,,12793,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,In vivo,,,1,CHEMBL625432,,10026.0,13346,,Bioavailability was evaluated in hamster,,12793,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625433,,10116.0,13347,,Bioavailability in rat,,12793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625434,,10116.0,13348,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,14793,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL625435,,10116.0,13349,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,14793,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625436,,10116.0,13350,,Bioavailability in rat (dose 10 mg/kg p.o.),,14793,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL874588,,9541.0,13351,,Bioavailability was measured in cynomolgus monkeys.,,14731,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625437,,10090.0,13352,,Bioavailability was measured in nude mice.,,14731,,,BAO_0000218
,,Mustela putorius furo,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625438,,9669.0,13353,,Bioavailability in ferret (dose 10 mg/kg i.d.),,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625439,,314293.0,13354,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625440,,314293.0,13355,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,12187,,,BAO_0000218
,,Simiiformes,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625441,,314293.0,13356,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,12187,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625442,,10116.0,13357,,Bioavailability in rat (dose 10 mg/kg i.d.),,12187,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625443,,10116.0,13358,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,12187,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625444,,,13359,,Bioavailability was determined; extremely poor,,17431,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL625445,,10090.0,13360,,% bioavailability in mice after oral administration of prodrug,,13318,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625446,,9615.0,13361,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL882960,,9615.0,13362,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625447,,9615.0,13363,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625448,,9615.0,13364,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625449,,9615.0,13365,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL874589,,9615.0,13366,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625450,,9615.0,13367,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625451,,9615.0,13368,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626584,,9615.0,13369,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626585,,9615.0,13370,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626586,,9615.0,13371,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626587,,9615.0,13372,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626588,,9615.0,13373,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626589,,9615.0,13374,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626590,,9615.0,13375,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL626591,,9615.0,13376,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL627181,,9615.0,13377,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628083,,9615.0,13378,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,9025,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628084,,,13379,,IV clearance determined at an peroral dose of 15 mg/kg.,,15173,,,BAO_0000218
,,Hymenolepis nana,Expert,1,50064,F,N,In vivo,,,1,CHEMBL628085,,102285.0,13380,,Mouse oral clearance was measured against Hymenolepiasis nana.,,7732,,,BAO_0000218
,,Heligmosomoides polygyrus,Expert,1,50545,F,N,In vivo,,,1,CHEMBL628086,,6339.0,13381,,Mouse oral clearance was measured against Nematospiroides dubius,,7732,,,BAO_0000218
,,,Autocuration,1,22224,F,U,In vivo,,,0,CHEMBL628087,,,13382,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,7732,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628088,,10090.0,13383,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,7732,,,BAO_0000218
,,,Autocuration,1,22224,B,U,In vivo,,,0,CHEMBL628089,,,13384,,Mouse oral clearance was measured against N. nana; NT is Not Tested,,7732,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628090,,,13385,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628091,,,13386,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628092,,,13387,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL628093,,,13388,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875607,,,13389,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625710,,,13390,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625711,,,13391,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625712,,,13392,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625713,,,13393,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,8328,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625714,,9615.0,13394,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,13376,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,,1,CHEMBL625715,,9544.0,13395,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625716,,10116.0,13396,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625717,,10116.0,13397,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,13477,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625718,,10116.0,13398,,Plasma clearance was determined for the compound in rats,,13313,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625719,,10116.0,13399,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625720,,10116.0,13400,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625721,,10116.0,13401,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625722,,10116.0,13402,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,12504,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625723,,10116.0,13403,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,13129,,,BAO_0000218
,,Heligmosomoides polygyrus,Intermediate,1,50545,A,N,In vivo,,,1,CHEMBL625724,,6339.0,13404,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,7732,,,BAO_0000218
,,Heligmosomoides polygyrus,Intermediate,1,50545,A,N,In vivo,,,1,CHEMBL625725,,6339.0,13405,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,7732,,,BAO_0000218
,,Heligmosomoides polygyrus,Intermediate,1,50545,A,N,In vivo,,,1,CHEMBL625726,,6339.0,13406,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,7732,,,BAO_0000218
,,Heligmosomoides polygyrus,Intermediate,1,50545,A,N,In vivo,,,1,CHEMBL875608,,6339.0,13407,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,7732,,,BAO_0000218
,,Heligmosomoides polygyrus,Intermediate,1,50545,A,N,In vivo,,,1,CHEMBL625727,,6339.0,13408,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,7732,,,BAO_0000218
,Urine,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,1088.0,0,CHEMBL625728,,10116.0,13409,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,9278,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625729,,10116.0,13410,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,9278,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL625730,,10116.0,13411,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,9278,,,BAO_0000218
,Urine,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,1088.0,0,CHEMBL625731,,10116.0,13412,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,9278,,,BAO_0000218
,Urine,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,1088.0,0,CHEMBL626417,,10116.0,13413,,Urinary clearance was determined in rat at 25 mg/kg os dosage,,9278,,,BAO_0000218
,Urine,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,1088.0,1,CHEMBL626418,,9606.0,13414,,Urinary clearance was determined at 100 mg/kg oral dosage in human,,9278,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1088.0,1,CHEMBL626419,,9615.0,13415,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,9278,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626592,,9615.0,13416,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,5932,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL626593,,10116.0,13417,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,5932,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626594,,10116.0,13418,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,5182,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625035,,9615.0,13419,,Clearance rate in dogs,,10499,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vitro,,,0,CHEMBL625036,,,13420,,Compound was measured for intrinsic clearance,,6051,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625037,,,13421,,Calculated partition coefficient (clogP),,17508,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625038,,,13422,,Calculated partition coefficient (clogP),,6228,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625039,,,13423,,Calculated partition coefficient (clogP),,6231,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625040,,,13424,,Calculated partition coefficient (clogP),,17740,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625041,,,13425,,Calculated partition coefficient (clogP),,6495,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625042,,,13426,,Calculated partition coefficient (clogP),,2171,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874411,,,13427,,Partition coefficient of the compound,,3255,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625043,,,13428,,Permeability,,6821,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625044,,,13429,,Calculated partition coefficient (clogP),,2685,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625045,,,13430,,Partition coefficient (logD),,17584,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625046,,,13431,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,13824,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625047,,,13432,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,13824,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625048,,,13433,,Calculated partition coefficient (clogP),,16479,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625049,,,13434,,Calculated partition coefficient (clogP),,11997,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625050,,,13435,,Calculated logarithm of partition coefficient (P) was determined,,2988,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625051,,,13436,,Calculated partition coefficient (clogP),,931,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL874412,,,13437,,Calculated partition coefficient (clogP),,4381,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625052,,,13438,,Calculated partition coefficient (clogP),,4397,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL625053,,,13439,,Calculated partition coefficient (clogP),,5889,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623250,,,13440,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623251,,,13441,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623252,,,13442,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623253,,,13443,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623254,,,13444,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623255,,,13445,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,6154,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626831,,,13446,,Percent degradation of compound at a pH of 1 over a 18 hr period,,6887,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL877494,,,13447,,Percent degradation of compound at pH of 1 over an 18 hr period,,6887,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626832,,,13448,,Delta Logarithm of Partition Coefficient value was determined.,,14116,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626833,,,13449,,Delta logPoct-cyc,,11137,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL626834,,,13450,,Lipophilicity estimated on reversed phase TLC,,7230,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626835,,,13451,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,15741,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626836,,,13452,,Delta logPoct-cyc,,9663,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626837,,,13453,,Change in logarithm of partition coefficient of the compound,,9663,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626838,,,13454,,Delta logD (pH 6.5),,13807,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL626839,,,13455,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,13807,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626840,,,13456,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,17425,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626841,,,13457,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,12143,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626842,,,13458,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,12608,,,BAO_0000219
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626843,,,13459,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,12608,,,BAO_0000219
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626844,,10116.0,13460,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL877495,,10116.0,13461,,Amount of deuterium retained was reported after normal workup in rats,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626845,,10116.0,13462,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626846,,10116.0,13463,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626847,,10116.0,13464,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628677,,10116.0,13465,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,8649,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628678,,10116.0,13466,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,8649,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628679,,,13467,,Compound was subjected to electrochemical oxidation,,9659,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628680,,,13468,,Compound was subjected to photochemical oxidation,,9659,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628681,,,13469,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,9659,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628682,,,13470,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,9659,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628683,,,13471,,Oxidation of compound by methemoglobin in presence of hydroperoxide,,9659,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628684,,10116.0,13472,,Percent diffusion through fuzzy rat skin after 48 h of incubation,,9607,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL877501,,,13473,,Dissociation constant (pKa),,7057,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL628685,,,13474,,Dissociation constant value of the compound; ND means not determined.,,7057,,,BAO_0000100
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628686,,10116.0,13475,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL628687,,10116.0,13476,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628688,,10116.0,13477,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628689,,10116.0,13478,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL628690,,10116.0,13479,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL629363,,10116.0,13480,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL629364,,10116.0,13481,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,,,2106.0,1,CHEMBL629365,,10116.0,13482,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629366,,10116.0,13483,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629367,,10116.0,13484,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,7911,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL629368,,10116.0,13485,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL877502,,10116.0,13486,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,7911,,,BAO_0000218
,Cerebellum,Mus musculus,Intermediate,1,50594,A,N,,,2037.0,1,CHEMBL629369,,10090.0,13487,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL629370,,10090.0,13488,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,13792,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL629371,,314293.0,13489,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL626276,,314293.0,13490,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL626277,,314293.0,13491,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL631250,,314293.0,13492,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631251,,10116.0,13493,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631252,,10116.0,13494,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631253,,10116.0,13495,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631254,,10116.0,13496,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631255,,10116.0,13497,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631256,,10116.0,13498,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631257,,10116.0,13499,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628009,,10116.0,13500,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628010,,10116.0,13501,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628011,,10116.0,13502,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628012,,10116.0,13503,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628013,,10116.0,13504,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628014,,10116.0,13505,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628015,,9615.0,13506,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628016,,9615.0,13507,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL874461,,9615.0,13508,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628017,,9615.0,13509,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628018,,9615.0,13510,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628019,,9615.0,13511,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628020,,9615.0,13512,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628021,,9615.0,13513,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628022,,9615.0,13514,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,8133,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL628023,,9615.0,13515,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL628024,,314293.0,13516,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL628025,,314293.0,13517,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL628026,,314293.0,13518,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL628027,,314293.0,13519,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,8133,,,BAO_0000218
,Urine,Simiiformes,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL628028,,314293.0,13520,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628029,,10116.0,13521,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628030,,10116.0,13522,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628031,,10116.0,13523,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628032,,10116.0,13524,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628033,,10116.0,13525,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628034,,10116.0,13526,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628035,,10116.0,13527,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628036,,10116.0,13528,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL874462,,10116.0,13529,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,8133,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628037,,9615.0,13530,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628123,,9615.0,13531,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628124,,9615.0,13532,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628125,,9615.0,13533,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628126,,9615.0,13534,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628127,,9615.0,13535,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628128,,9615.0,13536,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628129,,9615.0,13537,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628130,,9615.0,13538,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628131,,9615.0,13539,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628132,,9615.0,13540,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628133,,9615.0,13541,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628134,,9615.0,13542,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628135,,9615.0,13543,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628136,,9615.0,13544,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628137,,9615.0,13545,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628138,,9615.0,13546,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628139,,9615.0,13547,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628140,,9615.0,13548,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628141,,9615.0,13549,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628142,,9615.0,13550,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628143,,9615.0,13551,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628144,,9615.0,13552,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628145,,9615.0,13553,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL628146,,9615.0,13554,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625355,,9615.0,13555,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625356,,9615.0,13556,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625357,,9615.0,13557,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625527,,9615.0,13558,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL875473,,9615.0,13559,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,9025,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL625528,,9615.0,13560,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,9025,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626304,,10116.0,13561,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,9025,,,BAO_0000218
,Artery,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1637.0,1,CHEMBL624138,,9615.0,13562,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,9025,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624139,,,13563,,Calculated partition coefficient (clogP),,6448,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624140,,,13564,,Calculated partition coefficient (clogP),,17221,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624141,,,13565,,Calculated partition coefficient (clogP),,6545,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624142,,,13566,,Calculated partition coefficient (clogP),,577,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624143,,,13567,,Calculated partition coefficient (clogP),,6285,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624144,,,13568,,Calculated partition coefficient (clogP),,6500,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624145,,,13569,,Calculated partition coefficient (clogP),,6716,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624146,,,13570,,Calculated partition coefficient (clogP),,13658,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624147,,,13571,,Calculated partition coefficient (clogP),,6549,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL883123,,,13572,,Calculated partition coefficient (clogP) (MacLogP),,14685,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624148,,,13573,,Partition coefficient (logP),,6893,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874416,,,13574,,Kinetic parameter was determined,,3687,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624149,,,13575,,Calculated partition coefficient (clogP),,4207,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624150,,,13576,,Calculated partition coefficient (clogP),,4626,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL624151,,,13577,,Lipophilicity was determined,,1021,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL624152,,,13578,,Lipophilicity was determined,,3777,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL622139,,,13579,,Lipophilicity was determined,,17533,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622140,,,13580,,Calculated partition coefficient (clogP),,6524,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL622141,,,13581,,Lipophilicity was determined,,17533,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL622142,,,13582,,Lipophilicity in octanol-water,,6480,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622143,,,13583,,Calculated partition coefficient (clogP),,17606,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622144,,,13584,,Octanol-water partition coefficient was determined,,6863,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL877473,,,13585,,Partition coefficient (logP),,1356,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622145,,,13586,,Calculated partition coefficient (clogP),,3326,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622146,,,13587,,Partition coefficient was determined; ND means not determined,,1356,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622147,,,13588,,Calculated partition coefficient (clogP),,12984,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622148,,,13589,,Partition coefficient of the compound,,17363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL883124,,,13590,,Permeability was determined,,6827,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622149,,,13591,,The compound was evaluated for the partition coefficient,,261,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622150,,,13592,,Partition coefficient (logP),,2685,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL622151,,,13593,,The lipophilicity was reported,,414,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL622152,,,13594,,logarithm of the octanol-water partition coefficient for the compound,,15769,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL622153,,,13595,,Clogp value was determined,,17248,,,BAO_0000019
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL877474,,,13596,,Clp at a dose of 1.5 mg/kg,,16935,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622154,,,13597,,Clp at a dose of 2.0 mg/kg,,16935,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL622155,,,13598,,"Clp, plasma clearance at a dose of 10 mg/kg",,14832,,,BAO_0000218
,Plasma,,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL622156,,,13599,,"Clp, plasma clearance at a dose of 50 mg/kg",,14832,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622157,,10116.0,13600,,Compound was tested for plasma clearance in rat,,2399,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622158,,10116.0,13601,,Compound was tested for plasma clearance in rat; Not determined,,2399,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622807,,10116.0,13602,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,6227,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,,1,CHEMBL622808,,9544.0,13603,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,6227,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622809,,,13604,,Plasma clearance by iv administration at a dose 0.003 ug/mL,,5623,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622810,,,13605,,Plasma clearance determined,,4854,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,In vivo,,,1,CHEMBL876653,,10026.0,13606,,Plasma clearance after iv administration at 3 mg/kg in hamster,,4493,,,BAO_0000218
,,Cricetinae,Intermediate,1,100712,A,N,In vivo,,,1,CHEMBL622811,,10026.0,13607,,Plasma clearance after iv administration at 4 mg/kg in hamster,,4493,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622986,,10116.0,13608,,Rate of clearance in rat was determined,,14956,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622987,,10116.0,13609,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622988,,10116.0,13610,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622989,,10116.0,13611,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622990,,10116.0,13612,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,15372,,,BAO_0000218
,Plasma,Simiiformes,Autocuration,1,22224,A,U,In vivo,,1969.0,0,CHEMBL622991,,314293.0,13613,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,15604,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1969.0,1,CHEMBL622227,,10116.0,13614,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,15604,,,BAO_0000218
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL622228,,9615.0,13615,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,15604,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622229,,10116.0,13616,,Clpl value in rat,,14964,,,BAO_0000218
,,Cavia porcellus,Intermediate,1,50512,A,N,In vivo,,,1,CHEMBL622230,,10141.0,13617,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,15240,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL622231,,10116.0,13618,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,16449,,,BAO_0000218
,,Macaca fascicularis,Intermediate,1,100710,A,N,In vivo,,,1,CHEMBL622232,,9541.0,13619,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,16449,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622233,,,13620,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622234,,,13621,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622235,,,13622,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622236,,,13623,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622237,,,13624,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL877482,,,13625,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622238,,,13626,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,12902,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL622239,,,13627,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,12902,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL622240,,,13628,,Cmax was calculated as maximum concentration reached in the blood,,11149,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL622241,,,13629,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,11149,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631013,,10116.0,13630,,Cmax was determine after peroral administration at 10 mpk in Rat,,5669,,,BAO_0000218
,,Macaca mulatta,Intermediate,1,50797,A,N,In vivo,,,1,CHEMBL631014,,9544.0,13631,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,5669,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,,1,CHEMBL631015,,9615.0,13632,,Cmax was determine after peroral administration at 10 mpk in dog,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631016,,10116.0,13633,,Cmax was determine after peroral administration at 160 mpk in Rat,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631017,,10116.0,13634,,Cmax was determine after peroral administration at 20 mpk in Rat,,5669,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631018,,10116.0,13635,,Cmax was determine after peroral administration at 50 mpk in Rat,,5669,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL631019,,,13636,,Cmax was determined,,4236,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL875761,,10090.0,13637,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL631020,,10090.0,13638,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL631669,,10090.0,13639,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,13792,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL631670,,10090.0,13640,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,13792,,,BAO_0000218
,Striatum,Mus musculus,Intermediate,1,50594,A,N,,,2435.0,1,CHEMBL631671,,10090.0,13641,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,13792,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631672,,10116.0,13642,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631673,,10116.0,13643,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631856,,10116.0,13644,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631857,,10116.0,13645,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631858,,10116.0,13646,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631859,,10116.0,13647,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631860,,10116.0,13648,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631861,,10116.0,13649,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631862,,10116.0,13650,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631863,,10116.0,13651,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631864,,10116.0,13652,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631865,,10116.0,13653,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL631866,,10116.0,13654,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629360,,10116.0,13655,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629361,,10116.0,13656,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL629362,,10116.0,13657,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL630740,,10116.0,13658,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL630741,,10116.0,13659,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,8418,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,,,178.0,1,CHEMBL630742,,10116.0,13660,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630743,,10116.0,13661,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630744,,10116.0,13662,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630745,,10116.0,13663,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630746,,10116.0,13664,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630747,,10116.0,13665,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630748,,10116.0,13666,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632056,,10116.0,13667,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632057,,10116.0,13668,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632058,,10116.0,13669,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632059,,10116.0,13670,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632060,,10116.0,13671,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632061,,10116.0,13672,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629207,,10116.0,13673,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629208,,10116.0,13674,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629209,,10116.0,13675,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629210,,10116.0,13676,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629211,,10116.0,13677,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629212,,10116.0,13678,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,8418,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629213,,10116.0,13679,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,8418,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629214,,10116.0,13680,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629215,,10116.0,13681,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,8133,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL635154,,10116.0,13682,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,8133,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629216,,10116.0,13683,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629217,,10116.0,13684,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629218,,10116.0,13685,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629219,,10116.0,13686,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629220,,10116.0,13687,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629221,,10116.0,13688,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631127,,10116.0,13689,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631128,,10116.0,13690,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631129,,10116.0,13691,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631130,,10116.0,13692,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631131,,10116.0,13693,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631132,,10116.0,13694,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631133,,10116.0,13695,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631134,,10116.0,13696,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875120,,10116.0,13697,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631135,,10116.0,13698,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631136,,10116.0,13699,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631137,,10116.0,13700,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631138,,10116.0,13701,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631139,,10116.0,13702,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631140,,10116.0,13703,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631141,,10116.0,13704,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631142,,10116.0,13705,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631143,,10116.0,13706,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,6996,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631144,,10116.0,13707,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631145,,9615.0,13708,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631146,,9615.0,13709,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631147,,9615.0,13710,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631148,,9615.0,13711,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631149,,9615.0,13712,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631150,,9615.0,13713,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631151,,9615.0,13714,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631152,,9615.0,13715,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631443,,9615.0,13716,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631444,,9615.0,13717,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631445,,9615.0,13718,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631446,,9615.0,13719,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631447,,9615.0,13720,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631448,,9615.0,13721,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631449,,9615.0,13722,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL631450,,9615.0,13723,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,6996,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629724,,9615.0,13724,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,6996,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL629725,,10090.0,13725,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Zone of skin,Mus musculus,Intermediate,1,50594,A,N,In vivo,,14.0,1,CHEMBL629726,,10090.0,13726,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL629727,,10090.0,13727,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL630404,,10090.0,13728,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL630405,,10090.0,13729,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL630406,,10090.0,13730,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL630407,,10090.0,13731,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL630573,,10090.0,13732,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL630574,,10090.0,13733,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,In vivo,,945.0,1,CHEMBL630575,,10090.0,13734,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL630576,,10090.0,13735,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL630577,,10090.0,13736,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL630578,,10090.0,13737,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL630579,,10090.0,13738,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,9716,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL630580,,10090.0,13739,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,12192,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL630581,,10090.0,13740,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,12192,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,,,2113.0,1,CHEMBL630582,,10090.0,13741,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630583,,10090.0,13742,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630584,,10090.0,13743,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630585,,10090.0,13744,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630586,,10090.0,13745,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630587,,10090.0,13746,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630588,,10090.0,13747,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630589,,10090.0,13748,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,12192,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL630590,,10090.0,13749,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,12192,,,BAO_0000218
,Feces,,Autocuration,1,22224,A,U,,,1988.0,0,CHEMBL630591,,,13750,,Removal of 238-Plutonium(IV) in feces at 24 h,,12192,,,BAO_0000019
,Feces,,Autocuration,1,22224,A,U,,,1988.0,0,CHEMBL630592,,,13751,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,12192,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630593,,,13752,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,12192,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630594,,,13753,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630595,,,13754,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630596,,,13755,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630597,,,13756,,Removal of 238-Plutonium(IV) in urine after 0-24 h,,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630598,,,13757,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630599,,,13758,,Removal of 238-Plutonium(IV) in urine after 0-4 h,,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630600,,,13759,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630601,,,13760,,Removal of 238-Plutonium(IV) in urine after 4-24 h,,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630602,,,13761,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630603,,,13762,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,12192,,,BAO_0000019
,Urine,,Autocuration,1,22224,A,U,,,1088.0,0,CHEMBL630604,,,13763,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,12192,,,BAO_0000019
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624869,,10116.0,13764,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL624870,,10116.0,13765,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623189,,10116.0,13766,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623190,,10116.0,13767,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623191,,10116.0,13768,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623192,,10116.0,13769,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623193,,10116.0,13770,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623194,,10116.0,13771,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623195,,10116.0,13772,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623196,,10116.0,13773,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623197,,10116.0,13774,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,11836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623198,,10116.0,13775,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623199,,10116.0,13776,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623200,,10116.0,13777,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623201,,10116.0,13778,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623202,,10116.0,13779,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623203,,10116.0,13780,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623204,,10116.0,13781,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623205,,10116.0,13782,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623206,,10116.0,13783,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623207,,10116.0,13784,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623208,,10116.0,13785,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623209,,10116.0,13786,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL623210,,10116.0,13787,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,11836,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL623211,,10116.0,13788,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,,,995.0,1,CHEMBL623212,,10116.0,13789,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,11836,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623213,,,13790,,Tested in vitro for intrinsic activity relative to quinpirole,,12640,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623214,,,13791,,"Relative ion enhancement, determined in pulsed ultrafiltration",,14218,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623215,,,13792,,% ionization at the pH 7.4 at 37 degree Centigrade,,11296,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623216,,,13793,,Percentage ionization was measured,,10929,,,BAO_0000019
,,Bos taurus,Intermediate,1,50591,A,N,,,,1,CHEMBL623217,,9913.0,13794,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,13841,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623218,,,13795,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,10431,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623913,,,13796,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,10431,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL623914,,,13797,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,10431,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL623915,,,13798,,Compound was evaluated for the partition coefficient in octanol/water,,8826,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL624080,,,13799,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,8826,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL624081,,,13800,,Equilibrium constant measured by the pulse radiolysis at pH 7,,9884,,,BAO_0000019
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL624082,,9606.0,13801,,In vitro hydrolytic rate constant determined in human blood,,9827,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL625054,,9606.0,13802,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,10009,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL877485,,,13803,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,10009,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625055,,10090.0,13804,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625056,,10090.0,13805,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,10009,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL625057,,9606.0,13806,,In vitro oxidation of compound in presence of human plasma,,10009,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625058,,,13807,,In vitro oxidation of compound in presence of hydrogen peroxide,,10009,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625059,,10090.0,13808,,In vitro oxidation of compound in presence of mouse brain homogenate,,10009,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629536,,10090.0,13809,,In vitro oxidation of compound in presence of mouse liver homogenate,,10009,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629537,,10116.0,13810,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629538,,10116.0,13811,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629539,,10116.0,13812,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL874445,,10116.0,13813,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629540,,10116.0,13814,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629541,,10116.0,13815,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629542,,10116.0,13816,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630243,,10116.0,13817,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630244,,10116.0,13818,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630245,,10116.0,13819,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630246,,10116.0,13820,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630247,,10116.0,13821,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630248,,10116.0,13822,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,11510,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL630249,,10116.0,13823,,Biodistribution in rat blood at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL630250,,10116.0,13824,,Biodistribution in rat blood at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL630251,,10116.0,13825,,Biodistribution in rat blood at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL630252,,10116.0,13826,,Biodistribution in rat blood at 3 hr after dose administration.,,13100,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL630408,,10116.0,13827,,Biodistribution in rat blood at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630409,,10116.0,13828,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL874446,,10116.0,13829,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630410,,10116.0,13830,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630411,,10116.0,13831,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630412,,10116.0,13832,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630413,,10116.0,13833,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630414,,10116.0,13834,,Biodistribution in rat cerebellum at 3 hr after dose administration.,,13100,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL630415,,10116.0,13835,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630416,,10116.0,13836,,Biodistribution in rat cortex at 120 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630417,,10116.0,13837,,Biodistribution in rat cortex at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630418,,10116.0,13838,,Biodistribution in rat cortex at 15 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630419,,10116.0,13839,,Biodistribution in rat cortex at 240 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630420,,10116.0,13840,,Biodistribution in rat cortex at 30 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630421,,10116.0,13841,,Biodistribution in rat cortex at 360 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630422,,10116.0,13842,,Biodistribution in rat cortex at 3 hr after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630423,,10116.0,13843,,Biodistribution in rat cortex at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL630424,,10116.0,13844,,Biodistribution in rat heart at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL630425,,10116.0,13845,,Biodistribution in rat heart at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL629462,,10116.0,13846,,Biodistribution in rat heart at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL630426,,10116.0,13847,,Biodistribution in rat heart at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL630427,,10116.0,13848,,Biodistribution in rat heart at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625877,,10116.0,13849,,Biodistribution in rat heart at 3 hr after dose administration.,,13100,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625878,,10116.0,13850,,Biodistribution in rat heart at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625879,,10116.0,13851,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625880,,10116.0,13852,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625881,,10116.0,13853,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625882,,10116.0,13854,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625883,,10116.0,13855,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625884,,10116.0,13856,,Biodistribution in rat kidney at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625885,,10116.0,13857,,Biodistribution in rat kidney at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628649,,10116.0,13858,,Biodistribution in rat kidney at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628650,,10116.0,13859,,Biodistribution in rat kidney at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628651,,10116.0,13860,,Biodistribution in rat kidney at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628652,,10116.0,13861,,Biodistribution in rat kidney at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL628653,,10116.0,13862,,Biodistribution in rat kidney at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL628654,,10116.0,13863,,Biodistribution in rat liver at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL628655,,10116.0,13864,,Biodistribution in rat liver at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625238,,10116.0,13865,,Biodistribution in rat liver at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625239,,10116.0,13866,,Biodistribution in rat liver at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625240,,10116.0,13867,,Biodistribution in rat liver at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625241,,10116.0,13868,,Biodistribution in rat liver at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625242,,10116.0,13869,,Biodistribution in rat liver at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL874587,,10116.0,13870,,Biodistribution in rat lung at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625405,,10116.0,13871,,Biodistribution in rat lung at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625406,,10116.0,13872,,Biodistribution in rat lung at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625407,,10116.0,13873,,Biodistribution in rat lung at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625408,,10116.0,13874,,Biodistribution in rat lung at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625409,,10116.0,13875,,Biodistribution in rat lung at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625410,,10116.0,13876,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625411,,10116.0,13877,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625412,,10116.0,13878,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625413,,10116.0,13879,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625414,,10116.0,13880,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625415,,10116.0,13881,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,12361,,,BAO_0000218
,Thoracic aorta,Rattus norvegicus,Intermediate,1,50597,A,N,,,1515.0,1,CHEMBL625416,,10116.0,13882,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,12361,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625417,,10116.0,13883,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,12712,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL625418,,10116.0,13884,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,7415,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625419,,10116.0,13885,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,7415,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625420,,10116.0,13886,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,7415,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626996,,10116.0,13887,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,7415,,,BAO_0000218
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL626997,,10116.0,13888,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,7415,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626998,,10116.0,13889,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,7415,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626999,,10116.0,13890,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,7415,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627000,,10090.0,13891,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,8050,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627001,,10090.0,13892,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,8050,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627002,,10090.0,13893,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,8050,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627003,,10090.0,13894,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627004,,10090.0,13895,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627005,,10090.0,13896,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL874594,,10090.0,13897,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627006,,10090.0,13898,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627007,,10090.0,13899,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627884,,10090.0,13900,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627885,,10090.0,13901,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627886,,10090.0,13902,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627887,,10090.0,13903,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627888,,10090.0,13904,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL628057,,10090.0,13905,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,8050,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627405,,10090.0,13906,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,8050,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627406,,9615.0,13907,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627407,,9615.0,13908,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627408,,9615.0,13909,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627409,,9615.0,13910,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL875486,,9615.0,13911,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627410,,9615.0,13912,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627411,,9615.0,13913,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627412,,9615.0,13914,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627413,,9615.0,13915,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627414,,9615.0,13916,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627415,,9615.0,13917,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627416,,9615.0,13918,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627417,,9615.0,13919,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627418,,9615.0,13920,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627419,,9615.0,13921,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627320,,9615.0,13922,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627321,,9615.0,13923,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,12582,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627322,,10116.0,13924,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627323,,10116.0,13925,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627491,,10116.0,13926,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627492,,10116.0,13927,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL627493,,10116.0,13928,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627494,,10116.0,13929,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627495,,10116.0,13930,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627496,,10116.0,13931,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627497,,10116.0,13932,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL627498,,10116.0,13933,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627499,,10116.0,13934,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627500,,10116.0,13935,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627501,,10116.0,13936,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625616,,10116.0,13937,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625617,,10116.0,13938,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625618,,10116.0,13939,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625619,,10116.0,13940,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625620,,10116.0,13941,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625621,,10116.0,13942,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625622,,10116.0,13943,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625788,,10116.0,13944,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625789,,10116.0,13945,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625790,,10116.0,13946,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625791,,10116.0,13947,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL622334,,10116.0,13948,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622335,,10116.0,13949,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622336,,10116.0,13950,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622337,,10116.0,13951,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622338,,10116.0,13952,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL622339,,10116.0,13953,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL624153,,10116.0,13954,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628430,,10116.0,13955,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628431,,10116.0,13956,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628432,,10116.0,13957,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628433,,10116.0,13958,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL628434,,10116.0,13959,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL626789,,10116.0,13960,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL626790,,10116.0,13961,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL626791,,10116.0,13962,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL626792,,10116.0,13963,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL626793,,10116.0,13964,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627436,,10116.0,13965,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627437,,10116.0,13966,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627438,,10116.0,13967,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627439,,10116.0,13968,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627440,,10116.0,13969,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627602,,10116.0,13970,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627603,,10116.0,13971,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627604,,10116.0,13972,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627605,,10116.0,13973,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627606,,10116.0,13974,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627607,,10116.0,13975,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627608,,10116.0,13976,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627609,,10116.0,13977,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627610,,10116.0,13978,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627611,,10116.0,13979,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL627612,,10116.0,13980,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,11510,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL627613,,,13981,,Octanol:water partition coefficient is evaluated,,8362,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL627614,,,13982,,Partition coefficient in 1-octanol/water system,,8257,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL627615,,,13983,,Partition coefficient in 1-octanol/water system measured using radio active compounds,,8257,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL627616,,,13984,,Partition coefficient in octanol/water system was determined,,9468,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL627617,,,13985,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,9468,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627618,,,13986,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,10568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627619,,,13987,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,10568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627620,,,13988,,Pseudo-first-order rate constant of the compound,,15359,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627621,,,13989,,Pseudo-first-order rate constant with 1-min time point,,15359,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627622,,,13990,,Pseudo-first-order rate constant without 1-min time point,,15359,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627623,,,13991,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,10431,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627624,,,13992,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,10431,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627625,,,13993,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,10431,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628523,,,13994,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,15704,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628524,,,13995,,The alkaline hydrolysis second order rate constant(K OH) of the compound,,15287,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628525,,,13996,,The efflux rate constant of the compound,,7516,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625732,,,13997,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,12973,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625733,,,13998,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,12973,,,BAO_0000019
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL625734,,,13999,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,12973,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625913,,,14000,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,12973,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625914,,,14001,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,8696,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625915,,,14002,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,15052,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625916,,,14003,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,15052,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625917,,,14004,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,10503,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625918,,,14005,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625919,,,14006,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625920,,,14007,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874453,,,14008,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625921,,,14009,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625922,,,14010,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,10503,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625923,,,14011,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625924,,,14012,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625925,,,14013,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625926,,,14014,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL627704,,10116.0,14015,,Biodistribution in rat lung at 60 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627705,,10116.0,14016,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627706,,10116.0,14017,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627707,,10116.0,14018,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627708,,10116.0,14019,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628361,,10116.0,14020,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,13100,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628362,,10116.0,14021,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628363,,10116.0,14022,,Biodistribution in rat striatum at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628364,,10116.0,14023,,Biodistribution in rat striatum at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628365,,10116.0,14024,,Biodistribution in rat striatum at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL874454,,10116.0,14025,,Biodistribution in rat striatum at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628531,,10116.0,14026,,Biodistribution in rat striatum at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628532,,10116.0,14027,,Biodistribution in rat striatum at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628533,,10116.0,14028,,Biodistribution in rat striatum at 3 hr after dose administration.,,13100,,,BAO_0000218
,Striatum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2435.0,1,CHEMBL628534,,10116.0,14029,,Biodistribution in rat striatum at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL628535,,10116.0,14030,,Biodistribution in rat thyroid at 120 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL628536,,10116.0,14031,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL628537,,10116.0,14032,,Biodistribution in rat thyroid at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL628538,,10116.0,14033,,Biodistribution in rat thyroid at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL628539,,10116.0,14034,,Biodistribution in rat thyroid at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL630297,,10116.0,14035,,Biodistribution in rat thyroid at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL630298,,10116.0,14036,,Biodistribution in rat thyroid at 60 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL630299,,10116.0,14037,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL628094,,10116.0,14038,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL628095,,10116.0,14039,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL874648,,10116.0,14040,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL628096,,10116.0,14041,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL628097,,10116.0,14042,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,13100,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL628098,,10116.0,14043,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,13100,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628099,,,14044,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628100,,,14045,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628101,,,14046,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628102,,,14047,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628103,,,14048,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628104,,,14049,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628105,,,14050,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,13331,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628106,,,14051,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,13331,,,BAO_0000019
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628107,,10116.0,14052,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,10086,,,BAO_0000218
,Urine,,Autocuration,1,22224,F,U,,,1088.0,0,CHEMBL628108,,,14053,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,10086,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628109,,10116.0,14054,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,10086,,,BAO_0000218
,Urine,,Autocuration,1,22224,F,U,,,1088.0,0,CHEMBL625299,,,14055,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,10086,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625300,,10116.0,14056,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,10086,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625301,,10116.0,14057,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,10086,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625302,,10116.0,14058,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,10086,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL874649,,10116.0,14059,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,10086,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625303,,10116.0,14060,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,13248,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625463,,10116.0,14061,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,13248,,,BAO_0000218
,Liver,Homo sapiens,Intermediate,1,50587,A,N,,,2107.0,1,CHEMBL625464,,9606.0,14062,,In vitro metabolism in human liver microsomes,,14527,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL625465,,9606.0,14063,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,3008,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625466,,9615.0,14064,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625467,,9615.0,14065,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625468,,10116.0,14066,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625469,,10116.0,14067,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625470,,10116.0,14068,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL632418,,10116.0,14069,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627250,,10116.0,14070,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627251,,10116.0,14071,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627252,,10116.0,14072,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627253,,10116.0,14073,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627254,,10116.0,14074,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875471,,10116.0,14075,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627255,,10116.0,14076,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627256,,10116.0,14077,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627257,,10116.0,14078,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627258,,10116.0,14079,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627259,,10116.0,14080,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627260,,10116.0,14081,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623256,,10116.0,14082,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL874413,,10116.0,14083,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623257,,10116.0,14084,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623258,,10116.0,14085,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623259,,10116.0,14086,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623260,,10116.0,14087,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623261,,10116.0,14088,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623262,,10116.0,14089,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623263,,10116.0,14090,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623264,,10116.0,14091,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623265,,10116.0,14092,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623266,,10116.0,14093,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623267,,10116.0,14094,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623268,,10116.0,14095,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623269,,10116.0,14096,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623270,,10116.0,14097,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623271,,10116.0,14098,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623272,,10116.0,14099,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623273,,10116.0,14100,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623274,,10116.0,14101,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL874414,,10116.0,14102,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623275,,10116.0,14103,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629150,,10116.0,14104,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623276,,10116.0,14105,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623277,,10116.0,14106,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623112,,10116.0,14107,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623113,,10116.0,14108,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623800,,10116.0,14109,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623801,,10116.0,14110,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,12582,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL623802,,10116.0,14111,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,12017,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL623803,,10116.0,14112,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL623970,,10116.0,14113,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Uterus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,995.0,1,CHEMBL623971,,10116.0,14114,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623972,,10116.0,14115,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623973,,10116.0,14116,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623974,,10116.0,14117,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL623975,,10116.0,14118,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623976,,10116.0,14119,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623977,,10116.0,14120,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623978,,10116.0,14121,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL623979,,10116.0,14122,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623980,,10116.0,14123,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL623981,,10116.0,14124,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626278,,10116.0,14125,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626279,,10116.0,14126,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL626280,,10090.0,14127,,Biodistribution in mice bladder plus excreted urine was determined,,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626281,,10090.0,14128,,"Percentage biodistribution in mouse blood, 10 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626282,,10090.0,14129,,"Percentage biodistribution in mouse blood, 30 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626283,,10090.0,14130,,"Percentage biodistribution in mouse blood, 5 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626284,,10090.0,14131,,"Percentage biodistribution in mouse blood, 60 minutes post injection",,14045,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL626285,,10090.0,14132,,"Percentage biodistribution in mouse brain, 10 minutes post injection",,14045,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL626286,,10090.0,14133,,"Percentage biodistribution in mouse brain, 30 minutes post injection",,14045,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL626287,,10090.0,14134,,"Percentage biodistribution in mouse brain, 5 minutes post injection",,14045,,,BAO_0000218
,Brain,Mus musculus,Intermediate,1,50594,A,N,,,955.0,1,CHEMBL626288,,10090.0,14135,,"Percentage biodistribution in mouse brain, 60 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626289,,10090.0,14136,,"Percentage biodistribution in mouse heart, 10 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626290,,10090.0,14137,,"Percentage biodistribution in mouse heart, 30 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL626291,,10090.0,14138,,"Percentage biodistribution in mouse heart, 5 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL839888,,10090.0,14139,,"Percentage biodistribution in mouse heart, 60 minutes post injection",,14045,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,,,160.0,1,CHEMBL626292,,10090.0,14140,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,14045,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,,,160.0,1,CHEMBL626293,,10090.0,14141,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,14045,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,,,160.0,1,CHEMBL626294,,10090.0,14142,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,14045,,,BAO_0000218
,Intestine,Mus musculus,Intermediate,1,50594,A,N,,,160.0,1,CHEMBL626295,,10090.0,14143,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,14045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL627659,,10090.0,14144,,"Percentage biodistribution in mouse liver, 10 minutes post injection",,14045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL627660,,10090.0,14145,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,14045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,,,2107.0,1,CHEMBL627661,,10090.0,14146,,"Percentage biodistribution in mouse liver, 5 minutes post injection",,14045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL627662,,10090.0,14147,,Biodistribution in mice liver at 60 minutes of post injection,,14045,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL627663,,10090.0,14148,,Biodistribution in mice lungs at 10 min of post injection,,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627664,,10090.0,14149,,"Percentage biodistribution in mouse lung, 30 minutes post injection",,14045,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL627665,,10090.0,14150,,"Percentage biodistribution in mousee lung, 5 minutes post injection",,14045,,,BAO_0000218
,Lung,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2048.0,1,CHEMBL627666,,10090.0,14151,,Biodistribution in mice lungs at 60 min of post injection,,14045,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,,,2106.0,1,CHEMBL627667,,10090.0,14152,,Percentage biodistribution in mouse spleen,,14045,,,BAO_0000218
,Stomach,Mus musculus,Intermediate,1,50594,A,N,,,945.0,1,CHEMBL627668,,10090.0,14153,,Percentage biodistribution in mouse stomach,,14045,,,BAO_0000218
,Urine,Mus musculus,Intermediate,1,50594,A,N,,,1088.0,1,CHEMBL627669,,10090.0,14154,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,11745,,,BAO_0000218
,Urinary bladder,,Autocuration,1,22224,A,U,In vivo,,1255.0,0,CHEMBL627670,,,14155,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,13257,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL627671,,,14156,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,13257,,,BAO_0000218
,Bone element,,Autocuration,1,22224,A,U,In vivo,,1474.0,0,CHEMBL627672,,,14157,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627673,,,14158,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,13257,,,BAO_0000218
,Kidney,,Autocuration,1,22224,A,U,In vivo,,2113.0,0,CHEMBL627674,,,14159,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,13257,,,BAO_0000218
,Liver,,Autocuration,1,22224,A,U,In vivo,,2107.0,0,CHEMBL627675,,,14160,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,13257,,,BAO_0000218
,Lung,,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL627676,,,14161,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627677,,,14162,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627678,,,14163,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL627679,,10116.0,14164,,Affinity for protein binding expressed as association constant in fresh rat serum,,7095,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627680,,,14165,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,12185,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627681,,,14166,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,12185,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627682,,,14167,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,12185,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627683,,,14168,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,12185,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627684,,,14169,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,12686,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874441,,,14170,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,12686,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627685,,,14171,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,12686,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627686,,,14172,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,12686,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627687,,,14173,,Apparent rate constant Koff for inactivation of dTMP synthase.,,8057,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627688,,,14174,,The irreversible inhibitor activity by second order rate equation.,,15778,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628038,,10116.0,14175,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,12375,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628039,,10116.0,14176,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,12375,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628040,,10116.0,14177,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,12375,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628041,,,14178,,Dissociation rate calculated from the first-order equation using t1/2 value,,13588,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630226,,,14179,,The compound was tested for Binding constant against DNA,,15039,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628042,,,14180,,First order rate constant for cyclization of the compound,,9500,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625232,,,14181,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,10014,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625233,,,14182,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,10014,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625979,,,14183,,Hydrolysis rate constant was determined,,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625980,,,14184,,Observed first order rate constant,,10026,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625981,,,14185,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,10281,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625982,,,14186,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,10281,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625983,,,14187,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625984,,,14188,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625985,,,14189,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625986,,,14190,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625987,,,14191,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625988,,,14192,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625989,,,14193,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625990,,,14194,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625991,,,14195,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625992,,,14196,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625993,,,14197,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631973,,,14198,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632143,,,14199,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632144,,,14200,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632145,,,14201,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632146,,,14202,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632147,,,14203,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632148,,,14204,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632149,,,14205,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632150,,,14206,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632151,,,14207,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL632152,,9606.0,14208,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,3008,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL632153,,9606.0,14209,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,4509,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,,,,1,CHEMBL632154,,9606.0,14210,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,4509,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632155,,10298.0,14211,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632156,,10298.0,14212,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632157,,10298.0,14213,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632158,,10298.0,14214,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL632159,,10298.0,14215,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626305,,10298.0,14216,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626306,,10298.0,14217,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626307,,10298.0,14218,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626308,,10298.0,14219,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626479,,10298.0,14220,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,Human herpesvirus 1,Intermediate,1,50602,A,N,,,,1,CHEMBL626480,,10298.0,14221,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,8613,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626481,,,14222,,Calculated partition coefficient (clogP) (MlogP),,6021,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626482,,,14223,,Equipotent potent ratio relative to carbachol (nicotinic activity),,9348,,,BAO_0000019
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626483,,9615.0,14224,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,15592,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL626484,,9615.0,14225,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,15592,,,BAO_0000218
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626485,,,14226,,Solubility at pH 7.4 in micro g/mL;NA denotes available,,15592,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626486,,,14227,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,15592,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626487,,,14228,,Solubility at pH 7.4 in ug/mL;NA denotes not available,,15592,,,BAO_0000100
,Plasma,Canis lupus familiaris,Intermediate,1,50588,A,N,In vivo,,1969.0,1,CHEMBL626488,,9615.0,14229,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,15592,,,BAO_0000218
,Serum,Rattus norvegicus,Intermediate,1,50597,A,N,,,1977.0,1,CHEMBL626489,,10116.0,14230,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,7095,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626490,,,14231,,Area under the MAP curve measured over 5 min; ND means Not determined,,16618,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL626491,,,14232,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,16835,,,BAO_0000100
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL626492,,,14233,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,15284,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626493,,,14234,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,15750,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626494,,10116.0,14235,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,16618,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626495,,,14236,,Half life after oral tested,,16618,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626496,,10116.0,14237,,Half life was determined in plasma of rat; NT indicates not tested,,15812,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL626497,,10116.0,14238,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,16618,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL626498,,,14239,,Oral bioavailability after oral tested,,16618,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626499,,10116.0,14240,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,13098,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626500,,10116.0,14241,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,13098,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626501,,10116.0,14242,,half life was determined in plasma of rat; NT indicates not tested,,15812,,,BAO_0000218
,Plasma,Rattus norvegicus,Intermediate,1,50597,A,N,,,1969.0,1,CHEMBL626502,,10116.0,14243,,half life was determined in plasma of rat; NT means not tested,,15812,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626503,,10116.0,14244,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626504,,10116.0,14245,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626505,,10116.0,14246,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626506,,10116.0,14247,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626507,,10116.0,14248,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626508,,10116.0,14249,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626509,,10116.0,14250,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875480,,10116.0,14251,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626510,,10116.0,14252,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626511,,10116.0,14253,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL626512,,10116.0,14254,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628208,,10116.0,14255,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628209,,10116.0,14256,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628210,,10116.0,14257,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628211,,10116.0,14258,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628212,,10116.0,14259,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628213,,10116.0,14260,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,11510,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628214,,10116.0,14261,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628215,,10116.0,14262,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628216,,10116.0,14263,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626595,,10116.0,14264,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626596,,10116.0,14265,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626597,,10116.0,14266,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626598,,10116.0,14267,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622242,,10116.0,14268,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622243,,10116.0,14269,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622244,,10116.0,14270,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622245,,10116.0,14271,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622246,,10116.0,14272,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622247,,10116.0,14273,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622248,,10116.0,14274,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL877483,,10116.0,14275,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL622249,,10116.0,14276,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622250,,9615.0,14277,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622251,,9615.0,14278,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622252,,9615.0,14279,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622253,,9615.0,14280,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622254,,9615.0,14281,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622255,,9615.0,14282,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622256,,9615.0,14283,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622257,,9615.0,14284,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622258,,9615.0,14285,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622259,,9615.0,14286,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622927,,9615.0,14287,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622928,,9615.0,14288,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL622929,,9615.0,14289,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL623182,,9615.0,14290,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL623183,,9615.0,14291,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623184,,10116.0,14292,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623185,,10116.0,14293,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL877484,,10116.0,14294,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL627274,,10116.0,14295,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623186,,10116.0,14296,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623187,,10116.0,14297,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL623188,,10116.0,14298,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628055,,10116.0,14299,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628056,,10116.0,14300,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628200,,10116.0,14301,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628201,,10116.0,14302,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628202,,10116.0,14303,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628203,,10116.0,14304,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628204,,10116.0,14305,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628205,,10116.0,14306,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628206,,10116.0,14307,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,12582,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL628207,,,14308,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627220,,,14309,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627221,,,14310,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627222,,,14311,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627223,,,14312,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL632062,,,14313,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,13257,,,BAO_0000218
,Spleen,,Autocuration,1,22224,A,U,In vivo,,2106.0,0,CHEMBL632063,,,14314,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,13257,,,BAO_0000218
,Urinary bladder,,Autocuration,1,22224,A,U,In vivo,,1255.0,0,CHEMBL632064,,,14315,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,13257,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL632065,,,14316,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,13257,,,BAO_0000218
,Bone element,,Autocuration,1,22224,A,U,In vivo,,1474.0,0,CHEMBL632066,,,14317,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL632067,,,14318,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,13257,,,BAO_0000218
,Kidney,,Autocuration,1,22224,A,U,In vivo,,2113.0,0,CHEMBL629188,,,14319,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,13257,,,BAO_0000218
,Liver,,Autocuration,1,22224,A,U,In vivo,,2107.0,0,CHEMBL629189,,,14320,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,13257,,,BAO_0000218
,Lung,,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL629190,,,14321,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629191,,,14322,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629192,,,14323,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629193,,,14324,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629194,,,14325,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629195,,,14326,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629373,,,14327,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,13257,,,BAO_0000218
,Spleen,,Autocuration,1,22224,A,U,In vivo,,2106.0,0,CHEMBL629374,,,14328,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629375,,,14329,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,13257,,,BAO_0000218
,Urinary bladder,,Autocuration,1,22224,A,U,In vivo,,1255.0,0,CHEMBL629376,,,14330,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,13257,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL629377,,,14331,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,13257,,,BAO_0000218
,Bone element,,Autocuration,1,22224,A,U,In vivo,,1474.0,0,CHEMBL629378,,,14332,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629379,,,14333,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,13257,,,BAO_0000218
,Kidney,,Autocuration,1,22224,A,U,In vivo,,2113.0,0,CHEMBL629151,,,14334,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,13257,,,BAO_0000218
,Liver,,Autocuration,1,22224,A,U,In vivo,,2107.0,0,CHEMBL629152,,,14335,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,13257,,,BAO_0000218
,Lung,,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL629153,,,14336,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629154,,,14337,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629155,,,14338,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629156,,,14339,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629157,,,14340,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL629158,,,14341,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629159,,,14342,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629160,,,14343,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,13257,,,BAO_0000218
,Spleen,,Autocuration,1,22224,A,U,In vivo,,2106.0,0,CHEMBL629161,,,14344,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,13257,,,BAO_0000218
,Urinary bladder,,Autocuration,1,22224,A,U,In vivo,,1255.0,0,CHEMBL629162,,,14345,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,13257,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL629163,,,14346,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,13257,,,BAO_0000218
,Bone element,,Autocuration,1,22224,A,U,In vivo,,1474.0,0,CHEMBL629164,,,14347,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629165,,,14348,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,13257,,,BAO_0000218
,Liver,,Autocuration,1,22224,A,U,In vivo,,2107.0,0,CHEMBL629166,,,14349,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,13257,,,BAO_0000218
,Lung,,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL629167,,,14350,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL629168,,,14351,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629169,,,14352,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629170,,,14353,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631153,,,14354,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875121,,,14355,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631154,,,14356,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631155,,,14357,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,2193,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631156,,,14358,,Hydrolysis rate constant was determined,,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631157,,,14359,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631158,,,14360,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631159,,,14361,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631160,,,14362,,Observed second order rate constant,,10026,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631161,,,14363,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,10281,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631162,,,14364,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,10014,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630313,,,14365,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,10014,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630314,,,14366,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630315,,,14367,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630316,,,14368,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630986,,,14369,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630987,,,14370,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630988,,,14371,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630989,,,14372,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630990,,,14373,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630991,,,14374,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630992,,,14375,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630993,,,14376,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630994,,,14377,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,13028,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630995,,10116.0,14378,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,10014,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629252,,,14379,,Association constant for compound at 31 degree C was determined,,9962,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629253,,,14380,,Calculated antagonist equilibrium dissociation constant of the compound,,12029,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629944,,,14381,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,12029,,,BAO_0000019
,Trachea,Cavia porcellus,Intermediate,1,50512,A,N,,,3126.0,1,CHEMBL629945,,10141.0,14382,,Dissociation constants vs LTE4 on guinea pig trachea,,10583,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629946,,,14383,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629947,,,14384,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629948,,,14385,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL856024,,,14386,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629949,,,14387,,Affinity constant KD value was derived from TMP,,7493,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629950,,,14388,,Apparent dissociation (binding) rate constant was evaluated,,8371,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL630127,,,14389,,Dissociation constant (KD) of the compound,,13114,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL630128,,,14390,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,15515,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL630129,,,14391,,Dissociation constant from ESR titration experiments,,522,,,BAO_0000100
,,,Autocuration,1,22224,,U,,,,0,CHEMBL630130,,,14392,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,13888,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL875234,,,14393,,Dissociation constant was evaluated.,,2616,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL630131,,,14394,,Dissociation constant was reported,,3798,,,BAO_0000100
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630132,,10116.0,14395,,Dissociation constant was determined in rat pituitary cells.,,8731,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630133,,,14396,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,11892,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630134,,,14397,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,11892,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630135,,,14398,,Equilibrium dissociation constant of the compound,,2582,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630136,,,14399,,Equilibrium dissociation constant was determined,,11892,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630137,,,14400,,Kinetic constant KD was evaluated,,13396,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630138,,,14401,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,603,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630139,,,14402,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,15673,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630140,,,14403,,Rate constant for hydrolysis in aqueous acetone.,,10368,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875235,,,14404,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,14228,,,BAO_0000019
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876439,,10116.0,14405,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630605,,10116.0,14406,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630606,,10116.0,14407,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630607,,10116.0,14408,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630608,,10116.0,14409,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630609,,10116.0,14410,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630610,,10116.0,14411,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630611,,10116.0,14412,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629552,,10116.0,14413,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629733,,10116.0,14414,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629734,,10116.0,14415,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629735,,10116.0,14416,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629736,,10116.0,14417,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629737,,10116.0,14418,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629738,,10116.0,14419,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629739,,10116.0,14420,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629740,,10116.0,14421,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629741,,10116.0,14422,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629742,,10116.0,14423,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629743,,10116.0,14424,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629744,,10116.0,14425,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629745,,10116.0,14426,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629746,,10116.0,14427,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629747,,10116.0,14428,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629748,,10116.0,14429,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629749,,10116.0,14430,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629750,,10116.0,14431,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629751,,10116.0,14432,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629752,,10116.0,14433,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629753,,10116.0,14434,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629754,,10116.0,14435,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629755,,10116.0,14436,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629756,,10116.0,14437,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629757,,10116.0,14438,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629758,,10116.0,14439,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629759,,10116.0,14440,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL629760,,10116.0,14441,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,11510,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876443,,10116.0,14442,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,11510,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629761,,9615.0,14443,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,8310,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629762,,9615.0,14444,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629763,,10090.0,14445,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629764,,10090.0,14446,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629765,,10090.0,14447,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629766,,10090.0,14448,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629767,,10090.0,14449,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,8310,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629768,,9615.0,14450,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629769,,10090.0,14451,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,8310,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629770,,9615.0,14452,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,8310,,,BAO_0000218
,,Canis lupus familiaris,Intermediate,1,50588,A,N,,,,1,CHEMBL629771,,9615.0,14453,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629772,,10090.0,14454,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL629773,,10090.0,14455,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625455,,10090.0,14456,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625456,,10090.0,14457,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,8310,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL625457,,10090.0,14458,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,8310,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625458,,10116.0,14459,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625459,,10116.0,14460,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875483,,10116.0,14461,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL634779,,10116.0,14462,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625460,,10116.0,14463,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626117,,10116.0,14464,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626118,,10116.0,14465,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628342,,10116.0,14466,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628343,,10116.0,14467,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628344,,10116.0,14468,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628345,,10116.0,14469,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628346,,10116.0,14470,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628347,,10116.0,14471,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628348,,10116.0,14472,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628349,,10116.0,14473,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875611,,10116.0,14474,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628350,,10116.0,14475,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628351,,10116.0,14476,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628352,,10116.0,14477,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628353,,10116.0,14478,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628354,,10116.0,14479,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626667,,10116.0,14480,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626668,,10116.0,14481,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626669,,10116.0,14482,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626670,,10116.0,14483,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626671,,10116.0,14484,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626672,,10116.0,14485,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626673,,10116.0,14486,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626674,,10116.0,14487,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626675,,10116.0,14488,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626676,,10116.0,14489,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626677,,10116.0,14490,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626678,,10116.0,14491,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626679,,10116.0,14492,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875612,,10116.0,14493,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626680,,10116.0,14494,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626681,,10116.0,14495,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626682,,10116.0,14496,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626683,,10116.0,14497,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626684,,10116.0,14498,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626685,,10116.0,14499,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626686,,10116.0,14500,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626687,,10116.0,14501,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624978,,10116.0,14502,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624979,,10116.0,14503,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624980,,10116.0,14504,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL624981,,10116.0,14505,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL624982,,9615.0,14506,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,12582,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627564,,,14507,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627565,,,14508,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627566,,,14509,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627567,,,14510,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,13257,,,BAO_0000218
,Spleen,,Autocuration,1,22224,A,U,In vivo,,2106.0,0,CHEMBL627568,,,14511,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,13257,,,BAO_0000218
,Kidney,,Autocuration,1,22224,A,U,In vivo,,2113.0,0,CHEMBL627569,,,14512,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,13257,,,BAO_0000218
,Urinary bladder,,Autocuration,1,22224,A,U,In vivo,,1255.0,0,CHEMBL627570,,,14513,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,13257,,,BAO_0000218
,Blood,,Autocuration,1,22224,A,U,In vivo,,178.0,0,CHEMBL627571,,,14514,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,13257,,,BAO_0000218
,Bone element,,Autocuration,1,22224,A,U,In vivo,,1474.0,0,CHEMBL627572,,,14515,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627573,,,14516,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,13257,,,BAO_0000218
,Kidney,,Autocuration,1,22224,A,U,In vivo,,2113.0,0,CHEMBL627574,,,14517,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,13257,,,BAO_0000218
,Liver,,Autocuration,1,22224,A,U,In vivo,,2107.0,0,CHEMBL627575,,,14518,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,13257,,,BAO_0000218
,Lung,,Autocuration,1,22224,A,U,In vivo,,2048.0,0,CHEMBL627576,,,14519,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627577,,,14520,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627578,,,14521,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627579,,,14522,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627580,,,14523,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627581,,,14524,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,13257,,,BAO_0000218
,,,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL627582,,,14525,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627583,,,14526,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,13257,,,BAO_0000218
,Spleen,,Autocuration,1,22224,A,U,In vivo,,2106.0,0,CHEMBL627584,,,14527,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,13257,,,BAO_0000218
,Prostate gland,,Autocuration,1,22224,A,U,In vivo,,2367.0,0,CHEMBL627585,,,14528,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,13257,,,BAO_0000218
,Muscle tissue,,Autocuration,1,22224,A,U,In vivo,,2385.0,0,CHEMBL627586,,,14529,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,13257,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627587,,10116.0,14530,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL627588,,10116.0,14531,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628250,,10116.0,14532,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628251,,10116.0,14533,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628252,,10116.0,14534,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628253,,10116.0,14535,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL628254,,10116.0,14536,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL877493,,10116.0,14537,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628255,,10116.0,14538,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628256,,10116.0,14539,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL628257,,10116.0,14540,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL628258,,10116.0,14541,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628259,,10116.0,14542,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL628429,,10116.0,14543,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL626862,,10116.0,14544,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL626863,,10116.0,14545,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,15413,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL625886,,10116.0,14546,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,15413,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL625887,,10116.0,14547,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625888,,10116.0,14548,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625889,,10116.0,14549,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625890,,10116.0,14550,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,15413,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL625891,,10116.0,14551,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL625892,,10116.0,14552,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL625893,,10116.0,14553,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,15413,,,BAO_0000218
,Cerebellum,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2037.0,1,CHEMBL625894,,10116.0,14554,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,15413,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL625895,,10116.0,14555,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,15413,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625896,,,14556,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,12404,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625897,,,14557,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625898,,,14558,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL625899,,,14559,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,568,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL626124,,,14560,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,12404,,,BAO_0000019
,,Escherichia coli,Intermediate,1,50212,A,N,,,,1,CHEMBL628500,,562.0,14561,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,7624,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL857856,,10116.0,14562,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,7624,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628501,,10116.0,14563,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,7624,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628502,,,14564,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,4643,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628503,,,14565,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,11532,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628504,,,14566,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,11018,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628505,,,14567,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL874452,,,14568,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628506,,,14569,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628507,,,14570,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628508,,,14571,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628509,,,14572,,Michaelis constant (KM) was evaluated,,8949,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628510,,,14573,,Reaction rate parameter value for phosphate with transfer with respect to ATP,,12404,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL628511,,,14574,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,7625,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL628512,,,14575,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,7625,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL628513,,,14576,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,7625,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL628514,,,14577,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,7625,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628515,,,14578,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,12908,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628516,,,14579,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,10368,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628517,,,14580,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,13108,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628518,,,14581,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,13108,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628519,,,14582,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,15217,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628520,,,14583,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,15217,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628521,,,14584,,Binding constant was determined,,10933,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630443,,,14585,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630444,,,14586,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL857732,,,14587,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,2276,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL630445,,,14588,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,14915,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630446,,,14589,,Catalytic rate constant of the compound,,8847,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL630447,,,14590,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,15357,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630448,,,14591,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,2869,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630449,,,14592,,Catalytic rate constant against phospholipase A2 was determined,,3484,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630450,,,14593,,"Compound was evaluated for catalytic constant, Kcat",,1373,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630451,,,14594,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,8142,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630452,,,14595,,Kcat calculated from 0.693/T1/2,,14131,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630453,,,14596,,Kcat was determined,,17269,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630454,,,14597,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,3485,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630455,,,14598,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,3485,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631487,,,14599,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,3485,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631488,,,14600,,Kcat value was determined,,5962,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL876440,,,14601,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,3133,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631489,,,14602,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,3133,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL857742,,,14603,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631490,,,14604,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631491,,,14605,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631492,,,14606,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631493,,,14607,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631494,,,14608,,Kinetic parameter for rate of conversion to PABA was determined,,4892,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631495,,,14609,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,3133,,,BAO_0000019
,Feces,Rattus norvegicus,Intermediate,1,50597,A,N,,,1988.0,1,CHEMBL631496,,10116.0,14610,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,11488,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631497,,10116.0,14611,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,11488,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631498,,10116.0,14612,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,11488,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629776,,10116.0,14613,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,11488,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629777,,10116.0,14614,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,11488,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL629778,,10116.0,14615,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630456,,10116.0,14616,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630457,,10116.0,14617,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630458,,10116.0,14618,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630459,,10116.0,14619,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630460,,10116.0,14620,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL876550,,10116.0,14621,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630461,,10116.0,14622,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630462,,10116.0,14623,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630463,,10116.0,14624,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630464,,10116.0,14625,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630465,,10116.0,14626,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630466,,10116.0,14627,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630467,,10116.0,14628,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630633,,10116.0,14629,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630634,,10116.0,14630,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630635,,10116.0,14631,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630636,,10116.0,14632,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,11488,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630637,,10116.0,14633,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,11488,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL630638,,9986.0,14634,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL630639,,9986.0,14635,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL630640,,9986.0,14636,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL876551,,9986.0,14637,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL630641,,9986.0,14638,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL630642,,9986.0,14639,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL630643,,9986.0,14640,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL630644,,9986.0,14641,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL630645,,9986.0,14642,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL625599,,9986.0,14643,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL625600,,9986.0,14644,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL625601,,9986.0,14645,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,7132,,,BAO_0000218
,Feces,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1988.0,1,CHEMBL625602,,9986.0,14646,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL627470,,9986.0,14647,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL627471,,9986.0,14648,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL627472,,9986.0,14649,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL627473,,9986.0,14650,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,7132,,,BAO_0000218
,Urine,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,1088.0,1,CHEMBL627474,,9986.0,14651,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,7132,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627475,,10116.0,14652,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL627476,,10116.0,14653,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627477,,9615.0,14654,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627478,,9615.0,14655,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627479,,9615.0,14656,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627480,,9615.0,14657,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627481,,9615.0,14658,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627482,,9615.0,14659,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL627483,,9615.0,14660,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL875636,,9615.0,14661,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625764,,9615.0,14662,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625765,,9615.0,14663,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625766,,9615.0,14664,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625767,,9615.0,14665,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625768,,9615.0,14666,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625769,,9615.0,14667,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625770,,9615.0,14668,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625771,,9615.0,14669,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625772,,9615.0,14670,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Canis lupus familiaris,Intermediate,1,50588,A,N,,,1088.0,1,CHEMBL625773,,9615.0,14671,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625774,,10116.0,14672,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625775,,10116.0,14673,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625776,,10116.0,14674,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625777,,10116.0,14675,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625778,,10116.0,14676,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625779,,10116.0,14677,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625780,,10116.0,14678,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL625781,,10116.0,14679,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875637,,10116.0,14680,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626473,,10116.0,14681,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626474,,10116.0,14682,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626475,,10116.0,14683,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626476,,10116.0,14684,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL634397,,10116.0,14685,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL626477,,10116.0,14686,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631069,,10116.0,14687,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631070,,10116.0,14688,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631071,,10116.0,14689,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631072,,10116.0,14690,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631073,,10116.0,14691,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631074,,10116.0,14692,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631075,,10116.0,14693,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631725,,10116.0,14694,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631726,,10116.0,14695,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631727,,10116.0,14696,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631728,,10116.0,14697,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631729,,10116.0,14698,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631730,,10116.0,14699,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631731,,10116.0,14700,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631910,,10116.0,14701,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,12582,,,BAO_0000218
,Hippocampus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,10000000.0,1,CHEMBL631911,,10116.0,14702,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL631912,,10116.0,14703,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,15413,,,BAO_0000218
,Hypothalamus,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,1898.0,1,CHEMBL631913,,10116.0,14704,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,15413,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631914,,10116.0,14705,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631915,,10116.0,14706,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL875778,,10116.0,14707,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631916,,10116.0,14708,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631917,,10116.0,14709,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631918,,10116.0,14710,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631919,,10116.0,14711,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631920,,10116.0,14712,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631921,,10116.0,14713,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631922,,10116.0,14714,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL631923,,10116.0,14715,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL631924,,10116.0,14716,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630234,,10116.0,14717,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630235,,10116.0,14718,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630236,,10116.0,14719,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630237,,10116.0,14720,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630238,,10116.0,14721,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630239,,10116.0,14722,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630303,,10116.0,14723,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630304,,10116.0,14724,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,,1,CHEMBL630305,,10116.0,14725,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL630306,,10116.0,14726,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL630307,,10116.0,14727,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL630308,,10116.0,14728,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL630309,,10116.0,14729,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL629309,,10116.0,14730,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL629993,,10116.0,14731,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL629994,,10116.0,14732,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL629995,,10116.0,14733,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL631993,,10116.0,14734,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL631994,,10116.0,14735,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL631995,,10116.0,14736,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL631996,,10116.0,14737,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL631997,,10116.0,14738,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL631998,,10116.0,14739,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL631999,,10116.0,14740,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL632000,,10116.0,14741,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL632001,,10116.0,14742,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL874424,,10116.0,14743,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL632002,,10116.0,14744,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL632003,,10116.0,14745,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632004,,,14746,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,3133,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632005,,,14747,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632006,,,14748,,Compound was tested for amidase rate in the presence of N62C screen enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632007,,,14749,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632008,,,14750,,Compound was tested for amidase rate in the presence of S166C screen enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632009,,,14751,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632010,,,14752,,Compound was tested for esterase rate in the presence of N62C screen enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL857750,,,14753,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632011,,,14754,,Compound was tested for esterase rate in the presence of S166C screen enzyme,,2742,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632012,,,14755,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632013,,,14756,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL632014,,,14757,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629622,,,14758,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629623,,,14759,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629624,,,14760,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629625,,,14761,,Ratio of Kcat to that of Km was determined,,17269,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629626,,,14762,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629627,,,14763,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,2276,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629628,,,14764,,"Compound was evaluated for constant, Kd",,15917,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629629,,,14765,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,10933,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629630,,,14766,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,10933,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL856030,,,14767,,Dissociation Constant of compound determined,,14293,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL629631,,,14768,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,6698,,,BAO_0000019
,,,Autocuration,1,22224,B,U,,,,0,CHEMBL629632,,,14769,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,6698,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629633,,,14770,,Dissociation constant of compound with Fructose was determined,,4318,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629634,,,14771,,Dissociation constant of compound with Fructose was determined; Not determined,,4318,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629635,,,14772,,Dissociation constant of compound with Lactulose was determined,,4318,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629636,,,14773,,Dissociation constant of compound with Lactulose was determined; Not determined,,4318,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629637,,,14774,,Dissociation constant of the Compound,,14959,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629638,,,14775,,Dissociation constant by non-linear regression analysis,,5913,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629639,,,14776,,Dissociation constant was determined,,14218,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629640,,,14777,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,10689,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629641,,,14778,,Dissociation constant was determined,,13925,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL631344,,,14779,,Dissociation constant was determined,,16359,,,BAO_0000100
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL631345,,10116.0,14780,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,10944,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631346,,,14781,,The dissociation constant determined by fluorescence displacement assay,,11080,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631524,,,14782,,kd value surface plasmon resonance (SPR) method,,17805,,,BAO_0000019
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL631525,,10116.0,14783,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,10944,,,BAO_0000218
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL631526,,,14784,,First dissociation constant of the binding of compound to V30M TTR,,16645,,,BAO_0000019
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL631527,,,14785,,Second dissociation constant of the binding of compound to V30M TTR,,16645,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631528,,,14786,,"Compound was evaluated for equilibrium constant, Ke",,7793,,,BAO_0000019
,Hypothalamus,,Autocuration,1,22224,A,U,,,1898.0,0,CHEMBL631529,,,14787,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,12199,,,BAO_0000019
,Hypothalamus,,Autocuration,1,22224,A,U,,,1898.0,0,CHEMBL631530,,,14788,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,12199,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631531,,,14789,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631532,,,14790,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,9680,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL631533,,,14791,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,9680,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL876552,,10090.0,14792,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631534,,10090.0,14793,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631535,,10090.0,14794,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631536,,10090.0,14795,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631537,,10090.0,14796,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631538,,10090.0,14797,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631539,,10090.0,14798,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,13758,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,,,,1,CHEMBL631540,,10090.0,14799,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,13758,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625637,,10116.0,14800,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625638,,10116.0,14801,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,14393,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL625639,,10116.0,14802,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,15078,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625640,,10116.0,14803,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625641,,10116.0,14804,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625642,,10116.0,14805,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625643,,10116.0,14806,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625644,,10116.0,14807,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Kidney,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2113.0,1,CHEMBL625645,,10116.0,14808,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625646,,10116.0,14809,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625647,,10116.0,14810,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625648,,10116.0,14811,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL625649,,10116.0,14812,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625650,,10116.0,14813,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL625651,,10116.0,14814,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL625652,,10116.0,14815,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Zone of skin,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,14.0,1,CHEMBL625653,,10116.0,14816,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625654,,10116.0,14817,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL625655,,10116.0,14818,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,13925,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625656,,10116.0,14819,,Biodistribution of Compound in rat blood after 15 minutes of administration,,9712,,,BAO_0000218
,Blood,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,178.0,1,CHEMBL625657,,10116.0,14820,,Biodistribution of Compound in rat blood after 2 minutes of administration,,9712,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625658,,10116.0,14821,,Biodistribution of Compound in rat brain after 15 minutes of administration,,9712,,,BAO_0000218
,Brain,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,955.0,1,CHEMBL625659,,10116.0,14822,,Biodistribution of Compound in rat brain after 2 minutes of administration,,9712,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625660,,10116.0,14823,,Biodistribution of Compound in rat heart after 15 minutes of administration,,9712,,,BAO_0000218
,Heart,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,948.0,1,CHEMBL625661,,10116.0,14824,,Biodistribution of Compound in rat heart after 2 minutes of administration,,9712,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625662,,10116.0,14825,,Biodistribution of Compound in rat liver after 15 minutes of administration,,9712,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL625663,,10116.0,14826,,Biodistribution of Compound in rat liver after 2 minutes of administration,,9712,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL875621,,10116.0,14827,,Biodistribution of Compound in rat lung after 15 minutes of administration,,9712,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL628382,,10116.0,14828,,Biodistribution of Compound in rat lung after 2 minutes of administration,,9712,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL628383,,10116.0,14829,,Biodistribution of Compound in rat muscle after 15 minutes of administration,,9712,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL628384,,10116.0,14830,,Biodistribution of Compound in rat muscle after 2 minutes of administration,,9712,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628385,,10116.0,14831,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,13925,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875753,,10116.0,14832,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,13925,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628386,,10116.0,14833,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,13925,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628387,,10116.0,14834,,Organ distribution in rat blood 2 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628388,,10116.0,14835,,Organ distribution in rat blood 2 hr after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628389,,10116.0,14836,,Organ distribution in rat blood 30 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL632756,,10116.0,14837,,Organ distribution in rat blood 30 min after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628390,,10116.0,14838,,Organ distribution in rat brain 2 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631811,,10116.0,14839,,Organ distribution in rat brain 2 hr after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631812,,10116.0,14840,,Organ distribution in rat brain 30 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631813,,10116.0,14841,,Organ distribution in rat heart 2 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631814,,10116.0,14842,,Organ distribution in rat heart 2 hr after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631815,,10116.0,14843,,Organ distribution in rat heart 30 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631816,,10116.0,14844,,Organ distribution in rat kidney 2 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL875758,,10116.0,14845,,Organ distribution in rat kidney 2 hr after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631817,,10116.0,14846,,Organ distribution in rat kidney 30 minutes after intravenous injection,,6941,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631818,,10116.0,14847,,Organ distribution in rat liver 2 minutes after intravenous injection,,6941,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631819,,10116.0,14848,,Organ distribution in rat liver 2 hr after intravenous injection,,6941,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,,,2107.0,1,CHEMBL631820,,10116.0,14849,,Organ distribution in rat liver 30 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631821,,10116.0,14850,,Organ distribution in rat lung 2 minutes after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631822,,10116.0,14851,,Organ distribution in rat lung 2 hr after intravenous injection,,6941,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL631823,,10116.0,14852,,Organ distribution in rat lung 30 minutes after intravenous injection,,6941,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL631824,,10116.0,14853,,Organ distribution in rat muscle 2 minutes after intravenous injection,,6941,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL631825,,10116.0,14854,,Organ distribution in rat muscle 2 hr after intravenous injection,,6941,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,,,2385.0,1,CHEMBL631826,,10116.0,14855,,Organ distribution in rat muscle 30 minutes after intravenous injection,,6941,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL631827,,10090.0,14856,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL631828,,10090.0,14857,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL631829,,10090.0,14858,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,14439,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875759,,10116.0,14859,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631830,,10116.0,14860,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631831,,10116.0,14861,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631832,,10116.0,14862,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631833,,10116.0,14863,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631834,,10116.0,14864,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631835,,10116.0,14865,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631836,,10116.0,14866,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631837,,10116.0,14867,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631838,,10116.0,14868,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631839,,10116.0,14869,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631840,,10116.0,14870,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631841,,10116.0,14871,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631842,,10116.0,14872,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631843,,10116.0,14873,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631844,,10116.0,14874,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631845,,10116.0,14875,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631846,,10116.0,14876,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL875760,,10116.0,14877,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL632199,,10116.0,14878,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631847,,10116.0,14879,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL631848,,10116.0,14880,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628707,,10116.0,14881,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628708,,10116.0,14882,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628709,,10116.0,14883,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628710,,10116.0,14884,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628711,,10116.0,14885,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628712,,10116.0,14886,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628713,,10116.0,14887,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,12582,,,BAO_0000218
,Urine,Rattus norvegicus,Intermediate,1,50597,A,N,,,1088.0,1,CHEMBL628714,,10116.0,14888,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,12582,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL628715,,10116.0,14889,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,7415,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629179,,,14890,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,7313,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629180,,,14891,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,7313,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL875108,,,14892,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,7313,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629181,,,14893,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629182,,,14894,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629183,,,14895,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629184,,,14896,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629185,,,14897,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,7570,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629186,,,14898,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629187,,,14899,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629887,,,14900,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629888,,,14901,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629889,,,14902,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629890,,,14903,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629891,,,14904,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629892,,,14905,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,7570,,,BAO_0000019
,Adrenal cortex,,Autocuration,1,22224,A,U,,,1235.0,0,CHEMBL629893,,,14906,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629894,,,14907,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629895,,,14908,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,7570,,,BAO_0000019
,,Canis lupus familiaris,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL875109,,9615.0,14909,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,14122,,,BAO_0000218
,,Macaca fascicularis,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629896,,9541.0,14910,,Absolute bioavailability in male cynomolgus monkeys,,16449,,,BAO_0000218
,,Rattus norvegicus,Autocuration,1,22224,A,U,In vivo,,,0,CHEMBL629897,,10116.0,14911,,Absolute bioavailability in maleSprague-Dawley rats,,16449,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL629898,,10116.0,14912,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL630057,,10116.0,14913,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Liver,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2107.0,1,CHEMBL630058,,10116.0,14914,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630059,,10116.0,14915,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630060,,10116.0,14916,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630061,,10116.0,14917,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630062,,10116.0,14918,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630063,,10116.0,14919,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630064,,10116.0,14920,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630065,,10116.0,14921,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630066,,10116.0,14922,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630067,,10116.0,14923,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Lung,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2048.0,1,CHEMBL630068,,10116.0,14924,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL631113,,10116.0,14925,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL631114,,10116.0,14926,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL631115,,10116.0,14927,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL631116,,10116.0,14928,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630528,,10116.0,14929,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630529,,10116.0,14930,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630530,,10116.0,14931,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630531,,10116.0,14932,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630532,,10116.0,14933,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Muscle tissue,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2385.0,1,CHEMBL630533,,10116.0,14934,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL630534,,10090.0,14935,,Biodistribution in normal mice blood after 120 hr,,15045,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL630535,,10090.0,14936,,Biodistribution in normal mice blood after 24 hr,,15045,,,BAO_0000218
,Blood,Mus musculus,Intermediate,1,50594,A,N,In vivo,,178.0,1,CHEMBL630536,,10090.0,14937,,Biodistribution in normal mice blood after 4 hr,,15045,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL630537,,10090.0,14938,,Biodistribution in normal mice bone after 120 hr,,15045,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL630538,,10090.0,14939,,Biodistribution in normal mice bone after 24 hr,,15045,,,BAO_0000218
,Bone,Mus musculus,Intermediate,1,50594,A,N,In vivo,,10000001.0,1,CHEMBL630539,,10090.0,14940,,Biodistribution in normal mice bone after 4 hr,,15045,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL630540,,10090.0,14941,,Biodistribution in normal mice heart after 120 hr,,15045,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL630541,,10090.0,14942,,Biodistribution in normal mice heart after 24 hr,,15045,,,BAO_0000218
,Heart,Mus musculus,Intermediate,1,50594,A,N,In vivo,,948.0,1,CHEMBL630542,,10090.0,14943,,Biodistribution in normal mice heart after 4 hr,,15045,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL630543,,10090.0,14944,,Biodistribution in normal mice kidney after 120 hr,,15045,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL630544,,10090.0,14945,,Biodistribution in normal mice kidney after 24 hr,,15045,,,BAO_0000218
,Kidney,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2113.0,1,CHEMBL630545,,10090.0,14946,,Biodistribution in normal mice kidney after 4 hr,,15045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL630546,,10090.0,14947,,Biodistribution in normal mice liver after 120 hr,,15045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL630547,,10090.0,14948,,Biodistribution in normal mice liver after 24 hr,,15045,,,BAO_0000218
,Liver,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2107.0,1,CHEMBL630548,,10090.0,14949,,Biodistribution in normal mice liver after 4 hr,,15045,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL630549,,10090.0,14950,,Biodistribution in normal mice spleen after 120 hr,,15045,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL630550,,10090.0,14951,,Biodistribution in normal mice spleen after 24 hr,,15045,,,BAO_0000218
,Spleen,Mus musculus,Intermediate,1,50594,A,N,In vivo,,2106.0,1,CHEMBL876426,,10090.0,14952,,Biodistribution in normal mice spleen after 4 hr,,15045,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630551,,10116.0,14953,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630552,,10116.0,14954,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630553,,10116.0,14955,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630554,,10116.0,14956,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630555,,10116.0,14957,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630556,,10116.0,14958,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630557,,10116.0,14959,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630558,,10116.0,14960,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630559,,10116.0,14961,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Spleen,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2106.0,1,CHEMBL630560,,10116.0,14962,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,Thyroid gland,Rattus norvegicus,Intermediate,1,50597,A,N,In vivo,,2046.0,1,CHEMBL876427,,10116.0,14963,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,12017,,,BAO_0000218
,,Rattus norvegicus,Intermediate,1,50597,A,N,,,,1,CHEMBL630561,,10116.0,14964,,The Kel values in female wistar rats.,,14941,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630562,,,14965,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,4646,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL630563,,,14966,,Hydrolysis rate constant of the compound,,8847,,,BAO_0000019
,,,Autocuration,1,22229,P,U,,,,0,CHEMBL629673,,,14967,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,11778,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629674,,,14968,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629675,,,14969,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629676,,,14970,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629677,,,14971,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,2363,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629678,,,14972,,Apparent inactivation rate constant was evaluated,,8371,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629679,,,14973,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,14883,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629680,,,14974,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,14883,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629681,,,14975,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,4643,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629682,,,14976,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,3519,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL629683,,,14977,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,10600,,,BAO_0000019
,,,Autocuration,1,22224,F,U,,,,0,CHEMBL629684,,,14978,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,8501,,,BAO_0000019
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629685,,,14979,,Dissociation constant was determined,,8505,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629686,,,14980,,Dissociation constant was determined,,9778,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL872932,,,14981,,Dissociation constant at pH 7.4,,9778,,,BAO_0000100
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL629687,,,14982,,Dissociation constant in presence of 1 mM dithiothreitol,,9778,,,BAO_0000100
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL872931,,,14983,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,13007,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628151,,,14984,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,13007,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628152,,,14985,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,13007,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628153,,,14986,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,13007,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628154,,,14987,,Kinetic constant for aromatization of androstenedione,,11482,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628155,,,14988,,Kinetic constant for aromatization of testosterone,,11482,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628156,,,14989,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,2303,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628157,,,14990,,Local inhibition constant was determined,,11964,,,BAO_0000019
,,Saccharomyces cerevisiae,Intermediate,1,50347,A,N,,,,1,CHEMBL857533,,4932.0,14991,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,3140,,,BAO_0000218
,,,Autocuration,1,22224,P,U,,,,0,CHEMBL628158,,,14992,,Dissociation constant value of the compound,,10650,,,BAO_0000100
,Cornea,,Autocuration,1,22224,A,U,,,964.0,0,CHEMBL628159,,,14993,,In vitro permeability through cornea without epithelium,,4667,,,BAO_0000019
,Cornea,,Autocuration,1,22224,A,U,,,964.0,0,CHEMBL875616,,,14994,,In vitro permeability through intact cornea,,4667,,,BAO_0000019
,Cornea,Oryctolagus cuniculus,Intermediate,1,50592,A,N,,,964.0,1,CHEMBL628160,,9986.0,14995,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,9199,,,BAO_0000218
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628161,,,14996,,Rate of enzyme inactivation for the compound was determined,,11966,,,BAO_0000019
,Cornea,,Autocuration,1,22224,A,U,,,964.0,0,CHEMBL628162,,,14997,,In vitro permeability through cornea without epithelium,,4667,,,BAO_0000019
,Cornea,,Autocuration,1,22224,A,U,,,964.0,0,CHEMBL628163,,,14998,,In vitro permeability through intact cornea,,4667,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628164,,,14999,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628165,,,15000,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628166,,,15001,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628167,,,15002,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628168,,,15003,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628169,,,15004,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628170,,,15005,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628171,,,15006,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627434,,,15007,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL627435,,,15008,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628110,,,15009,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628111,,,15010,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628112,,,15011,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628260,,,15012,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,,Autocuration,1,22224,A,U,,,,0,CHEMBL628261,,,15013,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,8354,,,BAO_0000019
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628262,,10090.0,15014,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,14439,,,BAO_0000218
,,Homo sapiens,Intermediate,1,50587,A,N,In vivo,,,1,CHEMBL628263,,9606.0,15015,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628264,,10090.0,15016,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628265,,10090.0,15017,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628266,,10090.0,15018,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628267,,10090.0,15019,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628268,,10090.0,15020,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628269,,10090.0,15021,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628270,,10090.0,15022,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628271,,10090.0,15023,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,14439,,,BAO_0000218
,,Mus musculus,Intermediate,1,50594,A,N,In vivo,,,1,CHEMBL628272,,10090.0,15024,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,14439,,,BAO_0000218
